
<html lang="en"     class="pb-page"  data-request-id="8568f9cb-fe6f-4e67-8bd6-c7ebaba0b02f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00876;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Matin  Shaikh" /></meta><meta name="dc.Creator" content="Yashodeep  Shinde" /></meta><meta name="dc.Creator" content="Rahul  Pawara" /></meta><meta name="dc.Creator" content="Malleshappa  Noolvi" /></meta><meta name="dc.Creator" content="Sanjay  Surana" /></meta><meta name="dc.Creator" content="Iqrar  Ahmad" /></meta><meta name="dc.Creator" content="Harun  Patel" /></meta><meta name="dc.Description" content="The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Fo..." /></meta><meta name="Description" content="The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Fo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 29, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00876" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00876" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00876" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00876" /></link>
        
    
    

<title>Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00876" /></meta><meta property="og:title" content="Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0064.jpeg" /></meta><meta property="og:description" content="The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). It is nearly 200-fold more selective toward the mutant EGFR as compared to the WT EGFR. A tertiary cystein 797 to serine 797 (C797S) mutation in the EGFR kinase domain has hampered Osimertinib treatment in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). This C797S mutation is presumed to induce a tertiary-acquired resistance to all current reversible and irreversible EGFR TKIs. This review summarizes the molecular mechanisms of resistance to Osimertinib as well as different strategies for overcoming the EGFR-dependent and EGFR-independent mechanisms of resistance, new challenges, and a future direction." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00876"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00876">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00876&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00876&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00876&amp;href=/doi/10.1021/acs.jmedchem.1c00876" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00465" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00895" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Matin Shaikh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matin Shaikh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matin++Shaikh">Matin Shaikh</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yashodeep Shinde</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yashodeep Shinde</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yashodeep++Shinde">Yashodeep Shinde</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rahul Pawara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rahul Pawara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rahul++Pawara">Rahul Pawara</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Malleshappa Noolvi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Malleshappa Noolvi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shree Dhanvantari College of Pharmacy, Kim, Surat, Gujarat, India 394111</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Malleshappa++Noolvi">Malleshappa Noolvi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sanjay Surana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sanjay Surana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sanjay++Surana">Sanjay Surana</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iqrar Ahmad</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iqrar Ahmad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +91-9284541386. Fax: + 91-2563251808. Email: <a href="/cdn-cgi/l/email-protection#b6d7d8c5d7c4dfdfc7c4d7c48386f6d1dbd7dfda98d5d9db"><span class="__cf_email__" data-cfemail="ec8d829f8d9e85859d9e8d9ed9dcac8b818d8580c28f8381">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Iqrar++Ahmad">Iqrar Ahmad</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Harun Patel</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harun Patel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +91-8806621544. Fax: + 91-2563251808. Email: <a href="/cdn-cgi/l/email-protection#deb6aebfaabbb281ede69ea7bfb6b1b1f0bdb1b3"><span class="__cf_email__" data-cfemail="573f273623323b08646f172e363f38387934383a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harun++Patel">Harun Patel</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-0920-1266" title="Orcid link">https://orcid.org/0000-0003-0920-1266</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00876&amp;href=/doi/10.1021%2Facs.jmedchem.1c00876" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 29, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 May 2021</li><li><span class="item_label"><b>Published</b> online</span>29 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00876" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00876</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D39%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatin%2BShaikh%252C%2BYashodeep%2BShinde%252C%2BRahul%2BPawara%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00876%26title%3DEmerging%2BApproaches%2Bto%2BOvercome%2BAcquired%2BDrug%2BResistance%2BObstacles%2Bto%2BOsimertinib%2Bin%2BNon-Small-Cell%2BLung%2BCancer%26numPages%3D39%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D39%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00876"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">267</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00876" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matin&quot;,&quot;last_name&quot;:&quot;Shaikh&quot;},{&quot;first_name&quot;:&quot;Yashodeep&quot;,&quot;last_name&quot;:&quot;Shinde&quot;},{&quot;first_name&quot;:&quot;Rahul&quot;,&quot;last_name&quot;:&quot;Pawara&quot;},{&quot;first_name&quot;:&quot;Malleshappa&quot;,&quot;last_name&quot;:&quot;Noolvi&quot;},{&quot;first_name&quot;:&quot;Sanjay&quot;,&quot;last_name&quot;:&quot;Surana&quot;},{&quot;first_name&quot;:&quot;Iqrar&quot;,&quot;last_name&quot;:&quot;Ahmad&quot;},{&quot;first_name&quot;:&quot;Harun&quot;,&quot;last_name&quot;:&quot;Patel&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00876&quot;},&quot;abstract&quot;:&quot;The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). It is nearly 200-fold more selective toward the mutant EGFR as compared to the WT EGFR. A tertiary cystein 797 to serine 797 (C797S) mutation in the EGFR kinase domain has hampered Osimertinib treatment in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). This C797S mutation is presumed to induce a tertiary-acquired resistance to all current reversible and irreversible EGFR TKIs. This review summarizes the molecular mechanisms of resistance to Osimertinib as well as different strategies for overcoming the EGFR-dependent and EGFR-independent mechanisms of resistance, new challenges, and a future direction.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00876&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00876" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00876&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00876" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00876&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00876" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00876&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00876&amp;href=/doi/10.1021/acs.jmedchem.1c00876" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00876" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00876" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00876%26sid%3Dliteratum%253Aachs%26pmid%3D34323489%26genre%3Darticle%26aulast%3DShaikh%26date%3D2021%26atitle%3DEmerging%2BApproaches%2Bto%2BOvercome%2BAcquired%2BDrug%2BResistance%2BObstacles%2Bto%2BOsimertinib%2Bin%2BNon-Small-Cell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0064.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). It is nearly 200-fold more selective toward the mutant EGFR as compared to the WT EGFR. A tertiary cystein 797 to serine 797 (C797S) mutation in the EGFR kinase domain has hampered Osimertinib treatment in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). This C797S mutation is presumed to induce a tertiary-acquired resistance to all current reversible and irreversible EGFR TKIs. This review summarizes the molecular mechanisms of resistance to Osimertinib as well as different strategies for overcoming the EGFR-dependent and EGFR-independent mechanisms of resistance, new challenges, and a future direction.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On March 30, 2017, the US Food and Drug Administration (FDA) conceded regular approval to Osimertinib (AZD9291) for the management of patients with metastatic “EGFR-T790M Non-Small Cell Lung Cancer (NSCLC)”.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> The FDA-approved drug Osimertinib is at the forefront for the treatment of NSCLC patients (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> However, a significant proportion of Osimertinib-treated patients developed the EGFR kinase tertiary cystein 797 to serine 797 (C797S) mutation by the loss of covalent binding with the Cys797 residue, which renders a resistance to all the existing drugs.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Additional studies with mutant cell lines have shown that the allelic context of the activating gatekeeper and C797S mutations affects the sensitivity of three generations of EGFR inhibitors, with no epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) alone or in combination able to suppress activity when the mutation is in the <i>cis</i>-form.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> These data suggest that there is a pressing need for drugs that can overcome the ternary mutation (L858R/T790M/C797S EGFR) obstacle in NSCLC.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The crystallographic structure of C797S-EGFR revealed that the C797S mutation has no effect on the EGFR kinase’s structure or function but does increase the degree of local hydrophilicity around residue 797 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. EGFR-TK inhibitors (EGFR-TKIs) and problems associated with them.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The C797S undruggable tertiary mutation leads to a loss of the covalent bond of Osimertinib with the Cys797 residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The EGFR-independent pathway also contributes to the resistance to Osimertinib in addition to the acquired C797S mutation.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> The EGFR-independent pathway (bypass pathway) is ascribed to the modification of other signaling molecules, such as MET amplification, MEK activation, ALK activation, FGFR amplification, HER2 amplification, AKT activation, BRAF activation, and AXL activation.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> The tertiary undruggable C797S mutation in the EGFR kinase domain, which causes more than 20% of the incidence rate in clinical results, is the most difficult to deal with of all these potential mechanisms.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> The focus of this review is to provide an exhaustive overview of Osimertinib resistance mechanisms and use the available information to develop potential strategies to overcome the associated resistance problem.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  EGFR-Mediated Signaling Pathways in NSCLC</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Different growth factors, cytokines, and hormones bind to the receptor tyrosine kinases (RTKs). Structurally, RTKs consist of the ligand-binding extracellular domain, the hydrophobic transmembrane domain, and the intracellular protein tyrosine kinase region.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Therefore, intracellular pathways that signal EGFR play a major role in various cancers, specifically NSCLC. The binding of a ligand (growth factor) to the EGFR extracellular domain causes dimerization, which subsequently activates the cytoplasmic tyrosine kinase domain and triggers a cascade of signal transduction events.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> There are two major downstream pathways for EGFR activation: the PI3K/Ak strain transforming (AKT) pathway and the RAS/mitogen-activated protein kinase (MEK)/ERK/mTOR pathway (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The phosphorylated EGFR tyrosine kinase serves as the binding site for PI3K to stimulate phosphatidylinositol-3,4,5-tryphosphate (PIP-3), which in turn activates the AKT pathway.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EGFR-driven signaling mechanisms in NSCLC. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> under Creative Commons CC BY 4.0. Copyright 2018, Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The downstream target of AKT, mTOR, is then activated, causing the expression of the associated proteins required for cell cycle progression from the G1 phase to the S phase.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26−29)</a> In a similar way, EGFR dimerization activates RAS, which causes RAF kinases to phosphorylate MEK. MEK activation can trigger ERK activation, which can lead to the activation of cell cycle-related transcription factors such as c-Fos, Myc, NF-B, and CREB. These transcription factors in turn trigger the accumulation of cyclin D, which catalyzes cell division (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  Mechanisms of Osimertinib Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The U.S. FDA has approved three generations of EGFR inhibitors, including reversible Gefitinib and Erlotinib (first generation), irreversible Afatinib and Dacomitinib (second generation), and the wild-type-sparing Osimertinib (third generation), for NSCLC patients with EGFR-activating mutations or a secondary T790M mutation.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Osimertinib’s selectivity for mutant EGFR is demonstrated by its nearly 200-fold higher occupancy against L858R/T790M than WT EGFR.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31−34)</a> In spite of the positive survival outcomes and response rates reported in Osimertinib-treated patients, acquired resistance occurs after even about 10 months.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> To date, several acquired resistance mechanisms to Osimertinib have been identified, and these mechanisms of resistance can be broadly classified in the following two ways: EGFR-dependent and EGFR-independent mechanisms.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">EGFR-dependent resistance mechanisms comprise EGFR mutation, amplification, loss, ligand overexpression, and acquired tertiary EGFR resistance mutation to TKI. EGFR-independent resistance mechanisms include alternative kinase activation, activation of bypass RTK signaling, aberration in downstream signaling pathways, histological transformation, and phenotypic change epithelial–mesenchymal transition (EMT) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40 ref41">(37−41)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Resistance to Osimertinib in NSCLC involves both EGFR-dependent and EGFR-independent mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparative percentage of the EGFR-dependent and EGFR-independent resistance to Osimertinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  EGFR-Dependent Resistance Mechanisms</h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">3.1.1.  C797S Mutation</h4><div class="NLM_p">The circulating tumor DNA from the plasma of patients with T790M-positive NSCLC enrolled in the AURA3 trial sheds light on EGFR-dependent mechanisms of resistance to Osimertinib.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> One of the dominant mechanisms of resistance to targeted therapy is the sustained mutation of the targeted gene. The most common tertiary EGFR mutation is EGFR C797S, and the first evidence of this mutation was observed in NSCLC patients by Thress et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> They examined the plasma samples from 19 patients who had developed a resistance to Osimertinib and found that six of them had developed the C797S mutation. The C797S mutation disrupts the covalent bond between Osimertinib and the mutant EGFR, affecting 10–26% of patients.</div><div class="NLM_p">The C797S mutation, as anticipated, confers a cross-resistance to other irreversible third-generation TKIs, including Rociletinib, Olmutinib, and Nazartinib, by preventing them from binding to the EGFR active site.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> These mutations are thought to be responsible for steric interference, leading to the compound’s diminished affinity for the EGFR kinase domain.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a></div><div class="NLM_p last">The C797S mutation occurs in <i>cis</i>- (on the same allele) or <i>trans</i>-forms (on different alleles), according to <i>in vitro</i> studies (on separate alleles), and no EGFR TKIs alone or in combination is able to suppress activity when the mutation is in the <i>cis</i>-form.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49 ref50 ref51 ref52">(46−52)</a> Thus, C797S is a prone candidate for a mutation-mediated resistance.<a onclick="showRef(event, 'ref53 ref54 ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55 ref56 ref57">(53−57)</a></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">3.1.2.  Mutations in L718</h4><div class="NLM_p"><i>In vitro</i> and <i>in vivo</i> studies showed that a mutation in the L718 residue causes Osimertinib resistance.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The majority of patients with L718 mutations do not coexist with C797 mutations, indicating that such mutations may result in Osimertinib resistance independently.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p last">The EGFR L718Q mutation was first noted in a metastatic NSCLC patient (treated with Osimertinib) who had parallel EGFR L858R and T790M mutations.<a onclick="showRef(event, 'ref44 ref58'); return false;" href="javascript:void(0);" class="ref ref44 ref58">(44,58)</a> In a cohort study, EGFR L718Q mutations were identified in seven cases (8%), among which five cases did not have a coexisting T790M mutation.<a onclick="showRef(event, 'ref44 ref58'); return false;" href="javascript:void(0);" class="ref ref44 ref58">(44,58)</a> The L718 mutation is found inside the p-loop and interacts directly with the aniline ring of Osimertinib in the EGFR kinase domain of the ATP binding site. According to an <i>in silico</i> modeling study, substitution in this residue area can result in spatial restriction, preventing Osimertinib from binding to EGFR.<a onclick="showRef(event, 'ref44 ref58'); return false;" href="javascript:void(0);" class="ref ref44 ref58">(44,58)</a> Currently, there are no actionable treatment strategies available to overcome Osimertinib resistance mediated by the EGFR L858R/L718Q co-mutation.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> However, <i>in vitro</i> studies have shown that L718Q is still sensitive to first- and second-generation EGFR-TKIs, particularly when T790M is missing; this finding was confirmed in the clinical setting.<a onclick="showRef(event, 'ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61 ref62 ref63">(59−63)</a></div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">3.1.3.  Mutations in L792</h4><div class="NLM_p last">A number of hinge-region mutations in the L792 residue were identified, the most common of which is L792H. The L792 mutation usually co-exists with other EGFR mutations and exists in the <i>cis</i>-form with T790M and in the <i>trans</i>-form with G796/C797.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a><i>In silico</i> modeling disclosed that the mutations in the L792 residue sterically clash with a methoxy group of the phenyl ring present in Osimertinib, buckling its attachment to the kinase domain.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> In addition, <i>in vitro</i> L792 mutant variants remained susceptible to Gefitinib.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">3.1.4.  Mutations in G796</h4><div class="NLM_p last">Solvent-front mutations in the G796 residue (G796R, G796S, and G796D) adjacent to the C797 residue can sterically disrupt the Osimertinib–EGFR interaction. The G796R have a major impact on Osimertinib–EGFR binding, while G796S has a milder effect.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In Osimertinib-resistant patients, another EGFR G796D mutation was also observed, and EGFR G796D-driven cell proliferation was not inhibited by Osimertinib.<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a></div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.1.5.  Mutations in G724</h4><div class="NLM_p last">After being transferred to Osimertinib, some patients developed a G724S mutation in the EGFR kinase domain’s p-loop.<a onclick="showRef(event, 'ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73 ref74">(71−74)</a> The G724S mutation causes a conformational alteration in the receptor, impairing Osimertinib binding. Due to the lack of evidence, the prevalence of this unusual mutation after Osimertinib treatment is not clear.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> G724S-mediated resistance is thought to occur preferentially in ex19del but not L858R, thus operating in an allele-specific manner.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In G724S mutants, second-generation EGFR-TKIs remarkably have an affinity with the G724S mutation, and Afatinib is effective in overcoming the G724S-driven resistance <i>in vitro</i>.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">3.1.6.  T790M Loss, Reduction, or Disappearance</h4><div class="NLM_p">Acquired resistance to Osimertinib arbitrated by a loss of the T790M mutation is consistent with the initial resistance and a range of competing mechanisms. Kim et al. reported that after switching to Osimertinib, 4 of 15 (4/15) T790M-positive patients lost T790M plasmatic expression, while the remaining patients were positive for the EGFR activating mutation.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Chia et al. also reported T790M disappearance in two patients treated with Osimertinib.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p last">Oxnard Geoffrey and collaborators performed a cohort study using “next-generation sequencing” on tumor biopsy samples after the emergence of an acquired resistance to Osimertinib in 143 patients and found that the loss of the EGFR T790M mutation was common in Osimertinib resistance.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Second-line Osimertinib causes a loss of the T790M mutation, which is commonly associated with the development of KRAS mutations, gene fusions, small cell transformation, and mesenchymal epithelial transition factor (MET) amplification.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.2.  EGFR-Independent Resistance Mechanism</h3><div class="NLM_p">EGFR-independent mechanisms include a bypass pathway, activation or alternative pathway activation, and downstream signaling pathway activation.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> A number of RTKs follow the same downstream paths as EGFR-RTK.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Another RTK activation will transactivate the EGFR pathway, resulting in cell resistance to EGFR-TKIs.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Importantly, these mutations can coexist with EGFR tertiary mutations within the same tumor, demonstrating the ambiguity and heterogenecity of cancer evolution against the EGFR-TKIs.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.2.1.  MET Amplification</h4><div class="NLM_p">The MET receptor, a transmembrane tyrosine kinase encoded by proto-oncogene MET, has been shown to be an important reason for the acquired resistance of NSCLC TKIs.<a onclick="showRef(event, 'ref84 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref84 ref85 ref86">(84−86)</a> Hepatocyte growth factor (HGF) binding to the MET receptor elicits the phosphorylation of the MET tyrosine kinase and consequently triggers the activation of the downstream PI3K/AKT/mTOR pathway, which is the vital signaling pathway for cell proliferation, survival, and anti-apoptosis.<a onclick="showRef(event, 'ref87 ref88 ref89 ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89 ref90 ref91 ref92">(87−92)</a> Amplification of the MET gene is the most frequently observed mechanism of acquired resistance to EGFR-TKIs.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> This event triggers Osimertinib resistance by inducing downstream EGFR signaling pathways such as “Signal Transduction and Activator of Transcription (STAT), MAPK, and phosphatidylinositol 3-kinase (PI3K)–AKT ”, which are unaffected by EGFR activation and signaling.<a onclick="showRef(event, 'ref94 ref95 ref96 ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref94 ref95 ref96 ref97 ref98">(94−98)</a></div><div class="NLM_p">In a patient treated with Osimertinib, Planchard et al.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> reported the first signs of MET amplification. They discovered significant MET amplification (cMET/CEP7:5.32) in patients treated with Osimertinib for 10 months before pulmonary disease progression, which was validated by comparative genomic hybridization (CGH) and immunochemistry.</div><div class="NLM_p">The genomic profile of pre- and post-Osimertinib tumors was correlated by Ou et al.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> indicating that MET amplification is a mechanism of acquired resistance to third-generation EGFR-TKIs. They observed a high degree of MET amplification (30 copies) in Osimertinib-treated patients as well as a 21% EGFR T790M mutation prior to beginning Osimertinib and just 3% mutation in the post-Osimertinib progression study. Clinically, the tumor grew rapidly within two months, indicating MET amplification as a potential mechanism for tumor development.</div><div class="NLM_p last">Ortiz-Cuaran et al. found a substantial level of MET amplification in the pre- and post-tumor biopsy samples of a patient that was resistant to the Rociletinib and Osimertinib, respectively, after disease stabilization.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Their <i>in vitro</i> study supports the evidence of HER2 and MET amplification, confirming the inherent and acquired resistance to Osimertinib and third-generation TKIs.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> If Osimertinib is given after a failure result for prior EGFR TKIs, MET amplification can occur with or without the loss of T790M.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.2.2.  HER2 Amplification</h4><div class="NLM_p last">HER2 (ErbB2) is an EGFR-family tyrosine kinase receptor that activates the downstream PI3K–AKT and (MEK)–ERK/MAPK pathways.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Amplification of the HER2 (ErbB2) gene family is another Osimertinib resistance mechanism.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Exogenous expressions of HER2 in PC9 Gefitinib-resistant cells are associated with a decreased sensitivity to the third-generation EGFR inhibitors.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Furthermore, HER2 amplification can co-occur with EGFR G796S+MET amplification (1%), “EGFR L792X+C797X+PIK3CA amplification” (1%), and PIK3CA amplification (1%).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> HER2 amplification was first identified by Planchard et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> as a possible mechanism of acquired resistance to a third-generation TKI. A similar kind of study of HER2 amplification was also reported by Oxnard et al.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> in 2 patients among the 40 patients who were treated with Osimertinib. Ortiz-Cuaran et al.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> studied the impact of HER2 overexpression on Osimertinib and Rocletinib sensitivity in the PC9 cell line and found that the overexpression of HER2 was less sensitive to both drugs.</div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">3.2.3.  RAS-(ERK)MAPK Pathway Activation</h4><div class="NLM_p last">The KRAS mutation is related to the activation of the RAS-MAPK pathway, and KRAS amplification, KRAS mutation, and NRAS, MEK1, and BRAF mutation have all been linked to an acquired resistance to Osimertinib.<a onclick="showRef(event, 'ref107 ref108 ref109 ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref107 ref108 ref109 ref110 ref111">(107−111)</a> G12S, G12D, G12A, Q61H, and A146T are all KRAS mutants.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> In preclinical models, NRAS mutations (E63K) were identified after treatment with Osimertinib.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> A combination of MEK inhibitor, EGFR-TKI, and Selumetinib demonstrated the sensitivity in resistant cell lines.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111,112)</a> Osimertinib resistance has been linked to a mutation in the BRAF gene (V600E).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.2.4.  Phosphatase and Tensin Homolog (PTEN) Deletion</h4><div class="NLM_p last">PTEN is a tumor suppressor gene that shares sequence homology with protein tyrosine phosphatases and is located on chromosome 10q23.3.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The PTEN gene is inactivated by mutation, homozygotic deletion, methylation, and translational modification in various types of human tumors.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The PI3K/AKT signaling pathway is negatively regulated by it.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> When the PTEN function is lost, the expression of PIP-3 (a PI3K product) increases, resulting in AKT hyperactivation. PTEN loss has been linked to the development of EGFR-TKI resistance in certain tumor cell lines.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> PPAR agonist drugs, such as rosiglitazone, have recently been shown to sensitize PTEN-deficient lung cancer cells (human) to EGFR-TKI by causing autophagy.<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116,117)</a></div></div><div id="sec3_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.5.  PI3K/AKT/mTOR Pathway Activation</h4><div class="NLM_p">The PI3K/AKT/mTOR signaling pathway downstream of the RTKs plays a crucial role in promoting the proliferation, survival, and drug resistance of cancer cells.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Activating mutations of the PI3K lipid kinase family’s catalytic subunit-α (PIK3CA) through the PI3K/AKT/mTOR pathway describes 3% of the lung adenocarcinoma in a non-mutually exclusive way to those of other oncogenic drivers.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> Both PIK3CA mutation or amplification and PTEN deletion will result in a bypass activation of the PI3K pathway.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p last">Despite the fact that concomitant PIK3CA mutations are weak foreboding factors, no substantial differences in clinical results were observed in patients with concomitant PIK3CA and EGFR mutations treated with EGFR-TKI monotherapy, suggesting that EGFR-TKIs should be used in such patients.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> E545K, E542K, R88Q, N345K, and E418K are among the known PIK3CA mutations that impart a resistance to second-line Osimertinib therapy. They occur at a frequency of 4–11%.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div></div><div id="sec3_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.6.  Growth Arrest-Specific 6 (GAS6)/Anexelekto (AXL) Activation</h4><div class="NLM_p last">GAS6 is a ligand for the AXL receptor tyrosine kinase. The stimulation of the AXL by GAS6 triggers the MEK/ERK and PI3K/AKT pathways as well as an acquired resistance to EGFR-TKIs.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> In addition, GAS6/AXL triggering is often followed by EMT.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Foretinib, a VEGFR/MET/AXL inhibitor, enabled EGFR-TKI-resistant cells to regain partial sensitivity.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Furthermore, various AXL inhibitors are currently being developed for the treatment of NSCLC, including multitarget kinase inhibitors (Cabozantinib, S49076, MGCD265, MGCD516, and ASLAM002) and a specific AXL inhibitor (BGB324).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div></div><div id="sec3_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">3.2.7.  Fibroblast Growth Factor Receptor (FGFR) Amplification</h4><div class="NLM_p">FGR receptor 1 (FGFR1) amplification was seen as an acquired resistance mechanism in a patient who had disease progression on Osimertinib. Kim et al. reported a patient treated with Osimertinib that was identified with autocrine loop-mediated resistance FGF2/FGFR1.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The Osimertinib-resistant tumor harbored a focal amplification of the FGFR1 gene that exhibited about 20 times more FGF2 mRNA contrast with that of the baseline tumor.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In post-Osimertinib tumors, Next Generation Sequencing (NGS) analysis revealed the loss of the EGFR T790M mutation, where supplementing EGFR-mutant NSCLC cells with FGF2 conferred a resistance to Osimertinib.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p last">Quintanal-Villalonga et al. performed an experiment based on FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in mortalized lung cell lines.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> They provided <i>in vitro</i> and <i>in vivo</i> evidence showing that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in mutated EGFR and WT EGFR models. They described that, besides EGFR, the FGFR family is involved in the progression of a variety of cancers in lung cancer in which the amplification of the gene is frequently observed through the activation of relevant signaling pathways, such as STAT, AKT, and MAPK, in various types of lung cancer.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> On the basis of such findings, they conclude that FGFR1 overexpression in EGFR-mutated models produced an increase in tumorigenicity both <i>in vivo</i> and <i>in vitro</i>, which was accompanied by the activation of EGFR and downstream signaling.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div></div><div id="sec3_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">3.2.8.  Insulin-Like Growth Factor (IGF) Upregulation</h4><div class="NLM_p last">IGF1R (insulin-like growth factor receptor 1) is a transmembrane heterotetrameric protein that promotes the genetic transformation, survival, and growth of cancer cells.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways are activated by IGF1R. In the absence of the EGFR T790M mutation, IGF1R plays a crucial role in advancing Gefitinib resistance.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Furthermore, in EGFR T790M-mutated lung cancer cell lines, IGF1R is linked to building resistance to second-generation irreversible EGFR-TKI.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> It has been stated that the small-molecule inhibitor of IGF1R (AG-1024) or the monoclonal anti-IGF1/2 blocking antibody (BI 836845) may restore the sensitivity to third-generation EGFR-TKI therapy.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div></div><div id="sec3_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">3.2.9.  Cell-Cycle Gene Alterations</h4><div class="NLM_p last">Twelve patients who were treated with Osimertinib as a first-line and second-line therapy had changes in the genes that encode cell-cycle proteins.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Several studies have found an augmentation in the genes that encode cyclin E1, cyclin D1, cyclin D2, cyclin-dependent kinase 4 (CDK4), and CDK6 as well as a frameshift deletion in the CDK inhibitor 2A gene.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div></div><div id="sec3_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.2.10.  Oncogenic Fusions</h4><div class="NLM_p last">Oncogenic fusions have been found in 3–10% of cases of acquired resistance to Osimertinib and can co-exist with EGFR C797S mutations, MET amplification, and BRAF mutations.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> FGFR3–TACC3, NTRK1–TPM3, RET–ERC1, CCDC6–RET, GOPC-ROS1, AGK–BRAF, NCOA4–RET, and ESYT2–BRAF are oncogenic fusions that may be accountable for the acquired resistance to Osimertinib.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Patients who received front-line Osimertinib treatment had an oncogenic fusion SPTBN1–ALK, whereas those who received the second-line Osimertinib treatment did not.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In patients with advanced NSCLC, RTK fusions and BRAF kinase fusions were reported as rare incidences that interceded resistance to TKIs, including a novel PLEKHA7–ALK fusion following Osimertinib therapy, according to a report.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div></div><div id="sec3_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.2.11.  The Src-AKT Pathway</h4><div class="NLM_p last">Both activations of the Src-AKT pathway and the amplification of the WT EGFR will lead to the resistance to third-generation EGFR TKIs.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The amplification of the WT EGFR allele induces a resistance to the mutation-selective EGFR inhibitors by the activation or an EGFR ligand-induced activation mechanism.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Intrinsic resistance to first-, second-, and third-generation EGFR TKIs can be caused by STAT3 and Src-YAPI activation.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> In Osimertinib-sensitive cells, both focal adhesion kinase (FAK) and Src family kinases (SFKs) play an important role in assisting the AKT and MAPK pathways when EGFR is inhibited.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> In NSCLC cell lines, the augmentation of the SFK member YES1 has been identified as a mechanism of resistance to Osimertinib, and inhibiting SFK or FAK signaling enhanced Osimertinib’s effects <i>in vitro</i>.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a></div></div><div id="sec3_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">3.2.12.  JAK2/STAT3 Pathway</h4><div class="NLM_p last">In addition to the RAS/RAF/MAPK and PI3K/ARK pathways, the STAT protein, particularly STAT3, was stated to be another critical downstream signal transducer to activate EGFR.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The disproportionate activation of STAT3 was observed in lung cancer patients at a high (50%) frequency.<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> Zhao et al. published the clinical significance of JAK2/STAT3 during angiogenesis in NSCLC.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Recently, Chaib and collaborators<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> showed that treatment with Osimertinib results in the activation of not only STAT3 but also SrcYAP1 signaling, potentially operating downstream of IL-6 to promote cell survival.</div></div><div id="sec3_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">3.2.13.  Histologic and Phenotypic Transformation</h4><div class="NLM_p last">The histologic conversion of NSCLC to SCLC observed in 4–15% of patients is a recognized mechanism of resistance to first-generation EGFR-TKIs and has been established as a major cause of Osimertinib resistance.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> The mechanistic basis for the SCLC transformation is still largely unclear, but retinoblastoma gene (RB) loss could play a significant role.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> RB deficiency is common in SCLC, and primary evidence indicates that chronic EGFR inhibition in NSCLC triggers the emergence of SCLC-like histologic, genetic, and drug susceptibility profiles. The EMT has also been related to the small cell transformation, as demonstrated by low E-cadherin levels and increases vimentin expression.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The activation of AXL kinases can also trigger EMT.<a onclick="showRef(event, 'ref139 ref140 ref141 ref142 ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref139 ref140 ref141 ref142 ref143 ref144">(139−144)</a> Patients with this type of cancer can recover from platinum-based chemotherapy treatments, which are commonly used in the treatment of SCLC.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">4.  Emerging Therapeutic Strategies to Overcome EGFR-Dependent Osimertinib Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In advanced NSCLC patients, the promising findings with Osimertinib eventually lead to resistance due to the heterogeneous conditions of NSCLC.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The intrapatient heterogeneity of multiple resistance mechanisms and their co-occurrence pose a significant challenge in establishing an effective treatment strategy to impede tumor progression.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Osimertinib resistance is highly efficient in cancer treatment, particularly targeting specific mutations that primarily drive tumorigenesis.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> The majority of recent research has focused on using combination therapy to overcome EGFR tertiary mutations and alternative kinase activation.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> To date, no single drug or combination of therapeutic strategies for the treatment of Osimertinib resistance have been approved.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Here, we have summarized the emerging strategies to overcome Osimertinib resistance using different reported approaches (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Different strategies to overcome the acquired resistance to Osimertinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.1.  Strategies to Overcome the <i>cis</i>-C797S Mutation</h3><div class="NLM_p">If the T790M/C797S mutation is in the <i>cis</i>-form, that is, on the same DNA strand, it results in cells that are resistant to all existing three-generation TKI and prevents the suppression of EGFR.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49 ref50 ref51 ref52">(46−52)</a></div><div class="NLM_p">Uchibori et al. reported the Brigatinib (<b>1</b>), a dual-targeting inhibitor of the anaplastic lymphoma kinase ALK/EGFR, prevents cancer development in cells with EGFR Del19/T790M/<i>cis</i>-C797S triple mutations.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> They have conducted intensive drug screening, including 30 drugs, to evaluate their effectiveness against triple-mutant EGFR. Among them, Brigatinib (<b>1</b>) significantly suppressed the proliferation of Ba/F3 cells harboring the triple mutation, with approximately 50% growth inhibition at 100 nM. The <i>in vivo</i> and <i>in vitro</i> assays revealed that Brigatinib potently suppressed the growth of Ba/F3 cells expressing the triple-Del19 mutation with an IC<sub>50</sub> of 67.2 nM. Brigatinib (<b>1</b>) shows a synergy with the antibody Cetuximab and significantly reduces the IC<sub>50</sub> value against triple-Del19 Ba/F3 cells (IC<sub>50</sub> = 30 nM) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Activity profile and binding mode of Brigatinib. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> under Creative Commons CC BY 4.0. Copyright 2017, Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding approach revealed that Brigatinib (<b>1</b>) fit into the ATP binding pocket of EGFR triple-mutant Del19/T790M/C797S without sterically crowding T790M or C797S, forming bidentate hydrogen bonds with the backbone amide of the hinge residue Met793. Brigatinib’s effect, on the other hand, has not been documented in clinical practice.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p">Zhao et al. described the case of a lung cancer patient that had EGFR mutations of L858R/T790M/<i>cis</i>-C797S and was treated with the Osimertinib, Brigatinib, and Bevacizumab combination.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> From a circulating tumor DNA study, they have identified three mutations (Exon-21 has a 6% L858R mutation, Exon-20 has a 1.7% T790M mutation, and Exon-20 has a 0.6% <i>cis</i>-C797S mutation) after the administration of Osimertinib. A combination therapy of Osimertinib and the monoclonal antibody Bevacizumab was given to this patient, which resulted in partial relief or temporary stabilization, which then abrogated later as the disease progressed. As a result, Osimertinib, Bevacizumab, and Brigatinib were added to the combination regimen. EGFR mutations were significantly suppressed in a CT scan taken after two months of this combination therapy (shrinkage abundances were as follows: EGFR Exon-21 had a 2.7% L858R mutation, Exon-20 had a 1.6%, and Exon-20 had a 0.2% <i>cis</i>-C797S mutation). Remarkably, the prevalence of the <i>cis</i>-C797S mutation was reduced by 0.33 -fold. This is the first confirmation that the Osimertinib, Bevacizumab, and Brigatinib combined therapy is effective for pulmonary adenocarcinoma with EGFR ternary mutations (L858R/T790M/<i>cis</i>-C797S).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">Engelhardt et al. discovered the benzimidazole derivative BI-4020 (<b>3</b>), a noncovalent, mutant selective, and macrocyclic TKI.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Initially, they identified amino-benzimidazole (<b>2</b>), which had highly selective but moderate EGFR Del19/T790M/C797S inhibition activity, from the selective screening of the kinase inhibitor library. Afterward, highly active noncovalent EGFR inhibitor BI-4020 (<b>3</b>) was generated by the macro-cyclization of compound (<b>2</b>), which imparted the molecule with fully rigidity. Surprisingly, one more improvement in Ba/F3 cell antiproliferation was identified with ligand BI-4020 (<b>3</b>) (IC<sub>50</sub> EGFR Del19/T790M/C797S = 0.2 nM), which displayed a subnanomolar activity. The BI-4020 (<b>3</b>) compound suppressed complex EGFR mutations (L858R/T790M/<i>cis</i>-C797S) with an EGFR Del19 background. In general, BI-4020 (<b>3</b>) has highly active single-digit nanomolar antiproliferative activity against EGFR-mutant-dependent EGFR-TKI, with an excellent <i>in vitro</i> and <i>in vivo</i> activity (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rational design of macrocyclic BI-4020 (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.2.  Strategies to Overcome the <i>trans</i>-C797S Mutation</h3><div class="NLM_p">Osimertinib resistance caused by the <i>trans</i>-C797S mutation can be overcome by the following two approaches based on the binding mode to the kinase site: an either ATP-competitive inhibitor or a non-ATP competitive inhibitor or allosteric inhibitor.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">4.2.1.  ATP-Competitive Inhibitors</h4><div class="NLM_p">ATP-competitive inhibitors form from one to three hydrogen bonds to the amino acids situated in the hinge region of the target kinase, thereby mimicking the hydrogen bonds that are normally formed by the adenine ring of ATP.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> When high physiological or intracellular concentrations of ATP exist, may lead to the blocking of the phosphotransferase activity of their targets.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Here, we have reviewed the recently published ATP-competitive inhibitors against triple-mutant EGFR.</div><div class="NLM_p">Lu et al.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> screened an in-house kinase inhibitor library comprised of around 3000 compounds and reported the pyrimido-pyrimidinone derivative JND3229 (<b>4</b>) as an EGFR L858R/T790M/C797S inhibitor with a single-digit nanomolar potency. The ELISA assay of JND3229 (<b>4</b>) displayed a strong inhibitory effect toward the EGFR L858R/T790M/C797S, with an IC<sub>50</sub> value of 5.8 nM. To explore its potential, JND3229 (<b>4</b>) was further evaluated to suppress EGFR signals in transfected Ba/F3 cells with the EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S mutations, which revealed that JND3229 (<b>4</b>) strongly abolished the proliferation of mutations with IC<sub>50</sub> values of 510 and 320 nM, respectively.</div><div class="NLM_p">Docking simulations of JND3229 (<b>4</b>) suggested that it was situated in the ATP binding area of EGFR C797S with a “U-shaped” configuration. The JND3229 (<b>4</b>) central scaffold of pyrido-2,3-pyrimidine-7-one interacted with hinge region residue of Met793 via bidentate hydrogen bonding. The 2-chlorophenyl group was positioned in the hydrophobic back pocket, which included Lys745, Glu762, Leu788, Met766, and the mutant Met790 residues, while the pyrido-2,3-pyrimidine-7-one carbonyl group showed water-mediated hydrogen bonding with Lys745. The propionamide side chain was situated in a solvent-exposing area and interacted with Leu718 via a water-mediated hydrogen bond (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Biological data and binding mode of <b>JND3229</b> with EGFR L858R/T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>.)<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Engel et al.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> reported the novel class of covalent 4-amino pyrazolo-pyrimidine derivatives to target EGFR drug-resistant mutants. To avoid steric interference with the hydrophobic nature of the mutated gatekeeper residue methione 790, they employed the more lipophilic interaction group to enhance not only the affinity but also the selectivity toward the secondary T790M mutant variant of EGFR. They assessed the inhibitory activity of the synthesized 4-amino pyrazolo-pyrimidine derivatives in an activity-based assay with respect to that of WT EGFR, the activating mutation (EGFR L858R), the acquired drug-resistant mutant variants of EGFR L858R/T790M and EGFR L858R/T790M/C797S. Among them, compound <b>5</b> with a 2-naphthalene moiety showed potent enzymatic activity against the EGFR L858R/T790M/C797S drug resistance mutation, with an IC<sub>50</sub> value of 88 nM (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The compounds showed significant activity with a strong selectivity over WT EGFR against EGFR L858R and EGFR L858R/T790M.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure of compound <b>5</b> with its enzymatic activity against WT EGFR and L858R/T790M/C797S EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding mode analysis of compound <b>5</b> showed that the naphthyl group was sandwiched between Met790 and Lys745 and created beneficial lipophilic interactions with Met790, which suggested the promising affinity of this compound toward the T790M mutant variant of EGFR. Remarkably, this compound may potentially provide a significant opportunity to target acquired secondary T790M and tertiary C797S mutations with a single drug.</div><div class="NLM_p">Gunther et al.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> developed a new generation of triple-mutant EGFR inhibitors through the kinase selectivity screening of a strongly potent p38α MAP kinase inhibitor (<b>6</b>) with strong reversible binding properties. Previously, compound <b>6</b> was identified as an EGFR inhibitor as an off-target effect of this compound; additionally, its low toxicity and moderate physicochemical properties were reported by Selig et al.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p">Therefore, Gunther and his colleagues scrutinized around two thousand known compounds that had similar structures to that of <b>6</b> in an activity-guided screening against WT EGFR and identified compound <b>7</b> (WT EGFR IC<sub>50</sub> = 287 nM) as a potential lead structure for further optimization (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Lead structure compound <b>7</b> obtained from a WT EGFR enzyme assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among the synthesized compounds (analogs of compound <b>7</b>), the two inhibitors, <b>8</b> and <b>9</b>, showed the most potent enzymatic activity toward the cysteine-mutated L858R/T790M/C797S EGFR, with IC<sub>50</sub> values of 21 and 90 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). These compounds have a strong affinity for the active site of EGFR, indicating that imidazole may be a useful scaffold for fourth-generation inhibitors; however, further work is required to minimize inhibitory activity against the WT EGFR.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of <b>8</b> and <b>9</b> and their kinase-inhibitory activities against drug-resistant mutant variants of EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Juchum et al.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> synthesized a series of single-digit nanomolar-potent trisubstituted imidazoles with a hinge binding motif of 7-azaindole against the clinically challenging L858R/T790M/C797S mutant EGFR through target hopping strategies from compound <b>10</b>. The purpose of their studies was to optimize the well-known p38α MAPK inhibitor <b>10</b> to a novel class of EGFR inhibitors with high binding affinities toward undruggable NSCLC mutants (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Development of potent EGFR L858R/T790M/C797S inhibitors by the target hopping approach from p38α MAPK inhibitor <b>10</b> templates. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>. Copyright 2017, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">They altered the phenolic group of <b>10</b> to aliphatic alcohol chains that yielded the potent compounds <b>11</b> (2-hydroxypropyl) and <b>12</b> (4-hydroxybutyl), which inhibit the enzymatic activity of triple-mutant EGFR L858R/T790M/C797S with IC<sub>50</sub> values of 7.64 and 8.83 nM, respectively. The binding approach of <b>12</b> shows that the rigid azaindole ring interacts with Met793 via bidentate hydrogen bonding, and the 4-fluorophenyl group is directed toward the hydrophobic residue Met790 (HR I). The phenyl ring at the 2-position of 7-azaindole reaches toward the hydrophobic region II (HR II). Additionally, aliphatic alcohol chains have beneficial hydrophilic interactions with the phosphate-binding motif Asn842, which are expected to enhance the inhibitory activity (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of <b>11</b> and <b>12</b> with biological data against EGFR L858R/T790M/C797S and the binding mode of <b>12</b> at the ATP binding site. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>. Copyright 2017, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Engel et al.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> explained that more contacts between the compound and the ATP binding site minimize the covalent dependency for inhibitory activity and thus provide efficacy against the mutant EGFR L858R/T790M/C797S variant. Following this notation, Marcel Gunther et al.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> synthesized trisubstituted pyridinyl-imidazoles with an affinity to bind both hydrophobic regions and the phosphate-binding site of clinically resistant EGFR L858R/T790M/C797S (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of <b>13</b>, <b>14</b>, and <b>15</b> along with inhibitory activities toward EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The group studied the effect of both aliphatic and aromatic groups that may reach HR I (whose entry is restricted by the mutated Met790 gatekeeper residue), the aromatic moiety inhabiting HR II, and various H bond acceptors and donors that enhance inhibitory activity through interactions with the phosphate-binding site (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Binding mode of compound <b>13</b> occupying the ATP binding site (HR, hydrophobic region).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">They used molecular modeling to study all three substitution positions of the imidazole scaffold and created compounds with different noncovalent polar and hydrophobic interactions with different regions inside the ATP binding site. They were able to develop reversible interactions with this approach, resulting in metabolically stable inhibitors with improved activities against the EGFR L858R/T790M/C797S mutation. They synthesized the 40 compounds and studied the SARs; among them, compounds <b>13</b>, <b>14</b>, and <b>15</b> exhibited high cellular activity against the triple-mutant EGFR L858R/T790M/C797S, with an IC<sub>50</sub> values of 8, 7, and 11 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div><div class="NLM_p">Their synthesized compounds had the following three interaction patterns: (i) an aminopyridine group responsible for a bidentate hydrogen bonding to hinge residue Met793, (ii) hydrophobic residues that invaded HR II and HR I, and (iii) a polar side chain that reached the phosphate-binding site. Docking simulations indicate that the fluorophenyl group of compound <b>13</b> is situated at HR I, which is composed of different hydrophobic residues. The aminopyridine moiety forms bidentate hydrogen bonds with the hinge region. Similarly, two hydrogen bonds can be seen among the carbonyl group of the acrylamide functionality and the mutated Ser797 amino acid. Additionally, the hydroxyl group of <b>13</b> displayed polar interactions with the Arg841 amino acid of the phosphate-binding site (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</div><div class="NLM_p">Park et al.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> reported the discovery of 2-aryl-4-aminoquinazoline derivatives as a new generation EGFR inhibitors that are mutant-selective with a high activity toward the Del19/T790M/C797S mutation by a two-track virtual screening approach. To identify mutant-selective inhibitors, they screened around 330 000 druggable compounds through the docking study at the ATP binding site of the WT EGFR and the EGFR with the Del19/T790M/C797S mutation, which resulted in 38 compounds that met the filtration criteria. The inhibitory activity of these compounds against the Del19/T790M/C797S mutant and the WT EGFR yielded five compounds, one of which, compound <b>16</b>, significantly suppressed the EGFR Del19/T790M/C797S kinase (IC<sub>50</sub> value of 149 nM) with a 163-fold selectivity toward the WT EGFR. Inspired by the structural and dynamic features of compound <b>16</b>, they optimized its structure on the terminal phenyl and pyridine rings to strengthen the interactions at the EGFR ATP binding site that targets the pocket made by Lys745, Val726, Asp855, Thr854, and Met790 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a> and <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>).</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Biological activity profile of compounds <b>16</b>–<b>19</b> against Del19/T790M/C797S EGFR TK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of <b>19</b> and its illustrated binding interaction with EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a>. Copyright 2018, American Chemical Society”).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Remarkably, the introduction of nitrile (<b>17</b>) or methyl ester (<b>18</b>) moieties at the terminal phenyl resulted in potent compounds. Replacing the terminal pyridine ring in 1<b>6</b> with pyrazine and nitrile on the terminal phenyl (<b>19</b>) resulted in a greater than 1000-fold selectivity to the wild-type triple-mutant’s compounds (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a> and <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>).</div><div class="NLM_p">The binding interaction of <b>19</b> indicates the terminal phenolic moiety, showing two hydrogen bonds with Met-793 and Gln-791. Additionally, the pyridin-3-yl-methylamine moiety interacted with mutated Ser797 via two more hydrogen bonds, which iscrucial for the inhibitory activity as well as the triple-mutant specificity (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a> and <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>).</div><div class="NLM_p">Shen et al,<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> reported 5-methyl-pyrimidopyridone derivatives as novel selective triple-mutant EGFR L858R/T790M/C797S inhibitors. Previously, they reported a pyrimido-pyrimidinone derivative, JND3229, with a low selectivity toward the mutant EGFR, which may raise some concerns related to EGFR mechanism-associated toxicity. The binding mode of the JND3229-EGFR T790M/C797S complex showed a “U-shaped” configuration in an ATP binding pocket similar to that of the EGFR T790M-selective irreversible inhibitor <b>20</b> reported by Yu et al.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The 5-methyl substituent of <b>20</b> was moved toward the gatekeeper residue Met790, giving significant mutant EGFR T790M selectivity to the WT EGFR.</div><div class="NLM_p">The superimposition of compound <b>20</b> and JND3229 (<b>4</b>) revealed that the 5-methylpyrido-2,3-dipyrimidin-7-one scaffold of <b>20</b> was overlaid with the pyrimido-4,5-<i>d</i>-pyrimidine-7-one core of JND3229 in the EGFR T790M/C797S complex (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). Based on such observations, a series of 5-methyl pyrimidopyridone derivatives was designed and synthesized to maximize the mutant selectivity of this class to the wild-type EGFR.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of JND3229 (<b>4</b>) and the irreversible inhibitor <b>20</b> and the superimposition of JND3229 (<b>4</b>) with <b>20</b> in EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>). Reprinted (adapted) with permission from ref <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the synthesized series of 5-methyl-pyrimidopyridone derivatives, compound <b>21</b> exhibited an excellent enzymatic activity on the EGFR L858R/T790M/C797S triple mutant with an IC<sub>50</sub> value of 27.5 nM and was identified as nearly inactive against the WT EGFR kinase (IC<sub>50</sub> > 1000 nM). Additional biological analysis validated that compound <b>21</b> moderately suppressed EGFR signaling activation in Ba/F3 cells (EGFR L858R/T790M/C797S) with an IC<sub>50</sub> value of 662 nM (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Biological activity profile of compound <b>21</b> and its binding mode with EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>). Reprinted (adapted) with permission from ref <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular docking simulations indicated that compound <b>21</b> was bound with “U-shaped” confirmation in the ATP binding pocket of EGFR T790M/C797S and WT EGFR (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). The 5-methyl pyrimido-pyrimidinone core developed bidentate hydrogen bonding interactions with the hinge residue Met793, while the 6-(2-chloro-3-fluoro)-phenyl group headed toward the hydrophobic pocket made up of Lys745, Glu762, Leu788, Met766, and the mutated gatekeeper residue Met790. The 4-methylpiperazinyl phenyl tail and the propionyl-piperidine group entered directly into the solvent surface.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Crystallographic structure of compound <b>21</b> with (A) EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ">6JRJ</a>) and (B) WT EGFR (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK">6JRK</a>). Reprinted (adapted) with permission from ref <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Zhang et al.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> discovered pyrido[3,4-<i>d</i>]pyrimidine derivatives as a fourth generation EGFR TKIs for the first time, where they replaced previously reported EGFR-TKIs that contained a 2-phenylamino-pyrimidine or 2-phenylamino-heterocycle-pyrimidine skeleton with 6-phenylamino-pyrido[3,4-<i>d</i>]pyrimidine. Using the scaffold hopping approach, they designed compound <b>22A</b> from compound <b>22</b>. Accordingly, compound <b>22B</b> was designed, where the crucial hydrogen bonding was observed between pyridine-2-ylamino-pyrido[3,4-<i>d</i>]pyrimidine scaffold and the Met793 residue of the hinge region (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Design strategy of 2,4,6-trisubstituted pyrido[3,4-<i>d</i>]pyrimidine derivatives (<b>22B</b>) from previously reported EGFR-TKIs compound <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on such a designing strategy, compound <b>23</b> was synthesized and found to possess a moderate inhibitory activity against HCC827 and H1975 cells, with IC<sub>50</sub> values of 40 and 400 nM, respectively. Compound <b>23</b> is also considered to be the most promising one, potentially inhibiting the triple-mutant EGFR L858R/T790M/C797S with an IC<sub>50</sub> value of 7.2 nM.</div><div class="NLM_p">The docking study of compound <b>23</b> revealed that the 6-positioned hydrogen atom of amino-pyridine and the pyridine[3,4<i>-d</i>]pyrimidine’s nitrogen atom at 7-position displayed two hydrogen bonding interactions with the Met793 residue of the hinge region. The amino group of 2-fluoro-aniline made a hydrogen bond with the DFG motif residue Asp855. Simultaneously, the piperidine-attached hydroxyl group formed two hydrogen bonds with mutant serine and the solvent-exposed region residue Asp800 (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Biological activity profile of compound <b>23</b> and its binding interaction with EGFR L858R/T790M/C797S. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a>. Copyright 2018, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hei et al.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> synthesized novel chemotype EGFR inhibitors that contained a 2,9-disubstituted 8-phenylthio- or 8-phenylsulfinyl-9<i>H</i>-purine scaffold. In this study, they replaced the 8-phenylamino group of compound <b>24</b>, which was previously reported by Yang et al.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> and had a potent inhibitory active toward EGFR L858R, with an 8-phenylthio or 8-phenylsulfinyl group and discovered a novel EGFR-TKI (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Target scaffold hopping strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From this designing strategy, they have synthesized 31 compounds. Among them, compound <b>25</b> has a moderate inhibitory effect on EGFR L858R (IC<sub>50</sub> = 1.2 nM), EGFR L858R/T790M (IC<sub>50</sub> = 189 nM), and EGFR L858R/T790M/C797S (IC<sub>50</sub> = 114 nM) (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>). Such findings indicated that compound <b>25</b> containing 2,9-disubstituted 8-phenylthio-9<i>H</i>-purine needs additional optimization to discover the fourth-generation EGFR-TKIs.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure and enzyme activity of compound <b>25</b> against EGFR L858R/T790M/C797S</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lei et al.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> reported a novel series of EGFR-TKIs based on the previously reported 8-phenylamino-9<i>H</i>-purine compound <b>25</b>. By aiming to achieve extra hydrogen bonding interactions with the mutated residue of Ser797 in the ATP binding region of EGFR and strengthen the inhibitory activity toward the tertiary C797S mutation, they tailored a heterocyclic moiety with a sulfonyl, acyl, or 2-hydroxyacetyl group to the purine scaffold. These resultant compounds form an additional hydrogen bond interaction with triple-mutant Ser797 via sulfonyl oxygen or acyl functional groups (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Design strategy of target (mutant-selective) compounds</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">They measured the inhibitory enzymatic activity of the selected compounds toward EGFR L858R/T790M/C797S <i>in vitro</i>, taking the positive control Osimertinib into account, and discovered that compounds <b>27</b> (IC<sub>50</sub> = 40 nM), <b>28</b> (IC<sub>50</sub> = 18 nM), <b>29</b> (IC<sub>50</sub> = 22 nM), and <b>30</b> (IC<sub>50</sub> = 4 nM) showed more promising inhibitory activities than Osimertinib (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). Specifically, the most potent compound <b>28</b>, bearing a cyclopropyl sulfonamide group, may be a more appropriate substitute for the hydrogen bond acceptor (HBA) in their study. Additionally, compound <b>28</b> could noticeably block EGFR phosphorylation, induce apoptosis, induce cell-cycle arrest at the G0/G1 phase, and suppress colony formation in the HCC827 cell line, resulting in a potent and promising EGFR L858R/T790M/C797S inhibitor with a new chemotype.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structures of promising 9-heterocyclyl-substituted 9<i>H</i>-purines and their activity toward EGFR L858R/T790M/C797S (<b>27</b>–<b>30</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular docking studies suggested that the nitrogen atom of the 9<i>H</i>-purine ring made a hydrogen bond with the Met793 hinge residue. Interestingly, the cyclopropyl sulfonamide group of compound <b>28</b> and the hydroxyacetyl group of compound <b>30</b> showed additional hydrogen bonds with mutated residue Ser797, which played significant roles in creating effective EGFR L858R/T790M/C797S inhibitory activity (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). These outcomes of the study clearly suggested that 9-heterocyclyl-substituted 9<i>H</i>-purine derivatives were active against the tertiary-acquired L858R/T790M/C797S mutant EGFR.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Molecular docking of (A) <b>28</b> and (B) <b>30</b> with EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a>. Copyright 2019, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lategahn et al.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> examined known co-crystal structures of pyrrolo-pyrimidine ligands with kinases and designed novel selective inhibitors that were effective against multidrug-resistant EGFR. All the synthesized pyrrolo-pyrimidine compounds were evaluated for EGFR inhibition toward Osimertinib-resistant EGFR L858R/T790M/C797S, and it was found that among pyrrolo-pyrimidine derivatives compounds <b>31</b>–<b>34</b> significantly suppressed EGFR L858R/T790M/C797S. Additionally, these compounds <b>31</b>–<b>34</b> also showed significant inhibitory activity toward EGFR L858R/T790M, with an IC<sub>50</sub> value of 0.1 nM (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. EGFR inhibition data along with the chemical structure of the pyrrolo-pyrimidine scaffold-containing potent compounds <b>31</b>–<b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hu et al.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> developed 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines from a broad SAR study of JND3229 (<b>4</b>). They identified compound <b>35</b> in which the <i>trans</i>-cyclohexanamine moiety of JND3229 (<b>4</b>) is replaced with <i>cis</i>-cyclopyrrilidinamine. Compound <b>35</b> exhibited single-digit nanomolar EGFR suppression activity against EGFR L858R/T790M/C797S as well as most-significant antiproliferative activities against a Ba/F3 cell line transfected with EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S, with IC<sub>50</sub> values of 290 and 310 nM, respectively. Compound <b>35</b> showed the dose-dependent phosphorylation inhibition of EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S. Compound <b>35</b> showed a binding interaction similar to that of JND3229 (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>).</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Biological data of compound <b>35</b> and its binding interaction with the EGFR T790M/C797S cavity (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRX">6JRX</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a>. Copyright 2019, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Toenjes et al.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> identified a RET kinase inhibitor that had secondary activities against EGFR mutation by leveraging the stereochemical phenomenon known as atropisomerism (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>). They synthesized and evaluated the kinase activity of atropisomerically stable analogues of the pyrrolo-pyrimidine (PPY) scaffold. Compound <b>(R</b><sub><b>a</b></sub><b>)-37</b> is not only less potent toward the WT EGFR (IC<sub>50</sub> = 1623 nM) but also significantly inhibits the triple-mutant L858R/T790M/C797S EGFR (IC<sub>50</sub> = 53 nM). The cellular activity of <b>(R</b><sub><b>a</b></sub><b>)-37</b> against the triple-mutant cell lines Ba/F3 showed a moderate activity (EGFR L858R/T790M/C797SG IC<sub>50</sub> = 5420 nM) (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>).</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Bond rotation leads to the racemization of atropisomers with a selective kinase inhibitor</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Chemical structure of <b>(R</b><sub><b>a</b></sub><b>)-37</b></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Su et al.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> and collaborators designed and synthesized a series of Osimertinib derivatives where they introduced the hydroxyl group at the alkyl chain of the indole moiety to increase the polar interaction with the DFG motif amino acid residue Asp855, which is based on the work of Marchel gunter.<a onclick="showRef(event, 'ref154 ref156'); return false;" href="javascript:void(0);" class="ref ref154 ref156">(154,156)</a> In their study, compound <b>38</b> demonstrated a high inhibitory activity against EGFR Del19/T790M/C797S (IC<sub>50</sub> = 15.3 nM) and EGFR L858R/T790M/C797S (IC<sub>50</sub> = 218.3 nM) and a good selectivity over the WT EGFR (IC<sub>50</sub> > 1000 nM) (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>).</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Chemical structure and biological activity of compound <b>38</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similarly, compound <b>38</b> has a potent inhibitory effect on EGFR L858R/T790M (IC<sub>50</sub> = 156.6 nM). Moreover, <b>38</b> exhibited cell-cycle arrest in the G1 phase and apoptosis in Ba/F3 and EGFR Del19/T790M/C797S cells in a concentration-dependent manner by suppressing the EGFR phosphorylation signaling pathway.</div><div class="NLM_p">Zhang and co-worker<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> designed and synthesized a novel series of 2-aryl-4-amino-substituted quinazoline derivatives as inhibitors of the triple-mutant EGFR L858R/T790M/C797S kinase. They modified the Afatinib quinazoline at C-2 and C-4 with Br, CN, and different groups. In the well-established HTRF assay method, compound <b>39</b> was shown to have a powerful kinase inhibitory activity effect against EGFR L858R/T790M/C797S, with an IC<sub>50</sub> value of 0.63 μM. The cell line evaluation of <b>39</b> against H1975-EGFR L858R/T790M/C797S and H1975-EGFR L858R/T790M shows that <b>39</b> also demonstrated good microsomal stability in human, rat, and mouse liver species as well as a low (18.6%) oral bioavailability (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>).</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Chemical structure and biological activity of <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scientists in Korea synthesized and patented (CN 110740999A) novel class of <i>N</i>2,<i>N</i>4-diphenylpyrimidine-2,4-diamine derivatives as fourth-generation EGFR tyrosine kinase inhibitors.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Among the synthesized compounds, <b>40</b>–<b>42</b> potently inhibit the EGFR Del 19/T790M/C797S triple mutation with nanomolar IC<sub>50</sub> values (EGFR Del19/T790M/C797S < 0.10 nM) (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>). Unfortunately, these classes of inhibitors require further optimization because of their similar potency toward the WT EGFR.</div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Chemical structures and biological activities of <b>40</b>–<b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Medshine discovery group synthesized a novel series of spiro-aryl-phosphorus-oxygen scaffolds as fourth-generation EGFR kinase inhibitors, which are reported in WO 2018108064 A1.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> The antitumor activities of the synthesized compounds were assessed against Ba/F3, A431, and NCI-H1975 cell lines, and compounds <b>43</b>–<b>45</b> showed significant IC<sub>50</sub> values of <100 nM. In xenograft mouse models carrying the C797S mutation, these spiro-aryl-phosphorus-oxygen analogs also displayed strong antitumor activitues. In summary, the findings show that these compounds delivered a novel framework for further research into the tertiary C797S mutation (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Chemical structures and biological activities of <b>43</b>–<b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In CN 110461850A, Japanese scientists synthesized a series of novel 1,6-dihydro-7<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-7-one analogues, among which the most active compound <b>46</b> displayed a moderate cell antiproliferative activity against PC-9-EGFR Del19/T790M/C797S and PC-9-EGFR L858R/T790M/C797S with an IC<sub>50</sub> values of 739.9 and 595.7 nM, respectively.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Furthermore, compound <b>46</b> showed less affinity toward inhibiting the WT EGFR of the lung adenocarcinoma cell line A549, with an IC<sub>50</sub> value of 2861.7 nM, suggesting the selectivity of compound <b>46</b> toward the EGFR active mutation (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>). Interestingly, compound <b>46</b> suppressed not only the EGFR phosphorylation but also the downstream ERK signaling pathway in a dose-dependent manner and led to marked tumor volume shrinkage in the xenograft model of EGFR Del19/T790M/C797S at a dose of 0.2 mg per day without substantial weight loss.</div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Chemical structury and biological activity of <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Li and co-workers disclosed their invention of compounds <b>47</b> and <b>48</b> for the treatment of NSCLC with mutant EGFR, as reported in patent CN1 10790749 A.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> The antiproliferative activities of <b>47</b> and <b>48</b> demonstrated the potential activity toward Ba/F3 EGFR Del19/T790M/C797S cells with IC<sub>50</sub> values of 9 and 10 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>). Both these compounds demonstrated good pharmacokinetic properties and also did not cross the blood–brain barrier.</div><figure id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0038.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Chemical structure and antiproliferative activities of <b>47</b> and <b>48</b> against Ba/F3 EGFR Del19/T790M/C797S cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Boehringer-Ingelheim scrutinized the purine derivatives as fourth-generation EGFR kinase inhibitors, as reported in patent WO 201916232 A1.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Compound <b>49</b> exhibited significantly higher antitumor activity against EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S, with IC<sub>50</sub> values of 48.2 and 12.0 nM, respectively, as compared to that of Osimertinib (EGFR L858R/T790M/C797S IC<sub>50</sub> = 1082.3 nM and EGFR Del19/T790M/C797S IC<sub>50</sub>= 729.6 nM). Additionally, compound <b>49</b> demonstrated less affinity to the WT EGFR (IC<sub>50</sub> = 540 nM), suggesting its excellent selectivity (<a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">39</a></a>).</div><figure id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Chemical structure and enzymatic activity of compound <b>49</b> against EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lingyum and co-workers synthesized a pyrimidine scaffold contained aryl-phosphorus-oxygen as an EGFR kinase inhibitor, as disclosed in WO 2019015655 A1.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Among the synthesized compounds, <b>50</b> and <b>51</b> showed excellent enzyme activities against EGFR Del19/T790M/C797S and EGFR L858R/T790M/C797S, with IC<sub>50</sub> values of 0.218 and 0.16 nM and 0.212 and 0.26 nM, respectively. Additionally, compounds <b>50</b> (IC<sub>50</sub> = 7.92 nM) and <b>51</b> (IC<sub>50</sub> = 5.12 nM) showed less inhibition of the WT EGFR, which indicated that they were selective and potent triple-mutant EGFR inhibitors.</div><div class="NLM_p">Antiproliferative activity on Ba/F3 EGFR Del19/T790M/C797S cells revealed that the promising compounds <b>50</b> (IC<sub>50</sub> = 22 nM) and <b>51</b> (IC<sub>50</sub> = 9 nM) had a powerful inhibitory effect. Additionally, these compounds showed good stabilities in EGFR Ba/F3 xenograft nude mice liver microsomes, with <i>t</i><sub>1/2</sub> values of 10 and 20.5 h, respectively (<a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>).</div><figure id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0040.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Chemical structures and enzymatic activities of compound <b>50</b> and <b>51</b> against EGFR Del19/T790M/C797S and EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ding Jian and the group identified a series of pyrimidopyridone analogues as mutant-selective EGFR L858R/T790M/C797S inhibitors, as presented in WO2019015593A1.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The most potent compounds <b>52</b> and <b>53</b> exhibited moderate enzymatic activity toward EGFR L858R/T790M/C797S, with IC<sub>50</sub> values of 38.1 and 47.8 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">41</a></a>). Moreover, these compounds showed moderate antiproliferative activities against Ba/F3 EGFR L858R/T790M/C797S cells, with a dose-dependent manner of inhibition.</div><figure id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0041.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Chemical structures and enzymatic activities of compound <b>52</b> and <b>53</b> against EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">4.2.2.  Combination of First-Generation and Third-Generation EGFR Inhibitors</h4><div class="NLM_p">Wang et al.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> reported that a combination of first- and third-generation inhibitors is useful if the C797S and T790M mutations were in the <i>trans</i>-form. Treatment with either Gefitinib or WZ4002 partially blocked EGFR phosphorylation when Exon-19 del/T790M and Exon-19 del/C797S were in the <i>trans</i>-scenario, whereas combining Gefitinib and WZ4002 fully inhibited EGFR phosphorylation. Meanwhile, if the mutations are in a <i>cis</i>-situation, the tumor cells cannot be suppressed by any EGFR-TKI, alone or in combinations.</div><div class="NLM_p last">Arulananda et al.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> treated a patient with the T790M and C797S mutations in the <i>trans</i>-scenario with a combination of Gefitinib and Osimertinib. Within two weeks of starting combination therapy, rapid clinical progress was observed.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.2.3.  Allosteric Inhibitors</h4><div class="NLM_p">The adverse effects shown by the ATP-competitive inhibitors were because of nonselective inhibition at the ATP cleft. This was alleviated by discovering more selective TKIs, which bind to an allosteric site on the kinase. Allosteric inhibitors are another class of inhibitors, which bind outside the ATP binding site at an allosteric site and blocks kinase activity in an allosteric manner. Inhibitors belonging to this class demonstrate an excellent degree of kinase selectivity because they target binding sites and regulatory mechanisms specific to a particular kinase. Here, we describe the allosteric inhibitors recently reported to overcome an acquired resistance due to Osimertinib treatment.</div><div class="NLM_p">Jia et al.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> scrutinized approximately 2.5 million chemical compound libraries utilizing the purified EGFR kinase comprised of the L858R/T790M mutation toward the 80 NSCLC cell lines by high-throughput screening (HTS). The top hits were evaluated for their IC<sub>50</sub> values at 1 μM and 1 mM ATP to distinguish ATP-competitive compounds from noncompetitive compounds. They also conducted screening for the WT EGFR to pick those with more specificity toward the mutant EGFR. Among the screened compounds, the first EGFR allosteric inhibitor with a thiazole amide, EAI001 (<b>54</b>), was identified, which had a high selectivity over WT EGFR (IC<sub>50</sub> > 50000 nM) and was active toward EGFR L858R/T790M with an IC<sub>50</sub> of 24 nM (at 1 mM ATP).</div><div class="NLM_p">Further optimization of EAI001 (<b>54</b>) generated EAI045 (<b>55</b>), which was highly potent and selective for the L858R/T790M mutation (<a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">42</a></a>). EAI045 (<b>55</b>) was shown to have a potent mutant inhibitory activity (EGFR L858R/T790M IC<sub>50</sub> = 3 nM) and is also 1000-fold more selective for the WT EGFR (WT EGFR IC<sub>50</sub> = 4300 nM).</div><figure id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0042.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structural optimization of EAI045 (<b>55</b>) from EAI001 (<b>54</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding interaction of EAI001 (<b>54</b>) showed that it binds as a “three-bladed propeller” or a “Y-shaped” configuration where an aminothiazole ring is situated between the Met790 and Lys745 residues, as reported in PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>. The phenyl group moved toward the hydrophobic residues (Leu777 and Phe856) of the ATP binding pocket, while the indolin-1-one group extended toward the solvent-exposed area. Additionally, the amide group of EAI001 (<b>54</b>) forms a hydrogen bond with the DFG motif residue Asp855 (<a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">43</a></a>).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></div><figure id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0043.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Binding approach of EAI001 (<b>54</b>) in EGFR T790M/V948R kinase (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a>. Copyright 2018, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">EAI045 was not effective as a single agent to wholly block EGFR autophosphorylation in the H1975 NSCLC cell line harboring the L858R/T790M mutant. The marked synergy of EAI045 with the coadministration of the anti-EGFR antibody Cetuximab was observed.</div><div class="NLM_p">Jian et al. showed that EAI045(<b>55</b>) binds the “C-helix out” conformation of the kinase in the subunit of the receiver but not the activator; the outward displacement of the C-helix is hindered by the asymmetric interaction of the dimer. Therefore, they believed that EAI045 (<b>55</b>) was a potent inhibitor of the mutant-receptor activator subunit but a much less potent receiver subunit as the C-helix is in captivity (<a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">43</a></a>). This synergistic effect of EAI045 (<b>55</b>) and Cetuximab was observed in L858R/T790M and L858R/T790M/C797S mutant mice. Mice treated with EAI045 (<b>55</b>) alone did not respond, whereas mice treated with Cetuximab alone had a moderate response; when used at the same time, EAI045 (<b>55</b>) and Cetuximab shrunk the tumor volume by over 50%. Since EGFR dimerization is required for kinase enzyme activation, Cetuximab (an antibody) inhibits the dimerization of the EGFR, making the kinase vulnerable to the allosteric agent in a uniform way.</div><div class="NLM_p">Therefore, the clinical utilization of this treatment method is restricted because Cetuximab is not an EGFR-mutant-specific monoclonal antibody, which may cause on-target WT EGFR-associated toxicities.</div><div class="NLM_p">To et al.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> identified the mutant-selective JBJ-04-125-02 (<b>56</b>) EGFR allosteric inhibitor, which can inhibit cell proliferation and EGFR L858R/T790M/C797S signaling both <i>in vitro</i> and <i>in vivo</i> as a single agent in contrast to the first-generation allosteric EGFR inhibitor EAI045. Appending 5-indole substituent at the C-6 isoindolinone moiety of EAI001 resulted in JBJ-02-112-05 (<b>57</b>), which has a biochemical effectiveness of 15 nM for EGFR L858R/T790M. Similarly, phenylpiperazine was inserted at the C-6 isoindolinone moiety of EAI045 to yield <b>56</b>, which demonstrated a significant potency against EGFR L858R/T790M (IC<sub>50</sub> = 0.26 nM) (<a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>). In a panel of Ba/F3 cell lines, To et al. evaluated the ability of JBJ-04-125-02 (<b>56</b>) to inhibit cell proliferation. Remarkably, JBJ-04-125-02 (<b>56</b>) was most potent when compared to to EAI045 and JBJ-02-112-05 (<b>57</b>) in combination with Cetuximab.</div><figure id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0044.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Chemical structures of JBJ-04-125-02 (<b>56</b>) and JBJ-02-112-05 (<b>57</b>), which were functionalized from EAI045 and EAI001, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The JBJ-04-125-02 (<b>56</b>)–EGFR T790M crystal structure elucidates that JBJ-04-125-02 <b>(56)</b> binds to the allosteric pocket of the EGFR, which is formed by the outer displacement of the C-helix in the inactive kinase conformation. The binding interactions of the phenyl ring, the thiazoleamide, and the isoindolinone of JBJ-04-125-02 (<b>56</b>) are similar to those observed previously for EAI001, and one more hydrogen bond was observed in the DFG motif between the hydroxyl group of phenyl ring and the carbonyl functional group of the residue Phe856. The 4-piperazinophenyl group extends toward the solvent-exposed area (the αC-helix), and the phenyl ring forms a π–π stacking interaction with the Phe723 residue of the P-loop. JBJ-04-125-02 (<b>56</b>) has the most significant therapeutic potential when paired with Osimertinib; as a result, the two-drug combination could potentially provide clinical advantages beyond those presently available with a single agent in patients with mutant lung cancer.</div><div class="NLM_p">Lee et al.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> designed another EGFR allosteric inhibitor, TREA-0236 (<b>58</b>), through the SAR of EAI045 (<b>55</b>). The undesirable amino-thiazole moiety on EAI045 (<b>55</b>) was substituted with nonhydrolyzable quinazoline-4-one to improve the drug properties. EAI045 (<b>55</b>) has a dipeptide core with a <i>N</i>-terminal amino-thiazole and, according to the author, the peptides are metabolically unstable, yielding 2-aminothiazole metabolites. These metabolites were discovered via high-throughput screening to be promiscuous, hitting the scaffold and producing methemoglobinemia toxicity with reactive intermediate formation that leads to extensive covalent protein binding. To avert such heamatological toxicities, the structure of EAI045(<b>55</b>) was altered by cyclization, where 2-aminothiazole amide was converted into quinazoline-4-one for better safety and pharmacokinetic aspects (<a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>).</div><figure id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0045.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Development of a nonpeptidic analogue of EAI001 (<b>54</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding approach of both TREA-0236 (<b>58</b>) and EAI001 (<b>54</b>) was observed to be identical (<a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">46</a></a>). TREA-0236 (<b>58</b>) forms a hydrogen bond with the carboxylate of Asp855 via <i>N</i>-1 of quinazoline-4-one and additional hydrophobic interactions with Ala743, Val726, Lys745, and Met790. The isoindolin-1-one and phenyl group ring are stabilized by a hydrophobic interaction with Leu788 and Met766, and further hydrogen bonding is visible between the phenolic OH and the amide carbonyl of Phe856.</div><figure id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0046.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. The TREA-0236 (<b>58</b>) (thick yellow sticks) and EAI001 (<b>54</b>) (thin green lines) binding interaction with EGFR T790M/V948R. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a>. Copyright 2018, John Wiley and Sons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">De Clercqet al.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> reported mutant-selective EAI002 (<b>59</b>) allosteric EGFR inhibitors comprised of a 5,10-dihydro-11<i>H</i>-dibenzo[<i>b</i>,<i>e</i>][1,4]diazepin-11-one scaffold, which specifically inhibits mutant EGFR L858R/T790M with an IC<sub>50</sub> of 52 nM and spares the WT EGFR (IC<sub>50</sub> > 1000 nM). The slight optimization of this screened compound via a fluorine shift afforded DDC4002 (<b>60</b>,) having higher mutant-selective IC<sub>50</sub> values against L858R/T790M and L858R/T790M/C797S compared to that against the WT EGFR (<a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>).</div><figure id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0047.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structure-based optimization of EAI002 (<b>59</b>) afforded DDC4002 (<b>60</b>) and the chemical structure of C-2-functionalized compounds (<b>61</b>–<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the previous observation, C-2-functionalized EAI045 (<b>55</b>) and JBJ-04-125-02 (<b>56</b>) resulted in an enhancement of the biochemical potency; inspired from such an observation, the 4-(piperazinyl)-phenyl substituent was tied at C-2 to enhance the potency. The efficiency of these inhibitors was slightly improved by adding versatility at this position through an Ullmann biaryl ether linkage, which resulted in compound <b>61</b> having similar potencies to those of EAI045 (<b>55</b>) toward the L858R/T790M and L858R/T790M/C797S.</div><div class="NLM_p">Additionally, De Clercqet et al. determined the effect of EGFR suppression on cellular proliferation in Ba/F3 cells. Due to the EGFR dimer-tempted resistance, all the compounds were ineffective at limiting Ba/F3 proliferation. A co-treatment with Cetuximab had a significant effect on L858R/T790M and L858R/T790M/C797S cells, with IC<sub>50</sub> values of ∼0.2–0.4 μM.</div><div class="NLM_p">According to docking studies, the 8-fluorobenzene ring of DDC4002 (<b>60</b>) bound to the hydrophobic back pocket, and the 7-membered diazepinone ring folded inward toward the C-helix. One hydrogen bond was observed between the diazepaine NH and the backbone carbonyl of F856. The benzyl substitution spreads to the <i>N</i>-lobe, which is sandwiched between AMP-PNP and the L788, K745, and T790M residues (<a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">48</a></a>).</div><figure id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0048.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Binding of DDC4002 (<b>60</b>) at the allosteric pocket. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hoffmann La Roche synthesized a series of oxo-isoindolines as potent and selective allosteric EGFR inhibitors, as reported in WO2020002487A1.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Among them, <b>64</b> and <b>65</b> displayed excellent inhibitory activity toward the EGFR L858R/T790M/C797S kinase, with IC<sub>50</sub> values of 5 and 4 nM, respectively, against the Ba/F3 cell line (EGFR L858R/T790M/C797S) (<a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">49</a></a>).</div><figure id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0049.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Chemical structures and biological activities of <b>64</b> and <b>65</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Li et al.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> discovered potent and noncovalent reversible EGFR kinase inhibitors of EGFR L858R/T790M/C797S, which have both binding affinities toward ATP-competitive and allosteric sites. Here, investigators tailored the first non-ATP-competitive (EAI045 (<b>55</b>)) EGFR inhibitor and the known ATP-competitive VEGFR and EGFR inhibitor Vandetanib (<b>66</b>), which displayed a modest effectiveness (IC<sub>50</sub> = 369.2 nM) toward the EGFR L858R/T790M/C797S mutant. Inspired by the allosteric inhibitor EAI045 (<b>55</b>), they attempted to alter Vandetanib in order to inhabit the ATP binding site and the allosteric site of the EGFR kinase doamin with the goal of improving the binding affinity of toward EGFR L858R/T790M/C797S. Based on this assumption, they have developed and synthesized EGFR L858R/T790M/C797S noncovalent reversible inhibitors.</div><div class="NLM_p">Among the synthesized series, the most promising compound <b>67</b> inhibited the triple-mutant EGFR L858R/T790M/C797S with an IC<sub>50</sub> value of 2.2 nM (<a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a>). Compound <b>67</b> dose-dependently suppressed EGFR phosphorylation in Ba/F3 EGFR L858R/T790M/C797S cells, while AZD9291 failed to suppress EGFR phosphorylation. Compound <b>67</b> was also evaluated against the Exon-19 deletion-activating mutation EGFR Del19/T790M/C797S and was found to have weak inhibition in both the enzyme and the cell-based assay.</div><figure id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0050.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. Chemical structures of EAI045 (<b>55</b>), Vandetanib (<b>66</b>), and the tailored compound <b>67</b> along with their respective kinase binding sites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The results displayed that <b>67</b> had a moderate activity toward the EGFR Del19/T790M/C797S kinase (IC<sub>50</sub> 331.3 nM) and Ba/F3 EGFR 19D/T790M/C797S cells (IC<sub>50</sub> 3.54 μM). These data indicate that compound <b>67</b> is more potent toward EGFR L858R/T790M/C797S than EGFR Del19/T790M/C797S. Docking simulations indicated that compound <b>67</b> occupies both the allosteric region and the ATP binding region and interacts with the allosteric region, the hinge region, and the solvent-accessible region. The π–π stacking interaction was observed in the allosteric region between the phenyl of the Y-shaped group (oxoisoindolin-2-phenylacetamide) and the hydrophobic amino acids of the allosteric cavity, Phe856. Inside the ATP binding region, hydrogen bonding can be seen between the quinazoline ring and the hinge residue of Met793, while the piperidine tail was surrounded by a solvent-exposed region (<a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">51</a></a>).</div><figure id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0051.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. Binding pose of compound <b>67</b> in triple-mutant EGFR (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5d4">5d4</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">5.  Emerging Therapeutic Strategies to Overcome EGFR-Independent Osimertinib Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To overcome the resistance to Osimertinib, combination therapy is also a promising strategy besides developing new drugs. This approach is aimed at circumventing drug resistance through a so-called bypass signaling mechanism (EGFR-independent Pathway) by targeting horizontal pathways, vertical pathways, both.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15−18)</a> Here, we have summarized the different bypass signaling mechanism inhibitors to overcome Osimertinib resistance in the treatment of NSCLC.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">5.1.  Osimertinib with MET Inhibitors</h3><div class="NLM_p">The activation of the EGFR-independent phosphorylation of ErbB3 and the downstream activation of the PI3K/AKT pathway activates the bypass signaling pathway even in the existence of an EGFR-TKI, which is the primary mechanism by which MET amplification induces EGFR-TKI resistance. Hence, to overcome EGFR-TKI resistance caused by MET amplification, concurrent targeting of both EGFR and MET could be needed. Preclinical and clinical data suggest that combination therapy with a MET inhibitor might be useful in mutant EGFR NSCLC patients with MET amplification or patients who have a recurrence from Osimertinib due to MET amplification.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Recently, two small-molecule MET inhibitors, Carbozantinib (<b>68</b>) and Crizotinib (<b>69</b>), have been approved by regulatory authorities for the treatment of particular cancer types. In preclinical studies, a combination of the MET inhibitor and Osimertinib effectually suppressed the growth of HCC827/AR and HCC827/ER cells, both of which have MET amplification, and also inactivated or suppressed ErbB3 phosphorylation (<a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></div><figure id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0052.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. Chemical structures of MET inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An <i>in vivo</i> study from Shi et al.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> examined the effectiveness of the Osimertinib and Crizotinib (<b>69</b>) combination against the growth of Erlotinib-resistant HCC827/ER and Osimertinib-resistant HCC827/AR. Their results suggested that Osimertinib alone is ineffective at inhibiting the growth of the HCC827/ER and HCC827/AR xenografts, whereas Crizotinib (<b>69</b>) inhibited their growth. They demonstrated the vital role of MET in mediating the resistance to third-generation EGFR-TKIs. They also analyzed the effects of Osimertinib on the growth of HCC827/ER cells in the absence and presence of three different MET inhibitors, <i>i.e.</i>, Crizotinib (<b>69</b>), Tivantinib (<b>70</b>), and SGX523 (<a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>).</div><div class="NLM_p">Giroux-Leprieur et al.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> reported the outcomes of two patients treated with an association of EGFR-TKI and Crizotinib (<b>69</b>) for EGFR-mutated adenocarcinoma with acquired MET amplification. Their findings led to the conclusion that the combination of Osimertinib and Crizotinib (<b>69</b>) reduced tumor progression. Prospective clinical trials are needed for further examinations (<a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>).</div><div class="NLM_p">Kang et al.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> described an EGFR-mutant lung adenocarcinoma patient that clinically benefitted from a combinatorial therapy of Osimertinib and Carbozantinib (<b>68</b>) after developing four MET mutations simultaneously upon the Crizotinib (<b>69</b>) treatment. Their data reveal that four resistant mutations, <i>i.e.</i>, D1228N, D1228H, Y1230H, and D1231Y, emerged simultaneously after Crizotinib (<b>69</b>) treatment, while three of them responded to Carbozantinib (<b>68</b>). Thus, the combinatorial treatment of Carbozantinib (<b>68</b>) and Osimertinib significantly relieved her symptoms, which were accompanied by undetectable MET D1228H, Y1230H, and D1231Y mutations (<a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>).</div><div class="NLM_p last">Currently, a clinical trial is being conducted to assess the effectiveness of Osimertinib in combination with Savolitinib (<b>71</b>) in mutant EGFR (EGFRm+) and MET+ patients. According to interim outcomes from two expansion cohorts of the TATTON trial presented at the American Association for Cancer Research Annual Meeting, the combination of Savolitinib (<b>71</b>) and Osimertinib displayed significant clinical activity among the patients with EGFR-mutated NSCLS that was resistant to previous EGFR-targeted therapies over MET amplification (<a href="https://clinicaltrials.gov/ct2/show/NCT03778229" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03778229</a>). In summary, MET inhibitors and with Osimertinib may be a new therapeutic strategy for EGFR-TKI resistance induced by MET amplification, which needs further validation in the clinic.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">5.2.  Osimertinib with MEK Inhibitors</h3><div class="NLM_p">Trametinib (<b>72</b>), Selumetinib (<b>73</b>), and PD0325901 (<b>74</b>) all are very efficient in suppressing the growth of HCC827/AR cells when co-administered with Osimertinib.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Ortiz-Cuaran et al.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> reported that a combined treatment of Osimertinib and the Trametinib (<b>72</b>) (MEK inhibitor) was highly synergistic. Consistent with these results, Osimertinib failed to fully suppress downstream MAPK signaling except in the presence of Trametinib (<b>72</b>). Similar results were observed with the combination of Osimertinib and Selumetinib (<b>73</b>) (<a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">53</a></a>).</div><figure id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0053.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. Chemical structures of MEK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Della Corte et al.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> checked the effectiveness of whole EGFR inhibition by Osimertinib and the antibody Cetuximab or Selumetinib (<b>73</b>) in EGFR-mutated NCLC <i>in vivo</i> models. Based on the basic EGFR dependency and the role of the RAS/MAPK pathway as an escape mechanism to EGFR inhibition, they devised a treatment strategy that pointed to a more potent inhibition of EGFR signaling by inhibiting MAPK in conjunction with the selective MEK inhibitor Selumetinib (<b>73</b>).</div><div class="NLM_p last">They found that the combination of Selumetinib (<b>73</b>) or Cetuximab with Osimertinib in second-line therapy increased the sensibility of Osimertinib in the majority of mice, increased the response rate (RR) from 50% to 80%, and increased the median progression-free survival (mPFS) of the first- and second-line of therapy for 6 months. They concluded that the addition of Cetuximab or Selumetinib (<b>73</b>) potentiated the effectiveness of Osimertinib in terms of its clinical response rate (<a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">53</a></a>). They also suggested that the treatment of EGFR-mutated NSCLC by combining the most potent EGFR-TKI Osimertinib plus Cetuximab or Selumetinib (<b>73</b>) was an effective and safe novel therapeutic option, leading to the stronger inhibition of the EGFR by a dual vertical blockade.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">5.3.  Osimertinib with ALK Inhibitors</h3><div class="NLM_p">The recognition of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of NSCLC.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> ALK rearrangements are present in 3–5% of patients with NSCLC and define an important molecular subgroup of the disease.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Pfizer developed Lorlatinib (<b>75</b>), a novel oral ATP-competitive ALK-targeting inhibitor (<a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a>).<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div><figure id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0054.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. Chemical structures of ALK Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Uchibori et al.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> presented that the ALK inhibitor Brigatinib (<b>1</b>) could be repurposed to effectively diminish the viability of EGFR-C797S mutated cell lines. However, adequate plasma levels to efficiently inhibit EGFR-C797S <i>in vivo</i> could not be attained, so a combination treatment with EGFR-targeted antibodies, such as Cetuximab, was required to achieve marked effects in the mouse animal models (<a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a>).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">5.4.  Osimertinib with FGFR Inhibitors</h3><div class="NLM_p">Quintanal-Villalonga et al.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> provided evidence showing that FGFR1 expression increases tumorigenicity in cells along with high EGFR activation in mutated EGFR and WT EGFR models. They showed that combined EGFR and FGFR inhibition in FGFR1-overexpressing cells has a synergistic impact on tumor growth <i>in vitro</i> and in the cell line. They performed a practical experiment where they evaluated the efficacy of combined AZD4547 (<b>76</b>), an FGFR1 inhibitor, and Osimertinib, which resulted in a reduction of tumor growth. Their combined treatment effectively inhibited FGFR1, EGFR, AKT, and STAT3 more than either drug alone (<a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">55</a></a>).</div><figure id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0055.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Chemical structure of FGFR1 inhibitor AZD4547.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">5.5.  Osimertinib with HER2 Inhibitors</h3><div class="NLM_p">Liu et al.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> described how HER2 (ERB2) aberrations, including amplification and mutations, have been categorized as oncogenic drivers that add to 2–6% of lung adenocarcinomas. They performed a comprehensive preclinical study to evaluate the potential of a third-generation TKI, <i>i.e.</i>, Osimertinib. Their study suggested that a combined treatment with Osimertinib and the BET inhibitor JQ1 (<b>77</b>) significantly increased the response rate in HER2-mutant NSCLC. The combination of JQ1 (<b>77</b>) and Osimertinib could synergize to suppress the tumor growth of HER2-mutated lung cancers by reducing the phosphorylation of HER2, AKT and ERK. They provided the first <i>in vivo</i> evidence that although HER2 mutant tumors were resistant to Osimertinib, JQ1 (<b>77</b>) is the only agent that makes HER2 mutant tumors more vulnerable when treated in combination with Osimertinib (<a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">56</a></a>).</div><figure id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0056.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Chemical structures of HER2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">La Monica et al.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> examined the impact of Osimertinib in combination with monoclonal antibodies targeting the HER family. Trastuzumab-DM1 (T-DM1, <b>78</b>) is currently being studied in a phase II trial in NSCLC patients with HER-2 overexpression was recently approved by the FDA as a therapy for HER-2-positive pretreated breast cancers.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></div><div class="NLM_p last">They assessed the possible effectiveness of T-DM1(<b>78</b>) with Osimertinib to increase the effectiveness of third-generation EGFR-TKIs and overcome their resistance due to the HER2-amplification in NSCLC cell lines (<a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">56</a></a>). The results of their findings show that Osimertinib combined with T-DM1 (<b>78</b>) synergistically impacts the inhibition of cell growth when provided concurrently with HER-2 amplification.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">5.6.  Osimertinib with AKT Inhibitors</h3><div class="NLM_p">Jacobsen et al.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> described that AKT activation is a convergent aspect of the acquired resistance to the EGFR tyrosine kinase inhibitor. They showed that combined treatment with EGFR inhibitors and an AKT inhibitor in resistant EGFR-mutant NSCLC models synergistically inhibits the growth of this heterogeneous molecular background. They performed an experiment to measure whether the synergistic effect of Osimertinib with AKT inhibitors, namely, Uprosertib (GSK2141795) (<b>79</b>) and Capivasertib (AZD5363) (<b>80</b>), resulted in the simultaneous inhibition of EGFR phosphorylation and the downstream targets of AKT phosphorylates (PRAS40 and FOXO1/3A) (<a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">57</a></a>). Thus, the outcomes of their findings deliver a rationale for clinical trials to test AKT and EGFR inhibitor cotreatment in patients with raised phospho-AKT levels to therapeutically combat the heterogeneity of EGFR tyrosine kinase inhibitor resistance mechanisms.</div><figure id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0057.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Chemical structures of AKT Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">5.7.  Osimertinib with AXL Inhibitors</h3><div class="NLM_p">The activation of Axl protects cells from apoptosis and increases migration, aggregation, and growth through multiple downstream pathways. Namba et al.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> established various NSCLC cell lines with an acquired resistance to Osimertinib and inspected the molecular profiles of the resistant cells to identify the mechanisms of resistance. They experimentally investigated AXL expression and confirmed via Western blotting that AXL is associated with cell viability. Their results suggest that the survival of these resistant cell lines depends on AXL signaling.</div><div class="NLM_p">They examined the effect of Cabozantinib (AXL and MET inhibitor) in combination with Osimertinib, and their findings showed that the combined treatment was effective in overcoming an acquired resistance to Osimertinib by inhibiting the phosphorylation of AKT. These results suggest that the activation of multiple pathways, including AKT, may promote the resistance to EGFR-TKIs downstream of the AXL up-regulation. Their experimental data suggest that AXL might be a therapeutic target for overcoming an acquired resistance to Osimertinib.</div><div class="NLM_p">Jimbo et al.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> investigated the effect of the novel and selective AXL inhibitor DS-1205 (<b>81</b>) on tumor growth and a resistance to EGFR TKIs. Their study showed that DS-1205 in combination with Osimertinib inhibited phosphorylation more effectively than the Osimertinib monotreatment. Even at the lowest dose (16 nM), this co-treatment completely inhibited AKT phosphorylation; thus, such a combination may extend the therapeutic benefit of EGFR-TKI by suppressing the bypass pathway (<a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">58</a></a>).</div><figure id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0058.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Chemical structures of AXL Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Kim et al.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> demonstrated the association of AXL in the acquired resistance to Gefitinib and Osimertinib of EGFR-mutant NSCLC cells; they showed the combined effect of an AXL degrader and EGFR-TKIs to triumph over resistance in EGFR-mutant NSCLC cells. A natural antitumor agent, Yuanhuadine (YD, <b>82</b>) effectively suppressed the expression of AXL by accelerating protein degradation. YD (<b>82</b>) combined with Gefitinib or Osimertinib synergistically suppressed the growth of resistant cells <i>in vitro</i> and suppressed tumor growth in a nude mouse xenograft model (<a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">58</a></a>). Their results suggest that the combination of YD (<b>82</b>) with either Gefitinib or Osimertinib is a potentially effective treatment approach for overcoming and delaying acquired resistance in NSCLC by targeting AXL degradation.</div><div class="NLM_p last">Liu et al.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> demonstrated that STC2 expression was found to be upregulated in primary lung cancer cells isolated from pleural effusions of patients with an EGFR TKI-resistant disease. In STC2-overexpressing cells, AXL inhibition with the pharmacological inhibitor Bemcentinib (R428) (<b>83</b>) inhibited AXL and synergistically increased both TKI-induced cell death and PARP cleavage. PE2988 cells, C797S-independent Osimertinib-resistant primary cancer cells, responded to treatment with a combination of an AXL inhibitor and Osimertinib (<a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">58</a></a>). These results suggest that the AXL signaling induced by STC2 plays a key role in Osimertinib resistance in primary lung cancer cells.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">5.8.  Osimertinib with BRAF V600E Inhibitors</h3><div class="NLM_p">The BRAF V600E mutation is currently described as an emerging molecular resistance mechanism in Osimertinib-resistant EGFR-mutant NSCLC. BRAF V600E accounts for approximately 1.5% of lung adenocarcinoma and serves as one of the resistance mechanisms to Osimertinib.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> How to deal with BRAF V600E-mediated resistance still entails exploration.</div><div class="NLM_p">Ho et al.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> recognized a patient with the BRAF V600E mutation after treatment with Osimertinib. Encorafenib (LGX818, <b>84</b>) is a potent BRAF V600E inhibitor that inhibits MEK phosphorylation. Osimertinib inhibits EGFR phosphorylation without affecting MEK or ERK but it significantly inhibits AKT, MEK, and ERK phosphorylation in Osimertinib-sensitive cells. Encorafenib (<b>84</b>) and Osimertinib were used together to inhibit ERK phosphorylation even further. However, when Encorafenib (<b>84</b>) and Osimertinib were used together, the inhibitory effect was more significant than when Encorafenib (<b>84</b>) was used alone. The parallel blockade of BRAF and EGFR had a strong inhibitory effect (<a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>).</div><figure id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0059.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. Chemical structures of the BRAF V600E inhibitor Encorafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">6.  Immune-Checkpoint Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The recognition of interactions between the immune system and tumors has affirmed immunological evasion as an additional characteristic of cancer.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Recently, the paradigm of clinical treatment of lung cancers has shifted to drugs that target immune checkpoint pathways. Three drugs, namely, Nivolumab, Pembrolizumab, and Tezolizumab, have been approved by the U.S. FDA to target the immune checkpoint blockade and become part of the treatment regimen for advanced-stage NSCLC patients.<a onclick="showRef(event, 'ref209 ref210'); return false;" href="javascript:void(0);" class="ref ref209 ref210">(209,210)</a> An effective treatment of NSCLC has been shown by immune checkpoint inhibitors, including Nivolumab and Pembrolizumab, which target programmed cell death-1 (PD-1), and Atezolizumab and Durvalumab, which target programmed cell death–ligand 1 (PD-L1).<a onclick="showRef(event, 'ref208 ref209 ref210 ref211'); return false;" href="javascript:void(0);" class="ref ref208 ref209 ref210 ref211">(208−211)</a> Oncogenic signaling induced by EGFR mutations has been found to induce PD-L1 expression in cancer cells and immune escape due to T-cell weariness, implying that the combination of EGFR-TKIs with a PD-1 or PD-L1 blockade may be a beneficial treatment strategy.<a onclick="showRef(event, 'ref212 ref213 ref214 ref215 ref216 ref217 ref218'); return false;" href="javascript:void(0);" class="ref ref212 ref213 ref214 ref215 ref216 ref217 ref218">(212−218)</a></div><div class="NLM_p last">In a multiarm phase 1b trial of Osimertinib (TATTON study), the combination of Osimertinib and Durvalumab was examined in patients with NSCLC who had EGFR-activating mutations.<a onclick="showRef(event, 'ref219 ref220'); return false;" href="javascript:void(0);" class="ref ref219 ref220">(219,220)</a> Despite the promising efficacy of the combination treatment, there was a high rate of interstitial lung disease (38%). Other combinations of an EGFR-TKI and an immune-checkpoint inhibitor, such as Erlotinib plus Nivolumab, Gefitinib plus Durvalumab, and Erlotinib plus Atezolizumab, have shown promising efficacies in early phase studies.<a onclick="showRef(event, 'ref221 ref222'); return false;" href="javascript:void(0);" class="ref ref221 ref222">(221,222)</a> This combination also showed a high frequency of grade ≥3 treatment-related adverse effects, such as pyrexia, elevated SGOT or SGPT, and rash, implying that further research, including determining the optimal dose for such combinations, is needed.<a onclick="showRef(event, 'ref221 ref222'); return false;" href="javascript:void(0);" class="ref ref221 ref222">(221,222)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">7.  Proteolysis-Targeting Chimeric Molecules (PROTACs)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Proteolysis-targeting chimera (PROTAC) is a promising clinical strategy for drug resistance, which has been widely used a biological tool and medicinal molecule with a clinical application value for treating cancer.<a onclick="showRef(event, 'ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref223 ref224">(223,224)</a> Recently, proteolysis-targeting chimeric molecules (PROTACs) obtained from EGFR-TKIs have been developed to target drug resistance EGFR in NSCLC.<a onclick="showRef(event, 'ref225 ref226 ref227 ref228 ref229 ref230'); return false;" href="javascript:void(0);" class="ref ref225 ref226 ref227 ref228 ref229 ref230">(225−230)</a> The PROTACs are hetero-bifunctional small molecules that contain ligands of target proteins (also known as the protein-of-interest ligand (POI-ligand)), E3 ubiquitin ligase-recruiting elements (cereblon (CRBN), von Hippel-Lindau (VHL), and mouse double minute 2 (MDM2)) coupled by linkers (<a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">60</a></a>).<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> In the human body, the process of protein degradation is mainly regulated by the ubiquitin-proteasome system (UPS). PROTACs can hijack the intracellular inherent UPS in cells to perform their own degradation jobs. It has been reported that PROTACs have a higher potency and specificity than their parent small-molecule ligands, which can only inhibit protein activity.<a onclick="showRef(event, 'ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref231 ref232">(231,232)</a></div><figure id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0060.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Mechanism of protein degradation induced by proteolysis-targeting chimera (PROTAC) technology. (Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a>. Copyright 2018, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">He and colleagues reported EGFR degraders based on Osimertinib and Lenalidomide.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> Western blotting assays analyzed the effect of EGFR degradation, which revealed that the potent compound <b>85</b> showed a 68% maximum degradation rate (<i>D</i><sub>max</sub>) in PC9 cells (<a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">61</a></a>). The additional analysis of the degradation activity on EGFR C797S is ongoing in their lab, and the result will be reported in due course.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a></div><figure id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0061.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. Chemical structure and biological activity of the EGFR degrader <b>85</b> prepared from Osimertinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Zhang and co-workers recently published a series of PROTAC compounds that cause EGFR degradation and are based on the fourth-generation EGFR-TKI and VHL-recruiting E3 ligase. Among the synthesized 13 pyrido[3,4-<i>d</i>] pyrimidine moiety that contains EGFR degraders, PROTACs <b>86</b> and <b>87</b> induced the promising degradation of EGFR in HCC827 cells, with the DC<sub>50</sub> values of 45.2 and 34.8 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>).<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> This research suggested that PROTAC may represent a potent strategy to address drug resistance in NSCLC.</div><figure id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0062.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. Chemical structures of EGFR degraders <b>86</b> and <b>87</b> with their DC<sub>50</sub> values on HCC827 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">8.  Discussion and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In November 2015, the U.S. FDA approved Osimertinib for the treatment of secondary EGFR T790M mutant NSCLC. While Osimertinib-treated patients have shown promising survival and response rates, an acquired resistance by EGFR-dependent and EGFR-independent resistance mechanisms still occurs after about 10 months. The tertiary C797S mutation in Exon-20 of EGFR is a prominent mechanism (EGFR-dependent) of acquired resistance to Osimertinib. The C797S mutation occurs in the <i>cis-</i> (on the same allele) or <i>trans</i>-form (on different alleles), according to <i>in vitro</i> studies. When the T790M/C797S mutation is in the <i>cis</i>-form, the cell becomes resistant to all third-generation TKIs. In preclinical trials, a combination of Brigatinib and the monoclonal antibody Cetuximab was reported to treat C797S and T790M <i>cis</i>-scenarios. Zhao and colleagues reported that a combination of Osimertinib, Bevacizumab, and Brigatinib was successful in treating progressed pulmonary adenocarcinoma with ternary EGFR L858R/T790M/<i>cis</i>-C797S mutations. They predicted that Brigatinib improved the clinical efficiency by targeting the EGFR <i>cis</i>-C797S mutation.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">However, ATP-competitive and allosteric inhibitors, along with first-and third-generation EGFR-TKIs, are an option for treating the acquired resistance to Osimertinib when it is in the <i>trans</i>-form. It has been clear from the crystal structure of T790M/C797S (5XGN) that the tertiary-acquired C797S mutation enhances the local hydrophilicity around the 797 residue without altering the function and structure of the kinase domain. Hence, apart from Cys797, the development of fourth-generation EGFR inhibitors hinges on the development of small ATP-competitive inhibitors that improve the binding affinity to different regions of the EGFR kinase domain.</div><div class="NLM_p">Several ATP-competitive inhibitors against clinically challenging triple-mutant EGFR L858R/T790M/C797S with low IC<sub>50</sub> nanomolar-range values were recently reported. Such effective mutant EGFR inhibitors may be used for the further development of novel EGFR inhibitors. Among the described ATP-competitive inhibitors, the pyrimido-pyrimidinone derivative JND3229 (<b>4</b>) showed a potent single-digit nanomolecular activity toward the Osimertinib-resistant EGFR L858R/T790M/C797S triple-mutant. JND3229 (<b>4</b>) binds reversibly in a “U-shaped” configuration to the ATP binding site of mutated EGFR. Korean scientists patented (CN 110740999A) a novel class of <i>N</i>2,<i>N</i>4-diphenylpyrimidine-2,4-diamines as fourth-generation EGFR tyrosine kinase inhibitors. Among the synthesized compounds, <b>40</b>–<b>42</b> potently inhibit the EGFR Del19/T790M/C797S triple mutation with nanomolar IC<sub>50</sub> values (EGFR Del19/T790M/C797S < 0.10 nM). These compounds had typical the <i>N</i>-(2-aminophenyl)methane sulfonamide moiety as a Michael acceptor at the <i>N</i>4-position and a side chain of Brigatinib at the <i>N</i>2-position of the pyrimidine ring. Unfortunately, this class of inhibitors requires further optimization because of their similar potencies toward the WT EGFR. The irreversible compound <b>13</b> and the reversible compounds <b>11</b> and <b>14</b> showed significant inhibitory activities toward EGFR L858R/T790M/C797S, with IC<sub>50</sub> values of 8, 7.64, and 7 nM, respectively. This result proves that covalent binding, such as with third-generation EGFR inhibitors, is not mandatory to overcome a ternary EGFR mutation. These findings strongly suggest that reversible trisubstituted imidazole inhibitors could be promising candidates as fourth-generation inhibitors to triumph over the EGFR ternary C797S mutation. Several newly discovered molecules, <i>i.e.</i>, 4-aminopyrazolopyrimidines (<b>5</b>), 5-methylpyrimidopyridone (<b>21</b>), trisubstituted pyridopyrimidine (<b>23</b>), disubstituted 8-phenylthio- or 8-phenylsulfinyl purine (<b>26</b>–<b>30</b>), and pyrrolopyrimidine (<b>31</b>–<b>34</b> and <b>(R</b><sub><b>a</b></sub><b>)-37</b>), demonstrated potent activities toward the EGFR L858R/T790M/C797S mutation ,while 4-aminoquinazolin (<b>16</b>-<b>19</b>) and macrocyclic BI-4020 (<b>3</b>) both are potentially active against EGFR Del19/T790M/C797S. The molecular modeling study of these ATP-competitive inhibitors indicates that these compounds form a bidentate hydrogen bond with the Met793 residue of the hinge region of EGFR L858R/T790M/C797S (<a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">63</a></a>). Future developments in this field can also take benefit of framing hydrogen bonds with the mutant Ser797 residue and other essential residues in the EGFR ATP pocket, such as Lys745 or Asn842, to develop unique noncovalent ATP-competitive inhibitors.</div><figure id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0063.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. Bidentate binding of the ATP-competitive inhibitors at L858R/T790M/C797S EGFR-TK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Along with ATP-competitive inhibitors, allosteric inhibition is another crucially important strategy toward overcoming the challenging triple mutation in EGFR due to the different region of target binding. A novel class of allosteric EGFR inhibitors, including EAI001 (<b>54</b>) and EAI045 (<b>55</b>), bind to EGFR away from the ATP binding site. First, the EGFR allosteric EAI045 (<b>55</b>) inhibitor was developed via high-throughput screening. It binds to a “C-helix out” conformation of the kinase to overcome the EGFR T790M mutation and was later found to also be effective against the T790M/C797S mutation. EAI045 (<b>55</b>) was not effective as a single agent able to completely abolish EGFR autophosphorylation. Unfortunately, they showed marked synergy after coadministration with the EGFR antibody Cetuximab. Further research yielded JBJ-04-125-02 (<b>56</b>), which has a phenylpiperazine unit on the C-6 site of the isoindolinone moiety of EAI045 (<b>55</b>) and can inhibit mutant EGFR as a single agent. Replacing the unwanted aminothiazole from EAI045 (<b>55</b>) with nonhydrolyzable quinazoline-4-one gave one more allosteric inhibitor TREA-0236 (<b>58</b>), but it had an inferior biochemical activity to that of its parent EAI045 (<b>55</b>). Dibenzo-diazepinone DDC4002 (<b>60</b>), another allosteric inhibitor, was developed from the structural optimization of EAI002 (<b>59</b>); the co-treatment of this with Cetuximab led to the productive inhibition of mutant EGFR. The inadequacy of all allosteric inhibitors is that they bind specifically to an allosteric pocket formed due to the L858R mutation. Therefore, the development of an allosteric inhibitor that can target not only the point mutation (L858R) but also the frame deletion (Del19) mutations is highly needed.</div><div class="NLM_p">Under the intensive pressure of EGFR inhibition, alternative pathway activation or a histological transformation is responsible for Osimertinib resistance. This mechanism includes MET amplification, HER2 amplification, RAS-(ERK)/MAPK pathway activation, PI3K/AKT/mTOR pathway activation, GAS6-Anexelekto (AXL) activation, FGFR amplification, IGF upregulation, cell-cycle gene alterations, oncogenic fusions, and histologic and phenotypic transformations. These alternative pathways could be inactivated using their inhibitors along with Osimertinib.</div><div class="NLM_p last">Since EGFR is expressed in different tissues for normal biological processes, the severity of toxicity from EGFR inhibitors is one major concern of the inhibitors. Second-generation drugs have the same affinity for WT-EGFR and mutant EGFR, resulting in dose-limiting side effects, such as skin rashes and diarrhea. As a result, the use of these inhibitors in clinical application has been limited, particularly in patients with Erlotinib- or Gefitinib-resistant NSCLC.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> A third-generation EGFR inhibitor, Osimertinib’s selectivity for mutant EGFR is demonstrated by its nearly 200-fold higher occupancy against L858R/T790M than WT EGFR.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> However, Osimertinib’s selectivity for mutant kinases has not yielded the intended results. Its binding to nontarget EGFR receptors <i>in vivo</i> has also resulted in major adverse effects, including as rashes, nausea, diarrhea, hyperglycemia, decreased appetite, a prolonged QT interval, pneumonia,<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> and vortex keratopathy,<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> severely limiting the drug’s clinical application.<a onclick="showRef(event, 'ref236 ref237'); return false;" href="javascript:void(0);" class="ref ref236 ref237">(236,237)</a> Therefore, there is an immense need to identify a more potent mutant selective EGFR L858R/T790M inhibitor that targets the sensitizing mutations, secondary T790M mutation, and tertiary C797S mutation while also sparing the wild type of the receptor. No single drug and therapeutic strategy has yet been approved against Osimertinib resistance to treat NSCLC. In the near future, ongoing combination trials with Osimertinib could change the treatment paradigm for EGFR-mutant NSCLC. Checkpoint inhibitors (CPIs), PROTACs, and other impending immunotherapies provide a landscape for emerging agents against NSCLC.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00876" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iqrar Ahmad</span> - <span class="hlFld-Affiliation affiliation">R.
C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7b1a15081a0912120a091a094e4b3b1c161a121755181416"><span class="__cf_email__" data-cfemail="5b3a35283a2932322a293a296e6b1b3c363a323775383436">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harun Patel</span> - <span class="hlFld-Affiliation affiliation">R.
C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-0920-1266" title="Orcid link">https://orcid.org/0000-0003-0920-1266</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ec849c8d988980b3dfd4ac958d848383c28f8381"><span class="__cf_email__" data-cfemail="7018001104151c2f4348300911181f1f5e131f1d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matin Shaikh</span> - <span class="hlFld-Affiliation affiliation">H.
R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yashodeep Shinde</span> - <span class="hlFld-Affiliation affiliation">R.
C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rahul Pawara</span> - <span class="hlFld-Affiliation affiliation">R.
C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Malleshappa Noolvi</span> - <span class="hlFld-Affiliation affiliation">Shree
Dhanvantari College of Pharmacy, Kim, Surat, Gujarat, India 394111</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanjay Surana</span> - <span class="hlFld-Affiliation affiliation">R.
C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Matin Shaikh</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3795-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Matin Shaikh</b> completed his graduation from A.R.A. College of Pharmacy, Dhule, Maharashtra, India in 2018. He received his M. Pharmacy in Medicinal Chemistry from the R. C. Patel Institute of Pharmaceutical Education and Research Shirpur, Maharashtra, India in 2019. He is currently working as an Assistant Professor at the H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India. His area of interest includes the computational design of NSCLC inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Yashodeep Shinde</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3800-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yashodeep Shinde</b> earned his B. Pharm. and M. Pharm degrees from the R. C. Patel Institute of Pharmaceutical Education and Research Shirpur, Maharashtra, India. He is a young and active synthetic medicinal chemist. His area of interest includes the synthesis and <i>in vitro</i> evaluation of the anticancer drugs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Rahul Pawara</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3808-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rahul Pawara</b> is presently associated with the R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India as an Assistant Professor. He worked as a field officer in the ICMR-funded project of <i>Tuberculosis</i> in the Tribal area. He has completed the B. Pharm. and M. Pharm from the R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India. His area of interest includes the design and synthesis of novel anticancer agents.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Malleshappa Noolvi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3816-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Malleshappa Noolvi</b> received his Ph. D. degree from the Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka, India and is presently associated with Shree Dhanvantary Pharmacy College, Surat, Gujarat, India as a Principal and Professor in the Pharmaceutical Chemistry Department. Dr. Noolvi’s major fields of research interest involve working in the field of QSAR, the docking study and synthesis of newer anticancer agents, and analytical method development to provide improved selectivity and sensitivity for the quantitative analysis of drugs in biological samples and pharmaceuticals.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Sanjay Surana</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3821-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sanjay Surana</b> completed his doctoral degree from Devi Ahilya Vishwavidyalaya, Indore, Madhya Pardesh, India. He currently works as a Professor and Principal at the R. C. Patel Institute of Pharmaceutical Education and Research Shirpur, Maharashtra, India. His area of interest includes the isolation of phyto-constituents and their anticancer evaluation.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Iqrar Ahmad</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3826-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Iqrar Ahmad</b> obtained his postgraduation degree in Pharmaceutical Chemistry from the R.C. Patel Institute of Pharmaceutical Education and Research (RCPIPER), Shirpur, Maharashtra, India. He currently works as a Senior Research Fellow (SRF) under an ICMR-funded research project on development of novel NSCLC inhibitors. His field of interest includes the design of the NSCLC inhibitors using structure- and ligand-based drug design.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Harun Patel</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=BIO-d7e3831-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Harun Patel</b> is currently working as an Associate Professor at the R. C. Patel Institute of Pharmaceutical Education and Research Shirpur, Maharashtra, India. He completed his doctoral degree at Punjab Technical University, Jalandhar, Punjab, India and his Post-Doctoral study from the University of KwaZulu Natal, Durban, South Africa. He intends to continue his research work in the field of the design and development of novel anticancer drug molecule against NSCLC.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank the Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, Department of Health Research, Government of India (Grant ISRM/12(11)/2019) for funding the project.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">Ak strain-transforming (protein kinase B)</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">AXL</td><td class="NLM_def"><p class="first last">Anexelekto</p></td></tr><tr><td class="NLM_term">Ba/F3 cell</td><td class="NLM_def"><p class="first last">a murine interleukin-3-dependent pro-B cell line</p></td></tr><tr><td class="NLM_term">BRAF</td><td class="NLM_def"><p class="first last">v-raf murine sarcoma viral oncogene homologue B1</p></td></tr><tr><td class="NLM_term">C797S</td><td class="NLM_def"><p class="first last">cystein 797 to serine 790</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR-TKI</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">mouse double minute 2</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MET</td><td class="NLM_def"><p class="first last">mesenchymal epithelial transition factor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimera</p></td></tr><tr><td class="NLM_term">PROTACs</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimeric molecules</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">T790M/C797S</td><td class="NLM_def"><p class="first last">threonine 790 methionine/cysteine 797 serine</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin-proteasome system</p></td></tr><tr><td class="NLM_term">U.S. FDA</td><td class="NLM_def"><p class="first last">United States Food and Drug Administration</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">von Hippel-Lindau</p></td></tr><tr><td class="NLM_term">WT EGFR</td><td class="NLM_def"><p class="first last">wild-type epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">PIP-3</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3,4,5-tryphosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 237 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaby-Sandy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1634%2Ftheoncologist.2017-0582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29650685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=891-899&issue=8&author=C.+Y.+Chuauthor=J.+Choiauthor=B.+Eaby-Sandyauthor=C.+J.+Langerauthor=M.+E.+Lacouture&title=Osimertinib%3A+a+novel+dermatologic+adverse+event+profile+in+patients+with+lung+cancer&doi=10.1634%2Ftheoncologist.2017-0582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer</span></div><div class="casAuthors">Chu Chia-Yu; Choi Jennifer; Eaby-Sandy Beth; Langer Corey J; Lacouture Mario E</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.  First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described.  However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs.  Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S.  Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy.  Case summaries of patients from two of our institutions who received osimertinib and were referred to a dermatologist for dAEs are also presented.  Overall, the evidence suggests that osimertinib is associated with less severe and less frequent dAEs than first- and second-generation EGFR-TKIs and that therefore a different approach is warranted.  Finally, we outline dAE management approaches for osimertinib in the context of those typically employed with first- and second-generation EGFR-TKIs.  IMPLICATIONS FOR PRACTICE:  Appropriate prevention and management of dermatologic adverse events (dAEs) associated with the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) may help patients to continue therapy and lessen any negative impact on their quality of life.  EGFR-TKIs are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; however, dAEs associated with third-generation EGFR-TKIs are lower in frequency and severity.  Before therapy, health care providers should discuss the potential osimertinib-associated dAEs and encourage patients to report their dAEs.  Patients should also be educated on prophylactic measures to minimize the severity of dAEs and the importance of adherence to the treatment regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTh0a0oxGmJqYqdXsLcGTEUfW6udTcc2eZ7WpKGI1edVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D&md5=1dcf61eb0461f9495deaf9b7f2c77601</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0582%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DEaby-Sandy%26aufirst%3DB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26atitle%3DOsimertinib%253A%2520a%2520novel%2520dermatologic%2520adverse%2520event%2520profile%2520in%2520patients%2520with%2520lung%2520cancer%26jtitle%3DOncologist%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D891%26epage%3D899%26doi%3D10.1634%2Ftheoncologist.2017-0582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition</span>. <i>Comput. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.compbiolchem.2018.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.compbiolchem.2018.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29627693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1aqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=167-189&author=H.+Patelauthor=R.+Pawaraauthor=S.+Surana&title=In-silico+evidences+for+binding+of+Glucokinase+activators+to+EGFR+C797S+to+overcome+EGFR+resistance+obstacle+with+mutant-selective+allosteric+inhibition&doi=10.1016%2Fj.compbiolchem.2018.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Computational Biology and Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-189</span>CODEN:
                <span class="NLM_cas:coden">CBCOCH</span>;
        ISSN:<span class="NLM_cas:issn">1476-9271</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are generally utilized as a part of patients with non-small cell lung carcinoma (NSCLC).  However, EGFR T790M mutation results in resistance to most clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation has been in active clin. development to triumph the resistance problem; they covalently bind with conserved Cys797 inside the EGFR active site, offering both potency and kinase-selectivity.  Third generation drugs target C797, which makes the C797S resistance mutation more subtle.  EGFR C797S mutation was accounted to be a main mechanism of resistance to the third-generation inhibitors.  The C797S mutation gives off an impression of being an ideal target for conquering the acquired resistance to the third generation inhibitors.  We have performed structure based-virtual screening strategies for binding of glucokinase activator to EGFR C797S, which can overcome EGFR resistance impediment with mutant-selective allosteric inhibition towards all kinds of mutant EGFR (T790M, L858R, TMLR) and WT EGFR.  The final filter of Lipinski's Rule of Five, Jargan's Rule of Three and in silico ADME predictions gave 23 hits, which conform to Lipinski's rule and Jorgensen's rule and all their pharmacokinetic parameters are inside the appropriate range characterized for human use, in this manner demonstrating their potential as a drug-like mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9XS03I3Ohv7Vg90H21EOLACvtfcHk0lg9HIeImOTSDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1aqu7c%253D&md5=549aae7443376313c5bea468b401478c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiolchem.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiolchem.2018.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DIn-silico%2520evidences%2520for%2520binding%2520of%2520Glucokinase%2520activators%2520to%2520EGFR%2520C797S%2520to%2520overcome%2520EGFR%2520resistance%2520obstacle%2520with%2520mutant-selective%2520allosteric%2520inhibition%26jtitle%3DComput.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D74%26spage%3D167%26epage%3D189%26doi%3D10.1016%2Fj.compbiolchem.2018.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">FLAURA investigators. overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1913662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1913662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31751012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=41-50&issue=1&author=S.+S.+Ramalingamauthor=J.+Vansteenkisteauthor=D.+Planchardauthor=B.+C.+Choauthor=J.+E.+Grayauthor=Y.+Oheauthor=C.+Zhouauthor=T.+Reungwetwattanaauthor=Y.+Chengauthor=B.+Chewaskulyongauthor=R.+Shahauthor=M.+Coboauthor=K.+H.+Leeauthor=P.+Cheemaauthor=M.+Tiseoauthor=T.+Johnauthor=M.+C.+Linauthor=F.+Imamuraauthor=T.+Kurataauthor=A.+Toddauthor=R.+Hodgeauthor=M.+Saggeseauthor=Y.+Rukazenkovauthor=J.+C.+Soria&title=FLAURA+investigators.+overall+survival+with+osimertinib+in+untreated%2C+EGFR-mutated+advanced+NSCLC&doi=10.1056%2FNEJMoa1913662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span></div><div class="casAuthors">Ramalingam, S. S.; Vansteenkiste, J.; Planchard, D.; Cho, B. C.; Gray, J. E.; Ohe, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; Shah, R.; Cobo, M.; Lee, K. H.; Cheema, P.; Tiseo, M.; John, T.; Lin, M.-C.; Imamura, F.; Kurata, T.; Todd, A.; Hodge, R.; Saggese, M.; Rukazenkov, Y.; Soria, J.-C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI- sensitizing and EGFR T790M resistance mutations.  A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).  Data from the final anal. of overall survival have not been reported. methods In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).  Overall survival was a secondary end point. results The median overall survival was 38.6 mo (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 mo (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).  At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 mo and 11.5 mo, resp.  Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. conclusions Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.  The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq081UIt-O5nrVg90H21EOLACvtfcHk0liHXSGyUXNXSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D&md5=2f78a87d4578be09e07e91f303b71acf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1913662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1913662%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DCheema%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DM.%2BC.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DSaggese%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFLAURA%2520investigators.%2520overall%2520survival%2520with%2520osimertinib%2520in%2520untreated%252C%2520EGFR-mutated%2520advanced%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26issue%3D1%26spage%3D41%26epage%3D50%26doi%3D10.1056%2FNEJMoa1913662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranuma, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiraoka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uramoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in elderly patients with epidermal growth factor receptor T790M-positive non-small-cell lung cancer who progressed during prior treatment: a phase II trial</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">e170</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2019-0003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1634%2Ftheoncologist.2019-0003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30651400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKhsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=593-e170&issue=5&author=A.+Nakaoauthor=O.+Hiranumaauthor=J.+Uchinoauthor=C.+Sakaguchiauthor=T.+Kitaauthor=N.+Hiraokaauthor=T.+Ishizukaauthor=Y.+Kubotaauthor=M.+Kawasakiauthor=Y.+Gotoauthor=H.+Imaiauthor=N.+Hattoriauthor=K.+Nakatomiauthor=H.+Uramotoauthor=K.+Uryuauthor=M.+Fukudaauthor=Y.+Uchidaauthor=T.+Yokoyamaauthor=M.+Akaiauthor=T.+Mioauthor=S.+Nagashimaauthor=Y.+Chiharaauthor=N.+Tamiyaauthor=Y.+Kanekoauthor=T.+Mouriauthor=T.+Yamadaauthor=K.+Yoshimuraauthor=M.+Fujitaauthor=K.+Takayama&title=Osimertinib+in+elderly+patients+with+epidermal+growth+factor+receptor+T790M-positive+non-small-cell+lung+cancer+who+progressed+during+prior+treatment%3A+a+phase+II+trial&doi=10.1634%2Ftheoncologist.2019-0003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial</span></div><div class="casAuthors">Nakao, Akira; Hiranuma, Osamu; Uchino, Junji; Sakaguchi, Chikara; Kita, Toshiyuki; Hiraoka, Noriya; Ishizuka, Tamotsu; Kubota, Yutaka; Kawasaki, Masayuki; Goto, Yasuhiro; Imai, Hisao; Hattori, Noboru; Nakatomi, Keita; Uramoto, Hidetaka; Uryu, Kiyoaki; Fukuda, Minoru; Uchida, Yasuki; Yokoyama, Toshihide; Akai, Masaya; Mio, Tadashi; Nagashima, Seiji; Chihara, Yusuke; Tamiya, Nobuyo; Kaneko, Yoshiko; Mouri, Takako; Yamada, Tadaaki; Yoshimura, Kenichi; Fujita, Masaki; Takayama, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">593-e170</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.  In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-pos. NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.  Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted.  Previous findings suggest the possibility of relatively safe use of osimertinib for patients with T790M-pos. non-small-cell lung cancer (NSCLC), with few serious adverse events for the elderly in comparison with conventional endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and with an antitumor effect.  This phase II study was performed to prospectively investigate the efficacy and safety of osimertinib for elderly patients aged ≥75 years with ineffective prior EGFR TKI treatment or with recurrence in T790M EGFR TKI resistance mutation-pos. NSCLC.  A total of 36 patients were included in the analyses.  Among the 36 subjects, 63.9% were female, with mean age of 79.9 years.  The objective response rate (ORR) was 58.3% (95% confidence interval [CI], 42.2%-72.9%), demonstrating statistically significant efficacy of osimertinib (p = .0017).  The median duration of response (DOR) was 27.9 wk (95% CI, 21.1-82.0).  Complete response (CR) and partial response (PR) were 2.8% and 55.6%, resp.  Disease control rate (DCR) was 97.2%.  A waterfall plot revealed that 33 (91.6%) subjects exhibited tumor shrinkage during treatment, including 12 of 14 subjects who had stable disease (SD).  All adverse events were not reason for discontinuation of the study drug.  Osimertinib may be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrngojBHrIKvLVg90H21EOLACvtfcHk0liHXSGyUXNXSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKhsL7K&md5=1870d8be9a1a1f1f4b1e6f074a89139c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2019-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2019-0003%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DA.%26aulast%3DHiranuma%26aufirst%3DO.%26aulast%3DUchino%26aufirst%3DJ.%26aulast%3DSakaguchi%26aufirst%3DC.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DHiraoka%26aufirst%3DN.%26aulast%3DIshizuka%26aufirst%3DT.%26aulast%3DKubota%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DHattori%26aufirst%3DN.%26aulast%3DNakatomi%26aufirst%3DK.%26aulast%3DUramoto%26aufirst%3DH.%26aulast%3DUryu%26aufirst%3DK.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DAkai%26aufirst%3DM.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DNagashima%26aufirst%3DS.%26aulast%3DChihara%26aufirst%3DY.%26aulast%3DTamiya%26aufirst%3DN.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DMouri%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DYoshimura%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DTakayama%26aufirst%3DK.%26atitle%3DOsimertinib%2520in%2520elderly%2520patients%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520T790M-positive%2520non-small-cell%2520lung%2520cancer%2520who%2520progressed%2520during%2520prior%2520treatment%253A%2520a%2520phase%2520II%2520trial%26jtitle%3DOncologist%26date%3D2019%26volume%3D24%26issue%3D5%26spage%3D593%26epage%3De170%26doi%3D10.1634%2Ftheoncologist.2019-0003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokwani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S. J.</span></span> <span> </span><span class="NLM_article-title">BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non-small cell lung cancer (NSCLC)</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2838</span>– <span class="NLM_lpage">2856</span>, <span class="refDoi"> DOI: 10.1080/07391102.2020.1754918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F07391102.2020.1754918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32276580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslWgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2021&pages=2838-2856&author=H.+M.+Patelauthor=M.+Shaikhauthor=I.+Ahmadauthor=D.+Lokwaniauthor=S.+J.+Surana&title=BREED+based+de+novo+hybridization+approach%3A+generating+novel+T790M%2FC797S-EGFR+tyrosine+kinase+inhibitors+to+overcome+the+problem+of+mutation+and+resistance+in+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1080%2F07391102.2020.1754918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Patel, Harun M.; Shaikh, Matin; Ahmad, Iqrar; Lokwani, Deepak; Surana, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2838-2856</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-pos. Non-Small Cell Lung Cancer (NSCLC) patients in 2017.  However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs.  In this work, we have reported the novel T790M/C797S-EGFR Tyrosine Kinase inhibitors using BREED based de novo hybridization approach.  BREED generates novel inhibitors from structures of known ligands bound to a common target.  Among the generated hybridized breed compds., the top best scorer breed mols. were breed 436, breed 530, breed 450, breed 562 and breed 313.  Mol. Dynamics simulation of breed 436 for 10 ns further suggested that docked compd. was stable into the pocket of the T790M/C797S-EGFR Tyrosine Kinase.  In silico pharmacokinetic predictions of the breed hybridized compds. were within the defined range described for human use.Communicated by Ramaswamy H.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAu4MNDy34ibVg90H21EOLACvtfcHk0lgKa4h_rJW4OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslWgsLk%253D&md5=e00e6693d1c438495b7f19438a4ba0bc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F07391102.2020.1754918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2020.1754918%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BM.%26aulast%3DShaikh%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DLokwani%26aufirst%3DD.%26aulast%3DSurana%26aufirst%3DS.%2BJ.%26atitle%3DBREED%2520based%2520de%2520novo%2520hybridization%2520approach%253A%2520generating%2520novel%2520T790M%252FC797S-EGFR%2520tyrosine%2520kinase%2520inhibitors%2520to%2520overcome%2520the%2520problem%2520of%2520mutation%2520and%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2021%26volume%3D39%26spage%3D2838%26epage%3D2856%26doi%3D10.1080%2F07391102.2020.1754918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Advance online publication.</p></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnew, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascara, G. P.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation</span>. <i>J. Oncol. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1177/1078155217712401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1177%2F1078155217712401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28565936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyjsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=379-388&issue=5&author=M.+K.+Bollingerauthor=A.+S.+Agnewauthor=G.+P.+Mascara&title=Osimertinib%3A+a+third-generation+tyrosine+kinase+inhibitor+for+treatment+of+epidermal+growth+factor+receptor-mutated+non-small+cell+lung+cancer+with+the+acquired+Thr790Met+mutation&doi=10.1177%2F1078155217712401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation</span></div><div class="casAuthors">Bollinger, Meredith K.; Agnew, Amanda S.; Mascara, Gerard P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-388</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-pos. non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy.  The T790M mutation is an acquired resistance mechanism found in over half of patients with NSCLC progressing on first-generation TKIs.  First- and second-generation TKIs do not inhibit the T790M mutation at clin. relevant concns.  Osimertinib is selective for mutated forms of EGFR, including the TKI-sensitizing mutations L858R and exon 19 deletions, as well as the acquired T790M resistance mutation.  In a trial comparing osimertinib to platinum doublet therapy among patients with the T790M mutation progressing on first-line TKI therapy, median progression-free survival was significantly longer in patients receiving osimertinib.  Osimertinib has a favorable safety profile compared to platinum-doublet chemotherapy.  Common adverse events include diarrhea, skin rash, dry skin, and paronychia; however, because it spares wild-type EGFR, these toxicities appear to occur with less frequency and severity compared to other TKIs.  Serious, but rare, adverse events include pneumonitis, interstitial lung disease-like events, QT interval prolongation, and reduced ejection fraction.  Osimertinib has the unique ability to distribute readily into brain tissue compared with other TKIs, giving it a potential role in the treatment and/or prevention of CNS metastases; future studies are warranted in this area.  An ongoing study evaluating osimertinib vs. first-generation TKIs as first-line treatment for patients with EGFR mutation-pos. NSCLC may help to define the role of osimertinib as front-line therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq3k6YMavK87Vg90H21EOLACvtfcHk0lgKa4h_rJW4OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyjsL3I&md5=102942b63a5133229325e59b967565ea</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1177%2F1078155217712401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155217712401%26sid%3Dliteratum%253Aachs%26aulast%3DBollinger%26aufirst%3DM.%2BK.%26aulast%3DAgnew%26aufirst%3DA.%2BS.%26aulast%3DMascara%26aufirst%3DG.%2BP.%26atitle%3DOsimertinib%253A%2520a%2520third-generation%2520tyrosine%2520kinase%2520inhibitor%2520for%2520treatment%2520of%2520epidermal%2520growth%2520factor%2520receptor-mutated%2520non-small%2520cell%2520lung%2520cancer%2520with%2520the%2520acquired%2520Thr790Met%2520mutation%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2018%26volume%3D24%26issue%3D5%26spage%3D379%26epage%3D388%26doi%3D10.1177%2F1078155217712401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">BIM deletion polymorphism confers resistance to osimertinib in EGFR T790M lung cancer: a case report and literature review</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1007/s11523-018-0573-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1007%2Fs11523-018-0573-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29907952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MbnvVKnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=517-523&issue=4&author=X.+Liauthor=S.+Wangauthor=B.+Liauthor=Z.+Wangauthor=S.+Shangauthor=Y.+Shaoauthor=X.+Sunauthor=L.+Wang&title=BIM+deletion+polymorphism+confers+resistance+to+osimertinib+in+EGFR+T790M+lung+cancer%3A+a+case+report+and+literature+review&doi=10.1007%2Fs11523-018-0573-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review</span></div><div class="casAuthors">Li Xuanzong; Li Xuanzong; Wang Shijiang; Li Butuo; Shang Shuheng; Sun Xindong; Wang Linlin; Li Butuo; Wang Zhen; Shang Shuheng; Shao Yang; Shao Yang</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-523</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients.  However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated.  The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; and is a poor prognostic factor for NSCLC patients with EGFR mutations.  Nevertheless, the significance of this BIM deletion polymorphism in the resistance to osimertinib has not been reported.  Here, we show for the first time that a NSCLC patient harboring the EGFR L858R/T790M mutations, as well as the BIM deletion polymorphism, exhibited poor clinical outcomes with osimertinib treatment.  This result suggests that the BIM deletion polymorphism might have prognostic value for determining NSCLC patient outcomes following osimertinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZgrjbD2HJ_dhSDZx9hyjKfW6udTcc2eYX660QEDoqf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbnvVKnuw%253D%253D&md5=55a627f9ce4954677c388f4959ba6886</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs11523-018-0573-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-018-0573-2%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DShang%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DBIM%2520deletion%2520polymorphism%2520confers%2520resistance%2520to%2520osimertinib%2520in%2520EGFR%2520T790M%2520lung%2520cancer%253A%2520a%2520case%2520report%2520and%2520literature%2520review%26jtitle%3DTarget%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D4%26spage%3D517%26epage%3D523%26doi%3D10.1007%2Fs11523-018-0573-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaby-Sandy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1634%2Ftheoncologist.2017-0582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29650685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=891-899&issue=8&author=C.+Y.+Chuauthor=J.+Choiauthor=B.+Eaby-Sandyauthor=C.+J.+Langerauthor=M.+E.+Lacouture&title=Osimertinib%3A+a+novel+dermatologic+adverse+event+profile+in+patients+with+lung+cancer&doi=10.1634%2Ftheoncologist.2017-0582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer</span></div><div class="casAuthors">Chu Chia-Yu; Choi Jennifer; Eaby-Sandy Beth; Langer Corey J; Lacouture Mario E</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.  First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described.  However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs.  Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S.  Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy.  Case summaries of patients from two of our institutions who received osimertinib and were referred to a dermatologist for dAEs are also presented.  Overall, the evidence suggests that osimertinib is associated with less severe and less frequent dAEs than first- and second-generation EGFR-TKIs and that therefore a different approach is warranted.  Finally, we outline dAE management approaches for osimertinib in the context of those typically employed with first- and second-generation EGFR-TKIs.  IMPLICATIONS FOR PRACTICE:  Appropriate prevention and management of dermatologic adverse events (dAEs) associated with the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) may help patients to continue therapy and lessen any negative impact on their quality of life.  EGFR-TKIs are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; however, dAEs associated with third-generation EGFR-TKIs are lower in frequency and severity.  Before therapy, health care providers should discuss the potential osimertinib-associated dAEs and encourage patients to report their dAEs.  Patients should also be educated on prophylactic measures to minimize the severity of dAEs and the importance of adherence to the treatment regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTh0a0oxGmJqYqdXsLcGTEUfW6udTcc2eZ8OPX7rdap9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D&md5=1dcf61eb0461f9495deaf9b7f2c77601</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0582%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DEaby-Sandy%26aufirst%3DB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26atitle%3DOsimertinib%253A%2520a%2520novel%2520dermatologic%2520adverse%2520event%2520profile%2520in%2520patients%2520with%2520lung%2520cancer%26jtitle%3DOncologist%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D891%26epage%3D899%26doi%3D10.1634%2Ftheoncologist.2017-0582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">i20</span>– <span class="NLM_lpage">i27</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29462255" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i20-i27&issue=1&author=J.+Remonauthor=C.+E.+Steuerauthor=S.+S.+Ramalingamauthor=E.+Felip&title=Osimertinib+and+other+third-generation+EGFR+TKI+in+EGFR-mutant+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdx704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx704%26sid%3Dliteratum%253Aachs%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DSteuer%26aufirst%3DC.%2BE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DOsimertinib%2520and%2520other%2520third-generation%2520EGFR%2520TKI%2520in%2520EGFR-mutant%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D1%26spage%3Di20%26epage%3Di27%26doi%3D10.1093%2Fannonc%2Fmdx704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title"><i>In silico</i> search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): A combined approach of structure-based virtual screening and molecular dynamics simulation</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1505</span>, <span class="refDoi"> DOI: 10.1080/07391102.2020.1734092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F07391102.2020.1734092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32102624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVWlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2021&pages=1491-1505&issue=4&author=H.+M.+Patelauthor=I.+Ahmadauthor=R.+Pawaraauthor=M.+Shaikhauthor=S.+Surana&title=In+silico+search+of+triple+mutant+T790M%2FC797S+allosteric+inhibitors+to+conquer+acquired+resistance+problem+in+non-small+cell+lung+cancer+%28NSCLC%29%3A+A+combined+approach+of+structure-based+virtual+screening+and+molecular+dynamics+simulation&doi=10.1080%2F07391102.2020.1734092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation</span></div><div class="casAuthors">Patel, Harun M.; Ahmad, Iqrar; Pawara, Rahul; Shaikh, Matin; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1491-1505</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-pos. Non-Small Cell Lung Cancer (NSCLC) patients in 2017.  However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs.  Recently, EAI045 fourth-generation allosteric EGFR inhibitor has been reported, which binds away from the ATP-binding site and not rely on Cys 797 binding.  Here, we are reporting compd. ZINC20531199 by virtual based screening studies as allosteric inhibitor to overcome the EGFR T790M/C797S Tyrosine Kinase (TK) mutation problem.  Mol. Dynamics simulation for 10 ns further suggested that docked compd. ZINC20531199 was stable into the allosteric pocket of the C797S EGFR tyrosine kinase.  In silico pharmacokinetic predictions of the virtually screened compds. are within the defined range described for human use.  Results indicate that the virtual screened compds. could be potential leads for the further development of new allosteric EGFR T790M/C797S inhibitors to overcome the problem of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPl-guE2VQo7Vg90H21EOLACvtfcHk0ljUTi5MsKUZng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVWlt7w%253D&md5=f8ce92001fd1fa112fa5a7b34c215d49</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F07391102.2020.1734092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2020.1734092%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BM.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DShaikh%26aufirst%3DM.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DIn%2520silico%2520search%2520of%2520triple%2520mutant%2520T790M%252FC797S%2520allosteric%2520inhibitors%2520to%2520conquer%2520acquired%2520resistance%2520problem%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520A%2520combined%2520approach%2520of%2520structure-based%2520virtual%2520screening%2520and%2520molecular%2520dynamics%2520simulation%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2021%26volume%3D39%26issue%3D4%26spage%3D1491%26epage%3D1505%26doi%3D10.1080%2F07391102.2020.1734092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisamatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span> <span> </span><span class="NLM_article-title">Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status</span>. <i>Jpn. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1093/jjco/hyz041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fjjco%2Fhyz041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30920616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3cbptVeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=671-675&issue=7&author=K.+Nakashimaauthor=M.+Kimuraauthor=H.+Akamatsuauthor=H.+Dagaauthor=H.+Imaiauthor=T.+Tairaauthor=R.+Koauthor=Y.+Hisamatsuauthor=K.+Nishinoauthor=T.+Sugimotoauthor=Y.+Miyashitaauthor=T.+Takahashi&title=Osimertinib+for+patients+with+EGFR+T790M+mutation-positive+non-small-cell+lung+cancer+and+a+poor+performance+status&doi=10.1093%2Fjjco%2Fhyz041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status</span></div><div class="casAuthors">Nakashima Kazuhisa; Takahashi Toshiaki; Kimura Madoka; Nishino Kazumi; Akamatsu Hiroaki; Sugimoto Takeya; Daga Haruko; Imai Hisao; Taira Tetsuhiko; Ko Ryo; Miyashita Yosuke; Hisamatsu Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Japanese journal of clinical oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-675</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS).  However, the efficacy and safety of osimertinib for patients with poor PS is unknown.  METHODS:  We retrospectively evaluated the efficacy and safety of osimertinib in patients with EGFR T790M mutation-positive NSCLC who had Eastern Cooperative Oncology Group PS scores of 2-4 and who were administered 80 mg of osimertinib once daily between March 2016 and February 2017.  RESULTS:  Thirty patients (8 men and 22 women) with EGFR T790M mutation-positive NSCLC were evaluated; their median age was 66 years (range: 39-89 years).  Twenty-four and six patients had PS scores of 2 and 3, respectively; none had a PS score of 4.  All patients had previously been treated with first- or second-generation EGFR-TKIs.  T790M was detected in the tumor samples of 23 patients, the blood samples of two patients, and both the tumor and blood samples of five patients.  The overall response rate was 53% (95% confidence interval: 36-70%), and the PS score improvement rate was 63%.  The median progression-free survival was 8.2 months (95% confidence interval: 4.3-13.2 months), while the median overall survival time was not reached.  No patient required treatment cessation owing to adverse events, and no treatment-related deaths occurred.  CONCLUSIONS:  Osimertinib therapy demonstrates promising efficacy and acceptable safety in patients with EGFR T790M mutation-positive NSCLC who have poor PS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvK5k0nFqxFM25P7XSLhESfW6udTcc2eYEtFlIMprE4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbptVeltw%253D%253D&md5=ab3fc3ab1caf701b76966da6021719f1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Fjjco%2Fhyz041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjjco%252Fhyz041%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DM.%26aulast%3DAkamatsu%26aufirst%3DH.%26aulast%3DDaga%26aufirst%3DH.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DTaira%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DR.%26aulast%3DHisamatsu%26aufirst%3DY.%26aulast%3DNishino%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DMiyashita%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26atitle%3DOsimertinib%2520for%2520patients%2520with%2520EGFR%2520T790M%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520and%2520a%2520poor%2520performance%2520status%26jtitle%3DJpn.%2520J.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D49%26issue%3D7%26spage%3D671%26epage%3D675%26doi%3D10.1093%2Fjjco%2Fhyz041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0290-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs13045-016-0290-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27448564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=59&issue=1&author=S.+Wangauthor=S.+T.+Tsuiauthor=C.+Liuauthor=Y.+Songauthor=D.+Liu&title=EGFR+C797S+mutation+mediates+resistance+to+third-generation+inhibitors+in+T790M-positive+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0290-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Tsui, Stella T.; Liu, Christina; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59/1-59/5</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR).  Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance.  AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-pos. non-small cell lung cancer.  Resistance to AZD9291 has been described.  C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors.  This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIJ4ifH6CVz7Vg90H21EOLACvtfcHk0li-nem48hq7xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK&md5=f1c69b429f08a527b9a20bdd567fe21a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0290-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0290-1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520third-generation%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26issue%3D1%26spage%3D59%26doi%3D10.1186%2Fs13045-016-0290-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0li-nem48hq7xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lizaso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Effective Treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by Brigatinib and Cetuximab combination therapy</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1369</span>– <span class="NLM_lpage">1375</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2020.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2020.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32353596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1Witb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1369-1375&issue=8&author=Y.+Wangauthor=N.+Yangauthor=Y.+Zhangauthor=L.+Liauthor=R.+Hanauthor=M.+Zhuauthor=M.+Fengauthor=H.+Chenauthor=A.+Lizasoauthor=T.+Qinauthor=X.+Liuauthor=Y.+He&title=Effective+Treatment+of+lung+adenocarcinoma+harboring+EGFR-activating+mutation%2C+T790M%2C+and+cis-C797S+triple+mutations+by+Brigatinib+and+Cetuximab+combination+therapy&doi=10.1016%2Fj.jtho.2020.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy</span></div><div class="casAuthors">Wang, Yubo; Yang, Nong; Zhang, Yongchang; Li Li; Han, Rui; Zhu, Mengxiao; Feng, Mingxia; Chen, Hengyi; Lizaso, Analyn; Qin, Tian; Liu, Xiaoyan; He, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1369-1375</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Acquired resistance to osimertinib mediated by EGFR cis-C797S is now a growing challenge.  No effective treatment strategy is currently available to overcome cis-C797S-mediated resistance.In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing.  Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy.Among the five patients who were pos. for EGFR 19del-T790M-cis-C797S mutations, and who received brigatinib and cetuximab combination therapy, three patients achieved partial response, and two had stable disease, resulting in an overall objective response rate of 60% and disease control rate of 100%.  The median progression-free survival of patients who received combined targeted therapy was 14 mo, and 3 mo for those treated with chemotherapy.  No grade III to IV adverse events were obsd. in any patient.Our retrospective study provides clin. evidence that a combined targeted therapy of brigatinib and cetuximab could be of benefit and may potentially be an effective treatment strategy to improve survival outcomes in patients who acquire EGFR T790M-cis-C797S-mediated resistance to osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOpzxK8qh187Vg90H21EOLACvtfcHk0lh3vfxanHLO1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1Witb8%253D&md5=9416ba28fb6dc504c6015b5da2cc6284</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2020.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2020.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLizaso%26aufirst%3DA.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DEffective%2520Treatment%2520of%2520lung%2520adenocarcinoma%2520harboring%2520EGFR-activating%2520mutation%252C%2520T790M%252C%2520and%2520cis-C797S%2520triple%2520mutations%2520by%2520Brigatinib%2520and%2520Cetuximab%2520combination%2520therapy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D8%26spage%3D1369%26epage%3D1375%26doi%3D10.1016%2Fj.jtho.2020.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rangachari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpilsky, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderLaan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31377341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2rtbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1995-2002&issue=11&author=D.+Rangachariauthor=C.+Toauthor=J.+E.+Shpilskyauthor=P.+A.+VanderLaanauthor=S.+S.+Kobayashiauthor=M.+Mushajiangauthor=C.+J.+Lauauthor=C.+P.+Paweletzauthor=G.+R.+Oxnardauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costa&title=EGFR-mutated+lung+cancers+resistant+to+osimertinib+through+EGFR+C797S+respond+to+first-generation+reversible+EGFR+inhibitors+but+eventually+acquire+EGFR+T790M%2FC797S+in+preclinical+models+and+clinical+samples&doi=10.1016%2Fj.jtho.2019.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples</span></div><div class="casAuthors">Rangachari, Deepa; To, Ciric; Shpilsky, Jason E.; VanderLaan, Paul A.; Kobayashi, Susumu S.; Mushajiang, Mierzhati; Lau, Christie J.; Paweletz, Cloud P.; Oxnard, Geoffrey R.; Janne, Pasi A.; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1995-2002</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance to this third-generation EGFR inhibitor are evolving.  Whether durable control of subsequently osimertinib-resistant NSCLC with EGFR-sensitizing mutation (SM)/C797S is possible with first-generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resultant acquired resistance profile.  We used N-ethyl-N-nitrosourea mutagenesis to det. the profile of EGFR SM/C797S preclin. models exposed to reversible EGFR inhibitors.  A patient with EGFR delE746_T751insV NSCLC was treated with osimertinib with sustained response for 10 mo before acquiring EGFR C797S.  The patient was subsequently treated with erlotinib, with response for a period of 4 mo, but disease progression ensued.  Liq. biopsy disclosed EGFR delE746_T751insV with T790M and C797S present in cis.EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation.  In this clin. scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanisms of on-target resistance-in clin. specimens and preclin. systems-indicate that EGFR C797S along with EGFR T790M can evolve.  This report adds to the growing understanding of tumor evolution or adaptability to sequential EGFR inhibition and augments support for exploring combination therapies to delay or prevent on-target resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLLezOe5dZWbVg90H21EOLACvtfcHk0lh3vfxanHLO1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2rtbjP&md5=ff94c150198c71ec57c7a0a2cea1b746</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DRangachari%26aufirst%3DD.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DShpilsky%26aufirst%3DJ.%2BE.%26aulast%3DVanderLaan%26aufirst%3DP.%2BA.%26aulast%3DKobayashi%26aufirst%3DS.%2BS.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DC.%2BJ.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DEGFR-mutated%2520lung%2520cancers%2520resistant%2520to%2520osimertinib%2520through%2520EGFR%2520C797S%2520respond%2520to%2520first-generation%2520reversible%2520EGFR%2520inhibitors%2520but%2520eventually%2520acquire%2520EGFR%2520T790M%252FC797S%2520in%2520preclinical%2520models%2520and%2520clinical%2520samples%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D11%26spage%3D1995%26epage%3D2002%26doi%3D10.1016%2Fj.jtho.2019.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span> <span> </span><span class="NLM_article-title">Exon 16-Skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31557536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=50-61&issue=1&author=C.+C.+Hsuauthor=B.+C.+Liaoauthor=W.+Y.+Liaoauthor=A.+Markovetsauthor=D.+Stetsonauthor=K.+Thressauthor=J.+C.+Yang&title=Exon+16-Skipping+HER2+as+a+novel+mechanism+of+osimertinib+resistance+in+EGFR+L858R%2FT790M-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2019.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Hsu, Chia-Chi; Liao, Bin-Chi; Liao, Wei-Yu; Markovets, Aleksandra; Stetson, Daniel; Thress, Kenneth; Chih-Hsin Yang, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-61</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We had a patient with EGFR L858R/T790M-pos. NSCLC who initially responded to osimertinib therapy but eventually experienced development of resistance.  Plasma cell-free DNA anal. revealed the occurrence of exon 16-skipping HER2, which may have resulted in the erb-b2 receptor tyrosine kinase 2 gene (HER2) splice variant HER2D16.  HER2D16 has never been reported in lung cancer, and HER2D16-driven signaling is known to be regulated by Src kinase in breast cancer.  We investigated the role of HER2D16 as an osimertinib-resistant mechanism.We constructed and established H1975 cells stably expressing HER2D16.  The dimeric formation of HER2D16 was tested by using nonreducing polyacrylamide gel electrophoresis.  Synergistic effect was assessed by using the Chou-Talalay method.We found that HER2D16 can form a homodimer in NSCLC cells.  We also found that mutant EGFR and HER2D16 cooperated to activate downstream signaling for osimertinib resistance.  In addn., cotreatment with osimertinib and an Src kinase inhibitor failed to reverse resistance, indicating that HER2D16-driven signaling in NSCLC did not occur through a canonical pathway.  Finally, we revealed that the combination of osimertinib with the pan-HER small-mol. inhibitor afatinib could synergistically repress cell growth and signaling in H1975-HER2D16 cells.HER2D16 can contribute to osimertinib resistance through an Src-independent pathway.  HER2D16 should be included in the mol. diagnosis panel for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGJOlmIkbukrVg90H21EOLACvtfcHk0lgiFuEt9EumCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O&md5=b711bc98055e4be3f9f295688878b151</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DB.%2BC.%26aulast%3DLiao%26aufirst%3DW.%2BY.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DExon%252016-Skipping%2520HER2%2520as%2520a%2520novel%2520mechanism%2520of%2520osimertinib%2520resistance%2520in%2520EGFR%2520L858R%252FT790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D50%26epage%3D61%26doi%3D10.1016%2Fj.jtho.2019.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">EGFR-TKIs resistance via EGFR-independent signalling pathways</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0793-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs12943-018-0793-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29455669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=53&issue=1&author=Q.+Liuauthor=S.+Yuauthor=W.+Zhaoauthor=S.+Qinauthor=Q.+Chuauthor=K.+Wu&title=EGFR-TKIs+resistance+via+EGFR-independent+signalling+pathways&doi=10.1186%2Fs12943-018-0793-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-TKIs resistance via EGFR-independent signaling pathways</span></div><div class="casAuthors">Liu, Qian; Yu, Shengnan; Zhao, Weiheng; Qin, Shuang; Chu, Qian; Wu, Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53/1-53/9</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, esp. for those with lung cancer.  Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment.  Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling activations.  In an EGFR-dependent manner, acquired mutations, such as T790 M, interferes the interaction between TKIs and the kinase domain of EGFR.  While in an EGFR-independent manner, dysregulation of other receptor tyrosine kinases (RTKs) or abnormal activation of downstream compds. both have compensatory functions against the inhibition of EGFR through triggering phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) signaling axes.  Nowadays, many clin. trials aiming to overcome and prevent TKIs resistance in various cancers are ongoing or completed.  EGFR-TKIs in accompany with the targeted agents for resistance-related factors afford a promising first-line strategy to further clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSxU7DAlhei7Vg90H21EOLACvtfcHk0lgiFuEt9EumCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7rL&md5=82b2072295b267dffec9bb58467ae632</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0793-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0793-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DEGFR-TKIs%2520resistance%2520via%2520EGFR-independent%2520signalling%2520pathways%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D53%26doi%3D10.1186%2Fs12943-018-0793-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, M.</span></span> <span> </span><span class="NLM_article-title">Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.pharmthera.2016.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27000770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2016&pages=97-110&author=M.+Kuwanoauthor=K.+Sonodaauthor=Y.+Murakamiauthor=K.+Watariauthor=M.+Ono&title=Overcoming+drug+resistance+to+receptor+tyrosine+kinase+inhibitors%3A+Learning+from+lung+cancer&doi=10.1016%2Fj.pharmthera.2016.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer</span></div><div class="casAuthors">Kuwano, Michihiko; Sonoda, Kahori; Murakami, Yuichi; Watari, Kosuke; Ono, Mayumi</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97-110</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC).  Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied.  Receptor TKIs including EGFR TKIs have shown dramatic therapeutic efficacies in malignant tumors, which harbor activating mutations in the EGFR gene.  However, within 1 or 2 years after treatment, patients harboring these mutations often develop resistance to TKI therapy.  This review article is aimed at drawing attention to the fact that we must first understand how receptor TKI resistance is acquired to develop strategies for overcoming resistance to TKIs.  Furthermore, an insight into the specific mols. or signaling pathways that mediate resistance is a key factor for understanding and overcoming acquired drug resistance.  Finally, we present our views on the continuing battle against "drug resistance," and provide further guidelines and strategies on how to minimize the development of drug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYnPGJoZybbVg90H21EOLACvtfcHk0lgiFuEt9EumCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCqs7k%253D&md5=97b66a1438e50c7754e0fd06fee17bcb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DKuwano%26aufirst%3DM.%26aulast%3DSonoda%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DWatari%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DM.%26atitle%3DOvercoming%2520drug%2520resistance%2520to%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520Learning%2520from%2520lung%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D161%26spage%3D97%26epage%3D110%26doi%3D10.1016%2Fj.pharmthera.2016.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lgiFuEt9EumCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2017.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28526474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=32-47&author=H.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=S.+Surana&title=Recent+updates+on+third+generation+EGFR+inhibitors+and+emergence+of+fourth+generation+EGFR+inhibitors+to+combat+C797S+resistance&doi=10.1016%2Fj.ejmech.2017.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Ansari, Azim; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  EGFR T790M mutation leads to resistance to most of clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors.  This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprj-V5hUSHGrVg90H21EOLACvtfcHk0li5mbn2oVqIRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D&md5=d0ed35bc7deae5ea37a95910df356c1d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DRecent%2520updates%2520on%2520third%2520generation%2520EGFR%2520inhibitors%2520and%2520emergence%2520of%2520fourth%2520generation%2520EGFR%2520inhibitors%2520to%2520combat%2520C797S%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ejmech.2017.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span> <span> </span><span class="NLM_article-title">p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1080/07391102.2020.1844801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F07391102.2020.1844801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB2c%252FpvVWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-14&author=I.+Ahmadauthor=M.+Shaikhauthor=S.+Suranaauthor=A.+Ghoshauthor=H.+Patel&title=p38%CE%B1+MAP+kinase+inhibitors+to+overcome+EGFR+tertiary+C797S+point+mutation+associated+with+osimertinib+in+non-small+cell+lung+cancer+%28NSCLC%29%3A+emergence+of+fourth-generation+EGFR+inhibitor&doi=10.1080%2F07391102.2020.1844801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Heme-iron ligand (M80-Fe) in cytochrome c is destabilizing: combined in vitro and in silico approaches to monitor changes in structure, stability and dynamics of the protein on mutation</span></div><div class="casAuthors">Naiyer Abdullah; Khan Bushra; Islam Asimul; Hassan Md Imtaiyaz; Ahmad Faizan; Sundd Monica</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomolecular structure & dynamics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Structure, stability and dynamics properties of horse cytochrome c (cyt c) and its genetically engineered M80G mutant have been investigated.  The nature of the Met80 axial ligation to heme iron is believed to be the major determinant of the oxidation-reduction reactions inside and outside the cell of a particular cytochrome.  This ligation has played an important role in the studies of protein structure, stability and protein folding/unfolding.  To understand this ligation better, Met80 of horse cyt c has been mutated to Gly that is unable to bind to the heme iron.  We have examined the effect of the M80G mutation on the structure and stability of the WT (wild type) protein by using absorbance spectroscopy, far-UV, near-UV and Soret circular dichroism, fluorescence spectroscopy and differential scanning calorimetry.  We have observed that mutation caused a partial loss of secondary and tertiary structure with slightly increased overall stability of the protein.  We have also measured the dynamic behavior of WT cyt c and its M80G mutant in the oxidized form (Fe(3+)) using the essential dynamics (ED) method.  A 400 ns MD simulations were run for WT cyt c and its mutant M80G in water using GROMOS96 force field.  MD results revealed that the stability and flexibility increased in mutant M80G (Fe...S (Met80) bond removed).  Essential dynamics analysis revealed that the first five eigenvectors were mainly involved in overall motions of WT cyt c and its M80G mutant but the amplitude of concerted motions decreased in M80G mutant relative to WT cyt c.Communicated by Ramaswamy H.  Sarma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRraR2_U_2MCMK3uFsUIZtkfW6udTcc2eYuaWZmhCQBF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB2c%252FpvVWmtw%253D%253D&md5=79df1ce7be71c9a959c06f35b816473c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DShaikh%26aufirst%3DM.%26aulast%3DSurana%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DH.%26atitle%3Dp38%25CE%25B1%2520MAP%2520kinase%2520inhibitors%2520to%2520overcome%2520EGFR%2520tertiary%2520C797S%2520point%2520mutation%2520associated%2520with%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520emergence%2520of%2520fourth-generation%2520EGFR%2520inhibitor%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2020%26spage%3D1%26epage%3D14%26doi%3D10.1080%2F07391102.2020.1844801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signalling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&issue=7&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signalling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lha3EJYfcQcrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signalling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26issue%3D7%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L. M.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor in tumor angiogenesis</span>. <i>Hematol. Oncol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1016/j.hoc.2004.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.hoc.2004.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=15474332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BD2crgsF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1007-1021&issue=5&author=L.+M.+Ellis&title=Epidermal+growth+factor+receptor+in+tumor+angiogenesis&doi=10.1016%2Fj.hoc.2004.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor in tumor angiogenesis</span></div><div class="casAuthors">Ellis Lee M</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1007-21, viii</span>
        ISSN:<span class="NLM_cas:issn">0889-8588</span>.
    </div><div class="casAbstract">This article focuses on the preclinical evidence for activation of the epidermal growth factor receptor (EGFR) in promoting angiogenesis and the efficacy of anti-EGFR agents in inhibiting angiogenesis and tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9JT0MhqmWmHO4gDb7JggCfW6udTcc2ebpGH_5BN3vMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crgsF2kuw%253D%253D&md5=4de3bb0b6a106026f46949ca572797a1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2004.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2004.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520in%2520tumor%2520angiogenesis%26jtitle%3DHematol.%2520Oncol.%2520Clin.%26date%3D2004%26volume%3D18%26issue%3D5%26spage%3D1007%26epage%3D1021%26doi%3D10.1016%2Fj.hoc.2004.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">32S</span>– <span class="NLM_lpage">40S</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=11560969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVKqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=32S-40S&author=C.+L.+Arteaga&title=The+epidermal+growth+factor+receptor%3A+from+mutant+oncogene+in+nonhuman+cancers+to+therapeutic+target+in+human+neoplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia</span></div><div class="casAuthors">Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18, Suppl.</span>),
    <span class="NLM_cas:pages">32s-40s</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Approx. two decades ago, the epidermal growth factor receptor (EGFR) was discovered to be the proto-oncogene of the mutant, constitutively active oncogenic v-erbB tyrosine kinase, which induces avian erythroblastosis.  Unlike the mutant oncogene, the EGFR requires activation by binding of ligand to its extracellular (EC) domain, whereas its cellular effects depend on activation of its cytoplasmic tyrosine kinase.  The overexpression of EGFR and its ligands in several human carcinomas and their assocn. with accelerated tumor progression provided a rationale for targeting this network with tumor-selective strategies.  Two of those antireceptor approaches, both solidly based on the known structure and function of the EGFR, are discussed.  The first strategy involves the development of humanized monoclonal antibodies against the non-conserved receptor's EC domain.  These antibodies block ligand binding and can induce receptor endocytosis and downregulation.  The second approach is the generation of ATP mimetics that compete with ATP for binding to the receptor's kinase pocket, thus disabling signal transduction.  Preclin. and early clin. studies already suggest that both of these approaches, either alone or in combination with std. anticancer therapies, will be able to alter the natural history of EGFR-expressing cancers with little to no toxicity to the tumor-bearing host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpFLkhUx5kLVg90H21EOLACvtfcHk0lha3EJYfcQcrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVKqtr0%253D&md5=f3243f5fafb40749a6dd2bdb4e2c0028</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%253A%2520from%2520mutant%2520oncogene%2520in%2520nonhuman%2520cancers%2520to%2520therapeutic%2520target%2520in%2520human%2520neoplasia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D19%26spage%3D32S%26epage%3D40S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cully, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nrc1819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnrc1819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=16453012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhslelt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=184-192&issue=3&author=M.+Cullyauthor=H.+Youauthor=A.+J.+Levineauthor=T.+W.+Mak&title=Beyond+PTEN+mutations%3A+the+PI3K+pathway+as+an+integrator+of+multiple+inputs+during+tumorigenesis&doi=10.1038%2Fnrc1819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis</span></div><div class="casAuthors">Cully, Megan; You, Han; Levine, Arnold J.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-192</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The tumor-suppressor phosphatase with tensin homol. (PTEN) is the most important neg. regulator of the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase (PI3K).  Although PTEN is mutated or deleted in many tumors, deregulation of the PI3K-PTEN network also occurs through other mechanisms.  Crosstalk between the PI3K pathways and other tumorigenic signaling pathways, such as those that involve Ras, p53, TOR (target of rapamycin) or DJ1, can contribute to this deregulation.  How does the PI3K pathway integrate signals from numerous sources, and how can this information be used in the rational design of cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7UxMKOlX7X7Vg90H21EOLACvtfcHk0lha3EJYfcQcrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhslelt78%253D&md5=8769e7e349cc58f5c618cdce886186d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1819%26sid%3Dliteratum%253Aachs%26aulast%3DCully%26aufirst%3DM.%26aulast%3DYou%26aufirst%3DH.%26aulast%3DLevine%26aufirst%3DA.%2BJ.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DBeyond%2520PTEN%2520mutations%253A%2520the%2520PI3K%2520pathway%2520as%2520an%2520integrator%2520of%2520multiple%2520inputs%2520during%2520tumorigenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26issue%3D3%26spage%3D184%26epage%3D192%26doi%3D10.1038%2Fnrc1819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">The CXCL8-CXCR1/2 pathways in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cytogfr.2016.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27578214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaktLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=61-71&author=Q.+Liuauthor=A.+Liauthor=Y.+Tianauthor=J.+D.+Wuauthor=Y.+Liuauthor=T.+Liauthor=Y.+Chenauthor=X.+Hanauthor=K.+Wu&title=The+CXCL8-CXCR1%2F2+pathways+in+cancer&doi=10.1016%2Fj.cytogfr.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The CXCL8-CXCR1/2 pathways in cancer</span></div><div class="casAuthors">Liu, Qian; Li, Anping; Tian, Yijun; Wu, Jennifer D.; Liu, Yu; Li, Tengfei; Chen, Yuan; Han, Xinwei; Wu, Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61-71</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Persistent infection or chronic inflammation contributes significantly to tumorigenesis and tumor progression.  C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctional cytokine to modulate tumor proliferation, invasion and migration in an autocrine or paracrine manner.  Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including breast cancer, prostate cancer, lung cancer, colorectal carcinoma and melanoma.  CXCL8 also integrates with multiple intracellular signalling pathways to produce coordinated effects.  Neovascularisation, which provides a basis for fostering tumor growth and metastasis, is now recognized as a crit. function of CXCL8 in the tumor microenvironment.  In this review, we summarize the biol. functions and clin. significance of the CXCL8 signalling axis in cancer.  We also propose that CXCL8 may be a potential therapeutic target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCpvVEJgr0OLVg90H21EOLACvtfcHk0li7MPaFLBzDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaktLnE&md5=acdda5c9236667b00ac33c158f818676</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DThe%2520CXCL8-CXCR1%252F2%2520pathways%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2016%26volume%3D31%26spage%3D61%26epage%3D71%26doi%3D10.1016%2Fj.cytogfr.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signalling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cell.2017.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28388417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2017&pages=361-371&issue=2&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signalling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Signaling in Growth, Metabolism, and Disease [Erratum to document cited in CA166:281944]</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Earlier drafts of the figures in this Review were published in print and online; the figures have been updated online.  The information that the earlier figures contained was accurate and complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRgFTR-eFpLVg90H21EOLACvtfcHk0li7MPaFLBzDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKhsr8%253D&md5=5e3235c6302939ada00fc0e8d3f04293</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signalling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D169%26issue%3D2%26spage%3D361%26epage%3D371%26doi%3D10.1016%2Fj.cell.2017.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, H. L.</span></span> <span> </span><span class="NLM_article-title">PI3K/AKT/mTOR pathway as a target for cancer therapy</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1097/01.cad.0000173476.67239.3b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2F01.cad.0000173476.67239.3b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=16096426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntlSkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=797-803&issue=8&author=D.+Morgenszternauthor=H.+L.+McLeod&title=PI3K%2FAKT%2FmTOR+pathway+as+a+target+for+cancer+therapy&doi=10.1097%2F01.cad.0000173476.67239.3b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K/Akt/mTOR pathway as a target for cancer therapy</span></div><div class="casAuthors">Morgensztern, Daniel; McLeod, Howard L.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">797-803</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are also crit. for tumorigenesis, including cellular proliferation, growth, survival and mobility.  Components of this pathway are frequently abnormal in a variety of tumors, making them an attractive target for anti-cancer therapy.  Inhibition of mTOR in patients with cancer became more feasible after the development of rapamycin analogs with improved pharmacol. properties.  The promising activity of these agents in early clin. trials has led to the development of ongoing phase III trials in renal cell carcinoma and breast cancer.  Future studies are needed to identify the patients most likely to benefit from this form of therapy, and to define its role in combination with chemotherapy, hormones and growth factor inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqggRZvKh4ca7Vg90H21EOLACvtfcHk0li7MPaFLBzDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntlSkt78%253D&md5=b786a72594c9af727d35fa7e51f96a2a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000173476.67239.3b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000173476.67239.3b%26sid%3Dliteratum%253Aachs%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DMcLeod%26aufirst%3DH.%2BL.%26atitle%3DPI3K%252FAKT%252FmTOR%2520pathway%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2005%26volume%3D16%26issue%3D8%26spage%3D797%26epage%3D803%26doi%3D10.1097%2F01.cad.0000173476.67239.3b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">101042831771244</span>, <span class="refDoi"> DOI: 10.1177/1010428317712445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1177%2F1010428317712445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2017&pages=101042831771244&issue=6&author=Q.+Liuauthor=S.+Yuauthor=A.+Liauthor=H.+Xuauthor=X.+Hanauthor=K.+Wu&title=Targeting+interlukin-6+to+relieve+immunosuppression+in+tumor+microenvironment&doi=10.1177%2F1010428317712445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F1010428317712445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1010428317712445%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DTargeting%2520interlukin-6%2520to%2520relieve%2520immunosuppression%2520in%2520tumor%2520microenvironment%26jtitle%3DTumor%2520Biol.%26date%3D2017%26volume%3D39%26issue%3D6%26spage%3D101042831771244%26doi%3D10.1177%2F1010428317712445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&issue=1&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy&doi=10.1038%2Fnrc969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0lhG61P5ViYGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26issue%3D1%26spage%3D11%26epage%3D22%26doi%3D10.1038%2Fnrc969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liguori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffinà, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Aveni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altavilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in the treatment of non-small-cell lung cancer: Design, development and place in therapy</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S119644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FLCTT.S119644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkt1elsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=109-125&author=M.+Santarpiaauthor=A.+Liguoriauthor=N.+Karachaliouauthor=M.+Gonzalez-Caoauthor=M.+G.+Daffin%C3%A0author=A.+D%E2%80%99Aveniauthor=G.+Marabelloauthor=G.+Altavillaauthor=R.+Rosell&title=Osimertinib+in+the+treatment+of+non-small-cell+lung+cancer%3A+Design%2C+development+and+place+in+therapy&doi=10.2147%2FLCTT.S119644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy</span></div><div class="casAuthors">Santarpia, Mariacarmela; Liguori, Alessia; Karachaliou, Niki; Gonzalez-Cao, Maria; Daffina, Maria Grazia; D'Aveni, Alessandro; Marabello, Grazia; Altavilla, Giuseppe; Rosell, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-125</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase inhibitors (TKIs) marked the advent of the era of precision medicine for non-small-cell lung cancer (NSCLC).  First- and second-generation EGFR TKIs, including erlotinib, gefitinib and afatinib, have consistently shown superior efficacy and better toxicity compared with first-line platinum-based chemotherapy and currently represent the std. of care for EGFR-mutated advanced NSCLC patients.  However, tumors invariably develop acquired resistance to EGFR TKIs, thereby limiting the long-term efficacy of these agents.  The T790M mutation in exon 20 of the EGFR gene has been identified as the most common mechanism of acquired resistance.  Osimertinib is a third-generation TKI designed to target both EGFR TKI-sensitizing mutations and T790M, while sparing wild-type EGFR.  Based on its pronounced clin. activity and good safety profile demonstrated in early Phase I and II trials, osimertinib received first approval in 2015 by the US FDA and in early 2016 by European Medicines Agency for the treatment of EGFR T790M mutation-pos. NSCLC patients in progression after EGFR TKI therapy.  Recent results from the Phase III AURA3 trial demonstrated the superiority of osimertinib over std. platinum-based doublet chemotherapy for treatment of patients with advanced EGFR T790M mutation-pos. NSCLC with disease progression following first-line EGFR TKI therapy, thus definitively establishing this third-generation TKI as the std. of care in this setting.  Herein, we review preclin. findings and clin. data from Phase I-III trials of osimertinib, including its efficacy in patients with central nervous system metastases.  We further discuss currently available methods used to analyze T790M mutation status and the main mechanisms of resistance to osimertinib.  Finally, we provide an outlook on ongoing trials with osimertinib and novel therapeutic combinations that might continue to improve the clin. outcome of EGFR-mutated NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4QOXBThkV7Vg90H21EOLACvtfcHk0lhG61P5ViYGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkt1elsbo%253D&md5=95ce4c3135dc3be0d2a337d7306b3f63</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S119644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S119644%26sid%3Dliteratum%253Aachs%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DLiguori%26aufirst%3DA.%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DGonzalez-Cao%26aufirst%3DM.%26aulast%3DDaffin%25C3%25A0%26aufirst%3DM.%2BG.%26aulast%3DD%25E2%2580%2599Aveni%26aufirst%3DA.%26aulast%3DMarabello%26aufirst%3DG.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DOsimertinib%2520in%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%253A%2520Design%252C%2520development%2520and%2520place%2520in%2520therapy%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D109%26epage%3D125%26doi%3D10.2147%2FLCTT.S119644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span> <span> </span><span class="NLM_article-title">FLAURA investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.+C.+Suauthor=J.+E.+Grayauthor=S.+M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+Ramalingam&title=FLAURA+investigators.+Osimertinib+in+untreated+EGFR-mutated+advanced+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lhG61P5ViYGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%26atitle%3DFLAURA%2520investigators.%2520Osimertinib%2520in%2520untreated%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as first-line treatment in EGFR-mutated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1056/NEJMe1714580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMe1714580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29320658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MzpsVSjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=192-193&issue=2&author=S.+Popat&title=Osimertinib+as+first-line+treatment+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMe1714580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Popat Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">192-193</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJixxOfvRWuOWhZTslLrfffW6udTcc2eaFkKT4KI1ubrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzpsVSjug%253D%253D&md5=86cbd91280c44efabfd216464fcb75ab</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1714580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1714580%26sid%3Dliteratum%253Aachs%26aulast%3DPopat%26aufirst%3DS.%26atitle%3DOsimertinib%2520as%2520first-line%2520treatment%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D192%26epage%3D193%26doi%3D10.1056%2FNEJMe1714580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burri, S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in <i>EGFR</i> mutation-positive advanced NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1261</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1801669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMc1801669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29595922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MnmslOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1261&issue=13&author=M.+C.+Wardauthor=R.+S.+Prabhuauthor=S.+Burri&title=Osimertinib+in+EGFR+mutation-positive+advanced+NSCLC&doi=10.1056%2FNEJMc1801669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in EGFR Mutation-Positive Advanced NSCLC</span></div><div class="casAuthors">Ward Matthew C; Prabhu Roshan S; Burri Stuart H</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1261</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfcw0gKTxNoMSzjBFCN0BJfW6udTcc2eaFkKT4KI1ubrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnmslOltQ%253D%253D&md5=7efe415285a20e35355bdba9e018b94b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1801669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1801669%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DM.%2BC.%26aulast%3DPrabhu%26aufirst%3DR.%2BS.%26aulast%3DBurri%26aufirst%3DS.%26atitle%3DOsimertinib%2520in%2520EGFR%2520mutation-positive%2520advanced%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D13%26spage%3D1261%26doi%3D10.1056%2FNEJMc1801669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of osimertinib resistance and emerging treatment options</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2020.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2020.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32693293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB38jltlSrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2020&pages=123-129&author=S.+Schmidauthor=J.+Liauthor=N.+B.+Leighl&title=Mechanisms+of+osimertinib+resistance+and+emerging+treatment+options&doi=10.1016%2Fj.lungcan.2020.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of osimertinib resistance and emerging treatment options</span></div><div class="casAuthors">Schmid Sabine; Li Janice J N; Leighl Natasha B</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting and now emerging as the new standard of care for all EGFR positive patients as first-line treatment.  Despite its efficacy, resistance to osimertinib inevitably develops and mechanisms of resistance can be grouped broadly in two categories: on-target EGFR-dependent and off-target EGFR-independent mechanisms.  EGFR-dependent resistance typically is associated with additional EGFR-mutations disrupting the osimertinib binding through changes in the binding site by allosteric/ conformational transitions; EGFR-independent mechanisms are related mostly to alternate pathway activation or aberrant downstream signalling but also to lineage plasticity leading to small cell transformation.  MET amplification is the most frequent off-target mechanisms of resistance to osimertinib treatment and recently published early trials show promising results for combination of MET-inhibitors with osimertinib upon development of resistance.  This review will summarize mechanisms of resistance overall and in different treatment settings and will focus on potential new treatment options targeting specific acquired alterations after osimertinib failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPD9fFC8LTZzjk2McQZ6XmfW6udTcc2eaFkKT4KI1ubrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38jltlSrtA%253D%253D&md5=87275d4ceac6b3707ab369dfd599857c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2020.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2020.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DMechanisms%2520of%2520osimertinib%2520resistance%2520and%2520emerging%2520treatment%2520options%26jtitle%3DLung%2520Cancer%26date%3D2020%26volume%3D147%26spage%3D123%26epage%3D129%26doi%3D10.1016%2Fj.lungcan.2020.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2433</span>, <span class="refDoi"> DOI: 10.1007/s00432-020-03239-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1007%2Fs00432-020-03239-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32385709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=2427-2433&issue=9&author=Y.+Muauthor=X.+Haoauthor=P.+Xingauthor=X.+Huauthor=Y.+Wangauthor=T.+Liauthor=J.+Zhangauthor=Z.+Xuauthor=J.+Li&title=Acquired+resistance+to+osimertinib+in+patients+with+non-small-cell+lung+cancer%3A+mechanisms+and+clinical+outcomes&doi=10.1007%2Fs00432-020-03239-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span></div><div class="casAuthors">Mu, Yuxin; Hao, Xuezhi; Xing, Puyuan; Hu, Xingsheng; Wang, Yan; Li, Teng; Zhang, Jinyao; Xu, Ziyi; Li, Junling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2427-2433</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clin. benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation.  The aim of our study was to identify the mechanisms underlying resistance to osimertinib and to correlate them with clin. outcomes.  Methods: We retrospectively analyzed patients with advanced NSCLC who received osimertinib for T790M-mutated acquired resistance to prior EGFR-TKIs between March 1, 2017 and Dec. 31, 2018.  Patients with paired mol. data of pre-osimertinib and after resistance development, which were not confirmed with small-cell lung cancer (SCLC) transformation, were included in the mol. anal. set.  Results: Of 49 patients evaluated in the mol. anal. set, 24 patients maintained T790M mutation, while 25 patients exhibited T790M-loss.  Mol. modifications were identified in 27 of 49 patients including EGFR acquired mutations (C797S, C796S, G796S, V802I, V834L, E758D and G724S), non-EGFR-dependent mutations (PIK3CA, ALK, BRAF, KRAS and TP53), EGFR amplification and MET amplification.  At data cutoff, median progression-free survival (PFS) was 9.3 mo in the T790M-retain group compared with 7.8 mo in T790M-loss patients (P = 0.053).  Median PFS was significantly longer in patients with EGFR-dependent resistance mechanism (13.5 mo) than in those with alternative pathway activation (8.2 mo; P = 0.012).  Conclusions: The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their assocn. with clin. outcomes.  Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clin. outcome benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFg_CSXlnhSLVg90H21EOLACvtfcHk0lidtxUG8XlflA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D&md5=7edcba72acbbd6fa1befd01b0f248c95</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00432-020-03239-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-020-03239-1%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520osimertinib%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%253A%2520mechanisms%2520and%2520clinical%2520outcomes%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D146%26issue%3D9%26spage%3D2427%26epage%3D2433%26doi%3D10.1007%2Fs00432-020-03239-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perego, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1038/s41416-019-0573-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41416-019-0573-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31564718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3MnjtFWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2019&pages=725-737&issue=9&author=A.+Leonettiauthor=S.+Sharmaauthor=R.+Minariauthor=P.+Peregoauthor=E.+Giovannettiauthor=M.+Tiseo&title=Resistance+mechanisms+to+osimertinib+in+EGFR-mutated+non-small+cell+lung+cancer&doi=10.1038%2Fs41416-019-0573-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer</span></div><div class="casAuthors">Leonetti Alessandro; Minari Roberta; Tiseo Marcello; Leonetti Alessandro; Sharma Sugandhi; Giovannetti Elisa; Perego Paola; Giovannetti Elisa; Tiseo Marcello</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">725-737</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction.  Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals.  On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms.  Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution.  This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS-mitogen-activated protein kinase (MAPK) or RAS-phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ01_bxgPdEyAMthz5_Rx5rfW6udTcc2eaPvdZVUmiLMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnjtFWhsw%253D%253D&md5=a0a18b9a9d0aa2c31ea8391f279d1102</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41416-019-0573-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-019-0573-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeonetti%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DPerego%26aufirst%3DP.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DResistance%2520mechanisms%2520to%2520osimertinib%2520in%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D121%26issue%3D9%26spage%3D725%26epage%3D737%26doi%3D10.1038%2Fs41416-019-0573-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, T.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase-targeted cancer therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3491</span>, <span class="refDoi"> DOI: 10.3390/ijms19113491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fijms19113491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVWltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=3491&issue=11&author=T.+Yamaokaauthor=S.+Kusumotoauthor=K.+Andoauthor=M.+Ohbaauthor=T.+Ohmori&title=Receptor+tyrosine+kinase-targeted+cancer+therapy&doi=10.3390%2Fijms19113491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase-targeted cancer therapy</span></div><div class="casAuthors">Yamaoka, Toshimitsu; Kusumoto, Sojiro; Ando, Koichi; Ohba, Motoi; Ohmori, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3491/1-3491/35</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the past two decades, several mol. targeted inhibitors have been developed and evaluated clin. to improve the survival of patients with cancer.  Mol. targeted inhibitors inhibit the activities of pathogenic tyrosine kinases.  Particularly, aberrant receptor tyrosine kinase (RTK) activation is a potential therapeutic target.  An increased understanding of genetics, cellular biol. and structural biol. has led to the development of numerous important therapeutics.  Pathogenic RTK mutations, deletions, translocations and amplification/over-expressions have been identified and are currently being examd. for their roles in cancers.  Therapies targeting RTKs are categorized as small-mol. inhibitors and monoclonal antibodies.  Studies are underway to explore abnormalities in 20 types of RTK subfamilies in patients with cancer or other diseases.  In this review, we describe representative RTKs important for developing cancer therapeutics and predicting or evaluated resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2ODA5rnlFGrVg90H21EOLACvtfcHk0lidtxUG8XlflA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVWltb0%253D&md5=4f9b2dc13fbbfe76dd2a1dd49a422855</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3390%2Fijms19113491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19113491%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DT.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DOhba%26aufirst%3DM.%26aulast%3DOhmori%26aufirst%3DT.%26atitle%3DReceptor%2520tyrosine%2520kinase-targeted%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D11%26spage%3D3491%26doi%3D10.3390%2Fijms19113491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santoni-Rugiu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchior, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanska, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stricker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauslund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, J. B.</span></span> <span> </span><span class="NLM_article-title">Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">923</span>, <span class="refDoi"> DOI: 10.3390/cancers11070923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fcancers11070923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlCmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=923&issue=7&author=E.+Santoni-Rugiuauthor=L.+C.+Melchiorauthor=E.+M.+Urbanskaauthor=J.+N.+Jakobsenauthor=K.+Strickerauthor=M.+Grauslundauthor=J.+B.+S%C3%B8rensen&title=Intrinsic+resistance+to+EGFR-tyrosine+kinase+inhibitors+in+EGFR-mutant+non-small+cell+lung+cancer%3A+differences+and+similarities+with+acquired+resistance&doi=10.3390%2Fcancers11070923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance</span></div><div class="casAuthors">Santoni-Rugiu, Eric; Melchior, Linea C.; Urbanska, Edyta M.; Jakobsen, Jan N.; de Stricker, Karin; Grauslund, Morten; Soerensen, Jens B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">923</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene occur as early cancer-driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and result in increased sensitivity to EGFR-tyrosine-kinase-inhibitors (EGFR-TKIs).  Despite very frequent and often prolonged clin. response to EGFR-TKIs, virtually all advanced EGFR-mutated (EGFRM +) NSCLCs inevitably acquire resistance mechanisms and progress at some point during treatment.  Addnl., 20-30% of patients do not respond or respond for a very short time (< 3 mo) because of intrinsic resistance.  While several mechanisms of acquired EGFR-TKI-resistance have been detd. by analyzing tumor specimens obtained at disease progression, the factors causing intrinsic TKI-resistance are less understood.  However, recent comprehensive mol.-pathol. profiling of advanced EGFRM + NSCLC at baseline has illustrated the co-existence of multiple genetic, phenotypic, and functional mechanisms that may contribute to tumor progression and cause intrinsic TKI-resistance.  Several of these mechanisms have been further corroborated by preclin. expts.  Intrinsic resistance can be caused by mechanisms inherent in EGFR or by EGFR-independent processes, including genetic, phenotypic or functional tumor changes.  This comprehensive review describes the identified mechanisms connected with intrinsic EGFR-TKI-resistance and differences and similarities with acquired resistance and among clin. implemented EGFR-TKIs of different generations.  Addnl., the review highlights the need for extensive pre-treatment mol. profiling of advanced NSCLC for identifying inherently TKI-resistant cases and designing potential combinatorial targeted strategies to treat them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHx3k1mSjR2bVg90H21EOLACvtfcHk0liNLw2rBk9YLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlCmtLc%253D&md5=41ca442872e523e426e3b9520a26867a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3390%2Fcancers11070923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11070923%26sid%3Dliteratum%253Aachs%26aulast%3DSantoni-Rugiu%26aufirst%3DE.%26aulast%3DMelchior%26aufirst%3DL.%2BC.%26aulast%3DUrbanska%26aufirst%3DE.%2BM.%26aulast%3DJakobsen%26aufirst%3DJ.%2BN.%26aulast%3DStricker%26aufirst%3DK.%26aulast%3DGrauslund%26aufirst%3DM.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DJ.%2BB.%26atitle%3DIntrinsic%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%2520in%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%253A%2520differences%2520and%2520similarities%2520with%2520acquired%2520resistance%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D7%26spage%3D923%26doi%3D10.3390%2Fcancers11070923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.21037/tlcr.2016.12.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.21037%2Ftlcr.2016.12.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28149764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=695-708&issue=6&author=R.+Minariauthor=P.+Bordiauthor=M.+Tiseo&title=Third-generation+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+in+T790M-positive+non-small+cell+lung+cancer%3A+review+on+emerged+mechanisms+of+resistance&doi=10.21037%2Ftlcr.2016.12.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span></div><div class="casAuthors">Minari, Roberta; Bordi, Paola; Tiseo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-708</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-pos. non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib.  Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approx. 10 mo.  Mechanisms detg. progression of disease are heterogeneous and not fully understood.  EGFR-dependent resistance mechanisms (such as new EGFR mutations), bypass pathway activation [as erb-b2 receptor tyrosine kinase 2 (HER2) or MET amplification] and histol. transformation [in small cell lung cancer (SCLC)] have been reported, similarly to previous generation TKIs.  Here, we review principle mechanisms of innate and acquired resistance described in literature both in clin. and preclin. settings during NSCLC treatment with third-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqELenka7GwYrVg90H21EOLACvtfcHk0liNLw2rBk9YLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D&md5=b40df5074fe4944594507d6f3b4f24dd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.21037%2Ftlcr.2016.12.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftlcr.2016.12.02%26sid%3Dliteratum%253Aachs%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DThird-generation%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%253A%2520review%2520on%2520emerged%2520mechanisms%2520of%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2016%26volume%3D5%26issue%3D6%26spage%3D695%26epage%3D708%26doi%3D10.21037%2Ftlcr.2016.12.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">212</span>, <span class="refDoi"> DOI: 10.3390/cells7110212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fcells7110212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKhsbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=212&issue=11&author=T.+Naganoauthor=M.+Tachiharaauthor=Y.+Nishimura&title=Mechanism+of+resistance+to+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+and+a+potential+treatment+strategy&doi=10.3390%2Fcells7110212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy</span></div><div class="casAuthors">Nagano, Tatsuya; Tachihara, Motoko; Nishimura, Yoshihiro</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">212</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer (NSCLC).  First-generation EGFR-TKIs (e.g., gefitinib and erlotinib) or second-generation EGFR-TKIs (e.g., afatinib and dacomitinib) are effective for the treatment of EGFR-mutated NSCLC, esp. in patients with EGFR exon 19 deletions or an exon 21 L858R mutation.  However, almost all cases experience disease recurrence after 1 to 2 years due to acquired resistance.  The EGFR T790M mutation in exon 20 is the most frequent alteration assocd. with the development of acquired resistance.  Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against EGFR-mutated lung cancer.  However, the development of acquired resistance to third-generation EGFR-TKI, involving the cysteine residue at codon 797 mutation, has been obsd.  Other mechanisms of acquired resistance include the activation of alternative pathways or downstream targets and histol. transformation (i.e., epithelial-mesenchymal transition or conversion to small-cell lung cancer).  Furthermore, the development of primary resistance through overexpression of the hepatocyte growth factor and suppression of Bcl-2-like protein 11 expression may lead to problems.  In this report, we review these mechanisms and discuss therapeutic strategies to overcome resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9WqabZOCKdLVg90H21EOLACvtfcHk0liNLw2rBk9YLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKhsbvN&md5=69cffcd25c103e00c00502106d93848b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fcells7110212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells7110212%26sid%3Dliteratum%253Aachs%26aulast%3DNagano%26aufirst%3DT.%26aulast%3DTachihara%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DY.%26atitle%3DMechanism%2520of%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520and%2520a%2520potential%2520treatment%2520strategy%26jtitle%3DCells%26date%3D2018%26volume%3D7%26issue%3D11%26spage%3D212%26doi%3D10.3390%2Fcells7110212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsia, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">MA08.03 osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S386</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.436" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S386&issue=1&author=Y.+L.+Wuauthor=S.+Jenkinsauthor=S.+Ramalingamauthor=J.+Y.+Hanauthor=A.+Delmonteauthor=T.+C.+Hsiaauthor=J.+Laskinauthor=S.+W.+Kimauthor=Y.+Heauthor=S.+Patel&title=MA08.03+osimertinib+vs+platinum-pemetrexed+for+T790M-mutation+positive+advanced+NSCLC+%28AURA3%29%3A+plasma+ctDNA+analysis&doi=10.1016%2Fj.jtho.2016.11.436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.436%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DHsia%26aufirst%3DT.%2BC.%26aulast%3DLaskin%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DMA08.03%2520osimertinib%2520vs%2520platinum-pemetrexed%2520for%2520T790M-mutation%2520positive%2520advanced%2520NSCLC%2520%2528AURA3%2529%253A%2520plasma%2520ctDNA%2520analysis%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3DS386%26doi%3D10.1016%2Fj.jtho.2016.11.436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuang&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgBqreIUA8aOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shao&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lgBqreIUA8aOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zandwijk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">A consensus on the role of osimertinib in non-small cell lung cancer from the AME lung cancer collaborative group</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3909</span>, <span class="refDoi"> DOI: 10.21037/jtd.2018.07.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.21037%2Fjtd.2018.07.61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30174832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3c3kslyltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=3909&author=T.+Jiangauthor=C.+Suauthor=S.+Renauthor=F.+Cappuzzoauthor=G.+Roccoauthor=J.+D.+Palmerauthor=N.+van+Zandwijkauthor=F.+Blackhallauthor=X.+Leauthor=N.+A.+Pennellauthor=C.+Zhou&title=A+consensus+on+the+role+of+osimertinib+in+non-small+cell+lung+cancer+from+the+AME+lung+cancer+collaborative+group&doi=10.21037%2Fjtd.2018.07.61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group</span></div><div class="casAuthors">Jiang Tao; Su Chunxia; Ren Shengxiang; Zhou Caicun; Cappuzzo Federico; Rocco Gaetano; Palmer Joshua D; van Zandwijk Nico; Blackhall Fiona; Le Xiuning; Pennell Nathan A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3909-3921</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought substantial clinical benefit to patients with advanced non-small cell lung cancer (NSCLC) and sensitizing EGFR mutation.  However, acquired resistance is inevitable since the vast majority of patients experience disease relapse within ~1-2 years.  Osimertinib is a novel irreversible, covalent third-generation EGFR-TKI and potent inhibitor of EGFR T790M mutation, the most common mechanism of acquired resistance to first-generation EGFR-TKIs.  Several trials have consistently demonstrated the superior clinical activity and safety of osimertinib in patients with advanced NSCLC and acquired EGFR T790M mutation after treatment with a first-generation EGFR-TKI.  Recently, the efficacy of osimertinib in a first-line setting was demonstrated to be clearly superior to standard-first line treatment in patients with EGFR-mutant NSCLC regardless of T790M mutation status.  Nevertheless, this advance, several unresolved issues of osimertinib should be emphasized including the molecular mechanisms of acquired resistance to osimertinib, the feasibility of testing EGFR T790M mutation from plasma circulating tumor DNA, its efficacy to patients with central nervous system (CNS) metastases or exon 20 mutations, its combination with other therapeutic strategies such as immune checkpoint inhibitors and its role in adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZM8G1vkvdEgpJitSxOdIlfW6udTcc2eZ6yxSW3uumn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3kslyltw%253D%253D&md5=b4e20e3331e23f4fab6cf6188c077bdf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.21037%2Fjtd.2018.07.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjtd.2018.07.61%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DRocco%26aufirst%3DG.%26aulast%3DPalmer%26aufirst%3DJ.%2BD.%26aulast%3Dvan%2BZandwijk%26aufirst%3DN.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DPennell%26aufirst%3DN.%2BA.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DA%2520consensus%2520on%2520the%2520role%2520of%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520from%2520the%2520AME%2520lung%2520cancer%2520collaborative%2520group%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2018%26volume%3D10%26spage%3D3909%26doi%3D10.21037%2Fjtd.2018.07.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S. S.</span></span> <span> </span><span class="NLM_article-title">Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2015.05.05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3978%2Fj.issn.2218-6751.2015.05.05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26798593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFequr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=809-815&issue=6&author=D.+B.+Costaauthor=S.+S.+Kobayashi&title=Whacking+a+mole-cule%3A+clinical+activity+and+mechanisms+of+resistance+to+third+generation+EGFR+inhibitors+in+EGFR+mutated+lung+cancers+with+EGFR-T790M&doi=10.3978%2Fj.issn.2218-6751.2015.05.05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M</span></div><div class="casAuthors">Costa, Daniel B.; Kobayashi, Susumu S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-815</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations, esp. EGFR-exon 19 deletions and EGFR-L858R, are the most frequent actionable genomic events in lung adenocarcinomas.  Tumors arise due to constitutively activated EGFR signaling and are susceptible to EGFR tyrosine kinase inhibitors (TKIs).  First generation EGFR TKIs (gefitinib and erlotinib) and the second generation EGFR TKI afatinib are approved worldwide.  Although targeted therapies against EGFR mutants induce dramatic initial responses, acquired resistance (through multiple biol. mechanisms) to erlotinib, gefitinib and afatinib emerges within the first 1-2 years of continued monotherapy.  EGFR-T790M accounts for more than half of acquired resistance to first or second generation EGFR TKIs by modifying ATP affinity and drug binding kinetics.  Two new studies have shown that two covalent pyrimidine inhibitors-AZD9291 and rociletinib of EGFRT790M (i.e., third generation EGFR TKIs) shown remarkable clin. activity in patients with acquired resistance to erlotinib, gefitinib and afatinib when the tumor carries EGFR-T790M in conjunction with an activating mutation.  However, and regrettably, acquired resistance to these third generation EGFR TKIs has already been reported in preclin. models and clin. specimens; such as a tertiary mutation at EGFR-C797S that prevents covalent binding of EGFR TKIs.  The experience with sequential EGFR TKI monotherapy highlights tumor heterogeneity and adaptability (i.e., relentless game of whack-a-mole played between TKIs and cancer), and will help shape future clin. development of novel combinatory approaches to manage EGFR mutated lung adenocarcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouU0luqnexVrVg90H21EOLACvtfcHk0liLEdbKyjO6zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFequr3N&md5=841f953e75655784933a5db515329d6a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2015.05.05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2015.05.05%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DKobayashi%26aufirst%3DS.%2BS.%26atitle%3DWhacking%2520a%2520mole-cule%253A%2520clinical%2520activity%2520and%2520mechanisms%2520of%2520resistance%2520to%2520third%2520generation%2520EGFR%2520inhibitors%2520in%2520EGFR%2520mutated%2520lung%2520cancers%2520with%2520EGFR-T790M%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26issue%3D6%26spage%3D809%26epage%3D815%26doi%3D10.3978%2Fj.issn.2218-6751.2015.05.05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of EGFR-mutant lung cancer to a t790m-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26181354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=982-984&issue=7&author=H.+A.+Yuauthor=S.+K.+Tianauthor=A.+E.+Drilonauthor=L.+Borsuauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+resistance+of+EGFR-mutant+lung+cancer+to+a+t790m-specific+EGFR+inhibitor%3A+emergence+of+a+third+mutation+%28C797S%29+in+the+EGFR+tyrosine+kinase+domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span></div><div class="casAuthors">Yu Helena A; Drilon Alexander E; Riely Gregory J; Tian Shaozhou K; Borsu Laetitia; Arcila Maria E; Ladanyi Marc</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">982-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMt1QT_1O5WBYfW6udTcc2eZ6yxSW3uumn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D&md5=27ae39c3fce4067baca734fbc05101b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520of%2520EGFR-mutant%2520lung%2520cancer%2520to%2520a%2520t790m-specific%2520EGFR%2520inhibitor%253A%2520emergence%2520of%2520a%2520third%2520mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DJAMA%2520Oncol.%26date%3D2015%26volume%3D1%26issue%3D7%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span> <span> </span><span class="NLM_article-title">Mutational profiling of non-small-cell lung cancer resistant to osimertinib using next-generation sequencing in chinese patients</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">9010353</span>, <span class="refDoi"> DOI: 10.1155/2018/9010353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1155%2F2018%2F9010353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29713646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MjosFWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=9010353&author=K.+Nieauthor=H.+Jiangauthor=C.+Zhangauthor=C.+Gengauthor=X.+Xuauthor=L.+Zhangauthor=H.+Zhangauthor=Z.+Zhangauthor=K.+Lanauthor=Y.+Ji&title=Mutational+profiling+of+non-small-cell+lung+cancer+resistant+to+osimertinib+using+next-generation+sequencing+in+chinese+patients&doi=10.1155%2F2018%2F9010353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients</span></div><div class="casAuthors">Nie Keke; Geng Chuanxin; Zhang Ling; Zhang Zhongfa; Jiang Haiping; Zhang Chunling; Xu Xiajuan; Lan Ketao; Ji Youxin; Zhang Hao</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9010353</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose:  To identify the somatic mutated genes for optimal targets of non-small-cell lung cancer after resistance to osimertinib treatment.  Patients and Methods:  Study patients all had advanced lung adenocarcinoma and acquired resistance to osimertinib as a second- or third-line treatment.  These patients had harboring EGFR T790M mutation before osimertinib treatment, which was confirmed by Amplification Refractory Mutation System (ARMS) PCR or Next-Generation Sequencing (NGS).  After resistance to osimertinib treatment, tumor tissue was collected by core needle biopsy.  DNA was extracted from 15 × 5 um sliced section of formalin-fixed paraffin-embedded (FFPE) material and NGS was done.  The genetic changes were analyzed.  Results:  A total of 9 Chinese patients were studied, 5 females and 4 males, age 51-89 years.  After progression with osimertinib treatment, core needle biopsy was performed and next-generation sequencing was performed.  Nine patients had harboring 62 point mutations, 2 altered gene copies, 2 amplifications, and 1 EML4-ALK gene fusion.  No MET or HER2 amplification was found in this cohort study.  Nine patients still maintained initial EGFR 19 del or L858R activating mutations, while 7 of them kept EGFR T790M mutations.  Among the 7 patients, 5 had secondary EGFR C797S and/or C797G mutations, which all happened in the same allele with T790M mutation.  All patients were treated with targets therapies, chemotherapy, or best supportive care (BSC) in accordance with NGS genetic results and patients' performance status; 7 of them are still alive and 2 of them died of disease progression at last follow-up.  Conclusions:  EGFR C797S/G mutation and the same one presented on the same allele with EGFR T790M mutation were the most common mutation feature and played a key role in resistance to osimertinib in Chinese patients with NSCLC.  Tumor cells losing T790M mutation and maintaining EGFR activating mutation might benefit from first-generation EGFR-TKI treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKyN3tRjlzBeWhZTslLrfffW6udTcc2ebmERllEAcOzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjosFWktA%253D%253D&md5=560309f1f8198aa05373e59b1fae6f58</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1155%2F2018%2F9010353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F9010353%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGeng%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLan%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DY.%26atitle%3DMutational%2520profiling%2520of%2520non-small-cell%2520lung%2520cancer%2520resistant%2520to%2520osimertinib%2520using%2520next-generation%2520sequencing%2520in%2520chinese%2520patients%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2018%26volume%3D2018%26spage%3D9010353%26doi%3D10.1155%2F2018%2F9010353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maemondo, M.</span></span> <span> </span><span class="NLM_article-title">Frequency of cis and trans EGFR T790M and activation mutations in tumors treated with EGFR inhibitors</span>. <i>J. Iwate Med. Assioc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.24750/iwateishi.72.2_47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.24750%2Fiwateishi.72.2_47" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=47-58&issue=2&author=K.+Hiranoauthor=K.+Watanabeauthor=M.+Akiyamaauthor=R.+Chibaauthor=H.+Nagashimaauthor=H.+Satoauthor=M.+Sugaiauthor=H.+Terasakiauthor=T.+Fukuharaauthor=M.+Maemondo&title=Frequency+of+cis+and+trans+EGFR+T790M+and+activation+mutations+in+tumors+treated+with+EGFR+inhibitors&doi=10.24750%2Fiwateishi.72.2_47"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.24750%2Fiwateishi.72.2_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.24750%252Fiwateishi.72.2_47%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAkiyama%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DR.%26aulast%3DNagashima%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugai%26aufirst%3DM.%26aulast%3DTerasaki%26aufirst%3DH.%26aulast%3DFukuhara%26aufirst%3DT.%26aulast%3DMaemondo%26aufirst%3DM.%26atitle%3DFrequency%2520of%2520cis%2520and%2520trans%2520EGFR%2520T790M%2520and%2520activation%2520mutations%2520in%2520tumors%2520treated%2520with%2520EGFR%2520inhibitors%26jtitle%3DJ.%2520Iwate%2520Med.%2520Assioc.%26date%3D2020%26volume%3D72%26issue%3D2%26spage%3D47%26epage%3D58%26doi%3D10.24750%2Fiwateishi.72.2_47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span> <span> </span><span class="NLM_article-title">Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovichauthor=T.+C.+Hardingauthor=K.+A.+Durkinauthor=G.+A.+Ottersonauthor=W.+T.+Purcellauthor=D.+R.+Camidgeauthor=J.+W.+Goldmanauthor=L.+V.+Sequistauthor=Z.+Piotrowskaauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=A.+A.+Alizadehauthor=M.+Diehn&title=Circulating+tumor+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0libN6uWnb2Pwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DPurcell%26aufirst%3DW.%2BT.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DDiehn%26aufirst%3DM.%26atitle%3DCirculating%2520tumor%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR Inhibitor (HM61713) in non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e45</span>– <span class="NLM_lpage">e47</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2015.12.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26749488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e45-e47&issue=4&author=H.+N.+Songauthor=K.+S.+Jungauthor=K.+H.+Yooauthor=J.+Choauthor=J.+Y.+Leeauthor=S.+H.+Limauthor=H.+S.+Kimauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.+L.+Choiauthor=W.+Parkauthor=M.+J.+Ahn&title=Acquired+C797S+mutation+upon+treatment+with+a+T790M-specific+third-generation+EGFR+Inhibitor+%28HM61713%29+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2015.12.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.093%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%2BN.%26aulast%3DJung%26aufirst%3DK.%2BS.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DAcquired%2520C797S%2520mutation%2520upon%2520treatment%2520with%2520a%2520T790M-specific%2520third-generation%2520EGFR%2520Inhibitor%2520%2528HM61713%2529%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3De45%26epage%3De47%26doi%3D10.1016%2Fj.jtho.2015.12.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han-Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIS and shifts allelic configuration at resistance</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28662863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1723-1727&issue=11&author=Z.+Wangauthor=J.+J.+Yangauthor=J.+Huangauthor=J.+Y.+Yeauthor=X.+C.+Zhangauthor=H.+Y.+Tuauthor=H.+Han-Zhangauthor=Y.+L.+Wu&title=Lung+adenocarcinoma+harboring+EGFR+T790M+and+in+trans+C797S+responds+to+combination+therapy+of+first-+and+third-generation+EGFR+TKIS+and+shifts+allelic+configuration+at+resistance&doi=10.1016%2Fj.jtho.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance</span></div><div class="casAuthors">Wang Zhen; Yang Jin-Ji; Huang Jie; Zhang Xu-Chao; Tu Hai-Yan; Ye Jun-Yi; Han-Zhang Han; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-1727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S.  In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors.  However, this has not been reported clinically.  METHODS:  We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy.  RESULTS:  At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M.  He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib.  After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.  CONCLUSION:  We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans.  We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKksLRAl4nGUbxh97K6Vt6fW6udTcc2ebC-ncEI2fNjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D&md5=4a4e858b7e9b39034fd2035da629a88c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DHan-Zhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DLung%2520adenocarcinoma%2520harboring%2520EGFR%2520T790M%2520and%2520in%2520trans%2520C797S%2520responds%2520to%2520combination%2520therapy%2520of%2520first-%2520and%2520third-generation%2520EGFR%2520TKIS%2520and%2520shifts%2520allelic%2520configuration%2520at%2520resistance%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1723%26epage%3D1727%26doi%3D10.1016%2Fj.jtho.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&issue=10&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+progress+of+small-molecule+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+C797S+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0liXm1jjymIqPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520of%2520small-molecule%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520C797S%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&issue=17&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+allelic+context+of+the+C797S+mutation+acquired+upon+treatment+with+third-generation+EGFR+inhibitors+impacts+sensitivity+to+subsequent+treatment+strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0liMPqxE3JEDxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520allelic%2520context%2520of%2520the%2520C797S%2520mutation%2520acquired%2520upon%2520treatment%2520with%2520third-generation%2520EGFR%2520inhibitors%2520impacts%2520sensitivity%2520to%2520subsequent%2520treatment%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonesaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flavin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6770</span>– <span class="NLM_lpage">6779</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-13-1145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24063894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyhsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6770-6779&issue=22&author=J.+Choauthor=L.+Chenauthor=N.+Sangjiauthor=T.+Okabeauthor=K.+Yonesakaauthor=J.+M.+Francisauthor=R.+J.+Flavinauthor=W.+Johnsonauthor=J.+Kwonauthor=S.+Yuauthor=H.+Greulichauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=K.+K.+Wongauthor=M.+Meyerson&title=Cetuximab+response+of+lung+cancer-derived+EGF+receptor+mutants+is+associated+with+asymmetric+dimerization&doi=10.1158%2F0008-5472.CAN-13-1145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization</span></div><div class="casAuthors">Cho, Jeonghee; Chen, Liang; Sangji, Naveen; Okabe, Takafumi; Yonesaka, Kimio; Francis, Joshua M.; Flavin, Richard J.; Johnson, William; Kwon, Jihyun; Yu, Soyoung; Greulich, Heidi; Johnson, Bruce E.; Eck, Michael J.; Jaenne, Pasi A.; Wong, Kwok-Kin; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6770-6779</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Kinase domain mutations of the EGF receptor (EGFR) are common oncogenic events in lung adenocarcinoma.  Here, we explore the dependency upon asym. dimerization of the kinase domain for activation of lung cancer-derived EGFR mutants.  We show that whereas wild-type EGFR and the L858R mutant require dimerization for activation and oncogenic transformation, the exon 19 deletion, exon 20 insertion, and L858R/T790M EGFR mutants do not require dimerization.  In addn., treatment with the monoclonal antibody, cetuximab, shrinks mouse lung tumors induced by the dimerization-dependent L858R mutant, but exerts only a modest effect on tumors driven by dimerization-independent EGFR mutants.  These data imply that different EGFR mutants show differential requirements for dimerization and that disruption of dimerization may be among the antitumor mechanisms of cetuximab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUM0OobLjS2rVg90H21EOLACvtfcHk0liMPqxE3JEDxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyhsrbO&md5=11f535c9c05614e04d0a16b83e8ca427</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1145%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSangji%26aufirst%3DN.%26aulast%3DOkabe%26aufirst%3DT.%26aulast%3DYonesaka%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DJ.%2BM.%26aulast%3DFlavin%26aufirst%3DR.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DCetuximab%2520response%2520of%2520lung%2520cancer-derived%2520EGF%2520receptor%2520mutants%2520is%2520associated%2520with%2520asymmetric%2520dimerization%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D22%26spage%3D6770%26epage%3D6779%26doi%3D10.1158%2F0008-5472.CAN-13-1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilachã, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchel, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akele, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, M. R.</span></span> <span> </span><span class="NLM_article-title">Making NSCLC crystal clear: how kinase structures revolutionized lung cancer treatment</span>. <i>Crystals</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">725</span>, <span class="refDoi"> DOI: 10.3390/cryst10090725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fcryst10090725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGntrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=725&issue=9&author=J.+F.+Vilach%C3%A3author=S.+C.+Mitchelauthor=M.+Z.+Akeleauthor=S.+Evansauthor=M.+R.+Groves&title=Making+NSCLC+crystal+clear%3A+how+kinase+structures+revolutionized+lung+cancer+treatment&doi=10.3390%2Fcryst10090725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Making NSCLC crystal clear: how kinase structures revolutionized lung cancer treatment</span></div><div class="casAuthors">Vilacha, Juliana F.; Mitchel, Sarah C.; Akele, Muluembet Z.; Evans, Stephen; Groves, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Crystals</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">725</span>CODEN:
                <span class="NLM_cas:coden">CRYSBC</span>;
        ISSN:<span class="NLM_cas:issn">2073-4352</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The parallel advances of different scientific fields provide a contemporary scenario where collaboration is not a differential, but actually a requirement.  In this context, crystallog. has had a major contribution on the medical sciences, providing a "face" for targets of diseases that previously were known solely by name or sequence.  Worldwide, cancer still leads the no. of annual deaths, with 9.6 million assocd. deaths, with a major contribution from lung cancer and its 1.7 million deaths.  Since the relationship between cancer and kinases was unraveled, these proteins have been extensively explored and became assocd. with drugs that later attained blockbuster status.  Crystallog. structures of kinases related to lung cancer and their developed and marketed drugs provided insight on their conformation in the absence or presence of small mols.  Notwithstanding, these structures were also of service once the initially highly successful drugs started to lose their effectiveness in the emergence of mutations.  This review focuses on a subclassification of lung cancer, non-small cell lung cancer (NSCLC), and major oncogenic driver mutations in kinases, and how crystallog. structures can be used, not only to provide awareness of the function and inhibition of these mutations, but also how these structures can be used in further computational studies aiming at addressing these novel mutations in the field of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXlLjzGH6LabVg90H21EOLACvtfcHk0liMPqxE3JEDxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGntrrN&md5=cc56a9a961272d823ff49642ad3bcbfb</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3390%2Fcryst10090725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcryst10090725%26sid%3Dliteratum%253Aachs%26aulast%3DVilach%25C3%25A3%26aufirst%3DJ.%2BF.%26aulast%3DMitchel%26aufirst%3DS.%2BC.%26aulast%3DAkele%26aufirst%3DM.%2BZ.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DGroves%26aufirst%3DM.%2BR.%26atitle%3DMaking%2520NSCLC%2520crystal%2520clear%253A%2520how%2520kinase%2520structures%2520revolutionized%2520lung%2520cancer%2520treatment%26jtitle%3DCrystals%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D725%26doi%3D10.3390%2Fcryst10090725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma</span>. <i>J. Drug Target.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2020.1737934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F1061186X.2020.1737934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32118494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslaqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=861-872&issue=9&author=R.+Liauthor=X.+Zhouauthor=H.+Yaoauthor=L.+Li&title=Four+generations+of+EGFR+TKIs+associated+with+different+pathogenic+mutations+in+non-small+cell+lung+carcinoma&doi=10.1080%2F1061186X.2020.1737934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma</span></div><div class="casAuthors">Li, Rui; Zhou, Xiaofei; Yao, Hongjuan; Li, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">861-872</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Non-small cell lung carcinoma (NSCLC) is a malignant tumor with poor prognosis and high mortality.  Platinum-based dual-agent chemotherapy is the main therapeutic regimen for this disease.  In recent years, because of the introduction of mol. targeted therapy, various targeted therapeutic agents against epidermal growth factor receptor (EGFR) have been rapidly developed, which has become a research hotspot for NSCLC treatment.  Here, we review the latest studies describing the features and types of EGFR pathogenic mutations, currently established EGFR-tyrosine kinase inhibitors from the first to fourth generation, including their action mechanisms, acquired resistance, and clin. applications, and potential challenges and perspectives that current researchers should address.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi2a5fvJbhQ7Vg90H21EOLACvtfcHk0liEf0NuiK6m7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslaqtrc%253D&md5=c24cf710611dd0f1d9dddc41c62edb3a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2020.1737934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2020.1737934%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DFour%2520generations%2520of%2520EGFR%2520TKIs%2520associated%2520with%2520different%2520pathogenic%2520mutations%2520in%2520non-small%2520cell%2520lung%2520carcinoma%26jtitle%3DJ.%2520Drug%2520Target.%26date%3D2020%26volume%3D28%26issue%3D9%26spage%3D861%26epage%3D872%26doi%3D10.1080%2F1061186X.2020.1737934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bersanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrilli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrasta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">e121</span>– <span class="NLM_lpage">e123</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27257132" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e121-e123&issue=10&author=M.+Bersanelliauthor=R.+Minariauthor=P.+Bordiauthor=L.+Gnettiauthor=C.+Bozzettiauthor=A.+Squadrilliauthor=C.+A.+Lagrastaauthor=L.+Bottarelliauthor=G.+Osipovaauthor=E.+Capellettoauthor=M.+Morauthor=M.+Tiseo&title=L718Q+mutation+as+new+mechanism+of+acquired+resistance+to+AZD9291+in+EGFR-mutated+NSCLC&doi=10.1016%2Fj.jtho.2016.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBersanelli%26aufirst%3DM.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DBozzetti%26aufirst%3DC.%26aulast%3DSquadrilli%26aufirst%3DA.%26aulast%3DLagrasta%26aufirst%3DC.%2BA.%26aulast%3DBottarelli%26aufirst%3DL.%26aulast%3DOsipova%26aufirst%3DG.%26aulast%3DCapelletto%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DL718Q%2520mutation%2520as%2520new%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR-mutated%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3De121%26epage%3De123%26doi%3D10.1016%2Fj.jtho.2016.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span> <span> </span><span class="NLM_article-title">First-and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.3390/ijms20010146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fijms20010146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=146&issue=1&author=M.+Takedaauthor=K.+Nakagawa&title=First-and+second-generation+EGFR-TKIs+are+all+replaced+to+osimertinib+in+chemo-naive+EGFR+mutation-positive+non-small+cell+lung+cancer&doi=10.3390%2Fijms20010146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?</span></div><div class="casAuthors">Takeda, Masayuki; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">146/1-146/8</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force for some lung adenocarcinomas.  Several randomized phase III studies have revealed that treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) results in an improved progression-free survival (PFS) compared to std. chemotherapy in chemonaive patients with advanced non-small cell lung cancer (NSCLC), selected based on the presence of EGFR mutations.  Patients treated with second-generation EGFR-TKIs have also shown an improved PFS relative to those treated with first-generation EGRF-TKIs.  Osimertinib is a third-generation EGFR-TKI that still irreversibly inhibits the activity of EGFR after it has acquired the secondary T790M mutation that confers resistance to first- and second-generation drugs.  Its efficacy has been validated for patients whose tumors have developed T790M-mediated resistance, as well as for first-line treatment of those patients with EGFR mutation-pos. NSCLC.  Although there are five EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) currently available for the treatment of EGFR-mutated lung cancer, the optimal sequence for administration of these drugs remains to be detd.  In this review, we addressed this issue with regard to maximizing the duration of the EGFR-TKI treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5XXr90cV-ErVg90H21EOLACvtfcHk0liEf0NuiK6m7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7jL&md5=dc0a2970e83327622ae068f8119a9dd9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.3390%2Fijms20010146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20010146%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DFirst-and%2520second-generation%2520EGFR-TKIs%2520are%2520all%2520replaced%2520to%2520osimertinib%2520in%2520chemo-naive%2520EGFR%2520mutation-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D1%26spage%3D146%26doi%3D10.3390%2Fijms20010146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib</span>. <i>Ann. Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">207</span>, <span class="refDoi"> DOI: 10.21037/atm.2019.04.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.21037%2Fatm.2019.04.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31205925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3M3nsVanuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=207&issue=9&author=L.+Maauthor=R.+Chenauthor=F.+Wangauthor=L.+L.+Maauthor=M.+M.+Yuanauthor=R.+R.+Chenauthor=J.+Liu&title=EGFR+L718Q+mutation+occurs+without+T790M+mutation+in+a+lung+adenocarcinoma+patient+with+acquired+resistance+to+osimertinib&doi=10.21037%2Fatm.2019.04.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib</span></div><div class="casAuthors">Ma Lei; Chen Rui; Wang Fang; Ma Li-Li; Liu Jiang; Yuan Ming-Ming; Chen Rong-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Annals of translational medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">207</span>
        ISSN:<span class="NLM_cas:issn">2305-5839</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improve the clinical outcomes of EGFR-mutant non-small cell lung cancer (NSCLC) patients significantly, however, acquired resistance occurs almost inevitably.  The underlying mechanisms of osimertinib resistance and treatment strategies after resistance remain largely unknown.  Here we reported a case of lung adenocarcinoma patient who progressed on osimertinib with EGFR L718Q mutation in the absence of T790M mutation.  The patient received icotinib as an exploratory treatment regimen for a short while with stable disease observed.  Unfortunately, the therapy was discontinued due to intolerable hepatotoxicity.  This is the first clinical report of the use of the effective EGFR-TKI treatment after L718Q-induced osimertinib resistance.  The therapeutic regimens for NSCLC patients progressed on osimertinib still require large-scale investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKmnu-UFBQoJagfuraLLzSfW6udTcc2ebMsGEcWwfs67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3nsVanuw%253D%253D&md5=1a14d7c0fb12f47e32181bd2a9edd723</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.21037%2Fatm.2019.04.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2019.04.37%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DL.%2BL.%26aulast%3DYuan%26aufirst%3DM.%2BM.%26aulast%3DChen%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DEGFR%2520L718Q%2520mutation%2520occurs%2520without%2520T790M%2520mutation%2520in%2520a%2520lung%2520adenocarcinoma%2520patient%2520with%2520acquired%2520resistance%2520to%2520osimertinib%26jtitle%3DAnn.%2520Transl%2520Med.%26date%3D2019%26volume%3D7%26issue%3D9%26spage%3D207%26doi%3D10.21037%2Fatm.2019.04.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricordel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">i28</span>– <span class="NLM_lpage">i37</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29462256" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i28-i37&issue=1&author=C.+Ricordelauthor=L.+Fribouletauthor=F.+Facchinettiauthor=J.+C.+Soria&title=Molecular+mechanisms+of+acquired+resistance+to+third-generation+EGFR-TKIs+in+EGFR+T790M-mutant+lung+cancer&doi=10.1093%2Fannonc%2Fmdx705"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx705%26sid%3Dliteratum%253Aachs%26aulast%3DRicordel%26aufirst%3DC.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520third-generation%2520EGFR-TKIs%2520in%2520EGFR%2520T790M-mutant%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D1%26spage%3Di28%26epage%3Di37%26doi%3D10.1093%2Fannonc%2Fmdx705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2018.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30642450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhtlCgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2019&pages=33-39&author=S.+Zhaoauthor=X.+Liauthor=C.+Zhaoauthor=T.+Jiangauthor=Y.+Jiaauthor=J.+Shiauthor=Y.+Heauthor=J.+Liauthor=F.+Zhouauthor=G.+Gaoauthor=W.+Liauthor=X.+Chenauthor=C.+Suauthor=S.+Renauthor=C.+Zhou&title=Loss+of+T790M+mutation+is+associated+with+early+progression+to+osimertinib+in+Chinese+patients+with+advanced+NSCLC+who+are+harboring+EGFR+T790M&doi=10.1016%2Fj.lungcan.2018.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M</span></div><div class="casAuthors">Zhao Sha; Jiang Tao; Jia Yijun; Shi Jinpeng; He Yayi; Li Jiayu; Zhou Fei; Li Wei; Chen Xiaoxia; Su Chunxia; Ren Shengxiang; Li Xuefei; Zhao Chao; Gao Guanghui; Zhou Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Osimertinib demonstrates superior efficacy in patients with non-small cell lung cancer (NSCLC) who acquired EGFR T790M mutation as resistant mechanism to upfront EGFR tyrosine kinase inhibitors (TKIs).  Not all the T790M-positive tumors are homogeneously sensitive to osimertinib, however, and the duration of response often varies.  Previous studies suggest that loss of T790 M at osimertinib resistance is correlated with shortened survival benefit of osimertinib.  The aim of this study is to investigate the prevalence of T790 M loss after progression to osimertinib in Chinese patients with NSCLC harboring EGFR T790 M mutation and to compare their clinical outcomes and characteristics when stratified by T790 M mutational status at osimertinib resistance.  PATIENTS AND METHODS:  All patients with a secondary T790 M mutation after progression to prior-line EGFR TKIs and received single-agent osimertinib were reviewed.  The patients who were reassessed for T790 M mutation post-osimertinib resistance were included in final analysis.  Detailed clinicopathologic characteristics and response data were collected.  RESULTS:  Of the patients with confirmed T790 M mutation as acquired resistance to early-generation EGFR TKIs and subsequently received single-agent osimertinib, 84 patients experienced clinical progression after osimertinib treatment and were eligible for analysis.  Among them, 31 patients underwent repeated T790 M mutation testing on osimertinib resistance.  Sixteen patients had maintained T790 M mutation, whereas 15 patients lost T790 M at resistance.  Loss of T790 M at resistance was remarkably correlated with shorter duration of response to osimertinib (P = 0.0005).  Furthermore, the overall survival after osimertinib treatment was also decreased in T790M-loss group (P=0.021).  The objective response rates were comparable between T790M-maintain and T790M-loss group (31.3% and 26.7%, respectively).  In multivariate analysis, loss of T790M remained statistically associated with early progression to osimertinib.  CONCLUSION:  Loss of T790 M mutation at resistance was correlated with early progression and overall survival in response to osimertinib treatment in Chinese patients with NSCLC harboring acquired T790 M mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKFH6IImQHWGxpATR2EQURfW6udTcc2eYUc9py5ce0yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhtlCgtw%253D%253D&md5=2b826795bb48c91c2da53214ffc7014e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DLoss%2520of%2520T790M%2520mutation%2520is%2520associated%2520with%2520early%2520progression%2520to%2520osimertinib%2520in%2520Chinese%2520patients%2520with%2520advanced%2520NSCLC%2520who%2520are%2520harboring%2520EGFR%2520T790M%26jtitle%3DLung%2520Cancer%26date%3D2019%26volume%3D128%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.lungcan.2018.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3913</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-14-2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25948633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3913-3923&issue=17&author=D.+Ercanauthor=H.+G.+Choiauthor=C.+H.+Yunauthor=M.+Capellettiauthor=T.+Xieauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=EGFR+mutations+and+resistance+to+irreversible+pyrimidine-based+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-14-2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors</span></div><div class="casAuthors">Ercan, Dalia; Choi, Hwan Geun; Yun, Cai-Hong; Capelletti, Marzia; Xie, Ting; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3913-3923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclin. models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation.  However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors.  We sought to identify and study EGFR mutations that confer resistance to this class of agents.  Exptl. Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones.  We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.  Results: We identified 3 major drug resistance mutations.  EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance.  Cells contg. an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib.  The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.  Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clin. EGFR inhibitors.  These findings will guide the development of new strategies to inhibit EGFR.  Clin Cancer Res; 21(17); 3913-23. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEcpT5h6UJorVg90H21EOLACvtfcHk0lh2KHmnWeilyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE&md5=9c2916156cb18726ff2f2d2881345548</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2789%26sid%3Dliteratum%253Aachs%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DEGFR%2520mutations%2520and%2520resistance%2520to%2520irreversible%2520pyrimidine-based%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3913%26epage%3D3923%26doi%3D10.1158%2F1078-0432.CCR-14-2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28625641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=228-231&author=S.+I.+Ouauthor=J.+Cuiauthor=A.+B.+Schrockauthor=M.+E.+Goldbergauthor=V.+W.+Zhuauthor=L.+Albackerauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Ali&title=Emergence+of+novel+and+dominant+acquired+EGFR+solvent-front+mutations+at+Gly796+%28G796S%2FR%29+together+with+C797S%2FR+and+L792F%2FH+mutations+in+one+EGFR+%28L858R%2FT790M%29+NSCLC+patient+who+progressed+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Cui Jean; Schrock Alexa B; Goldberg Michael E; Albacker Lee; Stephens Philip J; Miller Vincent A; Ali Siraj M; Zhu Viola W</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR.  Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.  A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.  The patient was initiated on osimertinib with disease shrinkage after 2 months, but tumor regrowth was observed after 5 months of osimertinib treatment.  Assay of plasma ctDNA at this time revealed these different secondary resistance mutations all in trans with each other including distinct mutations at the same codon producing different amino acid changes: G796S/R (mutant allele frequency [MAF]; 14.4%), C797S/G (MAF: 2.26%), L792F/H (MAF: 0.36%), and V802F (MAF: 0.40%), in addition to the pre-existing L858R (MAF:17.9%) and T790M (MAF:18.2%) but all in cis with T790M.  The G796S/R mutations are homologous with known reported solvent front mutations in ALK G1202R, ROS1 G2032R, TrkA G595R and TrkC G623R, all of which are associated with acquired resistance to type I TKIs.  In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring.  Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTk4Muekmj_ccAKB7Fa-xrUfW6udTcc2eZcVJ6CuftBILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D&md5=f2cedb07d65360f42885e5cd46220f57</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGoldberg%26aufirst%3DM.%2BE.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAlbacker%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DEmergence%2520of%2520novel%2520and%2520dominant%2520acquired%2520EGFR%2520solvent-front%2520mutations%2520at%2520Gly796%2520%2528G796S%252FR%2529%2520together%2520with%2520C797S%252FR%2520and%2520L792F%252FH%2520mutations%2520in%2520one%2520EGFR%2520%2528L858R%252FT790M%2529%2520NSCLC%2520patient%2520who%2520progressed%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D228%26epage%3D231%26doi%3D10.1016%2Fj.lungcan.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oztan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L.</span></span> <span> </span><span class="NLM_article-title">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28838405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2017&pages=84-87&author=A.+Oztanauthor=S.+Fischerauthor=A.+B.+Schrockauthor=R.+L.+Erlichauthor=C.+M.+Lovlyauthor=P.+J.+Stephensauthor=J.+S.+Rossauthor=V.+Millerauthor=S.+M.+Aliauthor=S.+I.+Ouauthor=L.+Raez&title=Emergence+of+EGFR+G724S+mutation+in+EGFR-mutant+lung+adenocarcinoma+post+progression+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span></div><div class="casAuthors">Oztan A; Fischer S; Schrock A B; Erlich R L; Stephens P J; Ross J S; Miller V; Ali S M; Lovly C M; Ou S-H I; Raez L E</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers.  Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined.  The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment.  This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsycCvNkMcjjToTC3aBaesfW6udTcc2eZcVJ6CuftBILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D&md5=c7173dc6b94f44f48532bebb352e345f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DOztan%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DErlich%26aufirst%3DR.%2BL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DRaez%26aufirst%3DL.%26atitle%3DEmergence%2520of%2520EGFR%2520G724S%2520mutation%2520in%2520EGFR-mutant%2520lung%2520adenocarcinoma%2520post%2520progression%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D111%26spage%3D84%26epage%3D87%26doi%3D10.1016%2Fj.lungcan.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fairclough, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiedrowski, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelichov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarcic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinchcombe, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odegaard, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, R. J.</span></span> <span> </span><span class="NLM_article-title">Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/s40164-019-0148-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs40164-019-0148-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31632838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpvV2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=24&author=S.+R.+Faircloughauthor=L.+A.+Kiedrowskiauthor=J.+J.+Linauthor=O.+Zelichovauthor=G.+Tarcicauthor=T.+E.+Stinchcombeauthor=J.+I.+Odegaardauthor=R.+B.+Lanmanauthor=A.+T.+Shawauthor=R.+J.+Nagy&title=Identification+of+osimertinib-resistant+EGFR+L792+mutations+by+cfDNA+sequencing%3A+oncogenic+activity+assessment+and+prevalence+in+large+cfDNA+cohort&doi=10.1186%2Fs40164-019-0148-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort</span></div><div class="casAuthors">Fairclough Stephen R; Kiedrowski Lesli A; Odegaard Justin I; Lanman Richard B; Nagy Rebecca J; Lin Jessica J; Shaw Alice T; Zelichov Ori; Tarcic Gabi; Stinchcombe Thomas E</div><div class="citationInfo"><span class="NLM_cas:title">Experimental hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    </div><div class="casAbstract">Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner.  Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib.  We subsequently analyzed a large cohort of over 1800 additional patient samples harboring an EGFR T790M mutation and identified a concomitant L792 mutation in a total of 22 (1.2%) cases.  In vitro functional assays demonstrated that the EGFR L858R/T790M/L792F/H mutations conferred intermediate-level resistance to osimertinib.  Further understanding of potential acquired resistance mechanisms to targeted therapy may help inform treatment strategy in EGFR-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5BYysmWirH1UIs6wFK5xJfW6udTcc2eZcVJ6CuftBILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpvV2hsA%253D%253D&md5=d4a67bf45fed9beeab9368ad51b1bc0c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1186%2Fs40164-019-0148-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40164-019-0148-7%26sid%3Dliteratum%253Aachs%26aulast%3DFairclough%26aufirst%3DS.%2BR.%26aulast%3DKiedrowski%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZelichov%26aufirst%3DO.%26aulast%3DTarcic%26aufirst%3DG.%26aulast%3DStinchcombe%26aufirst%3DT.%2BE.%26aulast%3DOdegaard%26aufirst%3DJ.%2BI.%26aulast%3DLanman%26aufirst%3DR.%2BB.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DNagy%26aufirst%3DR.%2BJ.%26atitle%3DIdentification%2520of%2520osimertinib-resistant%2520EGFR%2520L792%2520mutations%2520by%2520cfDNA%2520sequencing%253A%2520oncogenic%2520activity%2520assessment%2520and%2520prevalence%2520in%2520large%2520cfDNA%2520cohort%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D8%26spage%3D24%26doi%3D10.1186%2Fs40164-019-0148-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR G796D mutation mediates resistance to osimertinib</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">49671</span>– <span class="NLM_lpage">49679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.17913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28572531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=49671-49679&issue=30&author=D.+Zhengauthor=M.+Huauthor=Y.+Baiauthor=X.+Zhuauthor=X.+Luauthor=C.+Wuauthor=J.+Wangauthor=L.+Liuauthor=Z.+Wangauthor=J.+Niauthor=Z.+Yangauthor=J.+Xu&title=EGFR+G796D+mutation+mediates+resistance+to+osimertinib&doi=10.18632%2Foncotarget.17913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR G796D mutation mediates resistance to osimertinib</span></div><div class="casAuthors">Zheng Di; Wang Jiying; Liu Li; Ni Jian; Xu Jianfang; Hu Min; Bai Yu; Zhu Xuehua; Yang Zhenfan; Lu Xuesong; Wang Zheng; Wu Chunyan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">49671-49679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).  Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound.  Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification.  However, a comprehensive view is still missing.  In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism.  Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVPEeosoOnpOLfW6udTcc2eaZPEF-6Fd1Irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D&md5=9a871c015caf328b0af6d6412efae5c3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17913%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEGFR%2520G796D%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D30%26spage%3D49671%26epage%3D49679%26doi%3D10.18632%2Foncotarget.17913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lg2Mna1oZ4eIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">EGFR L792H and G796R: Two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1421</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29857056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbisl2nsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1415-1421&issue=9&author=Q.+Zhangauthor=X.+C.+Zhangauthor=J.+J.+Yangauthor=Z.+F.+Yangauthor=Y.+Baiauthor=J.+Suauthor=Z.+Wangauthor=Z.+Zhangauthor=Y.+Shaoauthor=Q.+Zhouauthor=J.+Kangauthor=E.+E.+Keauthor=Y.+C.+Zhangauthor=Z.+Y.+Dongauthor=Z.+H.+Chenauthor=H.+Y.+Tuauthor=W.+Z.+Zhongauthor=X.+N.+Yangauthor=Y.+L.+Wu&title=EGFR+L792H+and+G796R%3A+Two+novel+mutations+mediating+resistance+to+the+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib&doi=10.1016%2Fj.jtho.2018.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib</span></div><div class="casAuthors">Zhang Qi; Zhang Xu-Chao; Yang Jin-Ji; Su Jian; Zhou Qing; Kang Jin; Ke E-E; Zhang Yi-Chen; Dong Zhong-Yi; Chen Zhi-Hong; Tu Hai-Yan; Zhong Wen-Zhao; Yang Xue-Ning; Yang Zhen-Fan; Bai Yu; Wang Zheng; Zhang Zhou; Shao Yang; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1415-1421</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M mutation.  As the development of acquired resistance is inevitable, it is urgent that the mechanisms of such resistance be clarified.  METHODS:  DNA samples from a cohort of 340 patients with lung adenocarcinoma who were taking osimertinib were subjected to next-generation sequencing and screened in terms of the frequencies of the L792H and G796R mutations.  Ba/F3 cells stably expressing the EGFR L858R/T790M mutations (in cis) with either the L792H or G796R mutation were created to investigate the impact of the two novel mutations on EGFR tyrosine kinase inhibitors and other potential drug combinations in vitro.  Structural analyses were performed by using Schrodinger/Maestro software (version 11.1.012, Schrodinger LLC, Cambridge, MA).  RESULTS:  L792H and G796R were detected in 1.76% (six of 340) and 0.56% (two of 340) patients with lung adenocarcinoma treated with osimertinib, respectively.  The introduction of L792H or G796R mutations against an L858R/T790M background caused dramatic reductions in osimertinib sensitivity.  Structural modeling showed that mutations in cis with T790M either forced the ligand (osimertinib) to rotate out (breaking the binding) or pulled the hinge loop (breaking the hinge).  Various other drug combinations. including cetuximab with EAI045, failed to inhibit either cis mutant effectively.  CONCLUSIONS:  The EGFR L858R/T790M/L792H and L858R/T790M/G796R mutations conferred resistance to osimertinib both in vitro and in silico.  For patients in whom the two resistance mutations occur at low frequency, more precise treatment strategies and additional combinational approaches are required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiqXObge7yFGlSCSgBhwJFfW6udTcc2eYAbIYRI84EU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbisl2nsg%253D%253D&md5=d08343eb44145455665eea3756d7eefa</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%2BF.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DE.%2BE.%26aulast%3DZhang%26aufirst%3DY.%2BC.%26aulast%3DDong%26aufirst%3DZ.%2BY.%26aulast%3DChen%26aufirst%3DZ.%2BH.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DZhong%26aufirst%3DW.%2BZ.%26aulast%3DYang%26aufirst%3DX.%2BN.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DEGFR%2520L792H%2520and%2520G796R%253A%2520Two%2520novel%2520mutations%2520mediating%2520resistance%2520to%2520the%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D1415%26epage%3D1421%26doi%3D10.1016%2Fj.jtho.2018.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical modeling of osimertinib for NSCLC with EGFR exon 20 insertion mutations</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31108249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSitbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1556-1566&issue=9&author=Y.+Leeauthor=T.+M.+Kimauthor=D.+W.+Kimauthor=S.+Kimauthor=M.+Kimauthor=B.+Keamauthor=J.+L.+Kuauthor=D.+S.+Heo&title=Preclinical+modeling+of+osimertinib+for+NSCLC+with+EGFR+exon+20+insertion+mutations&doi=10.1016%2Fj.jtho.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations</span></div><div class="casAuthors">Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1556-1566</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NSCLC with EGFR exon 20 insertion mutations is the third most common type of EGFR-mutant NSCLC and is resistant to EGFR tyrosine kinase inhibitors (TKIs).  This study was conducted to evaluate the efficacies of first- to third-generation EGFR TKIs against NSCLC cells harboring EGFR exon 20 insertion mutations.  We developed seven EGFR exon 20 insertion-mutant Ba/F3 models and one patient-derived NSCLC (SNU-3173) of subtypes A763insFQEA, V769insASV, D770insSVD, D770insNPG, P772insPR, H773insH, H773insNPH, and H773insAH.  Cell viability assays, immunoblotting, and N-ethyl-N-nitrosourea mutagenesis screenings were performed..  Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells.  N-ethyl-N-nitrosourea mutagenesis screening of EGFR exon 20 insertion-mutant Ba/F3 cells showed various second sites for EGFR mutations, mostly at exons 20 and 21, including E762K, P794S, and G796D.  In addn., osimertinib-resistant cells were established by stepwise exposure to osimertinib and harbored EGFR E762K mutation.  Osimertinib is active against EGFR exon 20 insertion-mutant NSCLC and flexibly binds within drug-binding pockets in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr14pmwkBhhvbVg90H21EOLACvtfcHk0ljSU90swZ6EjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSitbvK&md5=04baf4f8141ad4d8c3bb65953921f082</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DKu%26aufirst%3DJ.%2BL.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26atitle%3DPreclinical%2520modeling%2520of%2520osimertinib%2520for%2520NSCLC%2520with%2520EGFR%2520exon%252020%2520insertion%2520mutations%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D1556%26epage%3D1566%26doi%3D10.1016%2Fj.jtho.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span> <span> </span><span class="NLM_article-title">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.2147/OTT.S188612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FOTT.S188612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30588029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=51-56&author=Y.+Zhangauthor=B.+Heauthor=D.+Zhouauthor=M.+Liauthor=C.+Hu&title=Newly+emergent+acquired+EGFR+exon+18+G724S+mutation+after+resistance+of+a+T790M+specific+EGFR+inhibitor+osimertinib+in+non-small-cell+lung+cancer%3A+a+case+report&doi=10.2147%2FOTT.S188612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span></div><div class="casAuthors">Zhang, Yan; He, Bixiu; Zhou, Dongbo; Li, Min; Hu, Chengping</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non-small-cell lung cancer.  Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored.  Case presentation: A non-smoking 58-yr-old female patient was initially diagnosed with lung adenocarcinoma harboring EGFR exon 19 deletion and clin. responded to initial gefitinib treatment.  The patient progressed on gefitinib after > 1 yr and a T790M mutation was detected in tissue biopsy by next-generation sequencing (NGS).  Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance.  Conclusion: The specific mechanisms of acquiring drug resistance for EGFR-TKIs have not been fully explored.  EGFR G724S mutation might be assocd. with osimertinib resistance but more studies about the mechanism should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGCPcRDGUQb7Vg90H21EOLACvtfcHk0ljSU90swZ6EjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K&md5=87e7c138506ba5973a82cf7715aacff5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2147%2FOTT.S188612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S188612%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DC.%26atitle%3DNewly%2520emergent%2520acquired%2520EGFR%2520exon%252018%2520G724S%2520mutation%2520after%2520resistance%2520of%2520a%2520T790M%2520specific%2520EGFR%2520inhibitor%2520osimertinib%2520in%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520case%2520report%26jtitle%3DOncoTargets%2520Ther.%26date%3D2019%26volume%3D12%26spage%3D51%26epage%3D56%26doi%3D10.2147%2FOTT.S188612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brägelmann, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4655</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07078-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41467-018-07078-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30405134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4655&issue=1&author=J.+Fassunkeauthor=F.+M%C3%BCllerauthor=M.+Keulauthor=S.+Michelsauthor=M.+A.+Dammertauthor=A.+Schmittauthor=D.+Plenkerauthor=J.+Lategahnauthor=C.+Heydtauthor=J.+Br%C3%A4gelmann&title=Overcoming+EGFR+G724S-mediated+osimertinib+resistance+through+unique+binding+characteristics+of+second-generation+EGFR+inhibitors&doi=10.1038%2Fs41467-018-07078-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span></div><div class="casAuthors">Fassunke Jana; Heydt Carina; Klein Sebastian; Ihle Michaela A; Scheel Andreas H; Wagener Svenja; Merkelbach-Bruse Sabine; Buttner Reinhard; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Garbert Katia; Sos Martin L; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Dahmen Ilona; Garbert Katia; Buttner Reinhard; Sos Martin L; Keul Marina; Lategahn Jonas; Alber Yannic; Kast Stefan M; Rauh Daniel; Michels Sebastian; Fischer Rieke N; Scheffler Matthias; Priesner Vanessa; Kron Anna; Wolf Jurgen; Buttner Reinhard; Schmitt Anna; Reinhardt H Christian; Sos Martin L; Schmitt Anna; Reinhardt H Christian; Schmitt Anna; Reinhardt H Christian; Klein Sebastian; Frank Konrad; Persigehl Thorsten; Pusken Michael; Haneder Stefan; Schaaf Bernhard; Rodermann Ernst; Engel-Riedel Walburga; Felip Enriqueta; Smit Egbert F</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4655</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients.  In a subgroup of these patients we identified an association between selection of EGFR(T790M)-negative but EGFR(G724S)-positive subclones and osimertinib resistance.  We demonstrate that EGFR(G724S) limits the activity of third-generation EGFR inhibitors both in vitro and in vivo.  Structural analyses and computational modeling indicate that EGFR(G724S) mutations may induce a conformation of the glycine-rich loop, which is incompatible with the binding of third-generation TKIs.  Systematic inhibitor screening and in-depth kinetic profiling validate these findings and show that second-generation EGFR inhibitors retain kinase affinity and overcome EGFR(G724S)-mediated resistance.  In the case of afatinib this profile translates into a robust reduction of colony formation and tumor growth of EGFR(G724S)-driven cells.  Our data provide a mechanistic basis for the osimertinib-induced selection of EGFR(G724S)-mutant clones and a rationale to treat these patients with clinically approved second-generation EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbrRUzliurTsve_zCu79I8fW6udTcc2eZktbsn8yRzbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D&md5=a09a4c84fb50fd456dcab005d2d9366a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07078-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07078-0%26sid%3Dliteratum%253Aachs%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DF.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DDammert%26aufirst%3DM.%2BA.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBr%25C3%25A4gelmann%26aufirst%3DJ.%26atitle%3DOvercoming%2520EGFR%2520G724S-mediated%2520osimertinib%2520resistance%2520through%2520unique%2520binding%2520characteristics%2520of%2520second-generation%2520EGFR%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D4655%26doi%3D10.1038%2Fs41467-018-07078-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span> <span> </span><span class="NLM_article-title">Sensitivity and resistance of met exon 14 mutations in lung cancer to eight met tyrosine kinase inhibitors in vitro</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1753</span>– <span class="NLM_lpage">1765</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31279006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKgsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1753-1765&issue=10&author=T.+Fujinoauthor=Y.+Kobayashiauthor=K.+Sudaauthor=T.+Kogaauthor=M.+Nishinoauthor=S.+Oharaauthor=M.+Chibaauthor=M.+Shimojiauthor=K.+Tomizawaauthor=T.+Takemotoauthor=T.+Mitsudomi&title=Sensitivity+and+resistance+of+met+exon+14+mutations+in+lung+cancer+to+eight+met+tyrosine+kinase+inhibitors+in+vitro&doi=10.1016%2Fj.jtho.2019.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro</span></div><div class="casAuthors">Fujino, Toshio; Kobayashi, Yoshihisa; Suda, Kenichi; Koga, Takamasa; Nishino, Masaya; Ohara, Shuta; Chiba, Masato; Shimoji, Masaki; Tomizawa, Kenji; Takemoto, Toshiki; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1753-1765</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer, including exon 14 skipping and point mutations, have been attracting the attention of thoracic oncologists as new therapeutic targets.  Tumors with these mutations almost always acquire resistance, which also occurs in other oncogene-addicted lung cancers.  However, the resistance mechanisms and treatment strategies are not fully understood.  We generated Ba/F3 cells expressing MET exon 14 mutations by retroviral gene transfer.  The sensitivities of these cells to eight MET-tyrosine kinase inhibitors (TKIs) were detd. using a colorimetric assay.  In addn., using N-ethyl-N-nitrosourea mutagenesis, we generated resistant clones, searched for secondary MET mutations, and then examd. the sensitivities of these resistant cells to different TKIs.  Ba/F3 cells transfected with MET mutations grew in the absence of interleukin-3, indicating their oncogenic activity.  These cells were sensitive to all MET-TKIs except tivantinib.  We identified a variety of secondary mutations.  D1228 and Y1230 were common sites for resistance mutations for type I TKIs, which bind the active form of MET, whereas L1195 and F1200 were common sites for type II TKIs, which bind the inactive form.  In general, resistance mutations against type I were sensitive to type II, and vice versa.  MET-TKIs inhibited the growth of cells with MET exon 14 mutations.  We also identified mutation sites specific for TKI types as resistance mechanisms and complementary activities between type I and type II inhibitors against those mutations.  These finding should provide relevant clin. implication for treating patients with lung cancer harboring MET exon 14 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoId7snrArCoLVg90H21EOLACvtfcHk0liE76jm12Iemg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKgsrjJ&md5=964f83ad4a4edf6f121b1c47961e31df</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DFujino%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DSuda%26aufirst%3DK.%26aulast%3DKoga%26aufirst%3DT.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DOhara%26aufirst%3DS.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DShimoji%26aufirst%3DM.%26aulast%3DTomizawa%26aufirst%3DK.%26aulast%3DTakemoto%26aufirst%3DT.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DSensitivity%2520and%2520resistance%2520of%2520met%2520exon%252014%2520mutations%2520in%2520lung%2520cancer%2520to%2520eight%2520met%2520tyrosine%2520kinase%2520inhibitors%2520in%2520vitro%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D10%26spage%3D1753%26epage%3D1765%26doi%3D10.1016%2Fj.jtho.2019.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daneshbod, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe'er, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span> <span> </span><span class="NLM_article-title">Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with <i>EGFR</i>-mutant lung cancers</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">9028</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.9028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1200%2FJCO.2019.37.15_suppl.9028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=9028&issue=15&author=A.+J.+Schoenfeldauthor=J.+M.+Chanauthor=H.+Rizviauthor=N.+Rekhtmanauthor=Y.+Daneshbodauthor=D.+Kubotaauthor=J.+C.+Changauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=R.+Somwarauthor=M.+G.+Krisauthor=D.+Pe%27erauthor=G.+J.+Rielyauthor=H.+A.+Yu&title=Tissue-based+molecular+and+histological+landscape+of+acquired+resistance+to+osimertinib+given+initially+or+at+relapse+in+patients+with+EGFR-mutant+lung+cancers&doi=10.1200%2FJCO.2019.37.15_suppl.9028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.9028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.9028%26sid%3Dliteratum%253Aachs%26aulast%3DSchoenfeld%26aufirst%3DA.%2BJ.%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DRizvi%26aufirst%3DH.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DDaneshbod%26aufirst%3DY.%26aulast%3DKubota%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DJ.%2BC.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DPe%2527er%26aufirst%3DD.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DYu%26aufirst%3DH.%2BA.%26atitle%3DTissue-based%2520molecular%2520and%2520histological%2520landscape%2520of%2520acquired%2520resistance%2520to%2520osimertinib%2520given%2520initially%2520or%2520at%2520relapse%2520in%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26issue%3D15%26spage%3D9028%26doi%3D10.1200%2FJCO.2019.37.15_suppl.9028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3351</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-3829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-18-3829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30796031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=3341-3351&issue=11&author=B.+P.+Brownauthor=Y.+K.+Zhangauthor=D.+Westoverauthor=Y.+Yanauthor=H.+Qiaoauthor=V.+Huangauthor=Z.+Duauthor=J.+A.+Smithauthor=J.+S.+Rossauthor=V.+A.+Millerauthor=S.+Aliauthor=L.+Bazhenovaauthor=A.+B.+Schrockauthor=J.+Meilerauthor=C.+M.+Lovly&title=On-target+resistance+to+the+mutant-selective+EGFR+inhibitor+osimertinib+can+develop+in+an+allele-specific+manner+dependent+on+the+original+EGFR-activating+mutation&doi=10.1158%2F1078-0432.CCR-18-3829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span></div><div class="casAuthors">Brown, Benjamin P.; Zhang, Yun-Kai; Westover, David; Yan, Yingjun; Qiao, Huan; Huang, Vincent; Du, Zhenfang; Smith, Jarrod A.; Ross, Jeffrey S.; Miller, Vincent A.; Ali, Siraj; Bazhenova, Lyudmila; Schrock, Alexa B.; Meiler, Jens; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3341-3351</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer.  Here, we investigate how G724S confers resistance to osimertinib.  We combine structure-based predictive modeling of G724S in combination with the 2 most common EGFR-activating mutations, exon 19 deletion (Ex19Del) and L858R, with in vitro drug-response models and patient genomic profiling.  Our simulations suggest that the G724S mutation selectively reduces osimertinib-binding affinity in the context of Ex19Del.  Consistent with our simulations, cell lines transduced with Ex19Del/G724S demonstrate resistance to osimertinib, whereas cells transduced with L858R/G724S are sensitive to osimertinib.  Subsequent clin. genomic profiling data further suggest G724S occurs with Ex19Del but not L858R.  Furthermore, we demonstrate that Ex19Del/G724S retains sensitivity to afatinib, but not to erlotinib, suggesting a possible therapy for patients at the time of disease relapse.  Altogether, these data suggest that G724S is an allele-specific resistance mutation emerging in the context of Ex19Del but not L858R.  Our results fundamentally reframe the problem of targeted therapy resistance from one focused on the drug-resistance mutation pair to one focused on activating mutation-drug-resistance mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKneM5OFx3BrVg90H21EOLACvtfcHk0lifkoiP5K8vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO&md5=5ea6914733351fabdf1c59c19a66e49e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3829%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DB.%2BP.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DOn-target%2520resistance%2520to%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520osimertinib%2520can%2520develop%2520in%2520an%2520allele-specific%2520manner%2520dependent%2520on%2520the%2520original%2520EGFR-activating%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26issue%3D11%26spage%3D3341%26epage%3D3351%26doi%3D10.1158%2F1078-0432.CCR-18-3829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehlman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau-Bussac, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacave, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujals, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Théou-Anton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trédaniel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dujon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schischmanoff, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux Leprieur, E.</span></span> <span> </span><span class="NLM_article-title">Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2019.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2019.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31600593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnms1ygsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2019&pages=149-156&author=C.+Mehlmanauthor=J.+Cadranelauthor=G.+Rousseau-Bussacauthor=R.+Lacaveauthor=A.+Pujalsauthor=N.+Girardauthor=C.+Callensauthor=V.+Gounantauthor=N.+Th%C3%A9ou-Antonauthor=S.+Friardauthor=J.+Tr%C3%A9danielauthor=H.+Blonsauthor=C.+Dujonauthor=B.+Duchemannauthor=P.+O.+Schischmanoffauthor=T.+Chinetauthor=E.+Giroux+Leprieur&title=Resistance+mechanisms+to+osimertinib+in+EGFR-mutated+advanced+non-small-cell+lung+cancer%3A+A+multicentric+retrospective+French+study&doi=10.1016%2Fj.lungcan.2019.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study</span></div><div class="casAuthors">Mehlman Camille; Chinet Thierry; Cadranel Jacques; Rousseau-Bussac Gaelle; Lacave Roger; Pujals Anais; Girard Nicolas; Callens Celine; Gounant Valerie; Theou-Anton Nathalie; Friard Sylvie; Tredaniel Jean; Blons Helene; Dujon Cecile; Duchemann Boris; Schischmanoff Pierre Olivier; Giroux Leprieur Etienne</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC).  MATERIALS AND METHODS:  We performed a multicentric retrospective analysis on a cohort of consecutive patients treated with osimertinib for an advanced EGFR-mutated NSCLC and collected histo-molecular data from plasma and tumor samples at the time of progression.  Next-generation sequencing (NGS) was performed for all samples.  Best Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) and data on treatment post-progression efficacy were also collected.  RESULTS:  Two-hundred and twenty-six patients were included from 9 Academic French Hospitals between April 2015-October 2018.  Osimertinib was given in second-line or more in 219 patients (97%).  Best ORR was 52% and best central nervous system ORR was 56%.  Median PFS and OS were 9.5 months (IQR 4.0-17.2) and 24 months (IQR 12.4-NR) respectively.  At the time of analysis, 150 patients (66%) had tumor progression.  Among them, 73 contributive samples (56 tumor biopsies) were available.  The most frequent molecular alterations were C797S mutation (n = 9 (13%)) and MET amplification (n = 8 (11%)).  Histologic transformation occurred in 5 patients (9% of tumor biopsies).  In T790M + NSCLC, loss of T790 M occurred in 68% of cases.  Median PFS and OS with treatment beyond progression were 6.0 months (IQR 2.0-10.4) and 15.1 months (IQR 6.7-NR) respectively and longer in case of osimertinib continuation beyond progression.  CONCLUSION:  We confirmed the efficacy of osimertinib in patients with advanced EGFR mutation positive NSCLC.  At progression, the most frequent molecular alterations were MET amplification and C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEHjIbI2V17QHqQV89nF-2fW6udTcc2ebAHxcf0a6tJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnms1ygsA%253D%253D&md5=bff3c77fc71bcdc18568771b32352dc5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2019.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2019.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DMehlman%26aufirst%3DC.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DRousseau-Bussac%26aufirst%3DG.%26aulast%3DLacave%26aufirst%3DR.%26aulast%3DPujals%26aufirst%3DA.%26aulast%3DGirard%26aufirst%3DN.%26aulast%3DCallens%26aufirst%3DC.%26aulast%3DGounant%26aufirst%3DV.%26aulast%3DTh%25C3%25A9ou-Anton%26aufirst%3DN.%26aulast%3DFriard%26aufirst%3DS.%26aulast%3DTr%25C3%25A9daniel%26aufirst%3DJ.%26aulast%3DBlons%26aufirst%3DH.%26aulast%3DDujon%26aufirst%3DC.%26aulast%3DDuchemann%26aufirst%3DB.%26aulast%3DSchischmanoff%26aufirst%3DP.%2BO.%26aulast%3DChinet%26aufirst%3DT.%26aulast%3DGiroux%2BLeprieur%26aufirst%3DE.%26atitle%3DResistance%2520mechanisms%2520to%2520osimertinib%2520in%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520A%2520multicentric%2520retrospective%2520French%2520study%26jtitle%3DLung%2520Cancer.%26date%3D2019%26volume%3D137%26spage%3D149%26epage%3D156%26doi%3D10.1016%2Fj.lungcan.2019.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible egfr inhibitor</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0000000000000688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26473643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1736-1744&issue=12&author=T.+M.+Kimauthor=A.+Songauthor=D.+W.+Kimauthor=S.+Kimauthor=Y.+O.+Ahnauthor=B.+Keamauthor=Y.+K.+Jeonauthor=S.+H.+Leeauthor=D.+H.+Chungauthor=D.+S.+Heo&title=Mechanisms+of+acquired+resistance+to+AZD9291%3A+a+mutation-selective%2C+irreversible+egfr+inhibitor&doi=10.1097%2FJTO.0000000000000688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor</span></div><div class="casAuthors">Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1736-1744</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs.  However, acquired resistance to AZD9291 is inevitable.  In this study, we identified the mechanisms of acquired resistance to AZD9291 in EGFR-mutant NSCLC.  Methods: Four NSCLC patients with both an EGFR exon 19 deletion and the EGFR mutation after developing acquired resistance to first-generation EGFR TKIs received AZD9291 at doses of 20 to 80 mg/day in a phase I trial (NCT01802632).  Paired tumor samples before and after treatment were obtained to evaluate EGFR modifications, alternative pathway activation, and histol. transformation.  Genetic alterations were analyzed using Sanger sequencing, fluorescence in situ hybridization, real-time polymerase chain reaction, and targeted exome sequencing.  Results: All four patients achieved a partial response (median duration of response, 9 mo [range, 9-11 mo]) and subsequently showed resistance to AZD9291.  EGFR-mutant clones depopulated AZD9291-resistant tumors to below 1% (baseline, 14%-36%) in three patients with progression: one with the loss of EGFR-double mutant clones and two accompanied by transformation to small-cell carcinoma and focal fibroblast growth factor receptor 1 (FGFR1) amplification, resp.  EGFR-mutant clones remained and the EGFR ligand was overexpressed in one patient with focal progression to AZD9291.  Conclusion: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histol. transformation and EGFR ligand-dependent activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KLOZPHlkELVg90H21EOLACvtfcHk0lhYa6HXusDT2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE&md5=304e993133713a74dc817f3e05c7e9db</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000688%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DY.%2BO.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%253A%2520a%2520mutation-selective%252C%2520irreversible%2520egfr%2520inhibitor%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D1736%26epage%3D1744%26doi%3D10.1097%2FJTO.0000000000000688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chia, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span> <span> </span><span class="NLM_article-title">Temporal changes of EGFR mutations and T790M levels in tumor and plasma DNA following AZD9291 treatment</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2016.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27393503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2s7osVSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=29-32&author=P.+L.+Chiaauthor=H.+Doauthor=A.+Moreyauthor=P.+Mitchellauthor=A.+Dobrovicauthor=T.+John&title=Temporal+changes+of+EGFR+mutations+and+T790M+levels+in+tumor+and+plasma+DNA+following+AZD9291+treatment&doi=10.1016%2Fj.lungcan.2016.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment</span></div><div class="casAuthors">Chia Puey Ling; Do Hongdo; Dobrovic Alexander; Morey Adrienne; Mitchell Paul; John Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AZD9291, a T790M specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated impressive response rates in tumours harbouring the EGFR T790M resistance mutation.  Emergence of resistance to AZD9291 has been shown to occur through several different mechanisms including the development of new mutations (e.g.  C797S) in the EGFR tyrosine kinase domain.  We studied two patients with paired tumour biopsies and blood samples pre- and post-progression on AZD9291 to explore possible resistance mechanisms.  Pre- and Post-AZD9291 tumour biopsies as well as serial plasma samples were collected from two patients on the AURA clinical study (AZD9291 First Time in Patients Ascending Dose study).  Droplet digital PCR (ddPCR) assays were used to quantify T790M, the driver EGFR mutation, and the C797S mutation in genomic DNA from paired tumour biopsies and plasma cell-free DNA.  In the first patient, both EGFR T790M and L858R became undetectable in the plasma within 1 month after treatment with AZD9291.  However, the T790M and the original L858R mutation re-emerged with radiologically confirmed resistance to AZD9291.  In patient two, the levels of T790M were undetectable at the time of radiological resistance to AZD9291 but increasing levels of the original EGFR exon 19 deletion was detected.  MET amplification was detected in a biopsy performed on progression.  The EGFR C797S mutation was not detected in either patient at the time of relapse. ddPCR of cell free DNA enables real time monitoring of patients on 3rd generation TKIs.  As resistance mechanisms are variable, monitoring levels of the initial activating EGFR mutation may facilitate more reliable detection of progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcGTszAFtsmx8TEN9K18QfW6udTcc2eY7HHWFnHgTF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7osVSnug%253D%253D&md5=bd9fafac36d5b86e7ffb162794855292</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DP.%2BL.%26aulast%3DDo%26aufirst%3DH.%26aulast%3DMorey%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DDobrovic%26aufirst%3DA.%26aulast%3DJohn%26aufirst%3DT.%26atitle%3DTemporal%2520changes%2520of%2520EGFR%2520mutations%2520and%2520T790M%2520levels%2520in%2520tumor%2520and%2520plasma%2520DNA%2520following%2520AZD9291%2520treatment%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D98%26spage%3D29%26epage%3D32%26doi%3D10.1016%2Fj.lungcan.2016.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileham, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sholl, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redig, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Assessment of resistance mechanisms and clinical implications in patients with EGFR t790m-positive lung cancer and acquired resistance to osimertinib</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2018.2969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1001%2Fjamaoncol.2018.2969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30073261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ks1Ojuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=1527-1534&issue=11&author=G.+R.+Oxnardauthor=Y.+Huauthor=K.+F.+Milehamauthor=H.+Husainauthor=D.+B.+Costaauthor=P.+Tracyauthor=N.+Feeneyauthor=L.+M.+Shollauthor=S.+E.+Dahlbergauthor=A.+J.+Redigauthor=D.+J.+Kwiatkowskiauthor=M.+S.+Rabinauthor=C.+P.+Paweletzauthor=K.+S.+Thressauthor=P.+A.+J%C3%A4nne&title=Assessment+of+resistance+mechanisms+and+clinical+implications+in+patients+with+EGFR+t790m-positive+lung+cancer+and+acquired+resistance+to+osimertinib&doi=10.1001%2Fjamaoncol.2018.2969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib</span></div><div class="casAuthors">Oxnard Geoffrey R; Hu Yuebi; Tracy Philip; Dahlberg Suzanne E; Redig Amanda J; Kwiatkowski David J; Rabin Michael S; Janne Pasi A; Oxnard Geoffrey R; Redig Amanda J; Kwiatkowski David J; Rabin Michael S; Janne Pasi A; Mileham Kathryn F; Husain Hatim; Costa Daniel B; Tracy Philip; Feeney Nora; Paweletz Cloud P; Janne Pasi A; Sholl Lynette M; Thress Kenneth S</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1527-1534</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR T790M mutation.  Acquired resistance to osimertinib is a growing clinical challenge that is poorly understood.  Objective:  To understand the molecular mechanisms of acquired resistance to osimertinib and their clinical behavior.  Design, Setting, and Participants:  Patients with advanced NSCLC who received osimertinib for T790M-positive acquired resistance to prior EGFR tyrosine kinase inhibitor were identified from a multi-institutional cohort (n = 143) and a confirmatory trial cohort (NCT01802632) (n = 110).  Next-generation sequencing of tumor biopsies after osimertinib resistance was performed.  Genotyping of plasma cell-free DNA was studied as an orthogonal approach, including serial plasma samples when available.  The study and analysis were finalized on November 9, 2017.  Main Outcomes and Measures:  Mechanisms of resistance and their association with time to treatment discontinuation on osimertinib.  Results:  Of the 143 patients evaluated, 41 (28 [68%] women) had tumor next-generation sequencing after acquired resistance to osimertinib.  Among 13 patients (32%) with maintained T790M at the time of resistance, EGFR C797S was seen in 9 patients (22%).  Among 28 individuals (68%) with loss of T790M, a range of competing resistance mechanisms was detected, including novel mechanisms such as acquired KRAS mutations and targetable gene fusions.  Time to treatment discontinuation was shorter in patients with T790M loss (6.1 vs 15.2 months), suggesting emergence of pre-existing resistant clones; this finding was confirmed in a validation cohort of 110 patients with plasma cell-free DNA genotyping performed after osimertinib resistance.  In studies of serial plasma levels of mutant EGFR, loss of T790M at resistance was associated with a smaller decrease in levels of the EGFR driver mutation after 1 to 3 weeks of therapy (100% vs 83% decrease; P = .01).  Conclusions and Relevance:  Acquired resistance to osimertinib mediated by loss of the T790M mutation is associated with early resistance and a range of competing resistance mechanisms.  These data provide clinical evidence of the heterogeneity of resistance in advanced NSCLC and a need for clinical trial strategies that can overcome multiple concomitant resistance mechanisms or strategies for preventing such resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSI9tCQoeLmfNTiMd2aNQVUfW6udTcc2eY7HHWFnHgTF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ks1Ojuw%253D%253D&md5=92ac6f25c90f1152cb7b65160d2522bd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2018.2969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2018.2969%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMileham%26aufirst%3DK.%2BF.%26aulast%3DHusain%26aufirst%3DH.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DTracy%26aufirst%3DP.%26aulast%3DFeeney%26aufirst%3DN.%26aulast%3DSholl%26aufirst%3DL.%2BM.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DRedig%26aufirst%3DA.%2BJ.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DRabin%26aufirst%3DM.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DAssessment%2520of%2520resistance%2520mechanisms%2520and%2520clinical%2520implications%2520in%2520patients%2520with%2520EGFR%2520t790m-positive%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520osimertinib%26jtitle%3DJAMA%2520Oncol.%26date%3D2018%26volume%3D4%26issue%3D11%26spage%3D1527%26epage%3D1534%26doi%3D10.1001%2Fjamaoncol.2018.2969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulusu, K.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.S.K.</span></span> <span> </span><span class="NLM_article-title">Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">viii741</span> <span class="refDoi"> DOI: 10.1093/annonc/mdy424.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdy424.064" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&author=V.A.+Papadimitrakopoulouauthor=Y.-L.+Wuauthor=J.-Y.+Hanauthor=M.-J.+Ahnauthor=S.S.+Ramalingamauthor=T.+Johnauthor=I.+Okamotoauthor=J.C.-H.+Yangauthor=K.C.+Bulusuauthor=G.+Lausauthor=B.+Collinsauthor=J.C.+Barrettauthor=J.+Chmieleckiauthor=T.S.K.+Mok&title=Analysis+of+resistance+mechanisms+to+osimertinib+in+patients+with+EGFR+T790M+advanced+NSCLC+from+the+AURA3+study&doi=10.1093%2Fannonc%2Fmdy424.064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy424.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy424.064%26sid%3Dliteratum%253Aachs%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.A.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DHan%26aufirst%3DJ.-Y.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DRamalingam%26aufirst%3DS.S.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DJ.C.-H.%26aulast%3DBulusu%26aufirst%3DK.C.%26aulast%3DLaus%26aufirst%3DG.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DBarrett%26aufirst%3DJ.C.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DMok%26aufirst%3DT.S.K.%26atitle%3DAnalysis%2520of%2520resistance%2520mechanisms%2520to%2520osimertinib%2520in%2520patients%2520with%2520EGFR%2520T790M%2520advanced%2520NSCLC%2520from%2520the%2520AURA3%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26doi%3D10.1093%2Fannonc%2Fmdy424.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.apsb.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26579470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=390-401&issue=5&author=L.+Huangauthor=L.+Fu&title=Mechanisms+of+resistance+to+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.apsb.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Huang Lihua; Fu Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">390-401</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment.  However, patients eventually develop drug resistance.  Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.  Here we review and summarize the known resistant mechanisms to EGFR-TKIs and provide potential targets for development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl75XHngOXiV_fW6udTcc2eYO-R5TYvHyMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D&md5=8429fc78384f6e540b1fa8f6c57c363b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26issue%3D5%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.apsb.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span> <span> </span><span class="NLM_article-title">Exon 16-Skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31557536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=50-61&issue=1&author=C.+C.+Hsuauthor=B.+C.+Liaoauthor=W.+Y.+Liaoauthor=A.+Markovetsauthor=D.+Stetsonauthor=K.+Thressauthor=J.+C.+Yang&title=Exon+16-Skipping+HER2+as+a+novel+mechanism+of+osimertinib+resistance+in+EGFR+L858R%2FT790M-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2019.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Hsu, Chia-Chi; Liao, Bin-Chi; Liao, Wei-Yu; Markovets, Aleksandra; Stetson, Daniel; Thress, Kenneth; Chih-Hsin Yang, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-61</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We had a patient with EGFR L858R/T790M-pos. NSCLC who initially responded to osimertinib therapy but eventually experienced development of resistance.  Plasma cell-free DNA anal. revealed the occurrence of exon 16-skipping HER2, which may have resulted in the erb-b2 receptor tyrosine kinase 2 gene (HER2) splice variant HER2D16.  HER2D16 has never been reported in lung cancer, and HER2D16-driven signaling is known to be regulated by Src kinase in breast cancer.  We investigated the role of HER2D16 as an osimertinib-resistant mechanism.We constructed and established H1975 cells stably expressing HER2D16.  The dimeric formation of HER2D16 was tested by using nonreducing polyacrylamide gel electrophoresis.  Synergistic effect was assessed by using the Chou-Talalay method.We found that HER2D16 can form a homodimer in NSCLC cells.  We also found that mutant EGFR and HER2D16 cooperated to activate downstream signaling for osimertinib resistance.  In addn., cotreatment with osimertinib and an Src kinase inhibitor failed to reverse resistance, indicating that HER2D16-driven signaling in NSCLC did not occur through a canonical pathway.  Finally, we revealed that the combination of osimertinib with the pan-HER small-mol. inhibitor afatinib could synergistically repress cell growth and signaling in H1975-HER2D16 cells.HER2D16 can contribute to osimertinib resistance through an Src-independent pathway.  HER2D16 should be included in the mol. diagnosis panel for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGJOlmIkbukrVg90H21EOLACvtfcHk0lhOsoUwpJ_S3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O&md5=b711bc98055e4be3f9f295688878b151</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DB.%2BC.%26aulast%3DLiao%26aufirst%3DW.%2BY.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DExon%252016-Skipping%2520HER2%2520as%2520a%2520novel%2520mechanism%2520of%2520osimertinib%2520resistance%2520in%2520EGFR%2520L858R%252FT790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D50%26epage%3D61%26doi%3D10.1016%2Fj.jtho.2019.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovich&title=Circulating+tumor+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0lhOsoUwpJ_S3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26atitle%3DCirculating%2520tumor%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Organ, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span> <span> </span><span class="NLM_article-title">An overview of the c-MET signalling pathway</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S7</span>– <span class="NLM_lpage">S19</span>, <span class="refDoi"> DOI: 10.1177/1758834011422556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1177%2F1758834011422556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22128289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=S7-S19&issue=1&author=S.+L.+Organauthor=M.+S.+Tsao&title=An+overview+of+the+c-MET+signalling+pathway&doi=10.1177%2F1758834011422556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the c-MET signaling pathway</span></div><div class="casAuthors">Organ, Shawna Leslie; Tsao, Ming-Sound</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S7-S19</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  C-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion.  Although c-MET is important in the control of tissue homeostasis under normal physiol. conditions, it has also been found to be aberrantly activated in human cancers via mutation, amplification or protein overexpression.  This paper provides an overview of the c-MET signaling pathway, including its role in the development of cancers, and provides a rationale for targeting the pathway as a possible treatment option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp79uA73SrMTLVg90H21EOLACvtfcHk0lhS720JbykTCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSqsg%253D%253D&md5=94f1ef8e31e21a15edc525e2c6325f52</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1177%2F1758834011422556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834011422556%26sid%3Dliteratum%253Aachs%26aulast%3DOrgan%26aufirst%3DS.%2BL.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26atitle%3DAn%2520overview%2520of%2520the%2520c-MET%2520signalling%2520pathway%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2011%26volume%3D3%26issue%3D1%26spage%3DS7%26epage%3DS19%26doi%3D10.1177%2F1758834011422556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovinger, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinsurongkawong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glisson, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in <i>EGFR</i>-mutant NSCLC</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6203</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-18-1542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30228210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6195-6203&issue=24&author=X.+Leauthor=S.+Puriauthor=M.+V.+Negraoauthor=M.+B.+Nilssonauthor=J.+Robichauxauthor=T.+Boyleauthor=J.+K.+Hicksauthor=K.+L.+Lovingerauthor=E.+Roartyauthor=W.+Rinsurongkawongauthor=M.+Tangauthor=H.+Sunauthor=Y.+Elaminauthor=L.+C.+Lacerdaauthor=J.+Lewisauthor=J.+A.+Rothauthor=S.+G.+Swisherauthor=J.+J.+Leeauthor=W.+N.+Williamauthor=B.+S.+Glissonauthor=J.+Zhangauthor=V.+A.+Papadimitrakopoulouauthor=J.+E.+Grayauthor=J.+V.+Heymach&title=Landscape+of+EGFR-dependent+and+-independent+resistance+mechanisms+to+osimertinib+and+continuation+therapy+beyond+progression+in+EGFR-mutant+NSCLC&doi=10.1158%2F1078-0432.CCR-18-1542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC</span></div><div class="casAuthors">Le, Xiuning; Puri, Sonam; Negrao, Marcelo V.; Nilsson, Monique B.; Robichaux, Jacqulyne; Boyle, Theresa; Hicks, J. Kevin; Lovinger, Katherine L.; Roarty, Emily; Rinsurongkawong, Waree; Tang, Ming; Sun, Huiying; Elamin, Yasir; Lacerda, Lara C.; Lewis, Jeff; Roth, Jack A.; Swisher, Stephen G.; Lee, J. Jack; William, William N., Jr.; Glisson, Bonnie S.; Zhang, Jianjun; Papadimitrakopoulou, Vassiliki A.; Gray, Jhanelle E.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6195-6203</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Osimertinib was initially approved for T790M-pos. non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC.  However, resistance mechanisms to osimertinib have been incompletely described.  Exptl. Design: Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clin. data for patients treated with osimertinib.  Mol. profiling anal. was performed at the time of progression in a subset of the patients.  Results: In the 118 patients treated with osimertinib, 42 had mol. profiling at progression.  T790M was preserved in 21 (50%) patients and lost in 21 (50%).  EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were obsd. exclusively in T790M-preserved cases.  MET amplification was the second most common alteration (14%).  Recurrent alterations were obsd. in 22 genes/pathways, including PIK3CA, FGFR, and RET.  Preclin. studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers.  Alterations of cell-cycle genes were assocd. with shorter median progression-free survival (PFS, 4.4 vs. 8.8 mo, P = 0.01).  In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 mo; 21 patients received local consolidation radiation with a median PFS of 15.5 mo.  Continuation of osimertinib beyond progression was assocd. with a longer overall survival compared with discontinuation (11.2 vs. 6.1 mo, P = 0.02).  Conclusions: Osimertinib resistance is assocd. with diverse, predominantly EGFR-independent genomic alterations.  Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clin. benefit in selected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuIPI4o6FQeLVg90H21EOLACvtfcHk0lhS720JbykTCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FN&md5=b0770e4e5c9b8f55a4153f93acdae931</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1542%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DX.%26aulast%3DPuri%26aufirst%3DS.%26aulast%3DNegrao%26aufirst%3DM.%2BV.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DRobichaux%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DT.%26aulast%3DHicks%26aufirst%3DJ.%2BK.%26aulast%3DLovinger%26aufirst%3DK.%2BL.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DRinsurongkawong%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElamin%26aufirst%3DY.%26aulast%3DLacerda%26aufirst%3DL.%2BC.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26aulast%3DSwisher%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DWilliam%26aufirst%3DW.%2BN.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%2BA.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DLandscape%2520of%2520EGFR-dependent%2520and%2520-independent%2520resistance%2520mechanisms%2520to%2520osimertinib%2520and%2520continuation%2520therapy%2520beyond%2520progression%2520in%2520EGFR-mutant%2520NSCLC%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D24%26spage%3D6195%26epage%3D6203%26doi%3D10.1158%2F1078-0432.CCR-18-1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">viii740</span> <span class="refDoi"> DOI: 10.1093/annonc/mdy424.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdy424.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&author=S.S.+Ramalingamauthor=Y.+Chengauthor=C.+Zhouauthor=Y.+Oheauthor=F.+Imamuraauthor=B.C.+Choauthor=M.-C.+Linauthor=M.+Majemauthor=R.+Shahauthor=Y.+Rukazenkovauthor=A.+Toddauthor=A.+Markovetsauthor=J.C.+Barrettauthor=J.+Chmieleckiauthor=J.+Gray&title=Mechanisms+of+acquired+resistance+to+first-line+osimertinib%3A+Preliminary+data+from+the+phase+III+FLAURA+study&doi=10.1093%2Fannonc%2Fmdy424.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy424.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy424.063%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.S.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DB.C.%26aulast%3DLin%26aufirst%3DM.-C.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DJ.C.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520first-line%2520osimertinib%253A%2520Preliminary%2520data%2520from%2520the%2520phase%2520III%2520FLAURA%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26doi%3D10.1093%2Fannonc%2Fmdy424.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lhfvTodr1A-dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&issue=8&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lhfvTodr1A-dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D8%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldanzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, A.</span></span> <span> </span><span class="NLM_article-title">Physiological signalling and structure of the HGF receptor MET</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.3390/biomedicines3010001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fbiomedicines3010001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSht7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=1-31&issue=1&author=G.+Baldanziauthor=A.+Graziani&title=Physiological+signalling+and+structure+of+the+HGF+receptor+MET&doi=10.3390%2Fbiomedicines3010001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological signaling and structure of the HGF receptor MET</span></div><div class="casAuthors">Baldanzi, Gianluca; Graziani, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-31</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The "hepatocyte growth factor" also known as "scatter factor", is a multifunctional cytokine with the peculiar ability of simultaneously triggering epithelial cell proliferation, movement and survival.  The combination of those proprieties results in the induction of an epithelial to mesenchymal transition in target cells, fundamental for embryogenesis but also exploited by tumor cells during metastatization.  The hepatocyte growth factor receptor, MET, is a proto-oncogene and a prototypical transmembrane tyrosine kinase receptor.  Inhere we discuss the MET mol. structure and the hepatocyte growth factor driven physiol. signaling which coordinates epithelial proliferation, motility and morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWykX-YREQXrVg90H21EOLACvtfcHk0lhfvTodr1A-dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSht7fF&md5=fb2a5d6b8c84a29485d1a8f8accd8340</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines3010001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines3010001%26sid%3Dliteratum%253Aachs%26aulast%3DBaldanzi%26aufirst%3DG.%26aulast%3DGraziani%26aufirst%3DA.%26atitle%3DPhysiological%2520signalling%2520and%2520structure%2520of%2520the%2520HGF%2520receptor%2520MET%26jtitle%3DBiomedicines%26date%3D2015%26volume%3D3%26issue%3D1%26spage%3D1%26epage%3D31%26doi%3D10.3390%2Fbiomedicines3010001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hervieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kermorgant, S.</span></span> <span> </span><span class="NLM_article-title">The role of PI3K in Met driven cancer: A Recap</span>. <i>Front. Mol. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi"> DOI: 10.3389/fmolb.2018.00086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3389%2Ffmolb.2018.00086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30406111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=86&author=A.+Hervieuauthor=S.+Kermorgant&title=The+role+of+PI3K+in+Met+driven+cancer%3A+A+Recap&doi=10.3389%2Ffmolb.2018.00086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K in met driven cancer: a recap</span></div><div class="casAuthors">Hervieu, Alexia; Kermorgant, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Biosciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86</span>CODEN:
                <span class="NLM_cas:coden">FMBRBS</span>;
        ISSN:<span class="NLM_cas:issn">2296-889X</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The Receptor Tyrosine Kinase (RTK) Met, overexpressed or mutated in cancer, plays a major role in cancer progression and represents an attractive target for cancer therapy.  However RTK inhibitors can lead to drug resistance, explaining the necessity to develop therapies that target downstream signaling.  Phosphatidylinositide 3-kinase (PI3K) is one of the most deregulated pathways in cancer and implicated in various types of cancer.  PI3K signaling is also a major signaling pathway downstream of RTK, including Met.  PI3K major effectors include Akt and "mechanistic Target of Rapamycin" (mTOR), which each play key roles in numerous and various cell functions.  Advancements made due to the development of mol. and pharmaceutical tools now allow us to delve into the roles of each independently.  In this review, we summarize the current understanding we possess of the activation and role of PI3K/Akt/mTOR, downstream of Met, in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_PE6rCn4rk7Vg90H21EOLACvtfcHk0ljlFIrzRhvJIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmsrnJ&md5=bca2da2de3858f7cd4c65a9a284c90d7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffmolb.2018.00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmolb.2018.00086%26sid%3Dliteratum%253Aachs%26aulast%3DHervieu%26aufirst%3DA.%26aulast%3DKermorgant%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520PI3K%2520in%2520Met%2520driven%2520cancer%253A%2520A%2520Recap%26jtitle%3DFront.%2520Mol.%2520Biosci.%26date%3D2018%26volume%3D5%26spage%3D86%26doi%3D10.3389%2Ffmolb.2018.00086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Marti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mereu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedrés, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miquel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet-Adkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arqués, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuciforo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span> <span> </span><span class="NLM_article-title">Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2451</span>– <span class="NLM_lpage">2457</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28961841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252Fjs12itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2451-2457&issue=10&author=A.+Martinez-Martiauthor=E.+Felipauthor=J.+Matitoauthor=E.+Mereuauthor=A.+Navarroauthor=S.+Cedr%C3%A9sauthor=N.+Pardoauthor=A.+Martinez+de+Castroauthor=J.+Remonauthor=J.+M.+Miquelauthor=A.+Guillaumet-Adkinsauthor=E.+Nadalauthor=G.+Rodriguez-Estebanauthor=O.+Arqu%C3%A9sauthor=R.+Fasaniauthor=P.+Nuciforoauthor=H.+Heynauthor=A.+Villanuevaauthor=H.+G.+Palmerauthor=A.+Vivancos&title=Dual+MET+and+ERBB+inhibition+overcomes+intratumor+plasticity+in+osimertinib-resistant-advanced+non-small-cell+lung+cancer+%28NSCLC%29&doi=10.1093%2Fannonc%2Fmdx396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)</span></div><div class="casAuthors">Martinez-Marti A; Pardo N; Felip E; Matito J; Mereu E; Guillaumet-Adkins A; Rodriguez-Esteban G; Heyn H; Navarro A; Cedres S; Martinez de Castro A; Remon J; Miquel J M; Nadal E; Arques O; Palmer H G; Fasani R; Nuciforo P; Villanueva A; Vivancos A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2451-2457</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M.  Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed.  It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance.  Methods:  For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used.  All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist.  For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected.  Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis.  For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C.  Results:  In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib.  Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis.  In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones.  Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS-driven subclone.  We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs.  Conclusion:  Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR-mutant lung cancer patients may induce genetic plasticity.  We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET-amplification and propose new treatment strategies in this situation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3HhkQ1HkaEu-MdeMhXAHkfW6udTcc2eaw-EFvTfrMnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252Fjs12itg%253D%253D&md5=ffbfdbdcb5cb38336e1a9b143a6afa05</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx396%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Marti%26aufirst%3DA.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DMatito%26aufirst%3DJ.%26aulast%3DMereu%26aufirst%3DE.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DCedr%25C3%25A9s%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DN.%26aulast%3DMartinez%2Bde%2BCastro%26aufirst%3DA.%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DMiquel%26aufirst%3DJ.%2BM.%26aulast%3DGuillaumet-Adkins%26aufirst%3DA.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DRodriguez-Esteban%26aufirst%3DG.%26aulast%3DArqu%25C3%25A9s%26aufirst%3DO.%26aulast%3DFasani%26aufirst%3DR.%26aulast%3DNuciforo%26aufirst%3DP.%26aulast%3DHeyn%26aufirst%3DH.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DH.%2BG.%26aulast%3DVivancos%26aufirst%3DA.%26atitle%3DDual%2520MET%2520and%2520ERBB%2520inhibition%2520overcomes%2520intratumor%2520plasticity%2520in%2520osimertinib-resistant-advanced%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26issue%3D10%26spage%3D2451%26epage%3D2457%26doi%3D10.1093%2Fannonc%2Fmdx396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials</span>. <i>Curr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.3747/co.25.3796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3747%2Fco.25.3796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=28-37&issue=1&author=G.+M.+O%E2%80%99Kaneauthor=T.+A.+Barnesauthor=N.+B.+Leighl&title=Resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors%2C+T790M%2C+and+clinical+trials&doi=10.3747%2Fco.25.3796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3747%2Fco.25.3796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.25.3796%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DBarnes%26aufirst%3DT.%2BA.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DResistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%252C%2520T790M%252C%2520and%2520clinical%2520trials%26jtitle%3DCurr.%2520Oncol.%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D28%26epage%3D37%26doi%3D10.3747%2Fco.25.3796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugazagoitia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">i10</span>– <span class="NLM_lpage">i19</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29462254" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i10-i19&issue=1&author=D.+Westoverauthor=J.+Zugazagoitiaauthor=B.+C.+Choauthor=C.+M.+Lovlyauthor=L.+Paz-Ares&title=Mechanisms+of+acquired+resistance+to+first-+and+second-generation+EGFR+tyrosine+kinase+inhibitors&doi=10.1093%2Fannonc%2Fmdx703"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx703%26sid%3Dliteratum%253Aachs%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DZugazagoitia%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520first-%2520and%2520second-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D1%26spage%3Di10%26epage%3Di19%26doi%3D10.1093%2Fannonc%2Fmdx703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span> <span> </span><span class="NLM_article-title">Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>, <span class="NLM_elocation-id">ii48</span> <span class="refDoi"> DOI: 10.1093/annonc/mdz063.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdz063.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&author=C.+Xuauthor=W.+Wangauthor=Y.+Zhuauthor=Z.+Yuauthor=H.+Zhangauthor=H.+Wangauthor=J.+Zhangauthor=W.+Zhuangauthor=T.+Lvauthor=Y.+Song&title=Potential+resistance+mechanisms+using+next+generation+sequencing+from+Chinese+EGFR+T790M%2B+non-small+cell+lung+cancer+patients+with+primary+resistance+to+osimertinib%3A+A+multicenter+study&doi=10.1093%2Fannonc%2Fmdz063.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz063.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz063.012%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26atitle%3DPotential%2520resistance%2520mechanisms%2520using%2520next%2520generation%2520sequencing%2520from%2520Chinese%2520EGFR%2520T790M%252B%2520non-small%2520cell%2520lung%2520cancer%2520patients%2520with%2520primary%2520resistance%2520to%2520osimertinib%253A%2520A%2520multicenter%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2019%26volume%3D30%26doi%3D10.1093%2Fannonc%2Fmdz063.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">York, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Tolerable and effective combination of full-dose Crizotinib and osimertinib targeting met amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">e85</span>– <span class="NLM_lpage">e88</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28274743" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e85-e88&issue=7&author=E.+R.+Yorkauthor=M.+Varella-Garciaauthor=T.+J.+Bangauthor=D.+L.+Aisnerauthor=D.+R.+Camidge&title=Tolerable+and+effective+combination+of+full-dose+Crizotinib+and+osimertinib+targeting+met+amplification+sequentially+emerging+after+T790M+positivity+in+EGFR-mutant+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2017.02.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DYork%26aufirst%3DE.%2BR.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DBang%26aufirst%3DT.%2BJ.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DTolerable%2520and%2520effective%2520combination%2520of%2520full-dose%2520Crizotinib%2520and%2520osimertinib%2520targeting%2520met%2520amplification%2520sequentially%2520emerging%2520after%2520T790M%2520positivity%2520in%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D7%26spage%3De85%26epage%3De88%26doi%3D10.1016%2Fj.jtho.2017.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiedrowski, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">Response to dual Crizotinib and osimertinib treatment in a lung cancer patient with met amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e169</span>– <span class="NLM_lpage">e172</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30166014" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e169-e172&issue=9&author=L.+Dengauthor=L.+A.+Kiedrowskiauthor=E.+Raveraauthor=H.+Chengauthor=B.+Halmos&title=Response+to+dual+Crizotinib+and+osimertinib+treatment+in+a+lung+cancer+patient+with+met+amplification+detected+by+liquid+biopsy+who+acquired+secondary+resistance+to+EGFR+tyrosine+kinase+inhibition&doi=10.1016%2Fj.jtho.2018.04.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DKiedrowski%26aufirst%3DL.%2BA.%26aulast%3DRavera%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DResponse%2520to%2520dual%2520Crizotinib%2520and%2520osimertinib%2520treatment%2520in%2520a%2520lung%2520cancer%2520patient%2520with%2520met%2520amplification%2520detected%2520by%2520liquid%2520biopsy%2520who%2520acquired%2520secondary%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibition%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3De169%26epage%3De172%26doi%3D10.1016%2Fj.jtho.2018.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Differential response to a combination of full-dose osimertinib and Crizotinib in a patient with <i>EGFR</i>-mutant non-small cell lung cancer and emergent <i>MET</i> amplification</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S190403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FLCTT.S190403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWhurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=21-26&author=V.+W.+Zhuauthor=A.+B.+Schrockauthor=S.+M.+Aliauthor=S.+I.+Ou&title=Differential+response+to+a+combination+of+full-dose+osimertinib+and+Crizotinib+in+a+patient+with+EGFR-mutant+non-small+cell+lung+cancer+and+emergent+MET+amplification&doi=10.2147%2FLCTT.S190403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification</span></div><div class="casAuthors">Zhu, Viola W.; Schrock, Alexa B.; Ali, Siraj M.; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies.  Here we report a case of emergent MET amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.  The patient subsequently had a sustained partial response to a combination of full-dose osimertinib and crizotinib with excellent tolerance but eventually had central nervous system (CNS) progression.  Comprehensive genomic profiling performed on the resected brain sample continued to demonstrate MET amplification as an acquired resistance mechanism.  A review of literature shows several groups have utilized similar combination regimens (erlotinib or osimertinib + crizotinib or cabozantinib), albeit with various dosing to target MET alterations in patients with EGFR-mutant NSCLC.  As more actionable resistance mechanisms are identified, we envision combination TKI therapy will be readily adopted in clin. practice.  Our case report adds to a growing body of evidence that combination osimertinib and crizotinib should be recommended to EGFR-mutant NSCLC patients with emergent MET amplification as acquired resistance.  More importantly, as crizotinib has limited brain penetration, developing next-generation MET inhibitors with better CNS activity is urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe1mB30ctl0LVg90H21EOLACvtfcHk0lg6rkrpzj4Mzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWhurzM&md5=001064e18abe99bbafa83f20d882caea</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S190403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S190403%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DDifferential%2520response%2520to%2520a%2520combination%2520of%2520full-dose%2520osimertinib%2520and%2520Crizotinib%2520in%2520a%2520patient%2520with%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%2520and%2520emergent%2520MET%2520amplification%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2019%26volume%3D10%26spage%3D21%26epage%3D26%26doi%3D10.2147%2FLCTT.S190403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plodkowski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odintsov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired <i>MET</i> Exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer</span>. <i>CO Precis Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1200/PO.19.00011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1200%2FPO.19.00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30623031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=1-8&author=K.+Suzawaauthor=M.+Offinauthor=A.+J.+Schoenfeldauthor=A.+J.+Plodkowskiauthor=I.+Odintsovauthor=D.+Luauthor=W.+W.+Lockwoodauthor=M.+E.+Arcilaauthor=C.+M.+Rudinauthor=A.+Drilonauthor=H.+A.+Yuauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+Ladanyi&title=Acquired+MET+Exon+14+alteration+drives+secondary+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+in+EGFR-mutated+lung+cancer&doi=10.1200%2FPO.19.00011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FPO.19.00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FPO.19.00011%26sid%3Dliteratum%253Aachs%26aulast%3DSuzawa%26aufirst%3DK.%26aulast%3DOffin%26aufirst%3DM.%26aulast%3DSchoenfeld%26aufirst%3DA.%2BJ.%26aulast%3DPlodkowski%26aufirst%3DA.%2BJ.%26aulast%3DOdintsov%26aufirst%3DI.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLockwood%26aufirst%3DW.%2BW.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520MET%2520Exon%252014%2520alteration%2520drives%2520secondary%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520in%2520EGFR-mutated%2520lung%2520cancer%26jtitle%3DCO%2520Precis%2520Oncol.%26date%3D2019%26volume%3D3%26spage%3D1%26epage%3D8%26doi%3D10.1200%2FPO.19.00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2073</span>– <span class="NLM_lpage">2078</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdv319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26269204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2073-2078&issue=10&author=D.+Planchardauthor=Y.+Loriotauthor=F.+Andr%C3%A9author=A.+Gobertauthor=N.+Augerauthor=L.+Lacroixauthor=J.+C.+Soria&title=EGFR-independent+mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M-positive+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdv319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span></div><div class="casAuthors">Planchard D; Loriot Y; Andre F; Gobert A; Auger N; Lacroix L; Soria J C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2073-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations.  This compound has shown outstanding activity, in a phase I/II (AURA) trial.  However, despite impressive tumor responses in T790M-positive patients, acquired resistance to this drug limits the benefit of this compound.  Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients.  PATIENTS AND METHODS:  To identify potential mechanisms of resistance to AZD9291, we report here on two patients with resistant biopsy specimens that had been treated with AZD9291.  RESULTS:  We identified in two distinct cases, HER2 and MET amplification by FISH and CGH as a potential mechanism of acquired resistance to third-generation EGFR-TKI.  Interestingly, this event occurred with complete loss of the T790M mutation.  In one case, we observed a different molecular status at two biopsy sites (the T790M mutation at the primary site and wild-type T790M at the metastatic site with different pathways of acquired resistance to AZD9291).  CONCLUSION:  Our observations suggest that T790M-positive and wild-type T790M clones may coexist at baseline.  AZD9291 efficiently suppresses the growth of T790M-positive cells, but a population of wild-type T790M cells at baseline will mediate the development of resistance, here via a by-pass pathway activating either HER2 or MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS11uv1hoUHSrJzI8owOhpDfW6udTcc2eafKP9Vb6bxGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D&md5=2cba18208f215fd28fcf58d321d42618</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv319%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DAuger%26aufirst%3DN.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DEGFR-independent%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M-positive%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D2073%26epage%3D2078%26doi%3D10.1093%2Fannonc%2Fmdv319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to Crizotinib treatment post-osimertinib progression</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2016.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27393507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=59-61&author=S.+I.+Ouauthor=N.+Agarwalauthor=S.+M.+Ali&title=High+MET+amplification+level+as+a+resistance+mechanism+to+osimertinib+%28AZD9291%29+in+a+patient+that+symptomatically+responded+to+Crizotinib+treatment+post-osimertinib+progression&doi=10.1016%2Fj.lungcan.2016.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Agarwal Nikita; Ali Siraj M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Third-generation EGFR TKI has been approved in the US and EU for the treatment of EGFR mutant T790M+ NSCLC patients that are resistant to first- or second generation EGFR TKIs.  Here we report a patient who developed resistance to osimertinib after a confirmed partial response for 9 months.  Pre-osimertinib and post-osimertinib tumor biopsy revealed the emergence of high level of MET amplification (30 copies) post osimertinib treatment.  Patient was treated with single agent crizotinib, a known MET inhibitor, with transient symptomatic benefit.  MET amplification is one potential resistance mechanism to osimertinib and combination of osimertinib and a MET inhibitor should be investigated post-osimertinib progression in EGFR mutant T790M+ NSCLC patients whose harbored acquired MET amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcGTszAFtshWfpMXQLRstfW6udTcc2eafKP9Vb6bxGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D&md5=2cd5da962531483cb3092367da127c64</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DHigh%2520MET%2520amplification%2520level%2520as%2520a%2520resistance%2520mechanism%2520to%2520osimertinib%2520%2528AZD9291%2529%2520in%2520a%2520patient%2520that%2520symptomatically%2520responded%2520to%2520Crizotinib%2520treatment%2520post-osimertinib%2520progression%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D98%26spage%3D59%26epage%3D61%26doi%3D10.1016%2Fj.lungcan.2016.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Cuesta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildhaus, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuernberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-15-1915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27252416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4837-4847&issue=19&author=S.+Ortiz-Cuaranauthor=M.+Schefflerauthor=D.+Plenkerauthor=l.+Dahmenauthor=A.+H.+Scheelauthor=L.+Fernandez-Cuestaauthor=L.+Mederauthor=C.+M.+Lovlyauthor=T.+Persigehlauthor=S.+Merkelbach-Bruseauthor=M.+Bosauthor=S.+Michelsauthor=R.+Fischerauthor=K.+Albusauthor=K.+Konigauthor=H.-U.+Schildhausauthor=J.+Fassunkeauthor=M.+A.+Ihleauthor=H.+Pasternackauthor=C.+Heydtauthor=C.+Beckerauthor=J.+Altmullerauthor=H.+Jiauthor=C.+Mullerauthor=A.+Florinauthor=J.+M.+Heuckmannauthor=P.+Nuernbergauthor=S.+Ansenauthor=L.+C.+Heukampauthor=J.+Bergauthor=W.+Paoauthor=M.+Peiferauthor=R.+Buettnerauthor=J.+Wolfauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Heterogeneous+mechanisms+of+primary+and+acquired+resistance+to+third-generation+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-15-1915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span></div><div class="casAuthors">Ortiz-Cuaran, Sandra; Scheffler, Matthias; Plenker, Dennis; Dahmen, llona; Scheel, Andreas H.; Fernandez-Cuesta, Lynnette; Meder, Lydia; Lovly, Christine M.; Persigehl, Thorsten; Merkelbach-Bruse, Sabine; Bos, Marc; Michels, Sebastian; Fischer, Rieke; Albus, Kerstin; Koenig, Katharina; Schildhaus, Hans-Ulrich; Fassunke, Jana; Ihle, Michaela A.; Pasternack, Helen; Heydt, Carina; Becker, Christian; Altmueller, Janine; Ji, Hongbin; Mueller, Christian; Florin, Alexandra; Heuckmann, Johannes M.; Nuernberg, Peter; Ansen, Sascha; Heukamp, Lukas C.; Berg, Johannes; Pao, William; Peifer, Martin; Buettner, Reinhard; Wolf, Juergen; Thomas, Roman K.; Sos, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4837-4847</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).  We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686).  Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.  We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compds.  Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance.  Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS.  Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryi-78iIDGfrVg90H21EOLACvtfcHk0li4shxOGsn31g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K&md5=b30908de40ff48f067e067cfc3520a7b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1915%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DDahmen%26aufirst%3Dl.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DMeder%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DAlbus%26aufirst%3DK.%26aulast%3DKonig%26aufirst%3DK.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPasternack%26aufirst%3DH.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DAltmuller%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DA.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DNuernberg%26aufirst%3DP.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DHeterogeneous%2520mechanisms%2520of%2520primary%2520and%2520acquired%2520resistance%2520to%2520third-generation%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D19%26spage%3D4837%26epage%3D4847%26doi%3D10.1158%2F1078-0432.CCR-15-1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2433</span>, <span class="refDoi"> DOI: 10.1007/s00432-020-03239-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1007%2Fs00432-020-03239-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32385709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=2427-2433&issue=9&author=Y.+Muauthor=X.+Haoauthor=P.+Xingauthor=X.+Huauthor=Y.+Wangauthor=T.+Liauthor=J.+Zhangauthor=Z.+Xuauthor=J.+Li&title=Acquired+resistance+to+osimertinib+in+patients+with+non-small-cell+lung+cancer%3A+mechanisms+and+clinical+outcomes&doi=10.1007%2Fs00432-020-03239-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span></div><div class="casAuthors">Mu, Yuxin; Hao, Xuezhi; Xing, Puyuan; Hu, Xingsheng; Wang, Yan; Li, Teng; Zhang, Jinyao; Xu, Ziyi; Li, Junling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2427-2433</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clin. benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation.  The aim of our study was to identify the mechanisms underlying resistance to osimertinib and to correlate them with clin. outcomes.  Methods: We retrospectively analyzed patients with advanced NSCLC who received osimertinib for T790M-mutated acquired resistance to prior EGFR-TKIs between March 1, 2017 and Dec. 31, 2018.  Patients with paired mol. data of pre-osimertinib and after resistance development, which were not confirmed with small-cell lung cancer (SCLC) transformation, were included in the mol. anal. set.  Results: Of 49 patients evaluated in the mol. anal. set, 24 patients maintained T790M mutation, while 25 patients exhibited T790M-loss.  Mol. modifications were identified in 27 of 49 patients including EGFR acquired mutations (C797S, C796S, G796S, V802I, V834L, E758D and G724S), non-EGFR-dependent mutations (PIK3CA, ALK, BRAF, KRAS and TP53), EGFR amplification and MET amplification.  At data cutoff, median progression-free survival (PFS) was 9.3 mo in the T790M-retain group compared with 7.8 mo in T790M-loss patients (P = 0.053).  Median PFS was significantly longer in patients with EGFR-dependent resistance mechanism (13.5 mo) than in those with alternative pathway activation (8.2 mo; P = 0.012).  Conclusions: The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their assocn. with clin. outcomes.  Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clin. outcome benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFg_CSXlnhSLVg90H21EOLACvtfcHk0li4shxOGsn31g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D&md5=7edcba72acbbd6fa1befd01b0f248c95</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs00432-020-03239-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-020-03239-1%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520osimertinib%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%253A%2520mechanisms%2520and%2520clinical%2520outcomes%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D146%26issue%3D9%26spage%3D2427%26epage%3D2433%26doi%3D10.1007%2Fs00432-020-03239-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">90557</span>– <span class="NLM_lpage">90578</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.21164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.21164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29163853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1M3jvVWltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=90557-90578&issue=52&author=J.+Xuauthor=J.+Wangauthor=S.+Zhang&title=Mechanisms+of+resistance+to+irreversible+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+and+therapeutic+strategies+in+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.21164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer</span></div><div class="casAuthors">Xu Jing; Wang Jinghui; Zhang Shucai</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">90557-90578</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) T790M mutation is the most frequent mechanism which accounts for about 60% of acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations.  Irreversible EGFR-TKIs which include the second-generation and third-generation EGFR-TKIs are developed to overcome T790M mediated resistance.  The second-generation EGFR-TKIs inhibit the wide type (WT) EGFR combined with dose-limiting toxicity which limits its application in clinics, while the development of third-generation EGFR-TKIs brings inspiring efficacy either in vitro or in vivo.  The acquired resistance, however, will also occur and limit their response.  Understanding the mechanisms of resistance to irreversible EGFR-TKIs plays an important role in the choice of subsequent treatment.  In this review, we show the currently known mechanisms of resistance which can be summarized as EGFR dependent and independent mechanisms and potential therapeutic strategies to irreversible EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRx9429BdJqztTiMd2aNQVUfW6udTcc2eYosQwucfzEnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3jvVWltw%253D%253D&md5=af64510113cad151e6ad12852d82e66a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.21164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.21164%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520therapeutic%2520strategies%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D52%26spage%3D90557%26epage%3D90578%26doi%3D10.18632%2Foncotarget.21164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omerovic, J.</span></span> <span> </span><span class="NLM_article-title">Current approaches in NSCLC targeting K-RAS and EGFR</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5701</span>, <span class="refDoi"> DOI: 10.3390/ijms20225701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fijms20225701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptl2mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=5701&issue=22&author=V.+Aranauthor=J.+Omerovic&title=Current+approaches+in+NSCLC+targeting+K-RAS+and+EGFR&doi=10.3390%2Fijms20225701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches in NSCLC targeting K-RAS and EGFR</span></div><div class="casAuthors">Aran, Veronica; Omerovic, Jasminka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5701</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The research and treatment of non-small cell lung cancer (NSCLC) have achieved some important advances in recent years.  Nonetheless, the overall survival rates for NSCLC remain low, indicating the importance to effectively develop new therapies and improve current approaches.  The understanding of the function of different biomarkers involved in NSCLC progression, survival and response to therapy are important for the development of early detection tools and treatment options.  Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) are two of the main significant biomarkers for the management of NSCLC.  Mutations in these genes were assocd. with development and response to therapies.  For example, the use of small mol. tyrosine kinase (TK) inhibitors and immunotherapy has led to benefits in some, but not all patients with altered EGFR.  In contrast, there is still no effective approved drug to act upon patients harbouring K-RAS mutations.  In addn., K-RAS mutations have been assocd. with lack of activity of TK inhibitors.  However, promising approaches aimed to inhibit mutant K-RAS are currently under study.  Therefore, this review will discuss these approaches and also EGFR therapies, and hopefully, it will draw attention to the need of continued research in the field in order to improve the outcomes in NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfRnQV33SqmbVg90H21EOLACvtfcHk0lg9AuspWorGUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptl2mtLo%253D&md5=64d9edf38be249aa90779ace3e9c0c63</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.3390%2Fijms20225701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20225701%26sid%3Dliteratum%253Aachs%26aulast%3DAran%26aufirst%3DV.%26aulast%3DOmerovic%26aufirst%3DJ.%26atitle%3DCurrent%2520approaches%2520in%2520NSCLC%2520targeting%2520K-RAS%2520and%2520EGFR%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D5701%26doi%3D10.3390%2Fijms20225701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2073</span>– <span class="NLM_lpage">2078</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdv319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26269204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2073-2078&issue=10&author=D.+Planchardauthor=Y.+Loriotauthor=F.+Andr%C3%A9author=A.+Gobertauthor=N.+Augerauthor=L.+Lacroixauthor=J.+C.+Soria&title=EGFR-independent+mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M-positive+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdv319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span></div><div class="casAuthors">Planchard D; Loriot Y; Andre F; Gobert A; Auger N; Lacroix L; Soria J C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2073-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations.  This compound has shown outstanding activity, in a phase I/II (AURA) trial.  However, despite impressive tumor responses in T790M-positive patients, acquired resistance to this drug limits the benefit of this compound.  Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients.  PATIENTS AND METHODS:  To identify potential mechanisms of resistance to AZD9291, we report here on two patients with resistant biopsy specimens that had been treated with AZD9291.  RESULTS:  We identified in two distinct cases, HER2 and MET amplification by FISH and CGH as a potential mechanism of acquired resistance to third-generation EGFR-TKI.  Interestingly, this event occurred with complete loss of the T790M mutation.  In one case, we observed a different molecular status at two biopsy sites (the T790M mutation at the primary site and wild-type T790M at the metastatic site with different pathways of acquired resistance to AZD9291).  CONCLUSION:  Our observations suggest that T790M-positive and wild-type T790M clones may coexist at baseline.  AZD9291 efficiently suppresses the growth of T790M-positive cells, but a population of wild-type T790M cells at baseline will mediate the development of resistance, here via a by-pass pathway activating either HER2 or MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS11uv1hoUHSrJzI8owOhpDfW6udTcc2eZzEH8G0XXlirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D&md5=2cba18208f215fd28fcf58d321d42618</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv319%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DAuger%26aufirst%3DN.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DEGFR-independent%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M-positive%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D2073%26epage%3D2078%26doi%3D10.1093%2Fannonc%2Fmdv319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawelets, C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">Supp 2</span>),  <span class="NLM_fpage">ORAL17.07</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=ORAL17.07&issue=Supp+2&author=G.+R.+Oxnardauthor=K.+Thressauthor=C.+Pawelets&title=Mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M+positive+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DPawelets%26aufirst%3DC.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M%2520positive%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3DSupp%25202%26spage%3DORAL17.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span> <span> </span><span class="NLM_article-title">Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovichauthor=T.+C.+Hardingauthor=K.+A.+Durkinauthor=G.+A.+Ottersonauthor=W.+T.+Purcellauthor=D.+R.+Camidgeauthor=J.+W.+Goldmanauthor=L.+V.+Sequistauthor=Z.+Piotrowskaauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=A.+A.+Alizadehauthor=M.+Diehn&title=Circulating+tumor+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0lg9AuspWorGUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DPurcell%26aufirst%3DW.%2BT.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DDiehn%26aufirst%3DM.%26atitle%3DCirculating%2520tumor%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenonos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyprianou, K.</span></span> <span> </span><span class="NLM_article-title">RAS signalling pathways, mutations and their role in colorectal cancer</span>. <i>World J. Gastrointest. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.4251/wjgo.v5.i5.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.4251%2Fwjgo.v5.i5.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23799159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3sjls1Ohtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=97-101&issue=5&author=K.+Zenonosauthor=K.+Kyprianou&title=RAS+signalling+pathways%2C+mutations+and+their+role+in+colorectal+cancer&doi=10.4251%2Fwjgo.v5.i5.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">RAS signaling pathways, mutations and their role in colorectal cancer</span></div><div class="casAuthors">Zenonos Kypros; Kyprianou Katy</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastrointestinal oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">97-101</span>
        ISSN:<span class="NLM_cas:issn">1948-5204</span>.
    </div><div class="casAbstract">Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways.  In a normal cell, these are important in controlling several functions, such as cell growth and survival.  It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway.  Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed.  The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXy8P3_ShDTEQ0lWbKiCflfW6udTcc2eZzkjE_ZQcLN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjls1Ohtw%253D%253D&md5=4cd8ea0bfdb1abbb119e7a71960a604a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.4251%2Fwjgo.v5.i5.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4251%252Fwjgo.v5.i5.97%26sid%3Dliteratum%253Aachs%26aulast%3DZenonos%26aufirst%3DK.%26aulast%3DKyprianou%26aufirst%3DK.%26atitle%3DRAS%2520signalling%2520pathways%252C%2520mutations%2520and%2520their%2520role%2520in%2520colorectal%2520cancer%26jtitle%3DWorld%2520J.%2520Gastrointest.%2520Oncol.%26date%3D2013%26volume%3D5%26issue%3D5%26spage%3D97%26epage%3D101%26doi%3D10.4251%2Fwjgo.v5.i5.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.7576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1200%2FJCO.2017.74.7576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28841389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=841-849&issue=9&author=S.+S.+Ramalingamauthor=J.+C.+Yangauthor=C.+K.+Leeauthor=T.+Kurataauthor=D.+W.+Kimauthor=T.+Johnauthor=N.+Nogamiauthor=Y.+Oheauthor=H.+Mannauthor=Y.+Rukazenkovauthor=S.+Ghiorghiuauthor=D.+Stetsonauthor=A.+Markovetsauthor=J.+C.+Barrettauthor=K.+S.+Thressauthor=P.+A.+J%C3%A4nne&title=Osimertinib+as+first-line+treatment+of+EGFR+mutation-positive+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2017.74.7576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Yang, James C. H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Carl Barrett, J.; Thress, Kenneth S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">841-849</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naive patients to examine clin. activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC).  Patients and Methods: Sixty treatment-naive patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort).  End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation.  Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms.  Results: At data cutoff (Nov. 1, 2016), median follow-up was 19.1 mo.  Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses.  Median PFS time was 22.1 mo (95% CI, 13.7 to 30.2 mo) in the 80-mg group, 19.3 mo (95% CI, 13.7 to 26.0 mo) in the 160-mg group, and 20.5 mo (95% CI, 15.0 to 26.1 mo) across doses.  Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA.  Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1).  Acquired EGFR T790M was not detected.  Conclusion: Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naive patients with EGFRm advanced NSCLC.  There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqM3jWJfzwbVg90H21EOLACvtfcHk0liS3CQiDqWVhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL&md5=e6b63846658632b5f79460ee29022835</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.7576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.7576%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DOsimertinib%2520as%2520first-line%2520treatment%2520of%2520EGFR%2520mutation-positive%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D9%26spage%3D841%26epage%3D849%26doi%3D10.1200%2FJCO.2017.74.7576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiura, K.</span></span> <span> </span><span class="NLM_article-title">MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1955</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-20326-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41598-018-20326-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29386539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlvFGhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1955&issue=1&author=K.+Ninomiyaauthor=K.+Ohashiauthor=G.+Makimotoauthor=S.+Tomidaauthor=H.+Higoauthor=H.+Kayataniauthor=T.+Ninomiyaauthor=T.+Kuboauthor=E.+Ichiharaauthor=K.+Hottaauthor=M.+Tabataauthor=Y.+Maedaauthor=K.+Kiura&title=MET+or+NRAS+amplification+is+an+acquired+resistance+mechanism+to+the+third-generation+EGFR+inhibitor+naquotinib&doi=10.1038%2Fs41598-018-20326-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib</span></div><div class="casAuthors">Ninomiya Kiichiro; Ohashi Kadoaki; Makimoto Go; Higo Hisao; Kayatani Hiroe; Ninomiya Takashi; Maeda Yoshinobu; Ohashi Kadoaki; Ichihara Eiki; Kiura Katsuyuki; Tomida Shuta; Kubo Toshio; Tabata Masahiro; Hotta Katsuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1955</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer harboring the EGFR T790M mutation; however, acquired resistance inevitably develops.  Therefore, a next-generation treatment strategy is warranted in the osimertinib era.  We investigated the mechanism of resistance to a novel EGFR-TKI, naquotinib, with the goal of developing a novel treatment strategy.  We established multiple naquotinib-resistant cell lines or osimertinib-resistant cells, two of which were derived from EGFR-TKI-naive cells; the others were derived from gefitinib- or afatinib-resistant cells harboring EGFR T790M.  We comprehensively analyzed the RNA kinome sequence, but no universal gene alterations were detected in naquotinib-resistant cells.  Neuroblastoma RAS viral oncogene homolog (NRAS) amplification was detected in naquotinib-resistant cells derived from gefitinib-resistant cells.  The combination therapy of MEK inhibitors and naquotinib exhibited a highly beneficial effect in resistant cells with NRAS amplification, but the combination of MEK inhibitors and osimertinib had limited effects on naquotinib-resistant cells.  Moreover, the combination of MEK inhibitors and naquotinib inhibited the growth of osimertinib-resistant cells, while the combination of MEK inhibitors and osimertinib had little effect on osimertinib-resistant cells.  Clinical assessment of this novel combination (MEK inhibitors and naquotinib) is worth considering in osimertinib-resistant lung tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBm3S-Gjqn8e3MPKNEWB5RfW6udTcc2ebsObRJgOwptrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlvFGhuw%253D%253D&md5=95a8016e2c1de4635e9d3291d2aef2c8</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-20326-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-20326-z%26sid%3Dliteratum%253Aachs%26aulast%3DNinomiya%26aufirst%3DK.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMakimoto%26aufirst%3DG.%26aulast%3DTomida%26aufirst%3DS.%26aulast%3DHigo%26aufirst%3DH.%26aulast%3DKayatani%26aufirst%3DH.%26aulast%3DNinomiya%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DTabata%26aufirst%3DM.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DKiura%26aufirst%3DK.%26atitle%3DMET%2520or%2520NRAS%2520amplification%2520is%2520an%2520acquired%2520resistance%2520mechanism%2520to%2520the%2520third-generation%2520EGFR%2520inhibitor%2520naquotinib%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26issue%3D1%26spage%3D1955%26doi%3D10.1038%2Fs41598-018-20326-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meador, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahdesmaki, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Brien, E. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beran, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.E.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to the mutant-selective EGFR inhibitor azd9291 is associated with increased dependence on RAS signalling in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2489</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-14-3167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25870145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2489-2500&issue=12&author=C.+A.+Eberleinauthor=D.+Stetsonauthor=A.+A.+Markovetsauthor=K.+J.+Al-Kadhimiauthor=Z.+Laiauthor=P.+R.+Fisherauthor=C.+B.+Meadorauthor=P.+Spitzlerauthor=E.+Ichiharaauthor=S.+J.+Rossauthor=M.+J.+Ahdesmakiauthor=A.+Ahmedauthor=L.+E.+Ratcliffeauthor=E.+L.+C.+O%27Brienauthor=C.+H.+Barnesauthor=H.+Brownauthor=P.+D.+Smithauthor=J.+R.+Dryauthor=G.+Beranauthor=K.+S.+Thressauthor=B.+Doughertyauthor=W.+Paoauthor=D.+A.E.+Cross&title=Acquired+resistance+to+the+mutant-selective+EGFR+inhibitor+azd9291+is+associated+with+increased+dependence+on+RAS+signalling+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-14-3167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models</span></div><div class="casAuthors">Eberlein, Catherine A.; Stetson, Daniel; Markovets, Aleksandra A.; Al-Kadhimi, Katherine J.; Lai, Zhongwu; Fisher, Paul R.; Meador, Catherine B.; Spitzler, Paula; Ichihara, Eiki; Ross, Sarah J.; Ahdesmaki, Miika J.; Ahmed, Ambar; Ratcliffe, Laura E.; O'Brien, Elizabeth L. Christey; Barnes, Claire H.; Brown, Henry; Smith, Paul D.; Dry, Jonathan R.; Beran, Garry; Thress, Kenneth S.; Dougherty, Brian; Pao, William; Cross, Darren A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2489-2500</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These results offer early insight into how acquired resistance arises to a new mutation-selective inhibitor of EGFR that is in fast-track clin. development, illustrating the inescapable cat-and-mouse chase in the evolution of cancer cell-targeting drugs in the management of cancer patients.  Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers.  Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies.  We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291.  We report the detection of NRAS mutations, including a novel E63K mutation, and a gain of copy no. of WT NRAS or WT KRAS in cell populations resistant to gefitinib, afatinib, WZ4002, or AZD9291.  Compared with parental cells, a no. of resistant cell populations were more sensitive to inhibition by the MEK inhibitor selumetinib (AZD6244; ARRY-142886) when treated in combination with the originating EGFR inhibitor.  In vitro, a combination of AZD9291 with selumetinib prevented emergence of resistance in PC9 cells and delayed resistance in NCI-H1975 cells.  In vivo, concomitant dosing of AZD9291 with selumetinib caused regression of AZD9291-resistant tumors in an EGFRm/T790M transgenic model.  Our data support the use of a combination of AZD9291 with a MEK inhibitor to delay or prevent resistance to AZD9291 in EGFRm and/or EGFRm/T790M tumors.  Furthermore, these findings suggest that NRAS modifications in tumor samples from patients who have progressed on current or EGFR inhibitors in development may support subsequent treatment with a combination of EGFR and MEK inhibition.  Cancer Res; 75(12); 2489-500. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZwyXo13dZBbVg90H21EOLACvtfcHk0limxMoL7My3lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D&md5=63691ddbbf38e2079b39b5d8f43ddef4</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3167%26sid%3Dliteratum%253Aachs%26aulast%3DEberlein%26aufirst%3DC.%2BA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%2BA.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%2BJ.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DFisher%26aufirst%3DP.%2BR.%26aulast%3DMeador%26aufirst%3DC.%2BB.%26aulast%3DSpitzler%26aufirst%3DP.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DAhdesmaki%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DRatcliffe%26aufirst%3DL.%2BE.%26aulast%3DO%2527Brien%26aufirst%3DE.%2BL.%2BC.%26aulast%3DBarnes%26aufirst%3DC.%2BH.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DDry%26aufirst%3DJ.%2BR.%26aulast%3DBeran%26aufirst%3DG.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DCross%26aufirst%3DD.%2BA.E.%26atitle%3DAcquired%2520resistance%2520to%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520azd9291%2520is%2520associated%2520with%2520increased%2520dependence%2520on%2520RAS%2520signalling%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D12%26spage%3D2489%26epage%3D2500%26doi%3D10.1158%2F0008-5472.CAN-14-3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.2231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.2231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27923714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=567-572&issue=3&author=C.+C.+Hoauthor=W.+Y.+Liaoauthor=C.+A.+Linauthor=J.+Y.+Shihauthor=C.+J.+Yuauthor=J.+C.-H.+Yang&title=Acquired+BRAF+V600E+mutation+as+resistant+mechanism+after+treatment+with+osimertinib&doi=10.1016%2Fj.jtho.2016.11.2231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib</span></div><div class="casAuthors">Ho Chao-Chi; Liao Wei-Yu; Shih Jin-Yuan; Yu Chong-Jen; Lin Chih-An; Yang James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-572</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used.  Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified.  It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment.  METHODS:  Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib.  Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry.  EGFR, AKT, MEK, and ERK phosphorylation were determined.  An anchorage-dependent colony formation assay was used for drug sensitivity.  RESULTS:  An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib.  Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib.  CONCLUSIONS:  A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway.  Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyyK7fCSkFDQ8IxFYvehhofW6udTcc2ebsObRJgOwptrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D&md5=b4d27a7ed29dfc9f3470175998e3b529</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.2231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.2231%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DW.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BA.%26aulast%3DShih%26aufirst%3DJ.%2BY.%26aulast%3DYu%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAcquired%2520BRAF%2520V600E%2520mutation%2520as%2520resistant%2520mechanism%2520after%2520treatment%2520with%2520osimertinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.jtho.2016.11.2231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stambolic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Pompa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirtsos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderovski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of PKB/AKT-dependent cell survival by the tumor suppressor PTEN</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81780-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS0092-8674%2800%2981780-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=9778245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=29-39&issue=1&author=V.+Stambolicauthor=A.+Suzukiauthor=J.+L.+de+la+Pompaauthor=G.+M.+Brothersauthor=C.+Mirtsosauthor=T.+Sasakiauthor=J.+Rulandauthor=J.+M.+Penningerauthor=D.+P.+Siderovskiauthor=T.+W.+Mak&title=Negative+regulation+of+PKB%2FAKT-dependent+cell+survival+by+the+tumor+suppressor+PTEN&doi=10.1016%2FS0092-8674%2800%2981780-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of PKB/Akt-Dependent cell survival by the tumor suppressor PTEN</span></div><div class="casAuthors">Stambolic, Vuk; Suzuki, Akira; De La Pompa, Jose Lois; Brothers, Greg M.; Mirtsos, Christine; Sasaki, Takehiko; Ruland, Jurgen; Penninger, Josef M.; Siderovski, David P.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PTEN is a tumor suppressor with sequence homol. to protein tyrosine phosphatases and the cytoskeletal protein tensin.  MPTEN-mutant mouse embryos display regions of increased proliferation.  In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a no. of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival.  Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation.  Furthermore, PTEN neg. regulates intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate in cells and dephosphorylates it in vitro.  Our results show that PTEN may exert its role as a tumor suppressor by neg. regulating the PI3'K/PKB/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMeJuD58djBrVg90H21EOLACvtfcHk0lgMfUMo6vj8mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D&md5=d0ffd63a69325f1296d08bdbc16c5f0f</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981780-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981780-8%26sid%3Dliteratum%253Aachs%26aulast%3DStambolic%26aufirst%3DV.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPompa%26aufirst%3DJ.%2BL.%26aulast%3DBrothers%26aufirst%3DG.%2BM.%26aulast%3DMirtsos%26aufirst%3DC.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DSiderovski%26aufirst%3DD.%2BP.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DNegative%2520regulation%2520of%2520PKB%252FAKT-dependent%2520cell%2520survival%2520by%2520the%2520tumor%2520suppressor%2520PTEN%26jtitle%3DCell%26date%3D1998%26volume%3D95%26issue%3D1%26spage%3D29%26epage%3D39%26doi%3D10.1016%2FS0092-8674%2800%2981780-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurisu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated AKT</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5779</span>– <span class="NLM_lpage">5788</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-3020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-06-3020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=17575145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFCqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=5779-5788&issue=12&author=F.+Yamasakiauthor=M.+J.+Johansenauthor=D.+Zhangauthor=S.+Krishnamurthyauthor=E.+Felixauthor=C.+Bartholomeuszauthor=R.+J.+Aguilarauthor=K.+Kurisuauthor=G.+B.+Millsauthor=G.+N.+Hortobagyiauthor=N.+T.+Ueno&title=Acquired+resistance+to+erlotinib+in+A-431+epidermoid+cancer+cells+requires+down-regulation+of+MMAC1%2FPTEN+and+up-regulation+of+phosphorylated+AKT&doi=10.1158%2F0008-5472.CAN-06-3020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt</span></div><div class="casAuthors">Yamasaki, Fumiyuki; Johansen, Mary J.; Zhang, Dongwei; Krishnamurthy, Savitri; Felix, Edward; Bartholomeusz, Chandra; Aguilar, Richard J.; Kurisu, Kaoru; Mills, Gordon B.; Hortobagyi, Gabriel N.; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5779-5788</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has clin. activity in advanced lung cancer, but disease that initially responds to erlotinib eventually progresses.  The mechanism of this acquired resistance is unclear.  We established two erlotinib-resistant pools of A-431 cells, a well-characterized epidermoid cancer cell line that constitutively overexpresses EGFR and is sensitive to erlotinib, by continuous exposure to erlotinib over a 6-mo period.  The extent of EGFR gene amplification or mutation of the EGFR tyrosine kinase domain was not altered in the resistant cells.  Intracellular erlotinib concns., detd. by liq. chromatog.-tandem mass spectrometry, were almost the same in all three cell lines.  Immunopptn. with EGFR antibody followed by detection with phosphotyrosine antibody revealed that erlotinib effectively reduced EGFR phosphorylation in both parental cells and resistant cells.  Erlotinib induced mutated in multiple advanced cancers 1/phosphatase and tensin homolog (MMAC1/PTEN) and suppressed phosphorylated Akt (Ser473) but not in the erlotinib-resistant cells.  Overexpression of MMAC1/PTEN by transfection with Ad.MMAC1/PTEN or by pharmacol. suppression of Akt activity restored erlotinib sensitivity in both resistant pools.  Further, transfection of parental A-431 cells with constitutively active Akt was sufficient to cause resistance to erlotinib.  We propose that acquired erlotinib resistance assocd. with MMAC1/PTEN down-regulation and Akt activation could be overcome by inhibitors of signaling through the phosphatidylinositol 3-kinase pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofe_Ni20gPobVg90H21EOLACvtfcHk0lgMfUMo6vj8mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFCqsbg%253D&md5=a8e14c31cfdfd75f4bb2ce8f6a87ab74</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3020%26sid%3Dliteratum%253Aachs%26aulast%3DYamasaki%26aufirst%3DF.%26aulast%3DJohansen%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKrishnamurthy%26aufirst%3DS.%26aulast%3DFelix%26aufirst%3DE.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DAguilar%26aufirst%3DR.%2BJ.%26aulast%3DKurisu%26aufirst%3DK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DAcquired%2520resistance%2520to%2520erlotinib%2520in%2520A-431%2520epidermoid%2520cancer%2520cells%2520requires%2520down-regulation%2520of%2520MMAC1%252FPTEN%2520and%2520up-regulation%2520of%2520phosphorylated%2520AKT%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D12%26spage%3D5779%26epage%3D5788%26doi%3D10.1158%2F0008-5472.CAN-06-3020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">The BAD protein integrates survival signalling by EGFR/MAPK and PI3K/AKT kinase pathways in PTEN-deficient tumor cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ccr.2005.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=16226704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFOrtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=287-297&author=Q.+B.+Sheauthor=D.+B.+Solitauthor=Q.+Yeauthor=K.+E.+O%E2%80%99Reillyauthor=J.+Loboauthor=N.+Rosen&title=The+BAD+protein+integrates+survival+signalling+by+EGFR%2FMAPK+and+PI3K%2FAKT+kinase+pathways+in+PTEN-deficient+tumor+cells&doi=10.1016%2Fj.ccr.2005.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells</span></div><div class="casAuthors">She, Qing-Bai; Solit, David B.; Ye, Qing; O'Reilly, Kathryn E.; Lobo, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tumor cells with mutated PTEN proliferate in an EGFR-independent manner.  Induction of PTEN sensitizes cells to EGFR inhibition, and the combination causes synergistic apoptosis.  Synergy is due to inhibition of two parallel pathways that phosphorylate the proapoptotic protein BAD at distinct sites.  Serine 112 phosphorylation is EGFR/MEK/MAPK dependent, whereas serine 136 phosphorylation is PI3K/Akt dependent.  Either phosphorylation is sufficient to sequester BAD to 14-3-3.  BAD is released and apoptosis is induced only if both serines are dephosphorylated in response to inhibition of both pathways.  Redn. of BAD expression by RNA interference prevents apoptosis in response to pathway inhibition.  Thus, BAD integrates the antiapoptotic effects of both pathways.  Combined inhibition of EGFR and PI3K signaling may be a useful therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrybh2W1eQJY7Vg90H21EOLACvtfcHk0lgMfUMo6vj8mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFOrtLrE&md5=94a7bbd7229d9ab0330fbc55642aa0a1</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DLobo%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520BAD%2520protein%2520integrates%2520survival%2520signalling%2520by%2520EGFR%252FMAPK%2520and%2520PI3K%252FAKT%2520kinase%2520pathways%2520in%2520PTEN-deficient%2520tumor%2520cells%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D287%26epage%3D297%26doi%3D10.1016%2Fj.ccr.2005.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frommolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashkar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span> <span> </span><span class="NLM_article-title"><i>PTEN</i> loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of AKT and EGFR</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3256</span>– <span class="NLM_lpage">3261</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-08-4055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19351834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksV2hs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3256-3261&issue=8&author=M.+L.+Sosauthor=M.+Kokerauthor=B.+A.+Weirauthor=S.+Heynckauthor=R.+Rabinovskyauthor=T.+Zanderauthor=J.+M.+Seegerauthor=J.+Weissauthor=F.+Fischerauthor=P.+Frommoltauthor=K.+Michelauthor=M.+Peiferauthor=C.+Mermelauthor=L.+Girardauthor=M.+Peytonauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=L.+A.+Garrawayauthor=H.+Kashkarauthor=W.+Paoauthor=M.+Meyersonauthor=R.+K.+Thomas&title=PTEN+loss+contributes+to+erlotinib+resistance+in+EGFR-mutant+lung+cancer+by+activation+of+AKT+and+EGFR&doi=10.1158%2F0008-5472.CAN-08-4055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR</span></div><div class="casAuthors">Sos, Martin L.; Koker, Mirjam; Weir, Barbara A.; Heynck, Stefanie; Rabinovsky, Rosalia; Zander, Thomas; Seeger, Jens M.; Weiss, Jonathan; Fischer, Florian; Frommolt, Peter; Michel, Kathrin; Peifer, Martin; Mermel, Craig; Girard, Luc; Peyton, Michael; Gazdar, Adi F.; Minna, John D.; Garraway, Levi A.; Kashkar, Hamid; Pao, William; Meyerson, Matthew; Thomas, Roman K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3256-3261</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET.  Addnl. mechanisms contributing to EGFR inhibitor resistance remain elusive.  By applying combined analyses of gene expression, copy no., and biochem. analyses of EGFR inhibitor responsiveness, we identified homozygous loss of PTEN to segregate EGFR-dependent and EGFR-independent cells.  We show that in EGFR-dependent cells, PTEN loss partially uncouples mutant EGFR from downstream signaling and activates EGFR, thereby contributing to erlotinib resistance.  The clin. relevance of our findings is supported by the observation of PTEN loss in 1 out of 24 primary EGFR-mutant non-small cell lung cancer (NSCLC) tumors.  These results suggest a novel resistance mechanism in EGFR-mutant NSCLC involving PTEN loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRCf9WUZLXLVg90H21EOLACvtfcHk0lhIrFMXoZCPkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksV2hs7g%253D&md5=e420e3cc5c051ff1909a1253ae585f21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4055%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DRabinovsky%26aufirst%3DR.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DSeeger%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DKashkar%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPTEN%2520loss%2520contributes%2520to%2520erlotinib%2520resistance%2520in%2520EGFR-mutant%2520lung%2520cancer%2520by%2520activation%2520of%2520AKT%2520and%2520EGFR%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D8%26spage%3D3256%26epage%3D3261%26doi%3D10.1158%2F0008-5472.CAN-08-4055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H.</span></span> <span> </span><span class="NLM_article-title">PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>823</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejphar.2018.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29378193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVaksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=823&publication_year=2018&pages=19-26&author=K.+Toauthor=W.+Wuauthor=H.+Loong&title=PPARgamma+agonists+sensitize+PTEN-deficient+resistant+lung+cancer+cells+to+EGFR+tyrosine+kinase+inhibitors+by+inducing+autophagy&doi=10.1016%2Fj.ejphar.2018.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy</span></div><div class="casAuthors">To, Kenneth K. W.; Wu, William K. K.; Loong, Herbert H. F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">823</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We aimed to develop novel drug combination strategy to overcome drug resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in the treatment of non-small cell lung cancer (NSCLC).  Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor, which upon activation upregulates phosphatase and tensin homolog (PTEN) to inhibit cell signaling downstream of PI3K to mediate apoptosis.  To this end, PTEN loss is a known mechanism contributing to resistance to EGFR TKIs.  Therefore, PPARγ agonists are hypothesized to overcome EGFR TKI resistance.  Using human NSCLC cell models with PTEN deficiency, the potentiation of EGFR TKI anticancer activity by PPARγ agonists was evaluated.  PPARγ agonists were found to upregulate PTEN, subsequently inhibiting the PI3K-Akt signaling pathway, and thus enhancing the anticancer activity of gefitinib (a first generation EGFR TKI).  Chem. and genetic inhibition of PPARγ were shown to prevent this potentiation of anticancer activity by PPARγ agonists, thus confirming the crucial role played by PPARγ activation.  Interestingly, the tested PPARγ agonists were also found to induce autophagy, as evidenced by the increased expression of an autophagy marker LC3-II and the autophagic degrdn. of p62/SQSTM1.  PPARγ agonists-induced autophagic cell death was believed to contribute to the circumvention of resistance in PTEN-deficient cells because the genetic silencing of ATG5 (an autophagy mediator) was found to eliminate the drug potentiation effect by the PPARγ agonists.  Our findings thus provide the basis for the rational and personalized use of PPARγ agonists in combination with EGFR TKIs in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwVYOH_Zwn07Vg90H21EOLACvtfcHk0lhIrFMXoZCPkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVaksb0%253D&md5=e6e2f7c197317249a0595db9763837e7</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLoong%26aufirst%3DH.%26atitle%3DPPARgamma%2520agonists%2520sensitize%2520PTEN-deficient%2520resistant%2520lung%2520cancer%2520cells%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520by%2520inducing%2520autophagy%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D823%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.ejphar.2018.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietanza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span> <span> </span><span class="NLM_article-title">Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1535-7163.MCT-11-0692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22135231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=485-491&issue=2&author=J.+E.+Chaftauthor=M.+E.+Arcilaauthor=P.+K.+Paikauthor=C.+Lauauthor=G.+J.+Rielyauthor=M.+C.+Pietanzaauthor=M.+F.+Zakowskiauthor=V.+Ruschauthor=C.+S.+Simaauthor=M.+Ladanyiauthor=M.+G.+Kris&title=Coexistence+of+PIK3CA+and+other+oncogene+mutations+in+lung+adenocarcinoma-rationale+for+comprehensive+mutation+profiling&doi=10.1158%2F1535-7163.MCT-11-0692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling</span></div><div class="casAuthors">Chaft, Jamie E.; Arcila, Maria E.; Paik, Paul K.; Lau, Christopher; Riely, Gregory J.; Pietanza, M. Catherine; Zakowski, Maureen F.; Rusch, Valerie; Sima, Camelia S.; Ladanyi, Marc; Kris, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K).  PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein have been assocd. with tumorigenesis and treatment resistance in various malignancies.  Characteristics of patients with PIK3CA-mutant lung adenocarcinomas have not been reported.  We examd. epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.  Clin. data were obtained from the medical records of individuals with mutations in PIK3CA.  Twenty-three of 1,125 (2%, 95% CI: 1-3) patients had a mutation in PIK3CA, 12 in exon 9 (10 E545K and 2 E542K), and 11 in exon 20 (3 H1047L and 8 H1047R).  The patients (57% women) had a median age of 66 at diagnosis (range: 34-78).  Eight patients (35%) were never smokers.  Sixteen of 23 (70%, 95% CI: 49-86) had coexisting mutations in other oncogenes-10 KRAS, 1 MEK1, 1 BRAF, 1 ALK rearrangement, and 3 EGFR exon 19 deletions.  We conclude that PIK3CA mutations occur in lung adenocarcinomas, usually concurrently with EGFR, KRAS, and ALK.  The impact of PIK3CA mutations on the efficacy of targeted therapies such as erlotinib and crizotinib is unknown.  Given the high frequency of overlapping mutations, comprehensive genotyping should be carried out on tumor specimens from patients enrolling in clin. trials of PI3K and other targeted therapies.  Mol Cancer Ther; 11(2); 485-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotLJbbv7j8PbVg90H21EOLACvtfcHk0liIGoMljdOO_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrc%253D&md5=cbbbf6fa4af430599549f434747f6935</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0692%26sid%3Dliteratum%253Aachs%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DPaik%26aufirst%3DP.%2BK.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DKris%26aufirst%3DM.%2BG.%26atitle%3DCoexistence%2520of%2520PIK3CA%2520and%2520other%2520oncogene%2520mutations%2520in%2520lung%2520adenocarcinoma-rationale%2520for%2520comprehensive%2520mutation%2520profiling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D2%26spage%3D485%26epage%3D491%26doi%3D10.1158%2F1535-7163.MCT-11-0692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludovini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianconi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minotti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuffrida, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofanetti, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siggillino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mameli, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaliere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crinò, L.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">707</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e31820a3a6b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0b013e31820a3a6b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=21258250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3MrlsF2rsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=707-715&issue=4&author=V.+Ludoviniauthor=F.+Bianconiauthor=L.+Pistolaauthor=R.+Chiariauthor=V.+Minottiauthor=R.+Colellaauthor=D.+Giuffridaauthor=F.+R.+Tofanettiauthor=A.+Siggillinoauthor=A.+Flaccoauthor=E.+Baldelliauthor=D.+Iaconoauthor=M.+G.+Mameliauthor=A.+Cavaliereauthor=L.+Crin%C3%B2&title=Phosphoinositide-3-kinase+catalytic+alpha+and+KRAS+mutations+are+important+predictors+of+resistance+to+therapy+with+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+patients+with+advanced+non-small+cell+lung+cancer&doi=10.1097%2FJTO.0b013e31820a3a6b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer</span></div><div class="casAuthors">Ludovini Vienna; Bianconi Fortunato; Pistola Lorenza; Chiari Rita; Minotti Vincenzo; Colella Renato; Giuffrida Dario; Tofanetti Francesca Romana; Siggillino Annamaria; Flacco Antonella; Baldelli Elisa; Iacono Daniela; Mameli Maria Grazia; Cavaliere Antonio; Crino Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">707-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Specific mutations of the epidermal growth factor receptor (EGFR) gene are predictive for favorable response to tyrosine kinase inhibitors (TKIs) and are associated with a good prognosis.  In contrast, Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation has been shown to predict poor response to such therapy.  Nevertheless, tumor that initially responds to EGFR-TKIs almost inevitably becomes resistant later.  Other mechanisms of resistance to EGFR inhibitors could involve activating mutations of the other main EGFR effector pathway, i.e., the phosphoinositide-3-kinase/phosphate and tensin homologue deleted from chromosome 10 (PTEN)/alpha serine/threonine protein kinase (AKT) pathway.  The aim of this study was to investigate the role of phosphoinositide-3-kinase catalytic alpha (PIK3CA), EGFR, and KRAS gene mutations in predicting response and survival in patients with non-small cell lung cancer (NSCLC) treated with EGFR-TKIs.  PATIENTS AND METHODS:  A total of 166 patients with advanced NSCLC treated with EGFR-TKI with available archival tissue specimens were included.  PIK3CA, EGFR, and KRAS mutations were analyzed using polymerase chain reaction-based sequencing.  RESULTS:  EGFR mutation was detected in 25.3% of patients, PIK3CA mutation in 4.1%, and KRAS mutation in 6.7%.  PIK3CA mutation correlated with shorter median time to progression (TTP) (p = 0.01) and worse overall survival (OS) (p < 0.001).  EGFR mutation (p < 0.0001) correlated with favorable response to TKIs treatment and longer TTP (p < 0.0001).  KRAS mutation correlated with progressive disease (p = 0.05) and shorter median TTP (p = 0.003) but not with OS.  Cox multivariate analysis including histology and performance status showed that PIK3CA mutation was an independent factor to predict worse OS (p = 0.0001) and shorter TTP (p = 0.03), while KRAS mutation to predict shorter TTP (p = 0.01).  CONCLUSION:  PIK3CA and KRAS mutations seem to be indicators of resistance and poor survival in patients with NSCLC treated with EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4PDg1GrHoyeqrn-c4Of3KfW6udTcc2eapx0vrSFx_tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrlsF2rsg%253D%253D&md5=214e69ee636edc4000a10163d6590f65</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31820a3a6b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31820a3a6b%26sid%3Dliteratum%253Aachs%26aulast%3DLudovini%26aufirst%3DV.%26aulast%3DBianconi%26aufirst%3DF.%26aulast%3DPistola%26aufirst%3DL.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DMinotti%26aufirst%3DV.%26aulast%3DColella%26aufirst%3DR.%26aulast%3DGiuffrida%26aufirst%3DD.%26aulast%3DTofanetti%26aufirst%3DF.%2BR.%26aulast%3DSiggillino%26aufirst%3DA.%26aulast%3DFlacco%26aufirst%3DA.%26aulast%3DBaldelli%26aufirst%3DE.%26aulast%3DIacono%26aufirst%3DD.%26aulast%3DMameli%26aufirst%3DM.%2BG.%26aulast%3DCavaliere%26aufirst%3DA.%26aulast%3DCrin%25C3%25B2%26aufirst%3DL.%26atitle%3DPhosphoinositide-3-kinase%2520catalytic%2520alpha%2520and%2520KRAS%2520mutations%2520are%2520important%2520predictors%2520of%2520resistance%2520to%2520therapy%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26issue%3D4%26spage%3D707%26epage%3D715%26doi%3D10.1097%2FJTO.0b013e31820a3a6b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">113</span>, <span class="refDoi"> DOI: 10.3389/fonc.2017.00113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3389%2Ffonc.2017.00113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28620581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=113&author=T.+A.+Barnesauthor=G.+M.+O%E2%80%99Kaneauthor=M.+D.+Vincentauthor=N.+B.+Leighl&title=Third-generation+tyrosine+kinase+inhibitors+targeting+epidermal+growth+factor+receptor+mutations+in+non-small+cell+lung+cancer&doi=10.3389%2Ffonc.2017.00113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Barnes Tristan A; O'Kane Grainne M; Leighl Natasha B; Vincent Mark David</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer.  Eventual resistance develops with multiple mechanisms identifiable both upon repeat biopsy and in plasma circulating tumor DNA.  The T790M gatekeeper mutation is responsible for almost 60% of cases.  A number of third-generation TKIs are in clinical development, and osimertinib has been approved by the US Food and Drug Administration for the treatment of patients with EGFR T790M mutant lung cancer after failure of initial EGFR kinase therapy.  Resistance mechanisms are being identified to these novel agents, and the treatment landscape of EGFR-mutant lung cancer continues to evolve.  The sequence of EGFR TKIs may change in the future and combination therapies targeting resistance appear highly promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT45i3zpRyq-4hLSh9fo81bfW6udTcc2eapx0vrSFx_tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D&md5=591385d1fc87186675e46ad3621dc82b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2017.00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2017.00113%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DT.%2BA.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DVincent%26aufirst%3DM.%2BD.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DThird-generation%2520tyrosine%2520kinase%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2017%26volume%3D7%26spage%3D113%26doi%3D10.3389%2Ffonc.2017.00113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plodkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1713</span>– <span class="NLM_lpage">1719</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0000000000000671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26334752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1713-1719&issue=12&author=J.+Engauthor=K.+M.+Wooauthor=C.+S.+Simaauthor=A.+Plodkowskiauthor=M.+D.+Hellmannauthor=J.+E.+Chaftauthor=M.+G.+Krisauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=A.+Drilon&title=Impact+of+concurrent+PIK3CA+mutations+on+response+to+EGFR+tyrosine+kinase+inhibition+in+EGFR-mutant+lung+cancers+and+on+prognosis+in+oncogene-driven+lung+adenocarcinomas&doi=10.1097%2FJTO.0000000000000671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas</span></div><div class="casAuthors">Eng, Juliana; Woo, Kaitlin M.; Sima, Camelia S.; Plodkowski, Andrew; Hellmann, Matthew D.; Chaft, Jamie E.; Kris, Mark G.; Arcila, Maria E.; Ladanyi, Marc; Drilon, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1713-1719</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: In patients with epidermal growth factor receptor (EGFR)-mutant or KRAS-mutant lung adenocarcinomas, the prognostic impact of a concurrent PIK3CA mutation remains unclear.  Although preclin. data suggest that sensitivity to EGFR tyrosine kinase inhibition (TKI) is decreased in EGFR-mutant lung cancers also harboring a PIK3CA mutation, this interaction has not been explored clin.  Methods: Patients with lung adenocarcinomas harboring a PIK3CA mutation concurrent with a sep. driver mutation were identified through mutational hotspot testing, multiplex sizing assays, and fluorescence in situ hybridization.  Overall survival and outcomes with EGFR TKI monotherapy (EGFR-mutant) were estd. using Kaplan-Meier methods and compared between double-mutant (EGFR-mutant or KRAS-mutant, concurrent PIK3CA-mutant) and single-mutant patients (EGFR-mutant or KRAS-mutant, PIK3CA wild-type) using log-rank tests.  Results: In EGFR-mutant and KRAS-mutant lung cancers, a concurrent PIK3CA mutation was assocd. with a decrease in median overall survival: 18 vs. 33 mo (EGFR double mutant, n = 10 vs. single mutant, n = 43, p = 0.006), and 9 vs. 16 mo (KRAS double mutant, n = 16 vs. single mutant, n = 47, p = 0.020).  In EGFR-mutant lung cancers, a concurrent PIK3CA mutation did not impact benefit from EGFR TKI monotherapy.  Single vs. double mutant: objective response rate, 83% (n = 29) vs. 62% (n = 6, p = 0.80); median time to progression, 11 (n = 29) vs. 8 mo (n = 6, p = 0.84); and median duration of TKI therapy, 15 (n = 32) vs. 15 mo (n = 10, p = 0.65).  Conclusion: A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas.  There was no evidence that clin. benefit from EGFR TKI monotherapy is affected by a concurrent PIK3CA mutation in EGFR-mutant lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6JH4V50hFI7Vg90H21EOLACvtfcHk0ljWN_Pa0YMPXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rJ&md5=5566e6c5a8e5d62eeb24b072a34e2170</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000671%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DWoo%26aufirst%3DK.%2BM.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DPlodkowski%26aufirst%3DA.%26aulast%3DHellmann%26aufirst%3DM.%2BD.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DImpact%2520of%2520concurrent%2520PIK3CA%2520mutations%2520on%2520response%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibition%2520in%2520EGFR-mutant%2520lung%2520cancers%2520and%2520on%2520prognosis%2520in%2520oncogene-driven%2520lung%2520adenocarcinomas%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D1713%26epage%3D1719%26doi%3D10.1097%2FJTO.0000000000000671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFramboise, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moonsamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G</span></span> <span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&issue=8&author=Z.+Zhangauthor=J.+C.+Leeauthor=L.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Wangauthor=A.+D+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.-M.+Choiauthor=S.-W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.-S.+Leeauthor=V.+A+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J+Boggonauthor=P.+C+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0ljWN_Pa0YMPXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLevine%26aufirst%3DA.%2BD%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.-M.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DMiller%26aufirst%3DV.%2BA%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ%26aulast%3DMa%26aufirst%3DP.%2BC%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26issue%3D8%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&issue=12&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lidl8k6yZJCgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Giving AXL the axe: targeting AXL in human malignancy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fbjc.2016.428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28072762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=415-423&issue=4&author=C.+M.+Gayauthor=K.+Balajiauthor=L.+A.+Byers&title=Giving+AXL+the+axe%3A+targeting+AXL+in+human+malignancy&doi=10.1038%2Fbjc.2016.428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Giving AXL the axe: targeting AXL in human malignancy</span></div><div class="casAuthors">Gay, Carl M.; Balaji, Kavitha; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunol. response.  Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematol. and solid malignancies, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.  In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.  As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.  Several AXL inhibitors are currently in preclin. and clin. development.  This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumor microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXM9RJ8TVsLVg90H21EOLACvtfcHk0lidl8k6yZJCgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D&md5=c24668744fe4b017def75b08bac2a863</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.428%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DBalaji%26aufirst%3DK.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DGiving%2520AXL%2520the%2520axe%253A%2520targeting%2520AXL%2520in%2520human%2520malignancy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26issue%3D4%26spage%3D415%26epage%3D423%26doi%3D10.1038%2Fbjc.2016.428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintanal-Villalonga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Pinelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirauqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojeda-Márquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrugal, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce-Aix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enguita, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">FGFR1 Cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30639621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=641-655&issue=4&author=A.+Quintanal-Villalongaauthor=S.+Molina-Pineloauthor=C.+Cirauquiauthor=L.+Ojeda-M%C3%A1rquezauthor=%C3%81.+Marrugalauthor=R.+Suarezauthor=E.+Condeauthor=S.+Ponce-Aixauthor=A.+B.+Enguitaauthor=A.+Carneroauthor=I.+Ferrerauthor=L.+Paz-Ares&title=FGFR1+Cooperates+with+EGFR+in+lung+cancer+oncogenesis%2C+and+their+combined+inhibition+shows+improved+efficacy&doi=10.1016%2Fj.jtho.2018.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy</span></div><div class="casAuthors">Quintanal-Villalonga, Alvaro; Molina-Pinelo, Sonia; Cirauqui, Cristina; Ojeda-Marquez, Laura; Marrugal, Angela; Suarez, Rocio; Conde, Esther; Ponce-Aix, Santiago; Enguita, Ana Belen; Carnero, Amancio; Ferrer, Irene; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-655</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma.  We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays.  We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts.  We detd. FGFR1 mRNA expression in a cohort of patients with anti-EGFR therapy-treated adenocarcinoma.  We have reported a cooperative interaction between FGFR1 and EGFR in this context, resulting in increased EGFR activation and oncogenic signaling.  We have provided in vitro and in vivo evidence indicating that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in EGFR-mutated and EGFR wild-type models.  At the clin. level, we have shown that high FGFR1 expression levels predict higher resistance to erlotinib or gefitinib in a cohort of patients with tyrosine kinase inhibitor-treated EGFR-mutated and EGFR wild-type lung adenocarcinoma.  Dual EGFR and FGFR inhibition in FGFR1-overexpressing, EGFR-activated models shows synergistic effects on tumor growth in vitro and in cell line- and patient-derived xenografts, suggesting that patients with tumors bearing these characteristics may benefit from combined EGFR/FGFR inhibition.  These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJn8jLNuMQRLVg90H21EOLACvtfcHk0lidl8k6yZJCgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL&md5=d2a14b7b17cd9a65819d63760a7124e5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DQuintanal-Villalonga%26aufirst%3DA.%26aulast%3DMolina-Pinelo%26aufirst%3DS.%26aulast%3DCirauqui%26aufirst%3DC.%26aulast%3DOjeda-M%25C3%25A1rquez%26aufirst%3DL.%26aulast%3DMarrugal%26aufirst%3D%25C3%2581.%26aulast%3DSuarez%26aufirst%3DR.%26aulast%3DConde%26aufirst%3DE.%26aulast%3DPonce-Aix%26aufirst%3DS.%26aulast%3DEnguita%26aufirst%3DA.%2BB.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DFGFR1%2520Cooperates%2520with%2520EGFR%2520in%2520lung%2520cancer%2520oncogenesis%252C%2520and%2520their%2520combined%2520inhibition%2520shows%2520improved%2520efficacy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D641%26epage%3D655%26doi%3D10.1016%2Fj.jtho.2018.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finocchiaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toschi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incarbone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alloisio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span> <span> </span><span class="NLM_article-title">Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdp357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdp357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19767315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3c7isVGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=562-567&issue=3&author=F.+Cappuzzoauthor=G.+Talliniauthor=G.+Finocchiaroauthor=R.+S.+Wilsonauthor=C.+Ligorioauthor=L.+Giordanoauthor=L.+Toschiauthor=M.+Incarboneauthor=R.+Cavinaauthor=L.+Terraccianoauthor=M.+Roncalliauthor=M.+Alloisioauthor=M.+Varella-Garciaauthor=W.+A.+Franklinauthor=A.+Santoro&title=Insulin-like+growth+factor+receptor+1+%28IGF1R%29+expression+and+survival+in+surgically+resected+non-small-cell+lung+cancer+%28NSCLC%29+patients&doi=10.1093%2Fannonc%2Fmdp357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients</span></div><div class="casAuthors">Cappuzzo F; Tallini G; Ligorio C; Finocchiaro G; Toschi L; Incarbone M; Cavina R; Alloisio M; Santoro A; Wilson R S; Varella-Garcia M; Franklin W A; Giordano L; Terracciano L; Roncalli M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">562-567</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC).  Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients.  Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded.  IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections.  RESULTS:  A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02).  No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36).  No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status.  CONCLUSIONS:  IGF1R expression does not represent a prognostic factor in resected NSCLC patients.  Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQs8HJHlMdUpq-9TkgmBqTqfW6udTcc2ebgNV3fVOhfRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7isVGmtg%253D%253D&md5=428de4274517630d36a622543221e88d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp357%26sid%3Dliteratum%253Aachs%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DTallini%26aufirst%3DG.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DR.%2BS.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DGiordano%26aufirst%3DL.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DIncarbone%26aufirst%3DM.%26aulast%3DCavina%26aufirst%3DR.%26aulast%3DTerracciano%26aufirst%3DL.%26aulast%3DRoncalli%26aufirst%3DM.%26aulast%3DAlloisio%26aufirst%3DM.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DSantoro%26aufirst%3DA.%26atitle%3DInsulin-like%2520growth%2520factor%2520receptor%25201%2520%2528IGF1R%2529%2520expression%2520and%2520survival%2520in%2520surgically%2520resected%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26issue%3D3%26spage%3D562%26epage%3D567%26doi%3D10.1093%2Fannonc%2Fmdp357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of IGF1R signalling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1002/mc.22342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fmc.22342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26052929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=991-1001&issue=5&author=Y.+Leeauthor=Y.+Wangauthor=M.+Jamesauthor=J.+H.+Jeongauthor=M.+You&title=Inhibition+of+IGF1R+signalling+abrogates+resistance+to+afatinib+%28BIBW2992%29+in+EGFR+T790M+mutant+lung+cancer+cells&doi=10.1002%2Fmc.22342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells</span></div><div class="casAuthors">Lee, Yongik; Wang, Yian; James, Michael; Jeong, Joseph H.; You, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">991-1001</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib.  Acquisition of a secondary mutation in EGFR T790M is the most common mechanism of resistance to first generation EGFR TKIs, resulting in therapeutic failure.  Afatinib is a second generation of EGFR TKI that showed great efficacy against tumors bearing the EGFR T790M mutation, but it failed to show the improvement on overall survival of lung cancer patients with EGFR mutations possibly because of novel acquired resistance mechanisms.  Currently, there are no therapeutic options available for lung cancer patients who develop acquired resistance to afatinib.  To identify novel resistance mechanism(s) to afatinib, we developed afatinib resistant cell lines from a parental human-derived NSCLC cell line, H1975, harboring both EGFR L858R and T790M mutations.  We found that activation of the insulin-like growth factor 1 receptor (IGF1R) signaling pathway contributes to afatinib resistance in NSCLC cells harboring the T790M mutation.  IGF1R knockdown not only significantly sensitizes resistant cells to afatinib, but also induces apoptosis in afatinib resistance cells.  In addn., combination treatment with afatinib and linsitinib shows more than additive effects on tumor growth in in vivo H1975 xenograft.  Therefore, these finding suggest that IGF1R inhibition or combination of EGFR-IGF1R inhibition strategies would be potential ways to prevent or potentiate the effects of current therapeutic options to lung cancer patients demonstrating resistance to either first or second generation EGFR TKIs © 2015 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Fke9Vrm9TbVg90H21EOLACvtfcHk0libl3JBrrZ1sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFejtb0%253D&md5=66b4fc1ae65e8b94f39d329f31b34b6b</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fmc.22342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.22342%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DYou%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520IGF1R%2520signalling%2520abrogates%2520resistance%2520to%2520afatinib%2520%2528BIBW2992%2529%2520in%2520EGFR%2520T790M%2520mutant%2520lung%2520cancer%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2016%26volume%3D55%26issue%3D5%26spage%3D991%26epage%3D1001%26doi%3D10.1002%2Fmc.22342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">22005</span>– <span class="NLM_lpage">22015</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.8013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26980747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28fgsFChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=22005-22015&issue=16&author=J.+H.+Parkauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=J.+E.+Leeauthor=K.+J.+Sungauthor=S.+Parkauthor=W.+S.+Kimauthor=J.+S.+Songauthor=C.+M.+Choiauthor=Y.+H.+Sungauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Activation+of+the+IGF1R+pathway+potentially+mediates+acquired+resistance+to+mutant-selective+3rd-generation+EGF+receptor+tyrosine+kinase+inhibitors+in+advanced+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.8013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer</span></div><div class="casAuthors">Park Ji Hyun; Choi Chang-Min; Lee Jae Cheol; Choi Yun Jung; Kim Seon Ye; Lee Jung-Eun; Sung Ki Jung; Park Sojung; Kim Woo Sung; Choi Chang-Min; Choi Yun Jung; Kim Seon Ye; Lee Jung-Eun; Sung Ki Jung; Sung Young Hoon; Rho Jin Kyung; Song Joon Seon; Sung Young Hoon; Rho Jin Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">22005-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutant-selective, 3rd-generation EGFR-TKIs were recently developed to control lung cancer cells harboring T790M-mediated resistance.  However, the development of resistance to these novel drugs seems inevitable.  Thus, we investigated the mechanism of acquired resistance to the mutant-selective EGFR-TKI WZ4002.  We established five WZ4002-resistant cells, derived from cells harboring both EGFR and T790M mutations by long-term exposure to increasing doses of WZ4002.  Compared with the parental cells, all resistant cells showed 10-100-folds higher resistance to WZ4002, as well as cross-resistance to other mutant-selective inhibitors.  Among them, three resistant cells (HCC827/WR, PC-9/WR and H1975/WR) showed dependency on EGFR signaling, but two other cells (PC-9/GR/WR and PC-9/ER/WR) were not.  Notably, insulin-like growth factor-1 receptor (IGF1R) was aberrantly activated in PC-9/GR/WR cells in phospho-receptor tyrosine kinase array, consistently accompanied by loss of IGF binding protein-3 (IGFBP3).  Down-regulation of IGF1R by shRNA, as well as inhibition of IGF1R activity either by AG-1024 (a small molecule IGF1R inhibitor) or BI 836845 (a monoclonal anti-IGF1/2 blocking antibody), restored the sensitivity to WZ4002 both in vitro and xenograft.  Taken together, these results suggest that activation of the IGF1R pathway associated with IGFBP3 loss can induce an acquired resistance to the mutant-selective EGFR-TKI, WZ4002.  Therefore, a combined therapy of IGF1R inhibitors and mutant-selective EGFR-TKIs might be a viable treatment strategy for overcoming acquired resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtMwy_6CBS1suCWE5mhx1RfW6udTcc2ebgNV3fVOhfRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgsFChsQ%253D%253D&md5=17315869bfa45fb346648382a7dfcda5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8013%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DSung%26aufirst%3DK.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DSung%26aufirst%3DY.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DActivation%2520of%2520the%2520IGF1R%2520pathway%2520potentially%2520mediates%2520acquired%2520resistance%2520to%2520mutant-selective%25203rd-generation%2520EGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D16%26spage%3D22005%26epage%3D22015%26doi%3D10.18632%2Foncotarget.8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. B K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGranahan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkbak, N. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubens, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, K. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, R. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulin, A. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, A. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannikopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, P. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandara, D. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, J. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G</span></span> <span> </span><span class="NLM_article-title">Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1704</span>, <span class="refDoi"> DOI: 10.1038/ng.3990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fng.3990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29106415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslKmur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=1693-1704&issue=12&author=C.+M+Blakelyauthor=T.+B+K+Watkinsauthor=W.+Wuauthor=B.+Giniauthor=J.+J+Chabonauthor=C.+E+McCoachauthor=N.+McGranahanauthor=G.+A+Wilsonauthor=N.+J+Birkbakauthor=V.+R+Olivasauthor=J.+Rotowauthor=A.+Maynardauthor=V.+Wangauthor=M.+A+Gubensauthor=K.+C+Banksauthor=R.+B+Lanmanauthor=A.+F+Caulinauthor=J.+St+Johnauthor=A.+R+Corderoauthor=P.+Giannikopoulosauthor=A.+D+Simmonsauthor=P.+C+Mackauthor=D.+R+Gandaraauthor=H.+Husainauthor=R.+C+Doebeleauthor=J.+W+Riessauthor=M.+Diehnauthor=C.+Swantonauthor=T.+G+Bivona&title=Evolution+and+clinical+impact+of+co-occurring+genetic+alterations+in+advanced-stage+EGFR-mutant+lung+cancers&doi=10.1038%2Fng.3990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers</span></div><div class="casAuthors">Blakely, Collin M.; Watkins, Thomas B. K.; Wu, Wei; Gini, Beatrice; Chabon, Jacob J.; McCoach, Caroline E.; McGranahan, Nicholas; Wilson, Gareth A.; Birkbak, Nicolai J.; Olivas, Victor R.; Rotow, Julia; Maynard, Ashley; Wang, Victoria; Gubens, Matthew A.; Banks, Kimberly C.; Lanman, Richard B.; Caulin, Aleah F.; St. John, John; Cordero, Anibal R.; Giannikopoulos, Petros; Simmons, Andrew D.; Mack, Philip C.; Gandara, David R.; Husain, Hatim; Doebele, Robert C.; Riess, Jonathan W.; Diehn, Maximilian; Swanton, Charles; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1693-1704</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-mutant lung cancers).  However, genetically driven resistance to targeted therapy limits patient survival.  Through genomic anal. of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome anal. of seven longitudinally collected tumor samples from a patient with EGFR-mutant lung cancer, we identified crit. co-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers.  We defined new pathways limiting EGFR-inhibitor response, including WNT/β-catenin alterations and cell-cycle-gene (CDK4 and CDK6) mutations.  Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response.  This study calls for revisiting the prevailing single-gene driver-oncogene view and links clin. outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCM4IDANPTKrVg90H21EOLACvtfcHk0lj4MgpZpxGulA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslKmur3K&md5=9575aff401c35b4f422304b71005f28b</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fng.3990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.3990%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM%26aulast%3DWatkins%26aufirst%3DT.%2BB%2BK%26aulast%3DWu%26aufirst%3DW.%26aulast%3DGini%26aufirst%3DB.%26aulast%3DChabon%26aufirst%3DJ.%2BJ%26aulast%3DMcCoach%26aufirst%3DC.%2BE%26aulast%3DMcGranahan%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DG.%2BA%26aulast%3DBirkbak%26aufirst%3DN.%2BJ%26aulast%3DOlivas%26aufirst%3DV.%2BR%26aulast%3DRotow%26aufirst%3DJ.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DV.%26aulast%3DGubens%26aufirst%3DM.%2BA%26aulast%3DBanks%26aufirst%3DK.%2BC%26aulast%3DLanman%26aufirst%3DR.%2BB%26aulast%3DCaulin%26aufirst%3DA.%2BF%26aulast%3DSt%2BJohn%26aufirst%3DJ.%26aulast%3DCordero%26aufirst%3DA.%2BR%26aulast%3DGiannikopoulos%26aufirst%3DP.%26aulast%3DSimmons%26aufirst%3DA.%2BD%26aulast%3DMack%26aufirst%3DP.%2BC%26aulast%3DGandara%26aufirst%3DD.%2BR%26aulast%3DHusain%26aufirst%3DH.%26aulast%3DDoebele%26aufirst%3DR.%2BC%26aulast%3DRiess%26aufirst%3DJ.%2BW%26aulast%3DDiehn%26aufirst%3DM.%26aulast%3DSwanton%26aufirst%3DC.%26aulast%3DBivona%26aufirst%3DT.%2BG%26atitle%3DEvolution%2520and%2520clinical%2520impact%2520of%2520co-occurring%2520genetic%2520alterations%2520in%2520advanced-stage%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DNat.%2520Genet.%26date%3D2017%26volume%3D49%26issue%3D12%26spage%3D1693%26epage%3D1704%26doi%3D10.1038%2Fng.3990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creelan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosemani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolinakos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1312</span>– <span class="NLM_lpage">1323</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29883838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MblsVKnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1312-1323&issue=9&author=A.+B.+Schrockauthor=V.+W.+Zhuauthor=W.+S.+Hsiehauthor=R.+Madisonauthor=B.+Creelanauthor=J.+Silberbergauthor=D.+Costinauthor=A.+Bharneauthor=I.+Bontaauthor=T.+Bosemaniauthor=P.+Nikolinakosauthor=J.+S.+Rossauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=S.+I.+Ou&title=Receptor+tyrosine+kinase+fusions+and+BRAF+kinase+fusions+are+rare+but+actionable+resistance+mechanisms+to+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.jtho.2018.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Schrock Alexa B; Madison Russell; Miller Vincent A; Ali Siraj M; Zhu Viola W; Hsieh Wen-Son; Creelan Benjamin; Silberberg Jeffrey; Costin Dan; Bharne Anjali; Bonta Ioana; Bosemani Thangavijayan; Nikolinakos Petros; Ross Jeffrey S; Klempner Samuel J; Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1312-1323</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  We analyzed a large set of EGFR-mutated (EGFR+) NSCLC to identify and characterize cases with co-occurring kinase fusions as potential resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs).  METHODS:  EGFR+ (del 19, L858R, G719X, S768I, L851Q) NSCLC clinical samples (formalin-fixed paraffin-embedded tumor and blood) were analyzed for the presence of receptor tyrosine kinase (RTK) and BRAF fusions.  Treatment history and response were obtained from provided pathology reports and treating clinicians.  RESULTS:  Clinical samples from 3505 unique EGFR+ NSCLCs were identified from June 2012 to October 2017.  A total of 31 EGFR+ cases had concurrent kinase fusions detected: 10 (32%) BRAF, 7 (23%) ALK receptor tyrosine kinase (ALK), 6 (19%) ret proto-oncogene (RET), 6 (19%) fibroblast growth factor receptor 3 (FGFR3), 1 (3.2%) EGFR, and 1 (3.2%) neurotrophic receptor tyrosine kinase 1 (NTRK1), including two novel fusions (SALL2-BRAF and PLEKHA7-ALK).  Twenty-seven of 31 patients had either a known history of EGFR+ NSCLC diagnosis or prior treatment with an EGFR TKI before the fusion+ sample was collected.  Twelve of the 27 patients had paired pre-treatment samples where the fusion was not present before treatment with an EGFR TKI.  Multiple patients treated with combination therapy targeting EGFR and the acquired fusion had clinical benefit, including one patient with osimertinib resistance due to an acquired PLEKHA7-ALK fusion achieving a durable partial response with combination of full-dose osimertinib and alectinib.  CONCLUSIONS:  RTK and BRAF fusions are rare but potentially druggable resistance mechanisms to EGFR TKIs.  Detection of RTK and BRAF fusions should be part of comprehensive profiling panels to determine resistance to EGFR TKIs and direct appropriate combination therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD19Ex2E3-UGHOrQ6qeX-mfW6udTcc2ealJgEhb4FY17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MblsVKnsQ%253D%253D&md5=ad904aa2d6116e648d010e30ad083744</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DHsieh%26aufirst%3DW.%2BS.%26aulast%3DMadison%26aufirst%3DR.%26aulast%3DCreelan%26aufirst%3DB.%26aulast%3DSilberberg%26aufirst%3DJ.%26aulast%3DCostin%26aufirst%3DD.%26aulast%3DBharne%26aufirst%3DA.%26aulast%3DBonta%26aufirst%3DI.%26aulast%3DBosemani%26aufirst%3DT.%26aulast%3DNikolinakos%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520fusions%2520and%2520BRAF%2520kinase%2520fusions%2520are%2520rare%2520but%2520actionable%2520resistance%2520mechanisms%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D1312%26epage%3D1323%26doi%3D10.1016%2Fj.jtho.2018.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nukaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikemura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betsuyaku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soejima, K.</span></span> <span> </span><span class="NLM_article-title">Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2089</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-16-2359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28202511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFOqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2078-2089&issue=8&author=S.+Nukagaauthor=H.+Yasudaauthor=K.+Tsuchiharaauthor=J.+Hamamotoauthor=K.+Masuzawaauthor=I.+Kawadaauthor=K.+Naokiauthor=S.+Matsumotoauthor=S.+Mimakiauthor=S.+Ikemuraauthor=K.+Gotoauthor=T.+Betsuyakuauthor=K.+Soejima&title=Amplification+of+EGFR+wild-type+alleles+in+non-small+cell+lung+cancer+cells+confers+acquired+resistance+to+mutation-selective+EGFR+tyrosine+kinase+inhibitors&doi=10.1158%2F0008-5472.CAN-16-2359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Nukaga, Shigenari; Yasuda, Hiroyuki; Tsuchihara, Katsuya; Hamamoto, Junko; Masuzawa, Keita; Kawada, Ichiro; Naoki, Katsuhiko; Matsumoto, Shingo; Mimaki, Sachiyo; Ikemura, Shinnosuke; Goto, Koichi; Betsuyaku, Tomoko; Soejima, Kenzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2078-2089</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">EGFR-mutated lung cancers account for a significant subgroup of non-small cell lung cancers overall.  Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation-selective inhibitors with minimal effects on wild-type EGFR.  Acquired resistance develops to these agents, however, the mechanisms are as yet uncharacterized.  In this study, we report that the Src-AKT pathway contributes to acquired resistance to these TKI.  In addn., amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.  These findings underscore the importance of signals from wild-type EGFR alleles in acquiring resistance to mutant-selective EGFR-TKI.  Our data provide evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ewjdUcwnJbVg90H21EOLACvtfcHk0lg_HRm09FCdzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFOqur4%253D&md5=66ffdb2198a4b1caf3cdf5dcdde67e22</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2359%26sid%3Dliteratum%253Aachs%26aulast%3DNukaga%26aufirst%3DS.%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DTsuchihara%26aufirst%3DK.%26aulast%3DHamamoto%26aufirst%3DJ.%26aulast%3DMasuzawa%26aufirst%3DK.%26aulast%3DKawada%26aufirst%3DI.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DMimaki%26aufirst%3DS.%26aulast%3DIkemura%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DBetsuyaku%26aufirst%3DT.%26aulast%3DSoejima%26aufirst%3DK.%26atitle%3DAmplification%2520of%2520EGFR%2520wild-type%2520alleles%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%2520confers%2520acquired%2520resistance%2520to%2520mutation-selective%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D8%26spage%3D2078%26epage%3D2089%26doi%3D10.1158%2F0008-5472.CAN-16-2359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meador, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">SFK/FAK signalling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2990</span>– <span class="NLM_lpage">3000</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-16-2300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28416483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Siu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2990-3000&issue=11&author=E.+Ichiharaauthor=D.+Westoverauthor=C.+B.+Meadorauthor=Y.+Yanauthor=J.+A.+Bauerauthor=P.+Luauthor=F.+Yeauthor=A.+Kulickauthor=E.+de+Stanchinaauthor=R.+McEwenauthor=M.+Ladanyiauthor=D.+Crossauthor=W.+Paoauthor=C.+M.+Lovly&title=SFK%2FFAK+signalling+attenuates+osimertinib+efficacy+in+both+drug-sensitive+and+drug-resistant+models+of+EGFR-mutant+lung+cancer&doi=10.1158%2F0008-5472.CAN-16-2300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer</span></div><div class="casAuthors">Ichihara, Eiki; Westover, David; Meador, Catherine B.; Yan, Yingjun; Bauer, Joshua A.; Lu, Pengcheng; Ye, Fei; Kulick, Amanda; de Stanchina, Elisa; McEwen, Robert; Ladanyi, Marc; Cross, Darren; Pao, William; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2990-3000</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer.  Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clin. trials have documented their efficacy in patients with EGFR-mutant lung cancer.  Despite promising results, therapeutic efficacy is limited by the development of acquired resistance.  Here we report that Src family kinases (SFK) and focal adhesion kinase (FAK) sustain AKT and MAPK pathway signaling under continuous EGFR inhibition in osimertinib-sensitive cells.  Inhibiting either the MAPK pathway or the AKT pathway enhanced the effects of osimertinib.  Combined SFK/FAK inhibition exhibited the most potent effects on growth inhibition, induction of apoptosis, and delay of acquired resistance.  SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors.  In conclusion, our data suggest that the concomitant inhibition of both SFK/FAK and EGFR may be a promising therapeutic strategy for EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKuOvH2nXTXbVg90H21EOLACvtfcHk0lg_HRm09FCdzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Siu74%253D&md5=605a9f602eec228294194f4316ede972</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2300%26sid%3Dliteratum%253Aachs%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DMeador%26aufirst%3DC.%2BB.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DKulick%26aufirst%3DA.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMcEwen%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DSFK%252FFAK%2520signalling%2520attenuates%2520osimertinib%2520efficacy%2520in%2520both%2520drug-sensitive%2520and%2520drug-resistant%2520models%2520of%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D11%26spage%3D2990%26epage%3D3000%26doi%3D10.1158%2F0008-5472.CAN-16-2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. H.</span></span> <span> </span><span class="NLM_article-title">Signal transducers and activators of transcription 3 function in lung cancer</span>. <i>Cancer Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.4103/0973-1482.119100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.4103%2F0973-1482.119100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=67-73&issue=5&author=C.+J.+Liauthor=Y.+C.+Liauthor=D.+R.+Zhangauthor=J.+H.+Pan&title=Signal+transducers+and+activators+of+transcription+3+function+in+lung+cancer&doi=10.4103%2F0973-1482.119100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.4103%2F0973-1482.119100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0973-1482.119100%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BC.%26aulast%3DZhang%26aufirst%3DD.%2BR.%26aulast%3DPan%26aufirst%3DJ.%2BH.%26atitle%3DSignal%2520transducers%2520and%2520activators%2520of%2520transcription%25203%2520function%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%2520Ther.%26date%3D2013%26volume%3D9%26issue%3D5%26spage%3D67%26epage%3D73%26doi%3D10.4103%2F0973-1482.119100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunnumakkara, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikumar, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tharakan, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, B.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1171</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.04911.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1111%2Fj.1749-6632.2009.04911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19723038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Sntb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1171&publication_year=2009&pages=59-76&author=B.+B.+Aggarwalauthor=A.+B.+Kunnumakkaraauthor=K.+B.+Harikumarauthor=S.+R.+Guptaauthor=S.+T.+Tharakanauthor=C.+Kocaauthor=S.+Deyauthor=B.+Sung&title=Signal+transducer+and+activator+of+transcription-3%2C+inflammation%2C+and+cancer%3A+how+intimate+is+the+relationship%3F&doi=10.1111%2Fj.1749-6632.2009.04911.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?</span></div><div class="casAuthors">Aggarwal, Bharat B.; Kunnumakkara, Ajaikumar B.; Harikumar, Kuzhuvelil B.; Gupta, Shan R.; Tharakan, Sheeja T.; Koca, Cemile; Dey, Sanjit; Sung, Bokyung</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1171</span>
        (<span class="NLM_cas:issue">Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways</span>),
    <span class="NLM_cas:pages">59-76</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription-3 (STAT-3) is one of six members of a family of transcription factors.  It was discovered almost 15 years ago as an acute-phase response factor.  This factor has now been assocd. with inflammation, cellular transformation, survival, proliferation, invasion, angiogenesis, and metastasis of cancer.  Various types of carcinogens, radiation, viruses, growth factors, oncogenes, and inflammatory cytokines have been found to activate STAT-3.  STAT-3 is constitutively active in most tumor cells but not in normal cells.  Phosphorylation of STAT-3 at tyrosine 705 leads to its dimerization, nuclear translocation, DNA binding, and gene transcription.  The phosphorylation of STAT-3 at serine 727 may regulate its activity neg. or pos.  STAT-3 regulates the expression of genes that mediate survival (survivin, bcl-xl, mcl-1, cellular FLICE-like inhibitory protein), proliferation (c-fos, c-myc, cyclin D1), invasion (matrix metalloproteinase-2), and angiogenesis (vascular endothelial growth factor).  STAT-3 activation has also been assocd. with both chemoresistance and radioresistance.  STAT-3 mediates these effects through its collaboration with various other transcription factors, including nuclear factor-κB, hypoxia-inducible factor-1, and peroxisome proliferator activated receptor-γ.  Because of its crit. role in tumorigenesis, inhibitors of this factor's activation are being sought for both prevention and therapy of cancer.  This has led to identification of small peptides, oligonucleotides, and small mols. as potential STAT-3 inhibitors.  Several of these small mols. are chemopreventive agents derived from plants.  This review discusses the intimate relationship between STAT-3, inflammation, and cancer in more detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr9e25c7f6jLVg90H21EOLACvtfcHk0lgVQ2_bxMO7Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Sntb3J&md5=2d3aa124c0cffbeb6113ed3492e54210</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.04911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.04911.x%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26aulast%3DKunnumakkara%26aufirst%3DA.%2BB.%26aulast%3DHarikumar%26aufirst%3DK.%2BB.%26aulast%3DGupta%26aufirst%3DS.%2BR.%26aulast%3DTharakan%26aufirst%3DS.%2BT.%26aulast%3DKoca%26aufirst%3DC.%26aulast%3DDey%26aufirst%3DS.%26aulast%3DSung%26aufirst%3DB.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription-3%252C%2520inflammation%252C%2520and%2520cancer%253A%2520how%2520intimate%2520is%2520the%2520relationship%253F%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2009%26volume%3D1171%26spage%3D59%26epage%3D76%26doi%3D10.1111%2Fj.1749-6632.2009.04911.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">JAK2/STAT3 signalling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2011.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2011.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=21333372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3Mjit1arsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2011&pages=366-374&issue=3&author=M.+Zhaoauthor=F.+H.+Gaoauthor=J.+Y.+Wangauthor=F.+Liuauthor=H.+H.+Yuanauthor=W.+Y.+Zhangauthor=B.+Jiang&title=JAK2%2FSTAT3+signalling+pathway+activation+mediates+tumor+angiogenesis+by+upregulation+of+VEGF+and+bFGF+in+non-small-cell+lung+cancer&doi=10.1016%2Fj.lungcan.2011.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer</span></div><div class="casAuthors">Zhao Mei; Gao Feng-Hou; Wang Jiong-Yi; Liu Feng; Yuan Hai-Hua; Zhang Wen-Ying; Jiang Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We investigated the clinical significance of Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) during angiogenesis in non-small-cell lung carcinoma.  JAK2, phospho-JAK2 (pJAK2), STAT3, and phospho-STAT3 (pSATA3) were observed in 40/68 (58.8%), 39/68 (57.4%), 49/68 (72.1%) and 40/68 (58.8%) of the cases.  The high expression levels of molecules involved in the JAK2/STAT3 signaling pathway were associated with a decreased survival rate.  Of the total number of cases, 73.5% were positive for VEGF and 80.9% for bFGF.  Microvessel density (MVD), as determined by CD34 staining and morphology, was higher in NSCLC samples with high pJAK2 and pSTAT3 expression, and the patients with high MVD had poor survival status.  In addition, the expression of pSTAT3 correlated with VEGF (r=0.593) and bFGF (r=0.519) (p<0.05).  Inhibiting JAK2 and knocking down STAT3 both suppressed STAT3 activation and reduced the expression of VEGF and bFGF in A549 and NCI-H292 cells, demonstrating that STAT3 activation was associated with VEGF and bFGF expression in the two human lung carcinoma cell lines.  Therefore, STAT3 may be a critical molecular target for powerful intervention in NSCLC anti-angiogenesis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3dJ8SunQ2kZQHPYJuLg8TfW6udTcc2ea8Wr4B6WY9v7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mjit1arsA%253D%253D&md5=ca62ebc5ba2937ff72eb7980e3e284fa</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2011.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2011.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DF.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DH.%2BH.%26aulast%3DZhang%26aufirst%3DW.%2BY.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DJAK2%252FSTAT3%2520signalling%2520pathway%2520activation%2520mediates%2520tumor%2520angiogenesis%2520by%2520upregulation%2520of%2520VEGF%2520and%2520bFGF%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2011%26volume%3D73%26issue%3D3%26spage%3D366%26epage%3D374%26doi%3D10.1016%2Fj.lungcan.2011.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony Servat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servat, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergnenegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reguart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixido, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperduti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verlicchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Aguirre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queralt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Bellacasa, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viteri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant nsclc</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">djx014</span>, <span class="refDoi"> DOI: 10.1093/jnci/djx014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fjnci%2Fdjx014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=djx014&issue=9&author=I.+Chaibauthor=N.+Karachaliouauthor=S.+Pilottoauthor=J.+Codony+Servatauthor=X.+Caiauthor=X.+Liauthor=A.+Drozdowskyjauthor=C.+C.+Servatauthor=J.+Yangauthor=C.+Huauthor=A.+F.+Cardonaauthor=G.+L.+Vivancoauthor=A.+Vergnenegreauthor=J.+M.+Sanchezauthor=M.+Provencioauthor=F.+de+Marinisauthor=A.+Passaroauthor=E.+Carcerenyauthor=N.+Reguartauthor=C.+G.+Campeloauthor=C.+Teixidoauthor=I.+Sperdutiauthor=S.+Rodriguezauthor=C.+Lazzariauthor=A.+Verlicchiauthor=I.+de+Aguirreauthor=C.+Queraltauthor=J.+Weiauthor=R.+Estradaauthor=R.+P.+de+la+Bellacasaauthor=J.+L.+Ramirezauthor=K.+Jacobsenauthor=H.+J.+Ditzelauthor=M.+Santarpiaauthor=S.+Viteriauthor=M.+A.+Molinaauthor=C.+Zhouauthor=P.+Caoauthor=P.+C.+Maauthor=T.+G.+Bivonaauthor=R.+Rosell&title=Co-activation+of+STAT3+and+YES-associated+protein+1+%28YAP1%29+pathway+in+EGFR-mutant+nsclc&doi=10.1093%2Fjnci%2Fdjx014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjx014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjx014%26sid%3Dliteratum%253Aachs%26aulast%3DChaib%26aufirst%3DI.%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DPilotto%26aufirst%3DS.%26aulast%3DCodony%2BServat%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DServat%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DCardona%26aufirst%3DA.%2BF.%26aulast%3DVivanco%26aufirst%3DG.%2BL.%26aulast%3DVergnenegre%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DPassaro%26aufirst%3DA.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DCampelo%26aufirst%3DC.%2BG.%26aulast%3DTeixido%26aufirst%3DC.%26aulast%3DSperduti%26aufirst%3DI.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DLazzari%26aufirst%3DC.%26aulast%3DVerlicchi%26aufirst%3DA.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DEstrada%26aufirst%3DR.%26aulast%3Dde%2Bla%2BBellacasa%26aufirst%3DR.%2BP.%26aulast%3DRamirez%26aufirst%3DJ.%2BL.%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DDitzel%26aufirst%3DH.%2BJ.%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DViteri%26aufirst%3DS.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DCo-activation%2520of%2520STAT3%2520and%2520YES-associated%2520protein%25201%2520%2528YAP1%2529%2520pathway%2520in%2520EGFR-mutant%2520nsclc%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2017%26volume%3D109%26issue%3D9%26spage%3Ddjx014%26doi%3D10.1093%2Fjnci%2Fdjx014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Re, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortesi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petreni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2017.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29290257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzmtlykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=21-27&author=R.+Minariauthor=P.+Bordiauthor=M.+Del+Reauthor=F.+Facchinettiauthor=F.+Mazzoniauthor=F.+Barbieriauthor=A.+Cameriniauthor=C.+E.+Cominauthor=L.+Gnettiauthor=C.+Azzoniauthor=R.+Nizzoliauthor=B.+Bortesiauthor=E.+Rofiauthor=P.+Petreniauthor=N.+Campaniniauthor=G.+Rossiauthor=R.+Danesiauthor=M.+Tiseo&title=Primary+resistance+to+osimertinib+due+to+SCLC+transformation%3A+Issue+of+T790M+determination+on+liquid+re-biopsy&doi=10.1016%2Fj.lungcan.2017.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy</span></div><div class="casAuthors">Minari R; Bordi P; Facchinetti F; Nizzoli R; Bortesi B; Del Re M; Rofi E; Danesi R; Mazzoni F; Petreni P; Barbieri F; Camerini A; Comin C E; Gnetti L; Azzoni C; Campanini N; Rossi G; Tiseo M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib.  Liquid biopsy, a non-invasive technique used to test the presence of the resistant mutation, may help avoiding tissue re-biopsy.  However, analysing only circulating-free DNA, information about other less frequent and coexisting resistance mechanisms may remain unrevealed.  MATERIALS AND METHODS:  All patients reported in this series participated in the ASTRIS trial, a real world treatment study testing the efficacy of osimertinib (80mg os die) in advanced T790M-positive NSCLC progressed to prior EGFR-TKI.  Patients were considered eligible to osimertinib if T790M positive on tissue or plasma samples.  In our patients, EGFR molecular testing on blood sample was conducted with digital droplet PCR (ddPCR).  RESULTS:  We report our experience of five patients treated with osimertinib after T790M detection on liquid biopsy that presented a disease progression at first tumor assessment mediated by SCLC transformation, as evidenced at tissue re-biopsies.  All patients showed low ratio T790M/activating mutation in the blood before osimertinib (lower than 0.03).  For three patients, EGFR mutational analysis was T790M-negative when re-assessed by using a less sensitive method (therascreen(®)) on the same liquid biopsy sample analysed by ddPCR before osimertinib therapy.  CONCLUSION:  Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790M/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl4lzVsqGJNUwlCcfExbvbfW6udTcc2eY7tz602kt0a7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzmtlykug%253D%253D&md5=16d1b832c5363571028690a118bfb07b</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DDel%2BRe%26aufirst%3DM.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DMazzoni%26aufirst%3DF.%26aulast%3DBarbieri%26aufirst%3DF.%26aulast%3DCamerini%26aufirst%3DA.%26aulast%3DComin%26aufirst%3DC.%2BE.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DAzzoni%26aufirst%3DC.%26aulast%3DNizzoli%26aufirst%3DR.%26aulast%3DBortesi%26aufirst%3DB.%26aulast%3DRofi%26aufirst%3DE.%26aulast%3DPetreni%26aufirst%3DP.%26aulast%3DCampanini%26aufirst%3DN.%26aulast%3DRossi%26aufirst%3DG.%26aulast%3DDanesi%26aufirst%3DR.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DPrimary%2520resistance%2520to%2520osimertinib%2520due%2520to%2520SCLC%2520transformation%253A%2520Issue%2520of%2520T790M%2520determination%2520on%2520liquid%2520re-biopsy%26jtitle%3DLung%2520Cancer.%26date%3D2018%26volume%3D115%26spage%3D21%26epage%3D27%26doi%3D10.1016%2Fj.lungcan.2017.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ham, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byeon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e4</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2015.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26762749" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e1-e4&issue=1&author=J.+S.+Hamauthor=S.+Kimauthor=H.+K.+Kimauthor=S.+Byeonauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.+L.+Choiauthor=J.+Hanauthor=W.+Parkauthor=M.+J.+Ahn&title=Two+cases+of+small+cell+lung+cancer+transformation+from+EGFR+mutant+adenocarcinoma+during+AZD9291+treatment&doi=10.1016%2Fj.jtho.2015.09.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DHam%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BK.%26aulast%3DByeon%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DTwo%2520cases%2520of%2520small%2520cell%2520lung%2520cancer%2520transformation%2520from%2520EGFR%2520mutant%2520adenocarcinoma%2520during%2520AZD9291%2520treatment%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D1%26spage%3De1%26epage%3De4%26doi%3D10.1016%2Fj.jtho.2015.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span> <span> </span><span class="NLM_article-title">Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">18609</span>– <span class="NLM_lpage">18614</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.14506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28061471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1c7jtFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=18609-18614&issue=11&author=L.+Liauthor=H.+Wangauthor=C.+Liauthor=Z.+Wangauthor=P.+Zhangauthor=X.+Yan&title=Transformation+to+small-cell+carcinoma+as+an+acquired+resistance+mechanism+to+AZD9291%3A+A+case+report&doi=10.18632%2Foncotarget.14506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report</span></div><div class="casAuthors">Li Lin; Wang Hui; Li Chao; Zhang Ping; Yan Xu; Wang Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">18609-18614</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs.  Acquisition of resistance to AZD9291 occurs inevitable and mechanisms need to be explored.  We reported an advanced lung adenocarcinoma female with EGFR exon19 deletion treated on AZD9291 after failure of erlotinib and chemotherapy.  Disease progressed again after 6 months' treatment of AZD9291 with hepatic metastasis.  Re-biopsy of the hepatic lesion showed histopathology transformation to small cell lung cancer, which harbored EGFR exon19 deletion.  Therefore, small cell carcinoma transformation is one of potential resistance mechanisms to AZD9291 and regimen for small cell carcinoma may be one of the treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxkGrvC1iaU_3jf77P2BG3fW6udTcc2eY7tz602kt0a7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7jtFCrsg%253D%253D&md5=c10092a460fe0b93df3533431023cd69</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14506%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DX.%26atitle%3DTransformation%2520to%2520small-cell%2520carcinoma%2520as%2520an%2520acquired%2520resistance%2520mechanism%2520to%2520AZD9291%253A%2520A%2520case%2520report%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D11%26spage%3D18609%26epage%3D18614%26doi%3D10.18632%2Foncotarget.14506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turke, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergethon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosper, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhavanfard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wain, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernovsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanuti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">75</span>),  <span class="NLM_fpage">75ra26</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3002003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=21430269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&issue=75&author=L.+V.+Sequistauthor=B.+A.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotypic+and+histological+evolution+of+lung+cancers+acquiring+resistance+to+EGFR+inhibitors&doi=10.1126%2Fscitranslmed.3002003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DB.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotypic%2520and%2520histological%2520evolution%2520of%2520lung%2520cancers%2520acquiring%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26issue%3D75%26spage%3D75ra26%26doi%3D10.1126%2Fscitranslmed.3002003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R. Y.</span></span> <span> </span><span class="NLM_article-title">AXL-driven EMT state as a targetable conduit in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3725</span>– <span class="NLM_lpage">3732</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-17-0392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28667075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=3725-3732&issue=14&author=J.+Antonyauthor=R.+Y.+Huang&title=AXL-driven+EMT+state+as+a+targetable+conduit+in+cancer&doi=10.1158%2F0008-5472.CAN-17-0392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">AXL-Driven EMT State as a Targetable Conduit in Cancer</span></div><div class="casAuthors">Antony, Jane; Huang, Ruby Yun-Ju</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3725-3732</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase (RTK) AXL has been intrinsically linked to epithelial-mesenchymal transition (EMT) and promoting cell survival, anoikis resistance, invasion, and metastasis in several cancers.  AXL signaling has been shown to directly affect the mesenchymal state and confer it with aggressive phenotype and drug resistance.  Recently, the EMT gradient has also been shown to rewire the kinase signaling nodes that facilitate AXL-RTK cross-talk, protracted signaling, converging on ERK, and PI3K axes.  The mol. mechanisms underplaying the regulation between the kinome and EMT require further elucidation to define targetable conduits.  Therapeutically, as AXL inhibition has shown EMT reversal and resensitization to other tyrosine kinase inhibitors, mitotic inhibitors, and platinum-based therapy, there is a need to stratify patients based on AXL dependence.  This review elucidates the role of AXL in EMT-mediated oncogenesis and highlights the reciprocal control between AXL signaling and the EMT state.  In addn., we review the potential in inhibiting AXL for the development of different therapeutic strategies and inhibitors.  Cancer Res; 77(14); 3725-32. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOR2GnIrmIbVg90H21EOLACvtfcHk0ljCXMdFslGaIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurnM&md5=5d0b3f4baf6a9370f48f76b25bf56cb2</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0392%26sid%3Dliteratum%253Aachs%26aulast%3DAntony%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DR.%2BY.%26atitle%3DAXL-driven%2520EMT%2520state%2520as%2520a%2520targetable%2520conduit%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D14%26spage%3D3725%26epage%3D3732%26doi%3D10.1158%2F0008-5472.CAN-17-0392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamoud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderLaan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borger, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6377</span>, <span class="refDoi"> DOI: 10.1038/ncomms7377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms7377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25758528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlKhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6377&author=M.+J.+Niederstauthor=L.+V.+Sequistauthor=J.+T.+Poirierauthor=C.+H.+Mermelauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=R.+Katayamaauthor=C.+Costaauthor=K.+N.+Rossauthor=T.+Moranauthor=E.+Howeauthor=L.+E.+Fultonauthor=H.+E.+Mulveyauthor=L.+A.+Bernardoauthor=F.+Mohamoudauthor=N.+Miyoshiauthor=P.+A.+VanderLaanauthor=D.+B.+Costaauthor=P.+A.+Janneauthor=D.+R.+Borgerauthor=S.+Ramaswamyauthor=T.+Shiodaauthor=A.+J.+Iafrateauthor=G.+Getzauthor=C.+M.+Rudinauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=RB+loss+in+resistant+EGFR+mutant+lung+adenocarcinomas+that+transform+to+small-cell+lung+cancer&doi=10.1038%2Fncomms7377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer</span></div><div class="casAuthors">Niederst, Matthew J.; Sequist, Lecia V.; Poirier, John T.; Mermel, Craig H.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Bernardo, Lindsay A.; Mohamoud, Farhiya; Miyoshi, Norikatsu; Vander Laan, Paul A.; Costa, Daniel B.; Janne, Pasi A.; Borger, Darrell R.; Ramaswamy, Sridhar; Shioda, Toshi; Iafrate, Anthony J.; Getz, Gad; Rudin, Charles M.; Mino-Kenudson, Mari; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6377</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations.  However, relapse typically occurs after an av. of 1 yr of continuous treatment.  A fundamental histol. transformation from NSCLC to small-cell lung cancer (SCLC) is obsd. in a subset of the resistant cancers, but the mol. changes assocd. with this transformation remain unknown.  Anal. of tumor samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC.  Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are obsd. in resistant SCLC transformed cancers compared with resistant NSCLCs.  Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the mol. and phenotypic characteristics of classical SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq16cOEb-_r67Vg90H21EOLACvtfcHk0lh191fAQ3DkRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlKhs7g%253D&md5=9ca95efef14279dd9ca24aea12f89203</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fncomms7377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7377%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DMermel%26aufirst%3DC.%2BH.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DK.%2BN.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DHowe%26aufirst%3DE.%26aulast%3DFulton%26aufirst%3DL.%2BE.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DBernardo%26aufirst%3DL.%2BA.%26aulast%3DMohamoud%26aufirst%3DF.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DVanderLaan%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DBorger%26aufirst%3DD.%2BR.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DRB%2520loss%2520in%2520resistant%2520EGFR%2520mutant%2520lung%2520adenocarcinomas%2520that%2520transform%2520to%2520small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6377%26doi%3D10.1038%2Fncomms7377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capaccione, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minerowicz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, S. R.</span></span> <span> </span><span class="NLM_article-title">Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3636</span>– <span class="NLM_lpage">3650</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.1970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25004243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgs1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3636-3650&issue=11&author=K.+M.+Capaccioneauthor=X.+Hongauthor=K.+M.+Morganauthor=W.+Liuauthor=J.+M.+Bishopauthor=L.+Liuauthor=E.+Markertauthor=M.+Deenauthor=C.+Minerowiczauthor=J.+R.+Bertinoauthor=T.+Allenauthor=S.+R.+Pine&title=Sox9+mediates+Notch1-induced+mesenchymal+features+in+lung+adenocarcinoma&doi=10.18632%2Foncotarget.1970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma</span></div><div class="casAuthors">Capaccione Kathleen M; Hong Xuehui; Morgan Katherine M; Liu Wenyu; Bishop J Michael; Liu LianXin; Markert Elke; Deen Malik; Minerowicz Christine; Bertino Joseph R; Allen Thaddeus; Pine Sharon R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3636-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sox9 has gained increasing importance both functionally and as a prognostic factor in cancer.  We demonstrate a functional role for Sox9 in inducing a mesenchymal phenotype in lung ADC.  We show that Sox9 mRNA and protein are overexpressed in lung ADC, particularly those with KRAS mutations.  Sox9 expression correlated with the Notch target gene Hes1, and numerous other Notch pathway components.  We observed that Sox9 is a potent inducer of lung cancer cell motility and invasion, and a negative regulator of E-cadherin, a key protein that is lost during epithelial-mesenchymal transition (EMT).  Moreover, we show that Notch1 signaling directly regulates Sox9 expression through a SOX9 promoter binding site, independently of the TGF-β pathway, and that Sox9 participates in Notch-1 induced cell motility, cell invasion, and loss of E-cadherin expression.  Together, the results identify a new functional role for a Notch1-Sox9 signaling axis in lung ADC that may explain the correlation of Sox9 with tumor progression, higher tumor grade, and poor lung cancer survival.  In addition to Notch and TGF-β, Sox9 also acts downstream of NF-κB, BMP, EGFR, and Wnt/β-catenin signaling.  Thus, Sox9 could potentially act as a hub to mediate cross-talk among key oncogenic pathways in lung ADC.  Targeting Sox9 expression or transcriptional activity could potentially reduce resistance to targeted therapy for lung ADC caused by pathway redundancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTBouS59dOs_xQvRxYU81tfW6udTcc2eZF4rxlXn8aHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgs1Kluw%253D%253D&md5=fe3615dfa034c98d8bce8c0ce7c08868</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1970%26sid%3Dliteratum%253Aachs%26aulast%3DCapaccione%26aufirst%3DK.%2BM.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMorgan%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBishop%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMarkert%26aufirst%3DE.%26aulast%3DDeen%26aufirst%3DM.%26aulast%3DMinerowicz%26aufirst%3DC.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26aulast%3DAllen%26aufirst%3DT.%26aulast%3DPine%26aufirst%3DS.%2BR.%26atitle%3DSox9%2520mediates%2520Notch1-induced%2520mesenchymal%2520features%2520in%2520lung%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26issue%3D11%26spage%3D3636%26epage%3D3650%26doi%3D10.18632%2Foncotarget.1970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenoglio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camiolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsted, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlederer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altorki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span> <span> </span><span class="NLM_article-title">TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">15535</span>– <span class="NLM_lpage">15540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1009472107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1073%2Fpnas.1009472107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=20713723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaqu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=15535-15540&issue=35&author=Z.+Yaoauthor=S.+Fenoglioauthor=D.+C.+Gaoauthor=M.+Camioloauthor=B.+Stilesauthor=T.+Lindstedauthor=M.+Schledererauthor=C.+Johnsauthor=N.+Altorkiauthor=V.+Mittalauthor=L.+Kennerauthor=R.+Sordella&title=TGF-beta+IL-6+axis+mediates+selective+and+adaptive+mechanisms+of+resistance+to+molecular+targeted+therapy+in+lung+cancer&doi=10.1073%2Fpnas.1009472107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer</span></div><div class="casAuthors">Yao, Zhan; Fenoglio, Silvia; Gao, Ding Cheng; Camiolo, Matthew; Stiles, Brendon; Lindsted, Trine; Schlederer, Michaela; Johns, Chris; Altorki, Nasser; Mittal, Vivek; Kenner, Lukas; Sordella, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">15535-15540, S15535/1-S15535/34</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitor erlotinib has been proven to be highly effective in the treatment of nonsmall cell lung cancer (NSCLC) harboring oncogenic EGFR mutations.  The majority of patients, however, will eventually develop resistance and succumb to the disease.  Recent studies have identified secondary mutations in the EGFR (EGFR T790M) and amplification of the N-Methyl-N'-nitro-N-nitroso-guanidine (MNNG) HOS transforming gene (MET) oncogene as two principal mechanisms of acquired resistance.  Although they can account for approx. 50% of acquired resistance cases together, in the remaining 50%, the mechanism remains unknown.  In NSCLC-derived cell lines and early-stage tumors before erlotinib treatment, we have uncovered the existence of a subpopulation of cells that are intrinsically resistant to erlotinib and display features suggestive of epithelial-to-mesenchymal transition (EMT).  We showed that activation of TGF-β-mediated signaling was sufficient to induce these phenotypes.  In particular, we detd. that an increased TGF-β-dependent IL-6 secretion unleashed previously addicted lung tumor cells from their EGFR dependency.  Because IL-6 and TGF-β are prominently produced during inflammatory response, we used a mouse model system to det. whether inflammation might impair erlotinib sensitivity.  Indeed, induction of inflammation not only stimulated IL-6 secretion but was sufficient to decrease the tumor response to erlotinib.  Our data, thus, argue that both tumor cell-autonomous mechanisms and/ or activation of the tumor microenvironment could contribute to primary and acquired erlotinib resistance, and as such, treatments based on EGFR inhibition may not be sufficient for the effective treatment of lung-cancer patients harboring mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo8t7IyuGYvLVg90H21EOLACvtfcHk0lh191fAQ3DkRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaqu7%252FN&md5=5e47ea1b43e1a9840980b556a16705dd</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1009472107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1009472107%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DFenoglio%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DD.%2BC.%26aulast%3DCamiolo%26aufirst%3DM.%26aulast%3DStiles%26aufirst%3DB.%26aulast%3DLindsted%26aufirst%3DT.%26aulast%3DSchlederer%26aufirst%3DM.%26aulast%3DJohns%26aufirst%3DC.%26aulast%3DAltorki%26aufirst%3DN.%26aulast%3DMittal%26aufirst%3DV.%26aulast%3DKenner%26aufirst%3DL.%26aulast%3DSordella%26aufirst%3DR.%26atitle%3DTGF-beta%2520IL-6%2520axis%2520mediates%2520selective%2520and%2520adaptive%2520mechanisms%2520of%2520resistance%2520to%2520molecular%2520targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D35%26spage%3D15535%26epage%3D15540%26doi%3D10.1073%2Fpnas.1009472107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotherspoon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutting, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M.</span></span> <span> </span><span class="NLM_article-title">Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2012.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2012.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23312887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ovV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2013&pages=1-4&issue=1&author=S.+Popatauthor=A.+Wotherspoonauthor=C.+M.+Nuttingauthor=D.+Gonzalezauthor=A.+G.+Nicholsonauthor=M.+O%E2%80%99Brien&title=Transformation+to+%E2%80%9Chigh+grade%E2%80%9D+neuroendocrine+carcinoma+as+an+acquired+drug+resistance+mechanism+in+EGFR-mutant+lung+adenocarcinoma&doi=10.1016%2Fj.lungcan.2012.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma</span></div><div class="casAuthors">Popat S; Wotherspoon A; Nutting C M; Gonzalez D; Nicholson A G; O'Brien M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Several different acquired resistance mechanisms of EGFR mutant lung adenocarcinoma to EGFR-tyrosine kinase inhibitor (TKI) therapy have been described, most recently transformation to small cell lung carcinoma (SCLC).  We describe the case of a 46-year-old female with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with erlotinib, and on resistance, cisplatin-pemetrexed.  Liver rebiopsy identified an afatinib-resistant combined SCLC and non-small cell carcinoma with neuroendocrine morphology, retaining the EGFR exon 19 deletion.  This case highlights acquired EGFR-TKI resistance through transformation to the high-grade neuroendocrine carcinoma spectrum and that that such transformation may not be evident at time of progression on TKI therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTloEbz9SUyvROk4JA3soTqfW6udTcc2ebXskoBxkCUcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ovV2isQ%253D%253D&md5=9b43d545732791697fab1c82faeb2358</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2012.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2012.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DPopat%26aufirst%3DS.%26aulast%3DWotherspoon%26aufirst%3DA.%26aulast%3DNutting%26aufirst%3DC.%2BM.%26aulast%3DGonzalez%26aufirst%3DD.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%26atitle%3DTransformation%2520to%2520%25E2%2580%259Chigh%2520grade%25E2%2580%259D%2520neuroendocrine%2520carcinoma%2520as%2520an%2520acquired%2520drug%2520resistance%2520mechanism%2520in%2520EGFR-mutant%2520lung%2520adenocarcinoma%26jtitle%3DLung%2520Cancer.%26date%3D2013%26volume%3D80%26issue%3D1%26spage%3D1%26epage%3D4%26doi%3D10.1016%2Fj.lungcan.2012.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+combined+with+anti-EGFR+antibody+overcomes+osimertinib+resistance+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0ljAJB-ZaNi-LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520combined%2520with%2520anti-EGFR%2520antibody%2520overcomes%2520osimertinib%2520resistance%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, Bevacizumab, and Brigatinib combination therapy: a case report</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5545</span>, <span class="refDoi"> DOI: 10.2147/OTT.S170358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FOTT.S170358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30233215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOis73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=5545&author=J.+Zhaoauthor=M.+Zouauthor=J.+Lvauthor=Y.+Hanauthor=G.+Wangauthor=G.+Wang&title=Effective+treatment+of+pulmonary+adenocarcinoma+harboring+triple+EGFR+mutations+of+L858R%2C+T790M%2C+and+cis-C797S+by+osimertinib%2C+Bevacizumab%2C+and+Brigatinib+combination+therapy%3A+a+case+report&doi=10.2147%2FOTT.S170358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report</span></div><div class="casAuthors">Zhao, Jing; Zou, Ming; Lv, Jinyan; Han, Yingmin; Wang, Guangzhi; Wang, Gang</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5545-5550</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation.  However, the use of osimertinib may result in the development of further resistance, most commonly via the cis-C797S mutation.  Herein, we report a case of a lung cancer patient harboring triple EGFR mutations of L858R, T790M, and cis-C797S who was treated with a combination of osimertinib, bevacizumab, and brigatinib.  The above 3 mutations were detected by circulating tumor DNA anal. after osimertinib treatment.  Subsequently, the patient received combination therapy of osimertinib and bevacizumab; the partial relief obtained was negated by later disease progression.  The regimen was then changed to osimertinib, bevacizumab, and brigatinib combination therapy.  Partial remission was obsd., and a significant redn. in EGFR mutations was detected.  This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clin. use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and cis-C797S.  These combination therapies may provide potential novel treatment options for pulmonary adenocarcinoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgNWmyYKMaUbVg90H21EOLACvtfcHk0lhC05JnJ1K7ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOis73J&md5=3af68f75b4d3dad8c93989cee1d115bc</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.2147%2FOTT.S170358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S170358%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DM.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DEffective%2520treatment%2520of%2520pulmonary%2520adenocarcinoma%2520harboring%2520triple%2520EGFR%2520mutations%2520of%2520L858R%252C%2520T790M%252C%2520and%2520cis-C797S%2520by%2520osimertinib%252C%2520Bevacizumab%252C%2520and%2520Brigatinib%2520combination%2520therapy%253A%2520a%2520case%2520report%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D5545%26doi%3D10.2147%2FOTT.S170358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+Boseauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+Dobelauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtmullerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+selective+and+rigidify%3A+the+discovery+path+toward+a+next+generation+of+EGFR+tyrosine+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lhC05JnJ1K7ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DBose%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DDobel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520selective%2520and%2520rigidify%253A%2520the%2520discovery%2520path%2520toward%2520a%2520next%2520generation%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&issue=1&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0ljkx31Xt94IQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a new EGFR C797S mutant inhibitor with in vivo mono drug efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&issue=11&author=X.+Luauthor=T.+Zhangauthor=S.+J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.+H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+new+EGFR+C797S+mutant+inhibitor+with+in+vivo+mono+drug+efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0ljkx31Xt94IQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520new%2520EGFR%2520C797S%2520mutant%2520inhibitor%2520with%2520in%2520vivo%2520mono%2520drug%2520efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10909</span>– <span class="NLM_lpage">10912</span>, <span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&issue=36&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0ljkx31Xt94IQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung Cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S Mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&issue=36&author=M.+G%C3%BCntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+Cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+Mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Guenther, Marcel; Juchum, Michael; Kelter, Gerhard; Fiebig, Heiner; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-10894</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clin. relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that addnl. mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compds. show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1QH6nrxYrVg90H21EOLACvtfcHk0lhRXPaF15BdmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK&md5=c3909faa7f781c2a3679f75bd3b6c5ac</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520Cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520Mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8429</span>– <span class="NLM_lpage">8439</span>, <span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&issue=19&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+frozen+analogue+approach+to+aminopyridinylimidazoles+leading+to+novel+and+promising+p38+MAP+kinase+inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span></div><div class="casAuthors">Selig, Roland; Goettert, Marcia; Schattel, Verena; Schollmeyer, Dieter; Albrecht, Wolfgang; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8429-8439</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study the design, synthesis, and biol. evaluation of constrained aminopyridinyl- and aminopyrimidinyl-imidazoles, e.g. I [X, Y = CH, N: R1 = H, Ph, PhCH2, cyclohexyl; R2 = H, 4-HO, 3,4,5-(MeO)3, etc.], as p38α MAP kinase inhibitors are reported.  The frozen analog approach focused on the pyridinyl unit, using purine bioisosteres as constrained structure analogs.  The identification of the most potent bioisostere was followed by a further derivatization to address hydrophobic region II.  These studies in combination with C-2 modifications of the imidazole core allowed to design highly active inhibitors on the p38α MAP kinase.  The inhibitor design presented herein represents a promising and highly efficient advancement of recent stages of development in this class of p38 MAP kinase inhibitors.  In combination with the highly flexible synthetic strategy, directions toward further investigations of complex C-5 modifications of diarylimidazoles are indicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0shTYFbqnE7Vg90H21EOLACvtfcHk0lhRXPaF15BdmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO&md5=08ecb5b5ca3034b9ee3c6bc4b52f6ecf</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520frozen%2520analogue%2520approach%2520to%2520aminopyridinylimidazoles%2520leading%2520to%2520novel%2520and%2520promising%2520p38%2520MAP%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D19%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an example of target hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&issue=11&author=M.+Juchumauthor=M.+G%C3%BCntherauthor=E.+D%C3%B6ringauthor=A.+Sievers-Englerauthor=M.+L%C3%A4mmerhoferauthor=S.+Laufer&title=Trisubstituted+imidazoles+with+a+rigidized+hinge+binding+motif+act+as+single+digit+nM+inhibitors+of+clinically+relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+mutants%3A+an+example+of+target+hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0lhRXPaF15BdmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520imidazoles%2520with%2520a%2520rigidized%2520hinge%2520binding%2520motif%2520act%2520as%2520single%2520digit%2520nM%2520inhibitors%2520of%2520clinically%2520relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520mutants%253A%2520an%2520example%2520of%2520target%2520hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10909</span>– <span class="NLM_lpage">10912</span>, <span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&issue=36&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0ljCFltQUa1KnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&issue=13&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+pyridinylimidazoles+as+potent+inhibitors+of+the+clinically+resistant+L858R%2FT790M%2FC797S+EGFR+mutant%3A+targeting+of+both+hydrophobic+regions+and+the+phosphate+binding+site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0ljCFltQUa1KnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520pyridinylimidazoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520clinically%2520resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520mutant%253A%2520targeting%2520of%2520both%2520hydrophobic%2520regions%2520and%2520the%2520phosphate%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF receptor inhibitors that are selective for the D746–750/T790M/C797S mutant through structure-based de novo design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&issue=26&author=H.+Parkauthor=H.+Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+receptor+inhibitors+that+are+selective+for+the+D746%E2%80%93750%2FT790M%2FC797S+mutant+through+structure-based+de+novo+design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0ljCFltQUa1KnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BY.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520receptor%2520inhibitors%2520that%2520are%2520selective%2520for%2520the%2520D746%25E2%2580%2593750%252FT790M%252FC797S%2520mutant%2520through%2520structure-based%2520de%2520novo%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D26%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFR L858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&issue=15&author=J.+Shenauthor=T.+Zhangauthor=S.+J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.+H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-based+design+of+5-methylpyrimidopyridone+derivatives+as+new+wild-type+sparing+inhibitors+of+the+epidermal+growth+factor+receptor+triple+mutant+%28EGFR+L858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0lhHPwxZGGxL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-based%2520design%2520of%25205-methylpyrimidopyridone%2520derivatives%2520as%2520new%2520wild-type%2520sparing%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520triple%2520mutant%2520%2528EGFR%2520L858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span> <span> </span><span class="NLM_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28033579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=1107-1117&author=L.+Yuauthor=M.+Huangauthor=T.+Xuauthor=L.+Tongauthor=X.+E.+Yanauthor=Z.+Zhangauthor=Y.+Xuauthor=C.+Yunauthor=H.+Xieauthor=K.+Dingauthor=X.+Lu&title=A+structure-guided+optimization+of+pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+selective+inhibitors+of+EGFR+L858R%2FT790M+mutant+with+improved+pharmacokinetic+properties&doi=10.1016%2Fj.ejmech.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties</span></div><div class="casAuthors">Yu, Lei; Huang, Minhao; Xu, Tianfeng; Tong, Linjiang; Yan, Xiao-e; Zhang, Zhang; Xu, Yong; Yun, Caihong; Xie, Hua; Ding, Ke; Lu, Xiaoyun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1107-1117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790M inhibitors with improved pharmacokinetic properties.  One of the most promising compd. 9s (N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide) potently suppressed EGFRL858R/T790M kinase and inhibited the proliferation of H1975 cells with IC50 values of 2.0 nM and 40 nM, resp.  The compd. dose-dependently induced redn. of the phosphorylation of EGFR and downstream activation of ERK in NCI-H1975 cells.  It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%.  Compd. 9s may serve as a promising lead compd. for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwni9j-NB9ZrVg90H21EOLACvtfcHk0lhHPwxZGGxL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D&md5=0c4c9ab1f2e5eba185d817161c3e261b</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DX.%26atitle%3DA%2520structure-guided%2520optimization%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520selective%2520inhibitors%2520of%2520EGFR%2520L858R%252FT790M%2520mutant%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117%26doi%3D10.1016%2Fj.ejmech.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2018.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29466773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=221-237&author=H.+Zhangauthor=J.+Wangauthor=Y.+Shenauthor=H.+Y.+Wangauthor=W.+M.+Duanauthor=H.+Y.+Zhaoauthor=Y.+Y.+Heiauthor=M.+Xinauthor=Y.+X.+Caoauthor=S.+Q.+Zhang&title=Discovery+of+2%2C4%2C6-trisubstitued+pyrido%5B3%2C4-d%5Dpyrimidine+derivatives+as+new+EGFR-TKIs&doi=10.1016%2Fj.ejmech.2018.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs</span></div><div class="casAuthors">Zhang, Hao; Wang, Jin; Shen, Ying; Wang, Hui-Yan; Duan, Wei-Ming; Zhao, Hong-Yi; Hei, Yuan-Yuan; Xin, Minhang; Cao, Yong-Xiao; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">221-237</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance is the major challenge in the treatment of EGFR-driven non-small cell lung cancer (NSCLC).  In this study, a novel class of compds. contg. pyrido[3,4-d]pyrimidine scaffold was designed as new generation EGFR-TKIs to overcome this challenge.  The most promising compd. I inhibited HCC827 and H1975 cells growth with the IC50 values of 0.044μM and 0.40μM, resp.  Meanwhile, I displayed potent inhibitory activity against the EGFRL858R (IC50=1.1nM) and EGFRL858R/T790M/C797S (IC50=7.2nM).  I could suppress EGFR phosphorylation in a dose-dependent manner in HCC827 cell line and significantly induce the apoptosis of HCC827 cells.  Mol. docking indicated that the hydroxyl in I could form addnl. hydrogen bond with mutant Ser797.  These findings strongly support our assumption that 2,4,6-trisubstitued pyrido[3,4-d] pyrimidine derivs. can serve as EGFR-TKIs.  The predicted hydrogen bond interaction formed by a small mol. inhibitor with mutant Ser797 is available to design the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3S8daGHVu6bVg90H21EOLACvtfcHk0lhHPwxZGGxL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D&md5=533499fed54c750cfde176522bbdfd52</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DDuan%26aufirst%3DW.%2BM.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%25202%252C4%252C6-trisubstitued%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520as%2520new%2520EGFR-TKIs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237%26doi%3D10.1016%2Fj.ejmech.2018.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2173</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmc.2018.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29576272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2173-85&issue=8&author=Y.+Y.+Heiauthor=Y.+Shenauthor=J.+Wangauthor=H.+Zhangauthor=H.+Y.+Zhaoauthor=M.+Xinauthor=Y.+X.+Caoauthor=Y.+Liauthor=S.+Q.+Zhang&title=Synthesis+and+evaluation+of+2%2C+9-disubstituted+8-phenylthio%2Fphenylsulfinyl-9H-purine+as+new+EGFR+inhibitors&doi=10.1016%2Fj.bmc.2018.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors</span></div><div class="casAuthors">Hei, Yuan-Yuan; Shen, Ying; Wang, Jin; Zhang, Hao; Zhao, Hong-Yi; Xin, Minhang; Cao, Yong-Xiao; Li, Yan; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2173-2185</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In present study, we described the synthesis and biol. evaluation of a new class of EGFR inhibitors contg. 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine scaffold.  Thirty-one compds. were synthesized.  Among them, compd. I displayed the IC50 of 29.4 nM against HCC827 cell line and 1.9 nM against EGFRL858R.  Compd. II showed moderate inhibitory activity against EGFRL858R/T790M/C797S (IC50 = 114 nM).  Western bolt assay suggested that compd. I significantly inhibited EGFR phosphorylation.  In vivo test, compd. I remarkably exhibited inhibitory effect on tumor growth at 5.0 mg/kg by oral administration in established nude mouse HCC827 xenograft model.  These results indicate that the 2,9-disubstituted 8-phenylsulfinyl/phenylsulfinyl-9H-purine derivs. can act as potent EGFR(L858R) inhibitors and effective anticancer agents.  Addnl., optimization of compd. C12 may result in discovering the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkK03__RHpv7Vg90H21EOLACvtfcHk0ljIVlOh_TbvvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D&md5=e3c14297dde450c1b241946f9bb823a6</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25202%252C%25209-disubstituted%25208-phenylthio%252Fphenylsulfinyl-9H-purine%2520as%2520new%2520EGFR%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2173%26epage%3D85%26doi%3D10.1016%2Fj.bmc.2018.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl) phenyl)-N 8-phenyl-9 H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10685</span>– <span class="NLM_lpage">10699</span>, <span class="refDoi"> DOI: 10.1021/jm301365e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301365e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2qtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10685-10699&issue=23&author=J.+Yangauthor=L.-J.+Wangauthor=J.-J.+Liuauthor=L.+Zhongauthor=R.-L.+Zhengauthor=Y.+Xuauthor=P.+Jiauthor=C.-H.+Zhangauthor=W.-J.+Wangauthor=X.-D.+Linauthor=L.-L.+Liauthor=Y.-Q.+Weiauthor=S.-Y.+Yang&title=Structural+optimization+and+structure-activity+relationships+of+N+2-%284-%284-methylpiperazin-1-yl%29+phenyl%29-N+8-phenyl-9+H-purine-2%2C+8-diamine+derivatives%2C+a+new+class+of+reversible+kinase+inhibitors+targeting+both+EGFR-activating+and+resistance+mutations&doi=10.1021%2Fjm301365e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization and Structure-Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations</span></div><div class="casAuthors">Yang, Jiao; Wang, Li-Jiao; Liu, Jing-Jing; Zhong, Lei; Zheng, Ren-Lin; Xu, Yong; Ji, Pan; Zhang, Chun-Hui; Wang, Wen-Jing; Lin, Xing-Dong; Li, Lin-Li; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10685-10699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describe the structural optimization of a hit compd., N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine, which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity.  Structure-activity relation studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (I) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, resp.  Compd. I was further assessed for potency and selectivity in enzymic assays and in vivo anti-NSCLC studies.  The results indicated that compd. I is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome.  In vivo, oral administration of compd. I at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKOduljgSQLVg90H21EOLACvtfcHk0ljIVlOh_TbvvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2qtrbJ&md5=4e91afe2877babc658e2490fefed82aa</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301365e%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.-J.%26aulast%3DLiu%26aufirst%3DJ.-J.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DR.-L.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DW.-J.%26aulast%3DLin%26aufirst%3DX.-D.%26aulast%3DLi%26aufirst%3DL.-L.%26aulast%3DWei%26aufirst%3DY.-Q.%26aulast%3DYang%26aufirst%3DS.-Y.%26atitle%3DStructural%2520optimization%2520and%2520structure-activity%2520relationships%2520of%2520N%25202-%25284-%25284-methylpiperazin-1-yl%2529%2520phenyl%2529-N%25208-phenyl-9%2520H-purine-2%252C%25208-diamine%2520derivatives%252C%2520a%2520new%2520class%2520of%2520reversible%2520kinase%2520inhibitors%2520targeting%2520both%2520EGFR-activating%2520and%2520resistance%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699%26doi%3D10.1021%2Fjm301365e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111888</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2019.111888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31787359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12isrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111888&author=H.+Leiauthor=S.+Fanauthor=H.+Zhangauthor=Y.+J.+Liuauthor=Y.+Y.+Heiauthor=J.+J.+Zhangauthor=A.+Q.+Zhengauthor=M.+Xinauthor=S.+Q.+Zhang&title=Discovery+of+novel+9-heterocyclyl+substituted+9H-purines+as+L858R%2FT790M%2FC797S+mutant+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2019.111888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Lei, Hao; Fan, Shu; Zhang, Hao; Liu, Yan-Jie; Hei, Yuan-Yuan; Zhang, Jun-Jie; Zheng, A-Qun; Xin, Minhang; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111888</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.  In this study, a series of novel 9-heterocyclyl substituted 9H-purine derivs. were designed as EGFRL858 R/T790 M/C797S tyrosine kinase inhibitors.  Among these compds., D4, D9, D11 and D12 showed significantly potent anti-proliferation and EGFRL858 R/T790 M/C797S inhibition activity.  In particular, the most potent compd. D9 showed anti-proliferation against HCC827 and H1975 cell lines with the IC50 values of 0.00088 and 0.20 μM, resp.  And D9 inhibited the EGFRL858R/T790M/C797S with an IC50 value of 18 nM.  Furtherly, D9 could significantly suppress the EGFR phosphorylation, induce the apoptosis, arrest cell cycle at G0/G1, and inhibit colony formation in HCC827 cell line by a concn.-dependent manner.  Mol. docking indicated that the introduction of a cyclopropylsulfonamide group in D9 led to the formation of addnl. two hydrogen bonds with mutant Ser797 which played key roles in generating efficient EGFRL858 R/T790 M/C797S inhibitory activity.  These findings strongly indicated that 9-heterocyclyl substituted 9H-purine derivs. were promising L858R/T790M/C797S mutant EGFR-TKIs.  The introduction of extra hydrogen bond interaction with mutant Ser797 is efficient method for the design of the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfi_DwgYnA7Vg90H21EOLACvtfcHk0ljIVlOh_TbvvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12isrfP&md5=758013053347da4e2f83bd2aad46b52c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DA.%2BQ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%2520novel%25209-heterocyclyl%2520substituted%25209H-purines%2520as%2520L858R%252FT790M%252FC797S%2520mutant%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111888%26doi%3D10.1016%2Fj.ejmech.2019.111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klövekorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niggenaber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaßhoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabe, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">10789</span>– <span class="NLM_lpage">10801</span>, <span class="refDoi"> DOI: 10.1039/C9SC03445E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1039%2FC9SC03445E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31857889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=10789-10801&issue=46&author=J.+Lategahnauthor=M.+Keulauthor=P.+Kl%C3%B6vekornauthor=H.+L.+Tumbrinkauthor=J.+Niggenaberauthor=M.+P.+M%C3%BCllerauthor=L.+Hodsonauthor=M.+Fla%C3%9Fhoffauthor=J.+Hardickauthor=T.+Grabe&title=Inhibition+of+osimertinib-resistant+epidermal+growth+factor+receptor+EGFR-T790M%2FC797S&doi=10.1039%2FC9SC03445E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Kloevekorn, Philip; Tumbrink, Hannah L.; Niggenaber, Janina; Mueller, Matthias P.; Hodson, Luke; Flasshoff, Maren; Hardick, Julia; Grabe, Tobias; Engel, Julian; Schultz-Fademrecht, Carsten; Baumann, Matthias; Ketzer, Julia; Muehlenberg, Thomas; Hiller, Wolf; Guenther, Georgia; Unger, Anke; Mueller, Heiko; Heimsoeth, Alena; Golz, Christopher; Blank-Landeshammer, Bernhard; Kollipara, Laxmikanth; Zahedi, Rene P.; Strohmann, Carsten; Hengstler, Jan G.; van Otterlo, Willem A. L.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">10789-10801</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC).  Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy.  However, recurrent acquired drug resistance limits the success of targeted drugs in long-term treatment and requires the const. development of novel efficient inhibitors of drug resistant cancer subtypes.  Herein, we present covalent inhibitors of the drug resistant gatekeeper mutant EGFR-L858R/T790M based on the pyrrolopyrimidine scaffold.  Biochem. and cellular characterization, as well as kinase selectivity profiling and western blot anal., substantiate our approach.  Moreover, the developed compds. possess high activity against multi drug resistant EGFR-L858R/T790M/C797S in biochem. assays due to their highly reversible binding character, that was revealed by characterization of the binding kinetics.  In addn., we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR which provide detailed insight into their binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOILrK_TpebVg90H21EOLACvtfcHk0lj6xO5NN5SttA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N&md5=0dd60e9ade21e33ae5656d50175e39ba</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1039%2FC9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC03445E%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKl%25C3%25B6vekorn%26aufirst%3DP.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DNiggenaber%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DHodson%26aufirst%3DL.%26aulast%3DFla%25C3%259Fhoff%26aufirst%3DM.%26aulast%3DHardick%26aufirst%3DJ.%26aulast%3DGrabe%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520osimertinib-resistant%2520epidermal%2520growth%2520factor%2520receptor%2520EGFR-T790M%252FC797S%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10789%26epage%3D10801%26doi%3D10.1039%2FC9SC03445E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span> <span> </span><span class="NLM_article-title">2-Oxo-3, 4-dihydropyrimido [4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant</span>. <i>Chin. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1016/j.cclet.2019.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cclet.2019.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=1281-1287&issue=5&author=X.+Huauthor=Q.+Xunauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Liauthor=L.+Tongauthor=M.+Laiauthor=T.+Huangauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Dingauthor=X.+Lu&title=2-Oxo-3%2C+4-dihydropyrimido+%5B4%2C+5-d%5D+pyrimidines+as+new+reversible+inhibitors+of+EGFR+C797S+%28Cys797+to+Ser797%29+mutant&doi=10.1016%2Fj.cclet.2019.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">2-Oxo-3,4-dihydropyrimido[4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant</span></div><div class="casAuthors">Hu, Xianglong; Xun, Qiuju; Zhang, Tao; Zhu, Su-Jie; Li, Qian; Tong, Linjiang; Lai, Mengzhen; Huang, Tao; Yun, Cai-Hong; Xie, Hua; Ding, Ke; Lu, Xiaoyun</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Chemical Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1281-1287</span>CODEN:
                <span class="NLM_cas:coden">CCLEE7</span>;
        ISSN:<span class="NLM_cas:issn">1001-8417</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Extensive structure-activity relationships (SARs) study of JND3229 was conducted to yield a series of new reversible 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidine privileged scaffold as EGFRC797S inhibitors.  One of the most potent compd. 6i potently suppressed EGFRL858R/T790M/C797S kinase with an IC50 value of 3.1 nmol/L, and inhibited the proliferation of BaF3 cells harboring EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S mutants with IC50 values of 290 nmol/L and 316 nmol/L, resp.  Further, 6i dose-dependently induced suppression of the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in BaF3 cells.  Compd. 6i may serve as a promising lead compd. for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRZmOirSaUOrVg90H21EOLACvtfcHk0lj6xO5NN5SttA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKku7bK&md5=829969bb42ba7929888961396c3d5d4c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.cclet.2019.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cclet.2019.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DX.%26atitle%3D2-Oxo-3%252C%25204-dihydropyrimido%2520%255B4%252C%25205-d%255D%2520pyrimidines%2520as%2520new%2520reversible%2520inhibitors%2520of%2520EGFR%2520C797S%2520%2528Cys797%2520to%2520Ser797%2529%2520mutant%26jtitle%3DChin.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D31%26issue%3D5%26spage%3D1281%26epage%3D1287%26doi%3D10.1016%2Fj.cclet.2019.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toenjes, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piedrafita, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span> <span> </span><span class="NLM_article-title">Leveraging atropisomerism to obtain a selective inhibitor of RET kinase with secondary activities toward EGFR mutants</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1930</span>– <span class="NLM_lpage">1939</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2ntLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1930-1939&issue=9&author=S.+T.+Toenjesauthor=V.+Garciaauthor=S.+M.+Maddoxauthor=G.+A.+Dawsonauthor=M.+A.+Ortizauthor=F.+J.+Piedrafitaauthor=J.+L.+Gustafson&title=Leveraging+atropisomerism+to+obtain+a+selective+inhibitor+of+RET+kinase+with+secondary+activities+toward+EGFR+mutants&doi=10.1021%2Facschembio.9b00407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants</span></div><div class="casAuthors">Toenjes, Sean T.; Garcia, Valeria; Maddox, Sean M.; Dawson, Gregory A.; Ortiz, Maria A.; Piedrafita, F. Javier; Gustafson, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1930-1939</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Unstable atropisomerism is innate in many common scaffolds in drug discovery, commonly existing as freely rotating aryl-aryl bonds.  Such compds. can access the majority of dihedral conformations around the bond axis, however most small-mols. bind their target within a narrow range of these available conformations.  The remaining accessible conformations can interact with other proteins leading to compd. promiscuity.  Herein, the authors leverage atropisomerism to restrict the accessible low energy dihedral conformations available to a promiscuous kinase inhibitor and achieve highly selective and potent inhibitors of the oncogenic target RET kinase.  The authors then evaluate the lead inhibitor against kinases that were predicted to bind compds. in a similar conformational window to RET, discovering a potent inhibitor of drug resistant EGFR mutants including L858R/T790M/C797S EGFR.  Leveraging atropisomerism to restrict accessible conformational space should be a generally applicable strategy due to the prevalence of unstable atropisomerism in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryWhdro_5d97Vg90H21EOLACvtfcHk0lj6xO5NN5SttA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2ntLvO&md5=93897c4c19509082f7941a2745aee5d5</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00407%26sid%3Dliteratum%253Aachs%26aulast%3DToenjes%26aufirst%3DS.%2BT.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DMaddox%26aufirst%3DS.%2BM.%26aulast%3DDawson%26aufirst%3DG.%2BA.%26aulast%3DOrtiz%26aufirst%3DM.%2BA.%26aulast%3DPiedrafita%26aufirst%3DF.%2BJ.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DLeveraging%2520atropisomerism%2520to%2520obtain%2520a%2520selective%2520inhibitor%2520of%2520RET%2520kinase%2520with%2520secondary%2520activities%2520toward%2520EGFR%2520mutants%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D1930%26epage%3D1939%26doi%3D10.1021%2Facschembio.9b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wumaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">127327</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmcl.2020.127327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32631532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wmu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127327&issue=16&author=Z.+Suauthor=T.+Yangauthor=J.+Wangauthor=M.+Laiauthor=L.+Tongauthor=G.+Wumaierauthor=Z.+Chenauthor=S.+Liauthor=H.+Liauthor=H.+Xieauthor=Z.+Zhao&title=Design%2C+synthesis+and+biological+evaluation+of+potent+EGFR+kinase+inhibitors+against+19D%2FT790M%2FC797S+mutation&doi=10.1016%2Fj.bmcl.2020.127327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation</span></div><div class="casAuthors">Su, Zhicheng; Yang, Tingyuan; Wang, Jie; Lai, Mengzhen; Tong, Linjiang; Wumaier, Gulinuer; Chen, Zhuo; Li, Shengqing; Li, Honglin; Xie, Hua; Zhao, Zhenjiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">127327</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The efficacy of EGFR inhibitors is frequently affected by acquired resistance.  EGFR19D/T790M/C797S mutation is one of the primary reasons for the emergence of resistance after treatment with the third-generation EGFR inhibitors such as AZD9291, CO1686 and Olmutinib.  To overcome the resistance mutation 19D/T790M/C797S, we designed and prepd. a series of indole derivs. with the terminal hydroxyl of alkyl chain to increase extra interaction with the Asp855 in the conservative DFG site.  Activity evaluation, structure-activity relationship and docking anal. were also carried out.  Among them, compd. 12e displayed significant inhibitory activity against EGFR19D/T790M/C797S (IC50 = 15.3 nM) and good selectivity over EGFR WT (IC50 > 1000 nM), L858R/T790M (IC50, 156.6 nM) and L858R/T790M/C797S (IC50, 218.3 nM) resp.  Furthermore, 12e exhibited good growth inhibition activity, induced G1 phase cell cycle arrest and apoptosis in BaF3/EGFR19D/T790M/C797S cells by suppressing EGFR phosphorylation signaling pathway.  In all, our study might provide a novel structural design method and lay the solid foundation for the development of the 4th generation EGFR19D/T790M/C797S inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLugcH0mHed7Vg90H21EOLACvtfcHk0li0tLEURBHOsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wmu73J&md5=54681eeb47ce2c2b2e227677d7e1d40e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127327%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DWumaier%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520potent%2520EGFR%2520kinase%2520inhibitors%2520against%252019D%252FT790M%252FC797S%2520mutation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127327%26doi%3D10.1016%2Fj.bmcl.2020.127327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of the quinazoline derivatives as L858R/T790M/C797S triple mutant epidermal growth factor receptor tyrosine kinase inhibitors</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1248/cpb.c20-00411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1248%2Fcpb.c20-00411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32999149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3MXkvVChsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2020&pages=971-980&issue=10&author=M.+Zhangauthor=Y.+Wangauthor=J.+Wangauthor=Z.+Liuauthor=J.+Shiauthor=M.+Liauthor=Y.+Zhuauthor=S.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+the+quinazoline+derivatives+as+L858R%2FT790M%2FC797S+triple+mutant+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors&doi=10.1248%2Fcpb.c20-00411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of the quinazoline derivatives as L858R/T790M/C797S triple mutant epidermal growth factor receptor tyrosine kinase inhibitors</span></div><div class="casAuthors">Zhang, Mingguang; Wang, Yunyun; Wang, Jia; Liu, Zhaogang; Shi, Jingmiao; Li, Mingxin; Zhu, Yongqiang; Wang, Shifa</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-980</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of 2-aryl-4-amino substituted quinazoline derivs. I [R1 = NC, Br; R2 = ethylamino, piperazin-1-yl, (pyrimidin-2-ylmethyl)amino, etc.; R3 = H, MeO] were designed and synthesized with the purpose to overcome L858R/T790M/C797S (CTL) triple mutant drug resistance and the biol. activity for inhibition of CTL kinases and EGFR wild type (WT) were evaluated.  Three compds. I [R1 = Br, R2 = (pyrimidin-2-ylmethyl)amino, (pyrazin-2-ylmethyl)amino, R3 = H; R1 = NC, R2 = (pyrimidin-2-ylmethyl)amino, R3 = H] showed excellent inhibitory activities against EGFR kinases triple mutant CTL (IC50 < 1μM) and high selectivity (IC50: WT/CTL >10000).  Cell line evaluation showed that the most potent compd. I [R1 = NC, R2 = (pyrimidin-2-ylmethyl)amino, R3 = H] was significantly potent against H1975-EGFR L858R/T790M (IC50 = 3.3μM) and H1975-EGFR L858R/T790M/C797S (IC50 = 1.2μM).  Compd. I [R1 = NC, R2 = (pyrimidin-2-ylmethyl)amino, R3 = H] exhibited good microsomes stabilities in human, rat and mouse liver species, but with low bioavailability.  This work is very useful for discovering new quinazoline derivs. as tyrosine kinase inhibitors targeting triple mutant L858R/T790M/C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_QgIlxb3eCrVg90H21EOLACvtfcHk0li0tLEURBHOsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXkvVChsrw%253D&md5=a515d96f34de922966e8d4ad55d74bc8</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c20-00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c20-00411%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520the%2520quinazoline%2520derivatives%2520as%2520L858R%252FT790M%252FC797S%2520triple%2520mutant%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2020%26volume%3D68%26issue%3D10%26spage%3D971%26epage%3D980%26doi%3D10.1248%2Fcpb.c20-00411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span>; <span class="NLM_string-name">Shin, I.</span>; <span class="NLM_string-name">Choi, G.</span>; <span class="NLM_string-name">Chae, C H.</span>; <span class="NLM_string-name">Choe, H. J.</span>; <span class="NLM_string-name">Jung, M. E.</span>; <span class="NLM_string-name">Jeon, B. U.</span>; <span class="NLM_string-name">Cho, B. C.</span>; <span class="NLM_string-name">Park, C. W.</span>; <span class="NLM_string-name">Kim, H.</span>; <span class="NLM_string-name">Duggirala, K. B.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>2, <i>N</i>4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer</span>. <span class="NLM_patent">CN 110740999 A</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=K.+Lee&author=I.+Shin&author=G.+Choi&author=C+H.+Chae&author=H.+J.+Choe&author=M.+E.+Jung&author=B.+U.+Jeon&author=B.+C.+Cho&author=C.+W.+Park&author=H.+Kim&author=K.+B.+Duggirala&title=N2%2C+N4-diphenylpyrimidine-2%2C4-diamine+derivative%2C+method+for+preparing+same%2C+and+pharmaceutical+composition+containing+same+as+active+ingredient+for+prevention+or+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%26atitle%3DN2%252C%2520N4-diphenylpyrimidine-2%252C4-diamine%2520derivative%252C%2520method%2520for%2520preparing%2520same%252C%2520and%2520pharmaceutical%2520composition%2520containing%2520same%2520as%2520active%2520ingredient%2520for%2520prevention%2520or%2520treatment%2520of%2520cancer%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Liu, X.</span>; <span class="NLM_string-name">Ding, C. Z.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Zhao, L.</span>; <span class="NLM_string-name">Pan, W.</span>; <span class="NLM_string-name">Hu, G.</span>; <span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Spiro-aryl-phosphorus-oxygen compound as fourth generation of EGFR kinase inhibitor</span>. <span class="NLM_patent">WO 2018108064 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Wu&author=X.+Liu&author=C.+Z.+Ding&author=S.+Chen&author=L.+Hu&author=L.+Zhao&author=W.+Pan&author=G.+Hu&author=J.+Li&title=Spiro-aryl-phosphorus-oxygen+compound+as+fourth+generation+of+EGFR+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DSpiro-aryl-phosphorus-oxygen%2520compound%2520as%2520fourth%2520generation%2520of%2520EGFR%2520kinase%2520inhibitor%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwao, M.</span>; <span class="NLM_string-name">Fukuda, T.</span>; <span class="NLM_string-name">Ishibashi, F.</span>; <span class="NLM_string-name">Uehara, Y.</span>; <span class="NLM_string-name">Nishitani, N.</span>; <span class="NLM_string-name">Oku, Y.</span>; <span class="NLM_string-name">Dan, S.</span>; <span class="NLM_string-name">Yamori, T.</span></span> <span> </span><span class="NLM_article-title">Fourth-generation EGFR tyrosine kinase inhibitor</span>. <span class="NLM_patent">CN 110461850 A</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Iwao&author=T.+Fukuda&author=F.+Ishibashi&author=Y.+Uehara&author=N.+Nishitani&author=Y.+Oku&author=S.+Dan&author=T.+Yamori&title=Fourth-generation+EGFR+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIwao%26aufirst%3DM.%26atitle%3DFourth-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Wei, H.</span>; <span class="NLM_string-name">Wei, W.</span>; <span class="NLM_string-name">Yanqing, Y.</span>; <span class="NLM_string-name">Hui, Z.</span></span> <span> </span><span class="NLM_article-title">Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof</span>. <span class="NLM_patent">CN 110790749 A</span>, 2020.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Li%2C+Z.%3B+Wei%2C+H.%3B+Wei%2C+W.%3B+Yanqing%2C+Y.%3B+Hui%2C+Z.+Nitrogen-containing+heterocyclic+compound%2C+pharmaceutical+composition+and+application+thereof.+CN+110790749+A%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DNitrogen-containing%2520heterocyclic%2520compound%252C%2520pharmaceutical%2520composition%2520and%2520application%2520thereof" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boese, D.</span>; <span class="NLM_string-name">Dahmann, G.</span>; <span class="NLM_string-name">Engelhardt, H.</span>; <span class="NLM_string-name">Petronczki, M.</span>; <span class="NLM_string-name">Scharn, D.</span></span> <span> </span><span class="NLM_article-title">New benzimidazole compounds and derivatives as EGFR inhibitors</span>. <span class="NLM_patent">WO 2019162323 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Boese&author=G.+Dahmann&author=H.+Engelhardt&author=M.+Petronczki&author=D.+Scharn&title=New+benzimidazole+compounds+and+derivatives+as+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoese%26aufirst%3DD.%26atitle%3DNew%2520benzimidazole%2520compounds%2520and%2520derivatives%2520as%2520EGFR%2520inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Liu, X.</span>; <span class="NLM_string-name">Ding, C. Z.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Zhao, L.</span>; <span class="NLM_string-name">Pan, W.</span>; <span class="NLM_string-name">Hu, G.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Zhao, N.</span>; <span class="NLM_string-name">Zhao, J.</span></span> <span> </span><span class="NLM_article-title">Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor</span>. <span class="NLM_patent">WO 2019015655 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=L.+Wu&author=X.+Liu&author=C.+Z.+Ding&author=S.+Chen&author=L.+Hu&author=L.+Zhao&author=W.+Pan&author=G.+Hu&author=J.+Li&author=N.+Zhao&author=J.+Zhao&title=Aryl-phosphorus-oxygen+compound+as+EGFR+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DAryl-phosphorus-oxygen%2520compound%2520as%2520EGFR%2520kinase%2520inhibitor%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span>; <span class="NLM_string-name">Ding, J.</span>; <span class="NLM_string-name">Shen, J.</span>; <span class="NLM_string-name">Geng, M.</span>; <span class="NLM_string-name">Lu, X.</span>; <span class="NLM_string-name">Xie, H.</span>; <span class="NLM_string-name">Sun, M.</span>; <span class="NLM_string-name">Zong, Z.</span></span> <span> </span><span class="NLM_article-title">Pyrimidopyridone or pyridopyridone compound and use thereof</span>. <span class="NLM_patent">WO 2019015593 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.+Ding&author=J.+Ding&author=J.+Shen&author=M.+Geng&author=X.+Lu&author=H.+Xie&author=M.+Sun&author=Z.+Zong&title=Pyrimidopyridone+or+pyridopyridone+compound+and+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimidopyridone%2520or%2520pyridopyridone%2520compound%2520and%2520use%2520thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han-Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28662863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1723-1727&issue=11&author=Z.+Wangauthor=J.+J.+Yangauthor=J.+Huangauthor=J.+Y.+Yeauthor=X.+C.+Zhangauthor=H.+Y.+Tuauthor=H.+Han-Zhangauthor=Y.+L.+Wu&title=Lung+adenocarcinoma+harboring+EGFR+T790M+and+in+trans+C797S+responds+to+combination+therapy+of+first+and+third+generation+EGFR-TKIs+and+shifts+allelic+configuration+at+resistance&doi=10.1016%2Fj.jtho.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance</span></div><div class="casAuthors">Wang Zhen; Yang Jin-Ji; Huang Jie; Zhang Xu-Chao; Tu Hai-Yan; Ye Jun-Yi; Han-Zhang Han; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-1727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S.  In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors.  However, this has not been reported clinically.  METHODS:  We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy.  RESULTS:  At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M.  He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib.  After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.  CONCLUSION:  We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans.  We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKksLRAl4nGUbxh97K6Vt6fW6udTcc2eZsC3MbpxHmM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D&md5=4a4e858b7e9b39034fd2035da629a88c</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DHan-Zhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DLung%2520adenocarcinoma%2520harboring%2520EGFR%2520T790M%2520and%2520in%2520trans%2520C797S%2520responds%2520to%2520combination%2520therapy%2520of%2520first%2520and%2520third%2520generation%2520EGFR-TKIs%2520and%2520shifts%2520allelic%2520configuration%2520at%2520resistance%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1723%26epage%3D1727%26doi%3D10.1016%2Fj.jtho.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arulananda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musafer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span> <span> </span><span class="NLM_article-title">Combination of osimertinib and Gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1728</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28843359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhvVymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1728-1732&issue=11&author=S.+Arulanandaauthor=H.+Doauthor=A.+Musaferauthor=P.+Mitchellauthor=A.+Dobrovicauthor=T.+John&title=Combination+of+osimertinib+and+Gefitinib+in+C797S+and+T790M+EGFR-mutated+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Arulananda Surein; Do Hongdo; Dobrovic Alexander; Musafer Ashan; Mitchell Paul; John Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1728-1732</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Osimertinib, a third-generation EGFR tyrosine kinase inhibitor has demonstrated efficacy in tumors harboring the EGFR T790M resistance mutation.  Inevitably, resistance to third-generation inhibitors results in disease progression, with the EGFR C797S mutation being one of several resistance pathways identified to date.  On the basis of preclinical data, we report what is the first known case of a patient harboring the T790M and C797S mutations in trans treated with combination gefitinib and osimertinib.  METHODS:  On development of progressive disease after multiple therapies, the patient's plasma was sequenced using the Oncomine Lung cfDNA Assay (Thermo Fisher Scientific, Waltham, MA).  Subsequent monitoring of circulating tumor DNA in plasma was performed by droplet digital polymerase chain reaction.  RESULTS:  Sequencing showed that the T790M and C797S mutations were in trans.  Within 2 weeks of commencement of combination therapy, rapid clinical improvement occurred.  Accompanying this, a rapid decline in the C797S mutation subclone in plasma was detected.  However, the levels of the EGFR exon 19 deletion driver mutation and the T790M resistance mutation in the circulating tumor DNA continued to rise and the patient died from progressive disease 6 weeks after commencement of combination therapy.  There were no adverse events seen with the combination therapy.  CONCLUSION:  This is, to the best of our knowledge, the first reported case of combination EGFR tyrosine kinase inhibitor therapy tailored to the allelic conformation of T790M and C797S mutation that resulted in brief clinical improvement without toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJq-HpTS29KCjiVMCqkKxVfW6udTcc2eZsC3MbpxHmM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhvVymtg%253D%253D&md5=346d8b67e92b618e712c648b52a6e937</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DArulananda%26aufirst%3DS.%26aulast%3DDo%26aufirst%3DH.%26aulast%3DMusafer%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DDobrovic%26aufirst%3DA.%26aulast%3DJohn%26aufirst%3DT.%26atitle%3DCombination%2520of%2520osimertinib%2520and%2520Gefitinib%2520in%2520C797S%2520and%2520T790M%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1728%26epage%3D1732%26doi%3D10.1016%2Fj.jtho.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span> (<span class="NLM_issue">7605</span>),  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&issue=7605&author=Y.+Jiaauthor=C.-H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.-Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.-K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0liQ686AqXdHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26issue%3D7605%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>502</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.05.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bbrc.2018.05.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29802850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=502&publication_year=2018&pages=332-337&issue=3&author=P.+Zhaoauthor=M.+Y.+Yaoauthor=S.+J.+Zhuauthor=J.+Y.+Chenauthor=C.+H.+Yun&title=Crystal+structure+of+EGFR+T790M%2FC797S%2FV948R+in+complex+with+EAI045&doi=10.1016%2Fj.bbrc.2018.05.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045</span></div><div class="casAuthors">Zhao, Peng; Yao, Ming-Yu; Zhu, Su-Jie; Chen, Ji-Yun; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">502</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lung cancer is the leading cause of cancer deaths.  Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers.  Patients harboring most of these mutations respond well to the anti-EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib initially, but soon develop resistance to them in about half of the cases due to the emergence of the gatekeeper mutation T790M.  The third-generation TKIs such as AZD9291, HM61713, CO-1686 and WZ4002 can overcome T790M through covalent binding to the EGFR kinase through Cys 797, but ultimately lose their efficacy upon emergence of the C797S mutation that abolishes the covalent bonding.  Therefore to develop new TKIs to overcome EGFR drug-resistant mutants harboring T790M/C797S is urgently demanded.  EAI001 and EAI045 are a new type of EGFR TKIs that bind to EGFR reversibly and not relying on Cys 797.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR L858R/T790M and L858R/T790M/C797S.  Here we report the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, and compare it to EGFR T790M/V948R in complex with EAI001.  The complex structure reveals why EAI045 binds tighter to EGFR than does EAI001, and why EAI001 and EAI045 prefer binding to EGFR T790M.  The knowledge may facilitate future drug development studies targeting this very important cancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouEvBqE0oB5LVg90H21EOLACvtfcHk0liQ686AqXdHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I&md5=b76b6a40ffef581fa2d5ca0a45bb8c14</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.05.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.05.154%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520EGFR%2520T790M%252FC797S%252FV948R%2520in%2520complex%2520with%2520EAI045%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D502%26issue%3D3%26spage%3D332%26epage%3D337%26doi%3D10.1016%2Fj.bbrc.2018.05.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&issue=7&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Single+and+dual+targeting+of+mutant+EGFR+with+an+allosteric+inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0ljJjE3Fy2aAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520dual%2520targeting%2520of%2520mutant%2520EGFR%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggirala, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibitor TREA-0236 Containing non-hydrolysable quinazoline-4-one for EGFR T790M/C797S mutant’s inhibition</span>. <i>Bull. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1002/bkcs.11491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fbkcs.11491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyktLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=895-898&issue=7&author=S.+Leeauthor=J.+Kimauthor=K.+B.+Duggiralaauthor=A.+Goauthor=I.+Shinauthor=B.+C.+Choauthor=G.+Choiauthor=C.+H.+Chaeauthor=K.+Lee&title=Allosteric+Inhibitor+TREA-0236+Containing+non-hydrolysable+quinazoline-4-one+for+EGFR+T790M%2FC797S+mutant%E2%80%99s+inhibition&doi=10.1002%2Fbkcs.11491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition</span></div><div class="casAuthors">Lee, Seoyoung; Kim, Jiwon; Duggirala, Krishna Babu; Go, Areum; Shin, Inji; Cho, Byoung Chul; Choi, Gildon; Chae, Chong Hak; Lee, Kwangho</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">895-898</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) activating mutations such as EGFR L858R and EGFR ex19 deletions are responsible for 30-40% of NSCLC patients in East Asian populations and 10-15% in European descendants.  All the approved EGFR-tyrosine kinase inhibitors (TKIs) give clin. benefits to EGFR-related NSCLC patients in terms of overall survival and quality of patient life.  Novel EGFR allosteric inhibitors, EAI001 and EAI045, have been recently reported.  In order to investigate the binding mode of the inhibitors, a mol. docking study was first examd.  Based on EAI045 structure, we designed TREA-0236 featured with a quinazoline-4-one instead of the 2-aminothiazole amide, so that the unwanted metabolite formation is structurally prohibited.  The predicted binding pose of TREA-0236 is nearly identical to the crystal structure of EAI001 which is located next to ATP binding site.  Synthetic procedure of representative mol. TREA-0236 is outlined in Scheme 1.  We have attempted to replace the undesirable aminothiazole with non-hydrolysable quinazoline-4-one on the EAI045 for improved drug properties, however only TREA-0236 shows a level of biochem. activity and it is inferior to parent EAI045.  Further the non-hydrolysable scaffold search devoid of aminothiazole is currently underway and will be reported in due course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6lIGJlduNv7Vg90H21EOLACvtfcHk0ljJjE3Fy2aAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyktLbN&md5=bcd15bf0dcc1841cf9c927fed702e0af</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1002%2Fbkcs.11491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbkcs.11491%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DDuggirala%26aufirst%3DK.%2BB.%26aulast%3DGo%26aufirst%3DA.%26aulast%3DShin%26aufirst%3DI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DChoi%26aufirst%3DG.%26aulast%3DChae%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DK.%26atitle%3DAllosteric%2520Inhibitor%2520TREA-0236%2520Containing%2520non-hydrolysable%2520quinazoline-4-one%2520for%2520EGFR%2520T790M%252FC797S%2520mutant%25E2%2580%2599s%2520inhibition%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2018%26volume%3D39%26issue%3D7%26spage%3D895%26epage%3D898%26doi%3D10.1002%2Fbkcs.11491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1549-1553&issue=11&author=D.+De+Clercqauthor=D.+E.+Heppnerauthor=C.+Toauthor=J.+Jangauthor=E.+Parkauthor=C.+H.+Yunauthor=M.+Mushajiangauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=D.+A.+Scottauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Discovery+and+optimization+of+dibenzodiazepinones+as+allosteric+mutant-selective+EGFR+inhibitors&doi=10.1021%2Facsmedchemlett.9b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span></div><div class="casAuthors">De Clercq, Dries J. H.; Heppner, David E.; To, Ciric; Jang, Jaebong; Park, Eunyoung; Yun, Cai-Hong; Mushajiang, Mierzhati; Shin, Bo Hee; Gero, Thomas W.; Scott, David A.; Janne, Pasi A.; Eck, Michael J.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1549-1553</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers.  Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold.  Our structure-based medicinal chem. effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling.  Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyvHIT2KWY7Vg90H21EOLACvtfcHk0ljJjE3Fy2aAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM&md5=9d8771e7444fa58f06dff284f6f393da</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00381%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520dibenzodiazepinones%2520as%2520allosteric%2520mutant-selective%2520EGFR%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1549%26epage%3D1553%26doi%3D10.1021%2Facsmedchemlett.9b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span>; <span class="NLM_string-name">Goergler, A.</span>; <span class="NLM_string-name">Jaeschke, G.</span>; <span class="NLM_string-name">Kocer, B.</span>; <span class="NLM_string-name">Kuhn, B.</span>; <span class="NLM_string-name">Lazarski, K.</span>; <span class="NLM_string-name">Liang, Y.</span>; <span class="NLM_string-name">Nagel, Y. A.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Ricci, A.</span>; <span class="NLM_string-name">Rueher, D.</span>; <span class="NLM_string-name">Steiner, S.</span></span> <span> </span><span class="NLM_article-title">Compounds</span>. <span class="NLM_patent">WO 2020002487 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Duplessis&author=A.+Goergler&author=G.+Jaeschke&author=B.+Kocer&author=B.+Kuhn&author=K.+Lazarski&author=Y.+Liang&author=Y.+A.+Nagel&author=U.+Obst+Sander&author=A.+Ricci&author=D.+Rueher&author=S.+Steiner&title=Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDuplessis%26aufirst%3DM.%26atitle%3DCompounds%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFR L858R/T790M/C797S</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00564</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00564" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=869-873&issue=6&author=Q.+Liauthor=T.+Zhangauthor=S.+Liauthor=L.+Tongauthor=J.+Liauthor=Z.+Suauthor=F.+Fengauthor=D.+Sunauthor=Y.+Tongauthor=X.+Wangauthor=Z.+Zhaoauthor=L.+Zhuauthor=J.+Dingauthor=H.+Liauthor=H.+Xieauthor=Y.+Xu&title=Discovery+of+potent+and+noncovalent+reversible+EGFR+kinase+inhibitors+of+EGFR+L858R%2FT790M%2FC797S&doi=10.1021%2Facsmedchemlett.8b00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S</span></div><div class="casAuthors">Li, Qiannan; Zhang, Tao; Li, Shiliang; Tong, Linjiang; Li, Junyu; Su, Zhicheng; Feng, Fang; Sun, Deheng; Tong, Yi; Wang, Xia; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Li, Honglin; Xie, Hua; Xu, Yufang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">869-873</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFRL858R/T790M/C797S.  One of the most promising compds., I, inhibited the enzymic activity of EGFRL858R/T790M/C797S with an IC50 value of 2.2 nM.  Cell proliferation assays showed that I effectively and selectively inhibited the growth of EGFRL858R/T790M/C797S-dependent cells.  This series of compds., which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcQ04p4560bVg90H21EOLACvtfcHk0ljLoUH31Lm6JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D&md5=396eb9b29217fbb74189193a544819b3</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520noncovalent%2520reversible%2520EGFR%2520kinase%2520inhibitors%2520of%2520EGFR%2520L858R%252FT790M%252FC797S%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873%26doi%3D10.1021%2Facsmedchemlett.8b00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">LBA50 mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">viii740</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy424.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdy424.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=viii740&author=S.+S.+Ramalingamauthor=Y.+Chengauthor=C.+Zhouauthor=Y.+Oheauthor=F.+Imamuraauthor=B.+C.+Choauthor=M.+C.+Linauthor=M.+Majemauthor=R.+Shahauthor=Y.+Rukazenkov&title=LBA50+mechanisms+of+acquired+resistance+to+first-line+osimertinib%3A+preliminary+data+from+the+phase+III+FLAURA+study&doi=10.1093%2Fannonc%2Fmdy424.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy424.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy424.063%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLin%26aufirst%3DM.%2BC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DRukazenkov%26aufirst%3DY.%26atitle%3DLBA50%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520first-line%2520osimertinib%253A%2520preliminary%2520data%2520from%2520the%2520phase%2520III%2520FLAURA%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Dviii740%26doi%3D10.1093%2Fannonc%2Fmdy424.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. Y.</span></span> <span> </span><span class="NLM_article-title">Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent bim and Mcl-1 degradation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6567</span>– <span class="NLM_lpage">6579</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-1574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28765329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGis7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6567-6579&issue=21&author=P.+Shiauthor=Y.+T.+Ohauthor=L.+Dengauthor=G.+Zhangauthor=G.+Qianauthor=S.+Zhangauthor=H.+Renauthor=G.+Wuauthor=B.+Legendreauthor=E.+Andersonauthor=S.+S.+Ramalingamauthor=T.+K.+Owonikokoauthor=M.+Chenauthor=S.+Y.+Sun&title=Overcoming+acquired+resistance+to+AZD9291%2C+a+third-generation+EGFR+inhibitor%2C+through+modulation+of+MEK%2FERK-dependent+bim+and+Mcl-1+degradation&doi=10.1158%2F1078-0432.CCR-17-1574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation</span></div><div class="casAuthors">Shi, Puyu; Oh, You-Take; Deng, Liang; Zhang, Guojing; Qian, Guoqing; Zhang, Shuo; Ren, Hui; Wu, Grant; Legendre, Benjamin, Jr.; Anderson, Emily; Ramalingam, Suresh S.; Owonikoko, Taofeek K.; Chen, Mingwei; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6567-6579</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.  Exptl. Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291.  Protein alterations were detected with Western blotting.  Apoptosis was measured with annexin V/flow cytometry.  Growth-inhibitory effects of tested drugs were evaluated in vitro with cell no. estn. and colony formation assay and in vivo with mouse xenograft models.  Protein degrdn. was detd. by comparing protein half-lives and inhibiting proteasome.  Gene knockdown were achieved with siRNA or shRNA.  Results: AZD9291 potently induced apoptosis in EGFR-mutant NSCLC cell lines, in which ERK phosphorylation was suppressed accompanied with Bim elevation and Mcl-1 redn. likely due to enhanced Mcl-1 degrdn. and increased Bim stability.  Blocking Bim elevation by gene knockdown or enforcing Mcl-1 expression attenuated or abolished AZD9291-induced apoptosis.  Moreover, AZD9291 lost its ability to modulate Bim and Mcl-1 levels in AZD9291-resistant cell lines.  The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivo.  Conclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degrdn. critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291.  Clin Cancer Res; 23(21); 6567-79. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWh1Cdfq2IcLVg90H21EOLACvtfcHk0ljLoUH31Lm6JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGis7vJ&md5=c748c64e2654fa1ebd4c9e251570da5f</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1574%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DP.%26aulast%3DOh%26aufirst%3DY.%2BT.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLegendre%26aufirst%3DB.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.%2BY.%26atitle%3DOvercoming%2520acquired%2520resistance%2520to%2520AZD9291%252C%2520a%2520third-generation%2520EGFR%2520inhibitor%252C%2520through%2520modulation%2520of%2520MEK%252FERK-dependent%2520bim%2520and%2520Mcl-1%2520degradation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D21%26spage%3D6567%26epage%3D6579%26doi%3D10.1158%2F1078-0432.CCR-17-1574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanteti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. Y.</span></span> <span> </span><span class="NLM_article-title">Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.canlet.2016.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27450722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2016&pages=494-504&issue=2&author=P.+Shiauthor=Y.+T.+Ohauthor=G.+Zhangauthor=W.+Yaoauthor=P.+Yueauthor=Y.+Liauthor=R.+Kantetiauthor=J.+Riehmauthor=R.+Salgiaauthor=T.+K.+Owonikokoauthor=S.+S.+Ramalingamauthor=M.+Chenauthor=S.+Y.+Sun&title=Met+gene+amplification+and+protein+hyperactivation+is+a+mechanism+of+resistance+to+both+first+and+third+generation+EGFR+inhibitors+in+lung+cancer+treatment&doi=10.1016%2Fj.canlet.2016.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment</span></div><div class="casAuthors">Shi, Puyu; Oh, You-Take; Zhang, Guojing; Yao, Weilong; Yue, Ping; Li, Yikun; Kanteti, Rajani; Riehm, Jacob; Salgia, Ravi; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Chen, Mingwei; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">494-504</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs; e.g., AZD9291), which selectively and irreversibly inhibit EGFR activating and T790M mutants, represent very promising therapeutic options for patients with non-small cell lung cancer (NSCLC) that has become resistant to 1st generation EGFR-TKIs due to T790M mutation.  However, eventual resistance to the 3rd generation EGFR-TKIs has already been described in the clinic, resulting in disease progression.  Therefore, there is a great challenge and urgent need to understand how this resistance occurs and to develop effective strategies to delay or overcome the resistance.  The current study has demonstrated that Met amplification and hyperactivation is a resistance mechanism to both 1st and 3rd generation EGFR-TKIs since both erlotinib- and AZD9291-resistant HCC827 cell lines possessed amplified Met gene and hyperactivated Met, and were cross-resistant to AZD9291 or erlotinib.  Met inhibition overcame the resistance of these cell lines to AZD9291 both in vitro and in vivo, including enhancement of apoptosis or G1 cell cycle arrest.  Hence, we suggest that Met inhibition is also an effective strategy to overcome resistance of certain EGFR-mutated NSCLCs with Met amplification to AZD9291, warranting the further clin. validation of our findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Vyx3D_1ZkrVg90H21EOLACvtfcHk0lhraU0vUCFCKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FI&md5=de68cf0cd3fa3310a71bb959990630bd</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DP.%26aulast%3DOh%26aufirst%3DY.%2BT.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DRiehm%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.%2BY.%26atitle%3DMet%2520gene%2520amplification%2520and%2520protein%2520hyperactivation%2520is%2520a%2520mechanism%2520of%2520resistance%2520to%2520both%2520first%2520and%2520third%2520generation%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%2520treatment%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D380%26issue%3D2%26spage%3D494%26epage%3D504%26doi%3D10.1016%2Fj.canlet.2016.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giroux-Leprieur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumenil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinet, T.</span></span> <span> </span><span class="NLM_article-title">Combination of crizotinib and osimertinib or erlotinib might overcome met-mediated resistance to EGFR tyrosine kinase inhibitor in EGFR-mutated adenocarcinoma</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e232</span>– <span class="NLM_lpage">e234</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30368417" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e232-e234&issue=11&author=E.+Giroux-Leprieurauthor=C.+Dumenilauthor=T.+Chinet&title=Combination+of+crizotinib+and+osimertinib+or+erlotinib+might+overcome+met-mediated+resistance+to+EGFR+tyrosine+kinase+inhibitor+in+EGFR-mutated+adenocarcinoma&doi=10.1016%2Fj.jtho.2018.07.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DGiroux-Leprieur%26aufirst%3DE.%26aulast%3DDumenil%26aufirst%3DC.%26aulast%3DChinet%26aufirst%3DT.%26atitle%3DCombination%2520of%2520crizotinib%2520and%2520osimertinib%2520or%2520erlotinib%2520might%2520overcome%2520met-mediated%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520in%2520EGFR-mutated%2520adenocarcinoma%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D11%26spage%3De232%26epage%3De234%26doi%3D10.1016%2Fj.jtho.2018.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span> <span> </span><span class="NLM_article-title">Osimertinib and Cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to Crizotinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e49</span>– <span class="NLM_lpage">e53</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29128427" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e49-e53&issue=4&author=J.+Kangauthor=H.+J.+Chenauthor=Z.+Wangauthor=J.+Liuauthor=B.+Liauthor=T.+Zhangauthor=Z.+Yangauthor=Y.+L.+Wuauthor=J.+J.+Yang&title=Osimertinib+and+Cabozantinib+combinatorial+therapy+in+an+EGFR-mutant+lung+adenocarcinoma+patient+with+multiple+MET+secondary-site+mutations+after+resistance+to+Crizotinib&doi=10.1016%2Fj.jtho.2017.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26atitle%3DOsimertinib%2520and%2520Cabozantinib%2520combinatorial%2520therapy%2520in%2520an%2520EGFR-mutant%2520lung%2520adenocarcinoma%2520patient%2520with%2520multiple%2520MET%2520secondary-site%2520mutations%2520after%2520resistance%2520to%2520Crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D4%26spage%3De49%26epage%3De53%26doi%3D10.1016%2Fj.jtho.2017.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">MEK inhibitors under development for treatment of non-small-cell lung cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1415324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F13543784.2018.1415324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29216787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=17-30&issue=1&author=C.+Kimauthor=G.+Giaccone&title=MEK+inhibitors+under+development+for+treatment+of+non-small-cell+lung+cancer&doi=10.1080%2F13543784.2018.1415324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibitors under development for treatment of non-small-cell lung cancer</span></div><div class="casAuthors">Kim, Chul; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-30</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The mitogen-activated protein kinase (MAPK) pathway is intimately implicated in the mol. pathogenesis of non-small-cell lung cancer (NSCLC).  Aberrant MAPK signaling resulting from the upstream activating mutations converges on mitogen-activated protein kinase kinase 1/2 (MEK1/2), making MEK inhibition an attractive strategy for the treatment of NSCLC.  Several MEK inhibitors have demonstrated anticancer activity in patients with NSCLC.: In this article, we discuss the biol. rationale for the use of MEK inhibitors and summarize the clin. experience with MEK1/2 inhibitors for the treatment of NSCLC, from initial phase I studies to phase II/III studies, both as monotherapy or in combination with other anticancer agents.: Trametinib in combination with the BRAF inhibitor dabrafenib represents the first MEK1/2 inhibitor contg. regimen that is approved for advanced BRAFV600E-mutant NSCLC.  Other MEK1/2 inhibitors that are also in advanced stages of clin. development include selumetinib, cobimetinib, and binimetinib.  Several studies of MEK inhibitor combination therapies are underway, including trials using combined MEK inhibition and immune checkpoint blockade.  Further research aimed at discovering biomarkers of response and resistance to MEK1/2 inhibitors will be needed to develop rational combination strategies for the treatment of NSCLC driven by aberrant MAPK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD8kVwzoJ2r7Vg90H21EOLACvtfcHk0lgW_2yuepMGtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnN&md5=0de8dab092a5bdbe277b23dda3d6d605</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1415324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1415324%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DMEK%2520inhibitors%2520under%2520development%2520for%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26issue%3D1%26spage%3D17%26epage%3D30%26doi%3D10.1080%2F13543784.2018.1415324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Cuesta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildhaus, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuernberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-15-1915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27252416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4837-4847&issue=19&author=S.+Ortiz-Cuaranauthor=M.+Schefflerauthor=D.+Plenkerauthor=l.+Dahmenauthor=A.+H.+Scheelauthor=L.+Fernandez-Cuestaauthor=L.+Mederauthor=C.+M.+Lovlyauthor=T.+Persigehlauthor=S.+Merkelbach-Bruseauthor=M.+Bosauthor=S.+Michelsauthor=R.+Fischerauthor=K.+Albusauthor=K.+Konigauthor=H.-U.+Schildhausauthor=J.+Fassunkeauthor=M.+A.+Ihleauthor=H.+Pasternackauthor=C.+Heydtauthor=C.+Beckerauthor=J.+Altmullerauthor=H.+Jiauthor=C.+Mullerauthor=A.+Florinauthor=J.+M.+Heuckmannauthor=P.+Nuernbergauthor=S.+Ansenauthor=L.+C.+Heukampauthor=J.+Bergauthor=W.+Paoauthor=M.+Peiferauthor=R.+Buettnerauthor=J.+Wolfauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Heterogeneous+mechanisms+of+primary+and+acquired+resistance+to+third-generation+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-15-1915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span></div><div class="casAuthors">Ortiz-Cuaran, Sandra; Scheffler, Matthias; Plenker, Dennis; Dahmen, llona; Scheel, Andreas H.; Fernandez-Cuesta, Lynnette; Meder, Lydia; Lovly, Christine M.; Persigehl, Thorsten; Merkelbach-Bruse, Sabine; Bos, Marc; Michels, Sebastian; Fischer, Rieke; Albus, Kerstin; Koenig, Katharina; Schildhaus, Hans-Ulrich; Fassunke, Jana; Ihle, Michaela A.; Pasternack, Helen; Heydt, Carina; Becker, Christian; Altmueller, Janine; Ji, Hongbin; Mueller, Christian; Florin, Alexandra; Heuckmann, Johannes M.; Nuernberg, Peter; Ansen, Sascha; Heukamp, Lukas C.; Berg, Johannes; Pao, William; Peifer, Martin; Buettner, Reinhard; Wolf, Juergen; Thomas, Roman K.; Sos, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4837-4847</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).  We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686).  Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.  We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compds.  Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance.  Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS.  Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryi-78iIDGfrVg90H21EOLACvtfcHk0lgW_2yuepMGtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K&md5=b30908de40ff48f067e067cfc3520a7b</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1915%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DDahmen%26aufirst%3Dl.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DMeder%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DAlbus%26aufirst%3DK.%26aulast%3DKonig%26aufirst%3DK.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPasternack%26aufirst%3DH.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DAltmuller%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DA.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DNuernberg%26aufirst%3DP.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DHeterogeneous%2520mechanisms%2520of%2520primary%2520and%2520acquired%2520resistance%2520to%2520third-generation%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D19%26spage%3D4837%26epage%3D4847%26doi%3D10.1158%2F1078-0432.CCR-15-1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Della Corte, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciaramella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Monica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malapelle, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigliar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellone, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgillo, F.</span></span> <span> </span><span class="NLM_article-title">Antitumor efficacy of dual blockade of EGFR signalling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NCLC tumor models</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">810</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29526823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslemurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=810-820&issue=6&author=C.+M.+Della+Corteauthor=V.+Ciaramellaauthor=C.+Cardoneauthor=S.+La+Monicaauthor=R.+Alfieriauthor=P.+G.+Petroniniauthor=U.+Malapelleauthor=E.+Vigliarauthor=F.+Pepeauthor=G.+Tronconeauthor=M.+D.+Castelloneauthor=T.+Troianiauthor=E.+Martinelliauthor=F.+Ciardielloauthor=F.+Morgillo&title=Antitumor+efficacy+of+dual+blockade+of+EGFR+signalling+by+osimertinib+in+combination+with+selumetinib+or+cetuximab+in+activated+EGFR+human+NCLC+tumor+models&doi=10.1016%2Fj.jtho.2018.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models</span></div><div class="casAuthors">Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">810-820</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models.  We evaluated combinations of osimertinib plus selumetinib/cetuximab in HCC827 (E746-A759del/T790M-), H1975 (L858R/T790M+), and PC9-T790M (E746-A759del /T790M+) xenografts in second-line therapy after the development of resistance to osimertinib, and in first-line therapy, and we explored mechanisms of resistance to these treatments.  The early use of combinations in first-line therapy increased the RR to 90%, with an mPFS not reached in all combination arms in the three xenografts models, with a statistically significant superiority (p < 0.005) as compared to osimertinib, achieving in first-line therapy an mPFS time of 17 to 18 wk.  Moreover, in ex vivo primary cell cultures obtained from osimertinib plus selumetinib-resistant tumors, we found Hedgehog pathway activation and we showed that therapy with an SMO inhibitor plus osimertinib and selumetinib inhibited proliferation and migratory and invasive properties of resistant cells.  We showed that a dual vertical EGFR blockade with osimertinib plus selumetinib/cetuximab is a novel effective therapeutic option in EGFR-mutated NCLC and that hedgehog pathway activation and its interplay with MAPK is involved in resistance to these combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRni_glltKa7Vg90H21EOLACvtfcHk0lgW_2yuepMGtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslemurs%253D&md5=82ebd72f881c789bd4a20d0f0d3bde34</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DDella%2BCorte%26aufirst%3DC.%2BM.%26aulast%3DCiaramella%26aufirst%3DV.%26aulast%3DCardone%26aufirst%3DC.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMalapelle%26aufirst%3DU.%26aulast%3DVigliar%26aufirst%3DE.%26aulast%3DPepe%26aufirst%3DF.%26aulast%3DTroncone%26aufirst%3DG.%26aulast%3DCastellone%26aufirst%3DM.%2BD.%26aulast%3DTroiani%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DMorgillo%26aufirst%3DF.%26atitle%3DAntitumor%2520efficacy%2520of%2520dual%2520blockade%2520of%2520EGFR%2520signalling%2520by%2520osimertinib%2520in%2520combination%2520with%2520selumetinib%2520or%2520cetuximab%2520in%2520activated%2520EGFR%2520human%2520NCLC%2520tumor%2520models%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D810%26epage%3D820%26doi%3D10.1016%2Fj.jtho.2018.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calella, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span> <span> </span><span class="NLM_article-title">CROWN Trial Investigators First-Line Lorlatinib or Crizotinib in advanced <i>ALK</i>-positive lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2029</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2027187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa2027187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=33207094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=2018-2029&issue=21&author=A.+T.+Shawauthor=T.+M.+Bauerauthor=F.+de+Marinisauthor=E.+Felipauthor=Y.+Gotoauthor=G.+Liuauthor=J.+Mazieresauthor=D.+W.+Kimauthor=T.+Mokauthor=A.+Polliauthor=H.+Thurmauthor=A.+M.+Calellaauthor=G.+Peltzauthor=B.+J.+Solomon&title=CROWN+Trial+Investigators+First-Line+Lorlatinib+or+Crizotinib+in+advanced+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa2027187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna M.; Peltz, Gerson; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2018-2029</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-pos. non-small-cell lung cancer (NSCLC).  The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-pos. NSCLC is unclear.  We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-pos. NSCLC who had received no previous systemic treatment for metastatic disease.  The primary end point was progression-free survival as assessed by blinded independent central review.  Secondary end points included independently assessed objective response and intracranial response.  An interim anal. of efficacy was planned after approx. 133 of 177 (75%) expected events of disease progression or death had occurred.  The percentage of patients who were alive without disease progression at 12 mo was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001).  An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), resp., had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response.  The most common adverse events with lorlatinib were hyperlipidemia, edema, increased wt., peripheral neuropathy, and cognitive effects.  Lorlatinib was assocd. with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%).  Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, resp.  In an interim anal. of results among patients with previously untreated advanced ALK-pos. NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib.  The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPkJPLVUj8rVg90H21EOLACvtfcHk0ljvuTpTVu31kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN&md5=97baa919b685e4ece2c03e7788c76702</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2027187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2027187%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DCalella%26aufirst%3DA.%2BM.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26atitle%3DCROWN%2520Trial%2520Investigators%2520First-Line%2520Lorlatinib%2520or%2520Crizotinib%2520in%2520advanced%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26issue%3D21%26spage%3D2018%26epage%3D2029%26doi%3D10.1056%2FNEJMoa2027187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1654</span>– <span class="NLM_lpage">1667</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30649-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2818%2930649-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30413378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1654-1667&issue=12&author=B.+J+Solomonauthor=B.+Besseauthor=T.+M+Bauerauthor=E.+Felipauthor=R.+A+Sooauthor=D+R.+Camidgeauthor=R.+Chiariauthor=A.+Bearzauthor=C.-C.+Linauthor=S.+M+Gadgeelauthor=G.+J+Rielyauthor=E.+H.+Tanauthor=T.+Setoauthor=L.+P+Jamesauthor=J.+S+Clancyauthor=A.+Abbattistaauthor=J.-F.+Martiniauthor=J.+Chenauthor=G.+Peltzauthor=H.+Thurmauthor=S.-H.+I.+Ouauthor=A.+T+Shaw&title=Lorlatinib+in+patients+with+ALK-positive+non-small-cell+lung+cancer%3A+results+from+a+global+phase+2+study&doi=10.1016%2FS1470-2045%2818%2930649-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</span></div><div class="casAuthors">Solomon, Benjamin J.; Besse, Benjamin; Bauer, Todd M.; Felip, Enriqueta; Soo, Ross A.; Camidge, D. Ross; Chiari, Rita; Bearz, Alessandra; Lin, Chia-Chi; Gadgeel, Shirish M.; Riely, Gregory J.; Tan, Eng Huat; Seto, Takashi; James, Leonard P.; Clancy, Jill S.; Abbattista, Antonello; Martini, Jean-Francois; Chen, Joseph; Peltz, Gerson; Thurm, Holger; Ignatius Ou, Sai-Hong; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1654-1667</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We aimed to analyze the overall and intracranial antitumor activity of lorlatinib in patients with ALK-pos., advanced non-small-cell lung cancer.  In this phase 2 study, patients with histol. or cytol. ALK-pos. or ROS1-pos., advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncol. Group performance status of 0, 1, or 2, and adequate end-organ function were eligible.  Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, and were given lorlatinib 100 mg orally once daily continuously in 21-day cycles.  One patient in EXP4 died before receiving lorlatinib and was excluded from the safety anal. set.  In treatment-naive patients (EXP1), an objective response was achieved in 27 (90·0%; 95% CI 73·5-97·9) of 30 patients.  Objective intracranial response was achieved in 20 patients with measurable baseline CNS lesions in EXP2-3A, five (55·6%; 21·2-86·3) of nine patients in EXP3B, and 26 of 49 patients in EXP4-5.  The most common treatment-related adverse events across all patients were hypercholesterolemia (224 [81%] of 275 patients overall and 43 [16%] grade 3-4) and hypertriglyceridemia (166 [60%] overall and 43 [16%] grade 3-4).  Serious treatment-related adverse events occurred in 19 (7%) of 275 patients and seven patients (3%) permanently discontinued treatment because of treatment-related adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13AyVlJJCKrVg90H21EOLACvtfcHk0ljvuTpTVu31kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF&md5=0d47716d988ee784448e5cfc599cdef9</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930649-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930649-1%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DT.%2BM%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DSoo%26aufirst%3DR.%2BA%26aulast%3DCamidge%26aufirst%3DD%2BR.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DGadgeel%26aufirst%3DS.%2BM%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DJames%26aufirst%3DL.%2BP%26aulast%3DClancy%26aufirst%3DJ.%2BS%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DShaw%26aufirst%3DA.%2BT%26atitle%3DLorlatinib%2520in%2520patients%2520with%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%253A%2520results%2520from%2520a%2520global%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3D1654%26epage%3D1667%26doi%3D10.1016%2FS1470-2045%2818%2930649-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30680-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2817%2930680-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29074098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1590-1599&issue=12&author=A.+T.+Shawauthor=E.+Felipauthor=T.+M.+Bauerauthor=B.+Besseauthor=A.+Navarroauthor=S.+Postel-Vinayauthor=J.+F.+Gainorauthor=M.+Johnsonauthor=J.+Dietrichauthor=L.+P.+Jamesauthor=J.+S.+Clancyauthor=J.+Chenauthor=J.+F.+Martiniauthor=A.+Abbattistaauthor=B.+J.+Solomon&title=Lorlatinib+in+non-small-cell+lung+cancer+with+ALK+or+ROS1+rearrangement%3A+an+international%2C+multicentre%2C+open-label%2C+single-arm+first-in-man+phase+1+trial&doi=10.1016%2FS1470-2045%2817%2930680-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</span></div><div class="casAuthors">Shaw, Alice T.; Felip, Enriqueta; Bauer, Todd M.; Besse, Benjamin; Navarro, Alejandro; Postel-Vinay, Sophie; Gainor, Justin F.; Johnson, Melissa; Dietrich, Jorg; James, Leonard P.; Clancy, Jill S.; Chen, Joseph; Martini, Jean-Francois; Abbattista, Antonello; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1590-1599</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS.  This study aimed to analyze the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclin. activity against most known resistance mutations, in patients with advanced ALK-pos. or ROS1-pos. NSCLC.  In this international multicenter, open-label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-pos. or ROS1-pos. NSCLC and were older than 18 years, with an Eastern Cooperative Oncol. Group performance status of 0 or 1, and adequate end-organ function.  Lorlatinib was administered orally to patients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a min. of three patients receiving each dose.  For some patients, tumor biopsy was done before lorlatinib treatment to identify ALK resistance mutations.  Safety was assessed in patients who received at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment and had either ALK or ROS1 rearrangement).  The primary endpoint was dose-limiting toxicities during cycle 1 according to investigator assessment; secondary endpoints included safety, pharmacokinetics, and overall response.  This study is ongoing and is registered with ClinicalTrials.gov, no. NCT01970865.  Between Jan 22, 2014, and July 10, 2015, 54 patients received at least one dose of lorlatinib, including 41 (77%) with ALK-pos. and 12 (23%) with ROS1-pos. NSCLC; one patient had unconfirmed ALK and ROS1 status. 28 (52%) patients had received two or more TKIs, and 39 (72%) patients had CNS metastases.  The most common treatment-related adverse events among the 54 patients were hypercholesterolemia (39 [72%] of 54 patients), hypertriglyceridemia (21 [39%] of 54 patients), peripheral neuropathy (21 [39%] of 54 patients), and peripheral edema (21 [39%] of 54 patients).  One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributable to study drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation and word-finding difficulty).  No max. tolerated dose was identified.  The recommended phase 2 dose was selected as 100 mg once daily.  For ALK-pos. patients, the proportion of patients who achieved an objective response was 19 (46%) of 41 patients (95% CI 31-63); for those who had received two or more TKIs, the proportion of patients with an objective response was 11 (42%) of 26 patients (23-63).  In ROS1-pos. patients, including seven crizotinib-pretreated patients, an objective response was achieved by six (50%) of 12 patients (95% CI 21-79).  In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-pos. or ROS1-pos. NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.  Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-pos. NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomized controlled trial comparing lorlatinib to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU5uB3o0yZkrVg90H21EOLACvtfcHk0lgH18XjRHGLzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF&md5=aa28604c17c04fd005b70beda74ef2d6</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930680-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930680-0%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DClancy%26aufirst%3DJ.%2BS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26atitle%3DLorlatinib%2520in%2520non-small-cell%2520lung%2520cancer%2520with%2520ALK%2520or%2520ROS1%2520rearrangement%253A%2520an%2520international%252C%2520multicentre%252C%2520open-label%252C%2520single-arm%2520first-in-man%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D12%26spage%3D1590%26epage%3D1599%26doi%3D10.1016%2FS1470-2045%2817%2930680-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintanal-Villalonga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Pinelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirauqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojeda-Márquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrugal, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce-Aix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enguita, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30639621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=641-655&issue=4&author=A.+Quintanal-Villalongaauthor=S.+Molina-Pineloauthor=C.+Cirauquiauthor=L.+Ojeda-M%C3%A1rquezauthor=%C3%81.+Marrugalauthor=R.+Suarezauthor=E.+Condeauthor=S.+Ponce-Aixauthor=A.+B.+Enguitaauthor=A.+Carneroauthor=I.+Ferrerauthor=L.+Paz-Ares&title=FGFR1+Cooperates+with+EGFR+in+Lung+Cancer+Oncogenesis%2C+and+Their+Combined+Inhibition+Shows+Improved+Efficacy&doi=10.1016%2Fj.jtho.2018.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy</span></div><div class="casAuthors">Quintanal-Villalonga, Alvaro; Molina-Pinelo, Sonia; Cirauqui, Cristina; Ojeda-Marquez, Laura; Marrugal, Angela; Suarez, Rocio; Conde, Esther; Ponce-Aix, Santiago; Enguita, Ana Belen; Carnero, Amancio; Ferrer, Irene; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-655</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma.  We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays.  We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts.  We detd. FGFR1 mRNA expression in a cohort of patients with anti-EGFR therapy-treated adenocarcinoma.  We have reported a cooperative interaction between FGFR1 and EGFR in this context, resulting in increased EGFR activation and oncogenic signaling.  We have provided in vitro and in vivo evidence indicating that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in EGFR-mutated and EGFR wild-type models.  At the clin. level, we have shown that high FGFR1 expression levels predict higher resistance to erlotinib or gefitinib in a cohort of patients with tyrosine kinase inhibitor-treated EGFR-mutated and EGFR wild-type lung adenocarcinoma.  Dual EGFR and FGFR inhibition in FGFR1-overexpressing, EGFR-activated models shows synergistic effects on tumor growth in vitro and in cell line- and patient-derived xenografts, suggesting that patients with tumors bearing these characteristics may benefit from combined EGFR/FGFR inhibition.  These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJn8jLNuMQRLVg90H21EOLACvtfcHk0lgH18XjRHGLzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL&md5=d2a14b7b17cd9a65819d63760a7124e5</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DQuintanal-Villalonga%26aufirst%3DA.%26aulast%3DMolina-Pinelo%26aufirst%3DS.%26aulast%3DCirauqui%26aufirst%3DC.%26aulast%3DOjeda-M%25C3%25A1rquez%26aufirst%3DL.%26aulast%3DMarrugal%26aufirst%3D%25C3%2581.%26aulast%3DSuarez%26aufirst%3DR.%26aulast%3DConde%26aufirst%3DE.%26aulast%3DPonce-Aix%26aufirst%3DS.%26aulast%3DEnguita%26aufirst%3DA.%2BB.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DFGFR1%2520Cooperates%2520with%2520EGFR%2520in%2520Lung%2520Cancer%2520Oncogenesis%252C%2520and%2520Their%2520Combined%2520Inhibition%2520Shows%2520Improved%2520Efficacy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D641%26epage%3D655%26doi%3D10.1016%2Fj.jtho.2018.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Targeting <i>HER2</i> aberrations in non-small cell lung cancer with Osimertinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2594</span>– <span class="NLM_lpage">2604</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-1875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29298799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2594-2604&issue=11&author=S.+Liuauthor=S.+Liauthor=J.+Haiauthor=X.+Wangauthor=T.+Chenauthor=M.+M.+Quinnauthor=P.+Gaoauthor=Y.+Zhangauthor=H.+Jiauthor=D.+Crossauthor=K.+K.+Wong&title=Targeting+HER2+aberrations+in+non-small+cell+lung+cancer+with+Osimertinib&doi=10.1158%2F1078-0432.CCR-17-1875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib</span></div><div class="casAuthors">Liu, Shengwu; Li, Shuai; Hai, Josephine; Wang, Xiaoen; Chen, Ting; Quinn, Max M.; Gao, Peng; Zhang, Yanxi; Ji, Hongbin; Cross, Darren A. E.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2594-2604</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The HER2 (or ERBB2) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas.  The HER2 amplification is also an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  However, due to limited preclin. studies and clin. trials, currently there is still no available std. of care for lung cancer patients with HER2 aberrations.  To fulfill the clin. need for targeting HER2 in patients with non-small cell lung cancer (NSCLC), we performed a comprehensive preclin. study to evaluate the efficacy of a third-generation TKI, osimertinib (AZD9291).  Three genetically modified mouse models (GEMM) mimicking individual HER2 alterations in NSCLC were generated, and osimertinib was tested for its efficacy against these HER2 aberrations in vivo.  Osimertinib treatment showed robust efficacy in HER2 wt overexpression and EGFR del19/HER2 models, but not in HER2 exon 20 insertion tumors.  Interestingly, we further identified that combined treatment with osimertinib and the BET inhibitor JQ1 significantly increased the response rate in HER2-mutant NSCLC, whereas JQ1 single treatment did not show efficacy.  Overall, our data indicated robust antitumor efficacy of osimertinib against multiple HER2 aberrations in lung cancer, either as a single agent or in combination with JQ1.  Our study provides a strong rationale for future clin. trials using osimertinib either alone or in combination with epigenetic drugs to target aberrant HER2 in patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKfb04qUNTrVg90H21EOLACvtfcHk0lgH18XjRHGLzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnK&md5=2abb669debb9ef4dc000646879166dab</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1875%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DHai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DQuinn%26aufirst%3DM.%2BM.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DTargeting%2520HER2%2520aberrations%2520in%2520non-small%2520cell%2520lung%2520cancer%2520with%2520Osimertinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D11%26spage%3D2594%26epage%3D2604%26doi%3D10.1158%2F1078-0432.CCR-17-1875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Monica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cretella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumarola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digiacomo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flammini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">174</span>, <span class="refDoi"> DOI: 10.1186/s13046-017-0653-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs13046-017-0653-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29202823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1M3nslSqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=174&issue=1&author=S.+La+Monicaauthor=D.+Cretellaauthor=M.+Bonelliauthor=C.+Fumarolaauthor=A.+Cavazzoniauthor=G.+Digiacomoauthor=L.+Flamminiauthor=E.+Barocelliauthor=R.+Minariauthor=N.+Naldiauthor=P.+G.+Petroniniauthor=M.+Tiseoauthor=R.+Alfieri&title=Trastuzumab+emtansine+delays+and+overcomes+resistance+to+the+third-generation+EGFR-TKI+osimertinib+in+NSCLC+EGFR+mutated+cell+lines&doi=10.1186%2Fs13046-017-0653-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines</span></div><div class="casAuthors">La Monica Silvia; Cretella Daniele; Bonelli Mara; Fumarola Claudia; Cavazzoni Andrea; Digiacomo Graziana; Petronini Pier Giorgio; Alfieri Roberta; Flammini Lisa; Barocelli Elisabetta; Minari Roberta; Naldi Nadia; Tiseo Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients.  Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of resistance to osimertinib, this study was addressed to investigate the potential of combining osimertinib with trastuzumab emtansine (T-DM1) in order to improve the efficacy of osimertinib and delay or overcome resistance in NSCLC cell lines with EGFR activating mutation and with T790M mutation or HER-2 amplification.  METHODS:  The effects of osimertinib combined with T-DM1 on cell proliferation, cell cycle, cell death, antibody-dependent cell-mediated cytotoxicity (ADCC), and acquisition of osimertinib resistance was investigated in PC9, PC9-T790M and H1975 cell lines.  The potential of overcoming osimertinib resistance with T-DM1 was tested in a PC9/HER2c1 xenograft model.  RESULTS:  T-DM1 exerted an additive effect when combined with osimertinib in terms of inhibition of cell proliferation, cell death and ADCC induction in PC9, PC9-T790M and H1975 cell lines.  Combining osimertinib and T-DM1 using different schedules in long-term growth experiments revealed that the appearance of osimertinib-resistance was prevented in PC9-T790M and delayed in H1975 cells when the two drugs were given together.  By contrast, when osimertinib was followed by T-DM1 an antagonistic effect was observed on cell proliferation, cell death and resistance acquisition.  In xenograft models, we demonstrated that HER-2 amplification was associated with osimertinib-resistance and that T-DM1 co-administration is a potential strategy to overcome this resistance.  CONCLUSIONS:  Our data suggest that concomitant treatment with osimertinib and T-DM1 may be a promising therapeutic strategy for EGFR-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6nMGONSwIegxyojvcjibhfW6udTcc2eZ7MzCjoaoDsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3nslSqsQ%253D%253D&md5=b6febd4ec9d59ec0b20f34bb56510196</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1186%2Fs13046-017-0653-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-017-0653-7%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DCretella%26aufirst%3DD.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DDigiacomo%26aufirst%3DG.%26aulast%3DFlammini%26aufirst%3DL.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DNaldi%26aufirst%3DN.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DAlfieri%26aufirst%3DR.%26atitle%3DTrastuzumab%2520emtansine%2520delays%2520and%2520overcomes%2520resistance%2520to%2520the%2520third-generation%2520EGFR-TKI%2520osimertinib%2520in%2520NSCLC%2520EGFR%2520mutated%2520cell%2520lines%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D36%26issue%3D1%26spage%3D174%26doi%3D10.1186%2Fs13046-017-0653-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaguti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognetti, F.</span></span> <span> </span><span class="NLM_article-title">First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">104</span>, <span class="refDoi"> DOI: 10.1186/s13046-016-0380-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs13046-016-0380-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27357210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=104&author=A.+Fabiauthor=P.+Malagutiauthor=S.+Variauthor=F.+Cognetti&title=First-line+therapy+in+HER2+positive+metastatic+breast+cancer%3A+is+the+mosaic+fully+completed+or+are+we+missing+additional+pieces%3F&doi=10.1186%2Fs13046-016-0380-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?</span></div><div class="casAuthors">Fabi, Alessandra; Malaguti, Paola; Vari, Sabrina; Cognetti, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104/1-104/11</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biol. of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clin. outcomes for women with early-stage and advanced HER2-pos. breast cancer (BC).  HER-2 targeted therapies represent a major step forward in achieving the goal of delivering individualized targeted therapy for BC, and trastuzumab was the first anti-HER-2 strategy to be approved for treatment of HER-2 pos. BC.  This review discusses the treatment of metastatic HER2-pos. BC and describes efficacy and safety of novel anti-HER2 target therapies in first-line metastatic settings and the future challenges include refining such treatments, reducing toxicity and simultaneously developing innovative therapies.  Furthermore, combinations of trastuzumab and drugs targeting the downstream pathway are described.  In the next future will be possible to use an ample armamentarium of combination therapies directed against HER2 and key signaling components integrated in the HER network.  This approach will allow clinicians to tailor the management of the individual patient on the basis of tumor- specific biomarker profiles.  There is an urgent need for prospective biomarker-driven trials to identify patients for whom targeting is cost-effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0S74csgD1AbVg90H21EOLACvtfcHk0ljY0pgUhM51rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSlurY%253D&md5=11120955d5cf0da0a274fc6e59f1f335</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1186%2Fs13046-016-0380-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-016-0380-5%26sid%3Dliteratum%253Aachs%26aulast%3DFabi%26aufirst%3DA.%26aulast%3DMalaguti%26aufirst%3DP.%26aulast%3DVari%26aufirst%3DS.%26aulast%3DCognetti%26aufirst%3DF.%26atitle%3DFirst-line%2520therapy%2520in%2520HER2%2520positive%2520metastatic%2520breast%2520cancer%253A%2520is%2520the%2520mosaic%2520fully%2520completed%2520or%2520are%2520we%2520missing%2520additional%2520pieces%253F%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D35%26spage%3D104%26doi%3D10.1186%2Fs13046-016-0380-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vredenburgh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasser, J. S.</span></span> <i>Targeting HER2 in the treatment of non-small cell lung cancer.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2014.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2014.12.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mar%2C+N.%3B+Vredenburgh%2C+J.+J.%3B+Wasser%2C+J.+S.+Targeting+HER2+in+the+treatment+of+non-small+cell+lung+cancer.+2015%2C+87+%283%29%2C+220%E2%80%93225%2C+10.1016%2Fj.lungcan.2014.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2014.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2014.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DMar%26aufirst%3DN.%26aulast%3DVredenburgh%26aufirst%3DJ.%2BJ.%26aulast%3DWasser%26aufirst%3DJ.%2BS.%26jtitle%3DTargeting%2520HER2%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer.%26date%3D2015%26volume%3D87%26issue%3D3%26spage%3D220%26epage%3D225%26doi%3D10.1016%2Fj.lungcan.2014.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertran-Alamillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixidó, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellví, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzón, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony-Servat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony-Servat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giménez-Capitán, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viteri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Convergent AKT activation drives acquired EGFR inhibitor resistance in lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">410</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00450-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41467-017-00450-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28871105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cbks1Chuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=410&issue=1&author=K.+Jacobsenauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=C.+Teixid%C3%B3author=N.+Karachaliouauthor=M.+H.+Pedersenauthor=J.+Castellv%C3%ADauthor=M.+Garz%C3%B3nauthor=C.+Codony-Servatauthor=J.+Codony-Servatauthor=A.+Gim%C3%A9nez-Capit%C3%A1nauthor=A.+Drozdowskyjauthor=S.+Viteriauthor=M.+R.+Larsenauthor=U.+Lassenauthor=E.+Felipauthor=T.+G.+Bivonaauthor=H.+J.+Ditzelauthor=R.+Rosell&title=Convergent+AKT+activation+drives+acquired+EGFR+inhibitor+resistance+in+lung+cancer&doi=10.1038%2Fs41467-017-00450-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer</span></div><div class="casAuthors">Jacobsen Kirstine; Pedersen Martin Haar; Ditzel Henrik J; Bertran-Alamillo Jordi; Molina Miguel Angel; Teixido Cristina; Castellvi Josep; Garzon Monica; Codony-Servat Carles; Codony-Servat Jordi; Gimenez-Capitan Ana; Rosell Rafael; Karachaliou Niki; Drozdowskyj Ana; Viteri Santiago; Rosell Rafael; Larsen Martin R; Lassen Ulrik; Felip Enriqueta; Bivona Trever G; Bivona Trever G; Ditzel Henrik J; Rosell Rafael; Rosell Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">410</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment.  However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms.  The diversity and unpredictability of EGFR tyrosine kinase inhibitor resistance mechanisms presents a challenge for developing new treatments to overcome EGFR tyrosine kinase inhibitor resistance.  Here, we show that Akt activation is a convergent feature of acquired EGFR tyrosine kinase inhibitor resistance, across a spectrum of diverse, established upstream resistance mechanisms.  Combined treatment with an EGFR tyrosine kinase inhibitor and Akt inhibitor causes apoptosis and synergistic growth inhibition in multiple EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models.  Moreover, phospho-Akt levels are increased in most clinical specimens obtained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR tyrosine kinase inhibitor resistance.  Our findings provide a rationale for clinical trials testing Akt and EGFR inhibitor co-treatment in patients with elevated phospho-Akt levels to therapeutically combat the heterogeneity of EGFR tyrosine kinase inhibitor resistance mechanisms.EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment.  In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvWBwJCmQEN2gRQsDqrjW_fW6udTcc2eZsjx4phjDEc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbks1Chuw%253D%253D&md5=1c4b6432f5ae84679cba699b83389aec</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00450-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00450-6%26sid%3Dliteratum%253Aachs%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DC.%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DPedersen%26aufirst%3DM.%2BH.%26aulast%3DCastellv%25C3%25AD%26aufirst%3DJ.%26aulast%3DGarz%25C3%25B3n%26aufirst%3DM.%26aulast%3DCodony-Servat%26aufirst%3DC.%26aulast%3DCodony-Servat%26aufirst%3DJ.%26aulast%3DGim%25C3%25A9nez-Capit%25C3%25A1n%26aufirst%3DA.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DViteri%26aufirst%3DS.%26aulast%3DLarsen%26aufirst%3DM.%2BR.%26aulast%3DLassen%26aufirst%3DU.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DDitzel%26aufirst%3DH.%2BJ.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DConvergent%2520AKT%2520activation%2520drives%2520acquired%2520EGFR%2520inhibitor%2520resistance%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D410%26doi%3D10.1038%2Fs41467-017-00450-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torigoe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogoshi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span> <span> </span><span class="NLM_article-title">Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-0628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1541-7786.MCR-18-0628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30463991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=499-507&issue=2&author=K.+Nambaauthor=K.+Shienauthor=Y.+Takahashiauthor=H.+Torigoeauthor=H.+Satoauthor=T.+Yoshiokaauthor=T.+Takedaauthor=E.+Kuriharaauthor=Y.+Ogoshiauthor=H.+Yamamotoauthor=J.+Sohauthor=S.+Tomidaauthor=S.+Toyooka&title=Activation+of+AXL+as+a+preclinical+acquired+resistance+mechanism+against+osimertinib+treatment+in+EGFR-mutant+non-small+cell+lung+cancer+cells&doi=10.1158%2F1541-7786.MCR-18-0628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells</span></div><div class="casAuthors">Namba, Kei; Shien, Kazuhiko; Takahashi, Yuta; Torigoe, Hidejiro; Sato, Hiroki; Yoshioka, Takahiro; Takeda, Tatsuaki; Kurihara, Eisuke; Ogoshi, Yusuke; Yamamoto, Hiromasa; Soh, Junichi; Tomida, Shuta; Toyooka, Shinichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-507</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In this study, we exptl. established acquired osimertinib-resistant cell lines from EGFR-mutant NSCLC cell lines and investigated the mol. profiles of resistant cells to uncover the mechanisms of acquired resistance.  Various resistance mechanisms were identified, including the acquisition of MET amplification, EMT induction, and the upregulation of AXL.  Using targeted next-generation sequencing with a multigene panel, no secondary mutations were detected in our resistant cell lines.  Among three MET-amplified cell lines, one cell line was sensitive to a combination of osimertinib and crizotinib.  Acquired resistance cell lines derived from H1975 harboring the T790M mutation showed AXL upregulation, and the cell growth of these cell lines was suppressed by a combination of osimertinib and cabozantinib, an inhibitor of multiple tyrosine kinases including AXL, both in vitro and in vivo.  Our results suggest that AXL might be a therapeutic target for overcoming acquired resistance to osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop_sGYsYCpS7Vg90H21EOLACvtfcHk0li8zdqDQztJ5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCks7o%253D&md5=cc08acb1cddbc261dce0e12f42160b15</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-0628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-0628%26sid%3Dliteratum%253Aachs%26aulast%3DNamba%26aufirst%3DK.%26aulast%3DShien%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DTorigoe%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DTakeda%26aufirst%3DT.%26aulast%3DKurihara%26aufirst%3DE.%26aulast%3DOgoshi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DTomida%26aufirst%3DS.%26aulast%3DToyooka%26aufirst%3DS.%26atitle%3DActivation%2520of%2520AXL%2520as%2520a%2520preclinical%2520acquired%2520resistance%2520mechanism%2520against%2520osimertinib%2520treatment%2520in%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D499%26epage%3D507%26doi%3D10.1158%2F1541-7786.MCR-18-0628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimbo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haginoya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span> <span> </span><span class="NLM_article-title">DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.27114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31497246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrmtl2rtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5152-5167&issue=50&author=T.+Jimboauthor=M.+Hatanakaauthor=T.+Komatsuauthor=T.+Tairaauthor=K.+Kumazawaauthor=N.+Maedaauthor=T.+Suzukiauthor=M.+Otaauthor=N.+Haginoyaauthor=T.+Isoyamaauthor=K.+Fujiwara&title=DS-1205b%2C+a+novel+selective+inhibitor+of+AXL+kinase%2C+blocks+resistance+to+EGFR-tyrosine+kinase+inhibitors+in+a+non-small+cell+lung+cancer+xenograft+model&doi=10.18632%2Foncotarget.27114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model</span></div><div class="casAuthors">Jimbo Takeshi; Hatanaka Mana; Komatsu Takahiro; Taira Tomoe; Maeda Naoyuki; Haginoya Noriyasu; Isoyama Takeshi; Kumazawa Kentaro; Suzuki Takashi; Ota Masahiro; Fujiwara Kosaku</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5152-5167</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The AXL receptor tyrosine kinase is involved in signal transduction in malignant cells.  Recent studies have shown that the AXL upregulation underlies epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance in EGFR-mutant non-small cell lung cancer (NSCLC).  In this study, we investigated the effect of DS-1205b, a novel and selective inhibitor of AXL, on tumor growth and resistance to EGFR TKIs.  In AXL-overexpressing NIH3T3 cells, DS-1205b potently inhibited hGAS6 ligand-induced migration in vitro and exerted significant antitumor activity in vivo.  AXL was upregulated by long-term erlotinib or osimertinib treatment in HCC827 EGFR-mutant NSCLC cells, and DS-1205b treatment in combination with osimertinib or erlotinib effectively inhibited signaling downstream of EGFR in a cell-based assay.  In an HCC827 EGFR-mutant NSCLC xenograft mouse model, combination treatment with DS-1205b and erlotinib significantly delayed the onset of tumor resistance compared to erlotinib monotherapy, and DS-1205b restored the antitumor activity of erlotinib in erlotinib-resistant tumors.  DS-1205b also delayed the onset of resistance when used in combination with osimertinib in the model.  These findings strongly suggest that DS-1205b can prolong the therapeutic benefit of EGFR TKIs in nonclinical as well as clinical settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTA9vLx95SNZtXdcedVHT5tfW6udTcc2eZsjx4phjDEc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrmtl2rtA%253D%253D&md5=794e388a2bcdec6a2bce13357cccede8</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27114%26sid%3Dliteratum%253Aachs%26aulast%3DJimbo%26aufirst%3DT.%26aulast%3DHatanaka%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DT.%26aulast%3DTaira%26aufirst%3DT.%26aulast%3DKumazawa%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOta%26aufirst%3DM.%26aulast%3DHaginoya%26aufirst%3DN.%26aulast%3DIsoyama%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DK.%26atitle%3DDS-1205b%252C%2520a%2520novel%2520selective%2520inhibitor%2520of%2520AXL%2520kinase%252C%2520blocks%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520xenograft%2520model%26jtitle%3DOncotarget%26date%3D2019%26volume%3D10%26issue%3D50%26spage%3D5152%26epage%3D5167%26doi%3D10.18632%2Foncotarget.27114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, T.-T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span> <span> </span><span class="NLM_article-title">Abstract 337: Degradation of AXL overcome acquired cross-resistance to Gefitinib and osimertinib in non-small cell lung cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">337</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1538-7445.AM2019-337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=337&author=D.+Kimauthor=D.-H.+Bachauthor=Y.-h.+Fanauthor=T.-T.-T.+Luuauthor=J.-Y.+Hongauthor=H.-J.+Parkauthor=S.+K.+Lee&title=Abstract+337%3A+Degradation+of+AXL+overcome+acquired+cross-resistance+to+Gefitinib+and+osimertinib+in+non-small+cell+lung+cancer+cells&doi=10.1158%2F1538-7445.AM2019-337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-337%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DD.-H.%26aulast%3DFan%26aufirst%3DY.-h.%26aulast%3DLuu%26aufirst%3DT.-T.-T.%26aulast%3DHong%26aufirst%3DJ.-Y.%26aulast%3DPark%26aufirst%3DH.-J.%26aulast%3DLee%26aufirst%3DS.%2BK.%26atitle%3DAbstract%2520337%253A%2520Degradation%2520of%2520AXL%2520overcome%2520acquired%2520cross-resistance%2520to%2520Gefitinib%2520and%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2019%26spage%3D337%26doi%3D10.1158%2F1538-7445.AM2019-337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. Y.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signalling in lung cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>145</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1002/ijc.32487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fijc.32487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31162839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1eku7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2019&pages=1609-1624&issue=6&author=Y.+N.+Liuauthor=M.+F.+Tsaiauthor=S.+G.+Wuauthor=T.+H.+Changauthor=T.+H.+Tsaiauthor=C.+H.+Gowauthor=Y.+L.+Changauthor=J.+Y.+Shih&title=Acquired+resistance+to+EGFR+tyrosine+kinase+inhibitors+is+mediated+by+the+reactivation+of+STC2%2FJUN%2FAXL+signalling+in+lung+cancer&doi=10.1002%2Fijc.32487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer</span></div><div class="casAuthors">Liu, Yi-Nan; Tsai, Meng-Feng; Wu, Shang-Gin; Chang, Tzu-Hua; Tsai, Tzu-Hsiu; Gow, Chien-Hung; Chang, Yih-Leong; Shih, Jin-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1609-1624</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the std. treatment for nonsmall cell lung cancer (NSCLC) patients.  However, acquired resistance to these agents remains a major obstacle for managing NSCLC.  Here, we investigated a novel strategy to overcome EGFR TKI resistance by targeting the stanniocalcin 2 (STC2)-JUN-AXL pathway.  We revealed that STC2 was expressed at significantly higher levels in EGFR TKI-resistant cells.  Further, clin. anal. showed that STC2 expression was increased after the development of EGFR TKI resistance which correlated with shorter PFS in EGFR TKI-treated lung cancer patients.  Moreover, STC2 overexpression in EGFR TKI-sensitive cells resulted in EGFR TKI resistance.  Conversely, genetic silencing of STC2 rendered EGFR TKI-resistant cells more sensitive to EGFR TKIs.  Mech., STC2 enhanced AXL promoter activity by increasing the phosphorylation of c-Jun, which is an indispensable transcription factor that transactivates AXL.  STC2 promoted activation of the JUN-AXL-ERK signaling axis in lung cancer cells.  We also demonstrated that PE2988 cells, a C797S-independent osimertinib-resistant primary cancer cell line from a lung cancer patient, responded to combined AXL inhibitor and osimertinib treatment.  In conclusion, our research indicates that STC2 overexpression is important for acquired resistance to EGFR TKIs and that STC2-JUN-AXL-ERK signaling might be a potential therapeutic target to overcome resistance to EGFR TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv-LqEfzhGQ7Vg90H21EOLACvtfcHk0lhhgUxJna24fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1eku7vM&md5=88b8f3f6511981702b4a77ef0c7bf7bb</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1002%2Fijc.32487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32487%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BN.%26aulast%3DTsai%26aufirst%3DM.%2BF.%26aulast%3DWu%26aufirst%3DS.%2BG.%26aulast%3DChang%26aufirst%3DT.%2BH.%26aulast%3DTsai%26aufirst%3DT.%2BH.%26aulast%3DGow%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DShih%26aufirst%3DJ.%2BY.%26atitle%3DAcquired%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520is%2520mediated%2520by%2520the%2520reactivation%2520of%2520STC2%252FJUN%252FAXL%2520signalling%2520in%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D145%26issue%3D6%26spage%3D1609%26epage%3D1624%26doi%3D10.1002%2Fijc.32487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquet, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quoix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30146-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2816%2930146-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslyjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=984-993&issue=7&author=D.+Planchardauthor=B.+Besseauthor=H.+J.+Groenauthor=P.+J.+Souquetauthor=E.+Quoixauthor=C.+S.+Baikauthor=F.+Barlesiauthor=T.+M.+Kimauthor=J.+Mazieresauthor=S.+Novello&title=Dabrafenib+plus+trametinib+in+patients+with+previously+treated+BRAFV600E-mutant+metastatic+non-small+cell+lung+cancer%3A+an+open-label%2C+multicentre+phase+2+trial&doi=10.1016%2FS1470-2045%2816%2930146-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial</span></div><div class="casAuthors">Planchard, David; Besse, Benjamin; Groen, Harry J. M.; Souquet, Pierre-Jean; Quoix, Elisabeth; Baik, Christina S.; Barlesi, Fabrice; Kim, Tae Min; Mazieres, Julien; Novello, Silvia; Rigas, James R.; Upalawanna, Allison; D'Amelio, Anthony M. Jr; Zhang, Pingkuan; Mookerjee, Bijoyesh; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-993</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC).  BRAF inhibition has shown antitumor activity in patients with BRAFV600E-mutant NSCLC.  Dual MAPK pathway inhibition with BRAF and MEK inhibitors in BRAFV600E-mutant NSCLC might improve efficacy over BRAF inhibitor monotherapy based on observations in BRAFV600-mutant melanoma.  We aimed to assess the antitumor activity and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutant NSCLC.  In this phase 2, multicentre, non-randomized, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAFV600E-mutant NSCLC who had documented tumor progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.  Patients with previous BRAF or MEK inhibitor treatment were ineligible.  Patients with brain metastases were allowed to enroll only if the lesions were asymptomatic, untreated (or stable more than 3 wk after local therapy if treated), and measured less than 1 cm.  Enrolled patients received oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) in continuous 21-day cycles until disease progression, unacceptable adverse events, withdrawal of consent, or death.  The primary endpoint was investigator-assessed overall response, which was assessed by intention to treat in the protocol-defined population (patients who received second-line or later treatment); safety was also assessed in this population and was assessed at least once every 3 wk, with adverse events, lab. values, and vital signs graded according to the Common Terminol. Criteria for Adverse Events version 4.0.  The study is ongoing but no longer recruiting patients.  This trial is registered with ClinicalTrials.gov, no. NCT01336634.  Between Dec 20, 2013, and Jan 14, 2015, 59 patients from 30 centers in nine countries across North America, Europe, and Asia met eligibility criteria.  Two patients who had previously been untreated due to protocol deviation were excluded; thus, 57 eligible patients were enrolled. 36 patients (63·2% [95% CI 49·3-75·6]) achieved an investigator-assessed overall response.  Serious adverse events were reported in 32 (56%) of 57 patients and included pyrexia in nine (16%), anemia in three (5%), confusional state in two (4%), decreased appetite in two (4%), hemoptysis in two (4%), hypercalcemia in two (4%), nausea in two (4%), and cutaneous squamous cell carcinoma in two (4%).  The most common grade 3-4 adverse events were neutropenia in five patients (9%), hyponatremia in four (7%), and anemia in three (5%).  Four patients died during the study from fatal adverse events judged to be unrelated to treatment (one retroperitoneal hemorrhage, one subarachnoid hemorrhage, one respiratory distress, and one from disease progression that was more severe than typical progression, as assessed by the investigator).  Dabrafenib plus trametinib could represent a new targeted therapy with robust antitumor activity and a manageable safety profile in patients with BRAFV600E-mutant NSCLC.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-qPV5AvwdnrVg90H21EOLACvtfcHk0lhhgUxJna24fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslyjsL8%253D&md5=322443578a05f7f30ed21427413b38ca</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930146-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930146-2%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DGroen%26aufirst%3DH.%2BJ.%26aulast%3DSouquet%26aufirst%3DP.%2BJ.%26aulast%3DQuoix%26aufirst%3DE.%26aulast%3DBaik%26aufirst%3DC.%2BS.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DNovello%26aufirst%3DS.%26atitle%3DDabrafenib%2520plus%2520trametinib%2520in%2520patients%2520with%2520previously%2520treated%2520BRAFV600E-mutant%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%253A%2520an%2520open-label%252C%2520multicentre%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D7%26spage%3D984%26epage%3D993%26doi%3D10.1016%2FS1470-2045%2816%2930146-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chih-Hsin Yang, J.</span></span> <span> </span><span class="NLM_article-title">Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.2231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.2231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27923714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=567-572&issue=3&author=C.-C.+Hoauthor=W.-Y.+Liaoauthor=C.-A.+Linauthor=J.-Y.+Shihauthor=C.-J.+Yuauthor=J.+Chih-Hsin+Yang&title=Acquired+BRAF+V600E+mutation+as+resistant+mechanism+after+treatment+with+osimertinib&doi=10.1016%2Fj.jtho.2016.11.2231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib</span></div><div class="casAuthors">Ho Chao-Chi; Liao Wei-Yu; Shih Jin-Yuan; Yu Chong-Jen; Lin Chih-An; Yang James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-572</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used.  Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified.  It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment.  METHODS:  Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib.  Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry.  EGFR, AKT, MEK, and ERK phosphorylation were determined.  An anchorage-dependent colony formation assay was used for drug sensitivity.  RESULTS:  An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib.  Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib.  CONCLUSIONS:  A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway.  Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyyK7fCSkFDQ8IxFYvehhofW6udTcc2ebEDhmxBsDPMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D&md5=b4d27a7ed29dfc9f3470175998e3b529</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.2231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.2231%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DC.-C.%26aulast%3DLiao%26aufirst%3DW.-Y.%26aulast%3DLin%26aufirst%3DC.-A.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DChih-Hsin%2BYang%26aufirst%3DJ.%26atitle%3DAcquired%2520BRAF%2520V600E%2520mutation%2520as%2520resistant%2520mechanism%2520after%2520treatment%2520with%2520osimertinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.jtho.2016.11.2231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ready, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vokes, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhaufl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrieta, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgio, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poddubskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbison, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf
Finckenstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span> <span> </span><span class="NLM_article-title">Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1507643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26412456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFyitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1627-1639&issue=17&author=H.+Borghaeiauthor=L.+Paz-Aresauthor=L.+Hornauthor=D.+R.+Spigelauthor=M.+Steinsauthor=N.+E.+Readyauthor=L.+Q.+Chowauthor=E.+E.+Vokesauthor=E.+Felipauthor=E.+Holgadoauthor=F.+Barlesiauthor=M.+Kohlhauflauthor=O.+Arrietaauthor=M.+A.+Burgioauthor=J.+Fayetteauthor=H.+Lenaauthor=E.+Poddubskayaauthor=D.+E.+Gerberauthor=S.+N.+Gettingerauthor=C.+M.+Rudinauthor=N.+Rizviauthor=L.+Crinoauthor=G.+R.+Blumenscheinauthor=S.+J.+Antoniaauthor=C.+Dorangeauthor=C.+T.+Harbisonauthor=F.+Graf%0AFinckensteinauthor=J.+R.+Brahmer&title=Nivolumab+versus+Docetaxel+in+advanced+nonsquamous+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1507643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer</span></div><div class="casAuthors">Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D. R.; Steins, M.; Ready, N. E.; Chow, L. Q.; Vokes, E. E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhaufl, M.; Arrieta, O.; Burgio, M. A.; Fayette, J.; Lena, H.; Poddubskaya, E.; Gerber, D. E.; Gettinger, S. N.; Rudin, C. M.; Rizvi, N.; Crino, L.; Blumenschein, G. R., Jr.; Antonia, S. J.; Dorange, C.; Harbison, C. T.; Finckenstein, F. Graf; Brahmer, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1627-1639</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.  In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kg of body wt. every 2 wk or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 wk.  The primary end point was overall survival.  Overall survival was longer with nivolumab than with docetaxel.  The median overall survival was 12.2 mo (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 mo (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P = 0.002).  At 1 yr, the overall survival rate was 51% (95% CI, 45 to 56) with nivolumab vs. 39% (95% CI, 33 to 45) with docetaxel.  With addnl. follow-up, the overall survival rate at 18 mo was 39% (95% CI, 34 to 45) with nivolumab vs. 23% (95% CI, 19 to 28) with docetaxel.  The response rate was 19% with nivolumab vs. 12% with docetaxel (P = 0.02).  Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 mo and 4.2 mo, resp.), the rate of progression-free survival at 1 yr was higher with nivolumab than with docetaxel (19% and 8%, resp.).  Nivolumab was assocd. with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1%, ≥5%, and ≥10%) of the PD-1 ligand.  Treatment-related adverse events of grade 3 or 4 were reported in 10% of the patients in the nivolumab group, as compared with 54% of those in the docetaxel group.  Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo74iHTHau0bbVg90H21EOLACvtfcHk0ljBYLArjm7q0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFyitL0%253D&md5=b1fd759688c5dd8a28ac9709beaeab9e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507643%26sid%3Dliteratum%253Aachs%26aulast%3DBorghaei%26aufirst%3DH.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DReady%26aufirst%3DN.%2BE.%26aulast%3DChow%26aufirst%3DL.%2BQ.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DHolgado%26aufirst%3DE.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DKohlhaufl%26aufirst%3DM.%26aulast%3DArrieta%26aufirst%3DO.%26aulast%3DBurgio%26aufirst%3DM.%2BA.%26aulast%3DFayette%26aufirst%3DJ.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DPoddubskaya%26aufirst%3DE.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DRizvi%26aufirst%3DN.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DDorange%26aufirst%3DC.%26aulast%3DHarbison%26aufirst%3DC.%2BT.%26aulast%3DGraf%2BFinckenstein%26aufirst%3DF.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26atitle%3DNivolumab%2520versus%2520Docetaxel%2520in%2520advanced%2520nonsquamous%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D17%26spage%3D1627%26epage%3D1639%26doi%3D10.1056%2FNEJMoa1507643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhardt, W. E.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poddubskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vokes, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ready, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aren Frontera, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudelet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbison, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span> <span> </span><span class="NLM_article-title">Nivolumab versus Docetaxel in Advanced squamous-cell non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1504627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1504627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26028407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12qu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=123-135&issue=2&author=J.+Brahmerauthor=K.+L.+Reckampauthor=P.+Baasauthor=L.+Crinoauthor=W.+E.E.+Eberhardtauthor=E.+Poddubskayaauthor=S.+Antoniaauthor=A.+Pluzanskiauthor=E.+E.+Vokesauthor=E.+Holgadoauthor=D.+Waterhouseauthor=N.+Readyauthor=J.+Gainorauthor=O.+Aren+Fronteraauthor=L.+Havelauthor=M.+Steinsauthor=M.+C.+Garassinoauthor=J.+G.+Aertsauthor=M.+Domineauthor=L.+Paz-Aresauthor=M.+Reckauthor=C.+Baudeletauthor=C.+T.+Harbisonauthor=B.+Lestiniauthor=D.+R.+Spigel&title=Nivolumab+versus+Docetaxel+in+Advanced+squamous-cell+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1504627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer</span></div><div class="casAuthors">Brahmer, Julie; Reckamp, Karen L.; Baas, Paul; Crino, Lucio; Eberhardt, Wilfried E. E.; Poddubskaya, Elena; Antonia, Scott; Pluzanski, Adam; Vokes, Everett E.; Holgado, Esther; Waterhouse, David; Ready, Neal; Gainor, Justin; Frontera, Osvaldo Aren; Havel, Libor; Steins, Martin; Garassino, Marina C.; Aerts, Joachim G.; Domine, Manuel; Paz-Ares, Luis; Reck, Martin; Baudelet, Christine; Harbison, Christopher T.; Lestini, Brian; Spigel, David R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-135</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options.  This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population.  We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kg of body wt. every 2 wk, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 wk.  The primary end point was overall survival.  The median overall survival was 9.2 mo (95% confidence interval [CI], 7.3 to 13.3) with nivolumab vs. 6.0 mo (95% CI, 5.1 to 7.3) with docetaxel.  The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001).  At 1 yr, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab vs. 24% (95% CI, 17 to 31) with docetaxel.  The response rate was 20% with nivolumab vs. 9% with docetaxel (P = 0.008).  The median progression-free survival was 3.5 mo with nivolumab vs. 2.8 mo with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001).  The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit.  Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group.  Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhe7kKOA6JD7Vg90H21EOLACvtfcHk0ljBYLArjm7q0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12qu7%252FJ&md5=7428b27bffceddd6e119fcbb7a5b4177</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1504627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1504627%26sid%3Dliteratum%253Aachs%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DBaas%26aufirst%3DP.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.E.%26aulast%3DPoddubskaya%26aufirst%3DE.%26aulast%3DAntonia%26aufirst%3DS.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHolgado%26aufirst%3DE.%26aulast%3DWaterhouse%26aufirst%3DD.%26aulast%3DReady%26aufirst%3DN.%26aulast%3DGainor%26aufirst%3DJ.%26aulast%3DAren%2BFrontera%26aufirst%3DO.%26aulast%3DHavel%26aufirst%3DL.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DGarassino%26aufirst%3DM.%2BC.%26aulast%3DAerts%26aufirst%3DJ.%2BG.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DBaudelet%26aufirst%3DC.%26aulast%3DHarbison%26aufirst%3DC.%2BT.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DNivolumab%2520versus%2520Docetaxel%2520in%2520Advanced%2520squamous-cell%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D2%26spage%3D123%26epage%3D135%26doi%3D10.1056%2FNEJMoa1504627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Gracia, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shentu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span> (<span class="NLM_issue">10027</span>),  <span class="NLM_fpage">1540</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)01281-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS0140-6736%2815%2901281-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26712084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1540-1550&issue=10027&author=R.+S.+Herbstauthor=P.+Baasauthor=D.+W.+Kimauthor=E.+Felipauthor=J.+L.+P%C3%A9rez-Graciaauthor=J.+Y.+Hanauthor=J.+Molinaauthor=J.+H.+Kimauthor=C.+D.+Arvisauthor=M.+J.+Ahnauthor=M.+Majemauthor=M.+J.+Fidlerauthor=G.+de+Castroauthor=M.+Garridoauthor=G.+M.+Lubinieckiauthor=Y.+Shentuauthor=E.+Imauthor=M.+Dolled-Filhartauthor=E.+B.+Garon&title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2815%2901281-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span></div><div class="casAuthors">Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto Jr; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10027</span>),
    <span class="NLM_cas:pages">1540-1550</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease.  We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  We did this randomised, open-label, phase 2/3 study at 202 academic medical centers in 24 countries.  Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumor cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 wk.  The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumor cells.  We used a threshold for significance of p<0·00825 (one-sided) for the anal. of overall survival and a threshold of p<0·001 for progression-free survival.  This trial is registered at ClinicalTrials.gov, no. NCT01905657.  Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel.  By Sept 30, 2015, 521 patients had died.  In the total population, median overall survival was 10·4 mo with pembrolizumab 2 mg/kg, 12·7 mo with pembrolizumab 10 mg/kg, and 8·5 mo with docetaxel.  Overall survival was significantly longer for pembrolizumab 2 mg/kg vs. docetaxel (hazard ratio [HR] 0·71, 95% CI 0·58-0·88; p=0·0008) and for pembrolizumab 10 mg/kg vs. docetaxel (0·61, 0·49-0·75; p<0·0001).  Median progression-free survival was 3·9 mo with pembrolizumab 2 mg/kg, 4·0 mo with pembrolizumab 10 mg/kg, and 4·0 mo with docetaxel, with no significant difference for pembrolizumab 2 mg/kg vs. docetaxel (0·88, 0·74-1·05; p=0·07) or for pembrolizumab 10 mg/kg vs. docetaxel (HR 0·79, 95% CI 0·66-0·94; p=0·004).  Among patients with at least 50% of tumor cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14·9 mo vs 8·2 mo; HR 0·54, 95% CI 0·38-0·77; p=0·0002) and with pembrolizumab 10 mg/kg than with docetaxel (17·3 mo vs 8·2 mo; 0·50, 0·36-0·70; p<0·0001).  Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5·0 mo vs 4·1 mo; HR 0·59, 95% CI 0·44-0·78; p=0·0001) and with pembrolizumab 10 mg/kg than with docetaxel (5·2 mo vs 4·1 mo; 0·59, 0·45-0·78; p<0·0001).  Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel).  Pembrolizumab prolongs overall survival and has a favorable benefit-to-risk profile in patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection.Merck & Co.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnxRttuwvktbVg90H21EOLACvtfcHk0lhB4a6K7Ddjhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI&md5=333bd6a558ec0f3716e15a2a96b2c02f</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252901281-7%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBaas%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DP%25C3%25A9rez-Gracia%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DMolina%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DFidler%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DShentu%26aufirst%3DY.%26aulast%3DIm%26aufirst%3DE.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26atitle%3DPembrolizumab%2520versus%2520docetaxel%2520for%2520previously%2520treated%252C%2520PD-L1-positive%252C%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528KEYNOTE-010%2529%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26issue%3D10027%26spage%3D1540%26epage%3D1550%26doi%3D10.1016%2FS0140-6736%2815%2901281-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rittmeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterkamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Pawel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dols, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polikoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frontera, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turna, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandara, D. R</span></span> <span> </span><span class="NLM_article-title">Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span> (<span class="NLM_issue">10066</span>),  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(16)32517-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS0140-6736%2816%2932517-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27979383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FkvFCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=255-265&issue=10066&author=A.+Rittmeyerauthor=F.+Barlesiauthor=D.+Waterkampauthor=K.+Parkauthor=F.+Ciardielloauthor=J.+von+Pawelauthor=S.+M+Gadgeelauthor=T.+Hidaauthor=D.+M+Kowalskiauthor=M.+C.+Dolsauthor=D.+L+Cortinovisauthor=J.+Leachauthor=J.+Polikoffauthor=C.+Barriosauthor=F.+Kabbinavarauthor=O.+A.+Fronteraauthor=F.+De+Marinisauthor=H.+Turnaauthor=J.-S.+Leeauthor=M.+Ballingerauthor=M.+Kowanetzauthor=P.+Heauthor=D.+S+Chenauthor=A.+Sandlerauthor=D.+R+Gandara&title=Atezolizumab+versus+docetaxel+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28OAK%29%3A+a+phase+3%2C+open-label%2C+multicentre+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2816%2932517-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial</span></div><div class="casAuthors">Rittmeyer Achim; Barlesi Fabrice; Waterkamp Daniel; Ballinger Marcus; Kowanetz Marcin; He Pei; Chen Daniel S; Sandler Alan; Park Keunchil; Ciardiello Fortunato; von Pawel Joachim; Gadgeel Shirish M; Hida Toyoaki; Kowalski Dariusz M; Dols Manuel Cobo; Cortinovis Diego L; Leach Joseph; Polikoff Jonathan; Barrios Carlos; Kabbinavar Fairooz; Frontera Osvaldo Aren; De Marinis Filippo; Turna Hande; Lee Jong-Seok; Gandara David R</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10066</span>),
    <span class="NLM_cas:pages">255-265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity.  We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.  METHODS:  We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries.  We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1.  Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.  Patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded.  Patients were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 mg/m(2) every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or web response system.  Coprimary endpoints were overall survival in the intention-to-treat (ITT) and PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating immune cells).  The primary efficacy analysis was done in the first 850 of 1225 enrolled patients.  This study is registered with ClinicalTrials.gov, number NCT02008227.  FINDINGS:  Between March 11, 2014, and April 29, 2015, 1225 patients were recruited.  In the primary population, 425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to receive docetaxel.  Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations.  In the ITT population, overall survival was improved with atezolizumab compared with docetaxel (median overall survival was 13·8 months [95% CI 11·8-15·7] vs 9·6 months [8·6-11·2]; hazard ratio [HR] 0·73 [95% CI 0·62-0·87], p=0·0003).  Overall survival in the TC1/2/3 or IC1/2/3 population was improved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15·7 months [95% CI 12·6-18·0] with atezolizumab vs 10·3 months [8·8-12·0] with docetaxel; HR 0·74 [95% CI 0·58-0·93]; p=0·0102).  Patients in the PD-L1 low or undetectable subgroup (TC0 and IC0) also had improved survival with atezolizumab (median overall survival 12·6 months vs 8·9 months; HR 0·75 [95% CI 0·59-0·96]).  Overall survival improvement was similar in patients with squamous (HR 0·73 [95% CI 0·54-0·98]; n=112 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0·73 [0·60-0·89]; n=313 and n=315) histology.  Fewer patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients).  One treatment-related death from a respiratory tract infection was reported in the docetaxel group.  INTERPRETATION:  To our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology, with a favourable safety profile.  FUNDING:  F.  Hoffmann-La Roche Ltd, Genentech, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1bi5vtdP5pf9pSBfyDvp7fW6udTcc2eb4sHPn-kOfrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FkvFCmtg%253D%253D&md5=664efa0c7f7e9e48d6df33539088a5de</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932517-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932517-X%26sid%3Dliteratum%253Aachs%26aulast%3DRittmeyer%26aufirst%3DA.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DWaterkamp%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGadgeel%26aufirst%3DS.%2BM%26aulast%3DHida%26aufirst%3DT.%26aulast%3DKowalski%26aufirst%3DD.%2BM%26aulast%3DDols%26aufirst%3DM.%2BC.%26aulast%3DCortinovis%26aufirst%3DD.%2BL%26aulast%3DLeach%26aufirst%3DJ.%26aulast%3DPolikoff%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DKabbinavar%26aufirst%3DF.%26aulast%3DFrontera%26aufirst%3DO.%2BA.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26aulast%3DTurna%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DBallinger%26aufirst%3DM.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DD.%2BS%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DGandara%26aufirst%3DD.%2BR%26atitle%3DAtezolizumab%2520versus%2520docetaxel%2520in%2520patients%2520with%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%2520%2528OAK%2529%253A%2520a%2520phase%25203%252C%2520open-label%252C%2520multicentre%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26issue%3D10066%26spage%3D255%26epage%3D265%26doi%3D10.1016%2FS0140-6736%2816%2932517-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forde, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span> <span> </span><span class="NLM_article-title">Antagonists of PD-1 and PD-L1 in cancer treatment</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2015.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1053%2Fj.seminoncol.2015.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26320063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=587-600&issue=4&author=E.+J.+Lipsonauthor=P.+M.+Fordeauthor=H.+J.+Hammersauthor=L.+A.+Emensauthor=J.+M.+Taubeauthor=S.+L.+Topalian&title=Antagonists+of+PD-1+and+PD-L1+in+cancer+treatment&doi=10.1053%2Fj.seminoncol.2015.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of PD-1 and PD-L1 in Cancer Treatment</span></div><div class="casAuthors">Lipson, Evan J.; Forde, Patrick M.; Hammers, Hans-Joerg; Emens, Leisha A.; Taube, Janis M.; Topalian, Suzanne L.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment.  Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have demonstrated clin. activity in several types of advanced cancers, validating this pathway as a target for cancer therapy.  Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for addnl. cancer types are anticipated.  The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies.  Ongoing studies aim to identify biomarkers to guide patient selection, which would further improve the risk:benefit ratio for these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7CUgfoXsUXbVg90H21EOLACvtfcHk0lh2TdokIG7Iuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3I&md5=a34efc1ccb91868a941c42b389fffd76</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DE.%2BJ.%26aulast%3DForde%26aufirst%3DP.%2BM.%26aulast%3DHammers%26aufirst%3DH.%2BJ.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26atitle%3DAntagonists%2520of%2520PD-1%2520and%2520PD-L1%2520in%2520cancer%2520treatment%26jtitle%3DSemin.%2520Oncol.%26date%3D2015%26volume%3D42%26issue%3D4%26spage%3D587%26epage%3D600%26doi%3D10.1053%2Fj.seminoncol.2015.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elassaiss-Schaap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boasberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1305133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1305133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23724846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=134-144&issue=2&author=O.+Hamidauthor=C.+Robertauthor=A.+Daudauthor=F.+S.+Hodiauthor=W.-J.+Hwuauthor=R.+Keffordauthor=J.+D.+Wolchokauthor=P.+Herseyauthor=R.+W.+Josephauthor=J.+S.+Weberauthor=R.+Droncaauthor=T.+C.+Gangadharauthor=A.+Patnaikauthor=H.+Zarourauthor=A.+M.+Joshuaauthor=K.+Gergichauthor=J.+Elassaiss-Schaapauthor=A.+Algaziauthor=C.+Mateusauthor=P.+Boasbergauthor=P.+C.+Tumehauthor=B.+Chmielowskiauthor=S.+W.+Ebbinghausauthor=X.+N.+Liauthor=S.+P.+Kangauthor=A.+Ribas&title=Safety+and+tumor+responses+with+lambrolizumab+%28anti-PD-1%29+in+melanoma&doi=10.1056%2FNEJMoa1305133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</span></div><div class="casAuthors">Hamid, Omid; Robert, Caroline; Daud, Adil; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard; Wolchok, Jedd D.; Mersey, Peter; Joseph, Richard W.; Weber, Jeffrey S.; Dronca, Roxana; Gangadhar, Tara C.; Patnaik, Amita; Zarour, Hassane; Joshua, Anthony M.; Gergich, Kevin; Elassaiss-Schaap, Jeroen; Algazi, Alain; Mateus, Christine; Boasberg, Peter; Tumeh, Paul C.; Chmielowski, Bartosz; Ebbinghaus, Scot W.; Li, Xiaoyun Nicole; Kang, S. Peter; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-144</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The programmed death 1 (PD-1) receptor is a neg. regulator of T-cell effector mechanisms that limits immune responses against cancer.  The authors tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.  The authors administered lambrolizumab i.v. at a dose of 10 mg per kg of body wt. every 2 or 3 wk or 2 mg per kg every 3 wk in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not.  Tumor responses were assessed every 12 wk.  A total of 135 patients with advanced melanoma were treated.  Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade.  The confirmed response rate across all dose cohorts, evaluated by central radiol. review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate obsd. in the cohort that received 10 mg per kg every 2 wk (52%; 95% CI, 38 to 66).  The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], resp.).  Responses were durable in the majority of patients (median follow-up, 11 mo among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of anal. in March 2013.  The overall median progression-free survival among the 135 patients was longer than 7 mo.  In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX32-HobXKEbVg90H21EOLACvtfcHk0lh2TdokIG7Iuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP&md5=e325ca09569a6e2786f0523f197fd8c2</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1305133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1305133%26sid%3Dliteratum%253Aachs%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DHwu%26aufirst%3DW.-J.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DDronca%26aufirst%3DR.%26aulast%3DGangadhar%26aufirst%3DT.%2BC.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DZarour%26aufirst%3DH.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DGergich%26aufirst%3DK.%26aulast%3DElassaiss-Schaap%26aufirst%3DJ.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DBoasberg%26aufirst%3DP.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DEbbinghaus%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DKang%26aufirst%3DS.%2BP.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSafety%2520and%2520tumor%2520responses%2520with%2520lambrolizumab%2520%2528anti-PD-1%2529%2520in%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D2%26spage%3D134%26epage%3D144%26doi%3D10.1056%2FNEJMoa1305133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leming, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiller, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span> <span> </span><span class="NLM_article-title">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1200690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22658127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2443-2454&issue=26&author=S.+L.+Topalianauthor=F.+S.+Hodiauthor=J.+R.+Brahmerauthor=S.+N.+Gettingerauthor=D.+C.+Smithauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=R.+D.+Carvajalauthor=J.+A.+Sosmanauthor=M.+B.+Atkinsauthor=P.+D.+Lemingauthor=D.+R.+Spigelauthor=S.+J.+Antoniaauthor=L.+Hornauthor=C.+G.+Drakeauthor=D.+M.+Pardollauthor=L.+Chenauthor=W.+H.+Sharfmanauthor=R.+A.+Andersauthor=J.+M.+Taubeauthor=T.+L.+McMillerauthor=H.+Xuauthor=A.+J.+Kormanauthor=M.+Jure-Kunkelauthor=S.+Agrawalauthor=D.+McDonaldauthor=G.+D.+Kolliaauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=M.+Sznol&title=Safety%2C+activity%2C+and+immune+correlates+of+anti-PD-1+antibody+in+cancer&doi=10.1056%2FNEJMoa1200690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span></div><div class="casAuthors">Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; Smith, David C.; McDermott, David F.; Powderly, John D.; Carvajal, Richard D.; Sosman, Jeffrey A.; Atkins, Michael B.; Leming, Philip D.; Spigel, David R.; Antonia, Scott J.; Horn, Leora; Drake, Charles G.; Pardoll, Drew M.; Chen, Lieping; Sharfman, William H.; Anders, Robert A.; Taube, Janis M.; McMiller, Tracee L.; Xu, Haiying; Korman, Alan J.; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; Kollia, Georgia D.; Gupta, Ashok; Wigginton, Jon M.; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2443-2454</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance.  We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.  Methods: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kg of body wt. every 2 wk.  Response was assessed after each 8-wk treatment cycle.  Patients received up to 12 cycles until disease progression or a complete response occurred.  Results: A total of 296 patients received treatment through Feb. 24, 2012.  Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity.  No max. tolerated dose was defined.  Adverse events consistent with immune-related causes were obsd.  Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were obsd. in those with non-small-cell lung cancer, melanoma, or renal-cell cancer.  Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).  Responses were durable; 20 of 31 responses lasted 1 yr or more in patients with 1 yr or more of follow-up.  To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochem. anal. was performed on pretreatment tumor specimens obtained from 42 patients.  Of 17 patients with PD-L1-neg. tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-pos. tumors had an objective response (P = 0.006).  Conclusions: Anti-PD-1 antibody produced objective responses in approx. one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.  Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLOPvHybmlvbVg90H21EOLACvtfcHk0lhszdQtGH9RpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN&md5=7c13f228ef92b6089982fc878d3a394b</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200690%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLeming%26aufirst%3DP.%2BD.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DMcMiller%26aufirst%3DT.%2BL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DKollia%26aufirst%3DG.%2BD.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DSznol%26aufirst%3DM.%26atitle%3DSafety%252C%2520activity%252C%2520and%2520immune%2520correlates%2520of%2520anti-PD-1%2520antibody%2520in%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D26%26spage%3D2443%26epage%3D2454%26doi%3D10.1056%2FNEJMoa1200690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-1 and its ligands in tolerance and immunity</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.26.021607.090331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1146%2Fannurev.immunol.26.021607.090331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=18173375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=677-704&author=M.+E.+Keirauthor=M.+J.+Butteauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-1+and+its+ligands+in+tolerance+and+immunity&doi=10.1146%2Fannurev.immunol.26.021607.090331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and its ligands in tolerance and immunity</span></div><div class="casAuthors">Keir, Mary E.; Butte, Manish J.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">677-704</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathol.  Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance.  Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage.  The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival.  The identification of B7-1 as an addnl. binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance.  In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTbTIs2Ruos7Vg90H21EOLACvtfcHk0lhszdQtGH9RpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D&md5=4b9b36a8716b8b1b47b7953f134448cf</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.26.021607.090331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.26.021607.090331%26sid%3Dliteratum%253Aachs%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-1%2520and%2520its%2520ligands%2520in%2520tolerance%2520and%2520immunity%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D26%26spage%3D677%26epage%3D704%26doi%3D10.1146%2Fannurev.immunol.26.021607.090331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5542</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-13-2234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24048329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5542&issue=19&author=M.+Sznolauthor=L.+Chen&title=Antagonist+antibodies+to+PD-1+and+B7-H1+%28PD-L1%29+in+the+treatment+of+advanced+human+cancer%2D%2Dresponse&doi=10.1158%2F1078-0432.CCR-13-2234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer-Response</span></div><div class="casAuthors">Sznol, Mario; Chen, Lieping</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5542</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  This paper discusses the antagonist antibodies to PD-1 and B7-H1 (PD-L1) in treatment of advanced human cancer-response.  The application of anti-PD-L1 antibody for the treatment of cancer were generated in an adoptive T-cell transfer model were discussed.  The phase I trial of nivolumab and ipilimumab in metastatic melanoma provided evidence for the hypothesis that combining PD-1 signaling blockade with other immunotherapy agents or approaches will improve treatment outcome were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1G_xmDp6K87Vg90H21EOLACvtfcHk0lhszdQtGH9RpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7J&md5=c8c376aab4263d81b2d025418bbdca55</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2234%26sid%3Dliteratum%253Aachs%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DAntagonist%2520antibodies%2520to%2520PD-1%2520and%2520B7-H1%2520%2528PD-L1%2529%2520in%2520the%2520treatment%2520of%2520advanced%2520human%2520cancer--response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D19%26spage%3D5542%26doi%3D10.1158%2F1078-0432.CCR-13-2234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span> <span> </span><span class="NLM_article-title">Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5064</span>– <span class="NLM_lpage">5074</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-13-3271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24714771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5064-5074&issue=19&author=J.+M.+Taubeauthor=A.+Kleinauthor=J.+R.+Brahmerauthor=H.+Xuauthor=X.+Panauthor=J.+H.+Kimauthor=L.+Chenauthor=D.+M.+Pardollauthor=S.+L.+Topalianauthor=R.+A.+Anders&title=Association+of+PD-1%2C+PD-1+ligands%2C+and+other+features+of+the+tumor+immune+microenvironment+with+response+to+anti-PD-1+therapy&doi=10.1158%2F1078-0432.CCR-13-3271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy</span></div><div class="casAuthors">Taube, Janis M.; Klein, Alison; Brahmer, Julie R.; Xu, Haiying; Pan, Xiaoyu; Kim, Jung H.; Chen, Lieping; Pardoll, Drew M.; Topalian, Suzanne L.; Anders, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5064-5074</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies.  Identifying factors predicting clin. response could guide patient selection and therapeutic optimization.  Exptl. Design: Patients (N = 41) with melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma, or castration-resistant prostate cancer were treated on an early-phase trial of anti-PD-1 (nivolumab) at one institution and had evaluable pretreatment tumor specimens.  Immunoarchitectural features, including PD-1, PD-L1, and PD-L2 expression, patterns of immune cell infiltration, and lymphocyte subpopulations, were assessed for interrelationships and potential correlations with clin. outcomes.  Results: Membranous (cell surface) PD-L1 expression by tumor cells and immune infiltrates varied significantly by tumor type and was most abundant in melanoma, NSCLC, and RCC.  In the overall cohort, PD-L1 expression was geog. assocd. with infiltrating immune cells (P < 0.001), although lymphocyte-rich regions were not always assocd. with PD-L1 expression.  Expression of PD-L1 by tumor cells and immune infiltrates was significantly assocd. with expression of PD-1 on lymphocytes.  PD-L2, the second ligand for PD-1, was assocd. with PD-L1 expression.  Tumor cell PD-L1 expression correlated with objective response to anti-PD-1 therapy, when analyzing either the specimen obtained closest to therapy or the highest scoring sample among multiple biopsies from individual patients.  These correlations were stronger than borderline assocns. of PD-1 expression or the presence of intratumoral immune cell infiltrates with response.  Conclusions: Tumor PD-L1 expression reflects an immune-active microenvironment and, while assocd. other immunosuppressive mols., including PD-1 and PD-L2, is the single factor most closely correlated with response to anti-PD-1 blockade.  Clin Cancer Res; 20(19); 5064-74. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpww5KU2a0WuLVg90H21EOLACvtfcHk0lhRG1ej5zGc-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzK&md5=ed5b01512789ec750bd35623bf114938</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3271%26sid%3Dliteratum%253Aachs%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DKlein%26aufirst%3DA.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26atitle%3DAssociation%2520of%2520PD-1%252C%2520PD-1%2520ligands%252C%2520and%2520other%2520features%2520of%2520the%2520tumor%2520immune%2520microenvironment%2520with%2520response%2520to%2520anti-PD-1%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D19%26spage%3D5064%26epage%3D5074%26doi%3D10.1158%2F1078-0432.CCR-13-3271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danilova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunshine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaunitz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esandrio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span> <span> </span><span class="NLM_article-title">Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">e7769</span>– <span class="NLM_lpage">e7777</span>, <span class="refDoi"> DOI: 10.1073/pnas.1607836113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1073%2Fpnas.1607836113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27837027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCiur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=e7769-e7777&issue=48&author=L.+Danilovaauthor=H.+Wangauthor=J.+Sunshineauthor=G.+J.+Kaunitzauthor=T.+R.+Cottrellauthor=H.+Xuauthor=J.+Esandrioauthor=R.+A.+Andersauthor=L.+Copeauthor=D.+M.+Pardollauthor=C.+G.+Drakeauthor=J.+M.+Taube&title=Association+of+PD-1%2FPD-L+axis+expression+with+cytolytic+activity%2C+mutational+load%2C+and+prognosis+in+melanoma+and+other+solid+tumors&doi=10.1073%2Fpnas.1607836113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors</span></div><div class="casAuthors">Danilova, Ludmila; Wang, Hao; Sunshine, Joel; Kaunitz, Genevieve J.; Cottrell, Tricia R.; Xu, Haiying; Esandrio, Jessica; Anders, Robert A.; Cope, Leslie; Pardoll, Drew M.; Drake, Charles G.; Taube, Janis M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">E7769-E7777</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a no. of different tumor types.  A better understanding of factors assocd. with the PD-1/PD-L axis expression is desirable, as it informs their potential role as prognostic and predictive biomarkers and may suggest rational treatment combinations.  In the current study, we analyzed PD-L1, PD-L2, PD-1, and cytolytic activity (CYT) expression, as well as mutational d. from melanoma and eight other solid tumor types using The Cancer Genome Atlas database.  We found that in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1.  In contrast, mutational load was not correlated with a Th1/IFNG gene signature in any tumor type.  PD-L1, PD-L2, PD-1, CYT expression, and mutational d. are all pos. prognostic features in melanoma, and conditional inference modeling revealed PD-1/CYT expression (i.e., an inflamed tumor microenvironment) as the most impactful feature, followed by mutational d.  This study elucidates the highly interdependent nature of these parameters, and also indicates that future biomarkers for anti-PD-1/PD-L1 will benefit from tumor-type-specific, integrated, mRNA, protein, and genomic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdpBjYCMAoLLVg90H21EOLACvtfcHk0lhRG1ej5zGc-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCiur7J&md5=c1bcf48c595c2177864303ffd3123db4</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1607836113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1607836113%26sid%3Dliteratum%253Aachs%26aulast%3DDanilova%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSunshine%26aufirst%3DJ.%26aulast%3DKaunitz%26aufirst%3DG.%2BJ.%26aulast%3DCottrell%26aufirst%3DT.%2BR.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DEsandrio%26aufirst%3DJ.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DCope%26aufirst%3DL.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26atitle%3DAssociation%2520of%2520PD-1%252FPD-L%2520axis%2520expression%2520with%2520cytolytic%2520activity%252C%2520mutational%2520load%252C%2520and%2520prognosis%2520in%2520melanoma%2520and%2520other%2520solid%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D48%26spage%3De7769%26epage%3De7777%26doi%3D10.1073%2Fpnas.1607836113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouaid, C.</span></span> <span> </span><span class="NLM_article-title">Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30144-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2818%2930144-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29545095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFSruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=521-536&author=M.+Garassinoauthor=B.-C.+Choauthor=J.-H.+Kimauthor=J.+Mazieresauthor=J.+Vansteenkisteauthor=H.+Lenaauthor=J.+C.+Jaimeauthor=J.+E.+Grayauthor=J.+Powderlyauthor=C.+Chouaid&title=Durvalumab+as+third-line+or+later+treatment+for+advanced+non-small-cell+lung+cancer+%28ATLANTIC%29%3A+an+open-label%2C+single-arm%2C+phase+2+study&doi=10.1016%2FS1470-2045%2818%2930144-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study</span></div><div class="casAuthors">Garassino, Marina Chiara; Cho, Byoung-Chul; Kim, Joo-Hang; Mazieres, Julien; Vansteenkiste, Johan; Lena, Herve; Corral Jaime, Jesus; Gray, Jhanelle E.; Powderly, John; Chouaid, Christos; Bidoli, Paolo; Wheatley-Price, Paul; Park, Keunchil; Soo, Ross A.; Huang, Yifan; Wadsworth, Catherine; Dennis, Phillip A.; Rizvi, Naiyer A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">521-536</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors are a new std. of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clin. benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown.  We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumor expression of PD-L1.  ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centers in Asia, Europe, and North America.  Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.  Key exclusion criteria included mixed small-cell lung cancer and NSCLC histol.; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent.  Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumor cells with PD-L1 expression.  Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumor cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumor cells with PD-L1 expression.  Patients received durvalumab (10 mg/kg) every 2 wk, via i.v. infusion, for up to 12 mo.  Retreatment was allowed for patients who benefited but then progressed after completing 12 mo.  The primary endpoint was the proportion of patients with increased tumor expression of PD-L1 (defined as ≥25% of tumor cells in cohorts 1 and 2, and ≥90% of tumor cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1.  Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available.  The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, no. NCT02087423.  Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3.  Among patients with at least 25% of tumor cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2.  In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response.  Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3.  The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]).  Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3.  The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]).  Immune-mediated events were manageable with std. treatment guidelines.  In patients with advanced and heavily pretreated NSCLC, the clin. activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents.  Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response.  The clin. activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumor cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted.AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJgLQ4PuvqybVg90H21EOLACvtfcHk0lhRG1ej5zGc-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFSruro%253D&md5=66b95cc26de0e8e7619d500a44809157</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930144-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930144-X%26sid%3Dliteratum%253Aachs%26aulast%3DGarassino%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DB.-C.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DJaime%26aufirst%3DJ.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DPowderly%26aufirst%3DJ.%26aulast%3DChouaid%26aufirst%3DC.%26atitle%3DDurvalumab%2520as%2520third-line%2520or%2520later%2520treatment%2520for%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528ATLANTIC%2529%253A%2520an%2520open-label%252C%2520single-arm%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D521%26epage%3D536%26doi%3D10.1016%2FS1470-2045%2818%2930144-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villegas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhaba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quantin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapetis, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostoros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro
Carpeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozguroglu, M.</span></span> <span> </span><span class="NLM_article-title">PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">1919</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1709937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28885881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1919-1929&issue=20&author=S.+J.+Antoniaauthor=A.+Villegasauthor=D.+Danielauthor=D.+Vicenteauthor=S.+Murakamiauthor=R.+Huiauthor=T.+Yokoiauthor=A.+Chiapporiauthor=K.+H.+Leeauthor=M.+de+Witauthor=B.+C.+Choauthor=M.+Bourhabaauthor=X.+Quantinauthor=T.+Tokitoauthor=T.+Mekhailauthor=D.+Planchardauthor=Y.-C.+Kimauthor=C.+S.+Karapetisauthor=S.+Hiretauthor=G.+Ostorosauthor=K.+Kubotaauthor=J.+E.+Grayauthor=L.+Paz-Aresauthor=J.+de+Castro%0ACarpenoauthor=C.+Wadsworthauthor=G.+Melilloauthor=H.+Jiangauthor=Y.+Huangauthor=P.+A.+Dennisauthor=M.+Ozguroglu&title=PACIFIC+Investigators.+Durvalumab+after+Chemoradiotherapy+in+Stage+III+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1709937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</span></div><div class="casAuthors">Antonia, S. J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K. H.; de Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y.-C.; Karapetis, C. S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J. E.; Paz-Ares, L.; de Castro Carpeno, J.; Wadsworth, C.; Melillo, G.; Jiang, H.; Huang, Y.; Dennis, P. A.; Ozguroglu, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1919-1929</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy).  This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.  Methods: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kg of body wt. i.v.) or placebo every 2 wk for up to 12 mo.  The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy.  The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim anal.).  Secondary end points included 12-mo and 18-mo progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.  Results: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo).  The median progression-free survival from randomization was 16.8 mo (95% confidence interval [CI], 13.0 to 18.1) with durvalumab vs. 5.6 mo (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-mo progression-free survival rate was 55.9% vs. 35.3%, and the 18-mo progression-free survival rate was 44.2% vs. 27.0%.  The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 mo).  The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 mo vs. 14.6 mo; P<0.001).  Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, resp.).  A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.  Conclusions: Progression-free survival was significantly longer with durvalumab than with placebo.  The secondary end points also favored durvalumab, and safety was similar between the groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLr5-R3gHtVbVg90H21EOLACvtfcHk0lifDp6ff4-v7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVOr&md5=95be11a1c165acdc826c4ee049a5f010</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709937%26sid%3Dliteratum%253Aachs%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DVillegas%26aufirst%3DA.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DBourhaba%26aufirst%3DM.%26aulast%3DQuantin%26aufirst%3DX.%26aulast%3DTokito%26aufirst%3DT.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.-C.%26aulast%3DKarapetis%26aufirst%3DC.%2BS.%26aulast%3DHiret%26aufirst%3DS.%26aulast%3DOstoros%26aufirst%3DG.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3Dde%2BCastro%2BCarpeno%26aufirst%3DJ.%26aulast%3DWadsworth%26aufirst%3DC.%26aulast%3DMelillo%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26aulast%3DOzguroglu%26aufirst%3DM.%26atitle%3DPACIFIC%2520Investigators.%2520Durvalumab%2520after%2520Chemoradiotherapy%2520in%2520Stage%2520III%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D20%26spage%3D1919%26epage%3D1929%26doi%3D10.1056%2FNEJMoa1709937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmanoukian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakunnel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A.</span></span> <span> </span><span class="NLM_article-title">Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00544-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2815%2900544-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26858122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XitlCntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=299-308&issue=3&author=S.+Antoniaauthor=S.+B.+Goldbergauthor=A.+Balmanoukianauthor=J.+E.+Chaftauthor=R.+E.+Sanbornauthor=A.+Guptaauthor=R.+Narwalauthor=K.+Steeleauthor=Y.+Guauthor=J.+J.+Karakunnelauthor=N.+A.+Rizvi&title=Safety+and+antitumor+activity+of+durvalumab+plus+tremelimumab+in+non-small+cell+lung+cancer%3A+a+multicentre%2C+phase+1b+study&doi=10.1016%2FS1470-2045%2815%2900544-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study</span></div><div class="casAuthors">Antonia, Scott; Goldberg, Sarah B.; Balmanoukian, Ani; Chaft, Jamie E.; Sanborn, Rachel E.; Gupta, Ashok; Narwal, Rajesh; Steele, Keith; Gu, Yu; Karakunnel, Joyson J.; Rizvi, Naiyer A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-308</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PD-L1 and CTLA-4 immune checkpoints inhibit antitumor T-cell activity.  Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumor activity than either drug alone.  We aimed to assess durvalumab plus tremelimumab in patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC).  We did a multicentre, non-randomized, open-label, phase 1b study at five cancer centers in the USA.  We enrolled immunotherapy-naive patients aged 18 years or older with confirmed locally advanced or metastatic NSCLC.  We gave patients durvalumab in doses of 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 wk, or 10 mg/kg every 2 wk, and tremelimumab in doses of 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 wk for six doses then every 12 wk for three doses.  The primary endpoint of the dose-escalation phase was safety.  Safety analyses were based on the as-treated population.  The dose-expansion phase of the study is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02000947.  Between Oct 28, 2013, and Apr. 1, 2015, 102 patients were enrolled into the dose-escalation phase and received treatment.  At the time of this anal. (June 1, 2015), median follow-up was 18·8 wk (IQR 11-33).  The max. tolerated dose was exceeded in the cohort receiving durvalumab 20 mg/kg every 4 wk plus tremelimumab 3 mg/kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipase).  The most frequent treatment-related grade 3 and 4 adverse events were diarrhoea (11 [11%]), colitis (nine [9%]), and increased lipase (eight [8%]).  Discontinuations attributable to treatment-related adverse events occurred in 29 (28%) of 102 patients.  Treatment-related serious adverse events occurred in 37 (36%) of 102 patients. 22 patients died during the study, and three deaths were related to treatment.  The treatment-related deaths were due to complications arising from myasthenia gravis (durvalumab 10 mg/kg every 4 wk plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 wk plus tremelimumab 1 mg/kg), and neuromuscular disorder (durvalumab 20 mg/kg every 4 wk plus tremelimumab 3 mg/kg).  Evidence of clin. activity was noted both in patients with PD-L1-pos. tumors and in those with PD-L1-neg. tumors.  Investigator-reported confirmed objective responses were achieved by six (23%, 95% CI 9-44) of 26 patients in the combined tremelimumab 1 mg/kg cohort, comprising two (22%, 95% CI 3-60) of nine patients with PD-L1-pos. tumors and four (29%, 95% CI 8-58) of 14 patients with PD-L1-neg. tumors, including those with no PD-L1 staining (four [40%, 95% CI 12-74] of ten patients).  Durvalumab 20 mg/kg every 4 wk plus tremelimumab 1 mg/kg showed a manageable tolerability profile, with antitumor activity irresp. of PD-L1 status, and was selected as the dose for phase 3 studies, which are ongoing.MedImmune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83-IOZZVtArVg90H21EOLACvtfcHk0lifDp6ff4-v7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitlCntro%253D&md5=7ac0c9efa33d0ad683aba64f6f734765</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900544-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900544-6%26sid%3Dliteratum%253Aachs%26aulast%3DAntonia%26aufirst%3DS.%26aulast%3DGoldberg%26aufirst%3DS.%2BB.%26aulast%3DBalmanoukian%26aufirst%3DA.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DSanborn%26aufirst%3DR.%2BE.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DNarwal%26aufirst%3DR.%26aulast%3DSteele%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DKarakunnel%26aufirst%3DJ.%2BJ.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520durvalumab%2520plus%2520tremelimumab%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520multicentre%252C%2520phase%25201b%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D3%26spage%3D299%26epage%3D308%26doi%3D10.1016%2FS1470-2045%2815%2900544-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Castro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aren, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrieta, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottfried, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazieh, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timcheva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trani, L.</span></span> <span> </span><span class="NLM_article-title">P2. 06–022 First-Line durvalumab plus tremelimumab vs platinum-based chemotherapy for advanced/metastatic NSCLC: Phase 3 NEPTUNE Study</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S1084</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.1515" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S1084&issue=1&author=T.+Mokauthor=P.+Schmidauthor=G.+De+Castroauthor=K.+Syrigosauthor=C.+Martinauthor=N.+Yamamotoauthor=O.+Arenauthor=O.+Arrietaauthor=M.+Gottfriedauthor=A.+R.+Jaziehauthor=R.+Ramlauauthor=C.+Timchevaauthor=L.+Trani&title=P2.+06%E2%80%93022+First-Line+durvalumab+plus+tremelimumab+vs+platinum-based+chemotherapy+for+advanced%2Fmetastatic+NSCLC%3A+Phase+3+NEPTUNE+Study&doi=10.1016%2Fj.jtho.2016.11.1515"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.1515%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DDe%2BCastro%26aufirst%3DG.%26aulast%3DSyrigos%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DAren%26aufirst%3DO.%26aulast%3DArrieta%26aufirst%3DO.%26aulast%3DGottfried%26aufirst%3DM.%26aulast%3DJazieh%26aufirst%3DA.%2BR.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DTimcheva%26aufirst%3DC.%26aulast%3DTrani%26aufirst%3DL.%26atitle%3DP2.%252006%25E2%2580%2593022%2520First-Line%2520durvalumab%2520plus%2520tremelimumab%2520vs%2520platinum-based%2520chemotherapy%2520for%2520advanced%252Fmetastatic%2520NSCLC%253A%2520Phase%25203%2520NEPTUNE%2520Study%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3DS1084%26doi%3D10.1016%2Fj.jtho.2016.11.1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) for epigenetics research</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cbpa.2020.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32146413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=8-16&author=A.+Vogelmannauthor=D.+Robaaauthor=W.+Sipplauthor=M.+Jung&title=Proteolysis+targeting+chimeras+%28PROTACs%29+for+epigenetics+research&doi=10.1016%2Fj.cbpa.2020.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) for epigenetics research</span></div><div class="casAuthors">Vogelmann, Anja; Robaa, Dina; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-16</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional mols. and allow selective protein degrdn. by addressing the natural ubiquitin proteasome system.  As this new strategy of chem. induced protein degrdn. can serve as a biol. tool and provides new possibilities for drug discovery, it has been applied to a variety of targets including (nuclear) receptors, kinases, and epigenetic proteins.  A lot of PROTACs have already been designed in the field of epigenetics, and their synthesis and characterization highly contributed to structural optimization and improved mechanistic understanding of these mols.  In this review, we will discuss and summarize recent advances in PROTAC discovery with focus on epigenetic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW2o_9L2Y8GbVg90H21EOLACvtfcHk0liHNuGa9v7Srg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D&md5=6a4f3b70d6c6a446c744b9788b7582cf</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmann%26aufirst%3DA.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520for%2520epigenetics%2520research%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D8%26epage%3D16%26doi%3D10.1016%2Fj.cbpa.2020.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent small molecule PROTACs targeting mutant EGFR</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>,  <span class="NLM_fpage">112781</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2020.112781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32883633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslyjsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&pages=112781&author=H.+Y.+Zhaoauthor=X.+Y.+Yangauthor=H.+Leiauthor=X.+X.+Xiauthor=S.+M.+Luauthor=J.+J.+Zhangauthor=M.+Xinauthor=S.+Q.+Zhang&title=Discovery+of+potent+small+molecule+PROTACs+targeting+mutant+EGFR&doi=10.1016%2Fj.ejmech.2020.112781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent small molecule PROTACs targeting mutant EGFR</span></div><div class="casAuthors">Zhao, Hong-Yi; Yang, Xue-Yan; Lei, Hao; Xi, Xiao-Xiao; Lu, She-Min; Zhang, Jun-Jie; Xin, Minhang; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112781</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is an important therapeutic target for the treatment of non-small cell lung cancer.  A no. of efficacious EGFR tyrosine kinase inhibitors have been developed.  However, acquired drug resistance largely encumbered their clin. practicability.  Therefore, there is an urgent need to develop new therapeutic regime.  Herein, we designed and synthesized a set of EGFR-targeting small mol. PROTACs which showed promising efficacy.  In particular, VHL-recruiting compd. P3 showed potent anti-proliferative activity against HCC827 and H1975 cell lines with IC50 values of 0.83 and 203.01 nM, resp.  Furthermore, both EGFRdel19 and EGFRL858R/T790M could be significantly induced to be degraded under treatment of P3 with DC50 values of 0.51 and 126.2 nM, resp.  Compd. P3 was able to dramatically suppress EGFR pathway signal transduction.  Moreover, compd. P3 could significantly induce cell apoptosis, arrest cell cycle and suppress cell colony formation.  In addn., we identified that ubiquitination was indispensable in the degrdn. process, and found that the degrdn. was related to autophagy.  Our work would provide an alternative approach for development of potentially effective EGFR degraders and give a new clue for investigation of PROTAC-induced protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5kpQ3m5f49LVg90H21EOLACvtfcHk0liHNuGa9v7Srg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslyjsbrM&md5=88849f5b2a0ab95919ae6c0a85c5dd0f</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112781%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DXi%26aufirst%3DX.%2BX.%26aulast%3DLu%26aufirst%3DS.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%2520potent%2520small%2520molecule%2520PROTACs%2520targeting%2520mutant%2520EGFR%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26spage%3D112781%26doi%3D10.1016%2Fj.ejmech.2020.112781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponthier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">14481</span>– <span class="NLM_lpage">14489</span>, <span class="refDoi"> DOI: 10.1002/anie.202003500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.202003500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=14481-14489&issue=34&author=J.+Jangauthor=C.+Toauthor=D.+J.+H.+De+Clercqauthor=E.+Parkauthor=C.+M.+Ponthierauthor=B.+H.+Shinauthor=M.+Mushajiangauthor=R.+P.+Nowakauthor=E.+S.+Fischerauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Mutant-selective+allosteric+EGFR+degraders+are+effective+against+a+broad+range+of+drug-resistant+mutations&doi=10.1002%2Fanie.202003500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations</span></div><div class="casAuthors">Jang, Jaebong; To, Ciric; De Clercq, Dries J. H.; Park, Eunyoung; Ponthier, Charles M.; Shin, Bo Hee; Mushajiang, Mierzhati; Nowak, Radoslaw P.; Fischer, Eric S.; Eck, Michael J.; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">14481-14489</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting epidermal growth factor receptor (EGFR) through an allosteric mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mutations that emerge within the ATP binding site.  Here, we develop an allosteric EGFR degrader, DDC-01-163, which can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells while leaving wildtype EGFR Ba/F3 cells unaffected.  DDC-01-163 is also effective against osimertinib-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations.  When combined with an ATP-site EGFR inhibitor, osimertinib, the anti-proliferative activity of DDC-01-163 against L858R/T790M EGFR-Ba/F3 cells is enhanced.  Collectively, DDC-01-163 is a promising allosteric EGFR degrader with selective activity against various clin. relevant EGFR mutants as a single agent and when combined with an ATP-site inhibitor.  Our data suggests that targeted protein degrdn. is a promising drug development approach for mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-uPhJ2k9kLVg90H21EOLACvtfcHk0lhmqT0Wdpuyqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I&md5=4e24a6a1a746e446a052f27e404f8adf</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1002%2Fanie.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202003500%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DPonthier%26aufirst%3DC.%2BM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DMutant-selective%2520allosteric%2520EGFR%2520degraders%2520are%2520effective%2520against%2520a%2520broad%2520range%2520of%2520drug-resistant%2520mutations%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26issue%3D34%26spage%3D14481%26epage%3D14489%26doi%3D10.1002%2Fanie.202003500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">113328</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2021.113328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=33773286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnt1Oltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2021&pages=113328&author=X.+Quauthor=H.+Liuauthor=X.+Songauthor=N.+Sunauthor=H.+Zhongauthor=X.+Qiuauthor=X.+Yangauthor=B.+Jiang&title=Effective+degradation+of+EGFRL858R%2BT790M+mutant+proteins+by+CRBN-based+PROTACs+through+both+proteosome+and+autophagy%2Flysosome+degradation+systems&doi=10.1016%2Fj.ejmech.2021.113328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems</span></div><div class="casAuthors">Qu, Xiaojuan; Liu, Haixia; Song, Xiaoling; Sun, Ning; Zhong, Hui; Qiu, Xing; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113328</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeted therapy of treating patients with specific tyrosine kinase inhibitors (TKIs) is currently the std. care for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.  However, the inevitably developed drug resistance in patients to EGFR TKIs is the biggest obstacle for cancer targeted therapy.  About 60% of drug resistance to the 1st generation of EGFR TKIs was resulted from an acquired T790M mutation in the kinase domain of EGFR protein.  Proteolysis targeting chimera (PROTAC) is a lately-developed technol. to target point of interest proteins for degrdn.  Because EGFR-mutant lung cancers are highly dependent on EGFR proteins, designing specific PROTAC mols. to degrade EGFR proteins from cancer cells provides a very promising strategy to treat such patients and eradicate drug resistance.  Currently, there is no cereblon (CRBN)-based PROTAC reported able to degrade T790M-contg. EGFR resistant proteins.  In this study, we synthesized two novel CRBN-based EGFR PROTACs, SIAIS125 and SIAIS126, based on EGFR inhibitor canertinib and cereblon ligand pomalidomide.  These two degraders displayed potent and selective antitumor activities in EGFR TKI resistant lung cancer cells.  Firstly, they could selectively degrade EGFRL858R+T790M resistant proteins in H1975 cells at the concn. of 30-50 nM, and EGFREx19del proteins in PC9 cells.  But they did not degrade EGFREx19del+T790M mutant proteins in PC9Brca1 cells or wild type EGFR in A549 lung cancer cells.  They could also selectively inhibit the growth of EGFR mutant lung cancer cells but not that of normal cells or A549 cells.  Secondly, the degrdn. of EGFRL858R+T790M proteins was long lasting up to 72 h.  Thirdly, these degraders displayed better inhibition of EGFR phosphorylation in H1975 cells and PC9Brca1 cells comparing to canertinib.  Finally, these degraders could also induce significant apoptosis and cell cycles arrest in H1975 cells.  Pre-incubation with canertinib, pomalidomide or ubiquitination inhibitor MLN4924 totally blocked EGFR degrdn. by PROTACs.  Mechanistic studies showed that PROTAC could induce autophagy in lung cancer cells.  PROTAC-induced EGFR degrdn. acted through both ubiquitin/proteosome system and ubiquitin/autophagy/lysosome system.  Elevating autophagy activities enhanced EGFR degrdn. and cell apoptosis induced by PROTACs.  Our research not only offered a novel PROTAC tool to target EGFR TKI drug resistance in lung cancer, but also firstly demonstrated that the involvement of autophagy/lysosome system in PROTAC- mediated target protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0L26jmd6Y6bVg90H21EOLACvtfcHk0lhmqT0Wdpuyqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnt1Oltr4%253D&md5=1ff708cb430cdeee081e82b480a952a9</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113328%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DEffective%2520degradation%2520of%2520EGFRL858R%252BT790M%2520mutant%2520proteins%2520by%2520CRBN-based%2520PROTACs%2520through%2520both%2520proteosome%2520and%2520autophagy%252Flysosome%2520degradation%2520systems%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D218%26spage%3D113328%26doi%3D10.1016%2Fj.ejmech.2021.113328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112199</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2020.112199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32171162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112199&author=X.+Zhangauthor=F.+Xuauthor=L.+Tongauthor=T.+Zhangauthor=H.+Xieauthor=X.+Luauthor=X.+Renauthor=K.+Ding&title=Design+and+synthesis+of+selective+degraders+of+EGFRL858R%2FT790M+mutant&doi=10.1016%2Fj.ejmech.2020.112199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span></div><div class="casAuthors">Zhang, Xin; Xu, Fang; Tong, Linjiang; Zhang, Tao; Xie, Hua; Lu, Xiaoyun; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112199</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of PROTAC (proteolysis targeting chimera) based selective EGFRL858R/T790M (leucine 858 to arginine 858 mutation and threonine 790 to methionine 790) mutant degraders were designed and synthesized.  One of the most potent compds. (I) effectively and selectively degraded EGFRL858R/T790M with an DC50 value of 5.9 nM, while did not show obvious effect on the wild-type protein.  Further mechanism investigation revealed that the degrdn. was mediated by ubiquitin proteasome pathway.  Compd. I could be utilized as an initial lead mol. for development of new EGFRL858R/T790M degrader based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDW2mGkQNzbVg90H21EOLACvtfcHk0lhmqT0Wdpuyqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D&md5=e8fdd02842f6cfd94e362f3a53a39096</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520selective%2520degraders%2520of%2520EGFRL858R%252FT790M%2520mutant%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112199%26doi%3D10.1016%2Fj.ejmech.2020.112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuaid, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The advantages of targeted protein degradation over inhibition: an RTK case study</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.chembiol.2017.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29129716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=67-77&issue=1&author=G.+M.+Burslemauthor=B.+E.+Smithauthor=A.+C.+Laiauthor=S.+Jaime-Figueroaauthor=D.+C.+McQuaidauthor=D.+P.+Bondesonauthor=M.+Toureauthor=H.+Dongauthor=Y.+Qianauthor=J.+Wangauthor=A.+P.+Crewauthor=J.+Hinesauthor=C.+M.+Crews&title=The+advantages+of+targeted+protein+degradation+over+inhibition%3A+an+RTK+case+study&doi=10.1016%2Fj.chembiol.2017.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study</span></div><div class="casAuthors">Burslem, George M.; Smith, Blake E.; Lai, Ashton C.; Jaime-Figueroa, Saul; McQuaid, Daniel C.; Bondeson, Daniel P.; Toure, Momar; Dong, Hanqing; Qian, Yimin; Wang, Jing; Crew, Andrew P.; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proteolysis targeting chimera (PROTAC) technol. has emerged over the last two decades as a powerful tool for targeted degrdn. of endogenous proteins.  Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degrdn.  The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degrdn. over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degrdn. leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors.  Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degrdn. using the PROTAC technol. and outline the advantages of this degrdn.-based approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4yDhRDWqNv7Vg90H21EOLACvtfcHk0ljtdvib4HFohQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM&md5=0ac39a6f5836ea3772a0396356efb630</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DMcQuaid%26aufirst%3DD.%2BC.%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520advantages%2520of%2520targeted%2520protein%2520degradation%2520over%2520inhibition%253A%2520an%2520RTK%2520case%2520study%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D67%26epage%3D77%26doi%3D10.1016%2Fj.chembiol.2017.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1216-1232&issue=3&author=M.+Chengauthor=X.+Yuauthor=K.+Luauthor=L.+Xieauthor=L.+Wangauthor=F.+Mengauthor=X.+Hanauthor=X.+Chenauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Discovery+of+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+bifunctional+small-molecule+degraders&doi=10.1021%2Facs.jmedchem.9b01566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders</span></div><div class="casAuthors">Cheng, Meng; Yu, Xufen; Lu, Kaylene; Xie, Ling; Wang, Li; Meng, Fanye; Han, Xiaoran; Chen, Xian; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1216-1232</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by Food and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.  Here, we described the discovery of a novel E3 ligase von Hippel-Lindau-recruiting EGFR degrader, MS39 (compd. 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrader, MS154 (compd. 10), using the proteolysis targeting chimera technol.  These compds. potently induced the degrdn. of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth of lung cancer cells compared with the corresponding neg. controls.  The global proteomic analyses revealed that the compds. were highly selective for EGFR.  Furthermore, both compds. were bioavailable in mouse pharmacokinetic studies, and compd. 6 is the first EGFR degrader suitable for in vivo efficacy studies.  Overall, we provide a set of well-characterized chem. tools to the research community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFLSjUGE-6rVg90H21EOLACvtfcHk0ljtdvib4HFohQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D&md5=ec831897a4258f1968e254aa433426c3</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bifunctional%2520small-molecule%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D3%26spage%3D1216%26epage%3D1232%26doi%3D10.1021%2Facs.jmedchem.9b01566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cell.2019.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31955850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=102-114&issue=1&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Proteolysis-targeting+chimeras+as+therapeutics+and+tools+for+biological+discovery&doi=10.1016%2Fj.cell.2019.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-114</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  New biol. tools provide new techniques to probe fundamental biol. processes.  Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concns. at a post-translational level by co-opting the ubiquitin-proteasome system.  We describe the PROTAC technol. and its application to drug discovery and provide examples where PROTACs have enabled novel biol. insights.  Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues assocd. with PROTACs.  Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgumsEakVWrVg90H21EOLACvtfcHk0ljtdvib4HFohQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D&md5=3010929d2979cf04dc6003e66575f1b0</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteolysis-targeting%2520chimeras%2520as%2520therapeutics%2520and%2520tools%2520for%2520biological%2520discovery%26jtitle%3DCell%26date%3D2020%26volume%3D181%26issue%3D1%26spage%3D102%26epage%3D114%26doi%3D10.1016%2Fj.cell.2019.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00909</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00909" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVChtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=448-466&issue=2&author=Y.+Liauthor=J.+Yangauthor=A.+Aguilarauthor=D.+McEachernauthor=S.+Przybranowskiauthor=L.+Liuauthor=C.+Y.+Yangauthor=M.+Wangauthor=X.+Hanauthor=S.+Wang&title=Discovery+of+MD-224+as+a+first-in-class%2C+highly+potent%2C+and+efficacious+proteolysis+targeting+chimera+murine+double+minute+2+degrader+capable+of+achieving+complete+and+durable+tumor+regression&doi=10.1021%2Facs.jmedchem.8b00909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression</span></div><div class="casAuthors">Li, Yangbing; Yang, Jiuling; Aguilar, Angelo; McEachern, Donna; Przybranowski, Sally; Liu, Liu; Yang, Chao-Yie; Wang, Mi; Han, Xin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">448-466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human murine double minute 2 (MDM2) protein is a primary endogenous cellular inhibitor of the tumor suppressor p53 and has been pursued as an attractive cancer therapeutic target.  Several potent, nonpeptide, small-mol. inhibitors of MDM2 are currently in clin. development.  In this paper, we report our design, synthesis, and evaluation of small-mol. MDM2 degraders based on the proteolysis targeting chimera (PROTAC) concept.  The most promising compd. (MD-224, I) effectively induces rapid degrdn. of MDM2 at concns. <1 nM in human leukemia cells.  It achieves an IC50 value of 1.5 nM in inhibition of growth of RS4;11 cells and also low nanomolar IC50 values in a panel of leukemia cell lines.  MD-224 (I) achieves complete and durable tumor regression in vivo in the RS4;11 xenograft tumor model in mice at well-tolerated dose schedules.  MD-224 (I) is thus a highly potent and efficacious MDM2 degrader and warrants extensive evaluations as a new class of anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfVzK-tVEdk7Vg90H21EOLACvtfcHk0liQJ4KeJGR_Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVChtrfK&md5=3eaa40a8b0ae15c0172ef44a2fd1b902</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00909%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAguilar%26aufirst%3DA.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520MD-224%2520as%2520a%2520first-in-class%252C%2520highly%2520potent%252C%2520and%2520efficacious%2520proteolysis%2520targeting%2520chimera%2520murine%2520double%2520minute%25202%2520degrader%2520capable%2520of%2520achieving%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D448%26epage%3D466%26doi%3D10.1021%2Facs.jmedchem.8b00909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">127167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmcl.2020.127167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32317208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsV2qt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127167&issue=12&author=K.+Heauthor=Z.+Zhangauthor=W.+Wangauthor=X.+Zhengauthor=X.+Wangauthor=X.+Zhang&title=Discovery+and+biological+evaluation+of+proteolysis+targeting+chimeras+%28PROTACs%29+as+an+EGFR+degraders+based+on+osimertinib+and+lenalidomide&doi=10.1016%2Fj.bmcl.2020.127167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide</span></div><div class="casAuthors">He, Kailun; Zhang, Zhuo; Wang, Wenbing; Zheng, Xiaoliang; Wang, Xiaoju; Zhang, Xingxian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">127167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is one of the important and valuable drug targets.  Overexpression of EGFR is assocd. with the development of many types of cancer.  In this study, three PROTACs small mols. (16a-16c) were designed, synthesized and evaluated for their cytotoxicity against the growth in different NSCLC cell line and the degrdn. effect.  The bioassay results indicated that 16c has a good inhibition in PC9 cells and H1975 cells, and the corresponding IC50 value was 0.413 μM and 0.657 μM, resp.  Western blotting results demonstrated that compd. 16c could serve as an effective EGFRdel19-targeting degrader in PC9 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgut0gW1TkiLVg90H21EOLACvtfcHk0liQJ4KeJGR_Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsV2qt74%253D&md5=bf63e55c59176f262c8569824417b2ef</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127167%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520biological%2520evaluation%2520of%2520proteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520as%2520an%2520EGFR%2520degraders%2520based%2520on%2520osimertinib%2520and%2520lenalidomide%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D127167%26doi%3D10.1016%2Fj.bmcl.2020.127167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112061</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2020.112061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31951960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112061&author=H.+Zhangauthor=H.+Y.+Zhaoauthor=X.+X.+Xiauthor=Y.+J.+Liuauthor=M.+Xinauthor=S.+Maoauthor=J.+J.+Zhangauthor=A.+X.+Luauthor=S.+Q.+Zhang&title=Discovery+of+potent+epidermal+growth+factor+receptor+%28EGFR%29+degraders+by+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1016%2Fj.ejmech.2020.112061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Zhang, Hao; Zhao, Hong-Yi; Xi, Xiao-Xiao; Liu, Yan-Jie; Xin, Minhang; Mao, Shuai; Zhang, Jun-Jie; Lu, A-Xin; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112061</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Herein, the discovery of small mol. EGFR degraders based on the proteolysis targeting chimera (PROTAC) strategy was reported.  In the present study, 13 EGFR degraders contg. pyrido[3,4-d]pyrimidine moiety I [X = CH2C(O)NHCH2CH2C(O), CH2CH2CH2CH2C(O), CH2CH2CH2CH2CH2C(O), etc.], II [C = CH2C(O)NHCH2CH2C(O), CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2C(O), CH2CH2OCH2CH2OCH2CH2, CH2CH2CH2CH2CH2CH2C(O), etc.] were designed and synthesized.  Promising PROTACs I [X = CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2CH2CH2C(O)] induced degrdn. of EGFR in HCC827 cells with the DC50 values of 45.2 and 34.8 nM, resp.  Cellular protein-controlling machinery ubiquitin proteasome system (UPS) was involved in the degrdn. process.  Furthermore, the degraders I [X = CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2CH2CH2C(O)] could significantly induce the apoptosis of HCC827 cells and arrest the cells in G1 phase.  These findings demonstrated that compds. I [X = CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2CH2CH2C(O)] could serve as effective EGFRdel19-targeting degraders in HCC827 cells. v.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonJUw1b6N-77Vg90H21EOLACvtfcHk0liQJ4KeJGR_Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCltr8%253D&md5=8f8a1fbc8df721332a2a2b5d6bbc7875</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DXi%26aufirst%3DX.%2BX.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DA.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%2520potent%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520degraders%2520by%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112061%26doi%3D10.1016%2Fj.ejmech.2020.112061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&issue=18&author=P.+A.+J%C3%A4nneauthor=J.+C.+Yangauthor=D.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.+J.+Ahnauthor=S.+W.+Kimauthor=W.+C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.+H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+inhibitor-resistant+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eZdSddDPTUfHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D18%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chia, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span> <span> </span><span class="NLM_article-title">Vortex keratopathy presumed secondary to AZD9291</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0000000000000634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26709481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28rlsFejuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1807-1808&issue=12&author=P.+L.+Chiaauthor=T.+John&title=Vortex+keratopathy+presumed+secondary+to+AZD9291&doi=10.1097%2FJTO.0000000000000634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Vortex Keratopathy Presumed Secondary to AZD9291</span></div><div class="casAuthors">Chia Puey Ling; John Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1807-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvfZj9Z6tFZvxQvRxYU81tfW6udTcc2eZdSddDPTUfHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlsFejuw%253D%253D&md5=71c693934cbe37c168f69a1d86cb7fad</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000634%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DP.%2BL.%26aulast%3DJohn%26aufirst%3DT.%26atitle%3DVortex%2520keratopathy%2520presumed%2520secondary%2520to%2520AZD9291%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D1807%26epage%3D1808%26doi%3D10.1097%2FJTO.0000000000000634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">23–24</span>),  <span class="NLM_fpage">6135</span>– <span class="NLM_lpage">6145</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmc.2018.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30442506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKlsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=6135-6145&issue=23%E2%80%9324&author=P.+Zhouauthor=G.+Chenauthor=M.+Gaoauthor=J.+Wu&title=Design%2C+synthesis+and+evaluation+of+the+osimertinib+analogue+%28C-005%29+as+potent+EGFR+inhibitor+against+NSCLC&doi=10.1016%2Fj.bmc.2018.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC</span></div><div class="casAuthors">Zhou, Ping; Chen, Gang; Gao, Minqi; Wu, Jiaquan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">6135-6145</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Osimertinib has been approved as a first-line treatment for non-small-cell lung cancer (NSCLC) patients whose tumor carries EGFR activation and / or resistant mutations.  To mitigate Osimertinib's toxicity caused by AZ5104, the N-demethylation metabolite of Osimertinib, we designed and synthesized a series of Osimertinib analogs with different headpieces.  In vitro and in vivo anal. rendered a potential clin. candidate C-005 which had pyrrolo-pyridine headpiece.  Biochem., C-005 and its main human hepatocyte metabolite showed over 30 fold selectivity of L858R/T790M mutant EGFR over WT EGFR.  Such selectivity profile was retained at cellular level.  In general, C-005 is 2-14 fold more selective than Osimertinib in a panel of WT EGFR cancer cell lines.  Furthermore, C-005 demonstrated robust antitumor efficacy and good tolerability in NCI-H1975, PC-9 and HCC827 xenograft mouse models, making it a potential candidate for human test in clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSjal-LKXd9LVg90H21EOLACvtfcHk0lhChEwo2TRddw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKlsrbK&md5=0c4fd24d4f1b58ab1ee3e84e875304d3</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520the%2520osimertinib%2520analogue%2520%2528C-005%2529%2520as%2520potent%2520EGFR%2520inhibitor%2520against%2520NSCLC%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D23%25E2%2580%259324%26spage%3D6135%26epage%3D6145%26doi%3D10.1016%2Fj.bmc.2018.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1586/14737140.2016.1162103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1586%2F14737140.2016.1162103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26943236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=383-390&issue=4&author=X.+Gaoauthor=X.+Leauthor=D.+B.+Costa&title=The+safety+and+efficacy+of+osimertinib+for+the+treatment+of+EGFR+T790M+mutation+positive+non-small-cell+lung+cancer&doi=10.1586%2F14737140.2016.1162103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span></div><div class="casAuthors">Gao, Xin; Le, Xiuning; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-390</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R).  However, acquired resistance to EGFR TKI monotherapy occurs invariably within a median time frame of one year.  The most common form of biol. resistance is through the selection of tumor clones harboring the EGFR T790M mutation, present in >50% of repeat biopsies.  The presence of the EGFR T790M mutation negates the inhibitory activity of gefitinib, erlotinib, and afatinib.  A novel class of third-generation EGFR TKIs has been identified by probing a series of covalent pyrimidine EGFR inhibitors that bind to amino-acid residue C797 of EGFR and preferentially inhibit mutant forms of EGFR vs. the wild-type receptor.  We review the rapid clin. development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnBfOip3HqtrVg90H21EOLACvtfcHk0lh7iw5eP6HCjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D&md5=6fd22c935476d396b1560f9a784cb9df</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1586%2F14737140.2016.1162103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2016.1162103%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520osimertinib%2520for%2520the%2520treatment%2520of%2520EGFR%2520T790M%2520mutation%2520positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2016%26volume%3D16%26issue%3D4%26spage%3D383%26epage%3D390%26doi%3D10.1586%2F14737140.2016.1162103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0064.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. EGFR-TK inhibitors (EGFR-TKIs) and problems associated with them.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The C797S undruggable tertiary mutation leads to a loss of the covalent bond of Osimertinib with the Cys797 residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EGFR-driven signaling mechanisms in NSCLC. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> under Creative Commons CC BY 4.0. Copyright 2018, Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Resistance to Osimertinib in NSCLC involves both EGFR-dependent and EGFR-independent mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparative percentage of the EGFR-dependent and EGFR-independent resistance to Osimertinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Different strategies to overcome the acquired resistance to Osimertinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Activity profile and binding mode of Brigatinib. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> under Creative Commons CC BY 4.0. Copyright 2017, Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rational design of macrocyclic BI-4020 (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Biological data and binding mode of <b>JND3229</b> with EGFR L858R/T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>.)<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure of compound <b>5</b> with its enzymatic activity against WT EGFR and L858R/T790M/C797S EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Lead structure compound <b>7</b> obtained from a WT EGFR enzyme assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of <b>8</b> and <b>9</b> and their kinase-inhibitory activities against drug-resistant mutant variants of EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Development of potent EGFR L858R/T790M/C797S inhibitors by the target hopping approach from p38α MAPK inhibitor <b>10</b> templates. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>. Copyright 2017, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of <b>11</b> and <b>12</b> with biological data against EGFR L858R/T790M/C797S and the binding mode of <b>12</b> at the ATP binding site. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>. Copyright 2017, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of <b>13</b>, <b>14</b>, and <b>15</b> along with inhibitory activities toward EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Binding mode of compound <b>13</b> occupying the ATP binding site (HR, hydrophobic region).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Biological activity profile of compounds <b>16</b>–<b>19</b> against Del19/T790M/C797S EGFR TK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of <b>19</b> and its illustrated binding interaction with EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a>. Copyright 2018, American Chemical Society”).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of JND3229 (<b>4</b>) and the irreversible inhibitor <b>20</b> and the superimposition of JND3229 (<b>4</b>) with <b>20</b> in EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP">5GMP</a>). Reprinted (adapted) with permission from ref <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Biological activity profile of compound <b>21</b> and its binding mode with EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO">5ZTO</a>). Reprinted (adapted) with permission from ref <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Crystallographic structure of compound <b>21</b> with (A) EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ">6JRJ</a>) and (B) WT EGFR (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK">6JRK</a>). Reprinted (adapted) with permission from ref <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Design strategy of 2,4,6-trisubstituted pyrido[3,4-<i>d</i>]pyrimidine derivatives (<b>22B</b>) from previously reported EGFR-TKIs compound <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Biological activity profile of compound <b>23</b> and its binding interaction with EGFR L858R/T790M/C797S. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a>. Copyright 2018, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Target scaffold hopping strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure and enzyme activity of compound <b>25</b> against EGFR L858R/T790M/C797S</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Design strategy of target (mutant-selective) compounds</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structures of promising 9-heterocyclyl-substituted 9<i>H</i>-purines and their activity toward EGFR L858R/T790M/C797S (<b>27</b>–<b>30</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Molecular docking of (A) <b>28</b> and (B) <b>30</b> with EGFR T790M/C797S (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a>. Copyright 2019, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. EGFR inhibition data along with the chemical structure of the pyrrolo-pyrimidine scaffold-containing potent compounds <b>31</b>–<b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Biological data of compound <b>35</b> and its binding interaction with the EGFR T790M/C797S cavity (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRX">6JRX</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a>. Copyright 2019, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Bond rotation leads to the racemization of atropisomers with a selective kinase inhibitor</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Chemical structure of <b>(R</b><sub><b>a</b></sub><b>)-37</b></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Chemical structure and biological activity of compound <b>38</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Chemical structure and biological activity of <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Chemical structures and biological activities of <b>40</b>–<b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Chemical structures and biological activities of <b>43</b>–<b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Chemical structury and biological activity of <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0038.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Chemical structure and antiproliferative activities of <b>47</b> and <b>48</b> against Ba/F3 EGFR Del19/T790M/C797S cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Chemical structure and enzymatic activity of compound <b>49</b> against EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0040.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Chemical structures and enzymatic activities of compound <b>50</b> and <b>51</b> against EGFR Del19/T790M/C797S and EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0041.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Chemical structures and enzymatic activities of compound <b>52</b> and <b>53</b> against EGFR L858R/T790M/C797S.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0042.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structural optimization of EAI045 (<b>55</b>) from EAI001 (<b>54</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0043.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Binding approach of EAI001 (<b>54</b>) in EGFR T790M/V948R kinase (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a>. Copyright 2018, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0044.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Chemical structures of JBJ-04-125-02 (<b>56</b>) and JBJ-02-112-05 (<b>57</b>), which were functionalized from EAI045 and EAI001, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0045.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Development of a nonpeptidic analogue of EAI001 (<b>54</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0046.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. The TREA-0236 (<b>58</b>) (thick yellow sticks) and EAI001 (<b>54</b>) (thin green lines) binding interaction with EGFR T790M/V948R. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a>. Copyright 2018, John Wiley and Sons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0047.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structure-based optimization of EAI002 (<b>59</b>) afforded DDC4002 (<b>60</b>) and the chemical structure of C-2-functionalized compounds (<b>61</b>–<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0048.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Binding of DDC4002 (<b>60</b>) at the allosteric pocket. Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0049.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Chemical structures and biological activities of <b>64</b> and <b>65</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0050.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. Chemical structures of EAI045 (<b>55</b>), Vandetanib (<b>66</b>), and the tailored compound <b>67</b> along with their respective kinase binding sites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0051.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. Binding pose of compound <b>67</b> in triple-mutant EGFR (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5d4">5d4</a>). Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0052.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. Chemical structures of MET inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0053.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. Chemical structures of MEK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0054.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. Chemical structures of ALK Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0055.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Chemical structure of FGFR1 inhibitor AZD4547.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0056.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Chemical structures of HER2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0057.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Chemical structures of AKT Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0058.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Chemical structures of AXL Inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0059.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. Chemical structures of the BRAF V600E inhibitor Encorafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0060.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Mechanism of protein degradation induced by proteolysis-targeting chimera (PROTAC) technology. (Reprinted (adapted) with permission from ref. <a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a>. Copyright 2018, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0061.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. Chemical structure and biological activity of the EGFR degrader <b>85</b> prepared from Osimertinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0062.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. Chemical structures of EGFR degraders <b>86</b> and <b>87</b> with their DC<sub>50</sub> values on HCC827 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/medium/jm1c00876_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0063.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. Bidentate binding of the ATP-competitive inhibitors at L858R/T790M/C797S EGFR-TK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00876&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 237 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaby-Sandy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1634%2Ftheoncologist.2017-0582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29650685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=891-899&issue=8&author=C.+Y.+Chuauthor=J.+Choiauthor=B.+Eaby-Sandyauthor=C.+J.+Langerauthor=M.+E.+Lacouture&title=Osimertinib%3A+a+novel+dermatologic+adverse+event+profile+in+patients+with+lung+cancer&doi=10.1634%2Ftheoncologist.2017-0582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer</span></div><div class="casAuthors">Chu Chia-Yu; Choi Jennifer; Eaby-Sandy Beth; Langer Corey J; Lacouture Mario E</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.  First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described.  However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs.  Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S.  Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy.  Case summaries of patients from two of our institutions who received osimertinib and were referred to a dermatologist for dAEs are also presented.  Overall, the evidence suggests that osimertinib is associated with less severe and less frequent dAEs than first- and second-generation EGFR-TKIs and that therefore a different approach is warranted.  Finally, we outline dAE management approaches for osimertinib in the context of those typically employed with first- and second-generation EGFR-TKIs.  IMPLICATIONS FOR PRACTICE:  Appropriate prevention and management of dermatologic adverse events (dAEs) associated with the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) may help patients to continue therapy and lessen any negative impact on their quality of life.  EGFR-TKIs are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; however, dAEs associated with third-generation EGFR-TKIs are lower in frequency and severity.  Before therapy, health care providers should discuss the potential osimertinib-associated dAEs and encourage patients to report their dAEs.  Patients should also be educated on prophylactic measures to minimize the severity of dAEs and the importance of adherence to the treatment regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTh0a0oxGmJqYqdXsLcGTEUfW6udTcc2eaN3TNDXvpRB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D&md5=1dcf61eb0461f9495deaf9b7f2c77601</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0582%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DEaby-Sandy%26aufirst%3DB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26atitle%3DOsimertinib%253A%2520a%2520novel%2520dermatologic%2520adverse%2520event%2520profile%2520in%2520patients%2520with%2520lung%2520cancer%26jtitle%3DOncologist%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D891%26epage%3D899%26doi%3D10.1634%2Ftheoncologist.2017-0582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition</span>. <i>Comput. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.compbiolchem.2018.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.compbiolchem.2018.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29627693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1aqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=167-189&author=H.+Patelauthor=R.+Pawaraauthor=S.+Surana&title=In-silico+evidences+for+binding+of+Glucokinase+activators+to+EGFR+C797S+to+overcome+EGFR+resistance+obstacle+with+mutant-selective+allosteric+inhibition&doi=10.1016%2Fj.compbiolchem.2018.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Computational Biology and Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-189</span>CODEN:
                <span class="NLM_cas:coden">CBCOCH</span>;
        ISSN:<span class="NLM_cas:issn">1476-9271</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are generally utilized as a part of patients with non-small cell lung carcinoma (NSCLC).  However, EGFR T790M mutation results in resistance to most clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation has been in active clin. development to triumph the resistance problem; they covalently bind with conserved Cys797 inside the EGFR active site, offering both potency and kinase-selectivity.  Third generation drugs target C797, which makes the C797S resistance mutation more subtle.  EGFR C797S mutation was accounted to be a main mechanism of resistance to the third-generation inhibitors.  The C797S mutation gives off an impression of being an ideal target for conquering the acquired resistance to the third generation inhibitors.  We have performed structure based-virtual screening strategies for binding of glucokinase activator to EGFR C797S, which can overcome EGFR resistance impediment with mutant-selective allosteric inhibition towards all kinds of mutant EGFR (T790M, L858R, TMLR) and WT EGFR.  The final filter of Lipinski's Rule of Five, Jargan's Rule of Three and in silico ADME predictions gave 23 hits, which conform to Lipinski's rule and Jorgensen's rule and all their pharmacokinetic parameters are inside the appropriate range characterized for human use, in this manner demonstrating their potential as a drug-like mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9XS03I3Ohv7Vg90H21EOLACvtfcHk0lgrF0i-3PZAdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1aqu7c%253D&md5=549aae7443376313c5bea468b401478c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiolchem.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiolchem.2018.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DIn-silico%2520evidences%2520for%2520binding%2520of%2520Glucokinase%2520activators%2520to%2520EGFR%2520C797S%2520to%2520overcome%2520EGFR%2520resistance%2520obstacle%2520with%2520mutant-selective%2520allosteric%2520inhibition%26jtitle%3DComput.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D74%26spage%3D167%26epage%3D189%26doi%3D10.1016%2Fj.compbiolchem.2018.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">FLAURA investigators. overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1913662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1913662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31751012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=41-50&issue=1&author=S.+S.+Ramalingamauthor=J.+Vansteenkisteauthor=D.+Planchardauthor=B.+C.+Choauthor=J.+E.+Grayauthor=Y.+Oheauthor=C.+Zhouauthor=T.+Reungwetwattanaauthor=Y.+Chengauthor=B.+Chewaskulyongauthor=R.+Shahauthor=M.+Coboauthor=K.+H.+Leeauthor=P.+Cheemaauthor=M.+Tiseoauthor=T.+Johnauthor=M.+C.+Linauthor=F.+Imamuraauthor=T.+Kurataauthor=A.+Toddauthor=R.+Hodgeauthor=M.+Saggeseauthor=Y.+Rukazenkovauthor=J.+C.+Soria&title=FLAURA+investigators.+overall+survival+with+osimertinib+in+untreated%2C+EGFR-mutated+advanced+NSCLC&doi=10.1056%2FNEJMoa1913662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span></div><div class="casAuthors">Ramalingam, S. S.; Vansteenkiste, J.; Planchard, D.; Cho, B. C.; Gray, J. E.; Ohe, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; Shah, R.; Cobo, M.; Lee, K. H.; Cheema, P.; Tiseo, M.; John, T.; Lin, M.-C.; Imamura, F.; Kurata, T.; Todd, A.; Hodge, R.; Saggese, M.; Rukazenkov, Y.; Soria, J.-C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI- sensitizing and EGFR T790M resistance mutations.  A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).  Data from the final anal. of overall survival have not been reported. methods In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).  Overall survival was a secondary end point. results The median overall survival was 38.6 mo (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 mo (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).  At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 mo and 11.5 mo, resp.  Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. conclusions Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.  The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq081UIt-O5nrVg90H21EOLACvtfcHk0lgrF0i-3PZAdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D&md5=2f78a87d4578be09e07e91f303b71acf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1913662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1913662%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DCheema%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DM.%2BC.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DSaggese%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFLAURA%2520investigators.%2520overall%2520survival%2520with%2520osimertinib%2520in%2520untreated%252C%2520EGFR-mutated%2520advanced%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26issue%3D1%26spage%3D41%26epage%3D50%26doi%3D10.1056%2FNEJMoa1913662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranuma, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiraoka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uramoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in elderly patients with epidermal growth factor receptor T790M-positive non-small-cell lung cancer who progressed during prior treatment: a phase II trial</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">e170</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2019-0003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1634%2Ftheoncologist.2019-0003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30651400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKhsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=593-e170&issue=5&author=A.+Nakaoauthor=O.+Hiranumaauthor=J.+Uchinoauthor=C.+Sakaguchiauthor=T.+Kitaauthor=N.+Hiraokaauthor=T.+Ishizukaauthor=Y.+Kubotaauthor=M.+Kawasakiauthor=Y.+Gotoauthor=H.+Imaiauthor=N.+Hattoriauthor=K.+Nakatomiauthor=H.+Uramotoauthor=K.+Uryuauthor=M.+Fukudaauthor=Y.+Uchidaauthor=T.+Yokoyamaauthor=M.+Akaiauthor=T.+Mioauthor=S.+Nagashimaauthor=Y.+Chiharaauthor=N.+Tamiyaauthor=Y.+Kanekoauthor=T.+Mouriauthor=T.+Yamadaauthor=K.+Yoshimuraauthor=M.+Fujitaauthor=K.+Takayama&title=Osimertinib+in+elderly+patients+with+epidermal+growth+factor+receptor+T790M-positive+non-small-cell+lung+cancer+who+progressed+during+prior+treatment%3A+a+phase+II+trial&doi=10.1634%2Ftheoncologist.2019-0003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial</span></div><div class="casAuthors">Nakao, Akira; Hiranuma, Osamu; Uchino, Junji; Sakaguchi, Chikara; Kita, Toshiyuki; Hiraoka, Noriya; Ishizuka, Tamotsu; Kubota, Yutaka; Kawasaki, Masayuki; Goto, Yasuhiro; Imai, Hisao; Hattori, Noboru; Nakatomi, Keita; Uramoto, Hidetaka; Uryu, Kiyoaki; Fukuda, Minoru; Uchida, Yasuki; Yokoyama, Toshihide; Akai, Masaya; Mio, Tadashi; Nagashima, Seiji; Chihara, Yusuke; Tamiya, Nobuyo; Kaneko, Yoshiko; Mouri, Takako; Yamada, Tadaaki; Yoshimura, Kenichi; Fujita, Masaki; Takayama, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">593-e170</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.  In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-pos. NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.  Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted.  Previous findings suggest the possibility of relatively safe use of osimertinib for patients with T790M-pos. non-small-cell lung cancer (NSCLC), with few serious adverse events for the elderly in comparison with conventional endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and with an antitumor effect.  This phase II study was performed to prospectively investigate the efficacy and safety of osimertinib for elderly patients aged ≥75 years with ineffective prior EGFR TKI treatment or with recurrence in T790M EGFR TKI resistance mutation-pos. NSCLC.  A total of 36 patients were included in the analyses.  Among the 36 subjects, 63.9% were female, with mean age of 79.9 years.  The objective response rate (ORR) was 58.3% (95% confidence interval [CI], 42.2%-72.9%), demonstrating statistically significant efficacy of osimertinib (p = .0017).  The median duration of response (DOR) was 27.9 wk (95% CI, 21.1-82.0).  Complete response (CR) and partial response (PR) were 2.8% and 55.6%, resp.  Disease control rate (DCR) was 97.2%.  A waterfall plot revealed that 33 (91.6%) subjects exhibited tumor shrinkage during treatment, including 12 of 14 subjects who had stable disease (SD).  All adverse events were not reason for discontinuation of the study drug.  Osimertinib may be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrngojBHrIKvLVg90H21EOLACvtfcHk0lgrF0i-3PZAdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKhsL7K&md5=1870d8be9a1a1f1f4b1e6f074a89139c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2019-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2019-0003%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DA.%26aulast%3DHiranuma%26aufirst%3DO.%26aulast%3DUchino%26aufirst%3DJ.%26aulast%3DSakaguchi%26aufirst%3DC.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DHiraoka%26aufirst%3DN.%26aulast%3DIshizuka%26aufirst%3DT.%26aulast%3DKubota%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DHattori%26aufirst%3DN.%26aulast%3DNakatomi%26aufirst%3DK.%26aulast%3DUramoto%26aufirst%3DH.%26aulast%3DUryu%26aufirst%3DK.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DAkai%26aufirst%3DM.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DNagashima%26aufirst%3DS.%26aulast%3DChihara%26aufirst%3DY.%26aulast%3DTamiya%26aufirst%3DN.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DMouri%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DYoshimura%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DTakayama%26aufirst%3DK.%26atitle%3DOsimertinib%2520in%2520elderly%2520patients%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520T790M-positive%2520non-small-cell%2520lung%2520cancer%2520who%2520progressed%2520during%2520prior%2520treatment%253A%2520a%2520phase%2520II%2520trial%26jtitle%3DOncologist%26date%3D2019%26volume%3D24%26issue%3D5%26spage%3D593%26epage%3De170%26doi%3D10.1634%2Ftheoncologist.2019-0003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokwani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S. J.</span></span> <span> </span><span class="NLM_article-title">BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non-small cell lung cancer (NSCLC)</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2838</span>– <span class="NLM_lpage">2856</span>, <span class="refDoi"> DOI: 10.1080/07391102.2020.1754918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F07391102.2020.1754918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32276580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslWgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2021&pages=2838-2856&author=H.+M.+Patelauthor=M.+Shaikhauthor=I.+Ahmadauthor=D.+Lokwaniauthor=S.+J.+Surana&title=BREED+based+de+novo+hybridization+approach%3A+generating+novel+T790M%2FC797S-EGFR+tyrosine+kinase+inhibitors+to+overcome+the+problem+of+mutation+and+resistance+in+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1080%2F07391102.2020.1754918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Patel, Harun M.; Shaikh, Matin; Ahmad, Iqrar; Lokwani, Deepak; Surana, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2838-2856</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-pos. Non-Small Cell Lung Cancer (NSCLC) patients in 2017.  However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs.  In this work, we have reported the novel T790M/C797S-EGFR Tyrosine Kinase inhibitors using BREED based de novo hybridization approach.  BREED generates novel inhibitors from structures of known ligands bound to a common target.  Among the generated hybridized breed compds., the top best scorer breed mols. were breed 436, breed 530, breed 450, breed 562 and breed 313.  Mol. Dynamics simulation of breed 436 for 10 ns further suggested that docked compd. was stable into the pocket of the T790M/C797S-EGFR Tyrosine Kinase.  In silico pharmacokinetic predictions of the breed hybridized compds. were within the defined range described for human use.Communicated by Ramaswamy H.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAu4MNDy34ibVg90H21EOLACvtfcHk0lhLLzwZrxbi8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslWgsLk%253D&md5=e00e6693d1c438495b7f19438a4ba0bc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F07391102.2020.1754918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2020.1754918%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BM.%26aulast%3DShaikh%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DLokwani%26aufirst%3DD.%26aulast%3DSurana%26aufirst%3DS.%2BJ.%26atitle%3DBREED%2520based%2520de%2520novo%2520hybridization%2520approach%253A%2520generating%2520novel%2520T790M%252FC797S-EGFR%2520tyrosine%2520kinase%2520inhibitors%2520to%2520overcome%2520the%2520problem%2520of%2520mutation%2520and%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2021%26volume%3D39%26spage%3D2838%26epage%3D2856%26doi%3D10.1080%2F07391102.2020.1754918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Advance online publication.</p></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnew, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascara, G. P.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation</span>. <i>J. Oncol. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1177/1078155217712401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1177%2F1078155217712401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28565936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyjsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=379-388&issue=5&author=M.+K.+Bollingerauthor=A.+S.+Agnewauthor=G.+P.+Mascara&title=Osimertinib%3A+a+third-generation+tyrosine+kinase+inhibitor+for+treatment+of+epidermal+growth+factor+receptor-mutated+non-small+cell+lung+cancer+with+the+acquired+Thr790Met+mutation&doi=10.1177%2F1078155217712401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation</span></div><div class="casAuthors">Bollinger, Meredith K.; Agnew, Amanda S.; Mascara, Gerard P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-388</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-pos. non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy.  The T790M mutation is an acquired resistance mechanism found in over half of patients with NSCLC progressing on first-generation TKIs.  First- and second-generation TKIs do not inhibit the T790M mutation at clin. relevant concns.  Osimertinib is selective for mutated forms of EGFR, including the TKI-sensitizing mutations L858R and exon 19 deletions, as well as the acquired T790M resistance mutation.  In a trial comparing osimertinib to platinum doublet therapy among patients with the T790M mutation progressing on first-line TKI therapy, median progression-free survival was significantly longer in patients receiving osimertinib.  Osimertinib has a favorable safety profile compared to platinum-doublet chemotherapy.  Common adverse events include diarrhea, skin rash, dry skin, and paronychia; however, because it spares wild-type EGFR, these toxicities appear to occur with less frequency and severity compared to other TKIs.  Serious, but rare, adverse events include pneumonitis, interstitial lung disease-like events, QT interval prolongation, and reduced ejection fraction.  Osimertinib has the unique ability to distribute readily into brain tissue compared with other TKIs, giving it a potential role in the treatment and/or prevention of CNS metastases; future studies are warranted in this area.  An ongoing study evaluating osimertinib vs. first-generation TKIs as first-line treatment for patients with EGFR mutation-pos. NSCLC may help to define the role of osimertinib as front-line therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq3k6YMavK87Vg90H21EOLACvtfcHk0lhLLzwZrxbi8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyjsL3I&md5=102942b63a5133229325e59b967565ea</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1177%2F1078155217712401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155217712401%26sid%3Dliteratum%253Aachs%26aulast%3DBollinger%26aufirst%3DM.%2BK.%26aulast%3DAgnew%26aufirst%3DA.%2BS.%26aulast%3DMascara%26aufirst%3DG.%2BP.%26atitle%3DOsimertinib%253A%2520a%2520third-generation%2520tyrosine%2520kinase%2520inhibitor%2520for%2520treatment%2520of%2520epidermal%2520growth%2520factor%2520receptor-mutated%2520non-small%2520cell%2520lung%2520cancer%2520with%2520the%2520acquired%2520Thr790Met%2520mutation%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2018%26volume%3D24%26issue%3D5%26spage%3D379%26epage%3D388%26doi%3D10.1177%2F1078155217712401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">BIM deletion polymorphism confers resistance to osimertinib in EGFR T790M lung cancer: a case report and literature review</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1007/s11523-018-0573-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1007%2Fs11523-018-0573-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29907952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MbnvVKnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=517-523&issue=4&author=X.+Liauthor=S.+Wangauthor=B.+Liauthor=Z.+Wangauthor=S.+Shangauthor=Y.+Shaoauthor=X.+Sunauthor=L.+Wang&title=BIM+deletion+polymorphism+confers+resistance+to+osimertinib+in+EGFR+T790M+lung+cancer%3A+a+case+report+and+literature+review&doi=10.1007%2Fs11523-018-0573-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review</span></div><div class="casAuthors">Li Xuanzong; Li Xuanzong; Wang Shijiang; Li Butuo; Shang Shuheng; Sun Xindong; Wang Linlin; Li Butuo; Wang Zhen; Shang Shuheng; Shao Yang; Shao Yang</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-523</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients.  However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated.  The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; and is a poor prognostic factor for NSCLC patients with EGFR mutations.  Nevertheless, the significance of this BIM deletion polymorphism in the resistance to osimertinib has not been reported.  Here, we show for the first time that a NSCLC patient harboring the EGFR L858R/T790M mutations, as well as the BIM deletion polymorphism, exhibited poor clinical outcomes with osimertinib treatment.  This result suggests that the BIM deletion polymorphism might have prognostic value for determining NSCLC patient outcomes following osimertinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZgrjbD2HJ_dhSDZx9hyjKfW6udTcc2eap6JBFS9iJCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbnvVKnuw%253D%253D&md5=55a627f9ce4954677c388f4959ba6886</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs11523-018-0573-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-018-0573-2%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DShang%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DBIM%2520deletion%2520polymorphism%2520confers%2520resistance%2520to%2520osimertinib%2520in%2520EGFR%2520T790M%2520lung%2520cancer%253A%2520a%2520case%2520report%2520and%2520literature%2520review%26jtitle%3DTarget%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D4%26spage%3D517%26epage%3D523%26doi%3D10.1007%2Fs11523-018-0573-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaby-Sandy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1634%2Ftheoncologist.2017-0582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29650685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=891-899&issue=8&author=C.+Y.+Chuauthor=J.+Choiauthor=B.+Eaby-Sandyauthor=C.+J.+Langerauthor=M.+E.+Lacouture&title=Osimertinib%3A+a+novel+dermatologic+adverse+event+profile+in+patients+with+lung+cancer&doi=10.1634%2Ftheoncologist.2017-0582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer</span></div><div class="casAuthors">Chu Chia-Yu; Choi Jennifer; Eaby-Sandy Beth; Langer Corey J; Lacouture Mario E</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.  First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described.  However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs.  Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S.  Food and Drug Administration for the treatment of metastatic, EGFR T790M mutation-positive non-small cell lung cancer in patients whose disease has progressed on or after EGFR-TKI therapy.  Case summaries of patients from two of our institutions who received osimertinib and were referred to a dermatologist for dAEs are also presented.  Overall, the evidence suggests that osimertinib is associated with less severe and less frequent dAEs than first- and second-generation EGFR-TKIs and that therefore a different approach is warranted.  Finally, we outline dAE management approaches for osimertinib in the context of those typically employed with first- and second-generation EGFR-TKIs.  IMPLICATIONS FOR PRACTICE:  Appropriate prevention and management of dermatologic adverse events (dAEs) associated with the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) may help patients to continue therapy and lessen any negative impact on their quality of life.  EGFR-TKIs are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; however, dAEs associated with third-generation EGFR-TKIs are lower in frequency and severity.  Before therapy, health care providers should discuss the potential osimertinib-associated dAEs and encourage patients to report their dAEs.  Patients should also be educated on prophylactic measures to minimize the severity of dAEs and the importance of adherence to the treatment regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTh0a0oxGmJqYqdXsLcGTEUfW6udTcc2eZJBxwglgCINrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjit1emsg%253D%253D&md5=1dcf61eb0461f9495deaf9b7f2c77601</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0582%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DEaby-Sandy%26aufirst%3DB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26atitle%3DOsimertinib%253A%2520a%2520novel%2520dermatologic%2520adverse%2520event%2520profile%2520in%2520patients%2520with%2520lung%2520cancer%26jtitle%3DOncologist%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D891%26epage%3D899%26doi%3D10.1634%2Ftheoncologist.2017-0582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">i20</span>– <span class="NLM_lpage">i27</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29462255" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i20-i27&issue=1&author=J.+Remonauthor=C.+E.+Steuerauthor=S.+S.+Ramalingamauthor=E.+Felip&title=Osimertinib+and+other+third-generation+EGFR+TKI+in+EGFR-mutant+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdx704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx704%26sid%3Dliteratum%253Aachs%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DSteuer%26aufirst%3DC.%2BE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DOsimertinib%2520and%2520other%2520third-generation%2520EGFR%2520TKI%2520in%2520EGFR-mutant%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D1%26spage%3Di20%26epage%3Di27%26doi%3D10.1093%2Fannonc%2Fmdx704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title"><i>In silico</i> search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): A combined approach of structure-based virtual screening and molecular dynamics simulation</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1505</span>, <span class="refDoi"> DOI: 10.1080/07391102.2020.1734092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F07391102.2020.1734092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32102624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVWlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2021&pages=1491-1505&issue=4&author=H.+M.+Patelauthor=I.+Ahmadauthor=R.+Pawaraauthor=M.+Shaikhauthor=S.+Surana&title=In+silico+search+of+triple+mutant+T790M%2FC797S+allosteric+inhibitors+to+conquer+acquired+resistance+problem+in+non-small+cell+lung+cancer+%28NSCLC%29%3A+A+combined+approach+of+structure-based+virtual+screening+and+molecular+dynamics+simulation&doi=10.1080%2F07391102.2020.1734092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation</span></div><div class="casAuthors">Patel, Harun M.; Ahmad, Iqrar; Pawara, Rahul; Shaikh, Matin; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1491-1505</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-pos. Non-Small Cell Lung Cancer (NSCLC) patients in 2017.  However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs.  Recently, EAI045 fourth-generation allosteric EGFR inhibitor has been reported, which binds away from the ATP-binding site and not rely on Cys 797 binding.  Here, we are reporting compd. ZINC20531199 by virtual based screening studies as allosteric inhibitor to overcome the EGFR T790M/C797S Tyrosine Kinase (TK) mutation problem.  Mol. Dynamics simulation for 10 ns further suggested that docked compd. ZINC20531199 was stable into the allosteric pocket of the C797S EGFR tyrosine kinase.  In silico pharmacokinetic predictions of the virtually screened compds. are within the defined range described for human use.  Results indicate that the virtual screened compds. could be potential leads for the further development of new allosteric EGFR T790M/C797S inhibitors to overcome the problem of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPl-guE2VQo7Vg90H21EOLACvtfcHk0lixRzAhlOcM-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVWlt7w%253D&md5=f8ce92001fd1fa112fa5a7b34c215d49</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F07391102.2020.1734092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2020.1734092%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BM.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DShaikh%26aufirst%3DM.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DIn%2520silico%2520search%2520of%2520triple%2520mutant%2520T790M%252FC797S%2520allosteric%2520inhibitors%2520to%2520conquer%2520acquired%2520resistance%2520problem%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520A%2520combined%2520approach%2520of%2520structure-based%2520virtual%2520screening%2520and%2520molecular%2520dynamics%2520simulation%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2021%26volume%3D39%26issue%3D4%26spage%3D1491%26epage%3D1505%26doi%3D10.1080%2F07391102.2020.1734092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisamatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span> <span> </span><span class="NLM_article-title">Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status</span>. <i>Jpn. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1093/jjco/hyz041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fjjco%2Fhyz041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30920616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3cbptVeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=671-675&issue=7&author=K.+Nakashimaauthor=M.+Kimuraauthor=H.+Akamatsuauthor=H.+Dagaauthor=H.+Imaiauthor=T.+Tairaauthor=R.+Koauthor=Y.+Hisamatsuauthor=K.+Nishinoauthor=T.+Sugimotoauthor=Y.+Miyashitaauthor=T.+Takahashi&title=Osimertinib+for+patients+with+EGFR+T790M+mutation-positive+non-small-cell+lung+cancer+and+a+poor+performance+status&doi=10.1093%2Fjjco%2Fhyz041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status</span></div><div class="casAuthors">Nakashima Kazuhisa; Takahashi Toshiaki; Kimura Madoka; Nishino Kazumi; Akamatsu Hiroaki; Sugimoto Takeya; Daga Haruko; Imai Hisao; Taira Tetsuhiko; Ko Ryo; Miyashita Yosuke; Hisamatsu Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Japanese journal of clinical oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-675</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS).  However, the efficacy and safety of osimertinib for patients with poor PS is unknown.  METHODS:  We retrospectively evaluated the efficacy and safety of osimertinib in patients with EGFR T790M mutation-positive NSCLC who had Eastern Cooperative Oncology Group PS scores of 2-4 and who were administered 80 mg of osimertinib once daily between March 2016 and February 2017.  RESULTS:  Thirty patients (8 men and 22 women) with EGFR T790M mutation-positive NSCLC were evaluated; their median age was 66 years (range: 39-89 years).  Twenty-four and six patients had PS scores of 2 and 3, respectively; none had a PS score of 4.  All patients had previously been treated with first- or second-generation EGFR-TKIs.  T790M was detected in the tumor samples of 23 patients, the blood samples of two patients, and both the tumor and blood samples of five patients.  The overall response rate was 53% (95% confidence interval: 36-70%), and the PS score improvement rate was 63%.  The median progression-free survival was 8.2 months (95% confidence interval: 4.3-13.2 months), while the median overall survival time was not reached.  No patient required treatment cessation owing to adverse events, and no treatment-related deaths occurred.  CONCLUSIONS:  Osimertinib therapy demonstrates promising efficacy and acceptable safety in patients with EGFR T790M mutation-positive NSCLC who have poor PS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvK5k0nFqxFM25P7XSLhESfW6udTcc2eYBzuY81jElK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbptVeltw%253D%253D&md5=ab3fc3ab1caf701b76966da6021719f1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Fjjco%2Fhyz041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjjco%252Fhyz041%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DM.%26aulast%3DAkamatsu%26aufirst%3DH.%26aulast%3DDaga%26aufirst%3DH.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DTaira%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DR.%26aulast%3DHisamatsu%26aufirst%3DY.%26aulast%3DNishino%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DMiyashita%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26atitle%3DOsimertinib%2520for%2520patients%2520with%2520EGFR%2520T790M%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520and%2520a%2520poor%2520performance%2520status%26jtitle%3DJpn.%2520J.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D49%26issue%3D7%26spage%3D671%26epage%3D675%26doi%3D10.1093%2Fjjco%2Fhyz041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0290-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs13045-016-0290-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27448564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=59&issue=1&author=S.+Wangauthor=S.+T.+Tsuiauthor=C.+Liuauthor=Y.+Songauthor=D.+Liu&title=EGFR+C797S+mutation+mediates+resistance+to+third-generation+inhibitors+in+T790M-positive+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0290-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Tsui, Stella T.; Liu, Christina; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59/1-59/5</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR).  Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance.  AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-pos. non-small cell lung cancer.  Resistance to AZD9291 has been described.  C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors.  This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIJ4ifH6CVz7Vg90H21EOLACvtfcHk0ljpfAdl0T0_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGksbnK&md5=f1c69b429f08a527b9a20bdd567fe21a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0290-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0290-1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520third-generation%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26issue%3D1%26spage%3D59%26doi%3D10.1186%2Fs13045-016-0290-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0ljpfAdl0T0_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lizaso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Effective Treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by Brigatinib and Cetuximab combination therapy</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1369</span>– <span class="NLM_lpage">1375</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2020.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2020.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32353596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1Witb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1369-1375&issue=8&author=Y.+Wangauthor=N.+Yangauthor=Y.+Zhangauthor=L.+Liauthor=R.+Hanauthor=M.+Zhuauthor=M.+Fengauthor=H.+Chenauthor=A.+Lizasoauthor=T.+Qinauthor=X.+Liuauthor=Y.+He&title=Effective+Treatment+of+lung+adenocarcinoma+harboring+EGFR-activating+mutation%2C+T790M%2C+and+cis-C797S+triple+mutations+by+Brigatinib+and+Cetuximab+combination+therapy&doi=10.1016%2Fj.jtho.2020.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy</span></div><div class="casAuthors">Wang, Yubo; Yang, Nong; Zhang, Yongchang; Li Li; Han, Rui; Zhu, Mengxiao; Feng, Mingxia; Chen, Hengyi; Lizaso, Analyn; Qin, Tian; Liu, Xiaoyan; He, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1369-1375</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Acquired resistance to osimertinib mediated by EGFR cis-C797S is now a growing challenge.  No effective treatment strategy is currently available to overcome cis-C797S-mediated resistance.In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing.  Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy.Among the five patients who were pos. for EGFR 19del-T790M-cis-C797S mutations, and who received brigatinib and cetuximab combination therapy, three patients achieved partial response, and two had stable disease, resulting in an overall objective response rate of 60% and disease control rate of 100%.  The median progression-free survival of patients who received combined targeted therapy was 14 mo, and 3 mo for those treated with chemotherapy.  No grade III to IV adverse events were obsd. in any patient.Our retrospective study provides clin. evidence that a combined targeted therapy of brigatinib and cetuximab could be of benefit and may potentially be an effective treatment strategy to improve survival outcomes in patients who acquire EGFR T790M-cis-C797S-mediated resistance to osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOpzxK8qh187Vg90H21EOLACvtfcHk0lh-p29FWq8__g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1Witb8%253D&md5=9416ba28fb6dc504c6015b5da2cc6284</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2020.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2020.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLizaso%26aufirst%3DA.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DEffective%2520Treatment%2520of%2520lung%2520adenocarcinoma%2520harboring%2520EGFR-activating%2520mutation%252C%2520T790M%252C%2520and%2520cis-C797S%2520triple%2520mutations%2520by%2520Brigatinib%2520and%2520Cetuximab%2520combination%2520therapy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D8%26spage%3D1369%26epage%3D1375%26doi%3D10.1016%2Fj.jtho.2020.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rangachari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpilsky, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderLaan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31377341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2rtbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1995-2002&issue=11&author=D.+Rangachariauthor=C.+Toauthor=J.+E.+Shpilskyauthor=P.+A.+VanderLaanauthor=S.+S.+Kobayashiauthor=M.+Mushajiangauthor=C.+J.+Lauauthor=C.+P.+Paweletzauthor=G.+R.+Oxnardauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costa&title=EGFR-mutated+lung+cancers+resistant+to+osimertinib+through+EGFR+C797S+respond+to+first-generation+reversible+EGFR+inhibitors+but+eventually+acquire+EGFR+T790M%2FC797S+in+preclinical+models+and+clinical+samples&doi=10.1016%2Fj.jtho.2019.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples</span></div><div class="casAuthors">Rangachari, Deepa; To, Ciric; Shpilsky, Jason E.; VanderLaan, Paul A.; Kobayashi, Susumu S.; Mushajiang, Mierzhati; Lau, Christie J.; Paweletz, Cloud P.; Oxnard, Geoffrey R.; Janne, Pasi A.; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1995-2002</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance to this third-generation EGFR inhibitor are evolving.  Whether durable control of subsequently osimertinib-resistant NSCLC with EGFR-sensitizing mutation (SM)/C797S is possible with first-generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resultant acquired resistance profile.  We used N-ethyl-N-nitrosourea mutagenesis to det. the profile of EGFR SM/C797S preclin. models exposed to reversible EGFR inhibitors.  A patient with EGFR delE746_T751insV NSCLC was treated with osimertinib with sustained response for 10 mo before acquiring EGFR C797S.  The patient was subsequently treated with erlotinib, with response for a period of 4 mo, but disease progression ensued.  Liq. biopsy disclosed EGFR delE746_T751insV with T790M and C797S present in cis.EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation.  In this clin. scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanisms of on-target resistance-in clin. specimens and preclin. systems-indicate that EGFR C797S along with EGFR T790M can evolve.  This report adds to the growing understanding of tumor evolution or adaptability to sequential EGFR inhibition and augments support for exploring combination therapies to delay or prevent on-target resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLLezOe5dZWbVg90H21EOLACvtfcHk0lh-p29FWq8__g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2rtbjP&md5=ff94c150198c71ec57c7a0a2cea1b746</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DRangachari%26aufirst%3DD.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DShpilsky%26aufirst%3DJ.%2BE.%26aulast%3DVanderLaan%26aufirst%3DP.%2BA.%26aulast%3DKobayashi%26aufirst%3DS.%2BS.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DC.%2BJ.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DEGFR-mutated%2520lung%2520cancers%2520resistant%2520to%2520osimertinib%2520through%2520EGFR%2520C797S%2520respond%2520to%2520first-generation%2520reversible%2520EGFR%2520inhibitors%2520but%2520eventually%2520acquire%2520EGFR%2520T790M%252FC797S%2520in%2520preclinical%2520models%2520and%2520clinical%2520samples%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D11%26spage%3D1995%26epage%3D2002%26doi%3D10.1016%2Fj.jtho.2019.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span> <span> </span><span class="NLM_article-title">Exon 16-Skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31557536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=50-61&issue=1&author=C.+C.+Hsuauthor=B.+C.+Liaoauthor=W.+Y.+Liaoauthor=A.+Markovetsauthor=D.+Stetsonauthor=K.+Thressauthor=J.+C.+Yang&title=Exon+16-Skipping+HER2+as+a+novel+mechanism+of+osimertinib+resistance+in+EGFR+L858R%2FT790M-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2019.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Hsu, Chia-Chi; Liao, Bin-Chi; Liao, Wei-Yu; Markovets, Aleksandra; Stetson, Daniel; Thress, Kenneth; Chih-Hsin Yang, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-61</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We had a patient with EGFR L858R/T790M-pos. NSCLC who initially responded to osimertinib therapy but eventually experienced development of resistance.  Plasma cell-free DNA anal. revealed the occurrence of exon 16-skipping HER2, which may have resulted in the erb-b2 receptor tyrosine kinase 2 gene (HER2) splice variant HER2D16.  HER2D16 has never been reported in lung cancer, and HER2D16-driven signaling is known to be regulated by Src kinase in breast cancer.  We investigated the role of HER2D16 as an osimertinib-resistant mechanism.We constructed and established H1975 cells stably expressing HER2D16.  The dimeric formation of HER2D16 was tested by using nonreducing polyacrylamide gel electrophoresis.  Synergistic effect was assessed by using the Chou-Talalay method.We found that HER2D16 can form a homodimer in NSCLC cells.  We also found that mutant EGFR and HER2D16 cooperated to activate downstream signaling for osimertinib resistance.  In addn., cotreatment with osimertinib and an Src kinase inhibitor failed to reverse resistance, indicating that HER2D16-driven signaling in NSCLC did not occur through a canonical pathway.  Finally, we revealed that the combination of osimertinib with the pan-HER small-mol. inhibitor afatinib could synergistically repress cell growth and signaling in H1975-HER2D16 cells.HER2D16 can contribute to osimertinib resistance through an Src-independent pathway.  HER2D16 should be included in the mol. diagnosis panel for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGJOlmIkbukrVg90H21EOLACvtfcHk0lh-p29FWq8__g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O&md5=b711bc98055e4be3f9f295688878b151</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DB.%2BC.%26aulast%3DLiao%26aufirst%3DW.%2BY.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DExon%252016-Skipping%2520HER2%2520as%2520a%2520novel%2520mechanism%2520of%2520osimertinib%2520resistance%2520in%2520EGFR%2520L858R%252FT790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D50%26epage%3D61%26doi%3D10.1016%2Fj.jtho.2019.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">EGFR-TKIs resistance via EGFR-independent signalling pathways</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0793-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs12943-018-0793-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29455669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=53&issue=1&author=Q.+Liuauthor=S.+Yuauthor=W.+Zhaoauthor=S.+Qinauthor=Q.+Chuauthor=K.+Wu&title=EGFR-TKIs+resistance+via+EGFR-independent+signalling+pathways&doi=10.1186%2Fs12943-018-0793-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-TKIs resistance via EGFR-independent signaling pathways</span></div><div class="casAuthors">Liu, Qian; Yu, Shengnan; Zhao, Weiheng; Qin, Shuang; Chu, Qian; Wu, Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53/1-53/9</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, esp. for those with lung cancer.  Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment.  Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling activations.  In an EGFR-dependent manner, acquired mutations, such as T790 M, interferes the interaction between TKIs and the kinase domain of EGFR.  While in an EGFR-independent manner, dysregulation of other receptor tyrosine kinases (RTKs) or abnormal activation of downstream compds. both have compensatory functions against the inhibition of EGFR through triggering phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) signaling axes.  Nowadays, many clin. trials aiming to overcome and prevent TKIs resistance in various cancers are ongoing or completed.  EGFR-TKIs in accompany with the targeted agents for resistance-related factors afford a promising first-line strategy to further clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSxU7DAlhei7Vg90H21EOLACvtfcHk0lgHr9fwk1LsLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7rL&md5=82b2072295b267dffec9bb58467ae632</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0793-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0793-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DEGFR-TKIs%2520resistance%2520via%2520EGFR-independent%2520signalling%2520pathways%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D53%26doi%3D10.1186%2Fs12943-018-0793-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, M.</span></span> <span> </span><span class="NLM_article-title">Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.pharmthera.2016.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27000770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2016&pages=97-110&author=M.+Kuwanoauthor=K.+Sonodaauthor=Y.+Murakamiauthor=K.+Watariauthor=M.+Ono&title=Overcoming+drug+resistance+to+receptor+tyrosine+kinase+inhibitors%3A+Learning+from+lung+cancer&doi=10.1016%2Fj.pharmthera.2016.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer</span></div><div class="casAuthors">Kuwano, Michihiko; Sonoda, Kahori; Murakami, Yuichi; Watari, Kosuke; Ono, Mayumi</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97-110</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC).  Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied.  Receptor TKIs including EGFR TKIs have shown dramatic therapeutic efficacies in malignant tumors, which harbor activating mutations in the EGFR gene.  However, within 1 or 2 years after treatment, patients harboring these mutations often develop resistance to TKI therapy.  This review article is aimed at drawing attention to the fact that we must first understand how receptor TKI resistance is acquired to develop strategies for overcoming resistance to TKIs.  Furthermore, an insight into the specific mols. or signaling pathways that mediate resistance is a key factor for understanding and overcoming acquired drug resistance.  Finally, we present our views on the continuing battle against "drug resistance," and provide further guidelines and strategies on how to minimize the development of drug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYnPGJoZybbVg90H21EOLACvtfcHk0lgHr9fwk1LsLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCqs7k%253D&md5=97b66a1438e50c7754e0fd06fee17bcb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DKuwano%26aufirst%3DM.%26aulast%3DSonoda%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DWatari%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DM.%26atitle%3DOvercoming%2520drug%2520resistance%2520to%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520Learning%2520from%2520lung%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D161%26spage%3D97%26epage%3D110%26doi%3D10.1016%2Fj.pharmthera.2016.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lgHr9fwk1LsLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2017.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28526474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=32-47&author=H.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=S.+Surana&title=Recent+updates+on+third+generation+EGFR+inhibitors+and+emergence+of+fourth+generation+EGFR+inhibitors+to+combat+C797S+resistance&doi=10.1016%2Fj.ejmech.2017.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Ansari, Azim; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  EGFR T790M mutation leads to resistance to most of clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors.  This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprj-V5hUSHGrVg90H21EOLACvtfcHk0lgCaEKHHwlVhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D&md5=d0ed35bc7deae5ea37a95910df356c1d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DRecent%2520updates%2520on%2520third%2520generation%2520EGFR%2520inhibitors%2520and%2520emergence%2520of%2520fourth%2520generation%2520EGFR%2520inhibitors%2520to%2520combat%2520C797S%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ejmech.2017.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span> <span> </span><span class="NLM_article-title">p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1080/07391102.2020.1844801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F07391102.2020.1844801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB2c%252FpvVWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-14&author=I.+Ahmadauthor=M.+Shaikhauthor=S.+Suranaauthor=A.+Ghoshauthor=H.+Patel&title=p38%CE%B1+MAP+kinase+inhibitors+to+overcome+EGFR+tertiary+C797S+point+mutation+associated+with+osimertinib+in+non-small+cell+lung+cancer+%28NSCLC%29%3A+emergence+of+fourth-generation+EGFR+inhibitor&doi=10.1080%2F07391102.2020.1844801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Heme-iron ligand (M80-Fe) in cytochrome c is destabilizing: combined in vitro and in silico approaches to monitor changes in structure, stability and dynamics of the protein on mutation</span></div><div class="casAuthors">Naiyer Abdullah; Khan Bushra; Islam Asimul; Hassan Md Imtaiyaz; Ahmad Faizan; Sundd Monica</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomolecular structure & dynamics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Structure, stability and dynamics properties of horse cytochrome c (cyt c) and its genetically engineered M80G mutant have been investigated.  The nature of the Met80 axial ligation to heme iron is believed to be the major determinant of the oxidation-reduction reactions inside and outside the cell of a particular cytochrome.  This ligation has played an important role in the studies of protein structure, stability and protein folding/unfolding.  To understand this ligation better, Met80 of horse cyt c has been mutated to Gly that is unable to bind to the heme iron.  We have examined the effect of the M80G mutation on the structure and stability of the WT (wild type) protein by using absorbance spectroscopy, far-UV, near-UV and Soret circular dichroism, fluorescence spectroscopy and differential scanning calorimetry.  We have observed that mutation caused a partial loss of secondary and tertiary structure with slightly increased overall stability of the protein.  We have also measured the dynamic behavior of WT cyt c and its M80G mutant in the oxidized form (Fe(3+)) using the essential dynamics (ED) method.  A 400 ns MD simulations were run for WT cyt c and its mutant M80G in water using GROMOS96 force field.  MD results revealed that the stability and flexibility increased in mutant M80G (Fe...S (Met80) bond removed).  Essential dynamics analysis revealed that the first five eigenvectors were mainly involved in overall motions of WT cyt c and its M80G mutant but the amplitude of concerted motions decreased in M80G mutant relative to WT cyt c.Communicated by Ramaswamy H.  Sarma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRraR2_U_2MCMK3uFsUIZtkfW6udTcc2eatHza7FraNTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB2c%252FpvVWmtw%253D%253D&md5=79df1ce7be71c9a959c06f35b816473c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DShaikh%26aufirst%3DM.%26aulast%3DSurana%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DH.%26atitle%3Dp38%25CE%25B1%2520MAP%2520kinase%2520inhibitors%2520to%2520overcome%2520EGFR%2520tertiary%2520C797S%2520point%2520mutation%2520associated%2520with%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520emergence%2520of%2520fourth-generation%2520EGFR%2520inhibitor%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2020%26spage%3D1%26epage%3D14%26doi%3D10.1080%2F07391102.2020.1844801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signalling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&issue=7&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signalling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lgCaEKHHwlVhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signalling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26issue%3D7%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L. M.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor in tumor angiogenesis</span>. <i>Hematol. Oncol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1016/j.hoc.2004.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.hoc.2004.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=15474332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BD2crgsF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1007-1021&issue=5&author=L.+M.+Ellis&title=Epidermal+growth+factor+receptor+in+tumor+angiogenesis&doi=10.1016%2Fj.hoc.2004.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor in tumor angiogenesis</span></div><div class="casAuthors">Ellis Lee M</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1007-21, viii</span>
        ISSN:<span class="NLM_cas:issn">0889-8588</span>.
    </div><div class="casAbstract">This article focuses on the preclinical evidence for activation of the epidermal growth factor receptor (EGFR) in promoting angiogenesis and the efficacy of anti-EGFR agents in inhibiting angiogenesis and tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9JT0MhqmWmHO4gDb7JggCfW6udTcc2ea1ucv_L1Cz-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crgsF2kuw%253D%253D&md5=4de3bb0b6a106026f46949ca572797a1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2004.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2004.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520in%2520tumor%2520angiogenesis%26jtitle%3DHematol.%2520Oncol.%2520Clin.%26date%3D2004%26volume%3D18%26issue%3D5%26spage%3D1007%26epage%3D1021%26doi%3D10.1016%2Fj.hoc.2004.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">32S</span>– <span class="NLM_lpage">40S</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=11560969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVKqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=32S-40S&author=C.+L.+Arteaga&title=The+epidermal+growth+factor+receptor%3A+from+mutant+oncogene+in+nonhuman+cancers+to+therapeutic+target+in+human+neoplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia</span></div><div class="casAuthors">Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18, Suppl.</span>),
    <span class="NLM_cas:pages">32s-40s</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Approx. two decades ago, the epidermal growth factor receptor (EGFR) was discovered to be the proto-oncogene of the mutant, constitutively active oncogenic v-erbB tyrosine kinase, which induces avian erythroblastosis.  Unlike the mutant oncogene, the EGFR requires activation by binding of ligand to its extracellular (EC) domain, whereas its cellular effects depend on activation of its cytoplasmic tyrosine kinase.  The overexpression of EGFR and its ligands in several human carcinomas and their assocn. with accelerated tumor progression provided a rationale for targeting this network with tumor-selective strategies.  Two of those antireceptor approaches, both solidly based on the known structure and function of the EGFR, are discussed.  The first strategy involves the development of humanized monoclonal antibodies against the non-conserved receptor's EC domain.  These antibodies block ligand binding and can induce receptor endocytosis and downregulation.  The second approach is the generation of ATP mimetics that compete with ATP for binding to the receptor's kinase pocket, thus disabling signal transduction.  Preclin. and early clin. studies already suggest that both of these approaches, either alone or in combination with std. anticancer therapies, will be able to alter the natural history of EGFR-expressing cancers with little to no toxicity to the tumor-bearing host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpFLkhUx5kLVg90H21EOLACvtfcHk0liY042ZIdwjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVKqtr0%253D&md5=f3243f5fafb40749a6dd2bdb4e2c0028</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%253A%2520from%2520mutant%2520oncogene%2520in%2520nonhuman%2520cancers%2520to%2520therapeutic%2520target%2520in%2520human%2520neoplasia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D19%26spage%3D32S%26epage%3D40S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cully, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nrc1819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnrc1819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=16453012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhslelt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=184-192&issue=3&author=M.+Cullyauthor=H.+Youauthor=A.+J.+Levineauthor=T.+W.+Mak&title=Beyond+PTEN+mutations%3A+the+PI3K+pathway+as+an+integrator+of+multiple+inputs+during+tumorigenesis&doi=10.1038%2Fnrc1819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis</span></div><div class="casAuthors">Cully, Megan; You, Han; Levine, Arnold J.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-192</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The tumor-suppressor phosphatase with tensin homol. (PTEN) is the most important neg. regulator of the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase (PI3K).  Although PTEN is mutated or deleted in many tumors, deregulation of the PI3K-PTEN network also occurs through other mechanisms.  Crosstalk between the PI3K pathways and other tumorigenic signaling pathways, such as those that involve Ras, p53, TOR (target of rapamycin) or DJ1, can contribute to this deregulation.  How does the PI3K pathway integrate signals from numerous sources, and how can this information be used in the rational design of cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7UxMKOlX7X7Vg90H21EOLACvtfcHk0liY042ZIdwjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhslelt78%253D&md5=8769e7e349cc58f5c618cdce886186d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1819%26sid%3Dliteratum%253Aachs%26aulast%3DCully%26aufirst%3DM.%26aulast%3DYou%26aufirst%3DH.%26aulast%3DLevine%26aufirst%3DA.%2BJ.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DBeyond%2520PTEN%2520mutations%253A%2520the%2520PI3K%2520pathway%2520as%2520an%2520integrator%2520of%2520multiple%2520inputs%2520during%2520tumorigenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26issue%3D3%26spage%3D184%26epage%3D192%26doi%3D10.1038%2Fnrc1819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">The CXCL8-CXCR1/2 pathways in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cytogfr.2016.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27578214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaktLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=61-71&author=Q.+Liuauthor=A.+Liauthor=Y.+Tianauthor=J.+D.+Wuauthor=Y.+Liuauthor=T.+Liauthor=Y.+Chenauthor=X.+Hanauthor=K.+Wu&title=The+CXCL8-CXCR1%2F2+pathways+in+cancer&doi=10.1016%2Fj.cytogfr.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The CXCL8-CXCR1/2 pathways in cancer</span></div><div class="casAuthors">Liu, Qian; Li, Anping; Tian, Yijun; Wu, Jennifer D.; Liu, Yu; Li, Tengfei; Chen, Yuan; Han, Xinwei; Wu, Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61-71</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Persistent infection or chronic inflammation contributes significantly to tumorigenesis and tumor progression.  C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctional cytokine to modulate tumor proliferation, invasion and migration in an autocrine or paracrine manner.  Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including breast cancer, prostate cancer, lung cancer, colorectal carcinoma and melanoma.  CXCL8 also integrates with multiple intracellular signalling pathways to produce coordinated effects.  Neovascularisation, which provides a basis for fostering tumor growth and metastasis, is now recognized as a crit. function of CXCL8 in the tumor microenvironment.  In this review, we summarize the biol. functions and clin. significance of the CXCL8 signalling axis in cancer.  We also propose that CXCL8 may be a potential therapeutic target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCpvVEJgr0OLVg90H21EOLACvtfcHk0liY042ZIdwjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaktLnE&md5=acdda5c9236667b00ac33c158f818676</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DThe%2520CXCL8-CXCR1%252F2%2520pathways%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2016%26volume%3D31%26spage%3D61%26epage%3D71%26doi%3D10.1016%2Fj.cytogfr.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signalling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cell.2017.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28388417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2017&pages=361-371&issue=2&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signalling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Signaling in Growth, Metabolism, and Disease [Erratum to document cited in CA166:281944]</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Earlier drafts of the figures in this Review were published in print and online; the figures have been updated online.  The information that the earlier figures contained was accurate and complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRgFTR-eFpLVg90H21EOLACvtfcHk0li4R6uexSnx9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKhsr8%253D&md5=5e3235c6302939ada00fc0e8d3f04293</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signalling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D169%26issue%3D2%26spage%3D361%26epage%3D371%26doi%3D10.1016%2Fj.cell.2017.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, H. L.</span></span> <span> </span><span class="NLM_article-title">PI3K/AKT/mTOR pathway as a target for cancer therapy</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1097/01.cad.0000173476.67239.3b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2F01.cad.0000173476.67239.3b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=16096426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntlSkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=797-803&issue=8&author=D.+Morgenszternauthor=H.+L.+McLeod&title=PI3K%2FAKT%2FmTOR+pathway+as+a+target+for+cancer+therapy&doi=10.1097%2F01.cad.0000173476.67239.3b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K/Akt/mTOR pathway as a target for cancer therapy</span></div><div class="casAuthors">Morgensztern, Daniel; McLeod, Howard L.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">797-803</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are also crit. for tumorigenesis, including cellular proliferation, growth, survival and mobility.  Components of this pathway are frequently abnormal in a variety of tumors, making them an attractive target for anti-cancer therapy.  Inhibition of mTOR in patients with cancer became more feasible after the development of rapamycin analogs with improved pharmacol. properties.  The promising activity of these agents in early clin. trials has led to the development of ongoing phase III trials in renal cell carcinoma and breast cancer.  Future studies are needed to identify the patients most likely to benefit from this form of therapy, and to define its role in combination with chemotherapy, hormones and growth factor inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqggRZvKh4ca7Vg90H21EOLACvtfcHk0li4R6uexSnx9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntlSkt78%253D&md5=b786a72594c9af727d35fa7e51f96a2a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000173476.67239.3b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000173476.67239.3b%26sid%3Dliteratum%253Aachs%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DMcLeod%26aufirst%3DH.%2BL.%26atitle%3DPI3K%252FAKT%252FmTOR%2520pathway%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2005%26volume%3D16%26issue%3D8%26spage%3D797%26epage%3D803%26doi%3D10.1097%2F01.cad.0000173476.67239.3b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">101042831771244</span>, <span class="refDoi"> DOI: 10.1177/1010428317712445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1177%2F1010428317712445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2017&pages=101042831771244&issue=6&author=Q.+Liuauthor=S.+Yuauthor=A.+Liauthor=H.+Xuauthor=X.+Hanauthor=K.+Wu&title=Targeting+interlukin-6+to+relieve+immunosuppression+in+tumor+microenvironment&doi=10.1177%2F1010428317712445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F1010428317712445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1010428317712445%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DTargeting%2520interlukin-6%2520to%2520relieve%2520immunosuppression%2520in%2520tumor%2520microenvironment%26jtitle%3DTumor%2520Biol.%26date%3D2017%26volume%3D39%26issue%3D6%26spage%3D101042831771244%26doi%3D10.1177%2F1010428317712445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&issue=1&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy&doi=10.1038%2Fnrc969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0li4R6uexSnx9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26issue%3D1%26spage%3D11%26epage%3D22%26doi%3D10.1038%2Fnrc969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liguori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffinà, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Aveni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altavilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in the treatment of non-small-cell lung cancer: Design, development and place in therapy</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S119644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FLCTT.S119644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkt1elsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=109-125&author=M.+Santarpiaauthor=A.+Liguoriauthor=N.+Karachaliouauthor=M.+Gonzalez-Caoauthor=M.+G.+Daffin%C3%A0author=A.+D%E2%80%99Aveniauthor=G.+Marabelloauthor=G.+Altavillaauthor=R.+Rosell&title=Osimertinib+in+the+treatment+of+non-small-cell+lung+cancer%3A+Design%2C+development+and+place+in+therapy&doi=10.2147%2FLCTT.S119644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy</span></div><div class="casAuthors">Santarpia, Mariacarmela; Liguori, Alessia; Karachaliou, Niki; Gonzalez-Cao, Maria; Daffina, Maria Grazia; D'Aveni, Alessandro; Marabello, Grazia; Altavilla, Giuseppe; Rosell, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-125</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase inhibitors (TKIs) marked the advent of the era of precision medicine for non-small-cell lung cancer (NSCLC).  First- and second-generation EGFR TKIs, including erlotinib, gefitinib and afatinib, have consistently shown superior efficacy and better toxicity compared with first-line platinum-based chemotherapy and currently represent the std. of care for EGFR-mutated advanced NSCLC patients.  However, tumors invariably develop acquired resistance to EGFR TKIs, thereby limiting the long-term efficacy of these agents.  The T790M mutation in exon 20 of the EGFR gene has been identified as the most common mechanism of acquired resistance.  Osimertinib is a third-generation TKI designed to target both EGFR TKI-sensitizing mutations and T790M, while sparing wild-type EGFR.  Based on its pronounced clin. activity and good safety profile demonstrated in early Phase I and II trials, osimertinib received first approval in 2015 by the US FDA and in early 2016 by European Medicines Agency for the treatment of EGFR T790M mutation-pos. NSCLC patients in progression after EGFR TKI therapy.  Recent results from the Phase III AURA3 trial demonstrated the superiority of osimertinib over std. platinum-based doublet chemotherapy for treatment of patients with advanced EGFR T790M mutation-pos. NSCLC with disease progression following first-line EGFR TKI therapy, thus definitively establishing this third-generation TKI as the std. of care in this setting.  Herein, we review preclin. findings and clin. data from Phase I-III trials of osimertinib, including its efficacy in patients with central nervous system metastases.  We further discuss currently available methods used to analyze T790M mutation status and the main mechanisms of resistance to osimertinib.  Finally, we provide an outlook on ongoing trials with osimertinib and novel therapeutic combinations that might continue to improve the clin. outcome of EGFR-mutated NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4QOXBThkV7Vg90H21EOLACvtfcHk0ljueEKD5obcxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkt1elsbo%253D&md5=95ce4c3135dc3be0d2a337d7306b3f63</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S119644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S119644%26sid%3Dliteratum%253Aachs%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DLiguori%26aufirst%3DA.%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DGonzalez-Cao%26aufirst%3DM.%26aulast%3DDaffin%25C3%25A0%26aufirst%3DM.%2BG.%26aulast%3DD%25E2%2580%2599Aveni%26aufirst%3DA.%26aulast%3DMarabello%26aufirst%3DG.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DOsimertinib%2520in%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%253A%2520Design%252C%2520development%2520and%2520place%2520in%2520therapy%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D109%26epage%3D125%26doi%3D10.2147%2FLCTT.S119644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span> <span> </span><span class="NLM_article-title">FLAURA investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.+C.+Suauthor=J.+E.+Grayauthor=S.+M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+Ramalingam&title=FLAURA+investigators.+Osimertinib+in+untreated+EGFR-mutated+advanced+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0ljueEKD5obcxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%26atitle%3DFLAURA%2520investigators.%2520Osimertinib%2520in%2520untreated%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as first-line treatment in EGFR-mutated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1056/NEJMe1714580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMe1714580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29320658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MzpsVSjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=192-193&issue=2&author=S.+Popat&title=Osimertinib+as+first-line+treatment+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMe1714580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Popat Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">192-193</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJixxOfvRWuOWhZTslLrfffW6udTcc2ebWd1D1iLXRPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzpsVSjug%253D%253D&md5=86cbd91280c44efabfd216464fcb75ab</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1714580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1714580%26sid%3Dliteratum%253Aachs%26aulast%3DPopat%26aufirst%3DS.%26atitle%3DOsimertinib%2520as%2520first-line%2520treatment%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D192%26epage%3D193%26doi%3D10.1056%2FNEJMe1714580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burri, S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in <i>EGFR</i> mutation-positive advanced NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1261</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1801669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMc1801669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29595922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MnmslOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1261&issue=13&author=M.+C.+Wardauthor=R.+S.+Prabhuauthor=S.+Burri&title=Osimertinib+in+EGFR+mutation-positive+advanced+NSCLC&doi=10.1056%2FNEJMc1801669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in EGFR Mutation-Positive Advanced NSCLC</span></div><div class="casAuthors">Ward Matthew C; Prabhu Roshan S; Burri Stuart H</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1261</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfcw0gKTxNoMSzjBFCN0BJfW6udTcc2eYzXqziJWmXD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnmslOltQ%253D%253D&md5=7efe415285a20e35355bdba9e018b94b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1801669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1801669%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DM.%2BC.%26aulast%3DPrabhu%26aufirst%3DR.%2BS.%26aulast%3DBurri%26aufirst%3DS.%26atitle%3DOsimertinib%2520in%2520EGFR%2520mutation-positive%2520advanced%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D13%26spage%3D1261%26doi%3D10.1056%2FNEJMc1801669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of osimertinib resistance and emerging treatment options</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2020.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2020.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32693293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB38jltlSrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2020&pages=123-129&author=S.+Schmidauthor=J.+Liauthor=N.+B.+Leighl&title=Mechanisms+of+osimertinib+resistance+and+emerging+treatment+options&doi=10.1016%2Fj.lungcan.2020.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of osimertinib resistance and emerging treatment options</span></div><div class="casAuthors">Schmid Sabine; Li Janice J N; Leighl Natasha B</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting and now emerging as the new standard of care for all EGFR positive patients as first-line treatment.  Despite its efficacy, resistance to osimertinib inevitably develops and mechanisms of resistance can be grouped broadly in two categories: on-target EGFR-dependent and off-target EGFR-independent mechanisms.  EGFR-dependent resistance typically is associated with additional EGFR-mutations disrupting the osimertinib binding through changes in the binding site by allosteric/ conformational transitions; EGFR-independent mechanisms are related mostly to alternate pathway activation or aberrant downstream signalling but also to lineage plasticity leading to small cell transformation.  MET amplification is the most frequent off-target mechanisms of resistance to osimertinib treatment and recently published early trials show promising results for combination of MET-inhibitors with osimertinib upon development of resistance.  This review will summarize mechanisms of resistance overall and in different treatment settings and will focus on potential new treatment options targeting specific acquired alterations after osimertinib failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPD9fFC8LTZzjk2McQZ6XmfW6udTcc2eYzXqziJWmXD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38jltlSrtA%253D%253D&md5=87275d4ceac6b3707ab369dfd599857c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2020.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2020.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DMechanisms%2520of%2520osimertinib%2520resistance%2520and%2520emerging%2520treatment%2520options%26jtitle%3DLung%2520Cancer%26date%3D2020%26volume%3D147%26spage%3D123%26epage%3D129%26doi%3D10.1016%2Fj.lungcan.2020.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2433</span>, <span class="refDoi"> DOI: 10.1007/s00432-020-03239-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1007%2Fs00432-020-03239-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32385709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=2427-2433&issue=9&author=Y.+Muauthor=X.+Haoauthor=P.+Xingauthor=X.+Huauthor=Y.+Wangauthor=T.+Liauthor=J.+Zhangauthor=Z.+Xuauthor=J.+Li&title=Acquired+resistance+to+osimertinib+in+patients+with+non-small-cell+lung+cancer%3A+mechanisms+and+clinical+outcomes&doi=10.1007%2Fs00432-020-03239-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span></div><div class="casAuthors">Mu, Yuxin; Hao, Xuezhi; Xing, Puyuan; Hu, Xingsheng; Wang, Yan; Li, Teng; Zhang, Jinyao; Xu, Ziyi; Li, Junling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2427-2433</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clin. benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation.  The aim of our study was to identify the mechanisms underlying resistance to osimertinib and to correlate them with clin. outcomes.  Methods: We retrospectively analyzed patients with advanced NSCLC who received osimertinib for T790M-mutated acquired resistance to prior EGFR-TKIs between March 1, 2017 and Dec. 31, 2018.  Patients with paired mol. data of pre-osimertinib and after resistance development, which were not confirmed with small-cell lung cancer (SCLC) transformation, were included in the mol. anal. set.  Results: Of 49 patients evaluated in the mol. anal. set, 24 patients maintained T790M mutation, while 25 patients exhibited T790M-loss.  Mol. modifications were identified in 27 of 49 patients including EGFR acquired mutations (C797S, C796S, G796S, V802I, V834L, E758D and G724S), non-EGFR-dependent mutations (PIK3CA, ALK, BRAF, KRAS and TP53), EGFR amplification and MET amplification.  At data cutoff, median progression-free survival (PFS) was 9.3 mo in the T790M-retain group compared with 7.8 mo in T790M-loss patients (P = 0.053).  Median PFS was significantly longer in patients with EGFR-dependent resistance mechanism (13.5 mo) than in those with alternative pathway activation (8.2 mo; P = 0.012).  Conclusions: The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their assocn. with clin. outcomes.  Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clin. outcome benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFg_CSXlnhSLVg90H21EOLACvtfcHk0ljoQep8JSIexQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D&md5=7edcba72acbbd6fa1befd01b0f248c95</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00432-020-03239-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-020-03239-1%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520osimertinib%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%253A%2520mechanisms%2520and%2520clinical%2520outcomes%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D146%26issue%3D9%26spage%3D2427%26epage%3D2433%26doi%3D10.1007%2Fs00432-020-03239-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perego, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1038/s41416-019-0573-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41416-019-0573-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31564718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3MnjtFWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2019&pages=725-737&issue=9&author=A.+Leonettiauthor=S.+Sharmaauthor=R.+Minariauthor=P.+Peregoauthor=E.+Giovannettiauthor=M.+Tiseo&title=Resistance+mechanisms+to+osimertinib+in+EGFR-mutated+non-small+cell+lung+cancer&doi=10.1038%2Fs41416-019-0573-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer</span></div><div class="casAuthors">Leonetti Alessandro; Minari Roberta; Tiseo Marcello; Leonetti Alessandro; Sharma Sugandhi; Giovannetti Elisa; Perego Paola; Giovannetti Elisa; Tiseo Marcello</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">725-737</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction.  Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals.  On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms.  Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution.  This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS-mitogen-activated protein kinase (MAPK) or RAS-phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ01_bxgPdEyAMthz5_Rx5rfW6udTcc2eYzXqziJWmXD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnjtFWhsw%253D%253D&md5=a0a18b9a9d0aa2c31ea8391f279d1102</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41416-019-0573-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-019-0573-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeonetti%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DPerego%26aufirst%3DP.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DResistance%2520mechanisms%2520to%2520osimertinib%2520in%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D121%26issue%3D9%26spage%3D725%26epage%3D737%26doi%3D10.1038%2Fs41416-019-0573-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, T.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase-targeted cancer therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3491</span>, <span class="refDoi"> DOI: 10.3390/ijms19113491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fijms19113491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVWltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=3491&issue=11&author=T.+Yamaokaauthor=S.+Kusumotoauthor=K.+Andoauthor=M.+Ohbaauthor=T.+Ohmori&title=Receptor+tyrosine+kinase-targeted+cancer+therapy&doi=10.3390%2Fijms19113491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase-targeted cancer therapy</span></div><div class="casAuthors">Yamaoka, Toshimitsu; Kusumoto, Sojiro; Ando, Koichi; Ohba, Motoi; Ohmori, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3491/1-3491/35</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the past two decades, several mol. targeted inhibitors have been developed and evaluated clin. to improve the survival of patients with cancer.  Mol. targeted inhibitors inhibit the activities of pathogenic tyrosine kinases.  Particularly, aberrant receptor tyrosine kinase (RTK) activation is a potential therapeutic target.  An increased understanding of genetics, cellular biol. and structural biol. has led to the development of numerous important therapeutics.  Pathogenic RTK mutations, deletions, translocations and amplification/over-expressions have been identified and are currently being examd. for their roles in cancers.  Therapies targeting RTKs are categorized as small-mol. inhibitors and monoclonal antibodies.  Studies are underway to explore abnormalities in 20 types of RTK subfamilies in patients with cancer or other diseases.  In this review, we describe representative RTKs important for developing cancer therapeutics and predicting or evaluated resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2ODA5rnlFGrVg90H21EOLACvtfcHk0liYcoggtuORHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVWltb0%253D&md5=4f9b2dc13fbbfe76dd2a1dd49a422855</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3390%2Fijms19113491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19113491%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DT.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DOhba%26aufirst%3DM.%26aulast%3DOhmori%26aufirst%3DT.%26atitle%3DReceptor%2520tyrosine%2520kinase-targeted%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D11%26spage%3D3491%26doi%3D10.3390%2Fijms19113491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santoni-Rugiu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchior, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanska, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stricker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauslund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, J. B.</span></span> <span> </span><span class="NLM_article-title">Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">923</span>, <span class="refDoi"> DOI: 10.3390/cancers11070923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fcancers11070923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlCmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=923&issue=7&author=E.+Santoni-Rugiuauthor=L.+C.+Melchiorauthor=E.+M.+Urbanskaauthor=J.+N.+Jakobsenauthor=K.+Strickerauthor=M.+Grauslundauthor=J.+B.+S%C3%B8rensen&title=Intrinsic+resistance+to+EGFR-tyrosine+kinase+inhibitors+in+EGFR-mutant+non-small+cell+lung+cancer%3A+differences+and+similarities+with+acquired+resistance&doi=10.3390%2Fcancers11070923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance</span></div><div class="casAuthors">Santoni-Rugiu, Eric; Melchior, Linea C.; Urbanska, Edyta M.; Jakobsen, Jan N.; de Stricker, Karin; Grauslund, Morten; Soerensen, Jens B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">923</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene occur as early cancer-driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and result in increased sensitivity to EGFR-tyrosine-kinase-inhibitors (EGFR-TKIs).  Despite very frequent and often prolonged clin. response to EGFR-TKIs, virtually all advanced EGFR-mutated (EGFRM +) NSCLCs inevitably acquire resistance mechanisms and progress at some point during treatment.  Addnl., 20-30% of patients do not respond or respond for a very short time (< 3 mo) because of intrinsic resistance.  While several mechanisms of acquired EGFR-TKI-resistance have been detd. by analyzing tumor specimens obtained at disease progression, the factors causing intrinsic TKI-resistance are less understood.  However, recent comprehensive mol.-pathol. profiling of advanced EGFRM + NSCLC at baseline has illustrated the co-existence of multiple genetic, phenotypic, and functional mechanisms that may contribute to tumor progression and cause intrinsic TKI-resistance.  Several of these mechanisms have been further corroborated by preclin. expts.  Intrinsic resistance can be caused by mechanisms inherent in EGFR or by EGFR-independent processes, including genetic, phenotypic or functional tumor changes.  This comprehensive review describes the identified mechanisms connected with intrinsic EGFR-TKI-resistance and differences and similarities with acquired resistance and among clin. implemented EGFR-TKIs of different generations.  Addnl., the review highlights the need for extensive pre-treatment mol. profiling of advanced NSCLC for identifying inherently TKI-resistant cases and designing potential combinatorial targeted strategies to treat them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHx3k1mSjR2bVg90H21EOLACvtfcHk0liYcoggtuORHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlCmtLc%253D&md5=41ca442872e523e426e3b9520a26867a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3390%2Fcancers11070923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11070923%26sid%3Dliteratum%253Aachs%26aulast%3DSantoni-Rugiu%26aufirst%3DE.%26aulast%3DMelchior%26aufirst%3DL.%2BC.%26aulast%3DUrbanska%26aufirst%3DE.%2BM.%26aulast%3DJakobsen%26aufirst%3DJ.%2BN.%26aulast%3DStricker%26aufirst%3DK.%26aulast%3DGrauslund%26aufirst%3DM.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DJ.%2BB.%26atitle%3DIntrinsic%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%2520in%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%253A%2520differences%2520and%2520similarities%2520with%2520acquired%2520resistance%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D7%26spage%3D923%26doi%3D10.3390%2Fcancers11070923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.21037/tlcr.2016.12.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.21037%2Ftlcr.2016.12.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28149764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=695-708&issue=6&author=R.+Minariauthor=P.+Bordiauthor=M.+Tiseo&title=Third-generation+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+in+T790M-positive+non-small+cell+lung+cancer%3A+review+on+emerged+mechanisms+of+resistance&doi=10.21037%2Ftlcr.2016.12.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span></div><div class="casAuthors">Minari, Roberta; Bordi, Paola; Tiseo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-708</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-pos. non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib.  Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approx. 10 mo.  Mechanisms detg. progression of disease are heterogeneous and not fully understood.  EGFR-dependent resistance mechanisms (such as new EGFR mutations), bypass pathway activation [as erb-b2 receptor tyrosine kinase 2 (HER2) or MET amplification] and histol. transformation [in small cell lung cancer (SCLC)] have been reported, similarly to previous generation TKIs.  Here, we review principle mechanisms of innate and acquired resistance described in literature both in clin. and preclin. settings during NSCLC treatment with third-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqELenka7GwYrVg90H21EOLACvtfcHk0liYcoggtuORHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D&md5=b40df5074fe4944594507d6f3b4f24dd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.21037%2Ftlcr.2016.12.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftlcr.2016.12.02%26sid%3Dliteratum%253Aachs%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DThird-generation%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%253A%2520review%2520on%2520emerged%2520mechanisms%2520of%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2016%26volume%3D5%26issue%3D6%26spage%3D695%26epage%3D708%26doi%3D10.21037%2Ftlcr.2016.12.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">212</span>, <span class="refDoi"> DOI: 10.3390/cells7110212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fcells7110212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKhsbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=212&issue=11&author=T.+Naganoauthor=M.+Tachiharaauthor=Y.+Nishimura&title=Mechanism+of+resistance+to+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+and+a+potential+treatment+strategy&doi=10.3390%2Fcells7110212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy</span></div><div class="casAuthors">Nagano, Tatsuya; Tachihara, Motoko; Nishimura, Yoshihiro</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">212</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer (NSCLC).  First-generation EGFR-TKIs (e.g., gefitinib and erlotinib) or second-generation EGFR-TKIs (e.g., afatinib and dacomitinib) are effective for the treatment of EGFR-mutated NSCLC, esp. in patients with EGFR exon 19 deletions or an exon 21 L858R mutation.  However, almost all cases experience disease recurrence after 1 to 2 years due to acquired resistance.  The EGFR T790M mutation in exon 20 is the most frequent alteration assocd. with the development of acquired resistance.  Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against EGFR-mutated lung cancer.  However, the development of acquired resistance to third-generation EGFR-TKI, involving the cysteine residue at codon 797 mutation, has been obsd.  Other mechanisms of acquired resistance include the activation of alternative pathways or downstream targets and histol. transformation (i.e., epithelial-mesenchymal transition or conversion to small-cell lung cancer).  Furthermore, the development of primary resistance through overexpression of the hepatocyte growth factor and suppression of Bcl-2-like protein 11 expression may lead to problems.  In this report, we review these mechanisms and discuss therapeutic strategies to overcome resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9WqabZOCKdLVg90H21EOLACvtfcHk0liuawFBeQ2sCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKhsbvN&md5=69cffcd25c103e00c00502106d93848b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fcells7110212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells7110212%26sid%3Dliteratum%253Aachs%26aulast%3DNagano%26aufirst%3DT.%26aulast%3DTachihara%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DY.%26atitle%3DMechanism%2520of%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520and%2520a%2520potential%2520treatment%2520strategy%26jtitle%3DCells%26date%3D2018%26volume%3D7%26issue%3D11%26spage%3D212%26doi%3D10.3390%2Fcells7110212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsia, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">MA08.03 osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S386</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.436" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S386&issue=1&author=Y.+L.+Wuauthor=S.+Jenkinsauthor=S.+Ramalingamauthor=J.+Y.+Hanauthor=A.+Delmonteauthor=T.+C.+Hsiaauthor=J.+Laskinauthor=S.+W.+Kimauthor=Y.+Heauthor=S.+Patel&title=MA08.03+osimertinib+vs+platinum-pemetrexed+for+T790M-mutation+positive+advanced+NSCLC+%28AURA3%29%3A+plasma+ctDNA+analysis&doi=10.1016%2Fj.jtho.2016.11.436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.436%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DHsia%26aufirst%3DT.%2BC.%26aulast%3DLaskin%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DMA08.03%2520osimertinib%2520vs%2520platinum-pemetrexed%2520for%2520T790M-mutation%2520positive%2520advanced%2520NSCLC%2520%2528AURA3%2529%253A%2520plasma%2520ctDNA%2520analysis%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3DS386%26doi%3D10.1016%2Fj.jtho.2016.11.436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuang&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0liuawFBeQ2sCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shao&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0liuawFBeQ2sCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zandwijk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">A consensus on the role of osimertinib in non-small cell lung cancer from the AME lung cancer collaborative group</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3909</span>, <span class="refDoi"> DOI: 10.21037/jtd.2018.07.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.21037%2Fjtd.2018.07.61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30174832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3c3kslyltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=3909&author=T.+Jiangauthor=C.+Suauthor=S.+Renauthor=F.+Cappuzzoauthor=G.+Roccoauthor=J.+D.+Palmerauthor=N.+van+Zandwijkauthor=F.+Blackhallauthor=X.+Leauthor=N.+A.+Pennellauthor=C.+Zhou&title=A+consensus+on+the+role+of+osimertinib+in+non-small+cell+lung+cancer+from+the+AME+lung+cancer+collaborative+group&doi=10.21037%2Fjtd.2018.07.61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group</span></div><div class="casAuthors">Jiang Tao; Su Chunxia; Ren Shengxiang; Zhou Caicun; Cappuzzo Federico; Rocco Gaetano; Palmer Joshua D; van Zandwijk Nico; Blackhall Fiona; Le Xiuning; Pennell Nathan A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3909-3921</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought substantial clinical benefit to patients with advanced non-small cell lung cancer (NSCLC) and sensitizing EGFR mutation.  However, acquired resistance is inevitable since the vast majority of patients experience disease relapse within ~1-2 years.  Osimertinib is a novel irreversible, covalent third-generation EGFR-TKI and potent inhibitor of EGFR T790M mutation, the most common mechanism of acquired resistance to first-generation EGFR-TKIs.  Several trials have consistently demonstrated the superior clinical activity and safety of osimertinib in patients with advanced NSCLC and acquired EGFR T790M mutation after treatment with a first-generation EGFR-TKI.  Recently, the efficacy of osimertinib in a first-line setting was demonstrated to be clearly superior to standard-first line treatment in patients with EGFR-mutant NSCLC regardless of T790M mutation status.  Nevertheless, this advance, several unresolved issues of osimertinib should be emphasized including the molecular mechanisms of acquired resistance to osimertinib, the feasibility of testing EGFR T790M mutation from plasma circulating tumor DNA, its efficacy to patients with central nervous system (CNS) metastases or exon 20 mutations, its combination with other therapeutic strategies such as immune checkpoint inhibitors and its role in adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZM8G1vkvdEgpJitSxOdIlfW6udTcc2ebx7dB_afKKgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3kslyltw%253D%253D&md5=b4e20e3331e23f4fab6cf6188c077bdf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.21037%2Fjtd.2018.07.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjtd.2018.07.61%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DRocco%26aufirst%3DG.%26aulast%3DPalmer%26aufirst%3DJ.%2BD.%26aulast%3Dvan%2BZandwijk%26aufirst%3DN.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DPennell%26aufirst%3DN.%2BA.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DA%2520consensus%2520on%2520the%2520role%2520of%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520from%2520the%2520AME%2520lung%2520cancer%2520collaborative%2520group%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2018%26volume%3D10%26spage%3D3909%26doi%3D10.21037%2Fjtd.2018.07.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S. S.</span></span> <span> </span><span class="NLM_article-title">Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2015.05.05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3978%2Fj.issn.2218-6751.2015.05.05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26798593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFequr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=809-815&issue=6&author=D.+B.+Costaauthor=S.+S.+Kobayashi&title=Whacking+a+mole-cule%3A+clinical+activity+and+mechanisms+of+resistance+to+third+generation+EGFR+inhibitors+in+EGFR+mutated+lung+cancers+with+EGFR-T790M&doi=10.3978%2Fj.issn.2218-6751.2015.05.05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M</span></div><div class="casAuthors">Costa, Daniel B.; Kobayashi, Susumu S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-815</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations, esp. EGFR-exon 19 deletions and EGFR-L858R, are the most frequent actionable genomic events in lung adenocarcinomas.  Tumors arise due to constitutively activated EGFR signaling and are susceptible to EGFR tyrosine kinase inhibitors (TKIs).  First generation EGFR TKIs (gefitinib and erlotinib) and the second generation EGFR TKI afatinib are approved worldwide.  Although targeted therapies against EGFR mutants induce dramatic initial responses, acquired resistance (through multiple biol. mechanisms) to erlotinib, gefitinib and afatinib emerges within the first 1-2 years of continued monotherapy.  EGFR-T790M accounts for more than half of acquired resistance to first or second generation EGFR TKIs by modifying ATP affinity and drug binding kinetics.  Two new studies have shown that two covalent pyrimidine inhibitors-AZD9291 and rociletinib of EGFRT790M (i.e., third generation EGFR TKIs) shown remarkable clin. activity in patients with acquired resistance to erlotinib, gefitinib and afatinib when the tumor carries EGFR-T790M in conjunction with an activating mutation.  However, and regrettably, acquired resistance to these third generation EGFR TKIs has already been reported in preclin. models and clin. specimens; such as a tertiary mutation at EGFR-C797S that prevents covalent binding of EGFR TKIs.  The experience with sequential EGFR TKI monotherapy highlights tumor heterogeneity and adaptability (i.e., relentless game of whack-a-mole played between TKIs and cancer), and will help shape future clin. development of novel combinatory approaches to manage EGFR mutated lung adenocarcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouU0luqnexVrVg90H21EOLACvtfcHk0ljFIwQrxgZoAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFequr3N&md5=841f953e75655784933a5db515329d6a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2015.05.05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2015.05.05%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DKobayashi%26aufirst%3DS.%2BS.%26atitle%3DWhacking%2520a%2520mole-cule%253A%2520clinical%2520activity%2520and%2520mechanisms%2520of%2520resistance%2520to%2520third%2520generation%2520EGFR%2520inhibitors%2520in%2520EGFR%2520mutated%2520lung%2520cancers%2520with%2520EGFR-T790M%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26issue%3D6%26spage%3D809%26epage%3D815%26doi%3D10.3978%2Fj.issn.2218-6751.2015.05.05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of EGFR-mutant lung cancer to a t790m-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26181354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=982-984&issue=7&author=H.+A.+Yuauthor=S.+K.+Tianauthor=A.+E.+Drilonauthor=L.+Borsuauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+resistance+of+EGFR-mutant+lung+cancer+to+a+t790m-specific+EGFR+inhibitor%3A+emergence+of+a+third+mutation+%28C797S%29+in+the+EGFR+tyrosine+kinase+domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span></div><div class="casAuthors">Yu Helena A; Drilon Alexander E; Riely Gregory J; Tian Shaozhou K; Borsu Laetitia; Arcila Maria E; Ladanyi Marc</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">982-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMt1QT_1O5WBYfW6udTcc2ebx7dB_afKKgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D&md5=27ae39c3fce4067baca734fbc05101b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520of%2520EGFR-mutant%2520lung%2520cancer%2520to%2520a%2520t790m-specific%2520EGFR%2520inhibitor%253A%2520emergence%2520of%2520a%2520third%2520mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DJAMA%2520Oncol.%26date%3D2015%26volume%3D1%26issue%3D7%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span> <span> </span><span class="NLM_article-title">Mutational profiling of non-small-cell lung cancer resistant to osimertinib using next-generation sequencing in chinese patients</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">9010353</span>, <span class="refDoi"> DOI: 10.1155/2018/9010353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1155%2F2018%2F9010353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29713646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MjosFWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=9010353&author=K.+Nieauthor=H.+Jiangauthor=C.+Zhangauthor=C.+Gengauthor=X.+Xuauthor=L.+Zhangauthor=H.+Zhangauthor=Z.+Zhangauthor=K.+Lanauthor=Y.+Ji&title=Mutational+profiling+of+non-small-cell+lung+cancer+resistant+to+osimertinib+using+next-generation+sequencing+in+chinese+patients&doi=10.1155%2F2018%2F9010353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients</span></div><div class="casAuthors">Nie Keke; Geng Chuanxin; Zhang Ling; Zhang Zhongfa; Jiang Haiping; Zhang Chunling; Xu Xiajuan; Lan Ketao; Ji Youxin; Zhang Hao</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9010353</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose:  To identify the somatic mutated genes for optimal targets of non-small-cell lung cancer after resistance to osimertinib treatment.  Patients and Methods:  Study patients all had advanced lung adenocarcinoma and acquired resistance to osimertinib as a second- or third-line treatment.  These patients had harboring EGFR T790M mutation before osimertinib treatment, which was confirmed by Amplification Refractory Mutation System (ARMS) PCR or Next-Generation Sequencing (NGS).  After resistance to osimertinib treatment, tumor tissue was collected by core needle biopsy.  DNA was extracted from 15 × 5 um sliced section of formalin-fixed paraffin-embedded (FFPE) material and NGS was done.  The genetic changes were analyzed.  Results:  A total of 9 Chinese patients were studied, 5 females and 4 males, age 51-89 years.  After progression with osimertinib treatment, core needle biopsy was performed and next-generation sequencing was performed.  Nine patients had harboring 62 point mutations, 2 altered gene copies, 2 amplifications, and 1 EML4-ALK gene fusion.  No MET or HER2 amplification was found in this cohort study.  Nine patients still maintained initial EGFR 19 del or L858R activating mutations, while 7 of them kept EGFR T790M mutations.  Among the 7 patients, 5 had secondary EGFR C797S and/or C797G mutations, which all happened in the same allele with T790M mutation.  All patients were treated with targets therapies, chemotherapy, or best supportive care (BSC) in accordance with NGS genetic results and patients' performance status; 7 of them are still alive and 2 of them died of disease progression at last follow-up.  Conclusions:  EGFR C797S/G mutation and the same one presented on the same allele with EGFR T790M mutation were the most common mutation feature and played a key role in resistance to osimertinib in Chinese patients with NSCLC.  Tumor cells losing T790M mutation and maintaining EGFR activating mutation might benefit from first-generation EGFR-TKI treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKyN3tRjlzBeWhZTslLrfffW6udTcc2eZNJ5nlf24Bs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjosFWktA%253D%253D&md5=560309f1f8198aa05373e59b1fae6f58</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1155%2F2018%2F9010353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F9010353%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGeng%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLan%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DY.%26atitle%3DMutational%2520profiling%2520of%2520non-small-cell%2520lung%2520cancer%2520resistant%2520to%2520osimertinib%2520using%2520next-generation%2520sequencing%2520in%2520chinese%2520patients%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2018%26volume%3D2018%26spage%3D9010353%26doi%3D10.1155%2F2018%2F9010353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maemondo, M.</span></span> <span> </span><span class="NLM_article-title">Frequency of cis and trans EGFR T790M and activation mutations in tumors treated with EGFR inhibitors</span>. <i>J. Iwate Med. Assioc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.24750/iwateishi.72.2_47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.24750%2Fiwateishi.72.2_47" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=47-58&issue=2&author=K.+Hiranoauthor=K.+Watanabeauthor=M.+Akiyamaauthor=R.+Chibaauthor=H.+Nagashimaauthor=H.+Satoauthor=M.+Sugaiauthor=H.+Terasakiauthor=T.+Fukuharaauthor=M.+Maemondo&title=Frequency+of+cis+and+trans+EGFR+T790M+and+activation+mutations+in+tumors+treated+with+EGFR+inhibitors&doi=10.24750%2Fiwateishi.72.2_47"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.24750%2Fiwateishi.72.2_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.24750%252Fiwateishi.72.2_47%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAkiyama%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DR.%26aulast%3DNagashima%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugai%26aufirst%3DM.%26aulast%3DTerasaki%26aufirst%3DH.%26aulast%3DFukuhara%26aufirst%3DT.%26aulast%3DMaemondo%26aufirst%3DM.%26atitle%3DFrequency%2520of%2520cis%2520and%2520trans%2520EGFR%2520T790M%2520and%2520activation%2520mutations%2520in%2520tumors%2520treated%2520with%2520EGFR%2520inhibitors%26jtitle%3DJ.%2520Iwate%2520Med.%2520Assioc.%26date%3D2020%26volume%3D72%26issue%3D2%26spage%3D47%26epage%3D58%26doi%3D10.24750%2Fiwateishi.72.2_47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span> <span> </span><span class="NLM_article-title">Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovichauthor=T.+C.+Hardingauthor=K.+A.+Durkinauthor=G.+A.+Ottersonauthor=W.+T.+Purcellauthor=D.+R.+Camidgeauthor=J.+W.+Goldmanauthor=L.+V.+Sequistauthor=Z.+Piotrowskaauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=A.+A.+Alizadehauthor=M.+Diehn&title=Circulating+tumor+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0ljfjCSYtJf0QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DPurcell%26aufirst%3DW.%2BT.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DDiehn%26aufirst%3DM.%26atitle%3DCirculating%2520tumor%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR Inhibitor (HM61713) in non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e45</span>– <span class="NLM_lpage">e47</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2015.12.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26749488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e45-e47&issue=4&author=H.+N.+Songauthor=K.+S.+Jungauthor=K.+H.+Yooauthor=J.+Choauthor=J.+Y.+Leeauthor=S.+H.+Limauthor=H.+S.+Kimauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.+L.+Choiauthor=W.+Parkauthor=M.+J.+Ahn&title=Acquired+C797S+mutation+upon+treatment+with+a+T790M-specific+third-generation+EGFR+Inhibitor+%28HM61713%29+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2015.12.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.093%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%2BN.%26aulast%3DJung%26aufirst%3DK.%2BS.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DAcquired%2520C797S%2520mutation%2520upon%2520treatment%2520with%2520a%2520T790M-specific%2520third-generation%2520EGFR%2520Inhibitor%2520%2528HM61713%2529%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3De45%26epage%3De47%26doi%3D10.1016%2Fj.jtho.2015.12.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han-Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIS and shifts allelic configuration at resistance</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28662863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1723-1727&issue=11&author=Z.+Wangauthor=J.+J.+Yangauthor=J.+Huangauthor=J.+Y.+Yeauthor=X.+C.+Zhangauthor=H.+Y.+Tuauthor=H.+Han-Zhangauthor=Y.+L.+Wu&title=Lung+adenocarcinoma+harboring+EGFR+T790M+and+in+trans+C797S+responds+to+combination+therapy+of+first-+and+third-generation+EGFR+TKIS+and+shifts+allelic+configuration+at+resistance&doi=10.1016%2Fj.jtho.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance</span></div><div class="casAuthors">Wang Zhen; Yang Jin-Ji; Huang Jie; Zhang Xu-Chao; Tu Hai-Yan; Ye Jun-Yi; Han-Zhang Han; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-1727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S.  In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors.  However, this has not been reported clinically.  METHODS:  We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy.  RESULTS:  At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M.  He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib.  After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.  CONCLUSION:  We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans.  We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKksLRAl4nGUbxh97K6Vt6fW6udTcc2eZarIxug5ON0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D&md5=4a4e858b7e9b39034fd2035da629a88c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DHan-Zhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DLung%2520adenocarcinoma%2520harboring%2520EGFR%2520T790M%2520and%2520in%2520trans%2520C797S%2520responds%2520to%2520combination%2520therapy%2520of%2520first-%2520and%2520third-generation%2520EGFR%2520TKIS%2520and%2520shifts%2520allelic%2520configuration%2520at%2520resistance%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1723%26epage%3D1727%26doi%3D10.1016%2Fj.jtho.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&issue=10&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+progress+of+small-molecule+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+C797S+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lhh7fY_i-JZjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520of%2520small-molecule%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520C797S%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&issue=17&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+allelic+context+of+the+C797S+mutation+acquired+upon+treatment+with+third-generation+EGFR+inhibitors+impacts+sensitivity+to+subsequent+treatment+strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0lh32aB0zdb6gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520allelic%2520context%2520of%2520the%2520C797S%2520mutation%2520acquired%2520upon%2520treatment%2520with%2520third-generation%2520EGFR%2520inhibitors%2520impacts%2520sensitivity%2520to%2520subsequent%2520treatment%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonesaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flavin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6770</span>– <span class="NLM_lpage">6779</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-13-1145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24063894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyhsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6770-6779&issue=22&author=J.+Choauthor=L.+Chenauthor=N.+Sangjiauthor=T.+Okabeauthor=K.+Yonesakaauthor=J.+M.+Francisauthor=R.+J.+Flavinauthor=W.+Johnsonauthor=J.+Kwonauthor=S.+Yuauthor=H.+Greulichauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=K.+K.+Wongauthor=M.+Meyerson&title=Cetuximab+response+of+lung+cancer-derived+EGF+receptor+mutants+is+associated+with+asymmetric+dimerization&doi=10.1158%2F0008-5472.CAN-13-1145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization</span></div><div class="casAuthors">Cho, Jeonghee; Chen, Liang; Sangji, Naveen; Okabe, Takafumi; Yonesaka, Kimio; Francis, Joshua M.; Flavin, Richard J.; Johnson, William; Kwon, Jihyun; Yu, Soyoung; Greulich, Heidi; Johnson, Bruce E.; Eck, Michael J.; Jaenne, Pasi A.; Wong, Kwok-Kin; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6770-6779</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Kinase domain mutations of the EGF receptor (EGFR) are common oncogenic events in lung adenocarcinoma.  Here, we explore the dependency upon asym. dimerization of the kinase domain for activation of lung cancer-derived EGFR mutants.  We show that whereas wild-type EGFR and the L858R mutant require dimerization for activation and oncogenic transformation, the exon 19 deletion, exon 20 insertion, and L858R/T790M EGFR mutants do not require dimerization.  In addn., treatment with the monoclonal antibody, cetuximab, shrinks mouse lung tumors induced by the dimerization-dependent L858R mutant, but exerts only a modest effect on tumors driven by dimerization-independent EGFR mutants.  These data imply that different EGFR mutants show differential requirements for dimerization and that disruption of dimerization may be among the antitumor mechanisms of cetuximab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUM0OobLjS2rVg90H21EOLACvtfcHk0lh32aB0zdb6gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyhsrbO&md5=11f535c9c05614e04d0a16b83e8ca427</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1145%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSangji%26aufirst%3DN.%26aulast%3DOkabe%26aufirst%3DT.%26aulast%3DYonesaka%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DJ.%2BM.%26aulast%3DFlavin%26aufirst%3DR.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DCetuximab%2520response%2520of%2520lung%2520cancer-derived%2520EGF%2520receptor%2520mutants%2520is%2520associated%2520with%2520asymmetric%2520dimerization%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D22%26spage%3D6770%26epage%3D6779%26doi%3D10.1158%2F0008-5472.CAN-13-1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilachã, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchel, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akele, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, M. R.</span></span> <span> </span><span class="NLM_article-title">Making NSCLC crystal clear: how kinase structures revolutionized lung cancer treatment</span>. <i>Crystals</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">725</span>, <span class="refDoi"> DOI: 10.3390/cryst10090725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fcryst10090725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGntrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=725&issue=9&author=J.+F.+Vilach%C3%A3author=S.+C.+Mitchelauthor=M.+Z.+Akeleauthor=S.+Evansauthor=M.+R.+Groves&title=Making+NSCLC+crystal+clear%3A+how+kinase+structures+revolutionized+lung+cancer+treatment&doi=10.3390%2Fcryst10090725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Making NSCLC crystal clear: how kinase structures revolutionized lung cancer treatment</span></div><div class="casAuthors">Vilacha, Juliana F.; Mitchel, Sarah C.; Akele, Muluembet Z.; Evans, Stephen; Groves, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Crystals</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">725</span>CODEN:
                <span class="NLM_cas:coden">CRYSBC</span>;
        ISSN:<span class="NLM_cas:issn">2073-4352</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The parallel advances of different scientific fields provide a contemporary scenario where collaboration is not a differential, but actually a requirement.  In this context, crystallog. has had a major contribution on the medical sciences, providing a "face" for targets of diseases that previously were known solely by name or sequence.  Worldwide, cancer still leads the no. of annual deaths, with 9.6 million assocd. deaths, with a major contribution from lung cancer and its 1.7 million deaths.  Since the relationship between cancer and kinases was unraveled, these proteins have been extensively explored and became assocd. with drugs that later attained blockbuster status.  Crystallog. structures of kinases related to lung cancer and their developed and marketed drugs provided insight on their conformation in the absence or presence of small mols.  Notwithstanding, these structures were also of service once the initially highly successful drugs started to lose their effectiveness in the emergence of mutations.  This review focuses on a subclassification of lung cancer, non-small cell lung cancer (NSCLC), and major oncogenic driver mutations in kinases, and how crystallog. structures can be used, not only to provide awareness of the function and inhibition of these mutations, but also how these structures can be used in further computational studies aiming at addressing these novel mutations in the field of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXlLjzGH6LabVg90H21EOLACvtfcHk0lh32aB0zdb6gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGntrrN&md5=cc56a9a961272d823ff49642ad3bcbfb</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3390%2Fcryst10090725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcryst10090725%26sid%3Dliteratum%253Aachs%26aulast%3DVilach%25C3%25A3%26aufirst%3DJ.%2BF.%26aulast%3DMitchel%26aufirst%3DS.%2BC.%26aulast%3DAkele%26aufirst%3DM.%2BZ.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DGroves%26aufirst%3DM.%2BR.%26atitle%3DMaking%2520NSCLC%2520crystal%2520clear%253A%2520how%2520kinase%2520structures%2520revolutionized%2520lung%2520cancer%2520treatment%26jtitle%3DCrystals%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D725%26doi%3D10.3390%2Fcryst10090725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma</span>. <i>J. Drug Target.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2020.1737934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F1061186X.2020.1737934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32118494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslaqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=861-872&issue=9&author=R.+Liauthor=X.+Zhouauthor=H.+Yaoauthor=L.+Li&title=Four+generations+of+EGFR+TKIs+associated+with+different+pathogenic+mutations+in+non-small+cell+lung+carcinoma&doi=10.1080%2F1061186X.2020.1737934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma</span></div><div class="casAuthors">Li, Rui; Zhou, Xiaofei; Yao, Hongjuan; Li, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">861-872</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Non-small cell lung carcinoma (NSCLC) is a malignant tumor with poor prognosis and high mortality.  Platinum-based dual-agent chemotherapy is the main therapeutic regimen for this disease.  In recent years, because of the introduction of mol. targeted therapy, various targeted therapeutic agents against epidermal growth factor receptor (EGFR) have been rapidly developed, which has become a research hotspot for NSCLC treatment.  Here, we review the latest studies describing the features and types of EGFR pathogenic mutations, currently established EGFR-tyrosine kinase inhibitors from the first to fourth generation, including their action mechanisms, acquired resistance, and clin. applications, and potential challenges and perspectives that current researchers should address.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi2a5fvJbhQ7Vg90H21EOLACvtfcHk0lie3JF-l8R2ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslaqtrc%253D&md5=c24cf710611dd0f1d9dddc41c62edb3a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2020.1737934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2020.1737934%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DFour%2520generations%2520of%2520EGFR%2520TKIs%2520associated%2520with%2520different%2520pathogenic%2520mutations%2520in%2520non-small%2520cell%2520lung%2520carcinoma%26jtitle%3DJ.%2520Drug%2520Target.%26date%3D2020%26volume%3D28%26issue%3D9%26spage%3D861%26epage%3D872%26doi%3D10.1080%2F1061186X.2020.1737934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bersanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrilli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrasta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">e121</span>– <span class="NLM_lpage">e123</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27257132" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e121-e123&issue=10&author=M.+Bersanelliauthor=R.+Minariauthor=P.+Bordiauthor=L.+Gnettiauthor=C.+Bozzettiauthor=A.+Squadrilliauthor=C.+A.+Lagrastaauthor=L.+Bottarelliauthor=G.+Osipovaauthor=E.+Capellettoauthor=M.+Morauthor=M.+Tiseo&title=L718Q+mutation+as+new+mechanism+of+acquired+resistance+to+AZD9291+in+EGFR-mutated+NSCLC&doi=10.1016%2Fj.jtho.2016.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBersanelli%26aufirst%3DM.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DBozzetti%26aufirst%3DC.%26aulast%3DSquadrilli%26aufirst%3DA.%26aulast%3DLagrasta%26aufirst%3DC.%2BA.%26aulast%3DBottarelli%26aufirst%3DL.%26aulast%3DOsipova%26aufirst%3DG.%26aulast%3DCapelletto%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DL718Q%2520mutation%2520as%2520new%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR-mutated%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3De121%26epage%3De123%26doi%3D10.1016%2Fj.jtho.2016.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span> <span> </span><span class="NLM_article-title">First-and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.3390/ijms20010146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fijms20010146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=146&issue=1&author=M.+Takedaauthor=K.+Nakagawa&title=First-and+second-generation+EGFR-TKIs+are+all+replaced+to+osimertinib+in+chemo-naive+EGFR+mutation-positive+non-small+cell+lung+cancer&doi=10.3390%2Fijms20010146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?</span></div><div class="casAuthors">Takeda, Masayuki; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">146/1-146/8</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force for some lung adenocarcinomas.  Several randomized phase III studies have revealed that treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) results in an improved progression-free survival (PFS) compared to std. chemotherapy in chemonaive patients with advanced non-small cell lung cancer (NSCLC), selected based on the presence of EGFR mutations.  Patients treated with second-generation EGFR-TKIs have also shown an improved PFS relative to those treated with first-generation EGRF-TKIs.  Osimertinib is a third-generation EGFR-TKI that still irreversibly inhibits the activity of EGFR after it has acquired the secondary T790M mutation that confers resistance to first- and second-generation drugs.  Its efficacy has been validated for patients whose tumors have developed T790M-mediated resistance, as well as for first-line treatment of those patients with EGFR mutation-pos. NSCLC.  Although there are five EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) currently available for the treatment of EGFR-mutated lung cancer, the optimal sequence for administration of these drugs remains to be detd.  In this review, we addressed this issue with regard to maximizing the duration of the EGFR-TKI treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5XXr90cV-ErVg90H21EOLACvtfcHk0lie3JF-l8R2ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7jL&md5=dc0a2970e83327622ae068f8119a9dd9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.3390%2Fijms20010146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20010146%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DFirst-and%2520second-generation%2520EGFR-TKIs%2520are%2520all%2520replaced%2520to%2520osimertinib%2520in%2520chemo-naive%2520EGFR%2520mutation-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D1%26spage%3D146%26doi%3D10.3390%2Fijms20010146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib</span>. <i>Ann. Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">207</span>, <span class="refDoi"> DOI: 10.21037/atm.2019.04.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.21037%2Fatm.2019.04.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31205925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3M3nsVanuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=207&issue=9&author=L.+Maauthor=R.+Chenauthor=F.+Wangauthor=L.+L.+Maauthor=M.+M.+Yuanauthor=R.+R.+Chenauthor=J.+Liu&title=EGFR+L718Q+mutation+occurs+without+T790M+mutation+in+a+lung+adenocarcinoma+patient+with+acquired+resistance+to+osimertinib&doi=10.21037%2Fatm.2019.04.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib</span></div><div class="casAuthors">Ma Lei; Chen Rui; Wang Fang; Ma Li-Li; Liu Jiang; Yuan Ming-Ming; Chen Rong-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Annals of translational medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">207</span>
        ISSN:<span class="NLM_cas:issn">2305-5839</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improve the clinical outcomes of EGFR-mutant non-small cell lung cancer (NSCLC) patients significantly, however, acquired resistance occurs almost inevitably.  The underlying mechanisms of osimertinib resistance and treatment strategies after resistance remain largely unknown.  Here we reported a case of lung adenocarcinoma patient who progressed on osimertinib with EGFR L718Q mutation in the absence of T790M mutation.  The patient received icotinib as an exploratory treatment regimen for a short while with stable disease observed.  Unfortunately, the therapy was discontinued due to intolerable hepatotoxicity.  This is the first clinical report of the use of the effective EGFR-TKI treatment after L718Q-induced osimertinib resistance.  The therapeutic regimens for NSCLC patients progressed on osimertinib still require large-scale investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKmnu-UFBQoJagfuraLLzSfW6udTcc2ebt57F8F8XY-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3nsVanuw%253D%253D&md5=1a14d7c0fb12f47e32181bd2a9edd723</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.21037%2Fatm.2019.04.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2019.04.37%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DL.%2BL.%26aulast%3DYuan%26aufirst%3DM.%2BM.%26aulast%3DChen%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DEGFR%2520L718Q%2520mutation%2520occurs%2520without%2520T790M%2520mutation%2520in%2520a%2520lung%2520adenocarcinoma%2520patient%2520with%2520acquired%2520resistance%2520to%2520osimertinib%26jtitle%3DAnn.%2520Transl%2520Med.%26date%3D2019%26volume%3D7%26issue%3D9%26spage%3D207%26doi%3D10.21037%2Fatm.2019.04.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricordel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">i28</span>– <span class="NLM_lpage">i37</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29462256" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i28-i37&issue=1&author=C.+Ricordelauthor=L.+Fribouletauthor=F.+Facchinettiauthor=J.+C.+Soria&title=Molecular+mechanisms+of+acquired+resistance+to+third-generation+EGFR-TKIs+in+EGFR+T790M-mutant+lung+cancer&doi=10.1093%2Fannonc%2Fmdx705"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx705%26sid%3Dliteratum%253Aachs%26aulast%3DRicordel%26aufirst%3DC.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520third-generation%2520EGFR-TKIs%2520in%2520EGFR%2520T790M-mutant%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D1%26spage%3Di28%26epage%3Di37%26doi%3D10.1093%2Fannonc%2Fmdx705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2018.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30642450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhtlCgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2019&pages=33-39&author=S.+Zhaoauthor=X.+Liauthor=C.+Zhaoauthor=T.+Jiangauthor=Y.+Jiaauthor=J.+Shiauthor=Y.+Heauthor=J.+Liauthor=F.+Zhouauthor=G.+Gaoauthor=W.+Liauthor=X.+Chenauthor=C.+Suauthor=S.+Renauthor=C.+Zhou&title=Loss+of+T790M+mutation+is+associated+with+early+progression+to+osimertinib+in+Chinese+patients+with+advanced+NSCLC+who+are+harboring+EGFR+T790M&doi=10.1016%2Fj.lungcan.2018.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M</span></div><div class="casAuthors">Zhao Sha; Jiang Tao; Jia Yijun; Shi Jinpeng; He Yayi; Li Jiayu; Zhou Fei; Li Wei; Chen Xiaoxia; Su Chunxia; Ren Shengxiang; Li Xuefei; Zhao Chao; Gao Guanghui; Zhou Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Osimertinib demonstrates superior efficacy in patients with non-small cell lung cancer (NSCLC) who acquired EGFR T790M mutation as resistant mechanism to upfront EGFR tyrosine kinase inhibitors (TKIs).  Not all the T790M-positive tumors are homogeneously sensitive to osimertinib, however, and the duration of response often varies.  Previous studies suggest that loss of T790 M at osimertinib resistance is correlated with shortened survival benefit of osimertinib.  The aim of this study is to investigate the prevalence of T790 M loss after progression to osimertinib in Chinese patients with NSCLC harboring EGFR T790 M mutation and to compare their clinical outcomes and characteristics when stratified by T790 M mutational status at osimertinib resistance.  PATIENTS AND METHODS:  All patients with a secondary T790 M mutation after progression to prior-line EGFR TKIs and received single-agent osimertinib were reviewed.  The patients who were reassessed for T790 M mutation post-osimertinib resistance were included in final analysis.  Detailed clinicopathologic characteristics and response data were collected.  RESULTS:  Of the patients with confirmed T790 M mutation as acquired resistance to early-generation EGFR TKIs and subsequently received single-agent osimertinib, 84 patients experienced clinical progression after osimertinib treatment and were eligible for analysis.  Among them, 31 patients underwent repeated T790 M mutation testing on osimertinib resistance.  Sixteen patients had maintained T790 M mutation, whereas 15 patients lost T790 M at resistance.  Loss of T790 M at resistance was remarkably correlated with shorter duration of response to osimertinib (P = 0.0005).  Furthermore, the overall survival after osimertinib treatment was also decreased in T790M-loss group (P=0.021).  The objective response rates were comparable between T790M-maintain and T790M-loss group (31.3% and 26.7%, respectively).  In multivariate analysis, loss of T790M remained statistically associated with early progression to osimertinib.  CONCLUSION:  Loss of T790 M mutation at resistance was correlated with early progression and overall survival in response to osimertinib treatment in Chinese patients with NSCLC harboring acquired T790 M mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKFH6IImQHWGxpATR2EQURfW6udTcc2eZdr8knvoHM5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhtlCgtw%253D%253D&md5=2b826795bb48c91c2da53214ffc7014e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DLoss%2520of%2520T790M%2520mutation%2520is%2520associated%2520with%2520early%2520progression%2520to%2520osimertinib%2520in%2520Chinese%2520patients%2520with%2520advanced%2520NSCLC%2520who%2520are%2520harboring%2520EGFR%2520T790M%26jtitle%3DLung%2520Cancer%26date%3D2019%26volume%3D128%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.lungcan.2018.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3913</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-14-2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25948633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3913-3923&issue=17&author=D.+Ercanauthor=H.+G.+Choiauthor=C.+H.+Yunauthor=M.+Capellettiauthor=T.+Xieauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=EGFR+mutations+and+resistance+to+irreversible+pyrimidine-based+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-14-2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors</span></div><div class="casAuthors">Ercan, Dalia; Choi, Hwan Geun; Yun, Cai-Hong; Capelletti, Marzia; Xie, Ting; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3913-3923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclin. models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation.  However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors.  We sought to identify and study EGFR mutations that confer resistance to this class of agents.  Exptl. Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones.  We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.  Results: We identified 3 major drug resistance mutations.  EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance.  Cells contg. an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib.  The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.  Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clin. EGFR inhibitors.  These findings will guide the development of new strategies to inhibit EGFR.  Clin Cancer Res; 21(17); 3913-23. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEcpT5h6UJorVg90H21EOLACvtfcHk0lio5tB5EJrLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE&md5=9c2916156cb18726ff2f2d2881345548</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2789%26sid%3Dliteratum%253Aachs%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DEGFR%2520mutations%2520and%2520resistance%2520to%2520irreversible%2520pyrimidine-based%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3913%26epage%3D3923%26doi%3D10.1158%2F1078-0432.CCR-14-2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28625641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=228-231&author=S.+I.+Ouauthor=J.+Cuiauthor=A.+B.+Schrockauthor=M.+E.+Goldbergauthor=V.+W.+Zhuauthor=L.+Albackerauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Ali&title=Emergence+of+novel+and+dominant+acquired+EGFR+solvent-front+mutations+at+Gly796+%28G796S%2FR%29+together+with+C797S%2FR+and+L792F%2FH+mutations+in+one+EGFR+%28L858R%2FT790M%29+NSCLC+patient+who+progressed+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Cui Jean; Schrock Alexa B; Goldberg Michael E; Albacker Lee; Stephens Philip J; Miller Vincent A; Ali Siraj M; Zhu Viola W</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR.  Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.  A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.  The patient was initiated on osimertinib with disease shrinkage after 2 months, but tumor regrowth was observed after 5 months of osimertinib treatment.  Assay of plasma ctDNA at this time revealed these different secondary resistance mutations all in trans with each other including distinct mutations at the same codon producing different amino acid changes: G796S/R (mutant allele frequency [MAF]; 14.4%), C797S/G (MAF: 2.26%), L792F/H (MAF: 0.36%), and V802F (MAF: 0.40%), in addition to the pre-existing L858R (MAF:17.9%) and T790M (MAF:18.2%) but all in cis with T790M.  The G796S/R mutations are homologous with known reported solvent front mutations in ALK G1202R, ROS1 G2032R, TrkA G595R and TrkC G623R, all of which are associated with acquired resistance to type I TKIs.  In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring.  Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTk4Muekmj_ccAKB7Fa-xrUfW6udTcc2eYKOyk8Nwo9g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D&md5=f2cedb07d65360f42885e5cd46220f57</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGoldberg%26aufirst%3DM.%2BE.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAlbacker%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DEmergence%2520of%2520novel%2520and%2520dominant%2520acquired%2520EGFR%2520solvent-front%2520mutations%2520at%2520Gly796%2520%2528G796S%252FR%2529%2520together%2520with%2520C797S%252FR%2520and%2520L792F%252FH%2520mutations%2520in%2520one%2520EGFR%2520%2528L858R%252FT790M%2529%2520NSCLC%2520patient%2520who%2520progressed%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D228%26epage%3D231%26doi%3D10.1016%2Fj.lungcan.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oztan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L.</span></span> <span> </span><span class="NLM_article-title">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28838405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2017&pages=84-87&author=A.+Oztanauthor=S.+Fischerauthor=A.+B.+Schrockauthor=R.+L.+Erlichauthor=C.+M.+Lovlyauthor=P.+J.+Stephensauthor=J.+S.+Rossauthor=V.+Millerauthor=S.+M.+Aliauthor=S.+I.+Ouauthor=L.+Raez&title=Emergence+of+EGFR+G724S+mutation+in+EGFR-mutant+lung+adenocarcinoma+post+progression+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span></div><div class="casAuthors">Oztan A; Fischer S; Schrock A B; Erlich R L; Stephens P J; Ross J S; Miller V; Ali S M; Lovly C M; Ou S-H I; Raez L E</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers.  Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined.  The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment.  This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsycCvNkMcjjToTC3aBaesfW6udTcc2eYKOyk8Nwo9g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D&md5=c7173dc6b94f44f48532bebb352e345f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DOztan%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DErlich%26aufirst%3DR.%2BL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DRaez%26aufirst%3DL.%26atitle%3DEmergence%2520of%2520EGFR%2520G724S%2520mutation%2520in%2520EGFR-mutant%2520lung%2520adenocarcinoma%2520post%2520progression%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D111%26spage%3D84%26epage%3D87%26doi%3D10.1016%2Fj.lungcan.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fairclough, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiedrowski, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelichov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarcic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinchcombe, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odegaard, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, R. J.</span></span> <span> </span><span class="NLM_article-title">Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/s40164-019-0148-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs40164-019-0148-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31632838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpvV2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=24&author=S.+R.+Faircloughauthor=L.+A.+Kiedrowskiauthor=J.+J.+Linauthor=O.+Zelichovauthor=G.+Tarcicauthor=T.+E.+Stinchcombeauthor=J.+I.+Odegaardauthor=R.+B.+Lanmanauthor=A.+T.+Shawauthor=R.+J.+Nagy&title=Identification+of+osimertinib-resistant+EGFR+L792+mutations+by+cfDNA+sequencing%3A+oncogenic+activity+assessment+and+prevalence+in+large+cfDNA+cohort&doi=10.1186%2Fs40164-019-0148-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort</span></div><div class="casAuthors">Fairclough Stephen R; Kiedrowski Lesli A; Odegaard Justin I; Lanman Richard B; Nagy Rebecca J; Lin Jessica J; Shaw Alice T; Zelichov Ori; Tarcic Gabi; Stinchcombe Thomas E</div><div class="citationInfo"><span class="NLM_cas:title">Experimental hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    </div><div class="casAbstract">Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner.  Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib.  We subsequently analyzed a large cohort of over 1800 additional patient samples harboring an EGFR T790M mutation and identified a concomitant L792 mutation in a total of 22 (1.2%) cases.  In vitro functional assays demonstrated that the EGFR L858R/T790M/L792F/H mutations conferred intermediate-level resistance to osimertinib.  Further understanding of potential acquired resistance mechanisms to targeted therapy may help inform treatment strategy in EGFR-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5BYysmWirH1UIs6wFK5xJfW6udTcc2eZqTgXOttfm67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpvV2hsA%253D%253D&md5=d4a67bf45fed9beeab9368ad51b1bc0c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1186%2Fs40164-019-0148-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40164-019-0148-7%26sid%3Dliteratum%253Aachs%26aulast%3DFairclough%26aufirst%3DS.%2BR.%26aulast%3DKiedrowski%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZelichov%26aufirst%3DO.%26aulast%3DTarcic%26aufirst%3DG.%26aulast%3DStinchcombe%26aufirst%3DT.%2BE.%26aulast%3DOdegaard%26aufirst%3DJ.%2BI.%26aulast%3DLanman%26aufirst%3DR.%2BB.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DNagy%26aufirst%3DR.%2BJ.%26atitle%3DIdentification%2520of%2520osimertinib-resistant%2520EGFR%2520L792%2520mutations%2520by%2520cfDNA%2520sequencing%253A%2520oncogenic%2520activity%2520assessment%2520and%2520prevalence%2520in%2520large%2520cfDNA%2520cohort%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D8%26spage%3D24%26doi%3D10.1186%2Fs40164-019-0148-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR G796D mutation mediates resistance to osimertinib</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">49671</span>– <span class="NLM_lpage">49679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.17913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28572531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=49671-49679&issue=30&author=D.+Zhengauthor=M.+Huauthor=Y.+Baiauthor=X.+Zhuauthor=X.+Luauthor=C.+Wuauthor=J.+Wangauthor=L.+Liuauthor=Z.+Wangauthor=J.+Niauthor=Z.+Yangauthor=J.+Xu&title=EGFR+G796D+mutation+mediates+resistance+to+osimertinib&doi=10.18632%2Foncotarget.17913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR G796D mutation mediates resistance to osimertinib</span></div><div class="casAuthors">Zheng Di; Wang Jiying; Liu Li; Ni Jian; Xu Jianfang; Hu Min; Bai Yu; Zhu Xuehua; Yang Zhenfan; Lu Xuesong; Wang Zheng; Wu Chunyan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">49671-49679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).  Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound.  Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification.  However, a comprehensive view is still missing.  In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism.  Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVPEeosoOnpOLfW6udTcc2eZqTgXOttfm67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D&md5=9a871c015caf328b0af6d6412efae5c3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17913%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEGFR%2520G796D%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D30%26spage%3D49671%26epage%3D49679%26doi%3D10.18632%2Foncotarget.17913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lh75jFPCurlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">EGFR L792H and G796R: Two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1421</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29857056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbisl2nsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1415-1421&issue=9&author=Q.+Zhangauthor=X.+C.+Zhangauthor=J.+J.+Yangauthor=Z.+F.+Yangauthor=Y.+Baiauthor=J.+Suauthor=Z.+Wangauthor=Z.+Zhangauthor=Y.+Shaoauthor=Q.+Zhouauthor=J.+Kangauthor=E.+E.+Keauthor=Y.+C.+Zhangauthor=Z.+Y.+Dongauthor=Z.+H.+Chenauthor=H.+Y.+Tuauthor=W.+Z.+Zhongauthor=X.+N.+Yangauthor=Y.+L.+Wu&title=EGFR+L792H+and+G796R%3A+Two+novel+mutations+mediating+resistance+to+the+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib&doi=10.1016%2Fj.jtho.2018.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib</span></div><div class="casAuthors">Zhang Qi; Zhang Xu-Chao; Yang Jin-Ji; Su Jian; Zhou Qing; Kang Jin; Ke E-E; Zhang Yi-Chen; Dong Zhong-Yi; Chen Zhi-Hong; Tu Hai-Yan; Zhong Wen-Zhao; Yang Xue-Ning; Yang Zhen-Fan; Bai Yu; Wang Zheng; Zhang Zhou; Shao Yang; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1415-1421</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M mutation.  As the development of acquired resistance is inevitable, it is urgent that the mechanisms of such resistance be clarified.  METHODS:  DNA samples from a cohort of 340 patients with lung adenocarcinoma who were taking osimertinib were subjected to next-generation sequencing and screened in terms of the frequencies of the L792H and G796R mutations.  Ba/F3 cells stably expressing the EGFR L858R/T790M mutations (in cis) with either the L792H or G796R mutation were created to investigate the impact of the two novel mutations on EGFR tyrosine kinase inhibitors and other potential drug combinations in vitro.  Structural analyses were performed by using Schrodinger/Maestro software (version 11.1.012, Schrodinger LLC, Cambridge, MA).  RESULTS:  L792H and G796R were detected in 1.76% (six of 340) and 0.56% (two of 340) patients with lung adenocarcinoma treated with osimertinib, respectively.  The introduction of L792H or G796R mutations against an L858R/T790M background caused dramatic reductions in osimertinib sensitivity.  Structural modeling showed that mutations in cis with T790M either forced the ligand (osimertinib) to rotate out (breaking the binding) or pulled the hinge loop (breaking the hinge).  Various other drug combinations. including cetuximab with EAI045, failed to inhibit either cis mutant effectively.  CONCLUSIONS:  The EGFR L858R/T790M/L792H and L858R/T790M/G796R mutations conferred resistance to osimertinib both in vitro and in silico.  For patients in whom the two resistance mutations occur at low frequency, more precise treatment strategies and additional combinational approaches are required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiqXObge7yFGlSCSgBhwJFfW6udTcc2eZZVpMepzkDuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbisl2nsg%253D%253D&md5=d08343eb44145455665eea3756d7eefa</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%2BF.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DE.%2BE.%26aulast%3DZhang%26aufirst%3DY.%2BC.%26aulast%3DDong%26aufirst%3DZ.%2BY.%26aulast%3DChen%26aufirst%3DZ.%2BH.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DZhong%26aufirst%3DW.%2BZ.%26aulast%3DYang%26aufirst%3DX.%2BN.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DEGFR%2520L792H%2520and%2520G796R%253A%2520Two%2520novel%2520mutations%2520mediating%2520resistance%2520to%2520the%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D1415%26epage%3D1421%26doi%3D10.1016%2Fj.jtho.2018.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical modeling of osimertinib for NSCLC with EGFR exon 20 insertion mutations</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31108249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSitbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1556-1566&issue=9&author=Y.+Leeauthor=T.+M.+Kimauthor=D.+W.+Kimauthor=S.+Kimauthor=M.+Kimauthor=B.+Keamauthor=J.+L.+Kuauthor=D.+S.+Heo&title=Preclinical+modeling+of+osimertinib+for+NSCLC+with+EGFR+exon+20+insertion+mutations&doi=10.1016%2Fj.jtho.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations</span></div><div class="casAuthors">Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1556-1566</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NSCLC with EGFR exon 20 insertion mutations is the third most common type of EGFR-mutant NSCLC and is resistant to EGFR tyrosine kinase inhibitors (TKIs).  This study was conducted to evaluate the efficacies of first- to third-generation EGFR TKIs against NSCLC cells harboring EGFR exon 20 insertion mutations.  We developed seven EGFR exon 20 insertion-mutant Ba/F3 models and one patient-derived NSCLC (SNU-3173) of subtypes A763insFQEA, V769insASV, D770insSVD, D770insNPG, P772insPR, H773insH, H773insNPH, and H773insAH.  Cell viability assays, immunoblotting, and N-ethyl-N-nitrosourea mutagenesis screenings were performed..  Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells.  N-ethyl-N-nitrosourea mutagenesis screening of EGFR exon 20 insertion-mutant Ba/F3 cells showed various second sites for EGFR mutations, mostly at exons 20 and 21, including E762K, P794S, and G796D.  In addn., osimertinib-resistant cells were established by stepwise exposure to osimertinib and harbored EGFR E762K mutation.  Osimertinib is active against EGFR exon 20 insertion-mutant NSCLC and flexibly binds within drug-binding pockets in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr14pmwkBhhvbVg90H21EOLACvtfcHk0ljXnDH3eHRCpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSitbvK&md5=04baf4f8141ad4d8c3bb65953921f082</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DKu%26aufirst%3DJ.%2BL.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26atitle%3DPreclinical%2520modeling%2520of%2520osimertinib%2520for%2520NSCLC%2520with%2520EGFR%2520exon%252020%2520insertion%2520mutations%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D1556%26epage%3D1566%26doi%3D10.1016%2Fj.jtho.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span> <span> </span><span class="NLM_article-title">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.2147/OTT.S188612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FOTT.S188612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30588029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=51-56&author=Y.+Zhangauthor=B.+Heauthor=D.+Zhouauthor=M.+Liauthor=C.+Hu&title=Newly+emergent+acquired+EGFR+exon+18+G724S+mutation+after+resistance+of+a+T790M+specific+EGFR+inhibitor+osimertinib+in+non-small-cell+lung+cancer%3A+a+case+report&doi=10.2147%2FOTT.S188612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span></div><div class="casAuthors">Zhang, Yan; He, Bixiu; Zhou, Dongbo; Li, Min; Hu, Chengping</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non-small-cell lung cancer.  Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored.  Case presentation: A non-smoking 58-yr-old female patient was initially diagnosed with lung adenocarcinoma harboring EGFR exon 19 deletion and clin. responded to initial gefitinib treatment.  The patient progressed on gefitinib after > 1 yr and a T790M mutation was detected in tissue biopsy by next-generation sequencing (NGS).  Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance.  Conclusion: The specific mechanisms of acquiring drug resistance for EGFR-TKIs have not been fully explored.  EGFR G724S mutation might be assocd. with osimertinib resistance but more studies about the mechanism should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGCPcRDGUQb7Vg90H21EOLACvtfcHk0lhSSGQXL4xAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K&md5=87e7c138506ba5973a82cf7715aacff5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2147%2FOTT.S188612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S188612%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DC.%26atitle%3DNewly%2520emergent%2520acquired%2520EGFR%2520exon%252018%2520G724S%2520mutation%2520after%2520resistance%2520of%2520a%2520T790M%2520specific%2520EGFR%2520inhibitor%2520osimertinib%2520in%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520case%2520report%26jtitle%3DOncoTargets%2520Ther.%26date%3D2019%26volume%3D12%26spage%3D51%26epage%3D56%26doi%3D10.2147%2FOTT.S188612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brägelmann, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4655</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07078-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41467-018-07078-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30405134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4655&issue=1&author=J.+Fassunkeauthor=F.+M%C3%BCllerauthor=M.+Keulauthor=S.+Michelsauthor=M.+A.+Dammertauthor=A.+Schmittauthor=D.+Plenkerauthor=J.+Lategahnauthor=C.+Heydtauthor=J.+Br%C3%A4gelmann&title=Overcoming+EGFR+G724S-mediated+osimertinib+resistance+through+unique+binding+characteristics+of+second-generation+EGFR+inhibitors&doi=10.1038%2Fs41467-018-07078-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span></div><div class="casAuthors">Fassunke Jana; Heydt Carina; Klein Sebastian; Ihle Michaela A; Scheel Andreas H; Wagener Svenja; Merkelbach-Bruse Sabine; Buttner Reinhard; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Garbert Katia; Sos Martin L; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Dahmen Ilona; Garbert Katia; Buttner Reinhard; Sos Martin L; Keul Marina; Lategahn Jonas; Alber Yannic; Kast Stefan M; Rauh Daniel; Michels Sebastian; Fischer Rieke N; Scheffler Matthias; Priesner Vanessa; Kron Anna; Wolf Jurgen; Buttner Reinhard; Schmitt Anna; Reinhardt H Christian; Sos Martin L; Schmitt Anna; Reinhardt H Christian; Schmitt Anna; Reinhardt H Christian; Klein Sebastian; Frank Konrad; Persigehl Thorsten; Pusken Michael; Haneder Stefan; Schaaf Bernhard; Rodermann Ernst; Engel-Riedel Walburga; Felip Enriqueta; Smit Egbert F</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4655</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients.  In a subgroup of these patients we identified an association between selection of EGFR(T790M)-negative but EGFR(G724S)-positive subclones and osimertinib resistance.  We demonstrate that EGFR(G724S) limits the activity of third-generation EGFR inhibitors both in vitro and in vivo.  Structural analyses and computational modeling indicate that EGFR(G724S) mutations may induce a conformation of the glycine-rich loop, which is incompatible with the binding of third-generation TKIs.  Systematic inhibitor screening and in-depth kinetic profiling validate these findings and show that second-generation EGFR inhibitors retain kinase affinity and overcome EGFR(G724S)-mediated resistance.  In the case of afatinib this profile translates into a robust reduction of colony formation and tumor growth of EGFR(G724S)-driven cells.  Our data provide a mechanistic basis for the osimertinib-induced selection of EGFR(G724S)-mutant clones and a rationale to treat these patients with clinically approved second-generation EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbrRUzliurTsve_zCu79I8fW6udTcc2eb50Fak38Zhubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D&md5=a09a4c84fb50fd456dcab005d2d9366a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07078-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07078-0%26sid%3Dliteratum%253Aachs%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DF.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DDammert%26aufirst%3DM.%2BA.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBr%25C3%25A4gelmann%26aufirst%3DJ.%26atitle%3DOvercoming%2520EGFR%2520G724S-mediated%2520osimertinib%2520resistance%2520through%2520unique%2520binding%2520characteristics%2520of%2520second-generation%2520EGFR%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D4655%26doi%3D10.1038%2Fs41467-018-07078-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span> <span> </span><span class="NLM_article-title">Sensitivity and resistance of met exon 14 mutations in lung cancer to eight met tyrosine kinase inhibitors in vitro</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1753</span>– <span class="NLM_lpage">1765</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31279006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKgsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1753-1765&issue=10&author=T.+Fujinoauthor=Y.+Kobayashiauthor=K.+Sudaauthor=T.+Kogaauthor=M.+Nishinoauthor=S.+Oharaauthor=M.+Chibaauthor=M.+Shimojiauthor=K.+Tomizawaauthor=T.+Takemotoauthor=T.+Mitsudomi&title=Sensitivity+and+resistance+of+met+exon+14+mutations+in+lung+cancer+to+eight+met+tyrosine+kinase+inhibitors+in+vitro&doi=10.1016%2Fj.jtho.2019.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro</span></div><div class="casAuthors">Fujino, Toshio; Kobayashi, Yoshihisa; Suda, Kenichi; Koga, Takamasa; Nishino, Masaya; Ohara, Shuta; Chiba, Masato; Shimoji, Masaki; Tomizawa, Kenji; Takemoto, Toshiki; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1753-1765</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer, including exon 14 skipping and point mutations, have been attracting the attention of thoracic oncologists as new therapeutic targets.  Tumors with these mutations almost always acquire resistance, which also occurs in other oncogene-addicted lung cancers.  However, the resistance mechanisms and treatment strategies are not fully understood.  We generated Ba/F3 cells expressing MET exon 14 mutations by retroviral gene transfer.  The sensitivities of these cells to eight MET-tyrosine kinase inhibitors (TKIs) were detd. using a colorimetric assay.  In addn., using N-ethyl-N-nitrosourea mutagenesis, we generated resistant clones, searched for secondary MET mutations, and then examd. the sensitivities of these resistant cells to different TKIs.  Ba/F3 cells transfected with MET mutations grew in the absence of interleukin-3, indicating their oncogenic activity.  These cells were sensitive to all MET-TKIs except tivantinib.  We identified a variety of secondary mutations.  D1228 and Y1230 were common sites for resistance mutations for type I TKIs, which bind the active form of MET, whereas L1195 and F1200 were common sites for type II TKIs, which bind the inactive form.  In general, resistance mutations against type I were sensitive to type II, and vice versa.  MET-TKIs inhibited the growth of cells with MET exon 14 mutations.  We also identified mutation sites specific for TKI types as resistance mechanisms and complementary activities between type I and type II inhibitors against those mutations.  These finding should provide relevant clin. implication for treating patients with lung cancer harboring MET exon 14 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoId7snrArCoLVg90H21EOLACvtfcHk0lhSSGQXL4xAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKgsrjJ&md5=964f83ad4a4edf6f121b1c47961e31df</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DFujino%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DSuda%26aufirst%3DK.%26aulast%3DKoga%26aufirst%3DT.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DOhara%26aufirst%3DS.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DShimoji%26aufirst%3DM.%26aulast%3DTomizawa%26aufirst%3DK.%26aulast%3DTakemoto%26aufirst%3DT.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DSensitivity%2520and%2520resistance%2520of%2520met%2520exon%252014%2520mutations%2520in%2520lung%2520cancer%2520to%2520eight%2520met%2520tyrosine%2520kinase%2520inhibitors%2520in%2520vitro%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D10%26spage%3D1753%26epage%3D1765%26doi%3D10.1016%2Fj.jtho.2019.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daneshbod, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe'er, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span> <span> </span><span class="NLM_article-title">Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with <i>EGFR</i>-mutant lung cancers</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">9028</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.9028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1200%2FJCO.2019.37.15_suppl.9028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=9028&issue=15&author=A.+J.+Schoenfeldauthor=J.+M.+Chanauthor=H.+Rizviauthor=N.+Rekhtmanauthor=Y.+Daneshbodauthor=D.+Kubotaauthor=J.+C.+Changauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=R.+Somwarauthor=M.+G.+Krisauthor=D.+Pe%27erauthor=G.+J.+Rielyauthor=H.+A.+Yu&title=Tissue-based+molecular+and+histological+landscape+of+acquired+resistance+to+osimertinib+given+initially+or+at+relapse+in+patients+with+EGFR-mutant+lung+cancers&doi=10.1200%2FJCO.2019.37.15_suppl.9028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.9028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.9028%26sid%3Dliteratum%253Aachs%26aulast%3DSchoenfeld%26aufirst%3DA.%2BJ.%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DRizvi%26aufirst%3DH.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DDaneshbod%26aufirst%3DY.%26aulast%3DKubota%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DJ.%2BC.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DPe%2527er%26aufirst%3DD.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DYu%26aufirst%3DH.%2BA.%26atitle%3DTissue-based%2520molecular%2520and%2520histological%2520landscape%2520of%2520acquired%2520resistance%2520to%2520osimertinib%2520given%2520initially%2520or%2520at%2520relapse%2520in%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26issue%3D15%26spage%3D9028%26doi%3D10.1200%2FJCO.2019.37.15_suppl.9028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3351</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-3829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-18-3829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30796031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=3341-3351&issue=11&author=B.+P.+Brownauthor=Y.+K.+Zhangauthor=D.+Westoverauthor=Y.+Yanauthor=H.+Qiaoauthor=V.+Huangauthor=Z.+Duauthor=J.+A.+Smithauthor=J.+S.+Rossauthor=V.+A.+Millerauthor=S.+Aliauthor=L.+Bazhenovaauthor=A.+B.+Schrockauthor=J.+Meilerauthor=C.+M.+Lovly&title=On-target+resistance+to+the+mutant-selective+EGFR+inhibitor+osimertinib+can+develop+in+an+allele-specific+manner+dependent+on+the+original+EGFR-activating+mutation&doi=10.1158%2F1078-0432.CCR-18-3829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span></div><div class="casAuthors">Brown, Benjamin P.; Zhang, Yun-Kai; Westover, David; Yan, Yingjun; Qiao, Huan; Huang, Vincent; Du, Zhenfang; Smith, Jarrod A.; Ross, Jeffrey S.; Miller, Vincent A.; Ali, Siraj; Bazhenova, Lyudmila; Schrock, Alexa B.; Meiler, Jens; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3341-3351</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer.  Here, we investigate how G724S confers resistance to osimertinib.  We combine structure-based predictive modeling of G724S in combination with the 2 most common EGFR-activating mutations, exon 19 deletion (Ex19Del) and L858R, with in vitro drug-response models and patient genomic profiling.  Our simulations suggest that the G724S mutation selectively reduces osimertinib-binding affinity in the context of Ex19Del.  Consistent with our simulations, cell lines transduced with Ex19Del/G724S demonstrate resistance to osimertinib, whereas cells transduced with L858R/G724S are sensitive to osimertinib.  Subsequent clin. genomic profiling data further suggest G724S occurs with Ex19Del but not L858R.  Furthermore, we demonstrate that Ex19Del/G724S retains sensitivity to afatinib, but not to erlotinib, suggesting a possible therapy for patients at the time of disease relapse.  Altogether, these data suggest that G724S is an allele-specific resistance mutation emerging in the context of Ex19Del but not L858R.  Our results fundamentally reframe the problem of targeted therapy resistance from one focused on the drug-resistance mutation pair to one focused on activating mutation-drug-resistance mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKneM5OFx3BrVg90H21EOLACvtfcHk0lh6-tK2XWYcXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO&md5=5ea6914733351fabdf1c59c19a66e49e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3829%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DB.%2BP.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DOn-target%2520resistance%2520to%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520osimertinib%2520can%2520develop%2520in%2520an%2520allele-specific%2520manner%2520dependent%2520on%2520the%2520original%2520EGFR-activating%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26issue%3D11%26spage%3D3341%26epage%3D3351%26doi%3D10.1158%2F1078-0432.CCR-18-3829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehlman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau-Bussac, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacave, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujals, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Théou-Anton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trédaniel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dujon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schischmanoff, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux Leprieur, E.</span></span> <span> </span><span class="NLM_article-title">Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2019.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2019.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31600593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnms1ygsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2019&pages=149-156&author=C.+Mehlmanauthor=J.+Cadranelauthor=G.+Rousseau-Bussacauthor=R.+Lacaveauthor=A.+Pujalsauthor=N.+Girardauthor=C.+Callensauthor=V.+Gounantauthor=N.+Th%C3%A9ou-Antonauthor=S.+Friardauthor=J.+Tr%C3%A9danielauthor=H.+Blonsauthor=C.+Dujonauthor=B.+Duchemannauthor=P.+O.+Schischmanoffauthor=T.+Chinetauthor=E.+Giroux+Leprieur&title=Resistance+mechanisms+to+osimertinib+in+EGFR-mutated+advanced+non-small-cell+lung+cancer%3A+A+multicentric+retrospective+French+study&doi=10.1016%2Fj.lungcan.2019.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study</span></div><div class="casAuthors">Mehlman Camille; Chinet Thierry; Cadranel Jacques; Rousseau-Bussac Gaelle; Lacave Roger; Pujals Anais; Girard Nicolas; Callens Celine; Gounant Valerie; Theou-Anton Nathalie; Friard Sylvie; Tredaniel Jean; Blons Helene; Dujon Cecile; Duchemann Boris; Schischmanoff Pierre Olivier; Giroux Leprieur Etienne</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC).  MATERIALS AND METHODS:  We performed a multicentric retrospective analysis on a cohort of consecutive patients treated with osimertinib for an advanced EGFR-mutated NSCLC and collected histo-molecular data from plasma and tumor samples at the time of progression.  Next-generation sequencing (NGS) was performed for all samples.  Best Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) and data on treatment post-progression efficacy were also collected.  RESULTS:  Two-hundred and twenty-six patients were included from 9 Academic French Hospitals between April 2015-October 2018.  Osimertinib was given in second-line or more in 219 patients (97%).  Best ORR was 52% and best central nervous system ORR was 56%.  Median PFS and OS were 9.5 months (IQR 4.0-17.2) and 24 months (IQR 12.4-NR) respectively.  At the time of analysis, 150 patients (66%) had tumor progression.  Among them, 73 contributive samples (56 tumor biopsies) were available.  The most frequent molecular alterations were C797S mutation (n = 9 (13%)) and MET amplification (n = 8 (11%)).  Histologic transformation occurred in 5 patients (9% of tumor biopsies).  In T790M + NSCLC, loss of T790 M occurred in 68% of cases.  Median PFS and OS with treatment beyond progression were 6.0 months (IQR 2.0-10.4) and 15.1 months (IQR 6.7-NR) respectively and longer in case of osimertinib continuation beyond progression.  CONCLUSION:  We confirmed the efficacy of osimertinib in patients with advanced EGFR mutation positive NSCLC.  At progression, the most frequent molecular alterations were MET amplification and C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEHjIbI2V17QHqQV89nF-2fW6udTcc2eadKmzlSeqf7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnms1ygsA%253D%253D&md5=bff3c77fc71bcdc18568771b32352dc5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2019.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2019.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DMehlman%26aufirst%3DC.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DRousseau-Bussac%26aufirst%3DG.%26aulast%3DLacave%26aufirst%3DR.%26aulast%3DPujals%26aufirst%3DA.%26aulast%3DGirard%26aufirst%3DN.%26aulast%3DCallens%26aufirst%3DC.%26aulast%3DGounant%26aufirst%3DV.%26aulast%3DTh%25C3%25A9ou-Anton%26aufirst%3DN.%26aulast%3DFriard%26aufirst%3DS.%26aulast%3DTr%25C3%25A9daniel%26aufirst%3DJ.%26aulast%3DBlons%26aufirst%3DH.%26aulast%3DDujon%26aufirst%3DC.%26aulast%3DDuchemann%26aufirst%3DB.%26aulast%3DSchischmanoff%26aufirst%3DP.%2BO.%26aulast%3DChinet%26aufirst%3DT.%26aulast%3DGiroux%2BLeprieur%26aufirst%3DE.%26atitle%3DResistance%2520mechanisms%2520to%2520osimertinib%2520in%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520A%2520multicentric%2520retrospective%2520French%2520study%26jtitle%3DLung%2520Cancer.%26date%3D2019%26volume%3D137%26spage%3D149%26epage%3D156%26doi%3D10.1016%2Fj.lungcan.2019.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible egfr inhibitor</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0000000000000688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26473643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1736-1744&issue=12&author=T.+M.+Kimauthor=A.+Songauthor=D.+W.+Kimauthor=S.+Kimauthor=Y.+O.+Ahnauthor=B.+Keamauthor=Y.+K.+Jeonauthor=S.+H.+Leeauthor=D.+H.+Chungauthor=D.+S.+Heo&title=Mechanisms+of+acquired+resistance+to+AZD9291%3A+a+mutation-selective%2C+irreversible+egfr+inhibitor&doi=10.1097%2FJTO.0000000000000688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor</span></div><div class="casAuthors">Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1736-1744</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs.  However, acquired resistance to AZD9291 is inevitable.  In this study, we identified the mechanisms of acquired resistance to AZD9291 in EGFR-mutant NSCLC.  Methods: Four NSCLC patients with both an EGFR exon 19 deletion and the EGFR mutation after developing acquired resistance to first-generation EGFR TKIs received AZD9291 at doses of 20 to 80 mg/day in a phase I trial (NCT01802632).  Paired tumor samples before and after treatment were obtained to evaluate EGFR modifications, alternative pathway activation, and histol. transformation.  Genetic alterations were analyzed using Sanger sequencing, fluorescence in situ hybridization, real-time polymerase chain reaction, and targeted exome sequencing.  Results: All four patients achieved a partial response (median duration of response, 9 mo [range, 9-11 mo]) and subsequently showed resistance to AZD9291.  EGFR-mutant clones depopulated AZD9291-resistant tumors to below 1% (baseline, 14%-36%) in three patients with progression: one with the loss of EGFR-double mutant clones and two accompanied by transformation to small-cell carcinoma and focal fibroblast growth factor receptor 1 (FGFR1) amplification, resp.  EGFR-mutant clones remained and the EGFR ligand was overexpressed in one patient with focal progression to AZD9291.  Conclusion: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histol. transformation and EGFR ligand-dependent activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KLOZPHlkELVg90H21EOLACvtfcHk0lgwjejzyUmYNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE&md5=304e993133713a74dc817f3e05c7e9db</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000688%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DY.%2BO.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%253A%2520a%2520mutation-selective%252C%2520irreversible%2520egfr%2520inhibitor%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D1736%26epage%3D1744%26doi%3D10.1097%2FJTO.0000000000000688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chia, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span> <span> </span><span class="NLM_article-title">Temporal changes of EGFR mutations and T790M levels in tumor and plasma DNA following AZD9291 treatment</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2016.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27393503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2s7osVSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=29-32&author=P.+L.+Chiaauthor=H.+Doauthor=A.+Moreyauthor=P.+Mitchellauthor=A.+Dobrovicauthor=T.+John&title=Temporal+changes+of+EGFR+mutations+and+T790M+levels+in+tumor+and+plasma+DNA+following+AZD9291+treatment&doi=10.1016%2Fj.lungcan.2016.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment</span></div><div class="casAuthors">Chia Puey Ling; Do Hongdo; Dobrovic Alexander; Morey Adrienne; Mitchell Paul; John Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AZD9291, a T790M specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated impressive response rates in tumours harbouring the EGFR T790M resistance mutation.  Emergence of resistance to AZD9291 has been shown to occur through several different mechanisms including the development of new mutations (e.g.  C797S) in the EGFR tyrosine kinase domain.  We studied two patients with paired tumour biopsies and blood samples pre- and post-progression on AZD9291 to explore possible resistance mechanisms.  Pre- and Post-AZD9291 tumour biopsies as well as serial plasma samples were collected from two patients on the AURA clinical study (AZD9291 First Time in Patients Ascending Dose study).  Droplet digital PCR (ddPCR) assays were used to quantify T790M, the driver EGFR mutation, and the C797S mutation in genomic DNA from paired tumour biopsies and plasma cell-free DNA.  In the first patient, both EGFR T790M and L858R became undetectable in the plasma within 1 month after treatment with AZD9291.  However, the T790M and the original L858R mutation re-emerged with radiologically confirmed resistance to AZD9291.  In patient two, the levels of T790M were undetectable at the time of radiological resistance to AZD9291 but increasing levels of the original EGFR exon 19 deletion was detected.  MET amplification was detected in a biopsy performed on progression.  The EGFR C797S mutation was not detected in either patient at the time of relapse. ddPCR of cell free DNA enables real time monitoring of patients on 3rd generation TKIs.  As resistance mechanisms are variable, monitoring levels of the initial activating EGFR mutation may facilitate more reliable detection of progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcGTszAFtsmx8TEN9K18QfW6udTcc2ebhbvVC6iueCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7osVSnug%253D%253D&md5=bd9fafac36d5b86e7ffb162794855292</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DP.%2BL.%26aulast%3DDo%26aufirst%3DH.%26aulast%3DMorey%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DDobrovic%26aufirst%3DA.%26aulast%3DJohn%26aufirst%3DT.%26atitle%3DTemporal%2520changes%2520of%2520EGFR%2520mutations%2520and%2520T790M%2520levels%2520in%2520tumor%2520and%2520plasma%2520DNA%2520following%2520AZD9291%2520treatment%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D98%26spage%3D29%26epage%3D32%26doi%3D10.1016%2Fj.lungcan.2016.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileham, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sholl, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redig, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Assessment of resistance mechanisms and clinical implications in patients with EGFR t790m-positive lung cancer and acquired resistance to osimertinib</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2018.2969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1001%2Fjamaoncol.2018.2969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30073261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ks1Ojuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=1527-1534&issue=11&author=G.+R.+Oxnardauthor=Y.+Huauthor=K.+F.+Milehamauthor=H.+Husainauthor=D.+B.+Costaauthor=P.+Tracyauthor=N.+Feeneyauthor=L.+M.+Shollauthor=S.+E.+Dahlbergauthor=A.+J.+Redigauthor=D.+J.+Kwiatkowskiauthor=M.+S.+Rabinauthor=C.+P.+Paweletzauthor=K.+S.+Thressauthor=P.+A.+J%C3%A4nne&title=Assessment+of+resistance+mechanisms+and+clinical+implications+in+patients+with+EGFR+t790m-positive+lung+cancer+and+acquired+resistance+to+osimertinib&doi=10.1001%2Fjamaoncol.2018.2969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib</span></div><div class="casAuthors">Oxnard Geoffrey R; Hu Yuebi; Tracy Philip; Dahlberg Suzanne E; Redig Amanda J; Kwiatkowski David J; Rabin Michael S; Janne Pasi A; Oxnard Geoffrey R; Redig Amanda J; Kwiatkowski David J; Rabin Michael S; Janne Pasi A; Mileham Kathryn F; Husain Hatim; Costa Daniel B; Tracy Philip; Feeney Nora; Paweletz Cloud P; Janne Pasi A; Sholl Lynette M; Thress Kenneth S</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1527-1534</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR T790M mutation.  Acquired resistance to osimertinib is a growing clinical challenge that is poorly understood.  Objective:  To understand the molecular mechanisms of acquired resistance to osimertinib and their clinical behavior.  Design, Setting, and Participants:  Patients with advanced NSCLC who received osimertinib for T790M-positive acquired resistance to prior EGFR tyrosine kinase inhibitor were identified from a multi-institutional cohort (n = 143) and a confirmatory trial cohort (NCT01802632) (n = 110).  Next-generation sequencing of tumor biopsies after osimertinib resistance was performed.  Genotyping of plasma cell-free DNA was studied as an orthogonal approach, including serial plasma samples when available.  The study and analysis were finalized on November 9, 2017.  Main Outcomes and Measures:  Mechanisms of resistance and their association with time to treatment discontinuation on osimertinib.  Results:  Of the 143 patients evaluated, 41 (28 [68%] women) had tumor next-generation sequencing after acquired resistance to osimertinib.  Among 13 patients (32%) with maintained T790M at the time of resistance, EGFR C797S was seen in 9 patients (22%).  Among 28 individuals (68%) with loss of T790M, a range of competing resistance mechanisms was detected, including novel mechanisms such as acquired KRAS mutations and targetable gene fusions.  Time to treatment discontinuation was shorter in patients with T790M loss (6.1 vs 15.2 months), suggesting emergence of pre-existing resistant clones; this finding was confirmed in a validation cohort of 110 patients with plasma cell-free DNA genotyping performed after osimertinib resistance.  In studies of serial plasma levels of mutant EGFR, loss of T790M at resistance was associated with a smaller decrease in levels of the EGFR driver mutation after 1 to 3 weeks of therapy (100% vs 83% decrease; P = .01).  Conclusions and Relevance:  Acquired resistance to osimertinib mediated by loss of the T790M mutation is associated with early resistance and a range of competing resistance mechanisms.  These data provide clinical evidence of the heterogeneity of resistance in advanced NSCLC and a need for clinical trial strategies that can overcome multiple concomitant resistance mechanisms or strategies for preventing such resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSI9tCQoeLmfNTiMd2aNQVUfW6udTcc2eamE-xlbRjumbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ks1Ojuw%253D%253D&md5=92ac6f25c90f1152cb7b65160d2522bd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2018.2969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2018.2969%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMileham%26aufirst%3DK.%2BF.%26aulast%3DHusain%26aufirst%3DH.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DTracy%26aufirst%3DP.%26aulast%3DFeeney%26aufirst%3DN.%26aulast%3DSholl%26aufirst%3DL.%2BM.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DRedig%26aufirst%3DA.%2BJ.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DRabin%26aufirst%3DM.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DAssessment%2520of%2520resistance%2520mechanisms%2520and%2520clinical%2520implications%2520in%2520patients%2520with%2520EGFR%2520t790m-positive%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520osimertinib%26jtitle%3DJAMA%2520Oncol.%26date%3D2018%26volume%3D4%26issue%3D11%26spage%3D1527%26epage%3D1534%26doi%3D10.1001%2Fjamaoncol.2018.2969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulusu, K.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.S.K.</span></span> <span> </span><span class="NLM_article-title">Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">viii741</span> <span class="refDoi"> DOI: 10.1093/annonc/mdy424.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdy424.064" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&author=V.A.+Papadimitrakopoulouauthor=Y.-L.+Wuauthor=J.-Y.+Hanauthor=M.-J.+Ahnauthor=S.S.+Ramalingamauthor=T.+Johnauthor=I.+Okamotoauthor=J.C.-H.+Yangauthor=K.C.+Bulusuauthor=G.+Lausauthor=B.+Collinsauthor=J.C.+Barrettauthor=J.+Chmieleckiauthor=T.S.K.+Mok&title=Analysis+of+resistance+mechanisms+to+osimertinib+in+patients+with+EGFR+T790M+advanced+NSCLC+from+the+AURA3+study&doi=10.1093%2Fannonc%2Fmdy424.064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy424.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy424.064%26sid%3Dliteratum%253Aachs%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.A.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DHan%26aufirst%3DJ.-Y.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DRamalingam%26aufirst%3DS.S.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DJ.C.-H.%26aulast%3DBulusu%26aufirst%3DK.C.%26aulast%3DLaus%26aufirst%3DG.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DBarrett%26aufirst%3DJ.C.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DMok%26aufirst%3DT.S.K.%26atitle%3DAnalysis%2520of%2520resistance%2520mechanisms%2520to%2520osimertinib%2520in%2520patients%2520with%2520EGFR%2520T790M%2520advanced%2520NSCLC%2520from%2520the%2520AURA3%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26doi%3D10.1093%2Fannonc%2Fmdy424.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.apsb.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26579470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=390-401&issue=5&author=L.+Huangauthor=L.+Fu&title=Mechanisms+of+resistance+to+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.apsb.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Huang Lihua; Fu Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">390-401</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment.  However, patients eventually develop drug resistance.  Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.  Here we review and summarize the known resistant mechanisms to EGFR-TKIs and provide potential targets for development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl75XHngOXiV_fW6udTcc2eamE-xlbRjumbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOqsw%253D%253D&md5=8429fc78384f6e540b1fa8f6c57c363b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26issue%3D5%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.apsb.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span> <span> </span><span class="NLM_article-title">Exon 16-Skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2019.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31557536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=50-61&issue=1&author=C.+C.+Hsuauthor=B.+C.+Liaoauthor=W.+Y.+Liaoauthor=A.+Markovetsauthor=D.+Stetsonauthor=K.+Thressauthor=J.+C.+Yang&title=Exon+16-Skipping+HER2+as+a+novel+mechanism+of+osimertinib+resistance+in+EGFR+L858R%2FT790M-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2019.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Hsu, Chia-Chi; Liao, Bin-Chi; Liao, Wei-Yu; Markovets, Aleksandra; Stetson, Daniel; Thress, Kenneth; Chih-Hsin Yang, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-61</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We had a patient with EGFR L858R/T790M-pos. NSCLC who initially responded to osimertinib therapy but eventually experienced development of resistance.  Plasma cell-free DNA anal. revealed the occurrence of exon 16-skipping HER2, which may have resulted in the erb-b2 receptor tyrosine kinase 2 gene (HER2) splice variant HER2D16.  HER2D16 has never been reported in lung cancer, and HER2D16-driven signaling is known to be regulated by Src kinase in breast cancer.  We investigated the role of HER2D16 as an osimertinib-resistant mechanism.We constructed and established H1975 cells stably expressing HER2D16.  The dimeric formation of HER2D16 was tested by using nonreducing polyacrylamide gel electrophoresis.  Synergistic effect was assessed by using the Chou-Talalay method.We found that HER2D16 can form a homodimer in NSCLC cells.  We also found that mutant EGFR and HER2D16 cooperated to activate downstream signaling for osimertinib resistance.  In addn., cotreatment with osimertinib and an Src kinase inhibitor failed to reverse resistance, indicating that HER2D16-driven signaling in NSCLC did not occur through a canonical pathway.  Finally, we revealed that the combination of osimertinib with the pan-HER small-mol. inhibitor afatinib could synergistically repress cell growth and signaling in H1975-HER2D16 cells.HER2D16 can contribute to osimertinib resistance through an Src-independent pathway.  HER2D16 should be included in the mol. diagnosis panel for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGJOlmIkbukrVg90H21EOLACvtfcHk0lhuRL1gWhNQMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKgs77O&md5=b711bc98055e4be3f9f295688878b151</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DB.%2BC.%26aulast%3DLiao%26aufirst%3DW.%2BY.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DExon%252016-Skipping%2520HER2%2520as%2520a%2520novel%2520mechanism%2520of%2520osimertinib%2520resistance%2520in%2520EGFR%2520L858R%252FT790M-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D50%26epage%3D61%26doi%3D10.1016%2Fj.jtho.2019.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovich&title=Circulating+tumor+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0liabJE_fKnLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26atitle%3DCirculating%2520tumor%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Organ, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span> <span> </span><span class="NLM_article-title">An overview of the c-MET signalling pathway</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S7</span>– <span class="NLM_lpage">S19</span>, <span class="refDoi"> DOI: 10.1177/1758834011422556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1177%2F1758834011422556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22128289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=S7-S19&issue=1&author=S.+L.+Organauthor=M.+S.+Tsao&title=An+overview+of+the+c-MET+signalling+pathway&doi=10.1177%2F1758834011422556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the c-MET signaling pathway</span></div><div class="casAuthors">Organ, Shawna Leslie; Tsao, Ming-Sound</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S7-S19</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  C-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion.  Although c-MET is important in the control of tissue homeostasis under normal physiol. conditions, it has also been found to be aberrantly activated in human cancers via mutation, amplification or protein overexpression.  This paper provides an overview of the c-MET signaling pathway, including its role in the development of cancers, and provides a rationale for targeting the pathway as a possible treatment option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp79uA73SrMTLVg90H21EOLACvtfcHk0liabJE_fKnLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSqsg%253D%253D&md5=94f1ef8e31e21a15edc525e2c6325f52</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1177%2F1758834011422556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834011422556%26sid%3Dliteratum%253Aachs%26aulast%3DOrgan%26aufirst%3DS.%2BL.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26atitle%3DAn%2520overview%2520of%2520the%2520c-MET%2520signalling%2520pathway%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2011%26volume%3D3%26issue%3D1%26spage%3DS7%26epage%3DS19%26doi%3D10.1177%2F1758834011422556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovinger, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinsurongkawong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glisson, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in <i>EGFR</i>-mutant NSCLC</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6203</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-18-1542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30228210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6195-6203&issue=24&author=X.+Leauthor=S.+Puriauthor=M.+V.+Negraoauthor=M.+B.+Nilssonauthor=J.+Robichauxauthor=T.+Boyleauthor=J.+K.+Hicksauthor=K.+L.+Lovingerauthor=E.+Roartyauthor=W.+Rinsurongkawongauthor=M.+Tangauthor=H.+Sunauthor=Y.+Elaminauthor=L.+C.+Lacerdaauthor=J.+Lewisauthor=J.+A.+Rothauthor=S.+G.+Swisherauthor=J.+J.+Leeauthor=W.+N.+Williamauthor=B.+S.+Glissonauthor=J.+Zhangauthor=V.+A.+Papadimitrakopoulouauthor=J.+E.+Grayauthor=J.+V.+Heymach&title=Landscape+of+EGFR-dependent+and+-independent+resistance+mechanisms+to+osimertinib+and+continuation+therapy+beyond+progression+in+EGFR-mutant+NSCLC&doi=10.1158%2F1078-0432.CCR-18-1542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC</span></div><div class="casAuthors">Le, Xiuning; Puri, Sonam; Negrao, Marcelo V.; Nilsson, Monique B.; Robichaux, Jacqulyne; Boyle, Theresa; Hicks, J. Kevin; Lovinger, Katherine L.; Roarty, Emily; Rinsurongkawong, Waree; Tang, Ming; Sun, Huiying; Elamin, Yasir; Lacerda, Lara C.; Lewis, Jeff; Roth, Jack A.; Swisher, Stephen G.; Lee, J. Jack; William, William N., Jr.; Glisson, Bonnie S.; Zhang, Jianjun; Papadimitrakopoulou, Vassiliki A.; Gray, Jhanelle E.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6195-6203</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Osimertinib was initially approved for T790M-pos. non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC.  However, resistance mechanisms to osimertinib have been incompletely described.  Exptl. Design: Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clin. data for patients treated with osimertinib.  Mol. profiling anal. was performed at the time of progression in a subset of the patients.  Results: In the 118 patients treated with osimertinib, 42 had mol. profiling at progression.  T790M was preserved in 21 (50%) patients and lost in 21 (50%).  EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were obsd. exclusively in T790M-preserved cases.  MET amplification was the second most common alteration (14%).  Recurrent alterations were obsd. in 22 genes/pathways, including PIK3CA, FGFR, and RET.  Preclin. studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers.  Alterations of cell-cycle genes were assocd. with shorter median progression-free survival (PFS, 4.4 vs. 8.8 mo, P = 0.01).  In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 mo; 21 patients received local consolidation radiation with a median PFS of 15.5 mo.  Continuation of osimertinib beyond progression was assocd. with a longer overall survival compared with discontinuation (11.2 vs. 6.1 mo, P = 0.02).  Conclusions: Osimertinib resistance is assocd. with diverse, predominantly EGFR-independent genomic alterations.  Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clin. benefit in selected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuIPI4o6FQeLVg90H21EOLACvtfcHk0liabJE_fKnLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FN&md5=b0770e4e5c9b8f55a4153f93acdae931</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1542%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DX.%26aulast%3DPuri%26aufirst%3DS.%26aulast%3DNegrao%26aufirst%3DM.%2BV.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DRobichaux%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DT.%26aulast%3DHicks%26aufirst%3DJ.%2BK.%26aulast%3DLovinger%26aufirst%3DK.%2BL.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DRinsurongkawong%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElamin%26aufirst%3DY.%26aulast%3DLacerda%26aufirst%3DL.%2BC.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26aulast%3DSwisher%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DWilliam%26aufirst%3DW.%2BN.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%2BA.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DLandscape%2520of%2520EGFR-dependent%2520and%2520-independent%2520resistance%2520mechanisms%2520to%2520osimertinib%2520and%2520continuation%2520therapy%2520beyond%2520progression%2520in%2520EGFR-mutant%2520NSCLC%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D24%26spage%3D6195%26epage%3D6203%26doi%3D10.1158%2F1078-0432.CCR-18-1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">viii740</span> <span class="refDoi"> DOI: 10.1093/annonc/mdy424.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdy424.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&author=S.S.+Ramalingamauthor=Y.+Chengauthor=C.+Zhouauthor=Y.+Oheauthor=F.+Imamuraauthor=B.C.+Choauthor=M.-C.+Linauthor=M.+Majemauthor=R.+Shahauthor=Y.+Rukazenkovauthor=A.+Toddauthor=A.+Markovetsauthor=J.C.+Barrettauthor=J.+Chmieleckiauthor=J.+Gray&title=Mechanisms+of+acquired+resistance+to+first-line+osimertinib%3A+Preliminary+data+from+the+phase+III+FLAURA+study&doi=10.1093%2Fannonc%2Fmdy424.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy424.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy424.063%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.S.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DB.C.%26aulast%3DLin%26aufirst%3DM.-C.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DJ.C.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520first-line%2520osimertinib%253A%2520Preliminary%2520data%2520from%2520the%2520phase%2520III%2520FLAURA%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26doi%3D10.1093%2Fannonc%2Fmdy424.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lg3WBBXf_n6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&issue=8&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lg3WBBXf_n6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D8%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldanzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, A.</span></span> <span> </span><span class="NLM_article-title">Physiological signalling and structure of the HGF receptor MET</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.3390/biomedicines3010001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fbiomedicines3010001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSht7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=1-31&issue=1&author=G.+Baldanziauthor=A.+Graziani&title=Physiological+signalling+and+structure+of+the+HGF+receptor+MET&doi=10.3390%2Fbiomedicines3010001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological signaling and structure of the HGF receptor MET</span></div><div class="casAuthors">Baldanzi, Gianluca; Graziani, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-31</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The "hepatocyte growth factor" also known as "scatter factor", is a multifunctional cytokine with the peculiar ability of simultaneously triggering epithelial cell proliferation, movement and survival.  The combination of those proprieties results in the induction of an epithelial to mesenchymal transition in target cells, fundamental for embryogenesis but also exploited by tumor cells during metastatization.  The hepatocyte growth factor receptor, MET, is a proto-oncogene and a prototypical transmembrane tyrosine kinase receptor.  Inhere we discuss the MET mol. structure and the hepatocyte growth factor driven physiol. signaling which coordinates epithelial proliferation, motility and morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWykX-YREQXrVg90H21EOLACvtfcHk0liwfy_GYF6zcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSht7fF&md5=fb2a5d6b8c84a29485d1a8f8accd8340</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines3010001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines3010001%26sid%3Dliteratum%253Aachs%26aulast%3DBaldanzi%26aufirst%3DG.%26aulast%3DGraziani%26aufirst%3DA.%26atitle%3DPhysiological%2520signalling%2520and%2520structure%2520of%2520the%2520HGF%2520receptor%2520MET%26jtitle%3DBiomedicines%26date%3D2015%26volume%3D3%26issue%3D1%26spage%3D1%26epage%3D31%26doi%3D10.3390%2Fbiomedicines3010001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hervieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kermorgant, S.</span></span> <span> </span><span class="NLM_article-title">The role of PI3K in Met driven cancer: A Recap</span>. <i>Front. Mol. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi"> DOI: 10.3389/fmolb.2018.00086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3389%2Ffmolb.2018.00086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30406111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=86&author=A.+Hervieuauthor=S.+Kermorgant&title=The+role+of+PI3K+in+Met+driven+cancer%3A+A+Recap&doi=10.3389%2Ffmolb.2018.00086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K in met driven cancer: a recap</span></div><div class="casAuthors">Hervieu, Alexia; Kermorgant, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Biosciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86</span>CODEN:
                <span class="NLM_cas:coden">FMBRBS</span>;
        ISSN:<span class="NLM_cas:issn">2296-889X</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The Receptor Tyrosine Kinase (RTK) Met, overexpressed or mutated in cancer, plays a major role in cancer progression and represents an attractive target for cancer therapy.  However RTK inhibitors can lead to drug resistance, explaining the necessity to develop therapies that target downstream signaling.  Phosphatidylinositide 3-kinase (PI3K) is one of the most deregulated pathways in cancer and implicated in various types of cancer.  PI3K signaling is also a major signaling pathway downstream of RTK, including Met.  PI3K major effectors include Akt and "mechanistic Target of Rapamycin" (mTOR), which each play key roles in numerous and various cell functions.  Advancements made due to the development of mol. and pharmaceutical tools now allow us to delve into the roles of each independently.  In this review, we summarize the current understanding we possess of the activation and role of PI3K/Akt/mTOR, downstream of Met, in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_PE6rCn4rk7Vg90H21EOLACvtfcHk0liwfy_GYF6zcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmsrnJ&md5=bca2da2de3858f7cd4c65a9a284c90d7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffmolb.2018.00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmolb.2018.00086%26sid%3Dliteratum%253Aachs%26aulast%3DHervieu%26aufirst%3DA.%26aulast%3DKermorgant%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520PI3K%2520in%2520Met%2520driven%2520cancer%253A%2520A%2520Recap%26jtitle%3DFront.%2520Mol.%2520Biosci.%26date%3D2018%26volume%3D5%26spage%3D86%26doi%3D10.3389%2Ffmolb.2018.00086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Marti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mereu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedrés, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miquel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet-Adkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arqués, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuciforo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span> <span> </span><span class="NLM_article-title">Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2451</span>– <span class="NLM_lpage">2457</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28961841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252Fjs12itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2451-2457&issue=10&author=A.+Martinez-Martiauthor=E.+Felipauthor=J.+Matitoauthor=E.+Mereuauthor=A.+Navarroauthor=S.+Cedr%C3%A9sauthor=N.+Pardoauthor=A.+Martinez+de+Castroauthor=J.+Remonauthor=J.+M.+Miquelauthor=A.+Guillaumet-Adkinsauthor=E.+Nadalauthor=G.+Rodriguez-Estebanauthor=O.+Arqu%C3%A9sauthor=R.+Fasaniauthor=P.+Nuciforoauthor=H.+Heynauthor=A.+Villanuevaauthor=H.+G.+Palmerauthor=A.+Vivancos&title=Dual+MET+and+ERBB+inhibition+overcomes+intratumor+plasticity+in+osimertinib-resistant-advanced+non-small-cell+lung+cancer+%28NSCLC%29&doi=10.1093%2Fannonc%2Fmdx396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)</span></div><div class="casAuthors">Martinez-Marti A; Pardo N; Felip E; Matito J; Mereu E; Guillaumet-Adkins A; Rodriguez-Esteban G; Heyn H; Navarro A; Cedres S; Martinez de Castro A; Remon J; Miquel J M; Nadal E; Arques O; Palmer H G; Fasani R; Nuciforo P; Villanueva A; Vivancos A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2451-2457</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M.  Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed.  It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance.  Methods:  For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used.  All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist.  For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected.  Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis.  For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C.  Results:  In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib.  Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis.  In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones.  Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS-driven subclone.  We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs.  Conclusion:  Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR-mutant lung cancer patients may induce genetic plasticity.  We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET-amplification and propose new treatment strategies in this situation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3HhkQ1HkaEu-MdeMhXAHkfW6udTcc2ea4mTErS0wR7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252Fjs12itg%253D%253D&md5=ffbfdbdcb5cb38336e1a9b143a6afa05</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx396%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Marti%26aufirst%3DA.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DMatito%26aufirst%3DJ.%26aulast%3DMereu%26aufirst%3DE.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DCedr%25C3%25A9s%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DN.%26aulast%3DMartinez%2Bde%2BCastro%26aufirst%3DA.%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DMiquel%26aufirst%3DJ.%2BM.%26aulast%3DGuillaumet-Adkins%26aufirst%3DA.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DRodriguez-Esteban%26aufirst%3DG.%26aulast%3DArqu%25C3%25A9s%26aufirst%3DO.%26aulast%3DFasani%26aufirst%3DR.%26aulast%3DNuciforo%26aufirst%3DP.%26aulast%3DHeyn%26aufirst%3DH.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DH.%2BG.%26aulast%3DVivancos%26aufirst%3DA.%26atitle%3DDual%2520MET%2520and%2520ERBB%2520inhibition%2520overcomes%2520intratumor%2520plasticity%2520in%2520osimertinib-resistant-advanced%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26issue%3D10%26spage%3D2451%26epage%3D2457%26doi%3D10.1093%2Fannonc%2Fmdx396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials</span>. <i>Curr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.3747/co.25.3796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3747%2Fco.25.3796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=28-37&issue=1&author=G.+M.+O%E2%80%99Kaneauthor=T.+A.+Barnesauthor=N.+B.+Leighl&title=Resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors%2C+T790M%2C+and+clinical+trials&doi=10.3747%2Fco.25.3796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3747%2Fco.25.3796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.25.3796%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DBarnes%26aufirst%3DT.%2BA.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DResistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%252C%2520T790M%252C%2520and%2520clinical%2520trials%26jtitle%3DCurr.%2520Oncol.%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D28%26epage%3D37%26doi%3D10.3747%2Fco.25.3796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugazagoitia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">i10</span>– <span class="NLM_lpage">i19</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdx703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29462254" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i10-i19&issue=1&author=D.+Westoverauthor=J.+Zugazagoitiaauthor=B.+C.+Choauthor=C.+M.+Lovlyauthor=L.+Paz-Ares&title=Mechanisms+of+acquired+resistance+to+first-+and+second-generation+EGFR+tyrosine+kinase+inhibitors&doi=10.1093%2Fannonc%2Fmdx703"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx703%26sid%3Dliteratum%253Aachs%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DZugazagoitia%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520first-%2520and%2520second-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D1%26spage%3Di10%26epage%3Di19%26doi%3D10.1093%2Fannonc%2Fmdx703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span> <span> </span><span class="NLM_article-title">Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>, <span class="NLM_elocation-id">ii48</span> <span class="refDoi"> DOI: 10.1093/annonc/mdz063.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdz063.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&author=C.+Xuauthor=W.+Wangauthor=Y.+Zhuauthor=Z.+Yuauthor=H.+Zhangauthor=H.+Wangauthor=J.+Zhangauthor=W.+Zhuangauthor=T.+Lvauthor=Y.+Song&title=Potential+resistance+mechanisms+using+next+generation+sequencing+from+Chinese+EGFR+T790M%2B+non-small+cell+lung+cancer+patients+with+primary+resistance+to+osimertinib%3A+A+multicenter+study&doi=10.1093%2Fannonc%2Fmdz063.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz063.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz063.012%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26atitle%3DPotential%2520resistance%2520mechanisms%2520using%2520next%2520generation%2520sequencing%2520from%2520Chinese%2520EGFR%2520T790M%252B%2520non-small%2520cell%2520lung%2520cancer%2520patients%2520with%2520primary%2520resistance%2520to%2520osimertinib%253A%2520A%2520multicenter%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2019%26volume%3D30%26doi%3D10.1093%2Fannonc%2Fmdz063.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">York, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Tolerable and effective combination of full-dose Crizotinib and osimertinib targeting met amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">e85</span>– <span class="NLM_lpage">e88</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28274743" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e85-e88&issue=7&author=E.+R.+Yorkauthor=M.+Varella-Garciaauthor=T.+J.+Bangauthor=D.+L.+Aisnerauthor=D.+R.+Camidge&title=Tolerable+and+effective+combination+of+full-dose+Crizotinib+and+osimertinib+targeting+met+amplification+sequentially+emerging+after+T790M+positivity+in+EGFR-mutant+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2017.02.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DYork%26aufirst%3DE.%2BR.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DBang%26aufirst%3DT.%2BJ.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DTolerable%2520and%2520effective%2520combination%2520of%2520full-dose%2520Crizotinib%2520and%2520osimertinib%2520targeting%2520met%2520amplification%2520sequentially%2520emerging%2520after%2520T790M%2520positivity%2520in%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D7%26spage%3De85%26epage%3De88%26doi%3D10.1016%2Fj.jtho.2017.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiedrowski, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">Response to dual Crizotinib and osimertinib treatment in a lung cancer patient with met amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e169</span>– <span class="NLM_lpage">e172</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30166014" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e169-e172&issue=9&author=L.+Dengauthor=L.+A.+Kiedrowskiauthor=E.+Raveraauthor=H.+Chengauthor=B.+Halmos&title=Response+to+dual+Crizotinib+and+osimertinib+treatment+in+a+lung+cancer+patient+with+met+amplification+detected+by+liquid+biopsy+who+acquired+secondary+resistance+to+EGFR+tyrosine+kinase+inhibition&doi=10.1016%2Fj.jtho.2018.04.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DKiedrowski%26aufirst%3DL.%2BA.%26aulast%3DRavera%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DResponse%2520to%2520dual%2520Crizotinib%2520and%2520osimertinib%2520treatment%2520in%2520a%2520lung%2520cancer%2520patient%2520with%2520met%2520amplification%2520detected%2520by%2520liquid%2520biopsy%2520who%2520acquired%2520secondary%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibition%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3De169%26epage%3De172%26doi%3D10.1016%2Fj.jtho.2018.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Differential response to a combination of full-dose osimertinib and Crizotinib in a patient with <i>EGFR</i>-mutant non-small cell lung cancer and emergent <i>MET</i> amplification</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S190403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FLCTT.S190403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWhurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=21-26&author=V.+W.+Zhuauthor=A.+B.+Schrockauthor=S.+M.+Aliauthor=S.+I.+Ou&title=Differential+response+to+a+combination+of+full-dose+osimertinib+and+Crizotinib+in+a+patient+with+EGFR-mutant+non-small+cell+lung+cancer+and+emergent+MET+amplification&doi=10.2147%2FLCTT.S190403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification</span></div><div class="casAuthors">Zhu, Viola W.; Schrock, Alexa B.; Ali, Siraj M.; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies.  Here we report a case of emergent MET amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.  The patient subsequently had a sustained partial response to a combination of full-dose osimertinib and crizotinib with excellent tolerance but eventually had central nervous system (CNS) progression.  Comprehensive genomic profiling performed on the resected brain sample continued to demonstrate MET amplification as an acquired resistance mechanism.  A review of literature shows several groups have utilized similar combination regimens (erlotinib or osimertinib + crizotinib or cabozantinib), albeit with various dosing to target MET alterations in patients with EGFR-mutant NSCLC.  As more actionable resistance mechanisms are identified, we envision combination TKI therapy will be readily adopted in clin. practice.  Our case report adds to a growing body of evidence that combination osimertinib and crizotinib should be recommended to EGFR-mutant NSCLC patients with emergent MET amplification as acquired resistance.  More importantly, as crizotinib has limited brain penetration, developing next-generation MET inhibitors with better CNS activity is urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe1mB30ctl0LVg90H21EOLACvtfcHk0lgpZqgeH49JBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWhurzM&md5=001064e18abe99bbafa83f20d882caea</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S190403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S190403%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DDifferential%2520response%2520to%2520a%2520combination%2520of%2520full-dose%2520osimertinib%2520and%2520Crizotinib%2520in%2520a%2520patient%2520with%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%2520and%2520emergent%2520MET%2520amplification%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2019%26volume%3D10%26spage%3D21%26epage%3D26%26doi%3D10.2147%2FLCTT.S190403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plodkowski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odintsov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired <i>MET</i> Exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer</span>. <i>CO Precis Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1200/PO.19.00011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1200%2FPO.19.00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30623031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=1-8&author=K.+Suzawaauthor=M.+Offinauthor=A.+J.+Schoenfeldauthor=A.+J.+Plodkowskiauthor=I.+Odintsovauthor=D.+Luauthor=W.+W.+Lockwoodauthor=M.+E.+Arcilaauthor=C.+M.+Rudinauthor=A.+Drilonauthor=H.+A.+Yuauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+Ladanyi&title=Acquired+MET+Exon+14+alteration+drives+secondary+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+in+EGFR-mutated+lung+cancer&doi=10.1200%2FPO.19.00011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FPO.19.00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FPO.19.00011%26sid%3Dliteratum%253Aachs%26aulast%3DSuzawa%26aufirst%3DK.%26aulast%3DOffin%26aufirst%3DM.%26aulast%3DSchoenfeld%26aufirst%3DA.%2BJ.%26aulast%3DPlodkowski%26aufirst%3DA.%2BJ.%26aulast%3DOdintsov%26aufirst%3DI.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLockwood%26aufirst%3DW.%2BW.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520MET%2520Exon%252014%2520alteration%2520drives%2520secondary%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520in%2520EGFR-mutated%2520lung%2520cancer%26jtitle%3DCO%2520Precis%2520Oncol.%26date%3D2019%26volume%3D3%26spage%3D1%26epage%3D8%26doi%3D10.1200%2FPO.19.00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2073</span>– <span class="NLM_lpage">2078</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdv319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26269204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2073-2078&issue=10&author=D.+Planchardauthor=Y.+Loriotauthor=F.+Andr%C3%A9author=A.+Gobertauthor=N.+Augerauthor=L.+Lacroixauthor=J.+C.+Soria&title=EGFR-independent+mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M-positive+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdv319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span></div><div class="casAuthors">Planchard D; Loriot Y; Andre F; Gobert A; Auger N; Lacroix L; Soria J C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2073-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations.  This compound has shown outstanding activity, in a phase I/II (AURA) trial.  However, despite impressive tumor responses in T790M-positive patients, acquired resistance to this drug limits the benefit of this compound.  Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients.  PATIENTS AND METHODS:  To identify potential mechanisms of resistance to AZD9291, we report here on two patients with resistant biopsy specimens that had been treated with AZD9291.  RESULTS:  We identified in two distinct cases, HER2 and MET amplification by FISH and CGH as a potential mechanism of acquired resistance to third-generation EGFR-TKI.  Interestingly, this event occurred with complete loss of the T790M mutation.  In one case, we observed a different molecular status at two biopsy sites (the T790M mutation at the primary site and wild-type T790M at the metastatic site with different pathways of acquired resistance to AZD9291).  CONCLUSION:  Our observations suggest that T790M-positive and wild-type T790M clones may coexist at baseline.  AZD9291 efficiently suppresses the growth of T790M-positive cells, but a population of wild-type T790M cells at baseline will mediate the development of resistance, here via a by-pass pathway activating either HER2 or MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS11uv1hoUHSrJzI8owOhpDfW6udTcc2eamcd2cfzA_O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D&md5=2cba18208f215fd28fcf58d321d42618</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv319%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DAuger%26aufirst%3DN.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DEGFR-independent%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M-positive%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D2073%26epage%3D2078%26doi%3D10.1093%2Fannonc%2Fmdv319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to Crizotinib treatment post-osimertinib progression</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2016.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27393507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=59-61&author=S.+I.+Ouauthor=N.+Agarwalauthor=S.+M.+Ali&title=High+MET+amplification+level+as+a+resistance+mechanism+to+osimertinib+%28AZD9291%29+in+a+patient+that+symptomatically+responded+to+Crizotinib+treatment+post-osimertinib+progression&doi=10.1016%2Fj.lungcan.2016.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Agarwal Nikita; Ali Siraj M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Third-generation EGFR TKI has been approved in the US and EU for the treatment of EGFR mutant T790M+ NSCLC patients that are resistant to first- or second generation EGFR TKIs.  Here we report a patient who developed resistance to osimertinib after a confirmed partial response for 9 months.  Pre-osimertinib and post-osimertinib tumor biopsy revealed the emergence of high level of MET amplification (30 copies) post osimertinib treatment.  Patient was treated with single agent crizotinib, a known MET inhibitor, with transient symptomatic benefit.  MET amplification is one potential resistance mechanism to osimertinib and combination of osimertinib and a MET inhibitor should be investigated post-osimertinib progression in EGFR mutant T790M+ NSCLC patients whose harbored acquired MET amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcGTszAFtshWfpMXQLRstfW6udTcc2ebgAqu83mrWDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D&md5=2cd5da962531483cb3092367da127c64</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DHigh%2520MET%2520amplification%2520level%2520as%2520a%2520resistance%2520mechanism%2520to%2520osimertinib%2520%2528AZD9291%2529%2520in%2520a%2520patient%2520that%2520symptomatically%2520responded%2520to%2520Crizotinib%2520treatment%2520post-osimertinib%2520progression%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D98%26spage%3D59%26epage%3D61%26doi%3D10.1016%2Fj.lungcan.2016.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Cuesta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildhaus, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuernberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-15-1915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27252416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4837-4847&issue=19&author=S.+Ortiz-Cuaranauthor=M.+Schefflerauthor=D.+Plenkerauthor=l.+Dahmenauthor=A.+H.+Scheelauthor=L.+Fernandez-Cuestaauthor=L.+Mederauthor=C.+M.+Lovlyauthor=T.+Persigehlauthor=S.+Merkelbach-Bruseauthor=M.+Bosauthor=S.+Michelsauthor=R.+Fischerauthor=K.+Albusauthor=K.+Konigauthor=H.-U.+Schildhausauthor=J.+Fassunkeauthor=M.+A.+Ihleauthor=H.+Pasternackauthor=C.+Heydtauthor=C.+Beckerauthor=J.+Altmullerauthor=H.+Jiauthor=C.+Mullerauthor=A.+Florinauthor=J.+M.+Heuckmannauthor=P.+Nuernbergauthor=S.+Ansenauthor=L.+C.+Heukampauthor=J.+Bergauthor=W.+Paoauthor=M.+Peiferauthor=R.+Buettnerauthor=J.+Wolfauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Heterogeneous+mechanisms+of+primary+and+acquired+resistance+to+third-generation+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-15-1915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span></div><div class="casAuthors">Ortiz-Cuaran, Sandra; Scheffler, Matthias; Plenker, Dennis; Dahmen, llona; Scheel, Andreas H.; Fernandez-Cuesta, Lynnette; Meder, Lydia; Lovly, Christine M.; Persigehl, Thorsten; Merkelbach-Bruse, Sabine; Bos, Marc; Michels, Sebastian; Fischer, Rieke; Albus, Kerstin; Koenig, Katharina; Schildhaus, Hans-Ulrich; Fassunke, Jana; Ihle, Michaela A.; Pasternack, Helen; Heydt, Carina; Becker, Christian; Altmueller, Janine; Ji, Hongbin; Mueller, Christian; Florin, Alexandra; Heuckmann, Johannes M.; Nuernberg, Peter; Ansen, Sascha; Heukamp, Lukas C.; Berg, Johannes; Pao, William; Peifer, Martin; Buettner, Reinhard; Wolf, Juergen; Thomas, Roman K.; Sos, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4837-4847</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).  We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686).  Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.  We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compds.  Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance.  Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS.  Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryi-78iIDGfrVg90H21EOLACvtfcHk0ljZhvx1mqGmJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K&md5=b30908de40ff48f067e067cfc3520a7b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1915%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DDahmen%26aufirst%3Dl.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DMeder%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DAlbus%26aufirst%3DK.%26aulast%3DKonig%26aufirst%3DK.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPasternack%26aufirst%3DH.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DAltmuller%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DA.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DNuernberg%26aufirst%3DP.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DHeterogeneous%2520mechanisms%2520of%2520primary%2520and%2520acquired%2520resistance%2520to%2520third-generation%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D19%26spage%3D4837%26epage%3D4847%26doi%3D10.1158%2F1078-0432.CCR-15-1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2433</span>, <span class="refDoi"> DOI: 10.1007/s00432-020-03239-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1007%2Fs00432-020-03239-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32385709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=2427-2433&issue=9&author=Y.+Muauthor=X.+Haoauthor=P.+Xingauthor=X.+Huauthor=Y.+Wangauthor=T.+Liauthor=J.+Zhangauthor=Z.+Xuauthor=J.+Li&title=Acquired+resistance+to+osimertinib+in+patients+with+non-small-cell+lung+cancer%3A+mechanisms+and+clinical+outcomes&doi=10.1007%2Fs00432-020-03239-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes</span></div><div class="casAuthors">Mu, Yuxin; Hao, Xuezhi; Xing, Puyuan; Hu, Xingsheng; Wang, Yan; Li, Teng; Zhang, Jinyao; Xu, Ziyi; Li, Junling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2427-2433</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clin. benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation.  The aim of our study was to identify the mechanisms underlying resistance to osimertinib and to correlate them with clin. outcomes.  Methods: We retrospectively analyzed patients with advanced NSCLC who received osimertinib for T790M-mutated acquired resistance to prior EGFR-TKIs between March 1, 2017 and Dec. 31, 2018.  Patients with paired mol. data of pre-osimertinib and after resistance development, which were not confirmed with small-cell lung cancer (SCLC) transformation, were included in the mol. anal. set.  Results: Of 49 patients evaluated in the mol. anal. set, 24 patients maintained T790M mutation, while 25 patients exhibited T790M-loss.  Mol. modifications were identified in 27 of 49 patients including EGFR acquired mutations (C797S, C796S, G796S, V802I, V834L, E758D and G724S), non-EGFR-dependent mutations (PIK3CA, ALK, BRAF, KRAS and TP53), EGFR amplification and MET amplification.  At data cutoff, median progression-free survival (PFS) was 9.3 mo in the T790M-retain group compared with 7.8 mo in T790M-loss patients (P = 0.053).  Median PFS was significantly longer in patients with EGFR-dependent resistance mechanism (13.5 mo) than in those with alternative pathway activation (8.2 mo; P = 0.012).  Conclusions: The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their assocn. with clin. outcomes.  Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clin. outcome benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFg_CSXlnhSLVg90H21EOLACvtfcHk0ljZhvx1mqGmJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFyksrY%253D&md5=7edcba72acbbd6fa1befd01b0f248c95</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs00432-020-03239-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-020-03239-1%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520osimertinib%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%253A%2520mechanisms%2520and%2520clinical%2520outcomes%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D146%26issue%3D9%26spage%3D2427%26epage%3D2433%26doi%3D10.1007%2Fs00432-020-03239-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">90557</span>– <span class="NLM_lpage">90578</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.21164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.21164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29163853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1M3jvVWltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=90557-90578&issue=52&author=J.+Xuauthor=J.+Wangauthor=S.+Zhang&title=Mechanisms+of+resistance+to+irreversible+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+and+therapeutic+strategies+in+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.21164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer</span></div><div class="casAuthors">Xu Jing; Wang Jinghui; Zhang Shucai</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">90557-90578</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) T790M mutation is the most frequent mechanism which accounts for about 60% of acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations.  Irreversible EGFR-TKIs which include the second-generation and third-generation EGFR-TKIs are developed to overcome T790M mediated resistance.  The second-generation EGFR-TKIs inhibit the wide type (WT) EGFR combined with dose-limiting toxicity which limits its application in clinics, while the development of third-generation EGFR-TKIs brings inspiring efficacy either in vitro or in vivo.  The acquired resistance, however, will also occur and limit their response.  Understanding the mechanisms of resistance to irreversible EGFR-TKIs plays an important role in the choice of subsequent treatment.  In this review, we show the currently known mechanisms of resistance which can be summarized as EGFR dependent and independent mechanisms and potential therapeutic strategies to irreversible EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRx9429BdJqztTiMd2aNQVUfW6udTcc2ea4M-S2UC7tirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3jvVWltw%253D%253D&md5=af64510113cad151e6ad12852d82e66a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.21164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.21164%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520therapeutic%2520strategies%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D52%26spage%3D90557%26epage%3D90578%26doi%3D10.18632%2Foncotarget.21164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omerovic, J.</span></span> <span> </span><span class="NLM_article-title">Current approaches in NSCLC targeting K-RAS and EGFR</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5701</span>, <span class="refDoi"> DOI: 10.3390/ijms20225701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3390%2Fijms20225701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptl2mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=5701&issue=22&author=V.+Aranauthor=J.+Omerovic&title=Current+approaches+in+NSCLC+targeting+K-RAS+and+EGFR&doi=10.3390%2Fijms20225701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches in NSCLC targeting K-RAS and EGFR</span></div><div class="casAuthors">Aran, Veronica; Omerovic, Jasminka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5701</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The research and treatment of non-small cell lung cancer (NSCLC) have achieved some important advances in recent years.  Nonetheless, the overall survival rates for NSCLC remain low, indicating the importance to effectively develop new therapies and improve current approaches.  The understanding of the function of different biomarkers involved in NSCLC progression, survival and response to therapy are important for the development of early detection tools and treatment options.  Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) are two of the main significant biomarkers for the management of NSCLC.  Mutations in these genes were assocd. with development and response to therapies.  For example, the use of small mol. tyrosine kinase (TK) inhibitors and immunotherapy has led to benefits in some, but not all patients with altered EGFR.  In contrast, there is still no effective approved drug to act upon patients harbouring K-RAS mutations.  In addn., K-RAS mutations have been assocd. with lack of activity of TK inhibitors.  However, promising approaches aimed to inhibit mutant K-RAS are currently under study.  Therefore, this review will discuss these approaches and also EGFR therapies, and hopefully, it will draw attention to the need of continued research in the field in order to improve the outcomes in NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfRnQV33SqmbVg90H21EOLACvtfcHk0lhYgfDaIH48TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptl2mtLo%253D&md5=64d9edf38be249aa90779ace3e9c0c63</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.3390%2Fijms20225701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20225701%26sid%3Dliteratum%253Aachs%26aulast%3DAran%26aufirst%3DV.%26aulast%3DOmerovic%26aufirst%3DJ.%26atitle%3DCurrent%2520approaches%2520in%2520NSCLC%2520targeting%2520K-RAS%2520and%2520EGFR%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D5701%26doi%3D10.3390%2Fijms20225701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2073</span>– <span class="NLM_lpage">2078</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdv319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26269204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2073-2078&issue=10&author=D.+Planchardauthor=Y.+Loriotauthor=F.+Andr%C3%A9author=A.+Gobertauthor=N.+Augerauthor=L.+Lacroixauthor=J.+C.+Soria&title=EGFR-independent+mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M-positive+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdv319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span></div><div class="casAuthors">Planchard D; Loriot Y; Andre F; Gobert A; Auger N; Lacroix L; Soria J C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2073-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations.  This compound has shown outstanding activity, in a phase I/II (AURA) trial.  However, despite impressive tumor responses in T790M-positive patients, acquired resistance to this drug limits the benefit of this compound.  Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients.  PATIENTS AND METHODS:  To identify potential mechanisms of resistance to AZD9291, we report here on two patients with resistant biopsy specimens that had been treated with AZD9291.  RESULTS:  We identified in two distinct cases, HER2 and MET amplification by FISH and CGH as a potential mechanism of acquired resistance to third-generation EGFR-TKI.  Interestingly, this event occurred with complete loss of the T790M mutation.  In one case, we observed a different molecular status at two biopsy sites (the T790M mutation at the primary site and wild-type T790M at the metastatic site with different pathways of acquired resistance to AZD9291).  CONCLUSION:  Our observations suggest that T790M-positive and wild-type T790M clones may coexist at baseline.  AZD9291 efficiently suppresses the growth of T790M-positive cells, but a population of wild-type T790M cells at baseline will mediate the development of resistance, here via a by-pass pathway activating either HER2 or MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS11uv1hoUHSrJzI8owOhpDfW6udTcc2ea4M-S2UC7tirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D&md5=2cba18208f215fd28fcf58d321d42618</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv319%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DAuger%26aufirst%3DN.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DEGFR-independent%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M-positive%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D2073%26epage%3D2078%26doi%3D10.1093%2Fannonc%2Fmdv319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawelets, C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">Supp 2</span>),  <span class="NLM_fpage">ORAL17.07</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=ORAL17.07&issue=Supp+2&author=G.+R.+Oxnardauthor=K.+Thressauthor=C.+Pawelets&title=Mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M+positive+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DPawelets%26aufirst%3DC.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M%2520positive%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3DSupp%25202%26spage%3DORAL17.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span> <span> </span><span class="NLM_article-title">Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovichauthor=T.+C.+Hardingauthor=K.+A.+Durkinauthor=G.+A.+Ottersonauthor=W.+T.+Purcellauthor=D.+R.+Camidgeauthor=J.+W.+Goldmanauthor=L.+V.+Sequistauthor=Z.+Piotrowskaauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=A.+A.+Alizadehauthor=M.+Diehn&title=Circulating+tumor+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0lhViJjpj7H7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DPurcell%26aufirst%3DW.%2BT.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DDiehn%26aufirst%3DM.%26atitle%3DCirculating%2520tumor%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenonos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyprianou, K.</span></span> <span> </span><span class="NLM_article-title">RAS signalling pathways, mutations and their role in colorectal cancer</span>. <i>World J. Gastrointest. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.4251/wjgo.v5.i5.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.4251%2Fwjgo.v5.i5.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23799159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3sjls1Ohtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=97-101&issue=5&author=K.+Zenonosauthor=K.+Kyprianou&title=RAS+signalling+pathways%2C+mutations+and+their+role+in+colorectal+cancer&doi=10.4251%2Fwjgo.v5.i5.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">RAS signaling pathways, mutations and their role in colorectal cancer</span></div><div class="casAuthors">Zenonos Kypros; Kyprianou Katy</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastrointestinal oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">97-101</span>
        ISSN:<span class="NLM_cas:issn">1948-5204</span>.
    </div><div class="casAbstract">Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways.  In a normal cell, these are important in controlling several functions, such as cell growth and survival.  It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway.  Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed.  The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXy8P3_ShDTEQ0lWbKiCflfW6udTcc2eam-jacI_SG67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjls1Ohtw%253D%253D&md5=4cd8ea0bfdb1abbb119e7a71960a604a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.4251%2Fwjgo.v5.i5.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4251%252Fwjgo.v5.i5.97%26sid%3Dliteratum%253Aachs%26aulast%3DZenonos%26aufirst%3DK.%26aulast%3DKyprianou%26aufirst%3DK.%26atitle%3DRAS%2520signalling%2520pathways%252C%2520mutations%2520and%2520their%2520role%2520in%2520colorectal%2520cancer%26jtitle%3DWorld%2520J.%2520Gastrointest.%2520Oncol.%26date%3D2013%26volume%3D5%26issue%3D5%26spage%3D97%26epage%3D101%26doi%3D10.4251%2Fwjgo.v5.i5.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.7576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1200%2FJCO.2017.74.7576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28841389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=841-849&issue=9&author=S.+S.+Ramalingamauthor=J.+C.+Yangauthor=C.+K.+Leeauthor=T.+Kurataauthor=D.+W.+Kimauthor=T.+Johnauthor=N.+Nogamiauthor=Y.+Oheauthor=H.+Mannauthor=Y.+Rukazenkovauthor=S.+Ghiorghiuauthor=D.+Stetsonauthor=A.+Markovetsauthor=J.+C.+Barrettauthor=K.+S.+Thressauthor=P.+A.+J%C3%A4nne&title=Osimertinib+as+first-line+treatment+of+EGFR+mutation-positive+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2017.74.7576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Yang, James C. H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Carl Barrett, J.; Thress, Kenneth S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">841-849</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naive patients to examine clin. activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC).  Patients and Methods: Sixty treatment-naive patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort).  End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation.  Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms.  Results: At data cutoff (Nov. 1, 2016), median follow-up was 19.1 mo.  Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses.  Median PFS time was 22.1 mo (95% CI, 13.7 to 30.2 mo) in the 80-mg group, 19.3 mo (95% CI, 13.7 to 26.0 mo) in the 160-mg group, and 20.5 mo (95% CI, 15.0 to 26.1 mo) across doses.  Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA.  Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1).  Acquired EGFR T790M was not detected.  Conclusion: Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naive patients with EGFRm advanced NSCLC.  There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqM3jWJfzwbVg90H21EOLACvtfcHk0lhViJjpj7H7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL&md5=e6b63846658632b5f79460ee29022835</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.7576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.7576%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DOsimertinib%2520as%2520first-line%2520treatment%2520of%2520EGFR%2520mutation-positive%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D9%26spage%3D841%26epage%3D849%26doi%3D10.1200%2FJCO.2017.74.7576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiura, K.</span></span> <span> </span><span class="NLM_article-title">MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1955</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-20326-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41598-018-20326-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29386539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlvFGhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1955&issue=1&author=K.+Ninomiyaauthor=K.+Ohashiauthor=G.+Makimotoauthor=S.+Tomidaauthor=H.+Higoauthor=H.+Kayataniauthor=T.+Ninomiyaauthor=T.+Kuboauthor=E.+Ichiharaauthor=K.+Hottaauthor=M.+Tabataauthor=Y.+Maedaauthor=K.+Kiura&title=MET+or+NRAS+amplification+is+an+acquired+resistance+mechanism+to+the+third-generation+EGFR+inhibitor+naquotinib&doi=10.1038%2Fs41598-018-20326-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib</span></div><div class="casAuthors">Ninomiya Kiichiro; Ohashi Kadoaki; Makimoto Go; Higo Hisao; Kayatani Hiroe; Ninomiya Takashi; Maeda Yoshinobu; Ohashi Kadoaki; Ichihara Eiki; Kiura Katsuyuki; Tomida Shuta; Kubo Toshio; Tabata Masahiro; Hotta Katsuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1955</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer harboring the EGFR T790M mutation; however, acquired resistance inevitably develops.  Therefore, a next-generation treatment strategy is warranted in the osimertinib era.  We investigated the mechanism of resistance to a novel EGFR-TKI, naquotinib, with the goal of developing a novel treatment strategy.  We established multiple naquotinib-resistant cell lines or osimertinib-resistant cells, two of which were derived from EGFR-TKI-naive cells; the others were derived from gefitinib- or afatinib-resistant cells harboring EGFR T790M.  We comprehensively analyzed the RNA kinome sequence, but no universal gene alterations were detected in naquotinib-resistant cells.  Neuroblastoma RAS viral oncogene homolog (NRAS) amplification was detected in naquotinib-resistant cells derived from gefitinib-resistant cells.  The combination therapy of MEK inhibitors and naquotinib exhibited a highly beneficial effect in resistant cells with NRAS amplification, but the combination of MEK inhibitors and osimertinib had limited effects on naquotinib-resistant cells.  Moreover, the combination of MEK inhibitors and naquotinib inhibited the growth of osimertinib-resistant cells, while the combination of MEK inhibitors and osimertinib had little effect on osimertinib-resistant cells.  Clinical assessment of this novel combination (MEK inhibitors and naquotinib) is worth considering in osimertinib-resistant lung tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBm3S-Gjqn8e3MPKNEWB5RfW6udTcc2eZqaVjrJ5KNprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlvFGhuw%253D%253D&md5=95a8016e2c1de4635e9d3291d2aef2c8</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-20326-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-20326-z%26sid%3Dliteratum%253Aachs%26aulast%3DNinomiya%26aufirst%3DK.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMakimoto%26aufirst%3DG.%26aulast%3DTomida%26aufirst%3DS.%26aulast%3DHigo%26aufirst%3DH.%26aulast%3DKayatani%26aufirst%3DH.%26aulast%3DNinomiya%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DTabata%26aufirst%3DM.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DKiura%26aufirst%3DK.%26atitle%3DMET%2520or%2520NRAS%2520amplification%2520is%2520an%2520acquired%2520resistance%2520mechanism%2520to%2520the%2520third-generation%2520EGFR%2520inhibitor%2520naquotinib%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26issue%3D1%26spage%3D1955%26doi%3D10.1038%2Fs41598-018-20326-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meador, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahdesmaki, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Brien, E. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beran, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.E.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to the mutant-selective EGFR inhibitor azd9291 is associated with increased dependence on RAS signalling in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2489</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-14-3167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25870145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2489-2500&issue=12&author=C.+A.+Eberleinauthor=D.+Stetsonauthor=A.+A.+Markovetsauthor=K.+J.+Al-Kadhimiauthor=Z.+Laiauthor=P.+R.+Fisherauthor=C.+B.+Meadorauthor=P.+Spitzlerauthor=E.+Ichiharaauthor=S.+J.+Rossauthor=M.+J.+Ahdesmakiauthor=A.+Ahmedauthor=L.+E.+Ratcliffeauthor=E.+L.+C.+O%27Brienauthor=C.+H.+Barnesauthor=H.+Brownauthor=P.+D.+Smithauthor=J.+R.+Dryauthor=G.+Beranauthor=K.+S.+Thressauthor=B.+Doughertyauthor=W.+Paoauthor=D.+A.E.+Cross&title=Acquired+resistance+to+the+mutant-selective+EGFR+inhibitor+azd9291+is+associated+with+increased+dependence+on+RAS+signalling+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-14-3167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models</span></div><div class="casAuthors">Eberlein, Catherine A.; Stetson, Daniel; Markovets, Aleksandra A.; Al-Kadhimi, Katherine J.; Lai, Zhongwu; Fisher, Paul R.; Meador, Catherine B.; Spitzler, Paula; Ichihara, Eiki; Ross, Sarah J.; Ahdesmaki, Miika J.; Ahmed, Ambar; Ratcliffe, Laura E.; O'Brien, Elizabeth L. Christey; Barnes, Claire H.; Brown, Henry; Smith, Paul D.; Dry, Jonathan R.; Beran, Garry; Thress, Kenneth S.; Dougherty, Brian; Pao, William; Cross, Darren A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2489-2500</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These results offer early insight into how acquired resistance arises to a new mutation-selective inhibitor of EGFR that is in fast-track clin. development, illustrating the inescapable cat-and-mouse chase in the evolution of cancer cell-targeting drugs in the management of cancer patients.  Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers.  Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies.  We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291.  We report the detection of NRAS mutations, including a novel E63K mutation, and a gain of copy no. of WT NRAS or WT KRAS in cell populations resistant to gefitinib, afatinib, WZ4002, or AZD9291.  Compared with parental cells, a no. of resistant cell populations were more sensitive to inhibition by the MEK inhibitor selumetinib (AZD6244; ARRY-142886) when treated in combination with the originating EGFR inhibitor.  In vitro, a combination of AZD9291 with selumetinib prevented emergence of resistance in PC9 cells and delayed resistance in NCI-H1975 cells.  In vivo, concomitant dosing of AZD9291 with selumetinib caused regression of AZD9291-resistant tumors in an EGFRm/T790M transgenic model.  Our data support the use of a combination of AZD9291 with a MEK inhibitor to delay or prevent resistance to AZD9291 in EGFRm and/or EGFRm/T790M tumors.  Furthermore, these findings suggest that NRAS modifications in tumor samples from patients who have progressed on current or EGFR inhibitors in development may support subsequent treatment with a combination of EGFR and MEK inhibition.  Cancer Res; 75(12); 2489-500. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZwyXo13dZBbVg90H21EOLACvtfcHk0lgs_WPmHzextA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D&md5=63691ddbbf38e2079b39b5d8f43ddef4</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3167%26sid%3Dliteratum%253Aachs%26aulast%3DEberlein%26aufirst%3DC.%2BA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%2BA.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%2BJ.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DFisher%26aufirst%3DP.%2BR.%26aulast%3DMeador%26aufirst%3DC.%2BB.%26aulast%3DSpitzler%26aufirst%3DP.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DAhdesmaki%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DRatcliffe%26aufirst%3DL.%2BE.%26aulast%3DO%2527Brien%26aufirst%3DE.%2BL.%2BC.%26aulast%3DBarnes%26aufirst%3DC.%2BH.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DDry%26aufirst%3DJ.%2BR.%26aulast%3DBeran%26aufirst%3DG.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DCross%26aufirst%3DD.%2BA.E.%26atitle%3DAcquired%2520resistance%2520to%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520azd9291%2520is%2520associated%2520with%2520increased%2520dependence%2520on%2520RAS%2520signalling%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D12%26spage%3D2489%26epage%3D2500%26doi%3D10.1158%2F0008-5472.CAN-14-3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.2231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.2231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27923714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=567-572&issue=3&author=C.+C.+Hoauthor=W.+Y.+Liaoauthor=C.+A.+Linauthor=J.+Y.+Shihauthor=C.+J.+Yuauthor=J.+C.-H.+Yang&title=Acquired+BRAF+V600E+mutation+as+resistant+mechanism+after+treatment+with+osimertinib&doi=10.1016%2Fj.jtho.2016.11.2231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib</span></div><div class="casAuthors">Ho Chao-Chi; Liao Wei-Yu; Shih Jin-Yuan; Yu Chong-Jen; Lin Chih-An; Yang James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-572</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used.  Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified.  It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment.  METHODS:  Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib.  Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry.  EGFR, AKT, MEK, and ERK phosphorylation were determined.  An anchorage-dependent colony formation assay was used for drug sensitivity.  RESULTS:  An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib.  Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib.  CONCLUSIONS:  A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway.  Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyyK7fCSkFDQ8IxFYvehhofW6udTcc2eZFNK68_IUnxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D&md5=b4d27a7ed29dfc9f3470175998e3b529</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.2231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.2231%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DW.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BA.%26aulast%3DShih%26aufirst%3DJ.%2BY.%26aulast%3DYu%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAcquired%2520BRAF%2520V600E%2520mutation%2520as%2520resistant%2520mechanism%2520after%2520treatment%2520with%2520osimertinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.jtho.2016.11.2231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stambolic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Pompa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirtsos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderovski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of PKB/AKT-dependent cell survival by the tumor suppressor PTEN</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81780-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS0092-8674%2800%2981780-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=9778245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=29-39&issue=1&author=V.+Stambolicauthor=A.+Suzukiauthor=J.+L.+de+la+Pompaauthor=G.+M.+Brothersauthor=C.+Mirtsosauthor=T.+Sasakiauthor=J.+Rulandauthor=J.+M.+Penningerauthor=D.+P.+Siderovskiauthor=T.+W.+Mak&title=Negative+regulation+of+PKB%2FAKT-dependent+cell+survival+by+the+tumor+suppressor+PTEN&doi=10.1016%2FS0092-8674%2800%2981780-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of PKB/Akt-Dependent cell survival by the tumor suppressor PTEN</span></div><div class="casAuthors">Stambolic, Vuk; Suzuki, Akira; De La Pompa, Jose Lois; Brothers, Greg M.; Mirtsos, Christine; Sasaki, Takehiko; Ruland, Jurgen; Penninger, Josef M.; Siderovski, David P.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PTEN is a tumor suppressor with sequence homol. to protein tyrosine phosphatases and the cytoskeletal protein tensin.  MPTEN-mutant mouse embryos display regions of increased proliferation.  In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a no. of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival.  Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation.  Furthermore, PTEN neg. regulates intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate in cells and dephosphorylates it in vitro.  Our results show that PTEN may exert its role as a tumor suppressor by neg. regulating the PI3'K/PKB/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMeJuD58djBrVg90H21EOLACvtfcHk0ljef0CxjOmidg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslWlsr0%253D&md5=d0ffd63a69325f1296d08bdbc16c5f0f</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981780-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981780-8%26sid%3Dliteratum%253Aachs%26aulast%3DStambolic%26aufirst%3DV.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPompa%26aufirst%3DJ.%2BL.%26aulast%3DBrothers%26aufirst%3DG.%2BM.%26aulast%3DMirtsos%26aufirst%3DC.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DSiderovski%26aufirst%3DD.%2BP.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DNegative%2520regulation%2520of%2520PKB%252FAKT-dependent%2520cell%2520survival%2520by%2520the%2520tumor%2520suppressor%2520PTEN%26jtitle%3DCell%26date%3D1998%26volume%3D95%26issue%3D1%26spage%3D29%26epage%3D39%26doi%3D10.1016%2FS0092-8674%2800%2981780-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurisu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated AKT</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5779</span>– <span class="NLM_lpage">5788</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-3020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-06-3020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=17575145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFCqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=5779-5788&issue=12&author=F.+Yamasakiauthor=M.+J.+Johansenauthor=D.+Zhangauthor=S.+Krishnamurthyauthor=E.+Felixauthor=C.+Bartholomeuszauthor=R.+J.+Aguilarauthor=K.+Kurisuauthor=G.+B.+Millsauthor=G.+N.+Hortobagyiauthor=N.+T.+Ueno&title=Acquired+resistance+to+erlotinib+in+A-431+epidermoid+cancer+cells+requires+down-regulation+of+MMAC1%2FPTEN+and+up-regulation+of+phosphorylated+AKT&doi=10.1158%2F0008-5472.CAN-06-3020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt</span></div><div class="casAuthors">Yamasaki, Fumiyuki; Johansen, Mary J.; Zhang, Dongwei; Krishnamurthy, Savitri; Felix, Edward; Bartholomeusz, Chandra; Aguilar, Richard J.; Kurisu, Kaoru; Mills, Gordon B.; Hortobagyi, Gabriel N.; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5779-5788</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has clin. activity in advanced lung cancer, but disease that initially responds to erlotinib eventually progresses.  The mechanism of this acquired resistance is unclear.  We established two erlotinib-resistant pools of A-431 cells, a well-characterized epidermoid cancer cell line that constitutively overexpresses EGFR and is sensitive to erlotinib, by continuous exposure to erlotinib over a 6-mo period.  The extent of EGFR gene amplification or mutation of the EGFR tyrosine kinase domain was not altered in the resistant cells.  Intracellular erlotinib concns., detd. by liq. chromatog.-tandem mass spectrometry, were almost the same in all three cell lines.  Immunopptn. with EGFR antibody followed by detection with phosphotyrosine antibody revealed that erlotinib effectively reduced EGFR phosphorylation in both parental cells and resistant cells.  Erlotinib induced mutated in multiple advanced cancers 1/phosphatase and tensin homolog (MMAC1/PTEN) and suppressed phosphorylated Akt (Ser473) but not in the erlotinib-resistant cells.  Overexpression of MMAC1/PTEN by transfection with Ad.MMAC1/PTEN or by pharmacol. suppression of Akt activity restored erlotinib sensitivity in both resistant pools.  Further, transfection of parental A-431 cells with constitutively active Akt was sufficient to cause resistance to erlotinib.  We propose that acquired erlotinib resistance assocd. with MMAC1/PTEN down-regulation and Akt activation could be overcome by inhibitors of signaling through the phosphatidylinositol 3-kinase pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofe_Ni20gPobVg90H21EOLACvtfcHk0ljef0CxjOmidg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFCqsbg%253D&md5=a8e14c31cfdfd75f4bb2ce8f6a87ab74</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3020%26sid%3Dliteratum%253Aachs%26aulast%3DYamasaki%26aufirst%3DF.%26aulast%3DJohansen%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKrishnamurthy%26aufirst%3DS.%26aulast%3DFelix%26aufirst%3DE.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DAguilar%26aufirst%3DR.%2BJ.%26aulast%3DKurisu%26aufirst%3DK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DAcquired%2520resistance%2520to%2520erlotinib%2520in%2520A-431%2520epidermoid%2520cancer%2520cells%2520requires%2520down-regulation%2520of%2520MMAC1%252FPTEN%2520and%2520up-regulation%2520of%2520phosphorylated%2520AKT%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D12%26spage%3D5779%26epage%3D5788%26doi%3D10.1158%2F0008-5472.CAN-06-3020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">The BAD protein integrates survival signalling by EGFR/MAPK and PI3K/AKT kinase pathways in PTEN-deficient tumor cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ccr.2005.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=16226704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFOrtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=287-297&author=Q.+B.+Sheauthor=D.+B.+Solitauthor=Q.+Yeauthor=K.+E.+O%E2%80%99Reillyauthor=J.+Loboauthor=N.+Rosen&title=The+BAD+protein+integrates+survival+signalling+by+EGFR%2FMAPK+and+PI3K%2FAKT+kinase+pathways+in+PTEN-deficient+tumor+cells&doi=10.1016%2Fj.ccr.2005.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells</span></div><div class="casAuthors">She, Qing-Bai; Solit, David B.; Ye, Qing; O'Reilly, Kathryn E.; Lobo, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tumor cells with mutated PTEN proliferate in an EGFR-independent manner.  Induction of PTEN sensitizes cells to EGFR inhibition, and the combination causes synergistic apoptosis.  Synergy is due to inhibition of two parallel pathways that phosphorylate the proapoptotic protein BAD at distinct sites.  Serine 112 phosphorylation is EGFR/MEK/MAPK dependent, whereas serine 136 phosphorylation is PI3K/Akt dependent.  Either phosphorylation is sufficient to sequester BAD to 14-3-3.  BAD is released and apoptosis is induced only if both serines are dephosphorylated in response to inhibition of both pathways.  Redn. of BAD expression by RNA interference prevents apoptosis in response to pathway inhibition.  Thus, BAD integrates the antiapoptotic effects of both pathways.  Combined inhibition of EGFR and PI3K signaling may be a useful therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrybh2W1eQJY7Vg90H21EOLACvtfcHk0ljCJKATnjWBjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFOrtLrE&md5=94a7bbd7229d9ab0330fbc55642aa0a1</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DLobo%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520BAD%2520protein%2520integrates%2520survival%2520signalling%2520by%2520EGFR%252FMAPK%2520and%2520PI3K%252FAKT%2520kinase%2520pathways%2520in%2520PTEN-deficient%2520tumor%2520cells%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D287%26epage%3D297%26doi%3D10.1016%2Fj.ccr.2005.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frommolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashkar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span> <span> </span><span class="NLM_article-title"><i>PTEN</i> loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of AKT and EGFR</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3256</span>– <span class="NLM_lpage">3261</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-08-4055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19351834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksV2hs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3256-3261&issue=8&author=M.+L.+Sosauthor=M.+Kokerauthor=B.+A.+Weirauthor=S.+Heynckauthor=R.+Rabinovskyauthor=T.+Zanderauthor=J.+M.+Seegerauthor=J.+Weissauthor=F.+Fischerauthor=P.+Frommoltauthor=K.+Michelauthor=M.+Peiferauthor=C.+Mermelauthor=L.+Girardauthor=M.+Peytonauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=L.+A.+Garrawayauthor=H.+Kashkarauthor=W.+Paoauthor=M.+Meyersonauthor=R.+K.+Thomas&title=PTEN+loss+contributes+to+erlotinib+resistance+in+EGFR-mutant+lung+cancer+by+activation+of+AKT+and+EGFR&doi=10.1158%2F0008-5472.CAN-08-4055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR</span></div><div class="casAuthors">Sos, Martin L.; Koker, Mirjam; Weir, Barbara A.; Heynck, Stefanie; Rabinovsky, Rosalia; Zander, Thomas; Seeger, Jens M.; Weiss, Jonathan; Fischer, Florian; Frommolt, Peter; Michel, Kathrin; Peifer, Martin; Mermel, Craig; Girard, Luc; Peyton, Michael; Gazdar, Adi F.; Minna, John D.; Garraway, Levi A.; Kashkar, Hamid; Pao, William; Meyerson, Matthew; Thomas, Roman K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3256-3261</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET.  Addnl. mechanisms contributing to EGFR inhibitor resistance remain elusive.  By applying combined analyses of gene expression, copy no., and biochem. analyses of EGFR inhibitor responsiveness, we identified homozygous loss of PTEN to segregate EGFR-dependent and EGFR-independent cells.  We show that in EGFR-dependent cells, PTEN loss partially uncouples mutant EGFR from downstream signaling and activates EGFR, thereby contributing to erlotinib resistance.  The clin. relevance of our findings is supported by the observation of PTEN loss in 1 out of 24 primary EGFR-mutant non-small cell lung cancer (NSCLC) tumors.  These results suggest a novel resistance mechanism in EGFR-mutant NSCLC involving PTEN loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRCf9WUZLXLVg90H21EOLACvtfcHk0ljCJKATnjWBjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksV2hs7g%253D&md5=e420e3cc5c051ff1909a1253ae585f21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4055%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DRabinovsky%26aufirst%3DR.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DSeeger%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DKashkar%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPTEN%2520loss%2520contributes%2520to%2520erlotinib%2520resistance%2520in%2520EGFR-mutant%2520lung%2520cancer%2520by%2520activation%2520of%2520AKT%2520and%2520EGFR%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D8%26spage%3D3256%26epage%3D3261%26doi%3D10.1158%2F0008-5472.CAN-08-4055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H.</span></span> <span> </span><span class="NLM_article-title">PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>823</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejphar.2018.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29378193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVaksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=823&publication_year=2018&pages=19-26&author=K.+Toauthor=W.+Wuauthor=H.+Loong&title=PPARgamma+agonists+sensitize+PTEN-deficient+resistant+lung+cancer+cells+to+EGFR+tyrosine+kinase+inhibitors+by+inducing+autophagy&doi=10.1016%2Fj.ejphar.2018.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy</span></div><div class="casAuthors">To, Kenneth K. W.; Wu, William K. K.; Loong, Herbert H. F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">823</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We aimed to develop novel drug combination strategy to overcome drug resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in the treatment of non-small cell lung cancer (NSCLC).  Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor, which upon activation upregulates phosphatase and tensin homolog (PTEN) to inhibit cell signaling downstream of PI3K to mediate apoptosis.  To this end, PTEN loss is a known mechanism contributing to resistance to EGFR TKIs.  Therefore, PPARγ agonists are hypothesized to overcome EGFR TKI resistance.  Using human NSCLC cell models with PTEN deficiency, the potentiation of EGFR TKI anticancer activity by PPARγ agonists was evaluated.  PPARγ agonists were found to upregulate PTEN, subsequently inhibiting the PI3K-Akt signaling pathway, and thus enhancing the anticancer activity of gefitinib (a first generation EGFR TKI).  Chem. and genetic inhibition of PPARγ were shown to prevent this potentiation of anticancer activity by PPARγ agonists, thus confirming the crucial role played by PPARγ activation.  Interestingly, the tested PPARγ agonists were also found to induce autophagy, as evidenced by the increased expression of an autophagy marker LC3-II and the autophagic degrdn. of p62/SQSTM1.  PPARγ agonists-induced autophagic cell death was believed to contribute to the circumvention of resistance in PTEN-deficient cells because the genetic silencing of ATG5 (an autophagy mediator) was found to eliminate the drug potentiation effect by the PPARγ agonists.  Our findings thus provide the basis for the rational and personalized use of PPARγ agonists in combination with EGFR TKIs in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwVYOH_Zwn07Vg90H21EOLACvtfcHk0ljCJKATnjWBjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVaksb0%253D&md5=e6e2f7c197317249a0595db9763837e7</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLoong%26aufirst%3DH.%26atitle%3DPPARgamma%2520agonists%2520sensitize%2520PTEN-deficient%2520resistant%2520lung%2520cancer%2520cells%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520by%2520inducing%2520autophagy%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D823%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.ejphar.2018.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietanza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span> <span> </span><span class="NLM_article-title">Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1535-7163.MCT-11-0692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22135231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=485-491&issue=2&author=J.+E.+Chaftauthor=M.+E.+Arcilaauthor=P.+K.+Paikauthor=C.+Lauauthor=G.+J.+Rielyauthor=M.+C.+Pietanzaauthor=M.+F.+Zakowskiauthor=V.+Ruschauthor=C.+S.+Simaauthor=M.+Ladanyiauthor=M.+G.+Kris&title=Coexistence+of+PIK3CA+and+other+oncogene+mutations+in+lung+adenocarcinoma-rationale+for+comprehensive+mutation+profiling&doi=10.1158%2F1535-7163.MCT-11-0692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling</span></div><div class="casAuthors">Chaft, Jamie E.; Arcila, Maria E.; Paik, Paul K.; Lau, Christopher; Riely, Gregory J.; Pietanza, M. Catherine; Zakowski, Maureen F.; Rusch, Valerie; Sima, Camelia S.; Ladanyi, Marc; Kris, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K).  PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein have been assocd. with tumorigenesis and treatment resistance in various malignancies.  Characteristics of patients with PIK3CA-mutant lung adenocarcinomas have not been reported.  We examd. epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.  Clin. data were obtained from the medical records of individuals with mutations in PIK3CA.  Twenty-three of 1,125 (2%, 95% CI: 1-3) patients had a mutation in PIK3CA, 12 in exon 9 (10 E545K and 2 E542K), and 11 in exon 20 (3 H1047L and 8 H1047R).  The patients (57% women) had a median age of 66 at diagnosis (range: 34-78).  Eight patients (35%) were never smokers.  Sixteen of 23 (70%, 95% CI: 49-86) had coexisting mutations in other oncogenes-10 KRAS, 1 MEK1, 1 BRAF, 1 ALK rearrangement, and 3 EGFR exon 19 deletions.  We conclude that PIK3CA mutations occur in lung adenocarcinomas, usually concurrently with EGFR, KRAS, and ALK.  The impact of PIK3CA mutations on the efficacy of targeted therapies such as erlotinib and crizotinib is unknown.  Given the high frequency of overlapping mutations, comprehensive genotyping should be carried out on tumor specimens from patients enrolling in clin. trials of PI3K and other targeted therapies.  Mol Cancer Ther; 11(2); 485-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotLJbbv7j8PbVg90H21EOLACvtfcHk0lh_dK4Abb6MVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrc%253D&md5=cbbbf6fa4af430599549f434747f6935</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0692%26sid%3Dliteratum%253Aachs%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DPaik%26aufirst%3DP.%2BK.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DKris%26aufirst%3DM.%2BG.%26atitle%3DCoexistence%2520of%2520PIK3CA%2520and%2520other%2520oncogene%2520mutations%2520in%2520lung%2520adenocarcinoma-rationale%2520for%2520comprehensive%2520mutation%2520profiling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D2%26spage%3D485%26epage%3D491%26doi%3D10.1158%2F1535-7163.MCT-11-0692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludovini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianconi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minotti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuffrida, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofanetti, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siggillino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mameli, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaliere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crinò, L.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">707</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e31820a3a6b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0b013e31820a3a6b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=21258250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3MrlsF2rsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=707-715&issue=4&author=V.+Ludoviniauthor=F.+Bianconiauthor=L.+Pistolaauthor=R.+Chiariauthor=V.+Minottiauthor=R.+Colellaauthor=D.+Giuffridaauthor=F.+R.+Tofanettiauthor=A.+Siggillinoauthor=A.+Flaccoauthor=E.+Baldelliauthor=D.+Iaconoauthor=M.+G.+Mameliauthor=A.+Cavaliereauthor=L.+Crin%C3%B2&title=Phosphoinositide-3-kinase+catalytic+alpha+and+KRAS+mutations+are+important+predictors+of+resistance+to+therapy+with+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+patients+with+advanced+non-small+cell+lung+cancer&doi=10.1097%2FJTO.0b013e31820a3a6b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer</span></div><div class="casAuthors">Ludovini Vienna; Bianconi Fortunato; Pistola Lorenza; Chiari Rita; Minotti Vincenzo; Colella Renato; Giuffrida Dario; Tofanetti Francesca Romana; Siggillino Annamaria; Flacco Antonella; Baldelli Elisa; Iacono Daniela; Mameli Maria Grazia; Cavaliere Antonio; Crino Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">707-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Specific mutations of the epidermal growth factor receptor (EGFR) gene are predictive for favorable response to tyrosine kinase inhibitors (TKIs) and are associated with a good prognosis.  In contrast, Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation has been shown to predict poor response to such therapy.  Nevertheless, tumor that initially responds to EGFR-TKIs almost inevitably becomes resistant later.  Other mechanisms of resistance to EGFR inhibitors could involve activating mutations of the other main EGFR effector pathway, i.e., the phosphoinositide-3-kinase/phosphate and tensin homologue deleted from chromosome 10 (PTEN)/alpha serine/threonine protein kinase (AKT) pathway.  The aim of this study was to investigate the role of phosphoinositide-3-kinase catalytic alpha (PIK3CA), EGFR, and KRAS gene mutations in predicting response and survival in patients with non-small cell lung cancer (NSCLC) treated with EGFR-TKIs.  PATIENTS AND METHODS:  A total of 166 patients with advanced NSCLC treated with EGFR-TKI with available archival tissue specimens were included.  PIK3CA, EGFR, and KRAS mutations were analyzed using polymerase chain reaction-based sequencing.  RESULTS:  EGFR mutation was detected in 25.3% of patients, PIK3CA mutation in 4.1%, and KRAS mutation in 6.7%.  PIK3CA mutation correlated with shorter median time to progression (TTP) (p = 0.01) and worse overall survival (OS) (p < 0.001).  EGFR mutation (p < 0.0001) correlated with favorable response to TKIs treatment and longer TTP (p < 0.0001).  KRAS mutation correlated with progressive disease (p = 0.05) and shorter median TTP (p = 0.003) but not with OS.  Cox multivariate analysis including histology and performance status showed that PIK3CA mutation was an independent factor to predict worse OS (p = 0.0001) and shorter TTP (p = 0.03), while KRAS mutation to predict shorter TTP (p = 0.01).  CONCLUSION:  PIK3CA and KRAS mutations seem to be indicators of resistance and poor survival in patients with NSCLC treated with EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4PDg1GrHoyeqrn-c4Of3KfW6udTcc2eY4qy-98yrRyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrlsF2rsg%253D%253D&md5=214e69ee636edc4000a10163d6590f65</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31820a3a6b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31820a3a6b%26sid%3Dliteratum%253Aachs%26aulast%3DLudovini%26aufirst%3DV.%26aulast%3DBianconi%26aufirst%3DF.%26aulast%3DPistola%26aufirst%3DL.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DMinotti%26aufirst%3DV.%26aulast%3DColella%26aufirst%3DR.%26aulast%3DGiuffrida%26aufirst%3DD.%26aulast%3DTofanetti%26aufirst%3DF.%2BR.%26aulast%3DSiggillino%26aufirst%3DA.%26aulast%3DFlacco%26aufirst%3DA.%26aulast%3DBaldelli%26aufirst%3DE.%26aulast%3DIacono%26aufirst%3DD.%26aulast%3DMameli%26aufirst%3DM.%2BG.%26aulast%3DCavaliere%26aufirst%3DA.%26aulast%3DCrin%25C3%25B2%26aufirst%3DL.%26atitle%3DPhosphoinositide-3-kinase%2520catalytic%2520alpha%2520and%2520KRAS%2520mutations%2520are%2520important%2520predictors%2520of%2520resistance%2520to%2520therapy%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26issue%3D4%26spage%3D707%26epage%3D715%26doi%3D10.1097%2FJTO.0b013e31820a3a6b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">113</span>, <span class="refDoi"> DOI: 10.3389/fonc.2017.00113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.3389%2Ffonc.2017.00113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28620581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=113&author=T.+A.+Barnesauthor=G.+M.+O%E2%80%99Kaneauthor=M.+D.+Vincentauthor=N.+B.+Leighl&title=Third-generation+tyrosine+kinase+inhibitors+targeting+epidermal+growth+factor+receptor+mutations+in+non-small+cell+lung+cancer&doi=10.3389%2Ffonc.2017.00113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Barnes Tristan A; O'Kane Grainne M; Leighl Natasha B; Vincent Mark David</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer.  Eventual resistance develops with multiple mechanisms identifiable both upon repeat biopsy and in plasma circulating tumor DNA.  The T790M gatekeeper mutation is responsible for almost 60% of cases.  A number of third-generation TKIs are in clinical development, and osimertinib has been approved by the US Food and Drug Administration for the treatment of patients with EGFR T790M mutant lung cancer after failure of initial EGFR kinase therapy.  Resistance mechanisms are being identified to these novel agents, and the treatment landscape of EGFR-mutant lung cancer continues to evolve.  The sequence of EGFR TKIs may change in the future and combination therapies targeting resistance appear highly promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT45i3zpRyq-4hLSh9fo81bfW6udTcc2eY27IIhjM9jNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D&md5=591385d1fc87186675e46ad3621dc82b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2017.00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2017.00113%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DT.%2BA.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DVincent%26aufirst%3DM.%2BD.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DThird-generation%2520tyrosine%2520kinase%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2017%26volume%3D7%26spage%3D113%26doi%3D10.3389%2Ffonc.2017.00113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plodkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1713</span>– <span class="NLM_lpage">1719</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0000000000000671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26334752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1713-1719&issue=12&author=J.+Engauthor=K.+M.+Wooauthor=C.+S.+Simaauthor=A.+Plodkowskiauthor=M.+D.+Hellmannauthor=J.+E.+Chaftauthor=M.+G.+Krisauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=A.+Drilon&title=Impact+of+concurrent+PIK3CA+mutations+on+response+to+EGFR+tyrosine+kinase+inhibition+in+EGFR-mutant+lung+cancers+and+on+prognosis+in+oncogene-driven+lung+adenocarcinomas&doi=10.1097%2FJTO.0000000000000671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas</span></div><div class="casAuthors">Eng, Juliana; Woo, Kaitlin M.; Sima, Camelia S.; Plodkowski, Andrew; Hellmann, Matthew D.; Chaft, Jamie E.; Kris, Mark G.; Arcila, Maria E.; Ladanyi, Marc; Drilon, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1713-1719</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: In patients with epidermal growth factor receptor (EGFR)-mutant or KRAS-mutant lung adenocarcinomas, the prognostic impact of a concurrent PIK3CA mutation remains unclear.  Although preclin. data suggest that sensitivity to EGFR tyrosine kinase inhibition (TKI) is decreased in EGFR-mutant lung cancers also harboring a PIK3CA mutation, this interaction has not been explored clin.  Methods: Patients with lung adenocarcinomas harboring a PIK3CA mutation concurrent with a sep. driver mutation were identified through mutational hotspot testing, multiplex sizing assays, and fluorescence in situ hybridization.  Overall survival and outcomes with EGFR TKI monotherapy (EGFR-mutant) were estd. using Kaplan-Meier methods and compared between double-mutant (EGFR-mutant or KRAS-mutant, concurrent PIK3CA-mutant) and single-mutant patients (EGFR-mutant or KRAS-mutant, PIK3CA wild-type) using log-rank tests.  Results: In EGFR-mutant and KRAS-mutant lung cancers, a concurrent PIK3CA mutation was assocd. with a decrease in median overall survival: 18 vs. 33 mo (EGFR double mutant, n = 10 vs. single mutant, n = 43, p = 0.006), and 9 vs. 16 mo (KRAS double mutant, n = 16 vs. single mutant, n = 47, p = 0.020).  In EGFR-mutant lung cancers, a concurrent PIK3CA mutation did not impact benefit from EGFR TKI monotherapy.  Single vs. double mutant: objective response rate, 83% (n = 29) vs. 62% (n = 6, p = 0.80); median time to progression, 11 (n = 29) vs. 8 mo (n = 6, p = 0.84); and median duration of TKI therapy, 15 (n = 32) vs. 15 mo (n = 10, p = 0.65).  Conclusion: A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas.  There was no evidence that clin. benefit from EGFR TKI monotherapy is affected by a concurrent PIK3CA mutation in EGFR-mutant lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6JH4V50hFI7Vg90H21EOLACvtfcHk0liagqFuh2w-0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rJ&md5=5566e6c5a8e5d62eeb24b072a34e2170</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000671%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DWoo%26aufirst%3DK.%2BM.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DPlodkowski%26aufirst%3DA.%26aulast%3DHellmann%26aufirst%3DM.%2BD.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DImpact%2520of%2520concurrent%2520PIK3CA%2520mutations%2520on%2520response%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibition%2520in%2520EGFR-mutant%2520lung%2520cancers%2520and%2520on%2520prognosis%2520in%2520oncogene-driven%2520lung%2520adenocarcinomas%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D1713%26epage%3D1719%26doi%3D10.1097%2FJTO.0000000000000671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFramboise, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moonsamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G</span></span> <span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&issue=8&author=Z.+Zhangauthor=J.+C.+Leeauthor=L.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Wangauthor=A.+D+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.-M.+Choiauthor=S.-W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.-S.+Leeauthor=V.+A+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J+Boggonauthor=P.+C+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0liagqFuh2w-0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLevine%26aufirst%3DA.%2BD%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.-M.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DMiller%26aufirst%3DV.%2BA%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ%26aulast%3DMa%26aufirst%3DP.%2BC%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26issue%3D8%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&issue=12&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgc23DfL7FDPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Giving AXL the axe: targeting AXL in human malignancy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fbjc.2016.428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28072762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=415-423&issue=4&author=C.+M.+Gayauthor=K.+Balajiauthor=L.+A.+Byers&title=Giving+AXL+the+axe%3A+targeting+AXL+in+human+malignancy&doi=10.1038%2Fbjc.2016.428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Giving AXL the axe: targeting AXL in human malignancy</span></div><div class="casAuthors">Gay, Carl M.; Balaji, Kavitha; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunol. response.  Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematol. and solid malignancies, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.  In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.  As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.  Several AXL inhibitors are currently in preclin. and clin. development.  This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumor microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXM9RJ8TVsLVg90H21EOLACvtfcHk0lgc23DfL7FDPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D&md5=c24668744fe4b017def75b08bac2a863</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.428%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DBalaji%26aufirst%3DK.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DGiving%2520AXL%2520the%2520axe%253A%2520targeting%2520AXL%2520in%2520human%2520malignancy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26issue%3D4%26spage%3D415%26epage%3D423%26doi%3D10.1038%2Fbjc.2016.428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintanal-Villalonga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Pinelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirauqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojeda-Márquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrugal, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce-Aix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enguita, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">FGFR1 Cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30639621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=641-655&issue=4&author=A.+Quintanal-Villalongaauthor=S.+Molina-Pineloauthor=C.+Cirauquiauthor=L.+Ojeda-M%C3%A1rquezauthor=%C3%81.+Marrugalauthor=R.+Suarezauthor=E.+Condeauthor=S.+Ponce-Aixauthor=A.+B.+Enguitaauthor=A.+Carneroauthor=I.+Ferrerauthor=L.+Paz-Ares&title=FGFR1+Cooperates+with+EGFR+in+lung+cancer+oncogenesis%2C+and+their+combined+inhibition+shows+improved+efficacy&doi=10.1016%2Fj.jtho.2018.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy</span></div><div class="casAuthors">Quintanal-Villalonga, Alvaro; Molina-Pinelo, Sonia; Cirauqui, Cristina; Ojeda-Marquez, Laura; Marrugal, Angela; Suarez, Rocio; Conde, Esther; Ponce-Aix, Santiago; Enguita, Ana Belen; Carnero, Amancio; Ferrer, Irene; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-655</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma.  We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays.  We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts.  We detd. FGFR1 mRNA expression in a cohort of patients with anti-EGFR therapy-treated adenocarcinoma.  We have reported a cooperative interaction between FGFR1 and EGFR in this context, resulting in increased EGFR activation and oncogenic signaling.  We have provided in vitro and in vivo evidence indicating that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in EGFR-mutated and EGFR wild-type models.  At the clin. level, we have shown that high FGFR1 expression levels predict higher resistance to erlotinib or gefitinib in a cohort of patients with tyrosine kinase inhibitor-treated EGFR-mutated and EGFR wild-type lung adenocarcinoma.  Dual EGFR and FGFR inhibition in FGFR1-overexpressing, EGFR-activated models shows synergistic effects on tumor growth in vitro and in cell line- and patient-derived xenografts, suggesting that patients with tumors bearing these characteristics may benefit from combined EGFR/FGFR inhibition.  These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJn8jLNuMQRLVg90H21EOLACvtfcHk0lgc23DfL7FDPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL&md5=d2a14b7b17cd9a65819d63760a7124e5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DQuintanal-Villalonga%26aufirst%3DA.%26aulast%3DMolina-Pinelo%26aufirst%3DS.%26aulast%3DCirauqui%26aufirst%3DC.%26aulast%3DOjeda-M%25C3%25A1rquez%26aufirst%3DL.%26aulast%3DMarrugal%26aufirst%3D%25C3%2581.%26aulast%3DSuarez%26aufirst%3DR.%26aulast%3DConde%26aufirst%3DE.%26aulast%3DPonce-Aix%26aufirst%3DS.%26aulast%3DEnguita%26aufirst%3DA.%2BB.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DFGFR1%2520Cooperates%2520with%2520EGFR%2520in%2520lung%2520cancer%2520oncogenesis%252C%2520and%2520their%2520combined%2520inhibition%2520shows%2520improved%2520efficacy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D641%26epage%3D655%26doi%3D10.1016%2Fj.jtho.2018.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finocchiaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toschi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incarbone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alloisio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span> <span> </span><span class="NLM_article-title">Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdp357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdp357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19767315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3c7isVGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=562-567&issue=3&author=F.+Cappuzzoauthor=G.+Talliniauthor=G.+Finocchiaroauthor=R.+S.+Wilsonauthor=C.+Ligorioauthor=L.+Giordanoauthor=L.+Toschiauthor=M.+Incarboneauthor=R.+Cavinaauthor=L.+Terraccianoauthor=M.+Roncalliauthor=M.+Alloisioauthor=M.+Varella-Garciaauthor=W.+A.+Franklinauthor=A.+Santoro&title=Insulin-like+growth+factor+receptor+1+%28IGF1R%29+expression+and+survival+in+surgically+resected+non-small-cell+lung+cancer+%28NSCLC%29+patients&doi=10.1093%2Fannonc%2Fmdp357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients</span></div><div class="casAuthors">Cappuzzo F; Tallini G; Ligorio C; Finocchiaro G; Toschi L; Incarbone M; Cavina R; Alloisio M; Santoro A; Wilson R S; Varella-Garcia M; Franklin W A; Giordano L; Terracciano L; Roncalli M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">562-567</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC).  Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients.  Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded.  IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections.  RESULTS:  A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02).  No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36).  No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status.  CONCLUSIONS:  IGF1R expression does not represent a prognostic factor in resected NSCLC patients.  Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQs8HJHlMdUpq-9TkgmBqTqfW6udTcc2eZYCa_DUKvHqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7isVGmtg%253D%253D&md5=428de4274517630d36a622543221e88d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp357%26sid%3Dliteratum%253Aachs%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DTallini%26aufirst%3DG.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DR.%2BS.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DGiordano%26aufirst%3DL.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DIncarbone%26aufirst%3DM.%26aulast%3DCavina%26aufirst%3DR.%26aulast%3DTerracciano%26aufirst%3DL.%26aulast%3DRoncalli%26aufirst%3DM.%26aulast%3DAlloisio%26aufirst%3DM.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DSantoro%26aufirst%3DA.%26atitle%3DInsulin-like%2520growth%2520factor%2520receptor%25201%2520%2528IGF1R%2529%2520expression%2520and%2520survival%2520in%2520surgically%2520resected%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26issue%3D3%26spage%3D562%26epage%3D567%26doi%3D10.1093%2Fannonc%2Fmdp357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of IGF1R signalling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1002/mc.22342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fmc.22342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26052929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=991-1001&issue=5&author=Y.+Leeauthor=Y.+Wangauthor=M.+Jamesauthor=J.+H.+Jeongauthor=M.+You&title=Inhibition+of+IGF1R+signalling+abrogates+resistance+to+afatinib+%28BIBW2992%29+in+EGFR+T790M+mutant+lung+cancer+cells&doi=10.1002%2Fmc.22342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells</span></div><div class="casAuthors">Lee, Yongik; Wang, Yian; James, Michael; Jeong, Joseph H.; You, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">991-1001</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib.  Acquisition of a secondary mutation in EGFR T790M is the most common mechanism of resistance to first generation EGFR TKIs, resulting in therapeutic failure.  Afatinib is a second generation of EGFR TKI that showed great efficacy against tumors bearing the EGFR T790M mutation, but it failed to show the improvement on overall survival of lung cancer patients with EGFR mutations possibly because of novel acquired resistance mechanisms.  Currently, there are no therapeutic options available for lung cancer patients who develop acquired resistance to afatinib.  To identify novel resistance mechanism(s) to afatinib, we developed afatinib resistant cell lines from a parental human-derived NSCLC cell line, H1975, harboring both EGFR L858R and T790M mutations.  We found that activation of the insulin-like growth factor 1 receptor (IGF1R) signaling pathway contributes to afatinib resistance in NSCLC cells harboring the T790M mutation.  IGF1R knockdown not only significantly sensitizes resistant cells to afatinib, but also induces apoptosis in afatinib resistance cells.  In addn., combination treatment with afatinib and linsitinib shows more than additive effects on tumor growth in in vivo H1975 xenograft.  Therefore, these finding suggest that IGF1R inhibition or combination of EGFR-IGF1R inhibition strategies would be potential ways to prevent or potentiate the effects of current therapeutic options to lung cancer patients demonstrating resistance to either first or second generation EGFR TKIs © 2015 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Fke9Vrm9TbVg90H21EOLACvtfcHk0lgya5tPCXK1Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFejtb0%253D&md5=66b4fc1ae65e8b94f39d329f31b34b6b</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fmc.22342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.22342%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DYou%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520IGF1R%2520signalling%2520abrogates%2520resistance%2520to%2520afatinib%2520%2528BIBW2992%2529%2520in%2520EGFR%2520T790M%2520mutant%2520lung%2520cancer%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2016%26volume%3D55%26issue%3D5%26spage%3D991%26epage%3D1001%26doi%3D10.1002%2Fmc.22342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">22005</span>– <span class="NLM_lpage">22015</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.8013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26980747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28fgsFChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=22005-22015&issue=16&author=J.+H.+Parkauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=J.+E.+Leeauthor=K.+J.+Sungauthor=S.+Parkauthor=W.+S.+Kimauthor=J.+S.+Songauthor=C.+M.+Choiauthor=Y.+H.+Sungauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Activation+of+the+IGF1R+pathway+potentially+mediates+acquired+resistance+to+mutant-selective+3rd-generation+EGF+receptor+tyrosine+kinase+inhibitors+in+advanced+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.8013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer</span></div><div class="casAuthors">Park Ji Hyun; Choi Chang-Min; Lee Jae Cheol; Choi Yun Jung; Kim Seon Ye; Lee Jung-Eun; Sung Ki Jung; Park Sojung; Kim Woo Sung; Choi Chang-Min; Choi Yun Jung; Kim Seon Ye; Lee Jung-Eun; Sung Ki Jung; Sung Young Hoon; Rho Jin Kyung; Song Joon Seon; Sung Young Hoon; Rho Jin Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">22005-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutant-selective, 3rd-generation EGFR-TKIs were recently developed to control lung cancer cells harboring T790M-mediated resistance.  However, the development of resistance to these novel drugs seems inevitable.  Thus, we investigated the mechanism of acquired resistance to the mutant-selective EGFR-TKI WZ4002.  We established five WZ4002-resistant cells, derived from cells harboring both EGFR and T790M mutations by long-term exposure to increasing doses of WZ4002.  Compared with the parental cells, all resistant cells showed 10-100-folds higher resistance to WZ4002, as well as cross-resistance to other mutant-selective inhibitors.  Among them, three resistant cells (HCC827/WR, PC-9/WR and H1975/WR) showed dependency on EGFR signaling, but two other cells (PC-9/GR/WR and PC-9/ER/WR) were not.  Notably, insulin-like growth factor-1 receptor (IGF1R) was aberrantly activated in PC-9/GR/WR cells in phospho-receptor tyrosine kinase array, consistently accompanied by loss of IGF binding protein-3 (IGFBP3).  Down-regulation of IGF1R by shRNA, as well as inhibition of IGF1R activity either by AG-1024 (a small molecule IGF1R inhibitor) or BI 836845 (a monoclonal anti-IGF1/2 blocking antibody), restored the sensitivity to WZ4002 both in vitro and xenograft.  Taken together, these results suggest that activation of the IGF1R pathway associated with IGFBP3 loss can induce an acquired resistance to the mutant-selective EGFR-TKI, WZ4002.  Therefore, a combined therapy of IGF1R inhibitors and mutant-selective EGFR-TKIs might be a viable treatment strategy for overcoming acquired resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtMwy_6CBS1suCWE5mhx1RfW6udTcc2eYVBsPUSMeK0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgsFChsQ%253D%253D&md5=17315869bfa45fb346648382a7dfcda5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8013%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DSung%26aufirst%3DK.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DSung%26aufirst%3DY.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DActivation%2520of%2520the%2520IGF1R%2520pathway%2520potentially%2520mediates%2520acquired%2520resistance%2520to%2520mutant-selective%25203rd-generation%2520EGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D16%26spage%3D22005%26epage%3D22015%26doi%3D10.18632%2Foncotarget.8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. B K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGranahan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkbak, N. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubens, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, K. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, R. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulin, A. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, A. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannikopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, P. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandara, D. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, J. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G</span></span> <span> </span><span class="NLM_article-title">Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1704</span>, <span class="refDoi"> DOI: 10.1038/ng.3990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fng.3990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29106415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslKmur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=1693-1704&issue=12&author=C.+M+Blakelyauthor=T.+B+K+Watkinsauthor=W.+Wuauthor=B.+Giniauthor=J.+J+Chabonauthor=C.+E+McCoachauthor=N.+McGranahanauthor=G.+A+Wilsonauthor=N.+J+Birkbakauthor=V.+R+Olivasauthor=J.+Rotowauthor=A.+Maynardauthor=V.+Wangauthor=M.+A+Gubensauthor=K.+C+Banksauthor=R.+B+Lanmanauthor=A.+F+Caulinauthor=J.+St+Johnauthor=A.+R+Corderoauthor=P.+Giannikopoulosauthor=A.+D+Simmonsauthor=P.+C+Mackauthor=D.+R+Gandaraauthor=H.+Husainauthor=R.+C+Doebeleauthor=J.+W+Riessauthor=M.+Diehnauthor=C.+Swantonauthor=T.+G+Bivona&title=Evolution+and+clinical+impact+of+co-occurring+genetic+alterations+in+advanced-stage+EGFR-mutant+lung+cancers&doi=10.1038%2Fng.3990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers</span></div><div class="casAuthors">Blakely, Collin M.; Watkins, Thomas B. K.; Wu, Wei; Gini, Beatrice; Chabon, Jacob J.; McCoach, Caroline E.; McGranahan, Nicholas; Wilson, Gareth A.; Birkbak, Nicolai J.; Olivas, Victor R.; Rotow, Julia; Maynard, Ashley; Wang, Victoria; Gubens, Matthew A.; Banks, Kimberly C.; Lanman, Richard B.; Caulin, Aleah F.; St. John, John; Cordero, Anibal R.; Giannikopoulos, Petros; Simmons, Andrew D.; Mack, Philip C.; Gandara, David R.; Husain, Hatim; Doebele, Robert C.; Riess, Jonathan W.; Diehn, Maximilian; Swanton, Charles; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1693-1704</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-mutant lung cancers).  However, genetically driven resistance to targeted therapy limits patient survival.  Through genomic anal. of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome anal. of seven longitudinally collected tumor samples from a patient with EGFR-mutant lung cancer, we identified crit. co-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers.  We defined new pathways limiting EGFR-inhibitor response, including WNT/β-catenin alterations and cell-cycle-gene (CDK4 and CDK6) mutations.  Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response.  This study calls for revisiting the prevailing single-gene driver-oncogene view and links clin. outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCM4IDANPTKrVg90H21EOLACvtfcHk0liE43R14X1B-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslKmur3K&md5=9575aff401c35b4f422304b71005f28b</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fng.3990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.3990%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM%26aulast%3DWatkins%26aufirst%3DT.%2BB%2BK%26aulast%3DWu%26aufirst%3DW.%26aulast%3DGini%26aufirst%3DB.%26aulast%3DChabon%26aufirst%3DJ.%2BJ%26aulast%3DMcCoach%26aufirst%3DC.%2BE%26aulast%3DMcGranahan%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DG.%2BA%26aulast%3DBirkbak%26aufirst%3DN.%2BJ%26aulast%3DOlivas%26aufirst%3DV.%2BR%26aulast%3DRotow%26aufirst%3DJ.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DV.%26aulast%3DGubens%26aufirst%3DM.%2BA%26aulast%3DBanks%26aufirst%3DK.%2BC%26aulast%3DLanman%26aufirst%3DR.%2BB%26aulast%3DCaulin%26aufirst%3DA.%2BF%26aulast%3DSt%2BJohn%26aufirst%3DJ.%26aulast%3DCordero%26aufirst%3DA.%2BR%26aulast%3DGiannikopoulos%26aufirst%3DP.%26aulast%3DSimmons%26aufirst%3DA.%2BD%26aulast%3DMack%26aufirst%3DP.%2BC%26aulast%3DGandara%26aufirst%3DD.%2BR%26aulast%3DHusain%26aufirst%3DH.%26aulast%3DDoebele%26aufirst%3DR.%2BC%26aulast%3DRiess%26aufirst%3DJ.%2BW%26aulast%3DDiehn%26aufirst%3DM.%26aulast%3DSwanton%26aufirst%3DC.%26aulast%3DBivona%26aufirst%3DT.%2BG%26atitle%3DEvolution%2520and%2520clinical%2520impact%2520of%2520co-occurring%2520genetic%2520alterations%2520in%2520advanced-stage%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DNat.%2520Genet.%26date%3D2017%26volume%3D49%26issue%3D12%26spage%3D1693%26epage%3D1704%26doi%3D10.1038%2Fng.3990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creelan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosemani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolinakos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1312</span>– <span class="NLM_lpage">1323</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29883838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1MblsVKnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1312-1323&issue=9&author=A.+B.+Schrockauthor=V.+W.+Zhuauthor=W.+S.+Hsiehauthor=R.+Madisonauthor=B.+Creelanauthor=J.+Silberbergauthor=D.+Costinauthor=A.+Bharneauthor=I.+Bontaauthor=T.+Bosemaniauthor=P.+Nikolinakosauthor=J.+S.+Rossauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=S.+I.+Ou&title=Receptor+tyrosine+kinase+fusions+and+BRAF+kinase+fusions+are+rare+but+actionable+resistance+mechanisms+to+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.jtho.2018.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Schrock Alexa B; Madison Russell; Miller Vincent A; Ali Siraj M; Zhu Viola W; Hsieh Wen-Son; Creelan Benjamin; Silberberg Jeffrey; Costin Dan; Bharne Anjali; Bonta Ioana; Bosemani Thangavijayan; Nikolinakos Petros; Ross Jeffrey S; Klempner Samuel J; Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1312-1323</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  We analyzed a large set of EGFR-mutated (EGFR+) NSCLC to identify and characterize cases with co-occurring kinase fusions as potential resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs).  METHODS:  EGFR+ (del 19, L858R, G719X, S768I, L851Q) NSCLC clinical samples (formalin-fixed paraffin-embedded tumor and blood) were analyzed for the presence of receptor tyrosine kinase (RTK) and BRAF fusions.  Treatment history and response were obtained from provided pathology reports and treating clinicians.  RESULTS:  Clinical samples from 3505 unique EGFR+ NSCLCs were identified from June 2012 to October 2017.  A total of 31 EGFR+ cases had concurrent kinase fusions detected: 10 (32%) BRAF, 7 (23%) ALK receptor tyrosine kinase (ALK), 6 (19%) ret proto-oncogene (RET), 6 (19%) fibroblast growth factor receptor 3 (FGFR3), 1 (3.2%) EGFR, and 1 (3.2%) neurotrophic receptor tyrosine kinase 1 (NTRK1), including two novel fusions (SALL2-BRAF and PLEKHA7-ALK).  Twenty-seven of 31 patients had either a known history of EGFR+ NSCLC diagnosis or prior treatment with an EGFR TKI before the fusion+ sample was collected.  Twelve of the 27 patients had paired pre-treatment samples where the fusion was not present before treatment with an EGFR TKI.  Multiple patients treated with combination therapy targeting EGFR and the acquired fusion had clinical benefit, including one patient with osimertinib resistance due to an acquired PLEKHA7-ALK fusion achieving a durable partial response with combination of full-dose osimertinib and alectinib.  CONCLUSIONS:  RTK and BRAF fusions are rare but potentially druggable resistance mechanisms to EGFR TKIs.  Detection of RTK and BRAF fusions should be part of comprehensive profiling panels to determine resistance to EGFR TKIs and direct appropriate combination therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD19Ex2E3-UGHOrQ6qeX-mfW6udTcc2eYVBsPUSMeK0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MblsVKnsQ%253D%253D&md5=ad904aa2d6116e648d010e30ad083744</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DHsieh%26aufirst%3DW.%2BS.%26aulast%3DMadison%26aufirst%3DR.%26aulast%3DCreelan%26aufirst%3DB.%26aulast%3DSilberberg%26aufirst%3DJ.%26aulast%3DCostin%26aufirst%3DD.%26aulast%3DBharne%26aufirst%3DA.%26aulast%3DBonta%26aufirst%3DI.%26aulast%3DBosemani%26aufirst%3DT.%26aulast%3DNikolinakos%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520fusions%2520and%2520BRAF%2520kinase%2520fusions%2520are%2520rare%2520but%2520actionable%2520resistance%2520mechanisms%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D1312%26epage%3D1323%26doi%3D10.1016%2Fj.jtho.2018.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nukaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikemura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betsuyaku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soejima, K.</span></span> <span> </span><span class="NLM_article-title">Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2089</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-16-2359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28202511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFOqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2078-2089&issue=8&author=S.+Nukagaauthor=H.+Yasudaauthor=K.+Tsuchiharaauthor=J.+Hamamotoauthor=K.+Masuzawaauthor=I.+Kawadaauthor=K.+Naokiauthor=S.+Matsumotoauthor=S.+Mimakiauthor=S.+Ikemuraauthor=K.+Gotoauthor=T.+Betsuyakuauthor=K.+Soejima&title=Amplification+of+EGFR+wild-type+alleles+in+non-small+cell+lung+cancer+cells+confers+acquired+resistance+to+mutation-selective+EGFR+tyrosine+kinase+inhibitors&doi=10.1158%2F0008-5472.CAN-16-2359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Nukaga, Shigenari; Yasuda, Hiroyuki; Tsuchihara, Katsuya; Hamamoto, Junko; Masuzawa, Keita; Kawada, Ichiro; Naoki, Katsuhiko; Matsumoto, Shingo; Mimaki, Sachiyo; Ikemura, Shinnosuke; Goto, Koichi; Betsuyaku, Tomoko; Soejima, Kenzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2078-2089</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">EGFR-mutated lung cancers account for a significant subgroup of non-small cell lung cancers overall.  Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation-selective inhibitors with minimal effects on wild-type EGFR.  Acquired resistance develops to these agents, however, the mechanisms are as yet uncharacterized.  In this study, we report that the Src-AKT pathway contributes to acquired resistance to these TKI.  In addn., amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.  These findings underscore the importance of signals from wild-type EGFR alleles in acquiring resistance to mutant-selective EGFR-TKI.  Our data provide evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ewjdUcwnJbVg90H21EOLACvtfcHk0lgZ9RXfnoSO_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFOqur4%253D&md5=66ffdb2198a4b1caf3cdf5dcdde67e22</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2359%26sid%3Dliteratum%253Aachs%26aulast%3DNukaga%26aufirst%3DS.%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DTsuchihara%26aufirst%3DK.%26aulast%3DHamamoto%26aufirst%3DJ.%26aulast%3DMasuzawa%26aufirst%3DK.%26aulast%3DKawada%26aufirst%3DI.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DMimaki%26aufirst%3DS.%26aulast%3DIkemura%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DBetsuyaku%26aufirst%3DT.%26aulast%3DSoejima%26aufirst%3DK.%26atitle%3DAmplification%2520of%2520EGFR%2520wild-type%2520alleles%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%2520confers%2520acquired%2520resistance%2520to%2520mutation-selective%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D8%26spage%3D2078%26epage%3D2089%26doi%3D10.1158%2F0008-5472.CAN-16-2359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meador, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">SFK/FAK signalling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2990</span>– <span class="NLM_lpage">3000</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-16-2300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28416483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Siu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2990-3000&issue=11&author=E.+Ichiharaauthor=D.+Westoverauthor=C.+B.+Meadorauthor=Y.+Yanauthor=J.+A.+Bauerauthor=P.+Luauthor=F.+Yeauthor=A.+Kulickauthor=E.+de+Stanchinaauthor=R.+McEwenauthor=M.+Ladanyiauthor=D.+Crossauthor=W.+Paoauthor=C.+M.+Lovly&title=SFK%2FFAK+signalling+attenuates+osimertinib+efficacy+in+both+drug-sensitive+and+drug-resistant+models+of+EGFR-mutant+lung+cancer&doi=10.1158%2F0008-5472.CAN-16-2300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer</span></div><div class="casAuthors">Ichihara, Eiki; Westover, David; Meador, Catherine B.; Yan, Yingjun; Bauer, Joshua A.; Lu, Pengcheng; Ye, Fei; Kulick, Amanda; de Stanchina, Elisa; McEwen, Robert; Ladanyi, Marc; Cross, Darren; Pao, William; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2990-3000</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer.  Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clin. trials have documented their efficacy in patients with EGFR-mutant lung cancer.  Despite promising results, therapeutic efficacy is limited by the development of acquired resistance.  Here we report that Src family kinases (SFK) and focal adhesion kinase (FAK) sustain AKT and MAPK pathway signaling under continuous EGFR inhibition in osimertinib-sensitive cells.  Inhibiting either the MAPK pathway or the AKT pathway enhanced the effects of osimertinib.  Combined SFK/FAK inhibition exhibited the most potent effects on growth inhibition, induction of apoptosis, and delay of acquired resistance.  SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors.  In conclusion, our data suggest that the concomitant inhibition of both SFK/FAK and EGFR may be a promising therapeutic strategy for EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKuOvH2nXTXbVg90H21EOLACvtfcHk0lgZ9RXfnoSO_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Siu74%253D&md5=605a9f602eec228294194f4316ede972</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2300%26sid%3Dliteratum%253Aachs%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DMeador%26aufirst%3DC.%2BB.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DKulick%26aufirst%3DA.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMcEwen%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DSFK%252FFAK%2520signalling%2520attenuates%2520osimertinib%2520efficacy%2520in%2520both%2520drug-sensitive%2520and%2520drug-resistant%2520models%2520of%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D11%26spage%3D2990%26epage%3D3000%26doi%3D10.1158%2F0008-5472.CAN-16-2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. H.</span></span> <span> </span><span class="NLM_article-title">Signal transducers and activators of transcription 3 function in lung cancer</span>. <i>Cancer Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.4103/0973-1482.119100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.4103%2F0973-1482.119100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=67-73&issue=5&author=C.+J.+Liauthor=Y.+C.+Liauthor=D.+R.+Zhangauthor=J.+H.+Pan&title=Signal+transducers+and+activators+of+transcription+3+function+in+lung+cancer&doi=10.4103%2F0973-1482.119100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.4103%2F0973-1482.119100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0973-1482.119100%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BC.%26aulast%3DZhang%26aufirst%3DD.%2BR.%26aulast%3DPan%26aufirst%3DJ.%2BH.%26atitle%3DSignal%2520transducers%2520and%2520activators%2520of%2520transcription%25203%2520function%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%2520Ther.%26date%3D2013%26volume%3D9%26issue%3D5%26spage%3D67%26epage%3D73%26doi%3D10.4103%2F0973-1482.119100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunnumakkara, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikumar, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tharakan, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, B.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1171</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.04911.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1111%2Fj.1749-6632.2009.04911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19723038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Sntb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1171&publication_year=2009&pages=59-76&author=B.+B.+Aggarwalauthor=A.+B.+Kunnumakkaraauthor=K.+B.+Harikumarauthor=S.+R.+Guptaauthor=S.+T.+Tharakanauthor=C.+Kocaauthor=S.+Deyauthor=B.+Sung&title=Signal+transducer+and+activator+of+transcription-3%2C+inflammation%2C+and+cancer%3A+how+intimate+is+the+relationship%3F&doi=10.1111%2Fj.1749-6632.2009.04911.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?</span></div><div class="casAuthors">Aggarwal, Bharat B.; Kunnumakkara, Ajaikumar B.; Harikumar, Kuzhuvelil B.; Gupta, Shan R.; Tharakan, Sheeja T.; Koca, Cemile; Dey, Sanjit; Sung, Bokyung</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1171</span>
        (<span class="NLM_cas:issue">Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways</span>),
    <span class="NLM_cas:pages">59-76</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription-3 (STAT-3) is one of six members of a family of transcription factors.  It was discovered almost 15 years ago as an acute-phase response factor.  This factor has now been assocd. with inflammation, cellular transformation, survival, proliferation, invasion, angiogenesis, and metastasis of cancer.  Various types of carcinogens, radiation, viruses, growth factors, oncogenes, and inflammatory cytokines have been found to activate STAT-3.  STAT-3 is constitutively active in most tumor cells but not in normal cells.  Phosphorylation of STAT-3 at tyrosine 705 leads to its dimerization, nuclear translocation, DNA binding, and gene transcription.  The phosphorylation of STAT-3 at serine 727 may regulate its activity neg. or pos.  STAT-3 regulates the expression of genes that mediate survival (survivin, bcl-xl, mcl-1, cellular FLICE-like inhibitory protein), proliferation (c-fos, c-myc, cyclin D1), invasion (matrix metalloproteinase-2), and angiogenesis (vascular endothelial growth factor).  STAT-3 activation has also been assocd. with both chemoresistance and radioresistance.  STAT-3 mediates these effects through its collaboration with various other transcription factors, including nuclear factor-κB, hypoxia-inducible factor-1, and peroxisome proliferator activated receptor-γ.  Because of its crit. role in tumorigenesis, inhibitors of this factor's activation are being sought for both prevention and therapy of cancer.  This has led to identification of small peptides, oligonucleotides, and small mols. as potential STAT-3 inhibitors.  Several of these small mols. are chemopreventive agents derived from plants.  This review discusses the intimate relationship between STAT-3, inflammation, and cancer in more detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr9e25c7f6jLVg90H21EOLACvtfcHk0lgAFWXG--q2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Sntb3J&md5=2d3aa124c0cffbeb6113ed3492e54210</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.04911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.04911.x%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26aulast%3DKunnumakkara%26aufirst%3DA.%2BB.%26aulast%3DHarikumar%26aufirst%3DK.%2BB.%26aulast%3DGupta%26aufirst%3DS.%2BR.%26aulast%3DTharakan%26aufirst%3DS.%2BT.%26aulast%3DKoca%26aufirst%3DC.%26aulast%3DDey%26aufirst%3DS.%26aulast%3DSung%26aufirst%3DB.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription-3%252C%2520inflammation%252C%2520and%2520cancer%253A%2520how%2520intimate%2520is%2520the%2520relationship%253F%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2009%26volume%3D1171%26spage%3D59%26epage%3D76%26doi%3D10.1111%2Fj.1749-6632.2009.04911.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">JAK2/STAT3 signalling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2011.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2011.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=21333372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3Mjit1arsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2011&pages=366-374&issue=3&author=M.+Zhaoauthor=F.+H.+Gaoauthor=J.+Y.+Wangauthor=F.+Liuauthor=H.+H.+Yuanauthor=W.+Y.+Zhangauthor=B.+Jiang&title=JAK2%2FSTAT3+signalling+pathway+activation+mediates+tumor+angiogenesis+by+upregulation+of+VEGF+and+bFGF+in+non-small-cell+lung+cancer&doi=10.1016%2Fj.lungcan.2011.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer</span></div><div class="casAuthors">Zhao Mei; Gao Feng-Hou; Wang Jiong-Yi; Liu Feng; Yuan Hai-Hua; Zhang Wen-Ying; Jiang Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We investigated the clinical significance of Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) during angiogenesis in non-small-cell lung carcinoma.  JAK2, phospho-JAK2 (pJAK2), STAT3, and phospho-STAT3 (pSATA3) were observed in 40/68 (58.8%), 39/68 (57.4%), 49/68 (72.1%) and 40/68 (58.8%) of the cases.  The high expression levels of molecules involved in the JAK2/STAT3 signaling pathway were associated with a decreased survival rate.  Of the total number of cases, 73.5% were positive for VEGF and 80.9% for bFGF.  Microvessel density (MVD), as determined by CD34 staining and morphology, was higher in NSCLC samples with high pJAK2 and pSTAT3 expression, and the patients with high MVD had poor survival status.  In addition, the expression of pSTAT3 correlated with VEGF (r=0.593) and bFGF (r=0.519) (p<0.05).  Inhibiting JAK2 and knocking down STAT3 both suppressed STAT3 activation and reduced the expression of VEGF and bFGF in A549 and NCI-H292 cells, demonstrating that STAT3 activation was associated with VEGF and bFGF expression in the two human lung carcinoma cell lines.  Therefore, STAT3 may be a critical molecular target for powerful intervention in NSCLC anti-angiogenesis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3dJ8SunQ2kZQHPYJuLg8TfW6udTcc2eaj_jSQBKk87bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mjit1arsA%253D%253D&md5=ca62ebc5ba2937ff72eb7980e3e284fa</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2011.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2011.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DF.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DH.%2BH.%26aulast%3DZhang%26aufirst%3DW.%2BY.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DJAK2%252FSTAT3%2520signalling%2520pathway%2520activation%2520mediates%2520tumor%2520angiogenesis%2520by%2520upregulation%2520of%2520VEGF%2520and%2520bFGF%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2011%26volume%3D73%26issue%3D3%26spage%3D366%26epage%3D374%26doi%3D10.1016%2Fj.lungcan.2011.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony Servat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servat, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergnenegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reguart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixido, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperduti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verlicchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Aguirre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queralt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Bellacasa, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viteri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant nsclc</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">djx014</span>, <span class="refDoi"> DOI: 10.1093/jnci/djx014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fjnci%2Fdjx014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=djx014&issue=9&author=I.+Chaibauthor=N.+Karachaliouauthor=S.+Pilottoauthor=J.+Codony+Servatauthor=X.+Caiauthor=X.+Liauthor=A.+Drozdowskyjauthor=C.+C.+Servatauthor=J.+Yangauthor=C.+Huauthor=A.+F.+Cardonaauthor=G.+L.+Vivancoauthor=A.+Vergnenegreauthor=J.+M.+Sanchezauthor=M.+Provencioauthor=F.+de+Marinisauthor=A.+Passaroauthor=E.+Carcerenyauthor=N.+Reguartauthor=C.+G.+Campeloauthor=C.+Teixidoauthor=I.+Sperdutiauthor=S.+Rodriguezauthor=C.+Lazzariauthor=A.+Verlicchiauthor=I.+de+Aguirreauthor=C.+Queraltauthor=J.+Weiauthor=R.+Estradaauthor=R.+P.+de+la+Bellacasaauthor=J.+L.+Ramirezauthor=K.+Jacobsenauthor=H.+J.+Ditzelauthor=M.+Santarpiaauthor=S.+Viteriauthor=M.+A.+Molinaauthor=C.+Zhouauthor=P.+Caoauthor=P.+C.+Maauthor=T.+G.+Bivonaauthor=R.+Rosell&title=Co-activation+of+STAT3+and+YES-associated+protein+1+%28YAP1%29+pathway+in+EGFR-mutant+nsclc&doi=10.1093%2Fjnci%2Fdjx014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjx014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjx014%26sid%3Dliteratum%253Aachs%26aulast%3DChaib%26aufirst%3DI.%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DPilotto%26aufirst%3DS.%26aulast%3DCodony%2BServat%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DServat%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DCardona%26aufirst%3DA.%2BF.%26aulast%3DVivanco%26aufirst%3DG.%2BL.%26aulast%3DVergnenegre%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DPassaro%26aufirst%3DA.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DCampelo%26aufirst%3DC.%2BG.%26aulast%3DTeixido%26aufirst%3DC.%26aulast%3DSperduti%26aufirst%3DI.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DLazzari%26aufirst%3DC.%26aulast%3DVerlicchi%26aufirst%3DA.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DEstrada%26aufirst%3DR.%26aulast%3Dde%2Bla%2BBellacasa%26aufirst%3DR.%2BP.%26aulast%3DRamirez%26aufirst%3DJ.%2BL.%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DDitzel%26aufirst%3DH.%2BJ.%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DViteri%26aufirst%3DS.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DCo-activation%2520of%2520STAT3%2520and%2520YES-associated%2520protein%25201%2520%2528YAP1%2529%2520pathway%2520in%2520EGFR-mutant%2520nsclc%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2017%26volume%3D109%26issue%3D9%26spage%3Ddjx014%26doi%3D10.1093%2Fjnci%2Fdjx014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Re, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortesi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petreni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2017.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29290257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzmtlykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=21-27&author=R.+Minariauthor=P.+Bordiauthor=M.+Del+Reauthor=F.+Facchinettiauthor=F.+Mazzoniauthor=F.+Barbieriauthor=A.+Cameriniauthor=C.+E.+Cominauthor=L.+Gnettiauthor=C.+Azzoniauthor=R.+Nizzoliauthor=B.+Bortesiauthor=E.+Rofiauthor=P.+Petreniauthor=N.+Campaniniauthor=G.+Rossiauthor=R.+Danesiauthor=M.+Tiseo&title=Primary+resistance+to+osimertinib+due+to+SCLC+transformation%3A+Issue+of+T790M+determination+on+liquid+re-biopsy&doi=10.1016%2Fj.lungcan.2017.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy</span></div><div class="casAuthors">Minari R; Bordi P; Facchinetti F; Nizzoli R; Bortesi B; Del Re M; Rofi E; Danesi R; Mazzoni F; Petreni P; Barbieri F; Camerini A; Comin C E; Gnetti L; Azzoni C; Campanini N; Rossi G; Tiseo M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib.  Liquid biopsy, a non-invasive technique used to test the presence of the resistant mutation, may help avoiding tissue re-biopsy.  However, analysing only circulating-free DNA, information about other less frequent and coexisting resistance mechanisms may remain unrevealed.  MATERIALS AND METHODS:  All patients reported in this series participated in the ASTRIS trial, a real world treatment study testing the efficacy of osimertinib (80mg os die) in advanced T790M-positive NSCLC progressed to prior EGFR-TKI.  Patients were considered eligible to osimertinib if T790M positive on tissue or plasma samples.  In our patients, EGFR molecular testing on blood sample was conducted with digital droplet PCR (ddPCR).  RESULTS:  We report our experience of five patients treated with osimertinib after T790M detection on liquid biopsy that presented a disease progression at first tumor assessment mediated by SCLC transformation, as evidenced at tissue re-biopsies.  All patients showed low ratio T790M/activating mutation in the blood before osimertinib (lower than 0.03).  For three patients, EGFR mutational analysis was T790M-negative when re-assessed by using a less sensitive method (therascreen(®)) on the same liquid biopsy sample analysed by ddPCR before osimertinib therapy.  CONCLUSION:  Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790M/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl4lzVsqGJNUwlCcfExbvbfW6udTcc2eZHdrL3GJbazbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzmtlykug%253D%253D&md5=16d1b832c5363571028690a118bfb07b</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DDel%2BRe%26aufirst%3DM.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DMazzoni%26aufirst%3DF.%26aulast%3DBarbieri%26aufirst%3DF.%26aulast%3DCamerini%26aufirst%3DA.%26aulast%3DComin%26aufirst%3DC.%2BE.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DAzzoni%26aufirst%3DC.%26aulast%3DNizzoli%26aufirst%3DR.%26aulast%3DBortesi%26aufirst%3DB.%26aulast%3DRofi%26aufirst%3DE.%26aulast%3DPetreni%26aufirst%3DP.%26aulast%3DCampanini%26aufirst%3DN.%26aulast%3DRossi%26aufirst%3DG.%26aulast%3DDanesi%26aufirst%3DR.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DPrimary%2520resistance%2520to%2520osimertinib%2520due%2520to%2520SCLC%2520transformation%253A%2520Issue%2520of%2520T790M%2520determination%2520on%2520liquid%2520re-biopsy%26jtitle%3DLung%2520Cancer.%26date%3D2018%26volume%3D115%26spage%3D21%26epage%3D27%26doi%3D10.1016%2Fj.lungcan.2017.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ham, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byeon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e4</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2015.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26762749" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e1-e4&issue=1&author=J.+S.+Hamauthor=S.+Kimauthor=H.+K.+Kimauthor=S.+Byeonauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.+L.+Choiauthor=J.+Hanauthor=W.+Parkauthor=M.+J.+Ahn&title=Two+cases+of+small+cell+lung+cancer+transformation+from+EGFR+mutant+adenocarcinoma+during+AZD9291+treatment&doi=10.1016%2Fj.jtho.2015.09.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DHam%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BK.%26aulast%3DByeon%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DTwo%2520cases%2520of%2520small%2520cell%2520lung%2520cancer%2520transformation%2520from%2520EGFR%2520mutant%2520adenocarcinoma%2520during%2520AZD9291%2520treatment%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D1%26spage%3De1%26epage%3De4%26doi%3D10.1016%2Fj.jtho.2015.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span> <span> </span><span class="NLM_article-title">Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">18609</span>– <span class="NLM_lpage">18614</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.14506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28061471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1c7jtFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=18609-18614&issue=11&author=L.+Liauthor=H.+Wangauthor=C.+Liauthor=Z.+Wangauthor=P.+Zhangauthor=X.+Yan&title=Transformation+to+small-cell+carcinoma+as+an+acquired+resistance+mechanism+to+AZD9291%3A+A+case+report&doi=10.18632%2Foncotarget.14506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report</span></div><div class="casAuthors">Li Lin; Wang Hui; Li Chao; Zhang Ping; Yan Xu; Wang Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">18609-18614</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs.  Acquisition of resistance to AZD9291 occurs inevitable and mechanisms need to be explored.  We reported an advanced lung adenocarcinoma female with EGFR exon19 deletion treated on AZD9291 after failure of erlotinib and chemotherapy.  Disease progressed again after 6 months' treatment of AZD9291 with hepatic metastasis.  Re-biopsy of the hepatic lesion showed histopathology transformation to small cell lung cancer, which harbored EGFR exon19 deletion.  Therefore, small cell carcinoma transformation is one of potential resistance mechanisms to AZD9291 and regimen for small cell carcinoma may be one of the treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxkGrvC1iaU_3jf77P2BG3fW6udTcc2eZHdrL3GJbazbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7jtFCrsg%253D%253D&md5=c10092a460fe0b93df3533431023cd69</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14506%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DX.%26atitle%3DTransformation%2520to%2520small-cell%2520carcinoma%2520as%2520an%2520acquired%2520resistance%2520mechanism%2520to%2520AZD9291%253A%2520A%2520case%2520report%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D11%26spage%3D18609%26epage%3D18614%26doi%3D10.18632%2Foncotarget.14506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turke, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergethon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosper, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhavanfard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wain, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernovsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanuti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">75</span>),  <span class="NLM_fpage">75ra26</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3002003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=21430269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&issue=75&author=L.+V.+Sequistauthor=B.+A.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotypic+and+histological+evolution+of+lung+cancers+acquiring+resistance+to+EGFR+inhibitors&doi=10.1126%2Fscitranslmed.3002003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DB.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotypic%2520and%2520histological%2520evolution%2520of%2520lung%2520cancers%2520acquiring%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26issue%3D75%26spage%3D75ra26%26doi%3D10.1126%2Fscitranslmed.3002003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R. Y.</span></span> <span> </span><span class="NLM_article-title">AXL-driven EMT state as a targetable conduit in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3725</span>– <span class="NLM_lpage">3732</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F0008-5472.CAN-17-0392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28667075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=3725-3732&issue=14&author=J.+Antonyauthor=R.+Y.+Huang&title=AXL-driven+EMT+state+as+a+targetable+conduit+in+cancer&doi=10.1158%2F0008-5472.CAN-17-0392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">AXL-Driven EMT State as a Targetable Conduit in Cancer</span></div><div class="casAuthors">Antony, Jane; Huang, Ruby Yun-Ju</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3725-3732</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase (RTK) AXL has been intrinsically linked to epithelial-mesenchymal transition (EMT) and promoting cell survival, anoikis resistance, invasion, and metastasis in several cancers.  AXL signaling has been shown to directly affect the mesenchymal state and confer it with aggressive phenotype and drug resistance.  Recently, the EMT gradient has also been shown to rewire the kinase signaling nodes that facilitate AXL-RTK cross-talk, protracted signaling, converging on ERK, and PI3K axes.  The mol. mechanisms underplaying the regulation between the kinome and EMT require further elucidation to define targetable conduits.  Therapeutically, as AXL inhibition has shown EMT reversal and resensitization to other tyrosine kinase inhibitors, mitotic inhibitors, and platinum-based therapy, there is a need to stratify patients based on AXL dependence.  This review elucidates the role of AXL in EMT-mediated oncogenesis and highlights the reciprocal control between AXL signaling and the EMT state.  In addn., we review the potential in inhibiting AXL for the development of different therapeutic strategies and inhibitors.  Cancer Res; 77(14); 3725-32. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOR2GnIrmIbVg90H21EOLACvtfcHk0linkPbIvqwJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurnM&md5=5d0b3f4baf6a9370f48f76b25bf56cb2</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0392%26sid%3Dliteratum%253Aachs%26aulast%3DAntony%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DR.%2BY.%26atitle%3DAXL-driven%2520EMT%2520state%2520as%2520a%2520targetable%2520conduit%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D14%26spage%3D3725%26epage%3D3732%26doi%3D10.1158%2F0008-5472.CAN-17-0392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamoud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderLaan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borger, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6377</span>, <span class="refDoi"> DOI: 10.1038/ncomms7377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms7377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25758528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlKhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6377&author=M.+J.+Niederstauthor=L.+V.+Sequistauthor=J.+T.+Poirierauthor=C.+H.+Mermelauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=R.+Katayamaauthor=C.+Costaauthor=K.+N.+Rossauthor=T.+Moranauthor=E.+Howeauthor=L.+E.+Fultonauthor=H.+E.+Mulveyauthor=L.+A.+Bernardoauthor=F.+Mohamoudauthor=N.+Miyoshiauthor=P.+A.+VanderLaanauthor=D.+B.+Costaauthor=P.+A.+Janneauthor=D.+R.+Borgerauthor=S.+Ramaswamyauthor=T.+Shiodaauthor=A.+J.+Iafrateauthor=G.+Getzauthor=C.+M.+Rudinauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=RB+loss+in+resistant+EGFR+mutant+lung+adenocarcinomas+that+transform+to+small-cell+lung+cancer&doi=10.1038%2Fncomms7377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer</span></div><div class="casAuthors">Niederst, Matthew J.; Sequist, Lecia V.; Poirier, John T.; Mermel, Craig H.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Bernardo, Lindsay A.; Mohamoud, Farhiya; Miyoshi, Norikatsu; Vander Laan, Paul A.; Costa, Daniel B.; Janne, Pasi A.; Borger, Darrell R.; Ramaswamy, Sridhar; Shioda, Toshi; Iafrate, Anthony J.; Getz, Gad; Rudin, Charles M.; Mino-Kenudson, Mari; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6377</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations.  However, relapse typically occurs after an av. of 1 yr of continuous treatment.  A fundamental histol. transformation from NSCLC to small-cell lung cancer (SCLC) is obsd. in a subset of the resistant cancers, but the mol. changes assocd. with this transformation remain unknown.  Anal. of tumor samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC.  Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are obsd. in resistant SCLC transformed cancers compared with resistant NSCLCs.  Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the mol. and phenotypic characteristics of classical SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq16cOEb-_r67Vg90H21EOLACvtfcHk0linkPbIvqwJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlKhs7g%253D&md5=9ca95efef14279dd9ca24aea12f89203</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fncomms7377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7377%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DMermel%26aufirst%3DC.%2BH.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DK.%2BN.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DHowe%26aufirst%3DE.%26aulast%3DFulton%26aufirst%3DL.%2BE.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DBernardo%26aufirst%3DL.%2BA.%26aulast%3DMohamoud%26aufirst%3DF.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DVanderLaan%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DBorger%26aufirst%3DD.%2BR.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DRB%2520loss%2520in%2520resistant%2520EGFR%2520mutant%2520lung%2520adenocarcinomas%2520that%2520transform%2520to%2520small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6377%26doi%3D10.1038%2Fncomms7377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capaccione, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minerowicz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, S. R.</span></span> <span> </span><span class="NLM_article-title">Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3636</span>– <span class="NLM_lpage">3650</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.1970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25004243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgs1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3636-3650&issue=11&author=K.+M.+Capaccioneauthor=X.+Hongauthor=K.+M.+Morganauthor=W.+Liuauthor=J.+M.+Bishopauthor=L.+Liuauthor=E.+Markertauthor=M.+Deenauthor=C.+Minerowiczauthor=J.+R.+Bertinoauthor=T.+Allenauthor=S.+R.+Pine&title=Sox9+mediates+Notch1-induced+mesenchymal+features+in+lung+adenocarcinoma&doi=10.18632%2Foncotarget.1970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma</span></div><div class="casAuthors">Capaccione Kathleen M; Hong Xuehui; Morgan Katherine M; Liu Wenyu; Bishop J Michael; Liu LianXin; Markert Elke; Deen Malik; Minerowicz Christine; Bertino Joseph R; Allen Thaddeus; Pine Sharon R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3636-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sox9 has gained increasing importance both functionally and as a prognostic factor in cancer.  We demonstrate a functional role for Sox9 in inducing a mesenchymal phenotype in lung ADC.  We show that Sox9 mRNA and protein are overexpressed in lung ADC, particularly those with KRAS mutations.  Sox9 expression correlated with the Notch target gene Hes1, and numerous other Notch pathway components.  We observed that Sox9 is a potent inducer of lung cancer cell motility and invasion, and a negative regulator of E-cadherin, a key protein that is lost during epithelial-mesenchymal transition (EMT).  Moreover, we show that Notch1 signaling directly regulates Sox9 expression through a SOX9 promoter binding site, independently of the TGF-β pathway, and that Sox9 participates in Notch-1 induced cell motility, cell invasion, and loss of E-cadherin expression.  Together, the results identify a new functional role for a Notch1-Sox9 signaling axis in lung ADC that may explain the correlation of Sox9 with tumor progression, higher tumor grade, and poor lung cancer survival.  In addition to Notch and TGF-β, Sox9 also acts downstream of NF-κB, BMP, EGFR, and Wnt/β-catenin signaling.  Thus, Sox9 could potentially act as a hub to mediate cross-talk among key oncogenic pathways in lung ADC.  Targeting Sox9 expression or transcriptional activity could potentially reduce resistance to targeted therapy for lung ADC caused by pathway redundancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTBouS59dOs_xQvRxYU81tfW6udTcc2eaMt8E1kFDayLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgs1Kluw%253D%253D&md5=fe3615dfa034c98d8bce8c0ce7c08868</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1970%26sid%3Dliteratum%253Aachs%26aulast%3DCapaccione%26aufirst%3DK.%2BM.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMorgan%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBishop%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMarkert%26aufirst%3DE.%26aulast%3DDeen%26aufirst%3DM.%26aulast%3DMinerowicz%26aufirst%3DC.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26aulast%3DAllen%26aufirst%3DT.%26aulast%3DPine%26aufirst%3DS.%2BR.%26atitle%3DSox9%2520mediates%2520Notch1-induced%2520mesenchymal%2520features%2520in%2520lung%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26issue%3D11%26spage%3D3636%26epage%3D3650%26doi%3D10.18632%2Foncotarget.1970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenoglio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camiolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsted, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlederer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altorki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span> <span> </span><span class="NLM_article-title">TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">15535</span>– <span class="NLM_lpage">15540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1009472107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1073%2Fpnas.1009472107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=20713723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaqu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=15535-15540&issue=35&author=Z.+Yaoauthor=S.+Fenoglioauthor=D.+C.+Gaoauthor=M.+Camioloauthor=B.+Stilesauthor=T.+Lindstedauthor=M.+Schledererauthor=C.+Johnsauthor=N.+Altorkiauthor=V.+Mittalauthor=L.+Kennerauthor=R.+Sordella&title=TGF-beta+IL-6+axis+mediates+selective+and+adaptive+mechanisms+of+resistance+to+molecular+targeted+therapy+in+lung+cancer&doi=10.1073%2Fpnas.1009472107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer</span></div><div class="casAuthors">Yao, Zhan; Fenoglio, Silvia; Gao, Ding Cheng; Camiolo, Matthew; Stiles, Brendon; Lindsted, Trine; Schlederer, Michaela; Johns, Chris; Altorki, Nasser; Mittal, Vivek; Kenner, Lukas; Sordella, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">15535-15540, S15535/1-S15535/34</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitor erlotinib has been proven to be highly effective in the treatment of nonsmall cell lung cancer (NSCLC) harboring oncogenic EGFR mutations.  The majority of patients, however, will eventually develop resistance and succumb to the disease.  Recent studies have identified secondary mutations in the EGFR (EGFR T790M) and amplification of the N-Methyl-N'-nitro-N-nitroso-guanidine (MNNG) HOS transforming gene (MET) oncogene as two principal mechanisms of acquired resistance.  Although they can account for approx. 50% of acquired resistance cases together, in the remaining 50%, the mechanism remains unknown.  In NSCLC-derived cell lines and early-stage tumors before erlotinib treatment, we have uncovered the existence of a subpopulation of cells that are intrinsically resistant to erlotinib and display features suggestive of epithelial-to-mesenchymal transition (EMT).  We showed that activation of TGF-β-mediated signaling was sufficient to induce these phenotypes.  In particular, we detd. that an increased TGF-β-dependent IL-6 secretion unleashed previously addicted lung tumor cells from their EGFR dependency.  Because IL-6 and TGF-β are prominently produced during inflammatory response, we used a mouse model system to det. whether inflammation might impair erlotinib sensitivity.  Indeed, induction of inflammation not only stimulated IL-6 secretion but was sufficient to decrease the tumor response to erlotinib.  Our data, thus, argue that both tumor cell-autonomous mechanisms and/ or activation of the tumor microenvironment could contribute to primary and acquired erlotinib resistance, and as such, treatments based on EGFR inhibition may not be sufficient for the effective treatment of lung-cancer patients harboring mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo8t7IyuGYvLVg90H21EOLACvtfcHk0li4VH9J0UVCuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaqu7%252FN&md5=5e47ea1b43e1a9840980b556a16705dd</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1009472107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1009472107%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DFenoglio%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DD.%2BC.%26aulast%3DCamiolo%26aufirst%3DM.%26aulast%3DStiles%26aufirst%3DB.%26aulast%3DLindsted%26aufirst%3DT.%26aulast%3DSchlederer%26aufirst%3DM.%26aulast%3DJohns%26aufirst%3DC.%26aulast%3DAltorki%26aufirst%3DN.%26aulast%3DMittal%26aufirst%3DV.%26aulast%3DKenner%26aufirst%3DL.%26aulast%3DSordella%26aufirst%3DR.%26atitle%3DTGF-beta%2520IL-6%2520axis%2520mediates%2520selective%2520and%2520adaptive%2520mechanisms%2520of%2520resistance%2520to%2520molecular%2520targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D35%26spage%3D15535%26epage%3D15540%26doi%3D10.1073%2Fpnas.1009472107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotherspoon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutting, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M.</span></span> <span> </span><span class="NLM_article-title">Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2012.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2012.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23312887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ovV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2013&pages=1-4&issue=1&author=S.+Popatauthor=A.+Wotherspoonauthor=C.+M.+Nuttingauthor=D.+Gonzalezauthor=A.+G.+Nicholsonauthor=M.+O%E2%80%99Brien&title=Transformation+to+%E2%80%9Chigh+grade%E2%80%9D+neuroendocrine+carcinoma+as+an+acquired+drug+resistance+mechanism+in+EGFR-mutant+lung+adenocarcinoma&doi=10.1016%2Fj.lungcan.2012.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma</span></div><div class="casAuthors">Popat S; Wotherspoon A; Nutting C M; Gonzalez D; Nicholson A G; O'Brien M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Several different acquired resistance mechanisms of EGFR mutant lung adenocarcinoma to EGFR-tyrosine kinase inhibitor (TKI) therapy have been described, most recently transformation to small cell lung carcinoma (SCLC).  We describe the case of a 46-year-old female with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with erlotinib, and on resistance, cisplatin-pemetrexed.  Liver rebiopsy identified an afatinib-resistant combined SCLC and non-small cell carcinoma with neuroendocrine morphology, retaining the EGFR exon 19 deletion.  This case highlights acquired EGFR-TKI resistance through transformation to the high-grade neuroendocrine carcinoma spectrum and that that such transformation may not be evident at time of progression on TKI therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTloEbz9SUyvROk4JA3soTqfW6udTcc2eaMt8E1kFDayLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ovV2isQ%253D%253D&md5=9b43d545732791697fab1c82faeb2358</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2012.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2012.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DPopat%26aufirst%3DS.%26aulast%3DWotherspoon%26aufirst%3DA.%26aulast%3DNutting%26aufirst%3DC.%2BM.%26aulast%3DGonzalez%26aufirst%3DD.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%26atitle%3DTransformation%2520to%2520%25E2%2580%259Chigh%2520grade%25E2%2580%259D%2520neuroendocrine%2520carcinoma%2520as%2520an%2520acquired%2520drug%2520resistance%2520mechanism%2520in%2520EGFR-mutant%2520lung%2520adenocarcinoma%26jtitle%3DLung%2520Cancer.%26date%3D2013%26volume%3D80%26issue%3D1%26spage%3D1%26epage%3D4%26doi%3D10.1016%2Fj.lungcan.2012.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+combined+with+anti-EGFR+antibody+overcomes+osimertinib+resistance+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0lhoHHLf41mb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520combined%2520with%2520anti-EGFR%2520antibody%2520overcomes%2520osimertinib%2520resistance%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, Bevacizumab, and Brigatinib combination therapy: a case report</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5545</span>, <span class="refDoi"> DOI: 10.2147/OTT.S170358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.2147%2FOTT.S170358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30233215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOis73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=5545&author=J.+Zhaoauthor=M.+Zouauthor=J.+Lvauthor=Y.+Hanauthor=G.+Wangauthor=G.+Wang&title=Effective+treatment+of+pulmonary+adenocarcinoma+harboring+triple+EGFR+mutations+of+L858R%2C+T790M%2C+and+cis-C797S+by+osimertinib%2C+Bevacizumab%2C+and+Brigatinib+combination+therapy%3A+a+case+report&doi=10.2147%2FOTT.S170358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report</span></div><div class="casAuthors">Zhao, Jing; Zou, Ming; Lv, Jinyan; Han, Yingmin; Wang, Guangzhi; Wang, Gang</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5545-5550</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation.  However, the use of osimertinib may result in the development of further resistance, most commonly via the cis-C797S mutation.  Herein, we report a case of a lung cancer patient harboring triple EGFR mutations of L858R, T790M, and cis-C797S who was treated with a combination of osimertinib, bevacizumab, and brigatinib.  The above 3 mutations were detected by circulating tumor DNA anal. after osimertinib treatment.  Subsequently, the patient received combination therapy of osimertinib and bevacizumab; the partial relief obtained was negated by later disease progression.  The regimen was then changed to osimertinib, bevacizumab, and brigatinib combination therapy.  Partial remission was obsd., and a significant redn. in EGFR mutations was detected.  This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clin. use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and cis-C797S.  These combination therapies may provide potential novel treatment options for pulmonary adenocarcinoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgNWmyYKMaUbVg90H21EOLACvtfcHk0lhoHHLf41mb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOis73J&md5=3af68f75b4d3dad8c93989cee1d115bc</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.2147%2FOTT.S170358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S170358%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DM.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DEffective%2520treatment%2520of%2520pulmonary%2520adenocarcinoma%2520harboring%2520triple%2520EGFR%2520mutations%2520of%2520L858R%252C%2520T790M%252C%2520and%2520cis-C797S%2520by%2520osimertinib%252C%2520Bevacizumab%252C%2520and%2520Brigatinib%2520combination%2520therapy%253A%2520a%2520case%2520report%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D5545%26doi%3D10.2147%2FOTT.S170358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+Boseauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+Dobelauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtmullerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+selective+and+rigidify%3A+the+discovery+path+toward+a+next+generation+of+EGFR+tyrosine+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lg82FmWsczM-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DBose%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DDobel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520selective%2520and%2520rigidify%253A%2520the%2520discovery%2520path%2520toward%2520a%2520next%2520generation%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&issue=1&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lg82FmWsczM-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a new EGFR C797S mutant inhibitor with in vivo mono drug efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&issue=11&author=X.+Luauthor=T.+Zhangauthor=S.+J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.+H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+new+EGFR+C797S+mutant+inhibitor+with+in+vivo+mono+drug+efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0lg82FmWsczM-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520new%2520EGFR%2520C797S%2520mutant%2520inhibitor%2520with%2520in%2520vivo%2520mono%2520drug%2520efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10909</span>– <span class="NLM_lpage">10912</span>, <span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&issue=36&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0licngwsOfjjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung Cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S Mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&issue=36&author=M.+G%C3%BCntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+Cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+Mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Guenther, Marcel; Juchum, Michael; Kelter, Gerhard; Fiebig, Heiner; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-10894</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clin. relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that addnl. mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compds. show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1QH6nrxYrVg90H21EOLACvtfcHk0licngwsOfjjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK&md5=c3909faa7f781c2a3679f75bd3b6c5ac</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520Cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520Mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8429</span>– <span class="NLM_lpage">8439</span>, <span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&issue=19&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+frozen+analogue+approach+to+aminopyridinylimidazoles+leading+to+novel+and+promising+p38+MAP+kinase+inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span></div><div class="casAuthors">Selig, Roland; Goettert, Marcia; Schattel, Verena; Schollmeyer, Dieter; Albrecht, Wolfgang; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8429-8439</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study the design, synthesis, and biol. evaluation of constrained aminopyridinyl- and aminopyrimidinyl-imidazoles, e.g. I [X, Y = CH, N: R1 = H, Ph, PhCH2, cyclohexyl; R2 = H, 4-HO, 3,4,5-(MeO)3, etc.], as p38α MAP kinase inhibitors are reported.  The frozen analog approach focused on the pyridinyl unit, using purine bioisosteres as constrained structure analogs.  The identification of the most potent bioisostere was followed by a further derivatization to address hydrophobic region II.  These studies in combination with C-2 modifications of the imidazole core allowed to design highly active inhibitors on the p38α MAP kinase.  The inhibitor design presented herein represents a promising and highly efficient advancement of recent stages of development in this class of p38 MAP kinase inhibitors.  In combination with the highly flexible synthetic strategy, directions toward further investigations of complex C-5 modifications of diarylimidazoles are indicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0shTYFbqnE7Vg90H21EOLACvtfcHk0licngwsOfjjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO&md5=08ecb5b5ca3034b9ee3c6bc4b52f6ecf</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520frozen%2520analogue%2520approach%2520to%2520aminopyridinylimidazoles%2520leading%2520to%2520novel%2520and%2520promising%2520p38%2520MAP%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D19%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an example of target hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&issue=11&author=M.+Juchumauthor=M.+G%C3%BCntherauthor=E.+D%C3%B6ringauthor=A.+Sievers-Englerauthor=M.+L%C3%A4mmerhoferauthor=S.+Laufer&title=Trisubstituted+imidazoles+with+a+rigidized+hinge+binding+motif+act+as+single+digit+nM+inhibitors+of+clinically+relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+mutants%3A+an+example+of+target+hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0ljnf8IlUdUsww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520imidazoles%2520with%2520a%2520rigidized%2520hinge%2520binding%2520motif%2520act%2520as%2520single%2520digit%2520nM%2520inhibitors%2520of%2520clinically%2520relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520mutants%253A%2520an%2520example%2520of%2520target%2520hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10909</span>– <span class="NLM_lpage">10912</span>, <span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&issue=36&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0ljnf8IlUdUsww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&issue=13&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+pyridinylimidazoles+as+potent+inhibitors+of+the+clinically+resistant+L858R%2FT790M%2FC797S+EGFR+mutant%3A+targeting+of+both+hydrophobic+regions+and+the+phosphate+binding+site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0lj-puOY7T-sUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520pyridinylimidazoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520clinically%2520resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520mutant%253A%2520targeting%2520of%2520both%2520hydrophobic%2520regions%2520and%2520the%2520phosphate%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF receptor inhibitors that are selective for the D746–750/T790M/C797S mutant through structure-based de novo design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&issue=26&author=H.+Parkauthor=H.+Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+receptor+inhibitors+that+are+selective+for+the+D746%E2%80%93750%2FT790M%2FC797S+mutant+through+structure-based+de+novo+design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0lj-puOY7T-sUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BY.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520receptor%2520inhibitors%2520that%2520are%2520selective%2520for%2520the%2520D746%25E2%2580%2593750%252FT790M%252FC797S%2520mutant%2520through%2520structure-based%2520de%2520novo%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D26%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFR L858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&issue=15&author=J.+Shenauthor=T.+Zhangauthor=S.+J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.+H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-based+design+of+5-methylpyrimidopyridone+derivatives+as+new+wild-type+sparing+inhibitors+of+the+epidermal+growth+factor+receptor+triple+mutant+%28EGFR+L858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0lj-puOY7T-sUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-based%2520design%2520of%25205-methylpyrimidopyridone%2520derivatives%2520as%2520new%2520wild-type%2520sparing%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520triple%2520mutant%2520%2528EGFR%2520L858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span> <span> </span><span class="NLM_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28033579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=1107-1117&author=L.+Yuauthor=M.+Huangauthor=T.+Xuauthor=L.+Tongauthor=X.+E.+Yanauthor=Z.+Zhangauthor=Y.+Xuauthor=C.+Yunauthor=H.+Xieauthor=K.+Dingauthor=X.+Lu&title=A+structure-guided+optimization+of+pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+selective+inhibitors+of+EGFR+L858R%2FT790M+mutant+with+improved+pharmacokinetic+properties&doi=10.1016%2Fj.ejmech.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties</span></div><div class="casAuthors">Yu, Lei; Huang, Minhao; Xu, Tianfeng; Tong, Linjiang; Yan, Xiao-e; Zhang, Zhang; Xu, Yong; Yun, Caihong; Xie, Hua; Ding, Ke; Lu, Xiaoyun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1107-1117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790M inhibitors with improved pharmacokinetic properties.  One of the most promising compd. 9s (N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide) potently suppressed EGFRL858R/T790M kinase and inhibited the proliferation of H1975 cells with IC50 values of 2.0 nM and 40 nM, resp.  The compd. dose-dependently induced redn. of the phosphorylation of EGFR and downstream activation of ERK in NCI-H1975 cells.  It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%.  Compd. 9s may serve as a promising lead compd. for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwni9j-NB9ZrVg90H21EOLACvtfcHk0liGw3UUQxETNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVansL8%253D&md5=0c4c9ab1f2e5eba185d817161c3e261b</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DX.%26atitle%3DA%2520structure-guided%2520optimization%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520selective%2520inhibitors%2520of%2520EGFR%2520L858R%252FT790M%2520mutant%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117%26doi%3D10.1016%2Fj.ejmech.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2018.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29466773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=221-237&author=H.+Zhangauthor=J.+Wangauthor=Y.+Shenauthor=H.+Y.+Wangauthor=W.+M.+Duanauthor=H.+Y.+Zhaoauthor=Y.+Y.+Heiauthor=M.+Xinauthor=Y.+X.+Caoauthor=S.+Q.+Zhang&title=Discovery+of+2%2C4%2C6-trisubstitued+pyrido%5B3%2C4-d%5Dpyrimidine+derivatives+as+new+EGFR-TKIs&doi=10.1016%2Fj.ejmech.2018.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs</span></div><div class="casAuthors">Zhang, Hao; Wang, Jin; Shen, Ying; Wang, Hui-Yan; Duan, Wei-Ming; Zhao, Hong-Yi; Hei, Yuan-Yuan; Xin, Minhang; Cao, Yong-Xiao; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">221-237</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance is the major challenge in the treatment of EGFR-driven non-small cell lung cancer (NSCLC).  In this study, a novel class of compds. contg. pyrido[3,4-d]pyrimidine scaffold was designed as new generation EGFR-TKIs to overcome this challenge.  The most promising compd. I inhibited HCC827 and H1975 cells growth with the IC50 values of 0.044μM and 0.40μM, resp.  Meanwhile, I displayed potent inhibitory activity against the EGFRL858R (IC50=1.1nM) and EGFRL858R/T790M/C797S (IC50=7.2nM).  I could suppress EGFR phosphorylation in a dose-dependent manner in HCC827 cell line and significantly induce the apoptosis of HCC827 cells.  Mol. docking indicated that the hydroxyl in I could form addnl. hydrogen bond with mutant Ser797.  These findings strongly support our assumption that 2,4,6-trisubstitued pyrido[3,4-d] pyrimidine derivs. can serve as EGFR-TKIs.  The predicted hydrogen bond interaction formed by a small mol. inhibitor with mutant Ser797 is available to design the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3S8daGHVu6bVg90H21EOLACvtfcHk0liGw3UUQxETNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D&md5=533499fed54c750cfde176522bbdfd52</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DDuan%26aufirst%3DW.%2BM.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%25202%252C4%252C6-trisubstitued%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520as%2520new%2520EGFR-TKIs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237%26doi%3D10.1016%2Fj.ejmech.2018.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2173</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmc.2018.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29576272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2173-85&issue=8&author=Y.+Y.+Heiauthor=Y.+Shenauthor=J.+Wangauthor=H.+Zhangauthor=H.+Y.+Zhaoauthor=M.+Xinauthor=Y.+X.+Caoauthor=Y.+Liauthor=S.+Q.+Zhang&title=Synthesis+and+evaluation+of+2%2C+9-disubstituted+8-phenylthio%2Fphenylsulfinyl-9H-purine+as+new+EGFR+inhibitors&doi=10.1016%2Fj.bmc.2018.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors</span></div><div class="casAuthors">Hei, Yuan-Yuan; Shen, Ying; Wang, Jin; Zhang, Hao; Zhao, Hong-Yi; Xin, Minhang; Cao, Yong-Xiao; Li, Yan; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2173-2185</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In present study, we described the synthesis and biol. evaluation of a new class of EGFR inhibitors contg. 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine scaffold.  Thirty-one compds. were synthesized.  Among them, compd. I displayed the IC50 of 29.4 nM against HCC827 cell line and 1.9 nM against EGFRL858R.  Compd. II showed moderate inhibitory activity against EGFRL858R/T790M/C797S (IC50 = 114 nM).  Western bolt assay suggested that compd. I significantly inhibited EGFR phosphorylation.  In vivo test, compd. I remarkably exhibited inhibitory effect on tumor growth at 5.0 mg/kg by oral administration in established nude mouse HCC827 xenograft model.  These results indicate that the 2,9-disubstituted 8-phenylsulfinyl/phenylsulfinyl-9H-purine derivs. can act as potent EGFR(L858R) inhibitors and effective anticancer agents.  Addnl., optimization of compd. C12 may result in discovering the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkK03__RHpv7Vg90H21EOLACvtfcHk0liGw3UUQxETNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D&md5=e3c14297dde450c1b241946f9bb823a6</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25202%252C%25209-disubstituted%25208-phenylthio%252Fphenylsulfinyl-9H-purine%2520as%2520new%2520EGFR%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2173%26epage%3D85%26doi%3D10.1016%2Fj.bmc.2018.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl) phenyl)-N 8-phenyl-9 H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10685</span>– <span class="NLM_lpage">10699</span>, <span class="refDoi"> DOI: 10.1021/jm301365e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301365e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2qtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10685-10699&issue=23&author=J.+Yangauthor=L.-J.+Wangauthor=J.-J.+Liuauthor=L.+Zhongauthor=R.-L.+Zhengauthor=Y.+Xuauthor=P.+Jiauthor=C.-H.+Zhangauthor=W.-J.+Wangauthor=X.-D.+Linauthor=L.-L.+Liauthor=Y.-Q.+Weiauthor=S.-Y.+Yang&title=Structural+optimization+and+structure-activity+relationships+of+N+2-%284-%284-methylpiperazin-1-yl%29+phenyl%29-N+8-phenyl-9+H-purine-2%2C+8-diamine+derivatives%2C+a+new+class+of+reversible+kinase+inhibitors+targeting+both+EGFR-activating+and+resistance+mutations&doi=10.1021%2Fjm301365e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization and Structure-Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations</span></div><div class="casAuthors">Yang, Jiao; Wang, Li-Jiao; Liu, Jing-Jing; Zhong, Lei; Zheng, Ren-Lin; Xu, Yong; Ji, Pan; Zhang, Chun-Hui; Wang, Wen-Jing; Lin, Xing-Dong; Li, Lin-Li; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10685-10699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describe the structural optimization of a hit compd., N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine, which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity.  Structure-activity relation studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (I) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, resp.  Compd. I was further assessed for potency and selectivity in enzymic assays and in vivo anti-NSCLC studies.  The results indicated that compd. I is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome.  In vivo, oral administration of compd. I at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKOduljgSQLVg90H21EOLACvtfcHk0lj-l-yG6kyqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2qtrbJ&md5=4e91afe2877babc658e2490fefed82aa</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301365e%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.-J.%26aulast%3DLiu%26aufirst%3DJ.-J.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DR.-L.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DW.-J.%26aulast%3DLin%26aufirst%3DX.-D.%26aulast%3DLi%26aufirst%3DL.-L.%26aulast%3DWei%26aufirst%3DY.-Q.%26aulast%3DYang%26aufirst%3DS.-Y.%26atitle%3DStructural%2520optimization%2520and%2520structure-activity%2520relationships%2520of%2520N%25202-%25284-%25284-methylpiperazin-1-yl%2529%2520phenyl%2529-N%25208-phenyl-9%2520H-purine-2%252C%25208-diamine%2520derivatives%252C%2520a%2520new%2520class%2520of%2520reversible%2520kinase%2520inhibitors%2520targeting%2520both%2520EGFR-activating%2520and%2520resistance%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699%26doi%3D10.1021%2Fjm301365e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111888</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2019.111888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31787359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12isrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111888&author=H.+Leiauthor=S.+Fanauthor=H.+Zhangauthor=Y.+J.+Liuauthor=Y.+Y.+Heiauthor=J.+J.+Zhangauthor=A.+Q.+Zhengauthor=M.+Xinauthor=S.+Q.+Zhang&title=Discovery+of+novel+9-heterocyclyl+substituted+9H-purines+as+L858R%2FT790M%2FC797S+mutant+EGFR+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2019.111888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Lei, Hao; Fan, Shu; Zhang, Hao; Liu, Yan-Jie; Hei, Yuan-Yuan; Zhang, Jun-Jie; Zheng, A-Qun; Xin, Minhang; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111888</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.  In this study, a series of novel 9-heterocyclyl substituted 9H-purine derivs. were designed as EGFRL858 R/T790 M/C797S tyrosine kinase inhibitors.  Among these compds., D4, D9, D11 and D12 showed significantly potent anti-proliferation and EGFRL858 R/T790 M/C797S inhibition activity.  In particular, the most potent compd. D9 showed anti-proliferation against HCC827 and H1975 cell lines with the IC50 values of 0.00088 and 0.20 μM, resp.  And D9 inhibited the EGFRL858R/T790M/C797S with an IC50 value of 18 nM.  Furtherly, D9 could significantly suppress the EGFR phosphorylation, induce the apoptosis, arrest cell cycle at G0/G1, and inhibit colony formation in HCC827 cell line by a concn.-dependent manner.  Mol. docking indicated that the introduction of a cyclopropylsulfonamide group in D9 led to the formation of addnl. two hydrogen bonds with mutant Ser797 which played key roles in generating efficient EGFRL858 R/T790 M/C797S inhibitory activity.  These findings strongly indicated that 9-heterocyclyl substituted 9H-purine derivs. were promising L858R/T790M/C797S mutant EGFR-TKIs.  The introduction of extra hydrogen bond interaction with mutant Ser797 is efficient method for the design of the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfi_DwgYnA7Vg90H21EOLACvtfcHk0lj-l-yG6kyqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12isrfP&md5=758013053347da4e2f83bd2aad46b52c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DA.%2BQ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%2520novel%25209-heterocyclyl%2520substituted%25209H-purines%2520as%2520L858R%252FT790M%252FC797S%2520mutant%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111888%26doi%3D10.1016%2Fj.ejmech.2019.111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klövekorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niggenaber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaßhoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabe, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">10789</span>– <span class="NLM_lpage">10801</span>, <span class="refDoi"> DOI: 10.1039/C9SC03445E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1039%2FC9SC03445E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31857889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=10789-10801&issue=46&author=J.+Lategahnauthor=M.+Keulauthor=P.+Kl%C3%B6vekornauthor=H.+L.+Tumbrinkauthor=J.+Niggenaberauthor=M.+P.+M%C3%BCllerauthor=L.+Hodsonauthor=M.+Fla%C3%9Fhoffauthor=J.+Hardickauthor=T.+Grabe&title=Inhibition+of+osimertinib-resistant+epidermal+growth+factor+receptor+EGFR-T790M%2FC797S&doi=10.1039%2FC9SC03445E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Kloevekorn, Philip; Tumbrink, Hannah L.; Niggenaber, Janina; Mueller, Matthias P.; Hodson, Luke; Flasshoff, Maren; Hardick, Julia; Grabe, Tobias; Engel, Julian; Schultz-Fademrecht, Carsten; Baumann, Matthias; Ketzer, Julia; Muehlenberg, Thomas; Hiller, Wolf; Guenther, Georgia; Unger, Anke; Mueller, Heiko; Heimsoeth, Alena; Golz, Christopher; Blank-Landeshammer, Bernhard; Kollipara, Laxmikanth; Zahedi, Rene P.; Strohmann, Carsten; Hengstler, Jan G.; van Otterlo, Willem A. L.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">10789-10801</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC).  Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy.  However, recurrent acquired drug resistance limits the success of targeted drugs in long-term treatment and requires the const. development of novel efficient inhibitors of drug resistant cancer subtypes.  Herein, we present covalent inhibitors of the drug resistant gatekeeper mutant EGFR-L858R/T790M based on the pyrrolopyrimidine scaffold.  Biochem. and cellular characterization, as well as kinase selectivity profiling and western blot anal., substantiate our approach.  Moreover, the developed compds. possess high activity against multi drug resistant EGFR-L858R/T790M/C797S in biochem. assays due to their highly reversible binding character, that was revealed by characterization of the binding kinetics.  In addn., we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR which provide detailed insight into their binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOILrK_TpebVg90H21EOLACvtfcHk0lj-l-yG6kyqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N&md5=0dd60e9ade21e33ae5656d50175e39ba</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1039%2FC9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC03445E%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKl%25C3%25B6vekorn%26aufirst%3DP.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DNiggenaber%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DHodson%26aufirst%3DL.%26aulast%3DFla%25C3%259Fhoff%26aufirst%3DM.%26aulast%3DHardick%26aufirst%3DJ.%26aulast%3DGrabe%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520osimertinib-resistant%2520epidermal%2520growth%2520factor%2520receptor%2520EGFR-T790M%252FC797S%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10789%26epage%3D10801%26doi%3D10.1039%2FC9SC03445E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span> <span> </span><span class="NLM_article-title">2-Oxo-3, 4-dihydropyrimido [4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant</span>. <i>Chin. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1016/j.cclet.2019.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cclet.2019.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=1281-1287&issue=5&author=X.+Huauthor=Q.+Xunauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Liauthor=L.+Tongauthor=M.+Laiauthor=T.+Huangauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Dingauthor=X.+Lu&title=2-Oxo-3%2C+4-dihydropyrimido+%5B4%2C+5-d%5D+pyrimidines+as+new+reversible+inhibitors+of+EGFR+C797S+%28Cys797+to+Ser797%29+mutant&doi=10.1016%2Fj.cclet.2019.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">2-Oxo-3,4-dihydropyrimido[4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant</span></div><div class="casAuthors">Hu, Xianglong; Xun, Qiuju; Zhang, Tao; Zhu, Su-Jie; Li, Qian; Tong, Linjiang; Lai, Mengzhen; Huang, Tao; Yun, Cai-Hong; Xie, Hua; Ding, Ke; Lu, Xiaoyun</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Chemical Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1281-1287</span>CODEN:
                <span class="NLM_cas:coden">CCLEE7</span>;
        ISSN:<span class="NLM_cas:issn">1001-8417</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Extensive structure-activity relationships (SARs) study of JND3229 was conducted to yield a series of new reversible 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidine privileged scaffold as EGFRC797S inhibitors.  One of the most potent compd. 6i potently suppressed EGFRL858R/T790M/C797S kinase with an IC50 value of 3.1 nmol/L, and inhibited the proliferation of BaF3 cells harboring EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S mutants with IC50 values of 290 nmol/L and 316 nmol/L, resp.  Further, 6i dose-dependently induced suppression of the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in BaF3 cells.  Compd. 6i may serve as a promising lead compd. for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRZmOirSaUOrVg90H21EOLACvtfcHk0lgkLPHNxhtFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKku7bK&md5=829969bb42ba7929888961396c3d5d4c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.cclet.2019.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cclet.2019.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DX.%26atitle%3D2-Oxo-3%252C%25204-dihydropyrimido%2520%255B4%252C%25205-d%255D%2520pyrimidines%2520as%2520new%2520reversible%2520inhibitors%2520of%2520EGFR%2520C797S%2520%2528Cys797%2520to%2520Ser797%2529%2520mutant%26jtitle%3DChin.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D31%26issue%3D5%26spage%3D1281%26epage%3D1287%26doi%3D10.1016%2Fj.cclet.2019.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toenjes, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piedrafita, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span> <span> </span><span class="NLM_article-title">Leveraging atropisomerism to obtain a selective inhibitor of RET kinase with secondary activities toward EGFR mutants</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1930</span>– <span class="NLM_lpage">1939</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2ntLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1930-1939&issue=9&author=S.+T.+Toenjesauthor=V.+Garciaauthor=S.+M.+Maddoxauthor=G.+A.+Dawsonauthor=M.+A.+Ortizauthor=F.+J.+Piedrafitaauthor=J.+L.+Gustafson&title=Leveraging+atropisomerism+to+obtain+a+selective+inhibitor+of+RET+kinase+with+secondary+activities+toward+EGFR+mutants&doi=10.1021%2Facschembio.9b00407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants</span></div><div class="casAuthors">Toenjes, Sean T.; Garcia, Valeria; Maddox, Sean M.; Dawson, Gregory A.; Ortiz, Maria A.; Piedrafita, F. Javier; Gustafson, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1930-1939</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Unstable atropisomerism is innate in many common scaffolds in drug discovery, commonly existing as freely rotating aryl-aryl bonds.  Such compds. can access the majority of dihedral conformations around the bond axis, however most small-mols. bind their target within a narrow range of these available conformations.  The remaining accessible conformations can interact with other proteins leading to compd. promiscuity.  Herein, the authors leverage atropisomerism to restrict the accessible low energy dihedral conformations available to a promiscuous kinase inhibitor and achieve highly selective and potent inhibitors of the oncogenic target RET kinase.  The authors then evaluate the lead inhibitor against kinases that were predicted to bind compds. in a similar conformational window to RET, discovering a potent inhibitor of drug resistant EGFR mutants including L858R/T790M/C797S EGFR.  Leveraging atropisomerism to restrict accessible conformational space should be a generally applicable strategy due to the prevalence of unstable atropisomerism in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryWhdro_5d97Vg90H21EOLACvtfcHk0lgkLPHNxhtFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2ntLvO&md5=93897c4c19509082f7941a2745aee5d5</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00407%26sid%3Dliteratum%253Aachs%26aulast%3DToenjes%26aufirst%3DS.%2BT.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DMaddox%26aufirst%3DS.%2BM.%26aulast%3DDawson%26aufirst%3DG.%2BA.%26aulast%3DOrtiz%26aufirst%3DM.%2BA.%26aulast%3DPiedrafita%26aufirst%3DF.%2BJ.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DLeveraging%2520atropisomerism%2520to%2520obtain%2520a%2520selective%2520inhibitor%2520of%2520RET%2520kinase%2520with%2520secondary%2520activities%2520toward%2520EGFR%2520mutants%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D1930%26epage%3D1939%26doi%3D10.1021%2Facschembio.9b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wumaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">127327</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmcl.2020.127327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32631532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wmu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127327&issue=16&author=Z.+Suauthor=T.+Yangauthor=J.+Wangauthor=M.+Laiauthor=L.+Tongauthor=G.+Wumaierauthor=Z.+Chenauthor=S.+Liauthor=H.+Liauthor=H.+Xieauthor=Z.+Zhao&title=Design%2C+synthesis+and+biological+evaluation+of+potent+EGFR+kinase+inhibitors+against+19D%2FT790M%2FC797S+mutation&doi=10.1016%2Fj.bmcl.2020.127327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation</span></div><div class="casAuthors">Su, Zhicheng; Yang, Tingyuan; Wang, Jie; Lai, Mengzhen; Tong, Linjiang; Wumaier, Gulinuer; Chen, Zhuo; Li, Shengqing; Li, Honglin; Xie, Hua; Zhao, Zhenjiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">127327</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The efficacy of EGFR inhibitors is frequently affected by acquired resistance.  EGFR19D/T790M/C797S mutation is one of the primary reasons for the emergence of resistance after treatment with the third-generation EGFR inhibitors such as AZD9291, CO1686 and Olmutinib.  To overcome the resistance mutation 19D/T790M/C797S, we designed and prepd. a series of indole derivs. with the terminal hydroxyl of alkyl chain to increase extra interaction with the Asp855 in the conservative DFG site.  Activity evaluation, structure-activity relationship and docking anal. were also carried out.  Among them, compd. 12e displayed significant inhibitory activity against EGFR19D/T790M/C797S (IC50 = 15.3 nM) and good selectivity over EGFR WT (IC50 > 1000 nM), L858R/T790M (IC50, 156.6 nM) and L858R/T790M/C797S (IC50, 218.3 nM) resp.  Furthermore, 12e exhibited good growth inhibition activity, induced G1 phase cell cycle arrest and apoptosis in BaF3/EGFR19D/T790M/C797S cells by suppressing EGFR phosphorylation signaling pathway.  In all, our study might provide a novel structural design method and lay the solid foundation for the development of the 4th generation EGFR19D/T790M/C797S inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLugcH0mHed7Vg90H21EOLACvtfcHk0lgkLPHNxhtFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wmu73J&md5=54681eeb47ce2c2b2e227677d7e1d40e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127327%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DWumaier%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520potent%2520EGFR%2520kinase%2520inhibitors%2520against%252019D%252FT790M%252FC797S%2520mutation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127327%26doi%3D10.1016%2Fj.bmcl.2020.127327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of the quinazoline derivatives as L858R/T790M/C797S triple mutant epidermal growth factor receptor tyrosine kinase inhibitors</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1248/cpb.c20-00411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1248%2Fcpb.c20-00411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32999149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3MXkvVChsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2020&pages=971-980&issue=10&author=M.+Zhangauthor=Y.+Wangauthor=J.+Wangauthor=Z.+Liuauthor=J.+Shiauthor=M.+Liauthor=Y.+Zhuauthor=S.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+the+quinazoline+derivatives+as+L858R%2FT790M%2FC797S+triple+mutant+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors&doi=10.1248%2Fcpb.c20-00411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of the quinazoline derivatives as L858R/T790M/C797S triple mutant epidermal growth factor receptor tyrosine kinase inhibitors</span></div><div class="casAuthors">Zhang, Mingguang; Wang, Yunyun; Wang, Jia; Liu, Zhaogang; Shi, Jingmiao; Li, Mingxin; Zhu, Yongqiang; Wang, Shifa</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-980</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of 2-aryl-4-amino substituted quinazoline derivs. I [R1 = NC, Br; R2 = ethylamino, piperazin-1-yl, (pyrimidin-2-ylmethyl)amino, etc.; R3 = H, MeO] were designed and synthesized with the purpose to overcome L858R/T790M/C797S (CTL) triple mutant drug resistance and the biol. activity for inhibition of CTL kinases and EGFR wild type (WT) were evaluated.  Three compds. I [R1 = Br, R2 = (pyrimidin-2-ylmethyl)amino, (pyrazin-2-ylmethyl)amino, R3 = H; R1 = NC, R2 = (pyrimidin-2-ylmethyl)amino, R3 = H] showed excellent inhibitory activities against EGFR kinases triple mutant CTL (IC50 < 1μM) and high selectivity (IC50: WT/CTL >10000).  Cell line evaluation showed that the most potent compd. I [R1 = NC, R2 = (pyrimidin-2-ylmethyl)amino, R3 = H] was significantly potent against H1975-EGFR L858R/T790M (IC50 = 3.3μM) and H1975-EGFR L858R/T790M/C797S (IC50 = 1.2μM).  Compd. I [R1 = NC, R2 = (pyrimidin-2-ylmethyl)amino, R3 = H] exhibited good microsomes stabilities in human, rat and mouse liver species, but with low bioavailability.  This work is very useful for discovering new quinazoline derivs. as tyrosine kinase inhibitors targeting triple mutant L858R/T790M/C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_QgIlxb3eCrVg90H21EOLACvtfcHk0lg-uaT6OhG1lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXkvVChsrw%253D&md5=a515d96f34de922966e8d4ad55d74bc8</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c20-00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c20-00411%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520the%2520quinazoline%2520derivatives%2520as%2520L858R%252FT790M%252FC797S%2520triple%2520mutant%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2020%26volume%3D68%26issue%3D10%26spage%3D971%26epage%3D980%26doi%3D10.1248%2Fcpb.c20-00411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span>; <span class="NLM_string-name">Shin, I.</span>; <span class="NLM_string-name">Choi, G.</span>; <span class="NLM_string-name">Chae, C H.</span>; <span class="NLM_string-name">Choe, H. J.</span>; <span class="NLM_string-name">Jung, M. E.</span>; <span class="NLM_string-name">Jeon, B. U.</span>; <span class="NLM_string-name">Cho, B. C.</span>; <span class="NLM_string-name">Park, C. W.</span>; <span class="NLM_string-name">Kim, H.</span>; <span class="NLM_string-name">Duggirala, K. B.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>2, <i>N</i>4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer</span>. <span class="NLM_patent">CN 110740999 A</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=K.+Lee&author=I.+Shin&author=G.+Choi&author=C+H.+Chae&author=H.+J.+Choe&author=M.+E.+Jung&author=B.+U.+Jeon&author=B.+C.+Cho&author=C.+W.+Park&author=H.+Kim&author=K.+B.+Duggirala&title=N2%2C+N4-diphenylpyrimidine-2%2C4-diamine+derivative%2C+method+for+preparing+same%2C+and+pharmaceutical+composition+containing+same+as+active+ingredient+for+prevention+or+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%26atitle%3DN2%252C%2520N4-diphenylpyrimidine-2%252C4-diamine%2520derivative%252C%2520method%2520for%2520preparing%2520same%252C%2520and%2520pharmaceutical%2520composition%2520containing%2520same%2520as%2520active%2520ingredient%2520for%2520prevention%2520or%2520treatment%2520of%2520cancer%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Liu, X.</span>; <span class="NLM_string-name">Ding, C. Z.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Zhao, L.</span>; <span class="NLM_string-name">Pan, W.</span>; <span class="NLM_string-name">Hu, G.</span>; <span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Spiro-aryl-phosphorus-oxygen compound as fourth generation of EGFR kinase inhibitor</span>. <span class="NLM_patent">WO 2018108064 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Wu&author=X.+Liu&author=C.+Z.+Ding&author=S.+Chen&author=L.+Hu&author=L.+Zhao&author=W.+Pan&author=G.+Hu&author=J.+Li&title=Spiro-aryl-phosphorus-oxygen+compound+as+fourth+generation+of+EGFR+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DSpiro-aryl-phosphorus-oxygen%2520compound%2520as%2520fourth%2520generation%2520of%2520EGFR%2520kinase%2520inhibitor%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwao, M.</span>; <span class="NLM_string-name">Fukuda, T.</span>; <span class="NLM_string-name">Ishibashi, F.</span>; <span class="NLM_string-name">Uehara, Y.</span>; <span class="NLM_string-name">Nishitani, N.</span>; <span class="NLM_string-name">Oku, Y.</span>; <span class="NLM_string-name">Dan, S.</span>; <span class="NLM_string-name">Yamori, T.</span></span> <span> </span><span class="NLM_article-title">Fourth-generation EGFR tyrosine kinase inhibitor</span>. <span class="NLM_patent">CN 110461850 A</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Iwao&author=T.+Fukuda&author=F.+Ishibashi&author=Y.+Uehara&author=N.+Nishitani&author=Y.+Oku&author=S.+Dan&author=T.+Yamori&title=Fourth-generation+EGFR+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIwao%26aufirst%3DM.%26atitle%3DFourth-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Wei, H.</span>; <span class="NLM_string-name">Wei, W.</span>; <span class="NLM_string-name">Yanqing, Y.</span>; <span class="NLM_string-name">Hui, Z.</span></span> <span> </span><span class="NLM_article-title">Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof</span>. <span class="NLM_patent">CN 110790749 A</span>, 2020.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Li%2C+Z.%3B+Wei%2C+H.%3B+Wei%2C+W.%3B+Yanqing%2C+Y.%3B+Hui%2C+Z.+Nitrogen-containing+heterocyclic+compound%2C+pharmaceutical+composition+and+application+thereof.+CN+110790749+A%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DNitrogen-containing%2520heterocyclic%2520compound%252C%2520pharmaceutical%2520composition%2520and%2520application%2520thereof" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boese, D.</span>; <span class="NLM_string-name">Dahmann, G.</span>; <span class="NLM_string-name">Engelhardt, H.</span>; <span class="NLM_string-name">Petronczki, M.</span>; <span class="NLM_string-name">Scharn, D.</span></span> <span> </span><span class="NLM_article-title">New benzimidazole compounds and derivatives as EGFR inhibitors</span>. <span class="NLM_patent">WO 2019162323 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Boese&author=G.+Dahmann&author=H.+Engelhardt&author=M.+Petronczki&author=D.+Scharn&title=New+benzimidazole+compounds+and+derivatives+as+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoese%26aufirst%3DD.%26atitle%3DNew%2520benzimidazole%2520compounds%2520and%2520derivatives%2520as%2520EGFR%2520inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Liu, X.</span>; <span class="NLM_string-name">Ding, C. Z.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Zhao, L.</span>; <span class="NLM_string-name">Pan, W.</span>; <span class="NLM_string-name">Hu, G.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Zhao, N.</span>; <span class="NLM_string-name">Zhao, J.</span></span> <span> </span><span class="NLM_article-title">Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor</span>. <span class="NLM_patent">WO 2019015655 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=L.+Wu&author=X.+Liu&author=C.+Z.+Ding&author=S.+Chen&author=L.+Hu&author=L.+Zhao&author=W.+Pan&author=G.+Hu&author=J.+Li&author=N.+Zhao&author=J.+Zhao&title=Aryl-phosphorus-oxygen+compound+as+EGFR+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DAryl-phosphorus-oxygen%2520compound%2520as%2520EGFR%2520kinase%2520inhibitor%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span>; <span class="NLM_string-name">Ding, J.</span>; <span class="NLM_string-name">Shen, J.</span>; <span class="NLM_string-name">Geng, M.</span>; <span class="NLM_string-name">Lu, X.</span>; <span class="NLM_string-name">Xie, H.</span>; <span class="NLM_string-name">Sun, M.</span>; <span class="NLM_string-name">Zong, Z.</span></span> <span> </span><span class="NLM_article-title">Pyrimidopyridone or pyridopyridone compound and use thereof</span>. <span class="NLM_patent">WO 2019015593 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.+Ding&author=J.+Ding&author=J.+Shen&author=M.+Geng&author=X.+Lu&author=H.+Xie&author=M.+Sun&author=Z.+Zong&title=Pyrimidopyridone+or+pyridopyridone+compound+and+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimidopyridone%2520or%2520pyridopyridone%2520compound%2520and%2520use%2520thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han-Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28662863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1723-1727&issue=11&author=Z.+Wangauthor=J.+J.+Yangauthor=J.+Huangauthor=J.+Y.+Yeauthor=X.+C.+Zhangauthor=H.+Y.+Tuauthor=H.+Han-Zhangauthor=Y.+L.+Wu&title=Lung+adenocarcinoma+harboring+EGFR+T790M+and+in+trans+C797S+responds+to+combination+therapy+of+first+and+third+generation+EGFR-TKIs+and+shifts+allelic+configuration+at+resistance&doi=10.1016%2Fj.jtho.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance</span></div><div class="casAuthors">Wang Zhen; Yang Jin-Ji; Huang Jie; Zhang Xu-Chao; Tu Hai-Yan; Ye Jun-Yi; Han-Zhang Han; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-1727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S.  In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors.  However, this has not been reported clinically.  METHODS:  We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy.  RESULTS:  At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M.  He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib.  After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.  CONCLUSION:  We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans.  We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKksLRAl4nGUbxh97K6Vt6fW6udTcc2eZk-Q9ZbQwoKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D&md5=4a4e858b7e9b39034fd2035da629a88c</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DHan-Zhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DLung%2520adenocarcinoma%2520harboring%2520EGFR%2520T790M%2520and%2520in%2520trans%2520C797S%2520responds%2520to%2520combination%2520therapy%2520of%2520first%2520and%2520third%2520generation%2520EGFR-TKIs%2520and%2520shifts%2520allelic%2520configuration%2520at%2520resistance%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1723%26epage%3D1727%26doi%3D10.1016%2Fj.jtho.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arulananda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musafer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span> <span> </span><span class="NLM_article-title">Combination of osimertinib and Gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1728</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28843359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhvVymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1728-1732&issue=11&author=S.+Arulanandaauthor=H.+Doauthor=A.+Musaferauthor=P.+Mitchellauthor=A.+Dobrovicauthor=T.+John&title=Combination+of+osimertinib+and+Gefitinib+in+C797S+and+T790M+EGFR-mutated+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Arulananda Surein; Do Hongdo; Dobrovic Alexander; Musafer Ashan; Mitchell Paul; John Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1728-1732</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Osimertinib, a third-generation EGFR tyrosine kinase inhibitor has demonstrated efficacy in tumors harboring the EGFR T790M resistance mutation.  Inevitably, resistance to third-generation inhibitors results in disease progression, with the EGFR C797S mutation being one of several resistance pathways identified to date.  On the basis of preclinical data, we report what is the first known case of a patient harboring the T790M and C797S mutations in trans treated with combination gefitinib and osimertinib.  METHODS:  On development of progressive disease after multiple therapies, the patient's plasma was sequenced using the Oncomine Lung cfDNA Assay (Thermo Fisher Scientific, Waltham, MA).  Subsequent monitoring of circulating tumor DNA in plasma was performed by droplet digital polymerase chain reaction.  RESULTS:  Sequencing showed that the T790M and C797S mutations were in trans.  Within 2 weeks of commencement of combination therapy, rapid clinical improvement occurred.  Accompanying this, a rapid decline in the C797S mutation subclone in plasma was detected.  However, the levels of the EGFR exon 19 deletion driver mutation and the T790M resistance mutation in the circulating tumor DNA continued to rise and the patient died from progressive disease 6 weeks after commencement of combination therapy.  There were no adverse events seen with the combination therapy.  CONCLUSION:  This is, to the best of our knowledge, the first reported case of combination EGFR tyrosine kinase inhibitor therapy tailored to the allelic conformation of T790M and C797S mutation that resulted in brief clinical improvement without toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJq-HpTS29KCjiVMCqkKxVfW6udTcc2eZk-Q9ZbQwoKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhvVymtg%253D%253D&md5=346d8b67e92b618e712c648b52a6e937</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DArulananda%26aufirst%3DS.%26aulast%3DDo%26aufirst%3DH.%26aulast%3DMusafer%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DDobrovic%26aufirst%3DA.%26aulast%3DJohn%26aufirst%3DT.%26atitle%3DCombination%2520of%2520osimertinib%2520and%2520Gefitinib%2520in%2520C797S%2520and%2520T790M%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1728%26epage%3D1732%26doi%3D10.1016%2Fj.jtho.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span> (<span class="NLM_issue">7605</span>),  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&issue=7605&author=Y.+Jiaauthor=C.-H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.-Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.-K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lgYZJXUV0U6bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26issue%3D7605%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>502</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.05.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bbrc.2018.05.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29802850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=502&publication_year=2018&pages=332-337&issue=3&author=P.+Zhaoauthor=M.+Y.+Yaoauthor=S.+J.+Zhuauthor=J.+Y.+Chenauthor=C.+H.+Yun&title=Crystal+structure+of+EGFR+T790M%2FC797S%2FV948R+in+complex+with+EAI045&doi=10.1016%2Fj.bbrc.2018.05.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045</span></div><div class="casAuthors">Zhao, Peng; Yao, Ming-Yu; Zhu, Su-Jie; Chen, Ji-Yun; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">502</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lung cancer is the leading cause of cancer deaths.  Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers.  Patients harboring most of these mutations respond well to the anti-EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib initially, but soon develop resistance to them in about half of the cases due to the emergence of the gatekeeper mutation T790M.  The third-generation TKIs such as AZD9291, HM61713, CO-1686 and WZ4002 can overcome T790M through covalent binding to the EGFR kinase through Cys 797, but ultimately lose their efficacy upon emergence of the C797S mutation that abolishes the covalent bonding.  Therefore to develop new TKIs to overcome EGFR drug-resistant mutants harboring T790M/C797S is urgently demanded.  EAI001 and EAI045 are a new type of EGFR TKIs that bind to EGFR reversibly and not relying on Cys 797.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR L858R/T790M and L858R/T790M/C797S.  Here we report the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, and compare it to EGFR T790M/V948R in complex with EAI001.  The complex structure reveals why EAI045 binds tighter to EGFR than does EAI001, and why EAI001 and EAI045 prefer binding to EGFR T790M.  The knowledge may facilitate future drug development studies targeting this very important cancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouEvBqE0oB5LVg90H21EOLACvtfcHk0lgn9U7s1gB1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I&md5=b76b6a40ffef581fa2d5ca0a45bb8c14</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.05.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.05.154%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520EGFR%2520T790M%252FC797S%252FV948R%2520in%2520complex%2520with%2520EAI045%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D502%26issue%3D3%26spage%3D332%26epage%3D337%26doi%3D10.1016%2Fj.bbrc.2018.05.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&issue=7&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Single+and+dual+targeting+of+mutant+EGFR+with+an+allosteric+inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0lgn9U7s1gB1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520dual%2520targeting%2520of%2520mutant%2520EGFR%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggirala, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibitor TREA-0236 Containing non-hydrolysable quinazoline-4-one for EGFR T790M/C797S mutant’s inhibition</span>. <i>Bull. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1002/bkcs.11491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fbkcs.11491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyktLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=895-898&issue=7&author=S.+Leeauthor=J.+Kimauthor=K.+B.+Duggiralaauthor=A.+Goauthor=I.+Shinauthor=B.+C.+Choauthor=G.+Choiauthor=C.+H.+Chaeauthor=K.+Lee&title=Allosteric+Inhibitor+TREA-0236+Containing+non-hydrolysable+quinazoline-4-one+for+EGFR+T790M%2FC797S+mutant%E2%80%99s+inhibition&doi=10.1002%2Fbkcs.11491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition</span></div><div class="casAuthors">Lee, Seoyoung; Kim, Jiwon; Duggirala, Krishna Babu; Go, Areum; Shin, Inji; Cho, Byoung Chul; Choi, Gildon; Chae, Chong Hak; Lee, Kwangho</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">895-898</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) activating mutations such as EGFR L858R and EGFR ex19 deletions are responsible for 30-40% of NSCLC patients in East Asian populations and 10-15% in European descendants.  All the approved EGFR-tyrosine kinase inhibitors (TKIs) give clin. benefits to EGFR-related NSCLC patients in terms of overall survival and quality of patient life.  Novel EGFR allosteric inhibitors, EAI001 and EAI045, have been recently reported.  In order to investigate the binding mode of the inhibitors, a mol. docking study was first examd.  Based on EAI045 structure, we designed TREA-0236 featured with a quinazoline-4-one instead of the 2-aminothiazole amide, so that the unwanted metabolite formation is structurally prohibited.  The predicted binding pose of TREA-0236 is nearly identical to the crystal structure of EAI001 which is located next to ATP binding site.  Synthetic procedure of representative mol. TREA-0236 is outlined in Scheme 1.  We have attempted to replace the undesirable aminothiazole with non-hydrolysable quinazoline-4-one on the EAI045 for improved drug properties, however only TREA-0236 shows a level of biochem. activity and it is inferior to parent EAI045.  Further the non-hydrolysable scaffold search devoid of aminothiazole is currently underway and will be reported in due course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6lIGJlduNv7Vg90H21EOLACvtfcHk0lgn9U7s1gB1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyktLbN&md5=bcd15bf0dcc1841cf9c927fed702e0af</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1002%2Fbkcs.11491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbkcs.11491%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DDuggirala%26aufirst%3DK.%2BB.%26aulast%3DGo%26aufirst%3DA.%26aulast%3DShin%26aufirst%3DI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DChoi%26aufirst%3DG.%26aulast%3DChae%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DK.%26atitle%3DAllosteric%2520Inhibitor%2520TREA-0236%2520Containing%2520non-hydrolysable%2520quinazoline-4-one%2520for%2520EGFR%2520T790M%252FC797S%2520mutant%25E2%2580%2599s%2520inhibition%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2018%26volume%3D39%26issue%3D7%26spage%3D895%26epage%3D898%26doi%3D10.1002%2Fbkcs.11491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1549-1553&issue=11&author=D.+De+Clercqauthor=D.+E.+Heppnerauthor=C.+Toauthor=J.+Jangauthor=E.+Parkauthor=C.+H.+Yunauthor=M.+Mushajiangauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=D.+A.+Scottauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Discovery+and+optimization+of+dibenzodiazepinones+as+allosteric+mutant-selective+EGFR+inhibitors&doi=10.1021%2Facsmedchemlett.9b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span></div><div class="casAuthors">De Clercq, Dries J. H.; Heppner, David E.; To, Ciric; Jang, Jaebong; Park, Eunyoung; Yun, Cai-Hong; Mushajiang, Mierzhati; Shin, Bo Hee; Gero, Thomas W.; Scott, David A.; Janne, Pasi A.; Eck, Michael J.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1549-1553</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers.  Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold.  Our structure-based medicinal chem. effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling.  Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyvHIT2KWY7Vg90H21EOLACvtfcHk0li9_MKrCCKNfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM&md5=9d8771e7444fa58f06dff284f6f393da</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00381%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520dibenzodiazepinones%2520as%2520allosteric%2520mutant-selective%2520EGFR%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1549%26epage%3D1553%26doi%3D10.1021%2Facsmedchemlett.9b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span>; <span class="NLM_string-name">Goergler, A.</span>; <span class="NLM_string-name">Jaeschke, G.</span>; <span class="NLM_string-name">Kocer, B.</span>; <span class="NLM_string-name">Kuhn, B.</span>; <span class="NLM_string-name">Lazarski, K.</span>; <span class="NLM_string-name">Liang, Y.</span>; <span class="NLM_string-name">Nagel, Y. A.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Ricci, A.</span>; <span class="NLM_string-name">Rueher, D.</span>; <span class="NLM_string-name">Steiner, S.</span></span> <span> </span><span class="NLM_article-title">Compounds</span>. <span class="NLM_patent">WO 2020002487 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Duplessis&author=A.+Goergler&author=G.+Jaeschke&author=B.+Kocer&author=B.+Kuhn&author=K.+Lazarski&author=Y.+Liang&author=Y.+A.+Nagel&author=U.+Obst+Sander&author=A.+Ricci&author=D.+Rueher&author=S.+Steiner&title=Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDuplessis%26aufirst%3DM.%26atitle%3DCompounds%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFR L858R/T790M/C797S</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00564</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00564" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=869-873&issue=6&author=Q.+Liauthor=T.+Zhangauthor=S.+Liauthor=L.+Tongauthor=J.+Liauthor=Z.+Suauthor=F.+Fengauthor=D.+Sunauthor=Y.+Tongauthor=X.+Wangauthor=Z.+Zhaoauthor=L.+Zhuauthor=J.+Dingauthor=H.+Liauthor=H.+Xieauthor=Y.+Xu&title=Discovery+of+potent+and+noncovalent+reversible+EGFR+kinase+inhibitors+of+EGFR+L858R%2FT790M%2FC797S&doi=10.1021%2Facsmedchemlett.8b00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S</span></div><div class="casAuthors">Li, Qiannan; Zhang, Tao; Li, Shiliang; Tong, Linjiang; Li, Junyu; Su, Zhicheng; Feng, Fang; Sun, Deheng; Tong, Yi; Wang, Xia; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Li, Honglin; Xie, Hua; Xu, Yufang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">869-873</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFRL858R/T790M/C797S.  One of the most promising compds., I, inhibited the enzymic activity of EGFRL858R/T790M/C797S with an IC50 value of 2.2 nM.  Cell proliferation assays showed that I effectively and selectively inhibited the growth of EGFRL858R/T790M/C797S-dependent cells.  This series of compds., which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcQ04p4560bVg90H21EOLACvtfcHk0li9_MKrCCKNfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D&md5=396eb9b29217fbb74189193a544819b3</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520noncovalent%2520reversible%2520EGFR%2520kinase%2520inhibitors%2520of%2520EGFR%2520L858R%252FT790M%252FC797S%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873%26doi%3D10.1021%2Facsmedchemlett.8b00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">LBA50 mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">viii740</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy424.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1093%2Fannonc%2Fmdy424.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=viii740&author=S.+S.+Ramalingamauthor=Y.+Chengauthor=C.+Zhouauthor=Y.+Oheauthor=F.+Imamuraauthor=B.+C.+Choauthor=M.+C.+Linauthor=M.+Majemauthor=R.+Shahauthor=Y.+Rukazenkov&title=LBA50+mechanisms+of+acquired+resistance+to+first-line+osimertinib%3A+preliminary+data+from+the+phase+III+FLAURA+study&doi=10.1093%2Fannonc%2Fmdy424.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy424.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy424.063%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLin%26aufirst%3DM.%2BC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DRukazenkov%26aufirst%3DY.%26atitle%3DLBA50%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520first-line%2520osimertinib%253A%2520preliminary%2520data%2520from%2520the%2520phase%2520III%2520FLAURA%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Dviii740%26doi%3D10.1093%2Fannonc%2Fmdy424.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. Y.</span></span> <span> </span><span class="NLM_article-title">Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent bim and Mcl-1 degradation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6567</span>– <span class="NLM_lpage">6579</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-1574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28765329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGis7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6567-6579&issue=21&author=P.+Shiauthor=Y.+T.+Ohauthor=L.+Dengauthor=G.+Zhangauthor=G.+Qianauthor=S.+Zhangauthor=H.+Renauthor=G.+Wuauthor=B.+Legendreauthor=E.+Andersonauthor=S.+S.+Ramalingamauthor=T.+K.+Owonikokoauthor=M.+Chenauthor=S.+Y.+Sun&title=Overcoming+acquired+resistance+to+AZD9291%2C+a+third-generation+EGFR+inhibitor%2C+through+modulation+of+MEK%2FERK-dependent+bim+and+Mcl-1+degradation&doi=10.1158%2F1078-0432.CCR-17-1574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation</span></div><div class="casAuthors">Shi, Puyu; Oh, You-Take; Deng, Liang; Zhang, Guojing; Qian, Guoqing; Zhang, Shuo; Ren, Hui; Wu, Grant; Legendre, Benjamin, Jr.; Anderson, Emily; Ramalingam, Suresh S.; Owonikoko, Taofeek K.; Chen, Mingwei; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6567-6579</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.  Exptl. Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291.  Protein alterations were detected with Western blotting.  Apoptosis was measured with annexin V/flow cytometry.  Growth-inhibitory effects of tested drugs were evaluated in vitro with cell no. estn. and colony formation assay and in vivo with mouse xenograft models.  Protein degrdn. was detd. by comparing protein half-lives and inhibiting proteasome.  Gene knockdown were achieved with siRNA or shRNA.  Results: AZD9291 potently induced apoptosis in EGFR-mutant NSCLC cell lines, in which ERK phosphorylation was suppressed accompanied with Bim elevation and Mcl-1 redn. likely due to enhanced Mcl-1 degrdn. and increased Bim stability.  Blocking Bim elevation by gene knockdown or enforcing Mcl-1 expression attenuated or abolished AZD9291-induced apoptosis.  Moreover, AZD9291 lost its ability to modulate Bim and Mcl-1 levels in AZD9291-resistant cell lines.  The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivo.  Conclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degrdn. critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291.  Clin Cancer Res; 23(21); 6567-79. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWh1Cdfq2IcLVg90H21EOLACvtfcHk0lgF0AsFMX7M0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGis7vJ&md5=c748c64e2654fa1ebd4c9e251570da5f</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1574%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DP.%26aulast%3DOh%26aufirst%3DY.%2BT.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLegendre%26aufirst%3DB.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.%2BY.%26atitle%3DOvercoming%2520acquired%2520resistance%2520to%2520AZD9291%252C%2520a%2520third-generation%2520EGFR%2520inhibitor%252C%2520through%2520modulation%2520of%2520MEK%252FERK-dependent%2520bim%2520and%2520Mcl-1%2520degradation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D21%26spage%3D6567%26epage%3D6579%26doi%3D10.1158%2F1078-0432.CCR-17-1574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanteti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. Y.</span></span> <span> </span><span class="NLM_article-title">Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.canlet.2016.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27450722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2016&pages=494-504&issue=2&author=P.+Shiauthor=Y.+T.+Ohauthor=G.+Zhangauthor=W.+Yaoauthor=P.+Yueauthor=Y.+Liauthor=R.+Kantetiauthor=J.+Riehmauthor=R.+Salgiaauthor=T.+K.+Owonikokoauthor=S.+S.+Ramalingamauthor=M.+Chenauthor=S.+Y.+Sun&title=Met+gene+amplification+and+protein+hyperactivation+is+a+mechanism+of+resistance+to+both+first+and+third+generation+EGFR+inhibitors+in+lung+cancer+treatment&doi=10.1016%2Fj.canlet.2016.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment</span></div><div class="casAuthors">Shi, Puyu; Oh, You-Take; Zhang, Guojing; Yao, Weilong; Yue, Ping; Li, Yikun; Kanteti, Rajani; Riehm, Jacob; Salgia, Ravi; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Chen, Mingwei; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">494-504</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs; e.g., AZD9291), which selectively and irreversibly inhibit EGFR activating and T790M mutants, represent very promising therapeutic options for patients with non-small cell lung cancer (NSCLC) that has become resistant to 1st generation EGFR-TKIs due to T790M mutation.  However, eventual resistance to the 3rd generation EGFR-TKIs has already been described in the clinic, resulting in disease progression.  Therefore, there is a great challenge and urgent need to understand how this resistance occurs and to develop effective strategies to delay or overcome the resistance.  The current study has demonstrated that Met amplification and hyperactivation is a resistance mechanism to both 1st and 3rd generation EGFR-TKIs since both erlotinib- and AZD9291-resistant HCC827 cell lines possessed amplified Met gene and hyperactivated Met, and were cross-resistant to AZD9291 or erlotinib.  Met inhibition overcame the resistance of these cell lines to AZD9291 both in vitro and in vivo, including enhancement of apoptosis or G1 cell cycle arrest.  Hence, we suggest that Met inhibition is also an effective strategy to overcome resistance of certain EGFR-mutated NSCLCs with Met amplification to AZD9291, warranting the further clin. validation of our findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Vyx3D_1ZkrVg90H21EOLACvtfcHk0lgF0AsFMX7M0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FI&md5=de68cf0cd3fa3310a71bb959990630bd</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DP.%26aulast%3DOh%26aufirst%3DY.%2BT.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DRiehm%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.%2BY.%26atitle%3DMet%2520gene%2520amplification%2520and%2520protein%2520hyperactivation%2520is%2520a%2520mechanism%2520of%2520resistance%2520to%2520both%2520first%2520and%2520third%2520generation%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%2520treatment%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D380%26issue%3D2%26spage%3D494%26epage%3D504%26doi%3D10.1016%2Fj.canlet.2016.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giroux-Leprieur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumenil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinet, T.</span></span> <span> </span><span class="NLM_article-title">Combination of crizotinib and osimertinib or erlotinib might overcome met-mediated resistance to EGFR tyrosine kinase inhibitor in EGFR-mutated adenocarcinoma</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e232</span>– <span class="NLM_lpage">e234</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30368417" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e232-e234&issue=11&author=E.+Giroux-Leprieurauthor=C.+Dumenilauthor=T.+Chinet&title=Combination+of+crizotinib+and+osimertinib+or+erlotinib+might+overcome+met-mediated+resistance+to+EGFR+tyrosine+kinase+inhibitor+in+EGFR-mutated+adenocarcinoma&doi=10.1016%2Fj.jtho.2018.07.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DGiroux-Leprieur%26aufirst%3DE.%26aulast%3DDumenil%26aufirst%3DC.%26aulast%3DChinet%26aufirst%3DT.%26atitle%3DCombination%2520of%2520crizotinib%2520and%2520osimertinib%2520or%2520erlotinib%2520might%2520overcome%2520met-mediated%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520in%2520EGFR-mutated%2520adenocarcinoma%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D11%26spage%3De232%26epage%3De234%26doi%3D10.1016%2Fj.jtho.2018.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span> <span> </span><span class="NLM_article-title">Osimertinib and Cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to Crizotinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e49</span>– <span class="NLM_lpage">e53</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2017.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29128427" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e49-e53&issue=4&author=J.+Kangauthor=H.+J.+Chenauthor=Z.+Wangauthor=J.+Liuauthor=B.+Liauthor=T.+Zhangauthor=Z.+Yangauthor=Y.+L.+Wuauthor=J.+J.+Yang&title=Osimertinib+and+Cabozantinib+combinatorial+therapy+in+an+EGFR-mutant+lung+adenocarcinoma+patient+with+multiple+MET+secondary-site+mutations+after+resistance+to+Crizotinib&doi=10.1016%2Fj.jtho.2017.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26atitle%3DOsimertinib%2520and%2520Cabozantinib%2520combinatorial%2520therapy%2520in%2520an%2520EGFR-mutant%2520lung%2520adenocarcinoma%2520patient%2520with%2520multiple%2520MET%2520secondary-site%2520mutations%2520after%2520resistance%2520to%2520Crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D4%26spage%3De49%26epage%3De53%26doi%3D10.1016%2Fj.jtho.2017.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">MEK inhibitors under development for treatment of non-small-cell lung cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1415324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1080%2F13543784.2018.1415324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29216787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=17-30&issue=1&author=C.+Kimauthor=G.+Giaccone&title=MEK+inhibitors+under+development+for+treatment+of+non-small-cell+lung+cancer&doi=10.1080%2F13543784.2018.1415324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibitors under development for treatment of non-small-cell lung cancer</span></div><div class="casAuthors">Kim, Chul; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-30</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The mitogen-activated protein kinase (MAPK) pathway is intimately implicated in the mol. pathogenesis of non-small-cell lung cancer (NSCLC).  Aberrant MAPK signaling resulting from the upstream activating mutations converges on mitogen-activated protein kinase kinase 1/2 (MEK1/2), making MEK inhibition an attractive strategy for the treatment of NSCLC.  Several MEK inhibitors have demonstrated anticancer activity in patients with NSCLC.: In this article, we discuss the biol. rationale for the use of MEK inhibitors and summarize the clin. experience with MEK1/2 inhibitors for the treatment of NSCLC, from initial phase I studies to phase II/III studies, both as monotherapy or in combination with other anticancer agents.: Trametinib in combination with the BRAF inhibitor dabrafenib represents the first MEK1/2 inhibitor contg. regimen that is approved for advanced BRAFV600E-mutant NSCLC.  Other MEK1/2 inhibitors that are also in advanced stages of clin. development include selumetinib, cobimetinib, and binimetinib.  Several studies of MEK inhibitor combination therapies are underway, including trials using combined MEK inhibition and immune checkpoint blockade.  Further research aimed at discovering biomarkers of response and resistance to MEK1/2 inhibitors will be needed to develop rational combination strategies for the treatment of NSCLC driven by aberrant MAPK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD8kVwzoJ2r7Vg90H21EOLACvtfcHk0lgTNdepWlpIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnN&md5=0de8dab092a5bdbe277b23dda3d6d605</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1415324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1415324%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DMEK%2520inhibitors%2520under%2520development%2520for%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26issue%3D1%26spage%3D17%26epage%3D30%26doi%3D10.1080%2F13543784.2018.1415324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Cuesta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildhaus, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuernberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-15-1915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27252416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4837-4847&issue=19&author=S.+Ortiz-Cuaranauthor=M.+Schefflerauthor=D.+Plenkerauthor=l.+Dahmenauthor=A.+H.+Scheelauthor=L.+Fernandez-Cuestaauthor=L.+Mederauthor=C.+M.+Lovlyauthor=T.+Persigehlauthor=S.+Merkelbach-Bruseauthor=M.+Bosauthor=S.+Michelsauthor=R.+Fischerauthor=K.+Albusauthor=K.+Konigauthor=H.-U.+Schildhausauthor=J.+Fassunkeauthor=M.+A.+Ihleauthor=H.+Pasternackauthor=C.+Heydtauthor=C.+Beckerauthor=J.+Altmullerauthor=H.+Jiauthor=C.+Mullerauthor=A.+Florinauthor=J.+M.+Heuckmannauthor=P.+Nuernbergauthor=S.+Ansenauthor=L.+C.+Heukampauthor=J.+Bergauthor=W.+Paoauthor=M.+Peiferauthor=R.+Buettnerauthor=J.+Wolfauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Heterogeneous+mechanisms+of+primary+and+acquired+resistance+to+third-generation+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-15-1915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span></div><div class="casAuthors">Ortiz-Cuaran, Sandra; Scheffler, Matthias; Plenker, Dennis; Dahmen, llona; Scheel, Andreas H.; Fernandez-Cuesta, Lynnette; Meder, Lydia; Lovly, Christine M.; Persigehl, Thorsten; Merkelbach-Bruse, Sabine; Bos, Marc; Michels, Sebastian; Fischer, Rieke; Albus, Kerstin; Koenig, Katharina; Schildhaus, Hans-Ulrich; Fassunke, Jana; Ihle, Michaela A.; Pasternack, Helen; Heydt, Carina; Becker, Christian; Altmueller, Janine; Ji, Hongbin; Mueller, Christian; Florin, Alexandra; Heuckmann, Johannes M.; Nuernberg, Peter; Ansen, Sascha; Heukamp, Lukas C.; Berg, Johannes; Pao, William; Peifer, Martin; Buettner, Reinhard; Wolf, Juergen; Thomas, Roman K.; Sos, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4837-4847</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).  We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686).  Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.  We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compds.  Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance.  Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS.  Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryi-78iIDGfrVg90H21EOLACvtfcHk0lgTNdepWlpIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K&md5=b30908de40ff48f067e067cfc3520a7b</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1915%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DDahmen%26aufirst%3Dl.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DMeder%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DAlbus%26aufirst%3DK.%26aulast%3DKonig%26aufirst%3DK.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPasternack%26aufirst%3DH.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DAltmuller%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DA.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DNuernberg%26aufirst%3DP.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DHeterogeneous%2520mechanisms%2520of%2520primary%2520and%2520acquired%2520resistance%2520to%2520third-generation%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D19%26spage%3D4837%26epage%3D4847%26doi%3D10.1158%2F1078-0432.CCR-15-1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Della Corte, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciaramella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Monica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malapelle, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigliar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellone, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgillo, F.</span></span> <span> </span><span class="NLM_article-title">Antitumor efficacy of dual blockade of EGFR signalling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NCLC tumor models</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">810</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29526823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslemurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=810-820&issue=6&author=C.+M.+Della+Corteauthor=V.+Ciaramellaauthor=C.+Cardoneauthor=S.+La+Monicaauthor=R.+Alfieriauthor=P.+G.+Petroniniauthor=U.+Malapelleauthor=E.+Vigliarauthor=F.+Pepeauthor=G.+Tronconeauthor=M.+D.+Castelloneauthor=T.+Troianiauthor=E.+Martinelliauthor=F.+Ciardielloauthor=F.+Morgillo&title=Antitumor+efficacy+of+dual+blockade+of+EGFR+signalling+by+osimertinib+in+combination+with+selumetinib+or+cetuximab+in+activated+EGFR+human+NCLC+tumor+models&doi=10.1016%2Fj.jtho.2018.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models</span></div><div class="casAuthors">Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">810-820</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models.  We evaluated combinations of osimertinib plus selumetinib/cetuximab in HCC827 (E746-A759del/T790M-), H1975 (L858R/T790M+), and PC9-T790M (E746-A759del /T790M+) xenografts in second-line therapy after the development of resistance to osimertinib, and in first-line therapy, and we explored mechanisms of resistance to these treatments.  The early use of combinations in first-line therapy increased the RR to 90%, with an mPFS not reached in all combination arms in the three xenografts models, with a statistically significant superiority (p < 0.005) as compared to osimertinib, achieving in first-line therapy an mPFS time of 17 to 18 wk.  Moreover, in ex vivo primary cell cultures obtained from osimertinib plus selumetinib-resistant tumors, we found Hedgehog pathway activation and we showed that therapy with an SMO inhibitor plus osimertinib and selumetinib inhibited proliferation and migratory and invasive properties of resistant cells.  We showed that a dual vertical EGFR blockade with osimertinib plus selumetinib/cetuximab is a novel effective therapeutic option in EGFR-mutated NCLC and that hedgehog pathway activation and its interplay with MAPK is involved in resistance to these combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRni_glltKa7Vg90H21EOLACvtfcHk0liStvK7rStDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslemurs%253D&md5=82ebd72f881c789bd4a20d0f0d3bde34</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DDella%2BCorte%26aufirst%3DC.%2BM.%26aulast%3DCiaramella%26aufirst%3DV.%26aulast%3DCardone%26aufirst%3DC.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMalapelle%26aufirst%3DU.%26aulast%3DVigliar%26aufirst%3DE.%26aulast%3DPepe%26aufirst%3DF.%26aulast%3DTroncone%26aufirst%3DG.%26aulast%3DCastellone%26aufirst%3DM.%2BD.%26aulast%3DTroiani%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DMorgillo%26aufirst%3DF.%26atitle%3DAntitumor%2520efficacy%2520of%2520dual%2520blockade%2520of%2520EGFR%2520signalling%2520by%2520osimertinib%2520in%2520combination%2520with%2520selumetinib%2520or%2520cetuximab%2520in%2520activated%2520EGFR%2520human%2520NCLC%2520tumor%2520models%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D810%26epage%3D820%26doi%3D10.1016%2Fj.jtho.2018.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calella, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span> <span> </span><span class="NLM_article-title">CROWN Trial Investigators First-Line Lorlatinib or Crizotinib in advanced <i>ALK</i>-positive lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2029</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2027187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa2027187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=33207094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=2018-2029&issue=21&author=A.+T.+Shawauthor=T.+M.+Bauerauthor=F.+de+Marinisauthor=E.+Felipauthor=Y.+Gotoauthor=G.+Liuauthor=J.+Mazieresauthor=D.+W.+Kimauthor=T.+Mokauthor=A.+Polliauthor=H.+Thurmauthor=A.+M.+Calellaauthor=G.+Peltzauthor=B.+J.+Solomon&title=CROWN+Trial+Investigators+First-Line+Lorlatinib+or+Crizotinib+in+advanced+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa2027187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna M.; Peltz, Gerson; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2018-2029</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-pos. non-small-cell lung cancer (NSCLC).  The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-pos. NSCLC is unclear.  We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-pos. NSCLC who had received no previous systemic treatment for metastatic disease.  The primary end point was progression-free survival as assessed by blinded independent central review.  Secondary end points included independently assessed objective response and intracranial response.  An interim anal. of efficacy was planned after approx. 133 of 177 (75%) expected events of disease progression or death had occurred.  The percentage of patients who were alive without disease progression at 12 mo was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001).  An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), resp., had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response.  The most common adverse events with lorlatinib were hyperlipidemia, edema, increased wt., peripheral neuropathy, and cognitive effects.  Lorlatinib was assocd. with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%).  Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, resp.  In an interim anal. of results among patients with previously untreated advanced ALK-pos. NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib.  The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPkJPLVUj8rVg90H21EOLACvtfcHk0liStvK7rStDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN&md5=97baa919b685e4ece2c03e7788c76702</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2027187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2027187%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DCalella%26aufirst%3DA.%2BM.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26atitle%3DCROWN%2520Trial%2520Investigators%2520First-Line%2520Lorlatinib%2520or%2520Crizotinib%2520in%2520advanced%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26issue%3D21%26spage%3D2018%26epage%3D2029%26doi%3D10.1056%2FNEJMoa2027187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1654</span>– <span class="NLM_lpage">1667</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30649-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2818%2930649-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30413378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1654-1667&issue=12&author=B.+J+Solomonauthor=B.+Besseauthor=T.+M+Bauerauthor=E.+Felipauthor=R.+A+Sooauthor=D+R.+Camidgeauthor=R.+Chiariauthor=A.+Bearzauthor=C.-C.+Linauthor=S.+M+Gadgeelauthor=G.+J+Rielyauthor=E.+H.+Tanauthor=T.+Setoauthor=L.+P+Jamesauthor=J.+S+Clancyauthor=A.+Abbattistaauthor=J.-F.+Martiniauthor=J.+Chenauthor=G.+Peltzauthor=H.+Thurmauthor=S.-H.+I.+Ouauthor=A.+T+Shaw&title=Lorlatinib+in+patients+with+ALK-positive+non-small-cell+lung+cancer%3A+results+from+a+global+phase+2+study&doi=10.1016%2FS1470-2045%2818%2930649-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</span></div><div class="casAuthors">Solomon, Benjamin J.; Besse, Benjamin; Bauer, Todd M.; Felip, Enriqueta; Soo, Ross A.; Camidge, D. Ross; Chiari, Rita; Bearz, Alessandra; Lin, Chia-Chi; Gadgeel, Shirish M.; Riely, Gregory J.; Tan, Eng Huat; Seto, Takashi; James, Leonard P.; Clancy, Jill S.; Abbattista, Antonello; Martini, Jean-Francois; Chen, Joseph; Peltz, Gerson; Thurm, Holger; Ignatius Ou, Sai-Hong; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1654-1667</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We aimed to analyze the overall and intracranial antitumor activity of lorlatinib in patients with ALK-pos., advanced non-small-cell lung cancer.  In this phase 2 study, patients with histol. or cytol. ALK-pos. or ROS1-pos., advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncol. Group performance status of 0, 1, or 2, and adequate end-organ function were eligible.  Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, and were given lorlatinib 100 mg orally once daily continuously in 21-day cycles.  One patient in EXP4 died before receiving lorlatinib and was excluded from the safety anal. set.  In treatment-naive patients (EXP1), an objective response was achieved in 27 (90·0%; 95% CI 73·5-97·9) of 30 patients.  Objective intracranial response was achieved in 20 patients with measurable baseline CNS lesions in EXP2-3A, five (55·6%; 21·2-86·3) of nine patients in EXP3B, and 26 of 49 patients in EXP4-5.  The most common treatment-related adverse events across all patients were hypercholesterolemia (224 [81%] of 275 patients overall and 43 [16%] grade 3-4) and hypertriglyceridemia (166 [60%] overall and 43 [16%] grade 3-4).  Serious treatment-related adverse events occurred in 19 (7%) of 275 patients and seven patients (3%) permanently discontinued treatment because of treatment-related adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13AyVlJJCKrVg90H21EOLACvtfcHk0liStvK7rStDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF&md5=0d47716d988ee784448e5cfc599cdef9</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930649-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930649-1%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DT.%2BM%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DSoo%26aufirst%3DR.%2BA%26aulast%3DCamidge%26aufirst%3DD%2BR.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DGadgeel%26aufirst%3DS.%2BM%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DJames%26aufirst%3DL.%2BP%26aulast%3DClancy%26aufirst%3DJ.%2BS%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DShaw%26aufirst%3DA.%2BT%26atitle%3DLorlatinib%2520in%2520patients%2520with%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%253A%2520results%2520from%2520a%2520global%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3D1654%26epage%3D1667%26doi%3D10.1016%2FS1470-2045%2818%2930649-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30680-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2817%2930680-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29074098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1590-1599&issue=12&author=A.+T.+Shawauthor=E.+Felipauthor=T.+M.+Bauerauthor=B.+Besseauthor=A.+Navarroauthor=S.+Postel-Vinayauthor=J.+F.+Gainorauthor=M.+Johnsonauthor=J.+Dietrichauthor=L.+P.+Jamesauthor=J.+S.+Clancyauthor=J.+Chenauthor=J.+F.+Martiniauthor=A.+Abbattistaauthor=B.+J.+Solomon&title=Lorlatinib+in+non-small-cell+lung+cancer+with+ALK+or+ROS1+rearrangement%3A+an+international%2C+multicentre%2C+open-label%2C+single-arm+first-in-man+phase+1+trial&doi=10.1016%2FS1470-2045%2817%2930680-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</span></div><div class="casAuthors">Shaw, Alice T.; Felip, Enriqueta; Bauer, Todd M.; Besse, Benjamin; Navarro, Alejandro; Postel-Vinay, Sophie; Gainor, Justin F.; Johnson, Melissa; Dietrich, Jorg; James, Leonard P.; Clancy, Jill S.; Chen, Joseph; Martini, Jean-Francois; Abbattista, Antonello; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1590-1599</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS.  This study aimed to analyze the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclin. activity against most known resistance mutations, in patients with advanced ALK-pos. or ROS1-pos. NSCLC.  In this international multicenter, open-label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-pos. or ROS1-pos. NSCLC and were older than 18 years, with an Eastern Cooperative Oncol. Group performance status of 0 or 1, and adequate end-organ function.  Lorlatinib was administered orally to patients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a min. of three patients receiving each dose.  For some patients, tumor biopsy was done before lorlatinib treatment to identify ALK resistance mutations.  Safety was assessed in patients who received at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment and had either ALK or ROS1 rearrangement).  The primary endpoint was dose-limiting toxicities during cycle 1 according to investigator assessment; secondary endpoints included safety, pharmacokinetics, and overall response.  This study is ongoing and is registered with ClinicalTrials.gov, no. NCT01970865.  Between Jan 22, 2014, and July 10, 2015, 54 patients received at least one dose of lorlatinib, including 41 (77%) with ALK-pos. and 12 (23%) with ROS1-pos. NSCLC; one patient had unconfirmed ALK and ROS1 status. 28 (52%) patients had received two or more TKIs, and 39 (72%) patients had CNS metastases.  The most common treatment-related adverse events among the 54 patients were hypercholesterolemia (39 [72%] of 54 patients), hypertriglyceridemia (21 [39%] of 54 patients), peripheral neuropathy (21 [39%] of 54 patients), and peripheral edema (21 [39%] of 54 patients).  One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributable to study drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation and word-finding difficulty).  No max. tolerated dose was identified.  The recommended phase 2 dose was selected as 100 mg once daily.  For ALK-pos. patients, the proportion of patients who achieved an objective response was 19 (46%) of 41 patients (95% CI 31-63); for those who had received two or more TKIs, the proportion of patients with an objective response was 11 (42%) of 26 patients (23-63).  In ROS1-pos. patients, including seven crizotinib-pretreated patients, an objective response was achieved by six (50%) of 12 patients (95% CI 21-79).  In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-pos. or ROS1-pos. NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.  Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-pos. NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomized controlled trial comparing lorlatinib to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU5uB3o0yZkrVg90H21EOLACvtfcHk0lg1Ko_5kEkhDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF&md5=aa28604c17c04fd005b70beda74ef2d6</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930680-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930680-0%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DClancy%26aufirst%3DJ.%2BS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26atitle%3DLorlatinib%2520in%2520non-small-cell%2520lung%2520cancer%2520with%2520ALK%2520or%2520ROS1%2520rearrangement%253A%2520an%2520international%252C%2520multicentre%252C%2520open-label%252C%2520single-arm%2520first-in-man%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D12%26spage%3D1590%26epage%3D1599%26doi%3D10.1016%2FS1470-2045%2817%2930680-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintanal-Villalonga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Pinelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirauqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojeda-Márquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrugal, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce-Aix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enguita, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2018.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30639621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=641-655&issue=4&author=A.+Quintanal-Villalongaauthor=S.+Molina-Pineloauthor=C.+Cirauquiauthor=L.+Ojeda-M%C3%A1rquezauthor=%C3%81.+Marrugalauthor=R.+Suarezauthor=E.+Condeauthor=S.+Ponce-Aixauthor=A.+B.+Enguitaauthor=A.+Carneroauthor=I.+Ferrerauthor=L.+Paz-Ares&title=FGFR1+Cooperates+with+EGFR+in+Lung+Cancer+Oncogenesis%2C+and+Their+Combined+Inhibition+Shows+Improved+Efficacy&doi=10.1016%2Fj.jtho.2018.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy</span></div><div class="casAuthors">Quintanal-Villalonga, Alvaro; Molina-Pinelo, Sonia; Cirauqui, Cristina; Ojeda-Marquez, Laura; Marrugal, Angela; Suarez, Rocio; Conde, Esther; Ponce-Aix, Santiago; Enguita, Ana Belen; Carnero, Amancio; Ferrer, Irene; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-655</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma.  We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays.  We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts.  We detd. FGFR1 mRNA expression in a cohort of patients with anti-EGFR therapy-treated adenocarcinoma.  We have reported a cooperative interaction between FGFR1 and EGFR in this context, resulting in increased EGFR activation and oncogenic signaling.  We have provided in vitro and in vivo evidence indicating that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in EGFR-mutated and EGFR wild-type models.  At the clin. level, we have shown that high FGFR1 expression levels predict higher resistance to erlotinib or gefitinib in a cohort of patients with tyrosine kinase inhibitor-treated EGFR-mutated and EGFR wild-type lung adenocarcinoma.  Dual EGFR and FGFR inhibition in FGFR1-overexpressing, EGFR-activated models shows synergistic effects on tumor growth in vitro and in cell line- and patient-derived xenografts, suggesting that patients with tumors bearing these characteristics may benefit from combined EGFR/FGFR inhibition.  These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJn8jLNuMQRLVg90H21EOLACvtfcHk0lg1Ko_5kEkhDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtLvL&md5=d2a14b7b17cd9a65819d63760a7124e5</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DQuintanal-Villalonga%26aufirst%3DA.%26aulast%3DMolina-Pinelo%26aufirst%3DS.%26aulast%3DCirauqui%26aufirst%3DC.%26aulast%3DOjeda-M%25C3%25A1rquez%26aufirst%3DL.%26aulast%3DMarrugal%26aufirst%3D%25C3%2581.%26aulast%3DSuarez%26aufirst%3DR.%26aulast%3DConde%26aufirst%3DE.%26aulast%3DPonce-Aix%26aufirst%3DS.%26aulast%3DEnguita%26aufirst%3DA.%2BB.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DFGFR1%2520Cooperates%2520with%2520EGFR%2520in%2520Lung%2520Cancer%2520Oncogenesis%252C%2520and%2520Their%2520Combined%2520Inhibition%2520Shows%2520Improved%2520Efficacy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D641%26epage%3D655%26doi%3D10.1016%2Fj.jtho.2018.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Targeting <i>HER2</i> aberrations in non-small cell lung cancer with Osimertinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2594</span>– <span class="NLM_lpage">2604</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-17-1875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29298799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2594-2604&issue=11&author=S.+Liuauthor=S.+Liauthor=J.+Haiauthor=X.+Wangauthor=T.+Chenauthor=M.+M.+Quinnauthor=P.+Gaoauthor=Y.+Zhangauthor=H.+Jiauthor=D.+Crossauthor=K.+K.+Wong&title=Targeting+HER2+aberrations+in+non-small+cell+lung+cancer+with+Osimertinib&doi=10.1158%2F1078-0432.CCR-17-1875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib</span></div><div class="casAuthors">Liu, Shengwu; Li, Shuai; Hai, Josephine; Wang, Xiaoen; Chen, Ting; Quinn, Max M.; Gao, Peng; Zhang, Yanxi; Ji, Hongbin; Cross, Darren A. E.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2594-2604</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The HER2 (or ERBB2) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas.  The HER2 amplification is also an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  However, due to limited preclin. studies and clin. trials, currently there is still no available std. of care for lung cancer patients with HER2 aberrations.  To fulfill the clin. need for targeting HER2 in patients with non-small cell lung cancer (NSCLC), we performed a comprehensive preclin. study to evaluate the efficacy of a third-generation TKI, osimertinib (AZD9291).  Three genetically modified mouse models (GEMM) mimicking individual HER2 alterations in NSCLC were generated, and osimertinib was tested for its efficacy against these HER2 aberrations in vivo.  Osimertinib treatment showed robust efficacy in HER2 wt overexpression and EGFR del19/HER2 models, but not in HER2 exon 20 insertion tumors.  Interestingly, we further identified that combined treatment with osimertinib and the BET inhibitor JQ1 significantly increased the response rate in HER2-mutant NSCLC, whereas JQ1 single treatment did not show efficacy.  Overall, our data indicated robust antitumor efficacy of osimertinib against multiple HER2 aberrations in lung cancer, either as a single agent or in combination with JQ1.  Our study provides a strong rationale for future clin. trials using osimertinib either alone or in combination with epigenetic drugs to target aberrant HER2 in patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKfb04qUNTrVg90H21EOLACvtfcHk0lheR9GuGNL3zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnK&md5=2abb669debb9ef4dc000646879166dab</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1875%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DHai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DQuinn%26aufirst%3DM.%2BM.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DTargeting%2520HER2%2520aberrations%2520in%2520non-small%2520cell%2520lung%2520cancer%2520with%2520Osimertinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D11%26spage%3D2594%26epage%3D2604%26doi%3D10.1158%2F1078-0432.CCR-17-1875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Monica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cretella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumarola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digiacomo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flammini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">174</span>, <span class="refDoi"> DOI: 10.1186/s13046-017-0653-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs13046-017-0653-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29202823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1M3nslSqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=174&issue=1&author=S.+La+Monicaauthor=D.+Cretellaauthor=M.+Bonelliauthor=C.+Fumarolaauthor=A.+Cavazzoniauthor=G.+Digiacomoauthor=L.+Flamminiauthor=E.+Barocelliauthor=R.+Minariauthor=N.+Naldiauthor=P.+G.+Petroniniauthor=M.+Tiseoauthor=R.+Alfieri&title=Trastuzumab+emtansine+delays+and+overcomes+resistance+to+the+third-generation+EGFR-TKI+osimertinib+in+NSCLC+EGFR+mutated+cell+lines&doi=10.1186%2Fs13046-017-0653-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines</span></div><div class="casAuthors">La Monica Silvia; Cretella Daniele; Bonelli Mara; Fumarola Claudia; Cavazzoni Andrea; Digiacomo Graziana; Petronini Pier Giorgio; Alfieri Roberta; Flammini Lisa; Barocelli Elisabetta; Minari Roberta; Naldi Nadia; Tiseo Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients.  Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of resistance to osimertinib, this study was addressed to investigate the potential of combining osimertinib with trastuzumab emtansine (T-DM1) in order to improve the efficacy of osimertinib and delay or overcome resistance in NSCLC cell lines with EGFR activating mutation and with T790M mutation or HER-2 amplification.  METHODS:  The effects of osimertinib combined with T-DM1 on cell proliferation, cell cycle, cell death, antibody-dependent cell-mediated cytotoxicity (ADCC), and acquisition of osimertinib resistance was investigated in PC9, PC9-T790M and H1975 cell lines.  The potential of overcoming osimertinib resistance with T-DM1 was tested in a PC9/HER2c1 xenograft model.  RESULTS:  T-DM1 exerted an additive effect when combined with osimertinib in terms of inhibition of cell proliferation, cell death and ADCC induction in PC9, PC9-T790M and H1975 cell lines.  Combining osimertinib and T-DM1 using different schedules in long-term growth experiments revealed that the appearance of osimertinib-resistance was prevented in PC9-T790M and delayed in H1975 cells when the two drugs were given together.  By contrast, when osimertinib was followed by T-DM1 an antagonistic effect was observed on cell proliferation, cell death and resistance acquisition.  In xenograft models, we demonstrated that HER-2 amplification was associated with osimertinib-resistance and that T-DM1 co-administration is a potential strategy to overcome this resistance.  CONCLUSIONS:  Our data suggest that concomitant treatment with osimertinib and T-DM1 may be a promising therapeutic strategy for EGFR-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6nMGONSwIegxyojvcjibhfW6udTcc2ebt7sOo6G0NKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3nslSqsQ%253D%253D&md5=b6febd4ec9d59ec0b20f34bb56510196</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1186%2Fs13046-017-0653-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-017-0653-7%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DCretella%26aufirst%3DD.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DDigiacomo%26aufirst%3DG.%26aulast%3DFlammini%26aufirst%3DL.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DNaldi%26aufirst%3DN.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DAlfieri%26aufirst%3DR.%26atitle%3DTrastuzumab%2520emtansine%2520delays%2520and%2520overcomes%2520resistance%2520to%2520the%2520third-generation%2520EGFR-TKI%2520osimertinib%2520in%2520NSCLC%2520EGFR%2520mutated%2520cell%2520lines%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D36%26issue%3D1%26spage%3D174%26doi%3D10.1186%2Fs13046-017-0653-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaguti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognetti, F.</span></span> <span> </span><span class="NLM_article-title">First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">104</span>, <span class="refDoi"> DOI: 10.1186/s13046-016-0380-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1186%2Fs13046-016-0380-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27357210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=104&author=A.+Fabiauthor=P.+Malagutiauthor=S.+Variauthor=F.+Cognetti&title=First-line+therapy+in+HER2+positive+metastatic+breast+cancer%3A+is+the+mosaic+fully+completed+or+are+we+missing+additional+pieces%3F&doi=10.1186%2Fs13046-016-0380-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?</span></div><div class="casAuthors">Fabi, Alessandra; Malaguti, Paola; Vari, Sabrina; Cognetti, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104/1-104/11</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biol. of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clin. outcomes for women with early-stage and advanced HER2-pos. breast cancer (BC).  HER-2 targeted therapies represent a major step forward in achieving the goal of delivering individualized targeted therapy for BC, and trastuzumab was the first anti-HER-2 strategy to be approved for treatment of HER-2 pos. BC.  This review discusses the treatment of metastatic HER2-pos. BC and describes efficacy and safety of novel anti-HER2 target therapies in first-line metastatic settings and the future challenges include refining such treatments, reducing toxicity and simultaneously developing innovative therapies.  Furthermore, combinations of trastuzumab and drugs targeting the downstream pathway are described.  In the next future will be possible to use an ample armamentarium of combination therapies directed against HER2 and key signaling components integrated in the HER network.  This approach will allow clinicians to tailor the management of the individual patient on the basis of tumor- specific biomarker profiles.  There is an urgent need for prospective biomarker-driven trials to identify patients for whom targeting is cost-effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0S74csgD1AbVg90H21EOLACvtfcHk0lheR9GuGNL3zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSlurY%253D&md5=11120955d5cf0da0a274fc6e59f1f335</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1186%2Fs13046-016-0380-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-016-0380-5%26sid%3Dliteratum%253Aachs%26aulast%3DFabi%26aufirst%3DA.%26aulast%3DMalaguti%26aufirst%3DP.%26aulast%3DVari%26aufirst%3DS.%26aulast%3DCognetti%26aufirst%3DF.%26atitle%3DFirst-line%2520therapy%2520in%2520HER2%2520positive%2520metastatic%2520breast%2520cancer%253A%2520is%2520the%2520mosaic%2520fully%2520completed%2520or%2520are%2520we%2520missing%2520additional%2520pieces%253F%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D35%26spage%3D104%26doi%3D10.1186%2Fs13046-016-0380-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vredenburgh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasser, J. S.</span></span> <i>Targeting HER2 in the treatment of non-small cell lung cancer.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2014.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.lungcan.2014.12.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mar%2C+N.%3B+Vredenburgh%2C+J.+J.%3B+Wasser%2C+J.+S.+Targeting+HER2+in+the+treatment+of+non-small+cell+lung+cancer.+2015%2C+87+%283%29%2C+220%E2%80%93225%2C+10.1016%2Fj.lungcan.2014.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2014.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2014.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DMar%26aufirst%3DN.%26aulast%3DVredenburgh%26aufirst%3DJ.%2BJ.%26aulast%3DWasser%26aufirst%3DJ.%2BS.%26jtitle%3DTargeting%2520HER2%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer.%26date%3D2015%26volume%3D87%26issue%3D3%26spage%3D220%26epage%3D225%26doi%3D10.1016%2Fj.lungcan.2014.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertran-Alamillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixidó, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellví, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzón, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony-Servat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony-Servat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giménez-Capitán, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viteri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Convergent AKT activation drives acquired EGFR inhibitor resistance in lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">410</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00450-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1038%2Fs41467-017-00450-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28871105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1cbks1Chuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=410&issue=1&author=K.+Jacobsenauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=C.+Teixid%C3%B3author=N.+Karachaliouauthor=M.+H.+Pedersenauthor=J.+Castellv%C3%ADauthor=M.+Garz%C3%B3nauthor=C.+Codony-Servatauthor=J.+Codony-Servatauthor=A.+Gim%C3%A9nez-Capit%C3%A1nauthor=A.+Drozdowskyjauthor=S.+Viteriauthor=M.+R.+Larsenauthor=U.+Lassenauthor=E.+Felipauthor=T.+G.+Bivonaauthor=H.+J.+Ditzelauthor=R.+Rosell&title=Convergent+AKT+activation+drives+acquired+EGFR+inhibitor+resistance+in+lung+cancer&doi=10.1038%2Fs41467-017-00450-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer</span></div><div class="casAuthors">Jacobsen Kirstine; Pedersen Martin Haar; Ditzel Henrik J; Bertran-Alamillo Jordi; Molina Miguel Angel; Teixido Cristina; Castellvi Josep; Garzon Monica; Codony-Servat Carles; Codony-Servat Jordi; Gimenez-Capitan Ana; Rosell Rafael; Karachaliou Niki; Drozdowskyj Ana; Viteri Santiago; Rosell Rafael; Larsen Martin R; Lassen Ulrik; Felip Enriqueta; Bivona Trever G; Bivona Trever G; Ditzel Henrik J; Rosell Rafael; Rosell Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">410</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment.  However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms.  The diversity and unpredictability of EGFR tyrosine kinase inhibitor resistance mechanisms presents a challenge for developing new treatments to overcome EGFR tyrosine kinase inhibitor resistance.  Here, we show that Akt activation is a convergent feature of acquired EGFR tyrosine kinase inhibitor resistance, across a spectrum of diverse, established upstream resistance mechanisms.  Combined treatment with an EGFR tyrosine kinase inhibitor and Akt inhibitor causes apoptosis and synergistic growth inhibition in multiple EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models.  Moreover, phospho-Akt levels are increased in most clinical specimens obtained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR tyrosine kinase inhibitor resistance.  Our findings provide a rationale for clinical trials testing Akt and EGFR inhibitor co-treatment in patients with elevated phospho-Akt levels to therapeutically combat the heterogeneity of EGFR tyrosine kinase inhibitor resistance mechanisms.EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment.  In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvWBwJCmQEN2gRQsDqrjW_fW6udTcc2eaxBFthirDg5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbks1Chuw%253D%253D&md5=1c4b6432f5ae84679cba699b83389aec</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00450-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00450-6%26sid%3Dliteratum%253Aachs%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DC.%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DPedersen%26aufirst%3DM.%2BH.%26aulast%3DCastellv%25C3%25AD%26aufirst%3DJ.%26aulast%3DGarz%25C3%25B3n%26aufirst%3DM.%26aulast%3DCodony-Servat%26aufirst%3DC.%26aulast%3DCodony-Servat%26aufirst%3DJ.%26aulast%3DGim%25C3%25A9nez-Capit%25C3%25A1n%26aufirst%3DA.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DViteri%26aufirst%3DS.%26aulast%3DLarsen%26aufirst%3DM.%2BR.%26aulast%3DLassen%26aufirst%3DU.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DDitzel%26aufirst%3DH.%2BJ.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DConvergent%2520AKT%2520activation%2520drives%2520acquired%2520EGFR%2520inhibitor%2520resistance%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D410%26doi%3D10.1038%2Fs41467-017-00450-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torigoe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogoshi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span> <span> </span><span class="NLM_article-title">Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-0628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1541-7786.MCR-18-0628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30463991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=499-507&issue=2&author=K.+Nambaauthor=K.+Shienauthor=Y.+Takahashiauthor=H.+Torigoeauthor=H.+Satoauthor=T.+Yoshiokaauthor=T.+Takedaauthor=E.+Kuriharaauthor=Y.+Ogoshiauthor=H.+Yamamotoauthor=J.+Sohauthor=S.+Tomidaauthor=S.+Toyooka&title=Activation+of+AXL+as+a+preclinical+acquired+resistance+mechanism+against+osimertinib+treatment+in+EGFR-mutant+non-small+cell+lung+cancer+cells&doi=10.1158%2F1541-7786.MCR-18-0628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells</span></div><div class="casAuthors">Namba, Kei; Shien, Kazuhiko; Takahashi, Yuta; Torigoe, Hidejiro; Sato, Hiroki; Yoshioka, Takahiro; Takeda, Tatsuaki; Kurihara, Eisuke; Ogoshi, Yusuke; Yamamoto, Hiromasa; Soh, Junichi; Tomida, Shuta; Toyooka, Shinichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-507</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In this study, we exptl. established acquired osimertinib-resistant cell lines from EGFR-mutant NSCLC cell lines and investigated the mol. profiles of resistant cells to uncover the mechanisms of acquired resistance.  Various resistance mechanisms were identified, including the acquisition of MET amplification, EMT induction, and the upregulation of AXL.  Using targeted next-generation sequencing with a multigene panel, no secondary mutations were detected in our resistant cell lines.  Among three MET-amplified cell lines, one cell line was sensitive to a combination of osimertinib and crizotinib.  Acquired resistance cell lines derived from H1975 harboring the T790M mutation showed AXL upregulation, and the cell growth of these cell lines was suppressed by a combination of osimertinib and cabozantinib, an inhibitor of multiple tyrosine kinases including AXL, both in vitro and in vivo.  Our results suggest that AXL might be a therapeutic target for overcoming acquired resistance to osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop_sGYsYCpS7Vg90H21EOLACvtfcHk0lim7I62IbXhqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCks7o%253D&md5=cc08acb1cddbc261dce0e12f42160b15</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-0628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-0628%26sid%3Dliteratum%253Aachs%26aulast%3DNamba%26aufirst%3DK.%26aulast%3DShien%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DTorigoe%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DTakeda%26aufirst%3DT.%26aulast%3DKurihara%26aufirst%3DE.%26aulast%3DOgoshi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DTomida%26aufirst%3DS.%26aulast%3DToyooka%26aufirst%3DS.%26atitle%3DActivation%2520of%2520AXL%2520as%2520a%2520preclinical%2520acquired%2520resistance%2520mechanism%2520against%2520osimertinib%2520treatment%2520in%2520EGFR-mutant%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D499%26epage%3D507%26doi%3D10.1158%2F1541-7786.MCR-18-0628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimbo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haginoya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span> <span> </span><span class="NLM_article-title">DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.18632%2Foncotarget.27114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31497246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrmtl2rtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5152-5167&issue=50&author=T.+Jimboauthor=M.+Hatanakaauthor=T.+Komatsuauthor=T.+Tairaauthor=K.+Kumazawaauthor=N.+Maedaauthor=T.+Suzukiauthor=M.+Otaauthor=N.+Haginoyaauthor=T.+Isoyamaauthor=K.+Fujiwara&title=DS-1205b%2C+a+novel+selective+inhibitor+of+AXL+kinase%2C+blocks+resistance+to+EGFR-tyrosine+kinase+inhibitors+in+a+non-small+cell+lung+cancer+xenograft+model&doi=10.18632%2Foncotarget.27114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model</span></div><div class="casAuthors">Jimbo Takeshi; Hatanaka Mana; Komatsu Takahiro; Taira Tomoe; Maeda Naoyuki; Haginoya Noriyasu; Isoyama Takeshi; Kumazawa Kentaro; Suzuki Takashi; Ota Masahiro; Fujiwara Kosaku</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5152-5167</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The AXL receptor tyrosine kinase is involved in signal transduction in malignant cells.  Recent studies have shown that the AXL upregulation underlies epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance in EGFR-mutant non-small cell lung cancer (NSCLC).  In this study, we investigated the effect of DS-1205b, a novel and selective inhibitor of AXL, on tumor growth and resistance to EGFR TKIs.  In AXL-overexpressing NIH3T3 cells, DS-1205b potently inhibited hGAS6 ligand-induced migration in vitro and exerted significant antitumor activity in vivo.  AXL was upregulated by long-term erlotinib or osimertinib treatment in HCC827 EGFR-mutant NSCLC cells, and DS-1205b treatment in combination with osimertinib or erlotinib effectively inhibited signaling downstream of EGFR in a cell-based assay.  In an HCC827 EGFR-mutant NSCLC xenograft mouse model, combination treatment with DS-1205b and erlotinib significantly delayed the onset of tumor resistance compared to erlotinib monotherapy, and DS-1205b restored the antitumor activity of erlotinib in erlotinib-resistant tumors.  DS-1205b also delayed the onset of resistance when used in combination with osimertinib in the model.  These findings strongly suggest that DS-1205b can prolong the therapeutic benefit of EGFR TKIs in nonclinical as well as clinical settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTA9vLx95SNZtXdcedVHT5tfW6udTcc2eaxBFthirDg5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrmtl2rtA%253D%253D&md5=794e388a2bcdec6a2bce13357cccede8</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27114%26sid%3Dliteratum%253Aachs%26aulast%3DJimbo%26aufirst%3DT.%26aulast%3DHatanaka%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DT.%26aulast%3DTaira%26aufirst%3DT.%26aulast%3DKumazawa%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOta%26aufirst%3DM.%26aulast%3DHaginoya%26aufirst%3DN.%26aulast%3DIsoyama%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DK.%26atitle%3DDS-1205b%252C%2520a%2520novel%2520selective%2520inhibitor%2520of%2520AXL%2520kinase%252C%2520blocks%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520xenograft%2520model%26jtitle%3DOncotarget%26date%3D2019%26volume%3D10%26issue%3D50%26spage%3D5152%26epage%3D5167%26doi%3D10.18632%2Foncotarget.27114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, T.-T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span> <span> </span><span class="NLM_article-title">Abstract 337: Degradation of AXL overcome acquired cross-resistance to Gefitinib and osimertinib in non-small cell lung cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">337</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1538-7445.AM2019-337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=337&author=D.+Kimauthor=D.-H.+Bachauthor=Y.-h.+Fanauthor=T.-T.-T.+Luuauthor=J.-Y.+Hongauthor=H.-J.+Parkauthor=S.+K.+Lee&title=Abstract+337%3A+Degradation+of+AXL+overcome+acquired+cross-resistance+to+Gefitinib+and+osimertinib+in+non-small+cell+lung+cancer+cells&doi=10.1158%2F1538-7445.AM2019-337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-337%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DD.-H.%26aulast%3DFan%26aufirst%3DY.-h.%26aulast%3DLuu%26aufirst%3DT.-T.-T.%26aulast%3DHong%26aufirst%3DJ.-Y.%26aulast%3DPark%26aufirst%3DH.-J.%26aulast%3DLee%26aufirst%3DS.%2BK.%26atitle%3DAbstract%2520337%253A%2520Degradation%2520of%2520AXL%2520overcome%2520acquired%2520cross-resistance%2520to%2520Gefitinib%2520and%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2019%26spage%3D337%26doi%3D10.1158%2F1538-7445.AM2019-337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. Y.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signalling in lung cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>145</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1002/ijc.32487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fijc.32487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31162839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1eku7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2019&pages=1609-1624&issue=6&author=Y.+N.+Liuauthor=M.+F.+Tsaiauthor=S.+G.+Wuauthor=T.+H.+Changauthor=T.+H.+Tsaiauthor=C.+H.+Gowauthor=Y.+L.+Changauthor=J.+Y.+Shih&title=Acquired+resistance+to+EGFR+tyrosine+kinase+inhibitors+is+mediated+by+the+reactivation+of+STC2%2FJUN%2FAXL+signalling+in+lung+cancer&doi=10.1002%2Fijc.32487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer</span></div><div class="casAuthors">Liu, Yi-Nan; Tsai, Meng-Feng; Wu, Shang-Gin; Chang, Tzu-Hua; Tsai, Tzu-Hsiu; Gow, Chien-Hung; Chang, Yih-Leong; Shih, Jin-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1609-1624</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the std. treatment for nonsmall cell lung cancer (NSCLC) patients.  However, acquired resistance to these agents remains a major obstacle for managing NSCLC.  Here, we investigated a novel strategy to overcome EGFR TKI resistance by targeting the stanniocalcin 2 (STC2)-JUN-AXL pathway.  We revealed that STC2 was expressed at significantly higher levels in EGFR TKI-resistant cells.  Further, clin. anal. showed that STC2 expression was increased after the development of EGFR TKI resistance which correlated with shorter PFS in EGFR TKI-treated lung cancer patients.  Moreover, STC2 overexpression in EGFR TKI-sensitive cells resulted in EGFR TKI resistance.  Conversely, genetic silencing of STC2 rendered EGFR TKI-resistant cells more sensitive to EGFR TKIs.  Mech., STC2 enhanced AXL promoter activity by increasing the phosphorylation of c-Jun, which is an indispensable transcription factor that transactivates AXL.  STC2 promoted activation of the JUN-AXL-ERK signaling axis in lung cancer cells.  We also demonstrated that PE2988 cells, a C797S-independent osimertinib-resistant primary cancer cell line from a lung cancer patient, responded to combined AXL inhibitor and osimertinib treatment.  In conclusion, our research indicates that STC2 overexpression is important for acquired resistance to EGFR TKIs and that STC2-JUN-AXL-ERK signaling might be a potential therapeutic target to overcome resistance to EGFR TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv-LqEfzhGQ7Vg90H21EOLACvtfcHk0lijAzlBZYt6RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1eku7vM&md5=88b8f3f6511981702b4a77ef0c7bf7bb</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1002%2Fijc.32487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32487%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BN.%26aulast%3DTsai%26aufirst%3DM.%2BF.%26aulast%3DWu%26aufirst%3DS.%2BG.%26aulast%3DChang%26aufirst%3DT.%2BH.%26aulast%3DTsai%26aufirst%3DT.%2BH.%26aulast%3DGow%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DShih%26aufirst%3DJ.%2BY.%26atitle%3DAcquired%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520is%2520mediated%2520by%2520the%2520reactivation%2520of%2520STC2%252FJUN%252FAXL%2520signalling%2520in%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D145%26issue%3D6%26spage%3D1609%26epage%3D1624%26doi%3D10.1002%2Fijc.32487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquet, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quoix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30146-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2816%2930146-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27283860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslyjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=984-993&issue=7&author=D.+Planchardauthor=B.+Besseauthor=H.+J.+Groenauthor=P.+J.+Souquetauthor=E.+Quoixauthor=C.+S.+Baikauthor=F.+Barlesiauthor=T.+M.+Kimauthor=J.+Mazieresauthor=S.+Novello&title=Dabrafenib+plus+trametinib+in+patients+with+previously+treated+BRAFV600E-mutant+metastatic+non-small+cell+lung+cancer%3A+an+open-label%2C+multicentre+phase+2+trial&doi=10.1016%2FS1470-2045%2816%2930146-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial</span></div><div class="casAuthors">Planchard, David; Besse, Benjamin; Groen, Harry J. M.; Souquet, Pierre-Jean; Quoix, Elisabeth; Baik, Christina S.; Barlesi, Fabrice; Kim, Tae Min; Mazieres, Julien; Novello, Silvia; Rigas, James R.; Upalawanna, Allison; D'Amelio, Anthony M. Jr; Zhang, Pingkuan; Mookerjee, Bijoyesh; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-993</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC).  BRAF inhibition has shown antitumor activity in patients with BRAFV600E-mutant NSCLC.  Dual MAPK pathway inhibition with BRAF and MEK inhibitors in BRAFV600E-mutant NSCLC might improve efficacy over BRAF inhibitor monotherapy based on observations in BRAFV600-mutant melanoma.  We aimed to assess the antitumor activity and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutant NSCLC.  In this phase 2, multicentre, non-randomized, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAFV600E-mutant NSCLC who had documented tumor progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.  Patients with previous BRAF or MEK inhibitor treatment were ineligible.  Patients with brain metastases were allowed to enroll only if the lesions were asymptomatic, untreated (or stable more than 3 wk after local therapy if treated), and measured less than 1 cm.  Enrolled patients received oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) in continuous 21-day cycles until disease progression, unacceptable adverse events, withdrawal of consent, or death.  The primary endpoint was investigator-assessed overall response, which was assessed by intention to treat in the protocol-defined population (patients who received second-line or later treatment); safety was also assessed in this population and was assessed at least once every 3 wk, with adverse events, lab. values, and vital signs graded according to the Common Terminol. Criteria for Adverse Events version 4.0.  The study is ongoing but no longer recruiting patients.  This trial is registered with ClinicalTrials.gov, no. NCT01336634.  Between Dec 20, 2013, and Jan 14, 2015, 59 patients from 30 centers in nine countries across North America, Europe, and Asia met eligibility criteria.  Two patients who had previously been untreated due to protocol deviation were excluded; thus, 57 eligible patients were enrolled. 36 patients (63·2% [95% CI 49·3-75·6]) achieved an investigator-assessed overall response.  Serious adverse events were reported in 32 (56%) of 57 patients and included pyrexia in nine (16%), anemia in three (5%), confusional state in two (4%), decreased appetite in two (4%), hemoptysis in two (4%), hypercalcemia in two (4%), nausea in two (4%), and cutaneous squamous cell carcinoma in two (4%).  The most common grade 3-4 adverse events were neutropenia in five patients (9%), hyponatremia in four (7%), and anemia in three (5%).  Four patients died during the study from fatal adverse events judged to be unrelated to treatment (one retroperitoneal hemorrhage, one subarachnoid hemorrhage, one respiratory distress, and one from disease progression that was more severe than typical progression, as assessed by the investigator).  Dabrafenib plus trametinib could represent a new targeted therapy with robust antitumor activity and a manageable safety profile in patients with BRAFV600E-mutant NSCLC.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-qPV5AvwdnrVg90H21EOLACvtfcHk0lijAzlBZYt6RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslyjsL8%253D&md5=322443578a05f7f30ed21427413b38ca</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930146-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930146-2%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DGroen%26aufirst%3DH.%2BJ.%26aulast%3DSouquet%26aufirst%3DP.%2BJ.%26aulast%3DQuoix%26aufirst%3DE.%26aulast%3DBaik%26aufirst%3DC.%2BS.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DNovello%26aufirst%3DS.%26atitle%3DDabrafenib%2520plus%2520trametinib%2520in%2520patients%2520with%2520previously%2520treated%2520BRAFV600E-mutant%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%253A%2520an%2520open-label%252C%2520multicentre%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D7%26spage%3D984%26epage%3D993%26doi%3D10.1016%2FS1470-2045%2816%2930146-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chih-Hsin Yang, J.</span></span> <span> </span><span class="NLM_article-title">Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.2231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.2231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27923714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=567-572&issue=3&author=C.-C.+Hoauthor=W.-Y.+Liaoauthor=C.-A.+Linauthor=J.-Y.+Shihauthor=C.-J.+Yuauthor=J.+Chih-Hsin+Yang&title=Acquired+BRAF+V600E+mutation+as+resistant+mechanism+after+treatment+with+osimertinib&doi=10.1016%2Fj.jtho.2016.11.2231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib</span></div><div class="casAuthors">Ho Chao-Chi; Liao Wei-Yu; Shih Jin-Yuan; Yu Chong-Jen; Lin Chih-An; Yang James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-572</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used.  Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified.  It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment.  METHODS:  Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib.  Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry.  EGFR, AKT, MEK, and ERK phosphorylation were determined.  An anchorage-dependent colony formation assay was used for drug sensitivity.  RESULTS:  An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib.  Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib.  CONCLUSIONS:  A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway.  Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyyK7fCSkFDQ8IxFYvehhofW6udTcc2ebni4bPXzo9zLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjktFajtg%253D%253D&md5=b4d27a7ed29dfc9f3470175998e3b529</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.2231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.2231%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DC.-C.%26aulast%3DLiao%26aufirst%3DW.-Y.%26aulast%3DLin%26aufirst%3DC.-A.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DChih-Hsin%2BYang%26aufirst%3DJ.%26atitle%3DAcquired%2520BRAF%2520V600E%2520mutation%2520as%2520resistant%2520mechanism%2520after%2520treatment%2520with%2520osimertinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.jtho.2016.11.2231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ready, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vokes, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhaufl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrieta, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgio, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poddubskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbison, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf
Finckenstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span> <span> </span><span class="NLM_article-title">Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1507643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26412456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFyitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1627-1639&issue=17&author=H.+Borghaeiauthor=L.+Paz-Aresauthor=L.+Hornauthor=D.+R.+Spigelauthor=M.+Steinsauthor=N.+E.+Readyauthor=L.+Q.+Chowauthor=E.+E.+Vokesauthor=E.+Felipauthor=E.+Holgadoauthor=F.+Barlesiauthor=M.+Kohlhauflauthor=O.+Arrietaauthor=M.+A.+Burgioauthor=J.+Fayetteauthor=H.+Lenaauthor=E.+Poddubskayaauthor=D.+E.+Gerberauthor=S.+N.+Gettingerauthor=C.+M.+Rudinauthor=N.+Rizviauthor=L.+Crinoauthor=G.+R.+Blumenscheinauthor=S.+J.+Antoniaauthor=C.+Dorangeauthor=C.+T.+Harbisonauthor=F.+Graf%0AFinckensteinauthor=J.+R.+Brahmer&title=Nivolumab+versus+Docetaxel+in+advanced+nonsquamous+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1507643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer</span></div><div class="casAuthors">Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D. R.; Steins, M.; Ready, N. E.; Chow, L. Q.; Vokes, E. E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhaufl, M.; Arrieta, O.; Burgio, M. A.; Fayette, J.; Lena, H.; Poddubskaya, E.; Gerber, D. E.; Gettinger, S. N.; Rudin, C. M.; Rizvi, N.; Crino, L.; Blumenschein, G. R., Jr.; Antonia, S. J.; Dorange, C.; Harbison, C. T.; Finckenstein, F. Graf; Brahmer, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1627-1639</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.  In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kg of body wt. every 2 wk or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 wk.  The primary end point was overall survival.  Overall survival was longer with nivolumab than with docetaxel.  The median overall survival was 12.2 mo (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 mo (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P = 0.002).  At 1 yr, the overall survival rate was 51% (95% CI, 45 to 56) with nivolumab vs. 39% (95% CI, 33 to 45) with docetaxel.  With addnl. follow-up, the overall survival rate at 18 mo was 39% (95% CI, 34 to 45) with nivolumab vs. 23% (95% CI, 19 to 28) with docetaxel.  The response rate was 19% with nivolumab vs. 12% with docetaxel (P = 0.02).  Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 mo and 4.2 mo, resp.), the rate of progression-free survival at 1 yr was higher with nivolumab than with docetaxel (19% and 8%, resp.).  Nivolumab was assocd. with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1%, ≥5%, and ≥10%) of the PD-1 ligand.  Treatment-related adverse events of grade 3 or 4 were reported in 10% of the patients in the nivolumab group, as compared with 54% of those in the docetaxel group.  Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo74iHTHau0bbVg90H21EOLACvtfcHk0ljqVfOIf111Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFyitL0%253D&md5=b1fd759688c5dd8a28ac9709beaeab9e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507643%26sid%3Dliteratum%253Aachs%26aulast%3DBorghaei%26aufirst%3DH.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DReady%26aufirst%3DN.%2BE.%26aulast%3DChow%26aufirst%3DL.%2BQ.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DHolgado%26aufirst%3DE.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DKohlhaufl%26aufirst%3DM.%26aulast%3DArrieta%26aufirst%3DO.%26aulast%3DBurgio%26aufirst%3DM.%2BA.%26aulast%3DFayette%26aufirst%3DJ.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DPoddubskaya%26aufirst%3DE.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DRizvi%26aufirst%3DN.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DDorange%26aufirst%3DC.%26aulast%3DHarbison%26aufirst%3DC.%2BT.%26aulast%3DGraf%2BFinckenstein%26aufirst%3DF.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26atitle%3DNivolumab%2520versus%2520Docetaxel%2520in%2520advanced%2520nonsquamous%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D17%26spage%3D1627%26epage%3D1639%26doi%3D10.1056%2FNEJMoa1507643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhardt, W. E.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poddubskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vokes, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ready, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aren Frontera, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudelet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbison, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span> <span> </span><span class="NLM_article-title">Nivolumab versus Docetaxel in Advanced squamous-cell non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1504627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1504627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26028407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12qu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=123-135&issue=2&author=J.+Brahmerauthor=K.+L.+Reckampauthor=P.+Baasauthor=L.+Crinoauthor=W.+E.E.+Eberhardtauthor=E.+Poddubskayaauthor=S.+Antoniaauthor=A.+Pluzanskiauthor=E.+E.+Vokesauthor=E.+Holgadoauthor=D.+Waterhouseauthor=N.+Readyauthor=J.+Gainorauthor=O.+Aren+Fronteraauthor=L.+Havelauthor=M.+Steinsauthor=M.+C.+Garassinoauthor=J.+G.+Aertsauthor=M.+Domineauthor=L.+Paz-Aresauthor=M.+Reckauthor=C.+Baudeletauthor=C.+T.+Harbisonauthor=B.+Lestiniauthor=D.+R.+Spigel&title=Nivolumab+versus+Docetaxel+in+Advanced+squamous-cell+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1504627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer</span></div><div class="casAuthors">Brahmer, Julie; Reckamp, Karen L.; Baas, Paul; Crino, Lucio; Eberhardt, Wilfried E. E.; Poddubskaya, Elena; Antonia, Scott; Pluzanski, Adam; Vokes, Everett E.; Holgado, Esther; Waterhouse, David; Ready, Neal; Gainor, Justin; Frontera, Osvaldo Aren; Havel, Libor; Steins, Martin; Garassino, Marina C.; Aerts, Joachim G.; Domine, Manuel; Paz-Ares, Luis; Reck, Martin; Baudelet, Christine; Harbison, Christopher T.; Lestini, Brian; Spigel, David R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-135</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options.  This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population.  We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kg of body wt. every 2 wk, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 wk.  The primary end point was overall survival.  The median overall survival was 9.2 mo (95% confidence interval [CI], 7.3 to 13.3) with nivolumab vs. 6.0 mo (95% CI, 5.1 to 7.3) with docetaxel.  The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001).  At 1 yr, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab vs. 24% (95% CI, 17 to 31) with docetaxel.  The response rate was 20% with nivolumab vs. 9% with docetaxel (P = 0.008).  The median progression-free survival was 3.5 mo with nivolumab vs. 2.8 mo with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001).  The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit.  Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group.  Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhe7kKOA6JD7Vg90H21EOLACvtfcHk0ljqVfOIf111Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12qu7%252FJ&md5=7428b27bffceddd6e119fcbb7a5b4177</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1504627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1504627%26sid%3Dliteratum%253Aachs%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DBaas%26aufirst%3DP.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.E.%26aulast%3DPoddubskaya%26aufirst%3DE.%26aulast%3DAntonia%26aufirst%3DS.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHolgado%26aufirst%3DE.%26aulast%3DWaterhouse%26aufirst%3DD.%26aulast%3DReady%26aufirst%3DN.%26aulast%3DGainor%26aufirst%3DJ.%26aulast%3DAren%2BFrontera%26aufirst%3DO.%26aulast%3DHavel%26aufirst%3DL.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DGarassino%26aufirst%3DM.%2BC.%26aulast%3DAerts%26aufirst%3DJ.%2BG.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DBaudelet%26aufirst%3DC.%26aulast%3DHarbison%26aufirst%3DC.%2BT.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DNivolumab%2520versus%2520Docetaxel%2520in%2520Advanced%2520squamous-cell%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D2%26spage%3D123%26epage%3D135%26doi%3D10.1056%2FNEJMoa1504627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Gracia, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shentu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span> (<span class="NLM_issue">10027</span>),  <span class="NLM_fpage">1540</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)01281-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS0140-6736%2815%2901281-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26712084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1540-1550&issue=10027&author=R.+S.+Herbstauthor=P.+Baasauthor=D.+W.+Kimauthor=E.+Felipauthor=J.+L.+P%C3%A9rez-Graciaauthor=J.+Y.+Hanauthor=J.+Molinaauthor=J.+H.+Kimauthor=C.+D.+Arvisauthor=M.+J.+Ahnauthor=M.+Majemauthor=M.+J.+Fidlerauthor=G.+de+Castroauthor=M.+Garridoauthor=G.+M.+Lubinieckiauthor=Y.+Shentuauthor=E.+Imauthor=M.+Dolled-Filhartauthor=E.+B.+Garon&title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2815%2901281-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span></div><div class="casAuthors">Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto Jr; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10027</span>),
    <span class="NLM_cas:pages">1540-1550</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease.  We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  We did this randomised, open-label, phase 2/3 study at 202 academic medical centers in 24 countries.  Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumor cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 wk.  The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumor cells.  We used a threshold for significance of p<0·00825 (one-sided) for the anal. of overall survival and a threshold of p<0·001 for progression-free survival.  This trial is registered at ClinicalTrials.gov, no. NCT01905657.  Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel.  By Sept 30, 2015, 521 patients had died.  In the total population, median overall survival was 10·4 mo with pembrolizumab 2 mg/kg, 12·7 mo with pembrolizumab 10 mg/kg, and 8·5 mo with docetaxel.  Overall survival was significantly longer for pembrolizumab 2 mg/kg vs. docetaxel (hazard ratio [HR] 0·71, 95% CI 0·58-0·88; p=0·0008) and for pembrolizumab 10 mg/kg vs. docetaxel (0·61, 0·49-0·75; p<0·0001).  Median progression-free survival was 3·9 mo with pembrolizumab 2 mg/kg, 4·0 mo with pembrolizumab 10 mg/kg, and 4·0 mo with docetaxel, with no significant difference for pembrolizumab 2 mg/kg vs. docetaxel (0·88, 0·74-1·05; p=0·07) or for pembrolizumab 10 mg/kg vs. docetaxel (HR 0·79, 95% CI 0·66-0·94; p=0·004).  Among patients with at least 50% of tumor cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14·9 mo vs 8·2 mo; HR 0·54, 95% CI 0·38-0·77; p=0·0002) and with pembrolizumab 10 mg/kg than with docetaxel (17·3 mo vs 8·2 mo; 0·50, 0·36-0·70; p<0·0001).  Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5·0 mo vs 4·1 mo; HR 0·59, 95% CI 0·44-0·78; p=0·0001) and with pembrolizumab 10 mg/kg than with docetaxel (5·2 mo vs 4·1 mo; 0·59, 0·45-0·78; p<0·0001).  Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel).  Pembrolizumab prolongs overall survival and has a favorable benefit-to-risk profile in patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection.Merck & Co.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnxRttuwvktbVg90H21EOLACvtfcHk0lgrhAUVe5Cgug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI&md5=333bd6a558ec0f3716e15a2a96b2c02f</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252901281-7%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBaas%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DP%25C3%25A9rez-Gracia%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DMolina%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DFidler%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DShentu%26aufirst%3DY.%26aulast%3DIm%26aufirst%3DE.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26atitle%3DPembrolizumab%2520versus%2520docetaxel%2520for%2520previously%2520treated%252C%2520PD-L1-positive%252C%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528KEYNOTE-010%2529%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26issue%3D10027%26spage%3D1540%26epage%3D1550%26doi%3D10.1016%2FS0140-6736%2815%2901281-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rittmeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterkamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Pawel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dols, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polikoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frontera, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turna, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandara, D. R</span></span> <span> </span><span class="NLM_article-title">Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span> (<span class="NLM_issue">10066</span>),  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(16)32517-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS0140-6736%2816%2932517-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27979383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FkvFCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=255-265&issue=10066&author=A.+Rittmeyerauthor=F.+Barlesiauthor=D.+Waterkampauthor=K.+Parkauthor=F.+Ciardielloauthor=J.+von+Pawelauthor=S.+M+Gadgeelauthor=T.+Hidaauthor=D.+M+Kowalskiauthor=M.+C.+Dolsauthor=D.+L+Cortinovisauthor=J.+Leachauthor=J.+Polikoffauthor=C.+Barriosauthor=F.+Kabbinavarauthor=O.+A.+Fronteraauthor=F.+De+Marinisauthor=H.+Turnaauthor=J.-S.+Leeauthor=M.+Ballingerauthor=M.+Kowanetzauthor=P.+Heauthor=D.+S+Chenauthor=A.+Sandlerauthor=D.+R+Gandara&title=Atezolizumab+versus+docetaxel+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28OAK%29%3A+a+phase+3%2C+open-label%2C+multicentre+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2816%2932517-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial</span></div><div class="casAuthors">Rittmeyer Achim; Barlesi Fabrice; Waterkamp Daniel; Ballinger Marcus; Kowanetz Marcin; He Pei; Chen Daniel S; Sandler Alan; Park Keunchil; Ciardiello Fortunato; von Pawel Joachim; Gadgeel Shirish M; Hida Toyoaki; Kowalski Dariusz M; Dols Manuel Cobo; Cortinovis Diego L; Leach Joseph; Polikoff Jonathan; Barrios Carlos; Kabbinavar Fairooz; Frontera Osvaldo Aren; De Marinis Filippo; Turna Hande; Lee Jong-Seok; Gandara David R</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10066</span>),
    <span class="NLM_cas:pages">255-265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity.  We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.  METHODS:  We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries.  We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1.  Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.  Patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded.  Patients were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 mg/m(2) every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or web response system.  Coprimary endpoints were overall survival in the intention-to-treat (ITT) and PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating immune cells).  The primary efficacy analysis was done in the first 850 of 1225 enrolled patients.  This study is registered with ClinicalTrials.gov, number NCT02008227.  FINDINGS:  Between March 11, 2014, and April 29, 2015, 1225 patients were recruited.  In the primary population, 425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to receive docetaxel.  Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations.  In the ITT population, overall survival was improved with atezolizumab compared with docetaxel (median overall survival was 13·8 months [95% CI 11·8-15·7] vs 9·6 months [8·6-11·2]; hazard ratio [HR] 0·73 [95% CI 0·62-0·87], p=0·0003).  Overall survival in the TC1/2/3 or IC1/2/3 population was improved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15·7 months [95% CI 12·6-18·0] with atezolizumab vs 10·3 months [8·8-12·0] with docetaxel; HR 0·74 [95% CI 0·58-0·93]; p=0·0102).  Patients in the PD-L1 low or undetectable subgroup (TC0 and IC0) also had improved survival with atezolizumab (median overall survival 12·6 months vs 8·9 months; HR 0·75 [95% CI 0·59-0·96]).  Overall survival improvement was similar in patients with squamous (HR 0·73 [95% CI 0·54-0·98]; n=112 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0·73 [0·60-0·89]; n=313 and n=315) histology.  Fewer patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients).  One treatment-related death from a respiratory tract infection was reported in the docetaxel group.  INTERPRETATION:  To our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology, with a favourable safety profile.  FUNDING:  F.  Hoffmann-La Roche Ltd, Genentech, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1bi5vtdP5pf9pSBfyDvp7fW6udTcc2eb6YrnETmVomrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FkvFCmtg%253D%253D&md5=664efa0c7f7e9e48d6df33539088a5de</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932517-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932517-X%26sid%3Dliteratum%253Aachs%26aulast%3DRittmeyer%26aufirst%3DA.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DWaterkamp%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGadgeel%26aufirst%3DS.%2BM%26aulast%3DHida%26aufirst%3DT.%26aulast%3DKowalski%26aufirst%3DD.%2BM%26aulast%3DDols%26aufirst%3DM.%2BC.%26aulast%3DCortinovis%26aufirst%3DD.%2BL%26aulast%3DLeach%26aufirst%3DJ.%26aulast%3DPolikoff%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DKabbinavar%26aufirst%3DF.%26aulast%3DFrontera%26aufirst%3DO.%2BA.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26aulast%3DTurna%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DBallinger%26aufirst%3DM.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DD.%2BS%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DGandara%26aufirst%3DD.%2BR%26atitle%3DAtezolizumab%2520versus%2520docetaxel%2520in%2520patients%2520with%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%2520%2528OAK%2529%253A%2520a%2520phase%25203%252C%2520open-label%252C%2520multicentre%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26issue%3D10066%26spage%3D255%26epage%3D265%26doi%3D10.1016%2FS0140-6736%2816%2932517-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forde, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span> <span> </span><span class="NLM_article-title">Antagonists of PD-1 and PD-L1 in cancer treatment</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2015.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1053%2Fj.seminoncol.2015.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26320063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=587-600&issue=4&author=E.+J.+Lipsonauthor=P.+M.+Fordeauthor=H.+J.+Hammersauthor=L.+A.+Emensauthor=J.+M.+Taubeauthor=S.+L.+Topalian&title=Antagonists+of+PD-1+and+PD-L1+in+cancer+treatment&doi=10.1053%2Fj.seminoncol.2015.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of PD-1 and PD-L1 in Cancer Treatment</span></div><div class="casAuthors">Lipson, Evan J.; Forde, Patrick M.; Hammers, Hans-Joerg; Emens, Leisha A.; Taube, Janis M.; Topalian, Suzanne L.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment.  Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have demonstrated clin. activity in several types of advanced cancers, validating this pathway as a target for cancer therapy.  Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for addnl. cancer types are anticipated.  The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies.  Ongoing studies aim to identify biomarkers to guide patient selection, which would further improve the risk:benefit ratio for these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7CUgfoXsUXbVg90H21EOLACvtfcHk0ljF2AV0bXfX8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3I&md5=a34efc1ccb91868a941c42b389fffd76</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DE.%2BJ.%26aulast%3DForde%26aufirst%3DP.%2BM.%26aulast%3DHammers%26aufirst%3DH.%2BJ.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26atitle%3DAntagonists%2520of%2520PD-1%2520and%2520PD-L1%2520in%2520cancer%2520treatment%26jtitle%3DSemin.%2520Oncol.%26date%3D2015%26volume%3D42%26issue%3D4%26spage%3D587%26epage%3D600%26doi%3D10.1053%2Fj.seminoncol.2015.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elassaiss-Schaap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boasberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1305133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1305133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=23724846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=134-144&issue=2&author=O.+Hamidauthor=C.+Robertauthor=A.+Daudauthor=F.+S.+Hodiauthor=W.-J.+Hwuauthor=R.+Keffordauthor=J.+D.+Wolchokauthor=P.+Herseyauthor=R.+W.+Josephauthor=J.+S.+Weberauthor=R.+Droncaauthor=T.+C.+Gangadharauthor=A.+Patnaikauthor=H.+Zarourauthor=A.+M.+Joshuaauthor=K.+Gergichauthor=J.+Elassaiss-Schaapauthor=A.+Algaziauthor=C.+Mateusauthor=P.+Boasbergauthor=P.+C.+Tumehauthor=B.+Chmielowskiauthor=S.+W.+Ebbinghausauthor=X.+N.+Liauthor=S.+P.+Kangauthor=A.+Ribas&title=Safety+and+tumor+responses+with+lambrolizumab+%28anti-PD-1%29+in+melanoma&doi=10.1056%2FNEJMoa1305133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</span></div><div class="casAuthors">Hamid, Omid; Robert, Caroline; Daud, Adil; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard; Wolchok, Jedd D.; Mersey, Peter; Joseph, Richard W.; Weber, Jeffrey S.; Dronca, Roxana; Gangadhar, Tara C.; Patnaik, Amita; Zarour, Hassane; Joshua, Anthony M.; Gergich, Kevin; Elassaiss-Schaap, Jeroen; Algazi, Alain; Mateus, Christine; Boasberg, Peter; Tumeh, Paul C.; Chmielowski, Bartosz; Ebbinghaus, Scot W.; Li, Xiaoyun Nicole; Kang, S. Peter; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-144</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The programmed death 1 (PD-1) receptor is a neg. regulator of T-cell effector mechanisms that limits immune responses against cancer.  The authors tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.  The authors administered lambrolizumab i.v. at a dose of 10 mg per kg of body wt. every 2 or 3 wk or 2 mg per kg every 3 wk in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not.  Tumor responses were assessed every 12 wk.  A total of 135 patients with advanced melanoma were treated.  Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade.  The confirmed response rate across all dose cohorts, evaluated by central radiol. review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate obsd. in the cohort that received 10 mg per kg every 2 wk (52%; 95% CI, 38 to 66).  The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], resp.).  Responses were durable in the majority of patients (median follow-up, 11 mo among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of anal. in March 2013.  The overall median progression-free survival among the 135 patients was longer than 7 mo.  In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX32-HobXKEbVg90H21EOLACvtfcHk0ljF2AV0bXfX8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP&md5=e325ca09569a6e2786f0523f197fd8c2</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1305133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1305133%26sid%3Dliteratum%253Aachs%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DHwu%26aufirst%3DW.-J.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DDronca%26aufirst%3DR.%26aulast%3DGangadhar%26aufirst%3DT.%2BC.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DZarour%26aufirst%3DH.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DGergich%26aufirst%3DK.%26aulast%3DElassaiss-Schaap%26aufirst%3DJ.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DBoasberg%26aufirst%3DP.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DEbbinghaus%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DKang%26aufirst%3DS.%2BP.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSafety%2520and%2520tumor%2520responses%2520with%2520lambrolizumab%2520%2528anti-PD-1%2529%2520in%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D2%26spage%3D134%26epage%3D144%26doi%3D10.1056%2FNEJMoa1305133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leming, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiller, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span> <span> </span><span class="NLM_article-title">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1200690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=22658127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2443-2454&issue=26&author=S.+L.+Topalianauthor=F.+S.+Hodiauthor=J.+R.+Brahmerauthor=S.+N.+Gettingerauthor=D.+C.+Smithauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=R.+D.+Carvajalauthor=J.+A.+Sosmanauthor=M.+B.+Atkinsauthor=P.+D.+Lemingauthor=D.+R.+Spigelauthor=S.+J.+Antoniaauthor=L.+Hornauthor=C.+G.+Drakeauthor=D.+M.+Pardollauthor=L.+Chenauthor=W.+H.+Sharfmanauthor=R.+A.+Andersauthor=J.+M.+Taubeauthor=T.+L.+McMillerauthor=H.+Xuauthor=A.+J.+Kormanauthor=M.+Jure-Kunkelauthor=S.+Agrawalauthor=D.+McDonaldauthor=G.+D.+Kolliaauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=M.+Sznol&title=Safety%2C+activity%2C+and+immune+correlates+of+anti-PD-1+antibody+in+cancer&doi=10.1056%2FNEJMoa1200690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span></div><div class="casAuthors">Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; Smith, David C.; McDermott, David F.; Powderly, John D.; Carvajal, Richard D.; Sosman, Jeffrey A.; Atkins, Michael B.; Leming, Philip D.; Spigel, David R.; Antonia, Scott J.; Horn, Leora; Drake, Charles G.; Pardoll, Drew M.; Chen, Lieping; Sharfman, William H.; Anders, Robert A.; Taube, Janis M.; McMiller, Tracee L.; Xu, Haiying; Korman, Alan J.; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; Kollia, Georgia D.; Gupta, Ashok; Wigginton, Jon M.; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2443-2454</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance.  We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.  Methods: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kg of body wt. every 2 wk.  Response was assessed after each 8-wk treatment cycle.  Patients received up to 12 cycles until disease progression or a complete response occurred.  Results: A total of 296 patients received treatment through Feb. 24, 2012.  Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity.  No max. tolerated dose was defined.  Adverse events consistent with immune-related causes were obsd.  Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were obsd. in those with non-small-cell lung cancer, melanoma, or renal-cell cancer.  Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).  Responses were durable; 20 of 31 responses lasted 1 yr or more in patients with 1 yr or more of follow-up.  To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochem. anal. was performed on pretreatment tumor specimens obtained from 42 patients.  Of 17 patients with PD-L1-neg. tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-pos. tumors had an objective response (P = 0.006).  Conclusions: Anti-PD-1 antibody produced objective responses in approx. one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.  Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLOPvHybmlvbVg90H21EOLACvtfcHk0lhPt6Yr5vyiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN&md5=7c13f228ef92b6089982fc878d3a394b</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200690%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLeming%26aufirst%3DP.%2BD.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DMcMiller%26aufirst%3DT.%2BL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DKollia%26aufirst%3DG.%2BD.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DSznol%26aufirst%3DM.%26atitle%3DSafety%252C%2520activity%252C%2520and%2520immune%2520correlates%2520of%2520anti-PD-1%2520antibody%2520in%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D26%26spage%3D2443%26epage%3D2454%26doi%3D10.1056%2FNEJMoa1200690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-1 and its ligands in tolerance and immunity</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.26.021607.090331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1146%2Fannurev.immunol.26.021607.090331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=18173375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=677-704&author=M.+E.+Keirauthor=M.+J.+Butteauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-1+and+its+ligands+in+tolerance+and+immunity&doi=10.1146%2Fannurev.immunol.26.021607.090331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and its ligands in tolerance and immunity</span></div><div class="casAuthors">Keir, Mary E.; Butte, Manish J.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">677-704</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathol.  Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance.  Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage.  The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival.  The identification of B7-1 as an addnl. binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance.  In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTbTIs2Ruos7Vg90H21EOLACvtfcHk0lhPt6Yr5vyiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D&md5=4b9b36a8716b8b1b47b7953f134448cf</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.26.021607.090331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.26.021607.090331%26sid%3Dliteratum%253Aachs%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-1%2520and%2520its%2520ligands%2520in%2520tolerance%2520and%2520immunity%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D26%26spage%3D677%26epage%3D704%26doi%3D10.1146%2Fannurev.immunol.26.021607.090331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5542</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-13-2234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24048329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5542&issue=19&author=M.+Sznolauthor=L.+Chen&title=Antagonist+antibodies+to+PD-1+and+B7-H1+%28PD-L1%29+in+the+treatment+of+advanced+human+cancer%2D%2Dresponse&doi=10.1158%2F1078-0432.CCR-13-2234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer-Response</span></div><div class="casAuthors">Sznol, Mario; Chen, Lieping</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5542</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  This paper discusses the antagonist antibodies to PD-1 and B7-H1 (PD-L1) in treatment of advanced human cancer-response.  The application of anti-PD-L1 antibody for the treatment of cancer were generated in an adoptive T-cell transfer model were discussed.  The phase I trial of nivolumab and ipilimumab in metastatic melanoma provided evidence for the hypothesis that combining PD-1 signaling blockade with other immunotherapy agents or approaches will improve treatment outcome were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1G_xmDp6K87Vg90H21EOLACvtfcHk0lhPt6Yr5vyiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7J&md5=c8c376aab4263d81b2d025418bbdca55</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2234%26sid%3Dliteratum%253Aachs%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DAntagonist%2520antibodies%2520to%2520PD-1%2520and%2520B7-H1%2520%2528PD-L1%2529%2520in%2520the%2520treatment%2520of%2520advanced%2520human%2520cancer--response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D19%26spage%3D5542%26doi%3D10.1158%2F1078-0432.CCR-13-2234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span> <span> </span><span class="NLM_article-title">Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5064</span>– <span class="NLM_lpage">5074</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1158%2F1078-0432.CCR-13-3271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=24714771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5064-5074&issue=19&author=J.+M.+Taubeauthor=A.+Kleinauthor=J.+R.+Brahmerauthor=H.+Xuauthor=X.+Panauthor=J.+H.+Kimauthor=L.+Chenauthor=D.+M.+Pardollauthor=S.+L.+Topalianauthor=R.+A.+Anders&title=Association+of+PD-1%2C+PD-1+ligands%2C+and+other+features+of+the+tumor+immune+microenvironment+with+response+to+anti-PD-1+therapy&doi=10.1158%2F1078-0432.CCR-13-3271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy</span></div><div class="casAuthors">Taube, Janis M.; Klein, Alison; Brahmer, Julie R.; Xu, Haiying; Pan, Xiaoyu; Kim, Jung H.; Chen, Lieping; Pardoll, Drew M.; Topalian, Suzanne L.; Anders, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5064-5074</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies.  Identifying factors predicting clin. response could guide patient selection and therapeutic optimization.  Exptl. Design: Patients (N = 41) with melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma, or castration-resistant prostate cancer were treated on an early-phase trial of anti-PD-1 (nivolumab) at one institution and had evaluable pretreatment tumor specimens.  Immunoarchitectural features, including PD-1, PD-L1, and PD-L2 expression, patterns of immune cell infiltration, and lymphocyte subpopulations, were assessed for interrelationships and potential correlations with clin. outcomes.  Results: Membranous (cell surface) PD-L1 expression by tumor cells and immune infiltrates varied significantly by tumor type and was most abundant in melanoma, NSCLC, and RCC.  In the overall cohort, PD-L1 expression was geog. assocd. with infiltrating immune cells (P < 0.001), although lymphocyte-rich regions were not always assocd. with PD-L1 expression.  Expression of PD-L1 by tumor cells and immune infiltrates was significantly assocd. with expression of PD-1 on lymphocytes.  PD-L2, the second ligand for PD-1, was assocd. with PD-L1 expression.  Tumor cell PD-L1 expression correlated with objective response to anti-PD-1 therapy, when analyzing either the specimen obtained closest to therapy or the highest scoring sample among multiple biopsies from individual patients.  These correlations were stronger than borderline assocns. of PD-1 expression or the presence of intratumoral immune cell infiltrates with response.  Conclusions: Tumor PD-L1 expression reflects an immune-active microenvironment and, while assocd. other immunosuppressive mols., including PD-1 and PD-L2, is the single factor most closely correlated with response to anti-PD-1 blockade.  Clin Cancer Res; 20(19); 5064-74. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpww5KU2a0WuLVg90H21EOLACvtfcHk0lifW3Gh0Fv68w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzK&md5=ed5b01512789ec750bd35623bf114938</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3271%26sid%3Dliteratum%253Aachs%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DKlein%26aufirst%3DA.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26atitle%3DAssociation%2520of%2520PD-1%252C%2520PD-1%2520ligands%252C%2520and%2520other%2520features%2520of%2520the%2520tumor%2520immune%2520microenvironment%2520with%2520response%2520to%2520anti-PD-1%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D19%26spage%3D5064%26epage%3D5074%26doi%3D10.1158%2F1078-0432.CCR-13-3271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danilova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunshine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaunitz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esandrio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span> <span> </span><span class="NLM_article-title">Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">e7769</span>– <span class="NLM_lpage">e7777</span>, <span class="refDoi"> DOI: 10.1073/pnas.1607836113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1073%2Fpnas.1607836113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=27837027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCiur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=e7769-e7777&issue=48&author=L.+Danilovaauthor=H.+Wangauthor=J.+Sunshineauthor=G.+J.+Kaunitzauthor=T.+R.+Cottrellauthor=H.+Xuauthor=J.+Esandrioauthor=R.+A.+Andersauthor=L.+Copeauthor=D.+M.+Pardollauthor=C.+G.+Drakeauthor=J.+M.+Taube&title=Association+of+PD-1%2FPD-L+axis+expression+with+cytolytic+activity%2C+mutational+load%2C+and+prognosis+in+melanoma+and+other+solid+tumors&doi=10.1073%2Fpnas.1607836113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors</span></div><div class="casAuthors">Danilova, Ludmila; Wang, Hao; Sunshine, Joel; Kaunitz, Genevieve J.; Cottrell, Tricia R.; Xu, Haiying; Esandrio, Jessica; Anders, Robert A.; Cope, Leslie; Pardoll, Drew M.; Drake, Charles G.; Taube, Janis M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">E7769-E7777</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a no. of different tumor types.  A better understanding of factors assocd. with the PD-1/PD-L axis expression is desirable, as it informs their potential role as prognostic and predictive biomarkers and may suggest rational treatment combinations.  In the current study, we analyzed PD-L1, PD-L2, PD-1, and cytolytic activity (CYT) expression, as well as mutational d. from melanoma and eight other solid tumor types using The Cancer Genome Atlas database.  We found that in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1.  In contrast, mutational load was not correlated with a Th1/IFNG gene signature in any tumor type.  PD-L1, PD-L2, PD-1, CYT expression, and mutational d. are all pos. prognostic features in melanoma, and conditional inference modeling revealed PD-1/CYT expression (i.e., an inflamed tumor microenvironment) as the most impactful feature, followed by mutational d.  This study elucidates the highly interdependent nature of these parameters, and also indicates that future biomarkers for anti-PD-1/PD-L1 will benefit from tumor-type-specific, integrated, mRNA, protein, and genomic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdpBjYCMAoLLVg90H21EOLACvtfcHk0lifW3Gh0Fv68w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCiur7J&md5=c1bcf48c595c2177864303ffd3123db4</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1607836113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1607836113%26sid%3Dliteratum%253Aachs%26aulast%3DDanilova%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSunshine%26aufirst%3DJ.%26aulast%3DKaunitz%26aufirst%3DG.%2BJ.%26aulast%3DCottrell%26aufirst%3DT.%2BR.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DEsandrio%26aufirst%3DJ.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DCope%26aufirst%3DL.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26atitle%3DAssociation%2520of%2520PD-1%252FPD-L%2520axis%2520expression%2520with%2520cytolytic%2520activity%252C%2520mutational%2520load%252C%2520and%2520prognosis%2520in%2520melanoma%2520and%2520other%2520solid%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D48%26spage%3De7769%26epage%3De7777%26doi%3D10.1073%2Fpnas.1607836113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouaid, C.</span></span> <span> </span><span class="NLM_article-title">Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30144-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2818%2930144-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29545095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFSruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=521-536&author=M.+Garassinoauthor=B.-C.+Choauthor=J.-H.+Kimauthor=J.+Mazieresauthor=J.+Vansteenkisteauthor=H.+Lenaauthor=J.+C.+Jaimeauthor=J.+E.+Grayauthor=J.+Powderlyauthor=C.+Chouaid&title=Durvalumab+as+third-line+or+later+treatment+for+advanced+non-small-cell+lung+cancer+%28ATLANTIC%29%3A+an+open-label%2C+single-arm%2C+phase+2+study&doi=10.1016%2FS1470-2045%2818%2930144-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study</span></div><div class="casAuthors">Garassino, Marina Chiara; Cho, Byoung-Chul; Kim, Joo-Hang; Mazieres, Julien; Vansteenkiste, Johan; Lena, Herve; Corral Jaime, Jesus; Gray, Jhanelle E.; Powderly, John; Chouaid, Christos; Bidoli, Paolo; Wheatley-Price, Paul; Park, Keunchil; Soo, Ross A.; Huang, Yifan; Wadsworth, Catherine; Dennis, Phillip A.; Rizvi, Naiyer A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">521-536</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors are a new std. of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clin. benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown.  We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumor expression of PD-L1.  ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centers in Asia, Europe, and North America.  Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.  Key exclusion criteria included mixed small-cell lung cancer and NSCLC histol.; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent.  Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumor cells with PD-L1 expression.  Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumor cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumor cells with PD-L1 expression.  Patients received durvalumab (10 mg/kg) every 2 wk, via i.v. infusion, for up to 12 mo.  Retreatment was allowed for patients who benefited but then progressed after completing 12 mo.  The primary endpoint was the proportion of patients with increased tumor expression of PD-L1 (defined as ≥25% of tumor cells in cohorts 1 and 2, and ≥90% of tumor cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1.  Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available.  The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, no. NCT02087423.  Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3.  Among patients with at least 25% of tumor cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2.  In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response.  Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3.  The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]).  Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3.  The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]).  Immune-mediated events were manageable with std. treatment guidelines.  In patients with advanced and heavily pretreated NSCLC, the clin. activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents.  Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response.  The clin. activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumor cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted.AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJgLQ4PuvqybVg90H21EOLACvtfcHk0lifW3Gh0Fv68w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFSruro%253D&md5=66b95cc26de0e8e7619d500a44809157</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930144-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930144-X%26sid%3Dliteratum%253Aachs%26aulast%3DGarassino%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DB.-C.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DJaime%26aufirst%3DJ.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DPowderly%26aufirst%3DJ.%26aulast%3DChouaid%26aufirst%3DC.%26atitle%3DDurvalumab%2520as%2520third-line%2520or%2520later%2520treatment%2520for%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528ATLANTIC%2529%253A%2520an%2520open-label%252C%2520single-arm%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D521%26epage%3D536%26doi%3D10.1016%2FS1470-2045%2818%2930144-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villegas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhaba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quantin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapetis, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostoros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro
Carpeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozguroglu, M.</span></span> <span> </span><span class="NLM_article-title">PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">1919</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1709937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=28885881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1919-1929&issue=20&author=S.+J.+Antoniaauthor=A.+Villegasauthor=D.+Danielauthor=D.+Vicenteauthor=S.+Murakamiauthor=R.+Huiauthor=T.+Yokoiauthor=A.+Chiapporiauthor=K.+H.+Leeauthor=M.+de+Witauthor=B.+C.+Choauthor=M.+Bourhabaauthor=X.+Quantinauthor=T.+Tokitoauthor=T.+Mekhailauthor=D.+Planchardauthor=Y.-C.+Kimauthor=C.+S.+Karapetisauthor=S.+Hiretauthor=G.+Ostorosauthor=K.+Kubotaauthor=J.+E.+Grayauthor=L.+Paz-Aresauthor=J.+de+Castro%0ACarpenoauthor=C.+Wadsworthauthor=G.+Melilloauthor=H.+Jiangauthor=Y.+Huangauthor=P.+A.+Dennisauthor=M.+Ozguroglu&title=PACIFIC+Investigators.+Durvalumab+after+Chemoradiotherapy+in+Stage+III+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1709937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</span></div><div class="casAuthors">Antonia, S. J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K. H.; de Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y.-C.; Karapetis, C. S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J. E.; Paz-Ares, L.; de Castro Carpeno, J.; Wadsworth, C.; Melillo, G.; Jiang, H.; Huang, Y.; Dennis, P. A.; Ozguroglu, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1919-1929</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy).  This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.  Methods: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kg of body wt. i.v.) or placebo every 2 wk for up to 12 mo.  The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy.  The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim anal.).  Secondary end points included 12-mo and 18-mo progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.  Results: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo).  The median progression-free survival from randomization was 16.8 mo (95% confidence interval [CI], 13.0 to 18.1) with durvalumab vs. 5.6 mo (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-mo progression-free survival rate was 55.9% vs. 35.3%, and the 18-mo progression-free survival rate was 44.2% vs. 27.0%.  The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 mo).  The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 mo vs. 14.6 mo; P<0.001).  Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, resp.).  A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.  Conclusions: Progression-free survival was significantly longer with durvalumab than with placebo.  The secondary end points also favored durvalumab, and safety was similar between the groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLr5-R3gHtVbVg90H21EOLACvtfcHk0ljH9ZUkfkS1jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVOr&md5=95be11a1c165acdc826c4ee049a5f010</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709937%26sid%3Dliteratum%253Aachs%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DVillegas%26aufirst%3DA.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DBourhaba%26aufirst%3DM.%26aulast%3DQuantin%26aufirst%3DX.%26aulast%3DTokito%26aufirst%3DT.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.-C.%26aulast%3DKarapetis%26aufirst%3DC.%2BS.%26aulast%3DHiret%26aufirst%3DS.%26aulast%3DOstoros%26aufirst%3DG.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3Dde%2BCastro%2BCarpeno%26aufirst%3DJ.%26aulast%3DWadsworth%26aufirst%3DC.%26aulast%3DMelillo%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26aulast%3DOzguroglu%26aufirst%3DM.%26atitle%3DPACIFIC%2520Investigators.%2520Durvalumab%2520after%2520Chemoradiotherapy%2520in%2520Stage%2520III%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D20%26spage%3D1919%26epage%3D1929%26doi%3D10.1056%2FNEJMoa1709937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmanoukian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakunnel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A.</span></span> <span> </span><span class="NLM_article-title">Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00544-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2FS1470-2045%2815%2900544-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26858122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XitlCntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=299-308&issue=3&author=S.+Antoniaauthor=S.+B.+Goldbergauthor=A.+Balmanoukianauthor=J.+E.+Chaftauthor=R.+E.+Sanbornauthor=A.+Guptaauthor=R.+Narwalauthor=K.+Steeleauthor=Y.+Guauthor=J.+J.+Karakunnelauthor=N.+A.+Rizvi&title=Safety+and+antitumor+activity+of+durvalumab+plus+tremelimumab+in+non-small+cell+lung+cancer%3A+a+multicentre%2C+phase+1b+study&doi=10.1016%2FS1470-2045%2815%2900544-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study</span></div><div class="casAuthors">Antonia, Scott; Goldberg, Sarah B.; Balmanoukian, Ani; Chaft, Jamie E.; Sanborn, Rachel E.; Gupta, Ashok; Narwal, Rajesh; Steele, Keith; Gu, Yu; Karakunnel, Joyson J.; Rizvi, Naiyer A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-308</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PD-L1 and CTLA-4 immune checkpoints inhibit antitumor T-cell activity.  Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumor activity than either drug alone.  We aimed to assess durvalumab plus tremelimumab in patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC).  We did a multicentre, non-randomized, open-label, phase 1b study at five cancer centers in the USA.  We enrolled immunotherapy-naive patients aged 18 years or older with confirmed locally advanced or metastatic NSCLC.  We gave patients durvalumab in doses of 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 wk, or 10 mg/kg every 2 wk, and tremelimumab in doses of 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 wk for six doses then every 12 wk for three doses.  The primary endpoint of the dose-escalation phase was safety.  Safety analyses were based on the as-treated population.  The dose-expansion phase of the study is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02000947.  Between Oct 28, 2013, and Apr. 1, 2015, 102 patients were enrolled into the dose-escalation phase and received treatment.  At the time of this anal. (June 1, 2015), median follow-up was 18·8 wk (IQR 11-33).  The max. tolerated dose was exceeded in the cohort receiving durvalumab 20 mg/kg every 4 wk plus tremelimumab 3 mg/kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipase).  The most frequent treatment-related grade 3 and 4 adverse events were diarrhoea (11 [11%]), colitis (nine [9%]), and increased lipase (eight [8%]).  Discontinuations attributable to treatment-related adverse events occurred in 29 (28%) of 102 patients.  Treatment-related serious adverse events occurred in 37 (36%) of 102 patients. 22 patients died during the study, and three deaths were related to treatment.  The treatment-related deaths were due to complications arising from myasthenia gravis (durvalumab 10 mg/kg every 4 wk plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 wk plus tremelimumab 1 mg/kg), and neuromuscular disorder (durvalumab 20 mg/kg every 4 wk plus tremelimumab 3 mg/kg).  Evidence of clin. activity was noted both in patients with PD-L1-pos. tumors and in those with PD-L1-neg. tumors.  Investigator-reported confirmed objective responses were achieved by six (23%, 95% CI 9-44) of 26 patients in the combined tremelimumab 1 mg/kg cohort, comprising two (22%, 95% CI 3-60) of nine patients with PD-L1-pos. tumors and four (29%, 95% CI 8-58) of 14 patients with PD-L1-neg. tumors, including those with no PD-L1 staining (four [40%, 95% CI 12-74] of ten patients).  Durvalumab 20 mg/kg every 4 wk plus tremelimumab 1 mg/kg showed a manageable tolerability profile, with antitumor activity irresp. of PD-L1 status, and was selected as the dose for phase 3 studies, which are ongoing.MedImmune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83-IOZZVtArVg90H21EOLACvtfcHk0ljH9ZUkfkS1jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitlCntro%253D&md5=7ac0c9efa33d0ad683aba64f6f734765</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900544-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900544-6%26sid%3Dliteratum%253Aachs%26aulast%3DAntonia%26aufirst%3DS.%26aulast%3DGoldberg%26aufirst%3DS.%2BB.%26aulast%3DBalmanoukian%26aufirst%3DA.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DSanborn%26aufirst%3DR.%2BE.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DNarwal%26aufirst%3DR.%26aulast%3DSteele%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DKarakunnel%26aufirst%3DJ.%2BJ.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520durvalumab%2520plus%2520tremelimumab%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520multicentre%252C%2520phase%25201b%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D3%26spage%3D299%26epage%3D308%26doi%3D10.1016%2FS1470-2045%2815%2900544-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Castro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aren, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrieta, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottfried, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazieh, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timcheva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trani, L.</span></span> <span> </span><span class="NLM_article-title">P2. 06–022 First-Line durvalumab plus tremelimumab vs platinum-based chemotherapy for advanced/metastatic NSCLC: Phase 3 NEPTUNE Study</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S1084</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.11.1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.jtho.2016.11.1515" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S1084&issue=1&author=T.+Mokauthor=P.+Schmidauthor=G.+De+Castroauthor=K.+Syrigosauthor=C.+Martinauthor=N.+Yamamotoauthor=O.+Arenauthor=O.+Arrietaauthor=M.+Gottfriedauthor=A.+R.+Jaziehauthor=R.+Ramlauauthor=C.+Timchevaauthor=L.+Trani&title=P2.+06%E2%80%93022+First-Line+durvalumab+plus+tremelimumab+vs+platinum-based+chemotherapy+for+advanced%2Fmetastatic+NSCLC%3A+Phase+3+NEPTUNE+Study&doi=10.1016%2Fj.jtho.2016.11.1515"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.11.1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.11.1515%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DDe%2BCastro%26aufirst%3DG.%26aulast%3DSyrigos%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DAren%26aufirst%3DO.%26aulast%3DArrieta%26aufirst%3DO.%26aulast%3DGottfried%26aufirst%3DM.%26aulast%3DJazieh%26aufirst%3DA.%2BR.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DTimcheva%26aufirst%3DC.%26aulast%3DTrani%26aufirst%3DL.%26atitle%3DP2.%252006%25E2%2580%2593022%2520First-Line%2520durvalumab%2520plus%2520tremelimumab%2520vs%2520platinum-based%2520chemotherapy%2520for%2520advanced%252Fmetastatic%2520NSCLC%253A%2520Phase%25203%2520NEPTUNE%2520Study%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3DS1084%26doi%3D10.1016%2Fj.jtho.2016.11.1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) for epigenetics research</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cbpa.2020.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32146413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=8-16&author=A.+Vogelmannauthor=D.+Robaaauthor=W.+Sipplauthor=M.+Jung&title=Proteolysis+targeting+chimeras+%28PROTACs%29+for+epigenetics+research&doi=10.1016%2Fj.cbpa.2020.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) for epigenetics research</span></div><div class="casAuthors">Vogelmann, Anja; Robaa, Dina; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-16</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional mols. and allow selective protein degrdn. by addressing the natural ubiquitin proteasome system.  As this new strategy of chem. induced protein degrdn. can serve as a biol. tool and provides new possibilities for drug discovery, it has been applied to a variety of targets including (nuclear) receptors, kinases, and epigenetic proteins.  A lot of PROTACs have already been designed in the field of epigenetics, and their synthesis and characterization highly contributed to structural optimization and improved mechanistic understanding of these mols.  In this review, we will discuss and summarize recent advances in PROTAC discovery with focus on epigenetic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW2o_9L2Y8GbVg90H21EOLACvtfcHk0ljo79rQ9N8NOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D&md5=6a4f3b70d6c6a446c744b9788b7582cf</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmann%26aufirst%3DA.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520for%2520epigenetics%2520research%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D8%26epage%3D16%26doi%3D10.1016%2Fj.cbpa.2020.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent small molecule PROTACs targeting mutant EGFR</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>,  <span class="NLM_fpage">112781</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2020.112781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32883633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslyjsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&pages=112781&author=H.+Y.+Zhaoauthor=X.+Y.+Yangauthor=H.+Leiauthor=X.+X.+Xiauthor=S.+M.+Luauthor=J.+J.+Zhangauthor=M.+Xinauthor=S.+Q.+Zhang&title=Discovery+of+potent+small+molecule+PROTACs+targeting+mutant+EGFR&doi=10.1016%2Fj.ejmech.2020.112781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent small molecule PROTACs targeting mutant EGFR</span></div><div class="casAuthors">Zhao, Hong-Yi; Yang, Xue-Yan; Lei, Hao; Xi, Xiao-Xiao; Lu, She-Min; Zhang, Jun-Jie; Xin, Minhang; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112781</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is an important therapeutic target for the treatment of non-small cell lung cancer.  A no. of efficacious EGFR tyrosine kinase inhibitors have been developed.  However, acquired drug resistance largely encumbered their clin. practicability.  Therefore, there is an urgent need to develop new therapeutic regime.  Herein, we designed and synthesized a set of EGFR-targeting small mol. PROTACs which showed promising efficacy.  In particular, VHL-recruiting compd. P3 showed potent anti-proliferative activity against HCC827 and H1975 cell lines with IC50 values of 0.83 and 203.01 nM, resp.  Furthermore, both EGFRdel19 and EGFRL858R/T790M could be significantly induced to be degraded under treatment of P3 with DC50 values of 0.51 and 126.2 nM, resp.  Compd. P3 was able to dramatically suppress EGFR pathway signal transduction.  Moreover, compd. P3 could significantly induce cell apoptosis, arrest cell cycle and suppress cell colony formation.  In addn., we identified that ubiquitination was indispensable in the degrdn. process, and found that the degrdn. was related to autophagy.  Our work would provide an alternative approach for development of potentially effective EGFR degraders and give a new clue for investigation of PROTAC-induced protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5kpQ3m5f49LVg90H21EOLACvtfcHk0ljo79rQ9N8NOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslyjsbrM&md5=88849f5b2a0ab95919ae6c0a85c5dd0f</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112781%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DXi%26aufirst%3DX.%2BX.%26aulast%3DLu%26aufirst%3DS.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%2520potent%2520small%2520molecule%2520PROTACs%2520targeting%2520mutant%2520EGFR%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26spage%3D112781%26doi%3D10.1016%2Fj.ejmech.2020.112781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponthier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">14481</span>– <span class="NLM_lpage">14489</span>, <span class="refDoi"> DOI: 10.1002/anie.202003500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1002%2Fanie.202003500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=14481-14489&issue=34&author=J.+Jangauthor=C.+Toauthor=D.+J.+H.+De+Clercqauthor=E.+Parkauthor=C.+M.+Ponthierauthor=B.+H.+Shinauthor=M.+Mushajiangauthor=R.+P.+Nowakauthor=E.+S.+Fischerauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Mutant-selective+allosteric+EGFR+degraders+are+effective+against+a+broad+range+of+drug-resistant+mutations&doi=10.1002%2Fanie.202003500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations</span></div><div class="casAuthors">Jang, Jaebong; To, Ciric; De Clercq, Dries J. H.; Park, Eunyoung; Ponthier, Charles M.; Shin, Bo Hee; Mushajiang, Mierzhati; Nowak, Radoslaw P.; Fischer, Eric S.; Eck, Michael J.; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">14481-14489</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting epidermal growth factor receptor (EGFR) through an allosteric mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mutations that emerge within the ATP binding site.  Here, we develop an allosteric EGFR degrader, DDC-01-163, which can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells while leaving wildtype EGFR Ba/F3 cells unaffected.  DDC-01-163 is also effective against osimertinib-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations.  When combined with an ATP-site EGFR inhibitor, osimertinib, the anti-proliferative activity of DDC-01-163 against L858R/T790M EGFR-Ba/F3 cells is enhanced.  Collectively, DDC-01-163 is a promising allosteric EGFR degrader with selective activity against various clin. relevant EGFR mutants as a single agent and when combined with an ATP-site inhibitor.  Our data suggests that targeted protein degrdn. is a promising drug development approach for mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-uPhJ2k9kLVg90H21EOLACvtfcHk0ljo79rQ9N8NOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I&md5=4e24a6a1a746e446a052f27e404f8adf</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1002%2Fanie.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202003500%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DPonthier%26aufirst%3DC.%2BM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DMutant-selective%2520allosteric%2520EGFR%2520degraders%2520are%2520effective%2520against%2520a%2520broad%2520range%2520of%2520drug-resistant%2520mutations%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26issue%3D34%26spage%3D14481%26epage%3D14489%26doi%3D10.1002%2Fanie.202003500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">113328</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2021.113328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=33773286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnt1Oltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2021&pages=113328&author=X.+Quauthor=H.+Liuauthor=X.+Songauthor=N.+Sunauthor=H.+Zhongauthor=X.+Qiuauthor=X.+Yangauthor=B.+Jiang&title=Effective+degradation+of+EGFRL858R%2BT790M+mutant+proteins+by+CRBN-based+PROTACs+through+both+proteosome+and+autophagy%2Flysosome+degradation+systems&doi=10.1016%2Fj.ejmech.2021.113328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems</span></div><div class="casAuthors">Qu, Xiaojuan; Liu, Haixia; Song, Xiaoling; Sun, Ning; Zhong, Hui; Qiu, Xing; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113328</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeted therapy of treating patients with specific tyrosine kinase inhibitors (TKIs) is currently the std. care for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.  However, the inevitably developed drug resistance in patients to EGFR TKIs is the biggest obstacle for cancer targeted therapy.  About 60% of drug resistance to the 1st generation of EGFR TKIs was resulted from an acquired T790M mutation in the kinase domain of EGFR protein.  Proteolysis targeting chimera (PROTAC) is a lately-developed technol. to target point of interest proteins for degrdn.  Because EGFR-mutant lung cancers are highly dependent on EGFR proteins, designing specific PROTAC mols. to degrade EGFR proteins from cancer cells provides a very promising strategy to treat such patients and eradicate drug resistance.  Currently, there is no cereblon (CRBN)-based PROTAC reported able to degrade T790M-contg. EGFR resistant proteins.  In this study, we synthesized two novel CRBN-based EGFR PROTACs, SIAIS125 and SIAIS126, based on EGFR inhibitor canertinib and cereblon ligand pomalidomide.  These two degraders displayed potent and selective antitumor activities in EGFR TKI resistant lung cancer cells.  Firstly, they could selectively degrade EGFRL858R+T790M resistant proteins in H1975 cells at the concn. of 30-50 nM, and EGFREx19del proteins in PC9 cells.  But they did not degrade EGFREx19del+T790M mutant proteins in PC9Brca1 cells or wild type EGFR in A549 lung cancer cells.  They could also selectively inhibit the growth of EGFR mutant lung cancer cells but not that of normal cells or A549 cells.  Secondly, the degrdn. of EGFRL858R+T790M proteins was long lasting up to 72 h.  Thirdly, these degraders displayed better inhibition of EGFR phosphorylation in H1975 cells and PC9Brca1 cells comparing to canertinib.  Finally, these degraders could also induce significant apoptosis and cell cycles arrest in H1975 cells.  Pre-incubation with canertinib, pomalidomide or ubiquitination inhibitor MLN4924 totally blocked EGFR degrdn. by PROTACs.  Mechanistic studies showed that PROTAC could induce autophagy in lung cancer cells.  PROTAC-induced EGFR degrdn. acted through both ubiquitin/proteosome system and ubiquitin/autophagy/lysosome system.  Elevating autophagy activities enhanced EGFR degrdn. and cell apoptosis induced by PROTACs.  Our research not only offered a novel PROTAC tool to target EGFR TKI drug resistance in lung cancer, but also firstly demonstrated that the involvement of autophagy/lysosome system in PROTAC- mediated target protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0L26jmd6Y6bVg90H21EOLACvtfcHk0lg8ff4CGJrr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnt1Oltr4%253D&md5=1ff708cb430cdeee081e82b480a952a9</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113328%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DEffective%2520degradation%2520of%2520EGFRL858R%252BT790M%2520mutant%2520proteins%2520by%2520CRBN-based%2520PROTACs%2520through%2520both%2520proteosome%2520and%2520autophagy%252Flysosome%2520degradation%2520systems%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D218%26spage%3D113328%26doi%3D10.1016%2Fj.ejmech.2021.113328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112199</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2020.112199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32171162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112199&author=X.+Zhangauthor=F.+Xuauthor=L.+Tongauthor=T.+Zhangauthor=H.+Xieauthor=X.+Luauthor=X.+Renauthor=K.+Ding&title=Design+and+synthesis+of+selective+degraders+of+EGFRL858R%2FT790M+mutant&doi=10.1016%2Fj.ejmech.2020.112199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span></div><div class="casAuthors">Zhang, Xin; Xu, Fang; Tong, Linjiang; Zhang, Tao; Xie, Hua; Lu, Xiaoyun; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112199</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of PROTAC (proteolysis targeting chimera) based selective EGFRL858R/T790M (leucine 858 to arginine 858 mutation and threonine 790 to methionine 790) mutant degraders were designed and synthesized.  One of the most potent compds. (I) effectively and selectively degraded EGFRL858R/T790M with an DC50 value of 5.9 nM, while did not show obvious effect on the wild-type protein.  Further mechanism investigation revealed that the degrdn. was mediated by ubiquitin proteasome pathway.  Compd. I could be utilized as an initial lead mol. for development of new EGFRL858R/T790M degrader based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDW2mGkQNzbVg90H21EOLACvtfcHk0lg8ff4CGJrr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D&md5=e8fdd02842f6cfd94e362f3a53a39096</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520selective%2520degraders%2520of%2520EGFRL858R%252FT790M%2520mutant%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112199%26doi%3D10.1016%2Fj.ejmech.2020.112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuaid, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The advantages of targeted protein degradation over inhibition: an RTK case study</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.chembiol.2017.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=29129716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=67-77&issue=1&author=G.+M.+Burslemauthor=B.+E.+Smithauthor=A.+C.+Laiauthor=S.+Jaime-Figueroaauthor=D.+C.+McQuaidauthor=D.+P.+Bondesonauthor=M.+Toureauthor=H.+Dongauthor=Y.+Qianauthor=J.+Wangauthor=A.+P.+Crewauthor=J.+Hinesauthor=C.+M.+Crews&title=The+advantages+of+targeted+protein+degradation+over+inhibition%3A+an+RTK+case+study&doi=10.1016%2Fj.chembiol.2017.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study</span></div><div class="casAuthors">Burslem, George M.; Smith, Blake E.; Lai, Ashton C.; Jaime-Figueroa, Saul; McQuaid, Daniel C.; Bondeson, Daniel P.; Toure, Momar; Dong, Hanqing; Qian, Yimin; Wang, Jing; Crew, Andrew P.; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proteolysis targeting chimera (PROTAC) technol. has emerged over the last two decades as a powerful tool for targeted degrdn. of endogenous proteins.  Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degrdn.  The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degrdn. over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degrdn. leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors.  Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degrdn. using the PROTAC technol. and outline the advantages of this degrdn.-based approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4yDhRDWqNv7Vg90H21EOLACvtfcHk0lg8ff4CGJrr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM&md5=0ac39a6f5836ea3772a0396356efb630</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DMcQuaid%26aufirst%3DD.%2BC.%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520advantages%2520of%2520targeted%2520protein%2520degradation%2520over%2520inhibition%253A%2520an%2520RTK%2520case%2520study%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D67%26epage%3D77%26doi%3D10.1016%2Fj.chembiol.2017.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1216-1232&issue=3&author=M.+Chengauthor=X.+Yuauthor=K.+Luauthor=L.+Xieauthor=L.+Wangauthor=F.+Mengauthor=X.+Hanauthor=X.+Chenauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Discovery+of+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+bifunctional+small-molecule+degraders&doi=10.1021%2Facs.jmedchem.9b01566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders</span></div><div class="casAuthors">Cheng, Meng; Yu, Xufen; Lu, Kaylene; Xie, Ling; Wang, Li; Meng, Fanye; Han, Xiaoran; Chen, Xian; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1216-1232</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by Food and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.  Here, we described the discovery of a novel E3 ligase von Hippel-Lindau-recruiting EGFR degrader, MS39 (compd. 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrader, MS154 (compd. 10), using the proteolysis targeting chimera technol.  These compds. potently induced the degrdn. of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth of lung cancer cells compared with the corresponding neg. controls.  The global proteomic analyses revealed that the compds. were highly selective for EGFR.  Furthermore, both compds. were bioavailable in mouse pharmacokinetic studies, and compd. 6 is the first EGFR degrader suitable for in vivo efficacy studies.  Overall, we provide a set of well-characterized chem. tools to the research community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFLSjUGE-6rVg90H21EOLACvtfcHk0lg2cNmMftipBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D&md5=ec831897a4258f1968e254aa433426c3</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bifunctional%2520small-molecule%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D3%26spage%3D1216%26epage%3D1232%26doi%3D10.1021%2Facs.jmedchem.9b01566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.cell.2019.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31955850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=102-114&issue=1&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Proteolysis-targeting+chimeras+as+therapeutics+and+tools+for+biological+discovery&doi=10.1016%2Fj.cell.2019.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-114</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  New biol. tools provide new techniques to probe fundamental biol. processes.  Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concns. at a post-translational level by co-opting the ubiquitin-proteasome system.  We describe the PROTAC technol. and its application to drug discovery and provide examples where PROTACs have enabled novel biol. insights.  Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues assocd. with PROTACs.  Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgumsEakVWrVg90H21EOLACvtfcHk0lg2cNmMftipBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D&md5=3010929d2979cf04dc6003e66575f1b0</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteolysis-targeting%2520chimeras%2520as%2520therapeutics%2520and%2520tools%2520for%2520biological%2520discovery%26jtitle%3DCell%26date%3D2020%26volume%3D181%26issue%3D1%26spage%3D102%26epage%3D114%26doi%3D10.1016%2Fj.cell.2019.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00909</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00909" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVChtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=448-466&issue=2&author=Y.+Liauthor=J.+Yangauthor=A.+Aguilarauthor=D.+McEachernauthor=S.+Przybranowskiauthor=L.+Liuauthor=C.+Y.+Yangauthor=M.+Wangauthor=X.+Hanauthor=S.+Wang&title=Discovery+of+MD-224+as+a+first-in-class%2C+highly+potent%2C+and+efficacious+proteolysis+targeting+chimera+murine+double+minute+2+degrader+capable+of+achieving+complete+and+durable+tumor+regression&doi=10.1021%2Facs.jmedchem.8b00909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression</span></div><div class="casAuthors">Li, Yangbing; Yang, Jiuling; Aguilar, Angelo; McEachern, Donna; Przybranowski, Sally; Liu, Liu; Yang, Chao-Yie; Wang, Mi; Han, Xin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">448-466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human murine double minute 2 (MDM2) protein is a primary endogenous cellular inhibitor of the tumor suppressor p53 and has been pursued as an attractive cancer therapeutic target.  Several potent, nonpeptide, small-mol. inhibitors of MDM2 are currently in clin. development.  In this paper, we report our design, synthesis, and evaluation of small-mol. MDM2 degraders based on the proteolysis targeting chimera (PROTAC) concept.  The most promising compd. (MD-224, I) effectively induces rapid degrdn. of MDM2 at concns. <1 nM in human leukemia cells.  It achieves an IC50 value of 1.5 nM in inhibition of growth of RS4;11 cells and also low nanomolar IC50 values in a panel of leukemia cell lines.  MD-224 (I) achieves complete and durable tumor regression in vivo in the RS4;11 xenograft tumor model in mice at well-tolerated dose schedules.  MD-224 (I) is thus a highly potent and efficacious MDM2 degrader and warrants extensive evaluations as a new class of anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfVzK-tVEdk7Vg90H21EOLACvtfcHk0lg2cNmMftipBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVChtrfK&md5=3eaa40a8b0ae15c0172ef44a2fd1b902</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00909%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAguilar%26aufirst%3DA.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520MD-224%2520as%2520a%2520first-in-class%252C%2520highly%2520potent%252C%2520and%2520efficacious%2520proteolysis%2520targeting%2520chimera%2520murine%2520double%2520minute%25202%2520degrader%2520capable%2520of%2520achieving%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D448%26epage%3D466%26doi%3D10.1021%2Facs.jmedchem.8b00909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">127167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmcl.2020.127167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=32317208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsV2qt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127167&issue=12&author=K.+Heauthor=Z.+Zhangauthor=W.+Wangauthor=X.+Zhengauthor=X.+Wangauthor=X.+Zhang&title=Discovery+and+biological+evaluation+of+proteolysis+targeting+chimeras+%28PROTACs%29+as+an+EGFR+degraders+based+on+osimertinib+and+lenalidomide&doi=10.1016%2Fj.bmcl.2020.127167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide</span></div><div class="casAuthors">He, Kailun; Zhang, Zhuo; Wang, Wenbing; Zheng, Xiaoliang; Wang, Xiaoju; Zhang, Xingxian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">127167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is one of the important and valuable drug targets.  Overexpression of EGFR is assocd. with the development of many types of cancer.  In this study, three PROTACs small mols. (16a-16c) were designed, synthesized and evaluated for their cytotoxicity against the growth in different NSCLC cell line and the degrdn. effect.  The bioassay results indicated that 16c has a good inhibition in PC9 cells and H1975 cells, and the corresponding IC50 value was 0.413 μM and 0.657 μM, resp.  Western blotting results demonstrated that compd. 16c could serve as an effective EGFRdel19-targeting degrader in PC9 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgut0gW1TkiLVg90H21EOLACvtfcHk0lhsYlnHi82iTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsV2qt74%253D&md5=bf63e55c59176f262c8569824417b2ef</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127167%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520biological%2520evaluation%2520of%2520proteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520as%2520an%2520EGFR%2520degraders%2520based%2520on%2520osimertinib%2520and%2520lenalidomide%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D127167%26doi%3D10.1016%2Fj.bmcl.2020.127167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112061</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.ejmech.2020.112061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=31951960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112061&author=H.+Zhangauthor=H.+Y.+Zhaoauthor=X.+X.+Xiauthor=Y.+J.+Liuauthor=M.+Xinauthor=S.+Maoauthor=J.+J.+Zhangauthor=A.+X.+Luauthor=S.+Q.+Zhang&title=Discovery+of+potent+epidermal+growth+factor+receptor+%28EGFR%29+degraders+by+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1016%2Fj.ejmech.2020.112061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Zhang, Hao; Zhao, Hong-Yi; Xi, Xiao-Xiao; Liu, Yan-Jie; Xin, Minhang; Mao, Shuai; Zhang, Jun-Jie; Lu, A-Xin; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112061</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Herein, the discovery of small mol. EGFR degraders based on the proteolysis targeting chimera (PROTAC) strategy was reported.  In the present study, 13 EGFR degraders contg. pyrido[3,4-d]pyrimidine moiety I [X = CH2C(O)NHCH2CH2C(O), CH2CH2CH2CH2C(O), CH2CH2CH2CH2CH2C(O), etc.], II [C = CH2C(O)NHCH2CH2C(O), CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2C(O), CH2CH2OCH2CH2OCH2CH2, CH2CH2CH2CH2CH2CH2C(O), etc.] were designed and synthesized.  Promising PROTACs I [X = CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2CH2CH2C(O)] induced degrdn. of EGFR in HCC827 cells with the DC50 values of 45.2 and 34.8 nM, resp.  Cellular protein-controlling machinery ubiquitin proteasome system (UPS) was involved in the degrdn. process.  Furthermore, the degraders I [X = CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2CH2CH2C(O)] could significantly induce the apoptosis of HCC827 cells and arrest the cells in G1 phase.  These findings demonstrated that compds. I [X = CH2CH2CH2CH2CH2CH2CH2C(O)] and III [X = CH2CH2CH2CH2CH2CH2C(O)] could serve as effective EGFRdel19-targeting degraders in HCC827 cells. v.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonJUw1b6N-77Vg90H21EOLACvtfcHk0lhsYlnHi82iTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCltr8%253D&md5=8f8a1fbc8df721332a2a2b5d6bbc7875</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DXi%26aufirst%3DX.%2BX.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DA.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%2520potent%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520degraders%2520by%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112061%26doi%3D10.1016%2Fj.ejmech.2020.112061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&issue=18&author=P.+A.+J%C3%A4nneauthor=J.+C.+Yangauthor=D.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.+J.+Ahnauthor=S.+W.+Kimauthor=W.+C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.+H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+inhibitor-resistant+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eZTv3tJcz4g-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D18%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chia, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span> <span> </span><span class="NLM_article-title">Vortex keratopathy presumed secondary to AZD9291</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1097%2FJTO.0000000000000634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26709481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A280%3ADC%252BC28rlsFejuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1807-1808&issue=12&author=P.+L.+Chiaauthor=T.+John&title=Vortex+keratopathy+presumed+secondary+to+AZD9291&doi=10.1097%2FJTO.0000000000000634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Vortex Keratopathy Presumed Secondary to AZD9291</span></div><div class="casAuthors">Chia Puey Ling; John Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1807-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvfZj9Z6tFZvxQvRxYU81tfW6udTcc2eboiNMqiw2fgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlsFejuw%253D%253D&md5=71c693934cbe37c168f69a1d86cb7fad</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000634%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DP.%2BL.%26aulast%3DJohn%26aufirst%3DT.%26atitle%3DVortex%2520keratopathy%2520presumed%2520secondary%2520to%2520AZD9291%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D1807%26epage%3D1808%26doi%3D10.1097%2FJTO.0000000000000634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">23–24</span>),  <span class="NLM_fpage">6135</span>– <span class="NLM_lpage">6145</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1016%2Fj.bmc.2018.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=30442506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKlsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=6135-6145&issue=23%E2%80%9324&author=P.+Zhouauthor=G.+Chenauthor=M.+Gaoauthor=J.+Wu&title=Design%2C+synthesis+and+evaluation+of+the+osimertinib+analogue+%28C-005%29+as+potent+EGFR+inhibitor+against+NSCLC&doi=10.1016%2Fj.bmc.2018.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC</span></div><div class="casAuthors">Zhou, Ping; Chen, Gang; Gao, Minqi; Wu, Jiaquan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">6135-6145</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Osimertinib has been approved as a first-line treatment for non-small-cell lung cancer (NSCLC) patients whose tumor carries EGFR activation and / or resistant mutations.  To mitigate Osimertinib's toxicity caused by AZ5104, the N-demethylation metabolite of Osimertinib, we designed and synthesized a series of Osimertinib analogs with different headpieces.  In vitro and in vivo anal. rendered a potential clin. candidate C-005 which had pyrrolo-pyridine headpiece.  Biochem., C-005 and its main human hepatocyte metabolite showed over 30 fold selectivity of L858R/T790M mutant EGFR over WT EGFR.  Such selectivity profile was retained at cellular level.  In general, C-005 is 2-14 fold more selective than Osimertinib in a panel of WT EGFR cancer cell lines.  Furthermore, C-005 demonstrated robust antitumor efficacy and good tolerability in NCI-H1975, PC-9 and HCC827 xenograft mouse models, making it a potential candidate for human test in clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSjal-LKXd9LVg90H21EOLACvtfcHk0lg83PCser-aTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKlsrbK&md5=0c4fd24d4f1b58ab1ee3e84e875304d3</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520the%2520osimertinib%2520analogue%2520%2528C-005%2529%2520as%2520potent%2520EGFR%2520inhibitor%2520against%2520NSCLC%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D23%25E2%2580%259324%26spage%3D6135%26epage%3D6145%26doi%3D10.1016%2Fj.bmc.2018.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1586/14737140.2016.1162103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=10.1586%2F14737140.2016.1162103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=26943236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=383-390&issue=4&author=X.+Gaoauthor=X.+Leauthor=D.+B.+Costa&title=The+safety+and+efficacy+of+osimertinib+for+the+treatment+of+EGFR+T790M+mutation+positive+non-small-cell+lung+cancer&doi=10.1586%2F14737140.2016.1162103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</span></div><div class="casAuthors">Gao, Xin; Le, Xiuning; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-390</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R).  However, acquired resistance to EGFR TKI monotherapy occurs invariably within a median time frame of one year.  The most common form of biol. resistance is through the selection of tumor clones harboring the EGFR T790M mutation, present in >50% of repeat biopsies.  The presence of the EGFR T790M mutation negates the inhibitory activity of gefitinib, erlotinib, and afatinib.  A novel class of third-generation EGFR TKIs has been identified by probing a series of covalent pyrimidine EGFR inhibitors that bind to amino-acid residue C797 of EGFR and preferentially inhibit mutant forms of EGFR vs. the wild-type receptor.  We review the rapid clin. development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnBfOip3HqtrVg90H21EOLACvtfcHk0lg83PCser-aTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yhtb0%253D&md5=6fd22c935476d396b1560f9a784cb9df</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1586%2F14737140.2016.1162103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2016.1162103%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520osimertinib%2520for%2520the%2520treatment%2520of%2520EGFR%2520T790M%2520mutation%2520positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2016%26volume%3D16%26issue%3D4%26spage%3D383%26epage%3D390%26doi%3D10.1586%2F14737140.2016.1162103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTO','PDB','5ZTO'); return false;">PDB: 5ZTO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN','PDB','5XGN'); return false;">PDB: 5XGN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GMP','PDB','5GMP'); return false;">PDB: 5GMP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ','PDB','6JRJ'); return false;">PDB: 6JRJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRK','PDB','6JRK'); return false;">PDB: 6JRK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRX','PDB','6JRX'); return false;">PDB: 6JRX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41','PDB','5D41'); return false;">PDB: 5D41</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5d4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5d4','PDB','5d4'); return false;">PDB: 5d4</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00876&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00876%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00876" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a5f543968238c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
